<SEC-DOCUMENT>0001493152-20-011662.txt : 20200623
<SEC-HEADER>0001493152-20-011662.hdr.sgml : 20200623
<ACCEPTANCE-DATETIME>20200623172125
ACCESSION NUMBER:		0001493152-20-011662
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200623
DATE AS OF CHANGE:		20200623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beyond Air, Inc.
		CENTRAL INDEX KEY:			0001641631
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				473812456
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38892
		FILM NUMBER:		20983167

	BUSINESS ADDRESS:	
		STREET 1:		825 EAST GATE BOULEVARD, SUITE 320
		CITY:			GARDEN CITY
		STATE:			NY
		ZIP:			11530
		BUSINESS PHONE:		516-665-8200

	MAIL ADDRESS:	
		STREET 1:		825 EAST GATE BOULEVARD, SUITE 320
		CITY:			GARDEN CITY
		STATE:			NY
		ZIP:			11530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AIT Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KokiCare, Inc.
		DATE OF NAME CHANGE:	20150507
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Mark
One)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE FISCAL YEAR ENDED MARCH 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
file number: 001-38892</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>BEYOND
AIR, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-3812456</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or Other Jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporation
        or Organization)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>825
                                         East Gate Boulevard, Suite 320</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Garden
        City, NY </B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11530</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of Principal Executive Offices)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Zip
    Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>516-665-8200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Registrant&rsquo;s
Telephone Number, Including Area Code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(b) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered:</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, par value $0.0001 per share</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XAIR</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Nasdaq Stock Market LLC </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(g) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange
Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)
and (2) has been subject to such filing requirements for the past 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of the &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;non-accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule
12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
    [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    [X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2019, the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate
market value of the registrant&rsquo;s voting stock held by non-affiliates was approximately $32,811,314 based on the last reported
sale price of the registrant&rsquo;s common stock on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were 16,841,555 shares of common stock outstanding as of June 19, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beyond
Air, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Year Ended March 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-size: 10pt"><B>PART
    I</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Business</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Unresolved
    Staff Comments</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Properties</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Legal
    Proceedings</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Mine
    Safety Disclosures</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-size: 10pt"><B>PART
    II</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Market
    for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Selected
    Financial Data</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Quantitative
    and Qualitative Disclosures About Market Risk</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Financial
    Statements and Supplementary Data</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Controls
    and Procedures</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Other
    Information</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-size: 10pt"><B>PART
    III</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">77</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Directors,
    Executive Officers and Corporate Governance</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">Executive
    Compensation</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-size: 10pt">Certain
    Relationships and Related Transactions, and Director Independence</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">Principal
    Accounting Fees and Services</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_023"><FONT STYLE="font-size: 10pt"><B>PART
    IV</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">91</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-size: 10pt">Exhibits,
    Financial Statement Schedules</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">91</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_025"><FONT STYLE="font-size: 10pt">Form
    10-K Summary</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">93</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_026"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this Annual Report,
including statements regarding our future results of operations and financial position, business strategy, prospective products,
product approvals, research and development costs, timing and likelihood of success, and the plans and objectives of management
for future operations and future results of anticipated products are forward-looking statements. These statements involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential&rdquo;, or &ldquo;continue&rdquo; or the negative of these terms or other similar conditional expressions. The
forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely
on our current expectations and projections about future events and financial trends that we believe may affect our business,
financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report
and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking
statements, including the factors described under the sections in this Annual Report titled &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; as well as the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our status as a development-stage company and our expectation to incur losses in the future;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our future capital needs and our need to raise additional funds;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to build a pipeline of product candidates and develop and commercialize products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory
approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to maintain our existing or future collaborations or licenses;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to protect and enforce our intellectual property rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
federal, state, and foreign regulatory requirements, including the U.S. Food and Drug Administration or the FDA regulation of
our product candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to obtain and retain key executives and attract and retain qualified personnel;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to successfully manage our growth; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
our ability to address business disruption and related risks resulting from the recent pandemic of COVID-19, which could have
a material adverse effect on our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we reference in this Annual Report completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements
by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc. the Beyond Air logo, and other trademarks or service marks of Beyond Air, Inc. appearing in this Annual Report are the
property of Beyond Air, Inc. This Annual Report also includes trademarks, tradenames and service marks that are the property of
other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &reg;
and &trade; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_001"></A><FONT STYLE="font-size: 10pt"><B>PART
I</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>ITEM
1. BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc., sometimes referred to as &ldquo;we&rdquo; or the &ldquo;Company&rdquo;, was incorporated on April 24, 2015 as
KokiCare, Inc. (&ldquo;KokiCare&rdquo;) under the laws of the State of Delaware. On December 29, 2016, we entered into
an Agreement and Plan of Merger, which, as amended, we refer to as the Merger Agreement, together with Red Maple Ltd., or Merger
Sub, a wholly owned subsidiary of KokiCare, and Advanced Inhalation Therapies (AIT) Ltd., or AIT Ltd. The Merger Agreement provided
for (i) the merger of Merger Sub with and into AIT Ltd. pursuant to the laws of the State of Israel, referred to as the Israeli
Merger, and (ii) the conversion of the ordinary shares and other outstanding securities of AIT Ltd. into the right to receive
shares and other applicable securities of KokiCare, with&nbsp; AIT Ltd. surviving as our wholly owned subsidiary, which we refer
to as the Merger. The Israeli Merger became effective on December 29, 2016 and the Merger closed on January 13, 2017. On January
9, 2017, the Company changed its name to AIT Therapeutics, Inc. from KokiCare, Inc. On June 25, 2019, the Company changed
its name to Beyond Air, Inc. from AIT Therapeutics, Inc., effective June 26, 2019.</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">AIT
Ltd. was incorporated in Israel on May 1, 2011 and commenced its operations in May 2012. &nbsp;Effective July 4, 2019,
AIT Ltd. changed its name to Beyond Air Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging medical device and biopharmaceutical company developing a nitric oxide (&ldquo;NO&rdquo;) generator and delivery
system (the &ldquo;LungFit&trade; system&rdquo;) that is capable of generating NO from ambient air. LungFit&trade; can generate
NO up to 400 parts per million (&ldquo;ppm&rdquo;) for delivery to a patient&rsquo;s lungs. LungFit&trade; can deliver NO either
continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain
a constant dose. We believe that LungFit&trade; can be used to treat patients on ventilators that require NO, as well as patients
with chronic or acute severe lung infections via delivery through a breathing mask or similar apparatus. Furthermore, we believe
that there is a high unmet medical need for patients suffering from certain severe lung infections that LungFit&trade; can potentially
address. Our current areas of focus with the LungFit&trade; are persistent pulmonary hypertension of the newborn (&ldquo;PPHN&rdquo;),
severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), bronchiolitis (&ldquo;BRO&rdquo;) and nontuberculous mycobacteria
(&ldquo;NTM&rdquo;)<I>.</I> Our current product candidates will be subject to premarket reviews and approvals by the U.S. Food
and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If approved, our system
will be marketed as a medical device in the United States</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
additional focus of the Company is solid tumors. For this indication the LungFit&trade; system is not utilized due to the ultra-high
concentrations of NO used. We have developed a delivery system that can safely deliver NO concentrations in excess of 10,000
ppm directly to a solid tumor. This program is in pre-clinical development and will require FDA, or similar agency in another
country, approval to enter human studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to PPHN, our novel LungFit&trade; is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines
for delivery of 20 ppm NO with a range of 0.5 ppm &ndash; 80 ppm (low-concentration NO). We believe LungFit&trade; has many competitive
advantages over the current approved NO delivery systems in the U.S., European Union, Japan and other markets. For example, LungFit&trade;
does not require the use of a high-pressure cylinder, utilizes less space than other similar devices, does not require cumbersome
purging procedures and places less burden on hospital staff in carrying out safety procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
novel LungFit&trade; system can also deliver a high concentration of NO to the lungs, which we believe has the potential to eliminate
microbial infections, including bacteria, fungi and viruses, among other benefits. We believe current FDA-approved NO vasodilation
treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered. Given
that NO is produced naturally by the body as an innate immunity mechanism at a concentration of 200 ppm, supplemental high dose
NO should aid in the body&rsquo;s fight against infection. Based on our clinical studies, we believe that 150 ppm is the minimum
therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor equivalent regulatory
agencies in other countries or regions have approved any NO formulation and/or delivery system for the delivery of a dosage of
NO at 150 ppm or higher to the lungs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have conducted the following studies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form10-k_001.jpg" ALT="" STYLE="height: 159; width: 630"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
active pipeline of product candidates is shown in the table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form10-k_002.jpg" ALT="" STYLE="height: 265; width: 630"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>&dagger;</SUP>Caution
- LungFit&trade; is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
All dates are based on projections and appropriate financing, anticipated first launch on a global basis pending appropriate regulatory
approvals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
All figures are Company estimates for peak year sales: Global sales potential includes US sales potential</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
plan to submit for premarket approval or (&ldquo;PMA&rdquo;) to the FDA towards the end of the third quarter of 2020 for the use
of the LungFit&trade; in PPHN. We also expect to make certain regulatory filings outside of the U.S. later in 2020. According
to the 2019 year-end report from Mallinckrodt Pharmaceuticals, aggregate sales of low concentration NO in the U.S. were in excess
of $500 million in 2019, while sales outside of the U.S., where there are multiple market participants, sales were considerably
lower than in the U.S. We believe the U.S. sales potential of LungFit&trade; in PPHN to be greater than $300 million and worldwide
sales potential to be greater than $600 million. If regulatory approval is obtained, we anticipate a product launch in both the
U.S. and Israel in 2021 and will continue to launch globally throughout 2021 and beyond.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">SARS
CoV-2 is a global pandemic with a widespread impact across many countries. We have received approval from the FDA to run a study
in COVID-19 (the disease caused by SARS CoV-2 infections) patients using our LungFit<SUP>TM</SUP> system. We have also received
approval from Health Canada to run a similar study to the one approved by the FDA. We look forward to results from both of these
studies in the summer/fall of 2020. The fact that our system does not need cylinders allows us to potentially provide a practical
solution to this crisis. We have applied for grants related to COVID-19 in the United States and other countries. However, no
external funding is required to perform the clinical studies recently approved by FDA and Health Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With respect to bronchiolitis, we initiated in the fourth quarter
of 2019 a double blind, controlled trial in infants hospitalized due to bronchiolitis with three arms and 89 subjects randomized
1:1:1 to standard supportive therapy (SST), SST plus 85 ppm NO and SST plus 150 ppm NO. The trial is complete and we recently
released top line data. There were no SAE&rsquo;s related to NO therapy. With respect to efficacy, the 150 ppm arm was statistically
significant when compared to both the control arm and the 85 ppm arm on the Primary endpoint of fit for discharge from the hospital
and the key secondary endpoint of hospital length of stay. The 85 ppm was no different from control on both endpoints. We believe
this is an exceptional result given the low number of patients and provides compelling evidence of the value of 150 ppm in achieving
the desired efficacy. The pivotal study for bronchiolitis was originally set to be performed in the 2020/21 winter, but due to
the SARS CoV-2 pandemic, hospitals will not be considering any new study proposals not related to SARS CoV-2 or COVID-19. We anticipate
commencing a pivotal study in the United States in the fourth quarter of 2021 and completing it late in the second quarter of 2022.
We expect that we will submit a PMA to the FDA about 6 months after trial completion. Regulatory filings outside of the U.S. would
begin after our review process is completed in the U.S. as long as no additional trials are required. For this indication, we believe
U.S. sales potential to be greater than $500 million and worldwide sales potential to be greater than $1.2 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Over
3 million new cases of bronchiolitis are reported worldwide each year. In the U.S., there are approximately 130,000 annual bronchiolitis
hospitalizations among children two years of age or younger and approximately 177,000 annual hospitalizations among the elderly
population related to RSV infection only with the number rising higher due to other viruses similar to those that cause bronchiolitis
in very young children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Currently,
there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants
is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow
of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe these treatments do not successfully reduce hospital length
of stay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
NTM program has produced data from four compassionate use subjects and nine patients from a multi-center pilot study completed
in 2018. All patients suffered from NTM <I>abscessus</I> infection and had underlying cystic fibrosis. One compassion patient
was treated with our nitric oxide generator at the National Heart, Lung and Blood Institute (&ldquo;NHLBI&rdquo;). All others
were treated with our NO cylinder-based delivery system. All patients were treated with 160 ppm NO at intermittent 30-minute dosing
over 21 days, except one patient who was treated over 26 days and another patient who was treated with 250 ppm NO over 28 days.
We expected to begin a study by the end of 2020 (delayed about 6 months by the COVID-19 pandemic) where patients would self-administer
high concentration NO at home over a period of 12 weeks with LungFit&trade;. We now anticipate preliminary data for this study
will be available during the first half of 2021 and that a full dataset will be available in the second half of 2021. If the trial
is successful, we would commence a pivotal study in 2022. For this indication, we believe U.S. sales potential to be greater than
$1 billion and worldwide sales potential to be greater than $2.5 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NTM
lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. There is an increasing
rate of lung disease caused by NTM, which is an emerging public health concern worldwide. There are approximately 50,000 patients
diagnosed with NTM in the U.S., and there are an estimated additional 100,000 patients in the U.S. that have not yet been diagnosed.
In Asia, the number of patients suffering from NTM surpasses what is seen in the U.S. To date we have treated only the <I>abscessus
</I>form of NTM which comprises approximately 20-25% of all NTM. We will be treating both the <I>abscessus and mycobacterium avium
complex (MAC) </I>forms of NTM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patients
with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats,
blood in the sputum and fatigue. Patients with NTM lung disease, specifically <I>abscessus</I> and other forms of NTM that are
refractory to antibiotic therapy<I>,</I> frequently require lengthy and repeated hospital stays to manage their condition. There
are no treatments specifically indicated for the treatment of NTM <I>abscessus </I>lung disease in North America, Europe or Japan.
There is one inhaled antibiotic approved in the U.S. for the treatment of refractory NTM MAC. Current guideline-based approaches
to treat NTM lung disease involve multi-drug regimens of anti-biotics that may cause severe, long lasting side effects, and treatment
can be as long as 18 months or more. Median survival for NTM MAC patients is approximately 13 years while median survival for
patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable to NTM has increased
over the past two decades. In a study conducted between 1997 and 2007, researchers found that the prevalence of NTM in the U.S.
is increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 are 40% more likely to die over
the period of the study than those who did not have the disease (Adjemian et al., 2012). NTM <I>abscessus</I> treatment costs
are estimated to be more than double that of NTM MAC. In total, a 2015 publication from co-authors from several U.S. government
departments stated that prior year statistics led to a projected 181,037 national annual cases in 2014 costing the U.S. healthcare
system approximately $1.7 billion (Strollo et al., 2015).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
our solid tumor program, we released pre-clinical data at the virtual American Academy of Cancer Research (AACR) showing the promise
of delivering NO at concentrations of 25,000 ppm &ndash; 200,000 ppm directly to tumors. Results showed local tumor ablation with
complete eradication in 5 of 30 mice. Additionally, regardless of whether the tumor was completely or partially cleared, all colon
tumor bearing mice were resistant to a second challenge of colon cancer. Breast tumor bearing mice showed a 7-10 day delay in
the uptake of breast cancer post challenge. Pre-clinical work will continue throughout the rest of 2020 and most of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
program in chronic obstructive pulmonary disease is in the pre-clinical stage and will remain there, subject to our obtaining
additional financing</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background
and Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
is recognized as a vital molecule involved in many physiological and pathological processes. NO is naturally produced by the body&rsquo;s
immune system to provide a first line of defense against invading pathogens. It is a powerful molecule with a short half-life
of a few seconds in the blood, enabling it to be cleared rapidly from the body. NO has been shown to play a critical role in the
function of several body systems. For example, as vasodilator of smooth muscles, NO enhances blood flow and circulation. In addition,
NO is involved in regulation of a wound healing and immune responses to infection. The pharmacology, toxicity and other data for
NO in humans is generally well known, and its use has been approved by the FDA as a vasodilator. The precise effect of inhaled
NO is dependent on concentration, oxidation state and type of pathogen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
has multiple immunoregulatory and antimicrobial functions that are likely to be of relevance to inhaled NO therapy. <I>In vitro
</I>studies suggest that NO possesses anti-microbial activity against common bacteria, gram positive and gram negative, as well
as mycobacteria, fungi, yeast, parasites and helminthes. It has the potential to eliminate multi-drug resistant strains of the
above. Anti-viral activity covers respiratory viruses such as influenza, corona viruses, RSV and others. In healthy humans, NO
has been shown to stimulate mucocilary clearance, and low levels of nasal NO correlate with impaired mucociliary function in the
human upper airway. Unlike other inhaled drugs, NO is also a smooth muscle relaxant and avoids the concomitant bronchial constriction
often associated with inhaled antibiotics and mucolytics. A potential benefit of these multiple mechanisms may be that in addition
to treating lung infections in cystic fibrosis (CF) patients, this suggests that NO may be useful in directly treating the mucus
caused by CF, which is the principal manifestation of the disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitric
Oxide and Infection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
possesses broad-spectrum anti-microbial activity acting against bacteria, fungi and viruses. NO is produced at high output as
part of the innate immune response. NO and its by-products (for example, reactive nitrogen species, or RNS) are responsible for
the process of killing microorganisms within white blood cells called macrophages and in organs such as the lungs and other mucolytic
tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than a decade ago, several research groups showed that NO and RNS possess anti-viral activity and affect several viruses including
coxsackievirus, or CVB, RSV, influenza, severe acute respiratory syndrome, or SARS, coronavirus, rhinovirus, herpes simplex virus,
or HSV, Epstein-Barr virus, or EBV, and others. NO has also been shown to be useful in preventing bacterial growth on surfaces.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
exposure to 150 ppm NO and above, especially in the lungs, may have side effects and cause damage to host cells. Intermittent
exposure to NO in cycles retains NO anti-microbial activity both in vitro and in animal model of infection. Exposure of bacteria
to concomitant 30-minute treatments with 160 ppm NO resulted in a significant reduction in bacterial load. A similar dose has
been shown to reduce viruses (common influenza) by 30-100% in a canine kidney infection model. In vivo, in a pneumonia model in
rats, inhaled 160 ppm NO, for 30 minutes, every 4 hours, resulted in significant reduction in bacteria counts in the lungs, without
affecting the body&rsquo;s defense mechanisms, and without any other adverse effect. In addition, we believe a daily dose of 160
ppm of NO can treat bovine respiratory disease (&ldquo;BRD&rdquo;) in cattle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importantly,
several studies report synergy between NO and antibiotic drugs. Adjunctive treatment combining NO together with inhaled tobramycin
antibiotics or other anti-microbial agents has been shown to greatly enhance the efficacy of the antibiotics in dispersing P.
aeruginosa biofilms and to increase their ability to elicit anti-microbial activity. These studies suggest that adjuvant treatment
combining NO with antibiotics might have a beneficial role by reducing bacterial infectivity, and therefore reduce the dependency
on antibiotics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Beyond
Air Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed the Beyond Air nitric oxide generator and delivery system which we call LungFit&trade;, a novel and precise delivery
system that uses NO generated from ambient air with a novel NO generator. Our system provides continuous monitoring and control
of the gaseous content administered during intermittent and continuous NO inhalation treatments, as well as a precise and reliable
monitoring system that is able to monitor patient status and alert medical staff to any adverse effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LungFit&trade; system is innovatively designed to provide patients with a gaseous dose of NO (ranging from 0.5 ppm up to 400 ppm)
combined with ambient air. The gaseous blend is supplied to the patient via a ventilator for concentrations up to 80 ppm and a
face mask, or similar apparatus, for concentrations above 80 ppm. The LungFit&trade; is designed to minimize the time that NO
is mixed with oxygen and air. The system is also designed to continuously monitor inhaled NO concentration, NO<SUB>2 </SUB>concentration
and oxygen. A dedicated screen allows for monitoring of the gas mixture. Further, our product candidates resemble other inhalation
systems, making it user friendly, with operation and maintenance that we believe will be immediately familiar to medical staff.
Our LungFit&trade; system for use with a mask has been manufactured at commercial scale with a contract manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
programmed for lung infections, the LungFit&trade;, is designed to specifically deliver a NO dosage of 150 ppm and higher. We
believe that the LungFit&trade; has a number of advantages over other NO formulation delivery systems. For example, it is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">optimized
    to deliver 150 ppm and higher of NO, whereas existing formulations of NO currently on the market consist of a maximum deliverable
    NO concentration of 80 ppm;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equipped
    with a monitoring system that continuously monitors system parameters (e.g., NO, NO<SUB>2</SUB> and FiO<SUB>2 </SUB>concentrations);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">capable
    of providing constant flow of NO, which we believe allows it to adequately cover the surface area of the lung to eliminate
    bacteria, viruses, fungi and other microbes;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">programmable
    and able to deliver different dosage regimens for a wide range of lung infections;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">able
    to generate NO from ambient air, eliminating the need for the use of high-pressure cylinders;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed
    to be used by the patient, thus convenient and portable; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administered
                                         non-invasively through a facial mask, which has the potential to address severe infections
                                         in large, underserved chronic-care markets, such as CF and chronic obstructive pulmonary
                                         disease (COPD).</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our solution has the potential for a number of additional benefits and opportunities, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    antimicrobial and multiple other properties of the NO molecule delivered to the lungs suggest the potential for application
    in a wide range of respiratory diseases. In contrast to the often arduous and slow drug discovery process for small molecules,
    proteins, peptides, etc., the use of NO in medicine is well-known, and therefore the identification of conditions where NO
    provides benefits has been, and we expect will continue to be, much simpler, quicker and less costly.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA approved the use of NO as an inhaled drug for the treatment of pulmonary hypertension in newborns in 1999. More than 20
    years of clinical experience in the delivery, monitoring and understanding of NO in the clinical environment for vascular
    uses has been documented.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    is naturally produced by the immune system and acts as a first line of defense against infectious diseases. We believe therapeutic
    use of NO for viral and bacterial co-infections would potentially improve the success of antimicrobial and anti-viral treatments
    by mimicking the body&rsquo;s natural defense mechanism and thereby directly reduce viral infectivity, as well as antibiotic
    drug resistant bacteria.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO
    is used naturally by the body for vasodilation and we believe that the benefits to patients with various medical conditions
    will be seen via vasodilation when delivered with our system.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NitricGen
License</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018, we announced that we entered into a definitive agreement to acquire a global, exclusive, perpetual, transferable
license to the eNOGenerator and associated critical assets including intellectual property, know-how, trade secrets and confidential
information (the &ldquo;License&rdquo;) from NitricGen. The eNOGenerator is a novel and precise delivery system that uses NO generated
from ambient air with a novel NO generator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Beyond Air LungFit&trade; system, which incorporates the eNOGenerator, has been designated as a medical device by the U.S. Food
and Drug Administration. The eNOGenerator can generate NO on demand for delivery to the lungs at concentrations ranging from 0.5
to 400 ppm. With the License, we expect that we will be able to target all conditions requiring NO at any concentration, regardless
of the need for intermittent or continuous dosing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the License, we agree to pay NitricGen an aggregate of $2 million in up-front, clinical, and regulatory milestone
payments, with the majority pertaining to regulatory milestones, as well as royalties on net sales of the delivery system containing
the eNOGenerator at a percentage in the low-single digits. As partial consideration for the License, we issued to NitricGen options
to purchase 100,000 shares of our common stock at an exercise price of $6.90 per share. To date, $200,000 has been paid for milestones
that were earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
objective is to build a leading medical device company that will develop and commercialize patented and proprietary products for
the treatment of respiratory infections and diseases, with an initial focus on the treatment of PPHN, bronchiolitis, severe lung
infections such as NTM and SARS Cov-2, severe infections in chronic obstructive pulmonary disease, or COPD, and CF patients. If
our clinical trials for our product candidates are successful, we expect to seek marketing approval from the FDA and other worldwide
regulatory bodies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
completed clinical trials and plans for future clinical trials are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
We licensed Phase 1 study results in healthy volunteers from University of British Columbia Hospital, or UBC. Results showed safe
delivery of 160 ppm NO to the lung.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>Bronchiolitis</I>. We have completed three separate double blind, randomized, placebo controlled studies conducted in Israel
in infants with bronchiolitis. All three studies resulted in consistent data showing no serious adverse events (SAEs) related
to NO therapy and a significant reduction in hospital length of stay. Our most recent study completed in May 2020 showed results
in 89 subjects randomized 1:1:1 to SST, SST plus 85 ppm NO and SST plus 150 ppm NO where 150 ppm was statistically significant
compared to both the 85 ppm NO arm and the control arm on the primary endpoint and key secondary endpoint with the 85 ppm arm
no different from control. We intend to submit an Investigational Device Exemption (&ldquo;IDE&rdquo;) to the FDA in 2020 and
expect to commence a pivotal clinical trial in 2021 in the United States which will complete in 2022, </FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>NTM</I>. Four patients with CF suffering from NTM infections (specifically, M. Abscessus) have been treated under compassionate
use, including two patients at the Rambam healthcare campus in Israel, one at Soroka Medical Center in Israel and one patient
in the United States, treated with an early version of our LungFit&trade; system, at the National Heart, Lung and Blood Institute
(NHLBI). A pilot study of nine CF patients infected with NTM Abscessus in Israel treated with NO using cylinder gas was completed
in the fourth quarter of 2017. In addition, we intend to perform an at-home self-administration study. The study will use the
LungFit&trade; system and treat patients infected with NTM. Endpoints are expected to include physical function, bacterial load,
forced expiratory volume in one second (FEV1), quality of life and safety. The study is anticipated to commence late in 2020.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<I>CF-Related Lung Infections</I>. We completed a pilot open label, multi-center study in Israel of CF patients who are over 10
years old. Results showed a reduction in bacterial load in multiple infections.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Initial Disease Targets and Market Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial targets are PPHN, infants suffering from bronchiolitis, Covid-19 patients and patients with NTM lung infection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PPHN
is a condition at birth that requires mechanical ventilation. NO is added as a vasodilator to improve oxygenation and reduce the
need for ventilation in neonates with hypoxic respiratory failure. The use of NO in the hospital setting had associated net sales
of greater than $500m in 2019 in the United States alone according to published reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the World Health Organization, bronchiolitis is the most common acute lower respiratory infection in infants, and is the leading
cause of the hospitalization of infants during the first year of life. Bronchiolitis is an acute inflammatory injury of the bronchioles
that is usually caused by viruses, most commonly by RSV. While bronchiolitis may affect persons of any age, severe symptoms are
usually evident only in young infants. The initial symptoms of bronchiolitis are similar to that of a common cold, but the illness
sometimes leads to fast and troubled breathing due to spread of the infection to the lower respiratory system. To date, the standard
treatment has been supportive care consisting of assisted feeding and hydration, minimal handling, nasal suctioning and oxygen
administration. In addition, better airway cleaning, which improves the respiratory function, has been achieved using nebulized
hypertonic saline. We believe that many pharmacological therapies, ranging from bronchodilators to corticosteroids, have been
found to offer either no or short-term benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
year, according to the World Health Organization, 150 million new cases of bronchiolitis are reported worldwide in infants, and
2-3% of infants affected require hospitalization. In the U.S., there are greater than 150,000 annual bronchiolitis hospitalizations
among children younger than five years, of which greater than 100,000 hospitalizations are among children younger than two years
old. These hospital visits resulted in total hospital charges of $1.7 billion in 2009 according to a study published in 2013.
For infants, bronchiolitis accounts for 20% of annual hospitalizations and 18% of emergency department visits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
practice in the management of acute bronchiolitis varies widely even among medical centers in the same country, and there is much
controversy, confusion and lack of evidence concerning the best treatment option. Disease management mainly consists of supportive
care by means of oxygen supplementation, but also includes inhalations of hypertonic saline or steroids with or without beta agonist
drugs, anti-viral therapy and chest physiotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that none of the specified treatments has been proven to have a positive outcome on the course of the disease or a reduction
in the length of hospitalization. In addition, some treatment strategies have been subject to debate regarding whether they work.
For example, the anti-viral drug, Ribavirin, a broad-spectrum antiviral agent approved for treatment of RSV infections, is controversial
due to questions regarding its high cost and uncertain treatment effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
infection of the lungs is a chronic, as well as a progressive lung condition. NTM exhibits across a variety of lung diseases such
as bronchiectasis, COPD, Asthma, CF and Cancer. In certain severe NTM cases, life expectancy is under five years, for which we
believe there are no successful treatments available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are an estimated 50,000-86,000 cases of NTM lung infections in the U.S. with an annual 8% increase. More than 70% of NTM cases
are underreported, and therefore the projected number of NTM cases could be as high as 181,000 in the U.S. alone. With the rise
of NTM infections, NTM is currently more prevalent than tuberculosis in the U.S. NTM mostly affects adults middle-aged to elderly,
with increasing infection in patients aged 65 and over, a population that is expected to double by the year 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
lung infections also pose a substantial financial burden on the U.S. healthcare system. In 2010, the annual cost was over $800
million, and the same study estimated the cost for 2014 to be $1.7 billion in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
initial indication is for the treatment of both NTM <I>abscessus </I>and MAC, which is the vast majority of the market discussed
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no approved products in the U.S. and Europe to treat NTM <I>abscessus </I>infections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NTM patients, prolonged treatment is necessary and varies among different types of NTM species, severity of the disease and drug-susceptibility.
As NTM are typically antibiotic-resistant, treatment requires a combination of two, three or more different drugs. Therefore,
current treatment includes a mixture of IV antibiotics as well as steroids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Clinical Results to Date</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted several clinical trials to assess our &ge; 150 ppm NO inhalation-treatment in various indications. These trials
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospective, open label, controlled, single-center Phase 1 study was conducted on ten healthy adults between 20 and 62
years of age. Subjects received our proprietary 160 ppm NO formulation for 30 minutes, five times a day, for five consecutive
days by direct inhalation to the lungs via a prototype delivery system</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objective of the study was to determine the effect of the inhaled NO formulation treatment, to determine the effect of
the treatment based on pulmonary function test results, to determine the met hemoglobin (MetHb - a form of hemoglobin that cannot
bind oxygen, a bi-product of NO and hemoglobin) level associated with the inhaled NO formulation treatment and to assess adverse
events associated with the treatment. Secondary objectives of the study were to assess the changes in cytokine levels. NO and
NO<SUB>2</SUB> concentrations (a gaseous substance that is a bi-product of NO and O<SUB>2</SUB>, that can be toxic at high concentrations),
inhaled fraction of inspired oxygen (FiO<SUB>2</SUB>), as well as. MetHb and oxygen saturation (SaO2) were continuously monitored,
as elevation of MetHb or reduction in SaO<SUB>2 </SUB>levels may be harmful. Vital signs, lung function, blood chemistry (including
nitrite/nitrates), hematology, prothrombin time, inflammatory cytokine/chemokines levels and endothelial activation (angiopoietin
ratio) were also closely monitored.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
individuals tolerated the NO formulation treatment courses well. No significant adverse events occurred. The maximal amount of
air one can forcefully exhale in one second, known as forced expiratory volume in one second (&ldquo;FEV1&rdquo;) and other lung
function parameters, serum nitrites/nitrates, prothrombin, pro-inflammatory cytokine and chemokine levels did not differ between
baseline and day five, while MetHb increased during the study period to a level of 0.9%, as expected. These data suggest that
inhalation of 160 ppm NO for 30 minutes, five times a day, for five consecutive days is well tolerated in healthy individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rambam
healthcare campus in Israel conducted a compassionate use treatment for two patients with CF who suffer from NTM <I>Abscessus
</I>infections. The data were published in the Pediatric Infectious Disease Journal in 2017. The NO treatment regime, as well
as the device for this treatment, was supplied by AIT Ltd. Patients received intermittent 30-minute treatments of 160 ppm NO,
with two different regimes including hospitalization (5 times a day) and ambulatory treatment (2-3 inhalations a day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
was well tolerated with no evidence of any serious side effects. We observed significant improvement in sputum production (up
to 5-10 time more sputum), and subjective improvement in the well-being of both patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
reduction in systemic inflammation was observed in the first patient, as observed by reduction of CRP (C-reactive protein, a systemic
inflammation marker that rises in response to inflammation) levels during treatment. In addition, the first patient had a 2 log
(100-fold) reduction in NTM Abscessus during treatment (an effect that was lost after the treatment regime changed to ambulatory).
The second patient showed a significant increase in the 6-minute walk test and the sputum culture became negative, which is consistent
with eradication of the NTM Abscessus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
information is needed, but we believe these results suggest that the treatment of NTM Abcsessus with high dose inhaled NO is effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
one patient with CF who suffers from NTM infections (specifically, <I>M. abscessus</I>) has been treated under compassionate use
in the United Sates at the National Heart, Lung and Blood Institute with our generator based NO delivery system. The patient saw
improvements in 6-minute walk, FEV1, most Quality of Life measures and had no SAEs. The bacteria was not eradicated. The patient
requested to be treated again and this treatment was commenced in February 2018. A total of 38 treatments were administered over
8 days, 29 of them at a concentration of 240 ppm, with no SAEs believed to be related to NO reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
additional CF patient infected with <I>M. abscessus </I>was treated over a 4 week period with 76 of 84 treatments at 250 ppm NO
in Israel at Soroka Medical Center. The patient saw improvements in 6-minute walk, FEV1 and most Quality of Life measures. The
bacteria was not eradicated. Importantly, there were no SAE&rsquo;s reported and all treatments were completed without incident.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed a Phase 2 open label, multi-center study in nine CF patients (&ge;10 years old). Patients received intermittent
(30 minutes, three times a day) inhalation of 160 ppm NO formulation, five days a week, over a two-week period. The study was
performed in two centers, Soroka Medical Center and Schneider Children&rsquo;s Medical Center of Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoints of the study were to determine the MetHb percentage, adverse events associated with inhaled NO and the percentage
of subjects who prematurely discontinued the study due to adverse events, or AEs, and/or SAEs, or for any other reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEs
were reported by five (55.5%) subjects. There were no SAEs related to NO therapy, no treatment withdrawals due to AEs, and no
deaths. AEs considered by the investigator as possibly or probably related to treatment were reported for two (22.2%) subjects.
There were no AEs of MetHb elevation &gt;5% or NO <SUB>2</SUB> elevation &gt;5 ppm (study safety threshold of MetHb and NO <SUB>2</SUB>,
respectively). In total, seven cases of haemoptysis were reported in two subjects and all events were mild in severity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no subjects with MetHb &gt;5% at any point during the study and there was no cumulative effect of MetHb exposure during the
study. The maximum MetHb level reported was 4.6%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
secondary efficacy analyses were conducted in this study, and though the study was not powered for efficacy, results show various
positive effects of the treatment regime. Bacterial and fungal sputum load analysis results were highly variable, though marked
reductions of MSSA, Achromabacter, P. aeruginosa, and Asperigillus were seen in several subjects. These results suggest non-specific
targeting of bacteria and fungi that commonly manifest in CF patients. In subjects with systemic inflammation (CRP &gt;5 mg/mL)
at baseline, CRP levels decreased over the treatment period, showing the effect of NO in the reduction of systemic inflammation.
There were no statistically significant or clinically relevant changes in FEV1 over time, and lung function indices also remained
relatively constant throughout the study duration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed a double blind, randomized Pilot study for infants with bronchiolitis for which the data were published in the Pediatric
Pulmonology Journal in 2017. The study was performed at Soroka University Medical Center in Israel. Forty-three infants between
the ages of two to 12 months diagnosed with bronchiolitis were randomly assigned to either the treatment group or the control
group. The treatment group comprised 21 subjects who received intermittent (30 minutes, five times a day) inhalation of 160 ppm
NO formulation, in addition to supportive O<SUB>2 </SUB>treatment for up to five days. The control group, 22 subjects, received
ongoing inhalation of the supportive O<SUB>2 </SUB>treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
endpoints included determination of the MetHb levels, adverse events associated with the inhaled NO formulation and proportion
of subjects who prematurely discontinued the study. Baseline clinical score, indicating disease severity at screening, was similar
between treatment groups (~8).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
were encouraging, with similar overall incidence of AEs between the treatment groups. Out of 43 patients, 39 (~90%) completed
the study per protocol (&ldquo;PP&rdquo;), with similar percentages (90%) for both the control and the treatment groups, individually.
Only one subject from the treatment group discontinued treatment due to an adverse event, namely &ndash; repeated MetHb levels
above 5%. Adverse events were reported by 23 (53.5%) subjects overall, with ten (47.6%) subjects in the NO group reporting a total
of 22 AEs, and 13 (59.1%) subjects in the control group reporting a total of 22 AEs. Serious adverse events were reported by four
(19.0%) subjects in the NO group and four (18.2%) in the standard treatment group. There were no deaths during the study. There
were no treatment-related SAEs in the NO treatment group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the NO group, six (28.6%) subjects had any MetHb measurement &gt;5% during the study treatment period, and three of these subjects
had more than one MetHb &gt;5%. The maximum MetHb level was 5.6% in one subject in the NO group. There was no cumulative effect
of MetHb exposure during the study. It should be noted that MetHb levels in this study were defined to &lt;5% as a safety measure,
though previous findings have shown that higher levels (6.4%) are non-toxic in children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
and exploratory analyses were performed, and results show positive impact of the treatment regime. In a subgroup of subjects that
stayed at the hospital at least 24 hours (Length of Stay (&ldquo;LOS&rdquo;) &gt;24 hours), a statistically significant treatment
benefit of NO versus standard treatment was demonstrated. Mean results for subjects with LOS &gt; 24 hours show that LOS was shortened
by approximately 34% in the NO group compared to the standard treatment group, with a one-day difference between the groups (PP,
N=24). Time to normal oxygenation ((SaO2 of 92%) was shortened by approximately 44% (27.75 hours) in the NO group compared to
the standard treatment group (PP, N=24). An 80% improvement in time to clinical score (indicating improvement in disease severity)
and time to normal oxygenation (92%) was observed in favor of the NO group (PP, N=24).The results of preclinical studies and early
clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the FDA or other regulatory agencies may not concur with our assessment of safety and efficacy. Product candidates that have shown
promising results in early-stage clinical studies may still suffer significant setbacks in subsequent advanced clinical studies.
We do not know whether any Phase 2, Phase 3 or other clinical studies we may conduct will demonstrate consistent or adequate efficacy
and safety sufficient to obtain regulatory approval to market our product candidates. While we believe the results of our Phase
2 trials in bronchiolitis and CF demonstrated improvements in various endpoints and clinical outcomes, the trials were small,
and it is likely that the FDA will view them as not statistically or clinically significant because of their size and scope. We
must conduct larger clinical trials with statistically significant favorable results or we will not be able to obtain regulatory
approval to market our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed a single-arm, open-label Pilot trial in nine patients with MABSC, who were refractory to standard-of-care. The
patients were treated with inhaled NO at a concentration of 160 ppm for 30 minutes, in addition to treatment with standard-of-care.
Our inhaled NO treatment was administered intermittently five times per day over a 14-day period, followed by a seven-day period
with three treatments per day. The primary endpoint of safety, as measured by NO-related SAEs, over the 21-day treatment period
was met with no SAEs reported. Secondary endpoints of a 6-minute walk test, FEV1, Quality of Life and Mycobacterium abscessus
load in sputum all trended positively. 6MW showed an increase of &gt;40 meters at the end of treatment at day 21 versus baseline
and an increase of &gt;25 meters on day 81 (60 days after the cessation of therapy). The mean percentage change in FEV1 at day
21 and day 51 (30 days after the cessation of treatment) was &gt; 3.5% with FEV1 returning to baseline at day 81 (60 days after
the cessation of therapy). At day 81 (60 days after the cessation of therapy) bacterial load was 65% lower than baseline. 1 of
9 patients saw culture conversion. This study was published in the Journal of Cystic Fibrosis in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed a second pilot study in bronchiolitis in 6 centers in Israel. The prospective, randomized, double-blind, controlled
pilot study enroll 67 patients, aged 0-12 months, who were hospitalized due to bronchiolitis. The patients received either standard-of-care
(SoC) (typically oxygen and hydration) or SoC plus inhaled NO at a concentration of 160 ppm for 30 minutes 5 times per day for
up to 5 days. The primary endpoint of hospital length-of-stay (LOS) was met with a 23 hour reduction in hospital length of stay
demonstrated (p=0.085). Secondary endpoints of time required to achieve a clinical score of 5 or less on the modified Tal score
and time required to achieve oxygen saturation (SaO2) of 92% or greater showed improvement versus the standard-of-care. There
were no issues with NO2 or metHb and no SAEs were recorded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed a third pilot study in bronchiolitis in 8 centers in Israel. The prospective, randomized, double-blind, controlled
pilot study enrolled 89 patients, aged 0-12 months, who were hospitalized due to bronchiolitis. The patients were randomized 1:1:1
to receive either SoC (typically oxygen and hydration) or SoC plus inhaled NO at 85 ppm or SoC plus inhaled NO at 150 ppm for
40 minutes 4 times per day for up to 5 days. There were no SAEs related to NO therapy. Efficacy results are shown in the table
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form10-k_003.jpg" ALT="" STYLE="height: 241px; width: 626px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek regulatory approval for our current product candidates and, if approved, we expect they will be marketed as medical
devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we reach the commercialization stage, we expect that we will collaborate with companies outside the U.S. for all indications.
We are still determining whether to attempt to collaborate for any indication in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Pre-Clinical Results to Date</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have completed 4 separate studies in animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rats</B>:
    30 days of intermittent treatments with LungFit&trade; at 400 ppm NO showed no observations (differences) between control
    rats and treated rats on observation during the treatment period prior to sacrifice and no observations on histopathology
    </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rats</B>:
    12 weeks of intermittent treatments with LungFit&trade; at 250 ppm NO showed no observations (differences) between control
    rats and treated rats on observation during the treatment period prior to sacrifice and no observations on histopathology
    </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dogs</B>:
    12 weeks of intermittent treatments with LungFit&trade; at 250 ppm NO showed no observations (differences) between control
    rats and treated rats on observation during the treatment period prior to sacrifice and no observations on histopathology</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rats:
    </B>Geno toxicology study of intermittent NO at 200 &ndash; 400 ppm showed a <B>non-genotoxic</B> response at all concentrations</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Competition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology, pharmaceutical and medical device industries are highly competitive. There are many pharmaceutical companies, biotechnology
companies, medical device companies, public and private universities and research organizations actively engaged in the research
and development of products that may be similar to our product candidates. We are aware of several companies currently developing
and selling NO therapies for various indications such as pulmonary hypertension. For example, Mallinkrodt commercializes INOMAX&reg;
(nitric oxide) for inhalation, which is approved for use to treat newborns suffering from HRF-PPHN, in the U.S., Canada, Australia,
Mexico and Japan. Praxair markets a generic version of the Mallinkrodt offering with their delivery system called NOxBOX&reg;,
acquired from Bedfont, in the United States. The Linde Group has marketing rights to INOMAX&reg; in Europe. Air Liquide sells
a similar product in Europe, called VasoKINOX&trade;, together with their delivery platform called OptiKINOX&trade;, for the treatment
of pulmonary hypertension that occurs during or after heart surgery. In Europe, Bedfont Scientific Ltd. has a delivery system
called NOxBOX&reg; and Air Products PLC has a gas product called NOXAP&reg;, each used in delivering inhaled NO formulations.
Bellepheron Therapeutics is developing NO-based products for pulmonary arterial hypertension and pulmonary hypertension associated
with chronic obstructive pulmonary disease. Geno LLC is developing NO-based products for the treatment of a variety of pulmonary
and cardiac diseases such as acute vasoreactivity testing, pulmonary arterial hypertension and pulmonary hypertension associated
with idiopathic pulmonary fibrosis. In addition, other companies may be developing generic NO formulation delivery systems for
various dosages. Ceretec, Inc., a company affiliated with 12th Man Technologies Inc., recently obtained clearance from the FDA
to market a NO gas product for use in membrane diffusing capacity testing in pulmonary function laboratories in the U.S. Novoteris,
LLC previously received orphan drug designation from the FDA and the European Medicines Agency (&ldquo;EMA&rdquo;) for the use
of inhaled NO-based treatments in treating CF. If the FDA approves Novoteris&rsquo; product candidate for the indication for which
it received orphan drug designation, then Novoteris will be eligible for orphan drug exclusivity if its product receives approval
first, which would have no effect on our product given we are a medical device. In January 2015, Ikaria entered into an agreement
with Novoteris to collaborate on the development of an outpatient program for treating bacterial infections associated with CF.
Recently, we have become aware that each of Ikaria and Novoteris is conducting a Phase 2 clinical trial using a 160 ppm NO formulation
to treat patients with CF. Moreover, Novoteris is also conducting a Phase 2 study in NTM <I>Abscessus</I> in Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors, either alone or through their strategic partners, might have substantially greater name recognition and financial,
technical, manufacturing, marketing and human resources than we do and greater experience and infrastructure in the research and
clinical development of pharmaceutical products, obtaining FDA and other regulatory approvals of those products and commercializing
those products around the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have contracted with a third-party contract manufacturer, Sparton Corporation, who has completed a substantial portion of the
commercial manufacturing process for our generator based NO delivery system. We will be reliant on our partner for commercial
manufacture of our systems for both clinical studies and commercial supply, if regulatory approval is received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have exclusively licensed patents, pending patent applications, know how and trade secrets that relate to our NO generator,
NO2 filtration, delivery systems, devices configured for delivering NO to patients by inhalation, methods of exposing patients
to inhalation of NO, and methods for treating subjects in need of NO inhalation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, we are party to a global, exclusive, transferable license agreement with NitricGen, Inc. for the eNOGenerator, its
components, and all associated patents and know how related thereto. Additionally, we have a broad intellectual property portfolio
directed to our product candidates and mode of delivery, monitoring parameters and methods of treating specific disease indications.
Our intellectual property portfolio consists of issued patents and pending applications, which includes patents we acquired pursuant
to the exercise of an option in 2017 granted to us by Pulmonox Technologies Corporation (&ldquo;Pulmonox&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CareFusion
Non-Exclusive License Agreement. In October 2013, we entered into a non-exclusive worldwide license agreement with CareFusion,
whereby we licensed seven issued U.S. patents and corresponding foreign counterparts. Our intellectual property licensed from
CareFusion, for which the earliest expiring patent term is 2019 and the last to expire is 2025. The term of the agreement extends
through the life of the patents and may be terminated by either party with 60 days&rsquo; prior written notice in the event of
a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days&rsquo; prior written notice in the event
that we do not meet certain milestones. Pursuant to the agreement, we are required to pay CareFusion royalty payments of 5% of
the net sales of a licensed product by the Company and an annual fee of $50,000, which is creditable against the royalty payments
for the respective year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pulmonox
Patents and Assets - Option to Acquire</I>. On August 31, 2015, we entered into an agreement with Pulmonox whereby we acquired
the option, referred to as the Option, to purchase certain intellectual property assets, including Pulmonox&rsquo;s rights in
17 issued U.S. patents, including eight patents jointly owned with CareFusion which are directed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">devices
    and methods for delivering NO formulations to a patient at steady and alternating concentrations (80-400 ppm), including intermittent
    delivery of NO;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    device and methods for treatment of surface infections; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
    of NO as a mucolytic agent and for treatment and disinfection of biofilms.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
exercised the Option in January 2017, acquired Pulmonox&rsquo;s rights in the patents described above. Upon exercise of the Option,
we became obligated to make certain one-time development and sales milestone payments to Pulmonox, commencing with the date on
which we receive regulatory approval for the commercial sale of the first product candidate qualifying under the agreement. These
milestone payments are almost entirely sales related and are capped at a total of $87 million across three separate and distinct
indications that fall under the agreement with the majority of them, approximately $83 million, being sales related based on cumulative
sales milestones for each of the three products. In addition, the Company issued a fully vested warrant to purchase up to 178,570
common stock of the Company at an exercise price of $4.80 per share for each share of common stock. On May 10, 2018, the Company
issued to the same third-party additional fully vested warrants to purchase up to 29,763 common stock of the Company at an exercise
price of $4.80 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patent
Applications</I>. We have filed over 20 US and foreign patents and patent applications, PCT patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
PCT patent application is a filing under the Patent Cooperation Treaty to which the U.S. and a number of other countries are a
party. It provides a unified procedure for filing a single patent application to protect inventions in those countries. A search
with respect to the application is conducted by the International Searching Authority, accompanied by a written opinion regarding
the patentability of the invention. A PCT application does not itself result in the grant of a patent, and the grant of patent
is a prerogative of each national or regional authority where the PCT application is filed during national phase filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Government
Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>U.S.
Regulation.</I> In the U.S., the FDA regulates drug and medical device products under the Federal Food, Drug, and Cosmetic Act
(&ldquo;FFDCA&rdquo;), and its implementing regulations. Our products have been designated as devices by the FDA and will be regulated
by the Center for Devices and Radiological Health (CDRH). Given that currently approved NO products and delivery systems were
approved in the Unites States as drug-device combinations, we expect our device to not only be reviewed by CDRH, but also have
input from the Center for Drug Evaluation and research (CDER).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other things, we will have to demonstrate compliance with applicable QSRs, to ensure that the device is in compliance with applicable
performance standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Drug Designation and Exclusivity.</I> Under the Orphan Drug Act, the FDA may grant orphan drug designation to products that are
intended to treat rare diseases or conditions (i.e., those affecting fewer than 200,000 patients in the U.S.). Although orphan
drug designation does not convey any advantage in the regulatory review and approval process, it can provide certain tax benefits
and access to grants. Additionally, FDA user fees, which can be substantial, are waived for products that obtain orphan drug designation.
Further, if a product with orphan drug designation subsequently receives FDA approval for the designated disease or condition,
the product is entitled to orphan product exclusivity, which (with certain limited exceptions) blocks for seven years FDA approval
of another product with the same active ingredient for the same indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval
or Clearance of Medical Devices.</I> To varying degrees, each of the regulatory agencies having oversight over medical devices,
including the FDA and comparable foreign regulators, has laws and regulations governing the development, testing, manufacturing,
labeling, marketing and distribution of medical devices. In the U.S., medical device products are subject to regulation that is
intended to ensure that the device is either safe and effective or is substantially equivalent to a previously marketed device.
Medical devices are classified into one of three classes based on the level of control necessary to assure the safety and effectiveness
of the device. The three classes and the requirements that apply to them are: (i) Class I General Controls, with exemptions and
without exemptions, (ii) Class II General Controls and Special Controls, with exemptions and without exemptions and (iii) Class
III General Controls and Premarket Marketing authorization. The class to which a device is assigned determines the process that
applies for gaining marketing authorization. Most Class I devices are exempt from Premarket Notification 510(k); most Class II
devices require Premarket Notification clearance under section 510(k) of the Food, Drug, and Cosmetic Act; and most Class III
devices require Premarket Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
brief summary overview of the three classifications is set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exempt
Class I Medical Device:</I> Prior to marketing an exempt Class I medical device, the manufacturer must register its establishment,
list the generic category or classification name of the medical device being marketed and pay a registration fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>510(k)
Clearance Process:</I> A Class II medical device normally requires FDA clearance in the U.S. pursuant to the 510(k) clearance
process. The 510(k) clearance process is available to medical device developers that can demonstrate that their device is substantially
equivalent to a legally marketed medical device. In this process, the developer would be required to submit data that supports
the equivalence claim and wait for an order from the FDA finding substantial equivalence to another legally marketed medical device
before distributing the device for commercial sale. Modifications to cleared medical devices can be made without using the 510(k)
process if the changes do not significantly affect safety or effectiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Premarket
Approval:</I> A more rigorous and time-consuming process applicable to Class III medical devices, known as pre-market approval
(&ldquo;PMA&rdquo;) which would require the developer to independently demonstrate that a medical device is safe and effective.
This is done by submitting data regarding design, materials, bench and animal testing and human clinical data for the medical
device. The FDA will authorize commercial release of a Class III medical device if it determines there is reasonable assurance
that the medical device is safe and effective. This determination is based on benefit outweighing risk for the population intended
to be treated with the device. This process is much more detailed, time-consuming and expensive than the 510(k) clearance process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basic design of our delivery system will be similar to those functions used in current predicate devices. However, our therapy
requires the administration of a higher concentration of NO than is currently approved by the FDA. Therefore, the FDA could reject
a Class II-510(k) and declare it not substantially equivalent to a legally marketed device, and set it on the regulatory path
of Class III-PMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continuing
Regulation of Approved or Cleared Drugs and Medical Devices.</I> Products manufactured or distributed pursuant to FDA approval
or clearance are subject to continuing regulation by the FDA, including requirements for ongoing recordkeeping, annual product
quality review, annual reporting, post-market surveillance requirements, post-market study commitments, drug adverse experience
reporting in a timely fashion, maintenance of pharmacovigilance program to proactively monitor for adverse events and medical
device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have
caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death
or serious injury if the malfunction of the device or a similar device were to recur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quality
System Regulation.</I> Companies engaged in the manufacture of medical devices or their components are required to register their
establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain
state agencies for compliance with ongoing regulatory requirements. Medical devices must comply with QSR requirements. These requirements
impose certain procedural and documentation requirements upon us and our third-party manufacturers related to the methods used
in and the facilities and controls used for designing, manufacturing, packaging, labeling, storing, medical devices. Following
these inspections, the FDA may assert noncompliance with QSR requirements on a Form 483, which is a report of observations from
an inspection, or by way of &ldquo;untitled letters&rdquo; or &ldquo;warning letters&rdquo; that could cause us or any third-party
manufacturers to modify certain activities. A Form 483 notice, if issued at the conclusion of an FDA inspection, can list conditions
the FDA investigators believe may have violated QSR or other FDA requirements. We cannot be certain that we or our present or
any future third-party manufacturers or suppliers will be able to comply with QSR or other FDA regulatory requirements to the
agency&rsquo;s satisfaction. Failure to comply with these obligations may lead to possible legal or regulatory enforcement action
by the FDA, such as suspension of manufacturing, operating restrictions, seizure or recall of product, injunctive action, withdrawal
of approval or clearance, import detention, refusal or delay in approving or clearing new products or supplemental applications,
fines, civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advertising
and Promotion.</I> The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medical
devices, including standards and regulations for direct-to-consumer advertising, communications about unapproved uses, industry-
sponsored scientific and educational activities and promotional activities involving the internet. Devices may be marketed only
for the approved or cleared indications and in accordance with the provisions of the approved or cleared label.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers are permitted to prescribe approved devices for &ldquo;off-label&rdquo; uses&mdash;that is, uses not approved by the
FDA and therefore not described in the product&rsquo;s labeling. These off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate
the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&rsquo;
communications regarding off-label use. Thus, we may market our products, if approved by the FDA, only for their approved indications,
but under certain conditions may engage in non-promotional, balanced communication regarding off-label uses. Failure to comply
with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and a variety of sanctions,
which could harm our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Anti-Kickback,
False Claims Act and Other Laws.</I> In addition to the FDA&rsquo;s ongoing post-approval regulation of devices discussed above,
several other types of laws and regulations, subject to differing enforcement regimes, govern advertising and promotion. In recent
years, promotional activities regarding FDA-regulated products have come under intense scrutiny and have been the subject of enforcement
action brought by the Department of Justice and the Office of Inspector General of the Department of Health and Human Services,
as well as state authorities and even private individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
development affecting the healthcare industry is the increased use of the federal civil False Claims Act to impose liability on
any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for
payment by a federal healthcare program. In addition, many states have enacted false claim laws similar to the federal False Claims
Act. If certain conditions are met, the False Claims Act allows a private individual (typically a &ldquo;whistleblower&rdquo;)
to bring a civil action on behalf of the federal government and to share in any monetary recovery. Engaging in impermissible promotion
of our products for off-label uses can subject us to false claims litigation under federal and state statutes, which can lead
to civil money penalties, restitution, criminal fines and imprisonment and exclusion from participation in Medicare, Medicaid
and other federal and state health care programs In recent years, the number of suits brought by private individuals against pharmaceutical
and device companies for off-label promotion has increased dramatically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare
item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
to apply to arrangements between pharmaceutical or device manufacturers, on the one hand, and prescribers, purchasers and formulary
managers on the other. Violations are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from
participation in federal healthcare programs. Any sales or marketing practices that involve remuneration intended to induce prescribing,
purchases or recommendations may be subject to scrutiny under the Anti-Kickback statute. Many states have likewise adopted state
anti-kickback statutes and enforcement has been significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
host of other laws and regulations govern the advertising and promotion of devices. The federal Sunshine Law, which is part of
the Health Care Reform Law, each enacted in March 2010, imposes federal &ldquo;sunshine&rdquo; provisions, requiring annual reporting
of various types of payments to physicians and teaching hospitals. CMS published the first set of data about these financial relationships
on its website on September 30, 2014. Inaccurate or incomplete reports may be subject to enforcement. Like the federal Sunshine
Law, several states have existing laws that require manufacturers to report transfers of value to select healthcare providers
licensed within the state. Additionally, other laws such as the federal Lanham Act and similar state laws allow competitors and
others to initiate litigation relating to advertising claims. If the Company sells its device outside the United States, it must
comply with the Foreign Corrupt Practices Act (&ldquo;FCPA&rdquo;) and local laws of other countries. FCPA is a complex patchwork
of laws can change rapidly with relatively short notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Environmental
Laws.</I> Elements of our potential products may be classified as hazardous materials, subject to regulation by the Department
of Transportation, the International Air Transportation Association, the International Maritime Organization, the Environmental
Protection Agency and the Occupational Safety and Health Administration, which may impose various requirements pertaining to the
way we manufacture, transport, store, handle and dispose of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Canadian
Regulation. </I>In Canada, the Therapeutic Products Directorate of Health Canada (&ldquo;TPD&rdquo;) is the Canadian federal authority
that regulates pharmaceutical drugs and medical devices for human use. Prior to being given market authorization, a sponsor must
present substantive scientific evidence of a product&rsquo;s safety, efficacy and quality as required by the Food and Drugs Act
and other legislation and regulations. The requirements for the development and sale of pharmaceutical drugs in Canada are substantially
similar to those in the U.S., which are described above.</FONT></P>

<P STYLE="font: 8pt TimesNewRomanPSMT; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, prior to being given market authorization to sell a Class II, III or IV medical device in Canada, a manufacturer must
present and/or attest to substantive scientific evidence of a product&rsquo;s safety, efficacy and quality as required by the
Food and Drugs Act and the Medical Devices Regulations (&ldquo;Canada MDR&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Medical Devices Bureau (&ldquo;MDB&rdquo;) of the TPD applies the Canada MDR through a combination of pre-market review, post-approval
surveillance and quality systems in the manufacturing process. Medical devices are classified into one of four classes, where
Class I represents the lowest risk and Class IV represents the highest risk. In order to perform investigational testing in Canada
for a Class II, III or IV medical device, authorization for the testing must be granted by the MDB. A Medical Device License is
a pre-market requirement for a Class II, III and IV medical device, including for Class II, III or IV medical devices previously
authorized for sale for investigational testing now to be offered for general/commercial sale. A Medical Device License is issued
to the device manufacturer, provided the requirements of the Canada MDR are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Canada MDR requires that medical devices be manufactured under a certified quality management system that meets the criteria of
the international standard, ISO 13485 Medical devices &ndash; Quality management systems &ndash; Requirements for regulatory purposes.
The MDB currently recognizes the Medical Device Single Audit Program, a program designed to include compliance with the quality
management requirements of the Canada MDR.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>European
Regulation.</I> In order for our products to be marketed and sold in the EEA, we must obtain the required regulatory approvals
and comply with the extensive regulations regarding safety, manufacturing processes and quality requirements of the respective
countries. These regulations, including the requirements for approvals to market, and the various regulatory frameworks may differ.
In addition, there may be foreign regulatory barriers other than approval or clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Medicinal
Product Approval.</I> In the EEA, we expect our products to be regulated as a combination drug-delivery device product falling
within the scope of Directive 2001/83/EC, commonly known as the Community Code on medicinal products. Under this Directive, we
are required to obtain a marketing authorization for our products before they are placed on the market. Medicinal products must
be authorized in one of two ways, either through the decentralized procedure or mutual recognition procedure by the competent
authorities of the EEA Member States, or through the centralized procedure by the European Commission following a positive opinion
by the EMA. The authorization process is essentially the same irrespective of which route is used, and requires us to demonstrate
the quality, safety and efficacy of the NO delivered to the patient by our product. We are also required to demonstrate that the
drug delivery component of our products complies with the relevant Essential Requirements contained in Annex I to the Medical
Devices Directive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovative
medicinal products are authorized in the EEA on the basis of a full marketing authorization application that must contain the
results of pharmaceutical tests, pre-clinical tests and clinical trials conducted with the medicinal product for which marketing
authorization is sought, and demonstrating the product&rsquo;s quality, safety and efficacy. Once approved, an innovative medicinal
product is entitled to eight years of data exclusivity. During this period, no application for approval of a generic version of
the innovative product relying on data contained in the marketing authorization dossier for the innovative product may be submitted.
Innovative medicinal products are also entitled to ten years of market exclusivity. During this 10-year period, no generic medicinal
product can be placed on the EU market. The 10-year period of market exclusivity can be extended to a maximum of 11 years if,
during the first eight years of those ten years, the holder of the marketing authorization for the innovative product obtains
an authorization for one or more new therapeutic indications that are held to bring a significant clinical benefit in comparison
with existing therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
expiration of the data exclusivity period, an application for marketing authorization for a generic version of an approved innovative
medicinal product may be submitted. Such an application does not contain data demonstrating the proposed product&rsquo;s quality,
safety and efficacy, but instead relies on the data in the dossier for the related innovative product, and a demonstration that
the two products are the same and bioequivalent. If approved, the generic product may not be placed on the market until expiration
of the 10-year marketing exclusivity period for the innovative medicinal product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing application for a product that, although similar to an approved medicinal product does not qualify as a generic, may
also seek to rely to some degree on the data in the dossier for the approved product. As with a generic product, the application
may not be submitted until expiration of the data exclusivity period, and the product, if approved, may not be placed on the market
until expiration of the market exclusivity period. Such an application must also contain data specific to the proposed product,
however. The extent to which such a &ldquo;hybrid&rdquo; application requires new data is determined on a case-by-case basis by
the competent authorities, based on the differences between the innovative medicinal product and the medicinal product subject
to the hybrid application for marketing authorization. The purpose of the pre-clinical tests and clinical trials is to generate
additional data that complement the data relating to the innovative medicinal product and to demonstrate the quality, safety and
efficacy of the medicinal product for which authorization is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
a NO formulation is already authorized in the EEA for treating pulmonary hypertension, we expect to be able to seek marketing
authorization for our products under the &ldquo;hybrid&rdquo; approach described in the previous paragraph. We anticipate that
the hybrid application for marketing authorization will require the successful completion of limited studies confirming the quality,
safety and efficacy of the NO formulation delivered using our proprietary delivery technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continuing
Regulation.</I> As in the U.S., marketing authorization holders and manufacturers of medicinal products are subject to comprehensive
regulatory oversight by the EMA and/or the competent authorities of the EEA Member States. This oversight applies both before
and after grant of manufacturing and marketing authorizations. It includes control of compliance with EU GMP rules and pharmacovigilance
rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, the advertising and promotion of our products will also be subject to EEA Member States&rsquo; laws concerning promotion
of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices, as
well as other EEA Member State legislation that may apply to the advertising and promotion of medicinal products. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product&rsquo;s Summary of Product
Characteristics (&ldquo;SmPC&rdquo;), as approved by the competent authorities. The SmPC is the document that provides information
to physicians concerning the safe and effective use of the medicinal product. Promotion of a medicinal product that does not comply
with the SmPC is considered to constitute off-label promotion, which is prohibited. The applicable laws at the EU level and in
the individual EEA Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations
of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and
imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and
may also impose limitations on our promotional activities with health care professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactions
between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes
of conduct and physicians&rsquo; codes of professional conduct in the individual EEA Member States. The provision of benefits
or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use
of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery
laws of the EEA Members states, including the UK Bribery Act 2010. Payments made to physicians in certain EEA Member States must
be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the
physician&rsquo;s employer, his/her competent professional organization and/or the competent authorities of the individual EEA
Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable
in the EEA Member States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pricing
and Reimbursement.</I> Each EEA Member State is free to restrict the range of medicinal products for which their national health
insurance systems provide reimbursement and to control the prices and/or reimbursement levels of medicinal products for human
use. An EEA Member State may approve a specific price or level of reimbursement for the medicinal product, or alternatively adopt
a system of direct or indirect controls on the profitability of the company responsible for placing the medicinal product on the
market, including volume-based arrangements and reference pricing mechanisms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
technology assessment (&ldquo;HTA&rdquo;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some EEA Member States, particularly the United Kingdom, France, Germany and Sweden. The HTA process in each EEA
Member State is governed by the national laws of the country. HTA is the procedure according to which an assessment is conducted
of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the
national healthcare systems of the individual country. HTA generally focuses on the clinical efficacy and effectiveness, safety,
cost and cost-effectiveness of individual medicinal products, as well as their potential implications for the healthcare system.
Those elements of medicinal products are compared with other treatment options available on the market. The outcome of HTA regarding
specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the
competent authorities of individual EEA Member States. The extents to which pricing and reimbursement decisions are influenced
by the HTA of the specific medicinal product vary between EEA Member States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Data
Privacy Regulation.</I> The collection and use of personal health data in the EEA is governed by the provisions of the Data Protection
Directive. This Directive imposes a number of requirements relating to the consent of the individuals to whom the personal data
relates, the information provided to the individuals, notification of data processing obligations to the competent national data
protection authorities and the security and confidentiality of the personal data. The Data Protection Directive also imposes strict
rules on the transfer of personal data out of the EEA to the U.S. Failure to comply with the requirements of the Data Protection
Directive and the related national data protection laws of the EEA Member States may result in fines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Designation and Exclusivity.</I> In the European Union, the Committee for Medicinal Products for Human Use grants orphan drug
designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening
or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union Community and for
which no satisfactory method of diagnosis, prevention or treatment has been authorized (or the product would be a significant
benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention or treatment
of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that
sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers
and ten years of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if
the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable
not to justify maintenance of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey
any advantage in, or shorten the duration of, the regulatory review and approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exceptional
Circumstances/Conditional Approval.</I> Orphan medicinal product or products for unmet medical needs may be eligible for EU approval
under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable to orphan
products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions
of use because the indication for which the product is intended is encountered so rarely that the applicant cannot reasonably
be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive information
to be provided, or when it is medically unethical to collect such information. Conditional marketing authorization is applicable
to orphan medicinal products, medicinal products for seriously debilitating or life- threatening diseases or medicinal products
to be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted
on the basis of less complete data than is normally required in order to meet unmet medical needs and in the interest of public
health, provided the risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive
clinical data, and unmet medical needs will be fulfilled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditional
marketing authorization is subject to certain specific obligations to be reviewed annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Regulations.</I> We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances.
We may incur significant costs to comply with such laws and regulations now or in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regulation
in Israel.</I> In order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained
from the ethics committee and general manager of the institution in which the clinical studies are scheduled to be conducted,
as required under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations
(Clinical Trials in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require
authorization by the institutional ethics committee and general manager as well as from the Israeli Ministry of Health, except
in certain circumstances, and in the case of genetic trials, special fertility trials and complex clinical trials, an additional
authorization of the Ministry of Health&rsquo;s overseeing ethics committee. The institutional ethics committee must, among other
things, evaluate the anticipated benefits that are likely to be derived from the project to determine if it justifies the risks
and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection exists for the
rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical testing.
Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain
authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials,
and in most cases, from the Israeli Ministry of Health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Recent Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2019, we terminated our license agreement with Circassia Limited and its affiliates (collectively, &ldquo;Circassia&rdquo;)
pursuant to which we had granted Circassia an exclusive royalty-bearing license to distribute, market and sell our nitric oxide
generator and delivery system in the United States and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2020, we announced that we had submitted an Investigational Device Exemption (IDE) to the US Food and Drug Administration
(FDA for approval to study the use of our LungFit&trade; -BRO system in patients infected with COVID-19. An IDE approval from
the FDA is a necessary step before performing any clinical study with a medical device. The FDA typically responds within 30 days
of an IDE submission. On April 16, 2020, the FDA agreed with the initiation of a clinical study in the U.S. using our LungFit<SUP>TM
</SUP>system to treat COVID-19 patients. The LungFit<SUP>TM</SUP> will be used in an open-label study, to treat 20 patients between
the ages of 22 and 65 years hospitalized with COVID-19. Subjects will be randomized 1:1 and treated with 80 ppm NO administered
over 40 minutes, 4 times per day, in addition to standard of care (SOC) or treated with SOC alone. The primary endpoint is time
to clinical deterioration as measured by the need for: 1) non-invasive ventilation: or 2) high flow nasal cannula; or 3) intubation.
Other endpoints include reduction in viral load, need for supplemental oxygen, hospital length of stay, mortality, safety and
various biomarkers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2020, our wholly owned subsidiary Beyond Air Ireland Limited (&ldquo;BAL&rdquo;) entered into a facility agreement (the
&ldquo;Facility Agreement&rdquo;) with certain lenders pursuant to which the lenders shall loan to BAL up to $25,000,000 in five
tranches of $5,000,000 per tranche at the option of BAL (&ldquo;Tranches&rdquo;), provided however that BAL may only utilize tranches
three through five following FDA approval of our LungFit&trade; PH product. The loans bear interest at 10% per year and may be
prepaid with certain prepayment penalties. Each tranche shall be repaid in installments commencing June 15, 2023 with all amounts
outstanding under any tranche due on March 17, 2025. BAL borrowed the first tranche on March 17, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with BAL&rsquo;s utilization of the first tranche, on March 17, 2020 we issued to the lenders five-year warrants to
purchase up to 172,187 shares of common stock at an exercise price of $7.26 per share. The Company filed a Registration Statement
on Form S-3 (File No. 333-237958) to register for resale the shares issuable upon the exercise of the Warrants. The Registration
Statement was declared effective by the SEC on May 11, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2020 we entered into an At-The-Market Equity Offering Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with SunTrust
Robinson Humphrey, Inc. and Oppenheimer &amp; Co. (collectively, the &ldquo;Agents&rdquo;) under which we may offer and sell,
from time to time at its sole discretion, shares of our common stock having an aggregate offering price of up to $50,000,000 through
the Agents as our sales agent. The issuance and sale, if any, of common stock under the Sales Agreement was pursuant to our shelf
registration statement on Form S-3 (File No. 333-231416) declared effective by the SEC on July 2, 2019, the prospectus supplement
relating to the offering filed with the SEC on April 2, 2020, and any applicable additional prospectus supplements related to
the offering that form a part of the that registration statement. Subject to the terms and conditions of the Sales Agreement,
the Agents may sell the common stock by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined
in Rule 415(a)(4) of the Securities Act. The Agents will use commercially reasonable efforts to sell the common stock from time
to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions
we may impose). We will pay the Agents a commission equal to up to three percent (3%) of the gross sales proceeds of any common
stock sold through the Agents under the Sales Agreement, and also have provided the Agents with certain indemnification rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not obligated to make any sales of common stock under the Sales Agreement. The offering of shares of common stock pursuant
to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii)
termination of the Sales Agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2020, we entered into a Purchase Agreement (&ldquo;Purchase Agreement&rdquo;) with Lincoln Park Capital Fund
LLC (&ldquo;Lincoln Park&rdquo;), which provides that, upon the terms and subject to the conditions and limitations set forth
therein, we have the right to sell to Lincoln Park up to $40,000,000 of shares of our common stock at our discretion subject to
the terms and conditions of the Purchase Agreement. The issuance and sale of common stock under the Purchase Agreement was pursuant
to our shelf registration statement on Form S-3 (File No. 333-231416) declared effective by the SEC on July 2, 2019, the prospectus
supplement relating to the offering filed with the SEC on May 14, 2020, and any applicable additional prospectus supplements
related to the offering that form a part of the that registration statement. The offer and sale of up to $40,000,000 of shares
of our common stock consists of up to (i) 325,000 shares of our common stock that we may sell to Lincoln Park at any time within
30 days of the Commencement Date (as defined in the Purchase Agreement) as the initial purchase under the Purchase Agreement
and (ii) additional shares of our common stock with an aggregate offering price of up to $37,211,500, which we may sell from time
to time in our sole discretion to Lincoln Park over the next 36 months, subject to the conditions and limitations in the Purchase
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act enacted on April 5, 2012, referred
to as the JOBS Act. For as long as we are an emerging growth company, we may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not
limited to, not being required to comply with the auditor attestation requirements in the assessment of our internal control over
financial reporting, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding advisory &ldquo;say-on-pay&rdquo; and &ldquo;say-when-on-pay&rdquo; votes on executive
compensation and shareholder advisory votes on golden parachute compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the JOBS Act, we will remain an emerging growth company until the earliest of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
December 31, 2021;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the last day of the fiscal year during which we have total annual gross revenues of $1.07 billion or more;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the Securities Exchange Act of 1934, as amended,
referred to as the Exchange Act, (we would qualify as a large accelerated filer as of the first day of the first fiscal year after
we (i) have more than $700 million in aggregate market value of outstanding common equity held by our non-affiliates as of the
last day of our second fiscal quarter of our prior fiscal year and (ii) have been public for at least 12 months).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
JOBS Act also provides that an emerging growth company may utilize the extended transition period provided for complying with
new or revised accounting standards. We have irrevocably elected to take advantage of this extended transition period.
Because we will not be required to comply with new or revised accounting standards on the relevant dates on which adoption of
such standards is required for other public companies, our financial statements may not be comparable to the financial statements
of companies that comply with the effective dates of those accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Available
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file electronically with the Securities and Exchange Commission, or SEC, our annual report on Form 10-K, quarterly reports on
Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended.
We make available on our website at www.beyondair.net free of charge, copies of these reports, as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file
with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. The public may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains
reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The
address of that website is www.sec.gov. The information in or accessible through the SEC and our website are not incorporated
into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive
textual references only</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 19,  2020, we had 23 full-time employees. None of our employees are represented by a labor union and we consider
our employee relations to be good.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the
other information included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks occur,
our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.
In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or
that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Our Financial Position and Capital Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable
future. We are a clinical-stage company. We have no approved products and have generated no revenue to date and may never generate
revenue or achieve profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment
decision. These are not the only risks we face. These risks include, among others, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                         are a development-stage medical device and biopharmaceutical company and have a limited
                                         operating history on which to assess our business, have incurred significant losses since
                                         our inception, including a net loss attributed to common shareholders of $20.4
                                         million for the year ended March 31, 2020, and an accumulated deficit of approximately
                                         $57.6 million as of March 31, 2020, and anticipate that we will continue to incur
                                         significant losses for the foreseeable future;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are unable to predict the extent of future losses or when we will become profitable based on the sale of any product, if at
    all. Even if we succeed in developing and commercializing our product candidates, we may never generate revenue to sustain
    profitability;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    do not have an approved FDA product in the market, and we expect that we will need to raise additional funding before we can
    expect to become profitable from sales of our products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are heavily dependent upon the success of our product candidates, which are in various stages of clinical development, and
    we cannot provide any assurance that the FDA or other regulatory agencies will allow us to conduct further clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are in the process of developing our proprietary NO delivery system, and unexpected delays will adversely impact the timing
    of our U.S.-based clinical trials and approvals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    might be unable to develop product candidates that will achieve commercial success in a timely and cost-effective manner,
    or ever;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors may develop or commercialize products faster or more successfully than us;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">because
    some of the target patient populations of our product candidates are small, we must be able to successfully identify patients
    and achieve a significant market share to maintain profitability and growth;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to help conduct our pre-clinical studies, clinical trials and commercial scale manufacturing;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    do not have any products approved for sale by the FDA or any other regulatory agencies, and we cannot provide any assurance
    that any of our product candidates will receive regulatory approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we are unable to obtain and maintain effective intellectual property rights for our technologies, product candidates or any
    future product candidates, we may not be able to compete effectively in our markets; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future success depends in part upon our ability to retain our executive and scientific teams, and to attract, retain and motivate
    other qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is highly likely that we will need to raise additional capital to meet our business requirements in the future, and such capital
raising may be costly or difficult to obtain, and could dilute current stockholders&rsquo; ownership interests.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including the progress and results of our clinical trials, the timing
and outcome of regulatory review of our product candidates, commercial manufacturing success, the number and development requirements
of other product candidates that we pursue, and the costs of commercialization activities, including product marketing, sales,
and distribution. Because of the numerous risks and uncertainties associated with the development and commercialization of our
product candidates, we are unable to reasonably estimate the amounts of additional capital outlays and operating expenditures
that our business will require. It is likely that we will need to raise additional funds through public or private debt or equity
financings to meet various objectives including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trials for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">researching
    and developing new products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursuing
    growth opportunities, including more rapid expansion;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquiring
    complementary businesses or technologies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    capital improvements to improve our infrastructure;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring
    qualified management and key employees;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">responding
    to competitive pressures;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying
    with regulatory requirements; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    compliance with applicable laws.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional capital raised through the sale of equity or equity-linked securities may dilute our current stockholders&rsquo; ownership
in us and could also result in a decrease in the market price of our common stock. The terms of those securities issued
by us in future capital transactions may be more favorable to new investors and may include preferences, superior voting rights
and the issuance of warrants or other derivative securities, which may have a further dilutive effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
any debt or equity financing that we may need may not be available on terms favorable to us, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting
fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize
non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely
impact our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business,
and we may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to the Discovery and Development of Our Product Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. We cannot
give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be
commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have invested substantially all of our efforts and financial resources to design and develop our product candidates,
including conducting clinical studies and providing general and administrative support for these operations. Our future success
is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize one or
more product candidates. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize
a marketable product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
of our product candidates are in the early stages of development and will require additional clinical development (and in some
cases additional preclinical development), management of nonclinical, clinical and manufacturing activities, regulatory approval,
obtaining adequate manufacturing supply, building of a commercial organization and significant marketing efforts before we generate
any revenue from product sales. To date, we have conducted a pilot clinical trial involving 43 patients with bronchiolitis (mainly
caused by RSV) and a pilot clinical trial in nine patients with CF. In addition, Rambam healthcare campus in Israel conducted
a compassionate treatment for two patients with CF who suffer from NTM infections (specifically M. Abscessus). All of these studies
were conducted outside the U.S. and were not conducted pursuant to an FDA IND. The results of these three studies showed improvements
in various endpoints and clinical outcomes. The trials were small, however, and it is likely that the FDA will view them as not
significant because of their size and scope. In addition, the delivery systems were different from the one that we intend to test
and market, subject to FDA approval, in the U.S., further reducing the likelihood that FDA would view these test results as adequate
or sufficient to support marketing applications. We therefore intend to conduct larger clinical trials aiming for statistically
and clinically significant favorable results, or we will not be able to obtain regulatory approval to market our product candidates.
It may be years before a pivotal study is initiated, if at all. Before a medical device clinical trial can be undertaken in the
U.S., the sponsor of the trial must submit an IDE application for a medical device and the FDA must permit the trial to go forward.
We cannot assure that we will obtain such agency acquiescence in a timely manner, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot be sure that we will be successful in completing the development of our NO Delivery System to the satisfaction
of the FDA, which could lead to material delays in our ability to commence U.S.-based clinical trials, if at all. We are not permitted
to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory
authorities, and we may never receive such regulatory approval for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
as a company have never submitted marketing applications for approval of our product candidates to the FDA or comparable foreign
regulatory authorities; although in 2014 the FDA granted the Company orphan drug designation for the use of NO in the treatment
of CF and in 2015, the EU also granted the Company orphan drug designation for the use of NO in the treatment of CF. We are no
longer pursuing the drug regulatory pathway so the orphan drug designation may have no application. We cannot be certain that
any of our product candidates will be successful in clinical studies or receive regulatory approval. Further, our product candidates
may not receive regulatory approval even if they are successful in clinical studies. If we do not receive regulatory approvals
for our product candidates, we may not be able to continue our operations. Even if we do receive FDA approval for our drug, the
indications for which we are initially seeking approval are very narrow and this, as a result, may limit their commercial viability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally plan to seek regulatory approval to commercialize our product candidates in the U.S., the EU and in additional foreign
countries. To obtain regulatory approvals we must comply with the numerous and varying regulatory requirements of such countries
regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing and distribution
of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will
obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions,
our revenue and results of operations would be negatively affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following
the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations or the type
and amount of clinical data necessary to gain approval may change during the course of a product candidate&rsquo;s clinical development
and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have
not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or
any product candidates we may seek to develop in the future will ever obtain regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a new medical device may be marketed in the U.S. generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of or reference to extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with
    the FDA&rsquo;s Good Laboratory Practice (&ldquo;GLP&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a pre-IDE application, which the FDA authorizes before we may begin conducting human clinical trials, provided
    that the FDA does not object; the IDE must be updated annually;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials to establish the safety and efficacy of the medical device candidate
    for each proposed indication; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a 510(k) or PMA, after completion of all pivotal clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IDE application is a request for authorization from the FDA to administer an investigational medical device to humans. We currently
do not have any IDEs in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the medical device to human subjects under the supervision of qualified investigators in
accordance with current Good Clinical Practices (&ldquo;cGCPs&rdquo;) which include the requirement that all research subjects
provide their informed consent for participation in any clinical trial. A protocol for each clinical trial and any subsequent
protocol amendments must be submitted to the FDA as part of the IDE. Additionally, approval must also be obtained from each clinical
trial site&rsquo;s Institutional Review Board (&ldquo;IRB&rdquo;) before the trials may be initiated, and the IRB must monitor
the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting
of ongoing clinical trials and clinical trial results to public registries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials for medical devices are usually conducted in two phases. Pilot clinical trials are normally conducted in small groups of
patients to assess safety, find the optimal dosing range and assess potential efficacy. After a successful pilot study or studies,
the device is administered to a population of patients large enough to meet the requirements for regulatory approval. This size
of trial is usually multi-center, controlled and potentially double-blind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our product
candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials
are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring
board or committee, or DSMB. This group reviews unblinded data from clinical trials and provides authorization for whether a trial
may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a
clinical trial based on evolving business objectives or competitive climates. Assuming successful completion of all required testing
in accordance with all applicable regulatory requirements, detailed investigational medical device information is submitted to
the FDA in the form of an PMA requesting approval to market the product for one or more indications. The application includes
all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as
positive findings, together with detailed information relating to the product&rsquo;s chemistry, manufacturing, controls and proposed
labeling, among other things.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the PMA submission has been accepted for filing, the FDA&rsquo;s goal is to review applications within ten months of filing. However,
the review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer
the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved.
The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IDE is a request for authorization from the FDA to administer an investigational medical device to humans. We currently do not
have any IDEs in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications
for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&rsquo;s risk-benefit
    ratio for its proposed indication is acceptable;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may determine that the population studied in the clinical program was not sufficiently broad or representative to assure
    safety in the full population for which we seek approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or
    clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical studies of our product candidates may not be sufficient to support the submission of a PMA in
    the U.S. or elsewhere;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications
    or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
    rendering our clinical data insufficient for approval; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain
regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Medical
device development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not
be predictive of future study results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may
not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage
clinical studies may still suffer significant setbacks in subsequent advanced clinical studies. There is a high failure rate for
medical devices proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show
the desired safety and efficacy traits despite having progressed satisfactorily through preclinical studies and initial clinical
studies. A number of companies in the medical device and biopharmaceutical industry have suffered significant setbacks in advanced
clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover,
preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any pivotal
studies we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to
market our product candidates. Nor do we know whether the FDA will permit us to proceed directly to pivotal trials without performing
pilot trials in the U.S. using the same delivery system that we will seek approval by the agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are working on NTM Abscessus which is very rare.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
<I>Abscessus</I> is a very rare disease and only a small number of people suffer from this condition. As a result of these small
numbers, we may not be able to complete the study related to NTM <I>Abscessus</I> or, even if approved, the device for that indication
may never be profitable. In addition, there are many strains of NTM but our study is only on one of them, <I>Abscessus</I>. Therefore,
we may face a situation that this strain will disappear or there will be no candidates with this strain, so the FDA may not grant
us approval to treat other NTM strains without further validation and trials, or possibly ever, and/or the FDA may not allow us
to work on NTM in patients who do not have CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are working on bronchiolitis in infants that usually is caused by the RSV virus.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSV
is a seasonal virus (only in the winter). In our trial, we are heavily dependent on the occurrence and the severity of this virus.
Treating for RSV is highly reliant on the weather conditions in winter. The weather in the winter is not predictable. For example,
if the winter is warm or short, or the RSV infection was not severe enough when we conducted our trial, or the length of stay
in the hospital at the year that trial was conducted was different from previous seasons, then we might miss the season or the
results can be significantly different between two seasons or between different countries or even between different sites.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are working on PPHN which is a highly competitive market and regulatory approval may not be easily obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
NO Delivery System has not yet been manufactured for use with a ventilator and this process has significant risks. Additionally,
a delivery system with a generator of NO has never been approved anywhere in the world and this may cause significant delays in
the approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may find it difficult to enroll patients in our clinical studies. Difficulty in enrolling patients could delay or prevent clinical
studies of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of
our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the conditions for which we plan to evaluate our current product candidates are for rare diseases. For example, we estimate
that 5,000 patients suffer from NTM <I>abscessus</I> in the U.S. Accordingly, there is a limited patient pool from which to draw
for clinical studies. Further, the eligibility criteria of our clinical studies will further limit the pool of available study
participants as we will require that patients have specific characteristics that we can measure or to assure their disease is
either severe enough or not too advanced to include them in a study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number
of patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study,
particularly the toxicity of NO in certain doses, the availability and efficacy of competing therapies and clinical studies, the
proximity and availability of clinical study sites for prospective patients and the patient referral practices of physicians.
If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies
and obtaining regulatory approval of potential products will be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion or termination of any clinical study of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could
be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs, slow down our product
candidate development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction
of applicable regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical
studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time consuming
and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule,
if at all. Our clinical studies involve infants, children, and adults and, before we are permitted to enroll them in clinical
trials, we must demonstrate that although the research may pose a risk to the subjects, there is a prospect of direct benefit
to each patient. We must do so to the satisfaction of each research site&rsquo;s IRB. If we fail to adequately demonstrate this
to the satisfaction of the relevant IRB, it will decline to approve the research, which could have significant adverse consequences
for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful.
Events that may prevent successful or timely completion of clinical development include but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of human clinical
    studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory agencies on study design;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organizations (&ldquo;CROs&rdquo;) and clinical
    study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and
    clinical study sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required IRB approval at each clinical study site;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory agencies, after review of an IDE application, or equivalent application, or an inspection
    of our clinical study operations or study sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in recruiting suitable patients to participate in our clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    collaborating with patient groups and investigators;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CROs, other third parties or us to adhere to clinical study requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&rsquo;s GPC requirements, or applicable regulatory guidelines in other countries;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients complete participation in a study or return for post-treatment follow-up;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    dropping out of a study;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical studies of our product candidates being greater than we anticipate;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    studies of our product candidates producing negative or inconclusive results, which may result in us deciding, or regulators
    requiring us, to conduct additional clinical studies or abandon product development programs; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates
    for use in clinical studies or the inability to do any of the foregoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenue. We may also be required to conduct additional safety, efficacy and comparability studies before we will be
allowed to start clinical studies. Clinical study delays could also shorten any periods during which our products have patent
protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully
commercialize our product candidates and may harm our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval,
if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies
and could result in a more restrictive marketing label or the delay or denial of regulatory approval by the FDA or other comparable
foreign authorities. There is currently limited data regarding possible side effects for an antimicrobial dosage of NO treatments,
such as our product candidates. Potential side effects of NO treatments may include high methemoglobin, nitrogen dioxide (&ldquo;NO<SUB>2</SUB>&rdquo;)
toxicity, nose bleeding and low blood pressure. Results of our studies may identify unacceptable severity and prevalence of these
or other side effects. In such an event, our studies could be suspended or terminated, and the FDA or comparable foreign regulatory
authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted
indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO-related
side effects could affect patient recruitment, the ability of enrolled patients to complete the study or result in potential product
liability claims</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw approvals of such product;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    a condition of approval, we may be required to create a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) plan,
    which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication
    plan for healthcare providers and/or other elements to assure safe use;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for our product candidates, we will still face extensive, ongoing regulatory requirements and
review, and our products may face future development and regulatory difficulties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for one or more of our product candidates in the U.S., the FDA may still impose significant restrictions
on the indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval
studies, including post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a
company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss
of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product.
For example, the labeling for our product candidates, if approved, may include restrictions on use or warnings. The Food and Drug
Administration Amendments Act of 2007 (&ldquo;FDAAA&rdquo;) gives the FDA enhanced post-market authority, including the explicit
authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance
with FDA-approved REMS programs. If approved, our product candidates will also be subject to ongoing FDA requirements governing
the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and
reporting of safety and other post-market information. The FDA&rsquo;s exercise of its authority could result in delays or increased
costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval
regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar
authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by
regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely
affect sales of our product candidates once approved, and potentially our other marketed products. Further, the discovery of significant
problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products
could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect
demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product
withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies,
professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or
recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines
or recommendations may lead to lower sales of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of an approved PMA or cleared 510(k) also is subject to obligations to monitor and report adverse events and instances
of the failure of a product to meet the specifications in the marketing application. Application holders must submit new or supplemental
applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process.
Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials.
Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of FDA regulated products and their facilities are subject to continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with the FDA&rsquo;s cGMPs regulations. If we or a regulatory agency
discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems
with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing
facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring
new warnings or other labeling changes to limit use of the product, requiring that we conduct additional clinical trials, imposing
new monitoring requirements, or requiring that we establish a REMS program for our approved products. Advertising and promotional
materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product
samples to physicians must comply with the requirements of the Prescription Drug Marketing Act. Sales, marketing, and scientific/educational
grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, and similar
state laws. We would also be required under the Sunshine provision of the Affordable Care Act (&ldquo;ACA&rdquo;) to report annually
to the Centers for Medicare &amp; Medicaid Services on payments that we make to physicians and teaching hospitals and ownerships
interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of
the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized
users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional
laws and requirements apply. Our activities are also potentially subject to federal and state consumer protection and unfair competition
laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take
any of the following actions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    an investigation into our practices and any alleged violation of law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters or untitled letters asserting that we are in violation of the law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose civil or criminal penalties or monetary fines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    that we suspend or terminate any ongoing clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to applications filed by us;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or impose restrictions on operations, including costly new manufacturing requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclude
    us from providing our products to those participating in government health care programs, such as Medicare and Medicaid, and
    refuse to allow us to enter into supply contracts, including government contracts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly
inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign
jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not
be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and
clinical programs. We rely on these parties for execution of our preclinical and clinical studies, and we directly control only
certain aspects of their activities, although from a regulatory perspective we are responsible for their actions. We are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific
standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors
are required to comply with Good Clinical Practice (&ldquo;GCP&rdquo;), QSR and GLP, which are regulations and guidelines enforced
by the FDA, the Competent Authorities of the Member States of the European Economic Area (&ldquo;EEA&rdquo;), and comparable foreign
regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations
through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we or any of our
CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may be deemed
unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical studies
before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical studies comply with GCP regulations. In addition, our clinical studies must
be conducted with products that are produced under QSR regulations. Our failure to comply with these regulations may require us
to repeat clinical studies, which would delay the regulatory approval process, or have other adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative
CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available
to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going
clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical studies may
be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our
product candidates. CROs may also generate higher costs than anticipated. As a consequence, our results of operations and the
commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue
could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switching
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays may occur, which could materially impact our ability to meet our desired
clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we
will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will rely on third parties to manufacture our NO generator and delivery system. Our business could be harmed if those third parties
fail to provide us with sufficient quantities of our needed supplies, or fail to do so at acceptable quality levels or prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have the infrastructure or capability internally to manufacture the components of our NO generator and delivery
system, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial
scale. We plan to rely on third parties for such supplies. There are a limited number of manufacturers who have the ability to
produce our delivery system, and there may be a need to identify alternate manufacturers to prevent a possible disruption of our
clinical studies. Any significant delay or discontinuity in the supply of these components could considerably delay completion
of our clinical studies, product testing and potential regulatory approval of our product candidates, which could harm our business
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product
candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
entities involved in the preparation of medical devices for clinical studies or commercial sale, including our existing contract
manufacturers for our product candidates, are subject to extensive regulation. Components of a finished medical device product
approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with QSR. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems
to control and assure the quality of investigational products and products approved for sale. Poor control of production processes
can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates
that may not be detectable in final product testing. We, our collaborators or our contract manufacturers must supply all necessary
documentation in support of any marketing application on a timely basis and must adhere to GLP and QSR regulations enforced by
the FDA and other regulatory agencies through their facilities inspection program. The facilities and quality systems of some
or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable
regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition,
the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product
candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to
the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection,
regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the
satisfaction of the regulatory authority, if ever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our
collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations
or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we
or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third
party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales, or the
temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract
could materially harm our business. If we, our collaborators, or any of our third-party manufacturers fail to maintain regulatory
compliance, the FDA or other applicable regulatory authorities can impose regulatory sanctions including, among other things,
refuse to approve a pending application for a new drug product, withdrawal of an approval, suspend production, suspend clinical
studies, require a recall or suspension of production. As a result, our business, financial condition and results of operations
may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an PMA
or Marketing Authorization Application amendment, or equivalent foreign regulatory filing, which could result in further delay.
The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions,
required approvals or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements
and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical
studies may be delayed or we could lose potential revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or disclosed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them.
We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically
limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual
provisions employed when working with third parties, the need to share trade secrets and other confidential information increases
the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others,
or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how
and trade secrets, a competitor&rsquo;s discovery of our trade secrets or other unauthorized use or disclosure would impair our
competitive position and may have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Commercialization of Our Product Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected,
and our business may suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
projections of both the number of people who have our target diseases, as well as the subset of people with these diseases who
have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates
have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market
research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases.
The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat
is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally,
the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment
with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely
affect our results of operations and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
intend to rely on third-party manufacturers to produce our product candidates, but we have not entered into binding agreements
with any such manufacturers to support commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet secured manufacturing capabilities for commercial quantities of our product candidates. We intend to rely on third-party
manufacturers for commercialization. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization
activities on commercially reasonable terms, or at all. See <I>&ldquo;Risk Related to our Reliance on Third Parties&mdash;We and
our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates.
The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face intense competition and rapid technological change and the possibility that our competitors may discover, develop or commercialize
therapies that are similar, more advanced or more effective than ours, which may adversely affect our financial condition and
our ability to successfully commercialize our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device, biotechnology and pharmaceutical industries are highly competitive. There are many medical device companies, pharmaceutical
companies, biotechnology companies, public and private universities and research organizations actively engaged in the research
and development of products that may be similar to our products. We are aware of several companies currently developing and/or
selling NO therapies for various indications such as PPHN. For example, Mallinckrodt commercializes INOMAX&reg; (nitric oxide)
for inhalation, which is approved for use to treat newborns suffering from HRF-PPHN, in the U.S., Canada, Australia, Mexico and
Japan. The Linde Group has marketing rights to INOMAX&reg; in Europe. Air Liquide sells a similar product in Europe, called VasoKINOX&trade;,
together with their delivery platform called OptiKINOX&trade;, for the treatment of pulmonary hypertension that occurs during
or after heart surgery. In Europe, Bedfont Scientific Ltd. has a delivery system called NOxBOX&reg; and Air Products PLC has a
gas product called NOXAP&reg;, each used in delivering inhaled NO formulations. Bellepheron Therapeutics is developing NO-based
products for persistent arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease.
Vero Biotech has received US approval of a generic version to INOMAX using their GENOSYL delivery system. In addition, other companies
may be developing generic NO formulation delivery systems for various dosages. Ceretec, Inc., a company affiliated with 12th Man
Technologies Inc., recently obtained clearance from the FDA to market a NO gas product for use in membrane diffusing capacity
testing in pulmonary function laboratories in the U.S. Novoteris, LLC previously received orphan drug designation from the FDA
and EMA for the use of inhaled NO-based treatments in treating CF. In January 2015, Mallinckrodt entered into an agreement with
Novoteris to collaborate on the development of an outpatient program for treating bacterial infections associated with CF. Recently,
we have become aware that Mallinckrodt and Novoteris are running a Phase 2 clinical trial using a 160 ppm NO formulation to treat
patients with CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to NO treatments currently available or under development, we also face competition from non-NO-based drugs and therapies.
For example, the successful development of immunizations for bronchiolitis may render useless any product we develop for that
indication. Also, antibiotic treatments for infections associated with CF, and inhaled short-acting beta-2 agonist and oral corticosteroids
for the treatment of asthma may be preferred over any product that we develop. Even if we successfully develop our product candidates,
and obtain approval for them, other treatments may be preferred and we may not be successful in commercializing our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technical and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies
may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products
as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large, established companies. Competition may increase further as a result of advances in the commercial applicability of
technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing,
acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that
we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than
we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into
agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our employees may have sold other similar products in the past while employed at other companies, we as a company have no experience
selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize
any products that may result from our development programs, we will need to develop these capabilities, either on our own or with
others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization with
technical expertise and supporting distribution capabilities to commercialize our product candidates in major markets, which will
be expensive, difficult and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
given our lack of prior experience in marketing and selling medical device products, our initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our
product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization
of our product candidates or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect
to certain geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution
capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do
not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing
capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing
with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support
of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our product
candidates will depend in part on the medical community, patients and third-party payors accepting our product candidates as medically
useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients,
third-party payors and others in the medical community. The degree of market acceptance of any of our product candidates, if approved
for commercial sale, will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    safety and efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects, including any limitations or warnings contained in a product&rsquo;s approved
    labeling;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which approval is granted;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment, particularly in relation to competing treatments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of marketing and distribution support and timing of market introduction of competitive products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity
    concerning our products or competing products and treatments; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sufficient
    third-party insurance coverage and reimbursement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance
of the product will not be fully known until after it is launched. Our efforts to educate the medical community and third-party
payors on the benefits of the product candidates may require significant resources and may never be successful. If our product
candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors and others
in the medical community, we will not be able to generate sufficient revenue to become or remain profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate
revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pricing, coverage and reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure.
Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially achieve profitability.
Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for
most patients to be able to afford expensive treatments such as ours, assuming approval. Sales of our product candidates will
depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for
by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government
authorities, private health insurers and other third-party payors. If coverage and reimbursement are not available, or are available
only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided,
the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a
return on our investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., the principal
decisions about coverage and reimbursement for new medical devices are typically made by the Centers for Medicare &amp; Medicaid
Services (&ldquo;CMS&rdquo;), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to
what extent a new device will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement
policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement
for products such as ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject
to varying price control mechanisms as part of national health systems. In general, the prices of medical devices under such systems
are substantially lower than in the U.S. Other countries allow companies to fix their own prices for medical products, but monitor
and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount
that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products
may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such
organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover
or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale
of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations
and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and
surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to
the entry of new products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
legislative reform measures may have a material adverse effect on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in
March 2010, the Patient Protection and American Care Act (&ldquo;ACA&rdquo;) as amended by the ACA was passed, which substantially
changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. medical
device industry. We can&rsquo;t predict how our product candidates may be impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
legislation or regulations may adversely affect reimbursement from government programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama
signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction
to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve targeted deficit reductions,
triggering the legislation&rsquo;s automatic reduction of several government programs. This includes aggregate reductions to Medicare
payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into
law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to
five years. On December 13, 2016, the President signed into law the 21st Century Cures Act, which, among other things, may increase
the types of clinical trial designs that would be acceptable to support a PMA. It is unclear, at this time, how these provisions
will be implemented or whether they would have any effect on our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
medical device products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates
may be. In that regard, Congress has taken the first step in repealing the funding mechanism for certain aspects of the ACA. If
the ACA or parts of it are repealed, it is unclear what impact that would have on reimbursements or coverage and it is equally
unclear what programs, if any, Congress and the Trump Administration might enact and sign into law to replace the repealed portions
of the ACA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to additional federal and state laws and regulations relating to our business, and our failure to comply with those
laws could have a material adverse effect on our results of operations and financial conditions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to additional health care regulation and enforcement by the federal government and the states in which we conduct
our business. The laws that may affect our ability to operate include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal health care program Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
    soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or to induce either the referral
    of an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made under
    government health care programs such as the Medicare and Medicaid programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented,
    claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating
    to health care matters; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or
    services reimbursed by any third-party payor, including commercial insurers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes.
A person or entity can now be found guilty of fraud or false claims under the ACA without actual knowledge of the statute or specific
intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims
statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion
from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any
violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could
result in a material adverse effect on our reputation, business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ACA also imposes new reporting requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments
to certain health care providers and physician ownership of their stock by health care providers. Failure to submit required information
may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year
for &ldquo;knowing failures&rdquo;), for all payments, transfers of value, or ownership or investment interests that are not reported.
Manufacturers were required to begin data collection on August 1, 2013 and were required to report such data to CMS by March 31,
2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing.
Some states, such as California, Massachusetts and Vermont mandate implementation of corporate compliance programs, along with
the tracking and reporting of gifts, compensation, and other remuneration to physicians.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of these laws is uncertain and subject to change in the current environment of health care reform, especially
in light of the lack of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these
laws. Federal or state regulatory authorities may challenge our current or future activities under these laws. Any such challenge
could have a material adverse effect on our reputation, business, results of operations, and financial condition. Any state or
federal regulatory review of us, regardless of the outcome, would be costly and time-consuming.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may
not be able to compete effectively in our markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property
related to our technologies and product candidates. Our success depends in large part on our and our licensors&rsquo; ability
to obtain and maintain intellectual property protection in the U.S. and in other countries with respect to our proprietary technology
and products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies
and products that are important to our business. This process is expensive and time consuming, and we may not be able to file
and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of medical device, biotechnology and pharmaceutical companies generally is highly uncertain and involves complex
legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may
fail to result in issued patents with claims that cover our product candidates in the U.S. or in other foreign countries. There
is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which
can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue,
and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which
may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our
patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates
or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed several patent applications directed to various aspects of our product candidates. We cannot offer any assurances about
which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to
us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that
we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced. In addition, some or all of our patent applications may not result in issued
patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively and
our business and results of operations would be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B><I>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses
could be costly or not available on commercially reasonable terms.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the number of companies developing various types of NO devices, it is difficult to conclusively assess our freedom to operate
without infringing on third party rights. There are numerous companies that have pending patent applications and issued patents
in the field of therapeutic NO delivery. Our competitive position may suffer if patents issued to third parties or other third-party
intellectual property rights cover our products or elements thereof, or our manufacture or uses relevant to our development plans.
In such cases, we may not be in a position to develop or commercialize products or our product candidates unless we successfully
pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement
with the intellectual property right holder, if available on commercially reasonable terms. There may be pending patent applications
of which we are not aware, that if they result in issued patents, could be alleged to be infringed by our product candidates.
If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to
abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available
on commercially reasonable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications
filed before November 29, 2000 &nbsp;&nbsp;and certain U.S. applications filed after that date that will not be filed outside
the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18
months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the
priority date. Therefore, patent applications covering our product candidate or platform technology could have been filed by others
without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations,
be later amended in a manner that could cover our platform technologies, our product candidate or the use of our product candidate.
Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that
we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle
future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our product
candidate. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited
from commercializing our product candidate that is held to be infringing. We might, if possible, also be forced to redesign our
product candidate so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we
were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise
be able to devote to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent
terms are limited and we may not be able to effectively protect our products and business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after it is filed. Although various
extensions may be available, the life of a patent, and the protection it affords, is limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, upon issuance in the U.S., the patent term may be extended based on certain delays caused by the applicant(s) or the
U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;). Even if we obtain effective patent rights for our product candidates,
we may not have sufficient patent terms or regulatory exclusivity to protect our products, and our business and results of operations
would be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent
policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents
or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the
laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not
at all. We therefore cannot be certain that we or our licensor were the first to make the invention claimed in our owned and licensed
patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming
the other requirements for patentability are met, in the U.S. prior to March 15, 2013, the first to invent the claimed invention
is entitled to the patent, while outside the U.S., the first to file a patent application is entitled to the patent. After March
15, 2013, under the Leahy-Smith America Invents Act (&ldquo;Leahy-Smith Act&rdquo;), enacted on September 16, 2011, the U.S. has
moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent
applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the
USPTO must still implement various regulations, the courts have yet to address these provisions and the applicability of the act
and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not
be able to compete effectively in our markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other
elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our
premises and physical and electronic security of our information technology systems. While we have confidence in these individuals,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.
In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology
enter into confidentiality agreements and we expect they will assign all rights in their inventions to us pursuant to the terms
of such agreements; however, we cannot provide any assurances that all such agreements have been duly executed or that our trade
secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access
to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized
disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against
third parties for misappropriating the trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There
have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and
pharmaceutical industries, including with respect to NO delivery systems and formulations, including patent infringement lawsuits,
interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we
are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the
risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents
or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the
use or manufacture of our product candidates. We do not know whether there are any third-party patents that would impair our ability
to commercialize these product candidates. We also cannot be sure that we have identified each and every patent and pending patent
application in the U.S. and abroad that is relevant or necessary to the commercialization of our product candidates. Because patent
applications can take many years to issue, there may be currently pending patent applications that may later result in issued
patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use
of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to
cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate
unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid
or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for
manufacture or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the
applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid
or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a
successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&rsquo;
fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own and have in-licensed rights to intellectual property through licenses from third parties and under patents that
we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties,
the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In
addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these
formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other
third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing
and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies
are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These
established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development
and commercialization capabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development
underwritten agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license
to any of the institution&rsquo;s rights in technology resulting from the collaboration. Regardless of such option, we may be
unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do
so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable
to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our
investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, we may have to
abandon development of that program and our business and financial condition could suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third
parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that
are important to our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently a party to intellectual property license agreements that are important to our business, and we expect to enter into
additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements
will impose, various diligence, milestone payment, royalty and other obligations on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensing
of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues.
Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
    licensing agreement;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sublicensing of patent and other rights;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and
    us and our collaborators; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be involved in lawsuits or post-grant proceedings to protect or enforce our patents or the patents of our licensor, which
could be expensive, time consuming and unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe the patents of our licensor. If our licensing partner were to initiate legal proceedings against a third party to
enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product
candidate is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
patent applications may be subject to third-party pre-issuance submission of prior art to the USPTO, and any patents issuing thereon
may become involved in derivation, reexamination, inter partes review, post grant review, interference proceedings or other patent
office proceedings in the U.S. challenging our patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications or those of our licensor. An unfavorable outcome could require us to cease using
the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing
party does not offer us a license on commercially reasonable terms. Our defense of litigation or proceedings may fail and, even
if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties or enter into development partnerships
that would help us bring our product candidates to market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors
perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential
information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors
do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our
employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including
trade secrets or other proprietary information, of any of our employee&rsquo;s former employer or other third parties. Litigation
may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation
with respect to our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship
disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse
effect on our business. Even if 5we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. To the extent that our employees have not effectively waived the right
to compensation with respect to inventions that they helped create, they may be able to assert claims for compensation with respect
to our future revenue may be successful. As a result, we may receive less revenue from future products if such claims are successful
which in turn could impact our future profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity. Therefore, obtaining
and enforcing biotechnology patents is costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted
and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope
of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and
the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
new patents or to enforce our existing patents and patents that we might obtain in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in
the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also
export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that
in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights
generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated
or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against
us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain
a significant commercial advantage from the intellectual property that we develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Under
applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our
competitors from benefiting from the expertise of some of our former employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our
employees and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors
or clients for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which
our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees
or consultants developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete
undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited
number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&rsquo;s
confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests
will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants
and our ability to remain competitive may be diminished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
manage our business through a small number of employees and key consultants. We depend on them even more than similarly-situated
companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a total of 23&nbsp; full-time employees and a number of dedicated consultants, of whom work for us on a part-time basis.
In addition, any of our employees and consultants may leave our company at any time, subject to certain notice periods. The loss
of the services of any of our executive officers or any key employees or consultants would adversely affect our ability to execute
our business plan and harm our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently carry &ldquo;key person&rdquo; insurance on the lives of members of management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants,
which could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development and commercialization plans and strategies develop and because we are so leanly staffed, we will need additional
managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the
pharmaceutical field is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary
for the development of our business or to recruit suitable replacement personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations,
which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees
and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may
divert financial resources from other projects, such as the development of additional product candidates. If our management is
unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue
could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to
commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future
growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of our
existing product candidates, the success of our business also depends upon our ability to identify, license or discover additional
product candidates. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development
for a number of reasons, including but not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    research or business development methodology or search criteria and process may be unsuccessful in identifying potential product
    candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    product candidates may not succeed in preclinical or clinical testing;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the
    products unmarketable or unlikely to receive marketing approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitors
    may develop alternatives that render our product candidates obsolete or less attractive;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    candidates we develop may be covered by third parties&rsquo; patents or other exclusive rights;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market for a product candidate may change during our program so that such a product may become unreasonable to continue to
    develop;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able
to identify, license or discover additional product candidates, which would have a material adverse effect on our business and
could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical,
financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately
prove to be unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the U.S., our operations
may directly, or indirectly through our customers, subject us to various federal and state fraud and abuse laws, including, without
limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These
laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient
privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our
ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,
    offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an
    item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors
    that are false or fraudulent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;), which created new federal criminal
    statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to
    healthcare matters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology and Clinical Health Act (&ldquo;HITECH&rdquo;), and its implementing regulations,
    which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health
    information;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices and medical
    supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other
    transfers of value to physicians, other healthcare providers and teaching hospitals and ownership and investment interests
    held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or
    services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies
    to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
    by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral
    sources; state laws that require manufacturers to report information related to payments and other transfers of value to physicians
    and other healthcare providers or marketing expenditures and state laws governing the privacy and security of health information
    in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
    complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform
legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends the intent requirement
of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge
of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that the government may assert
that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or
fraudulent claim for purposes of the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply
to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in
government health care programs, such as Medicare and Medicaid, imprisonment and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated
with doing business outside of the U.S. or Israel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our operations that are located in Israel (as further described below), we currently have limited international operations,
but our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval
of our product candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities,
as well as clinical trials, outside of the U.S. and Israel. Doing business internationally involves a number of risks, including
but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
    conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment
    laws, regulatory requirements and other governmental approvals, permits and licenses;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us to obtain regulatory approvals for the use of our products in various countries;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    potentially relevant third-party patent rights;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    and difficulties in obtaining protection and enforcing our intellectual property;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing foreign operations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
    on our ability to penetrate international markets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial
    crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts,
    curtailment of trade and other business restrictions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    expenses including, among others, expenses for travel, translation and insurance; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within
    the purview of the FCPA, its books and records provisions or its anti-bribery provisions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or
incur costs that could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities and our third-party manufacturers&rsquo; and suppliers&rsquo; activities involve the controlled
storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds.
We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and
disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are
stored at our and our manufacturers&rsquo; facilities pending their use and disposal. We cannot eliminate the risk of contamination,
which could cause an interruption of our commercialization efforts, research and development efforts, business operations and
environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage,
handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized
by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed
by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or
injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed
our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our
business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become
more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently
carry biological or hazardous waste insurance coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
use of any of our product candidates could result in product liability or similar claims that could be expensive, damage our reputation
and harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to an inherent risk of potential product liability or similar claims. The medical device industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to
cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our
products might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of
these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance
on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities.
A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to
us, damage to our reputation, customer dissatisfaction and frustration and a substantial diversion of management attention. A
successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on
our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business and operations would suffer in the event of system failures.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable
to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the
loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval
efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted
in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we
could incur liability and/or the further development of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face business disruption and related risks resulting from the recent pandemic of COVID-19, which could have a material adverse
effect on our business plan.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our product candidates could be disrupted and materially adversely affected by the recent outbreak of COVID-19.
As a result of measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines
intended to contain this outbreak. The spread of SARS CoV-2 from China to other countries has resulted in the Director General
of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020. International stock markets have begun to reflect
the uncertainty associated with the slow-down in the Chinese economy and the reduced levels of international travel experienced
since the beginning of January and the significant declines in the Dow Industrial Average at the end of February and in March
2020 was largely attributed to the effects of COVID-19. We are still assessing our business plans and the impact COVID-19 may
have on our ability to conduct our preclinical studies and clinical trials or rely on our third-party manufacturing and supply
chain, but there can be no assurance that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19
or its consequences, including downturns in business sentiment generally or in our sector in particular. Site initiation and patient
enrollment for non-COVID-19 studies may be delayed or disrupted due to prioritization of hospital and medical resources toward
the COVID-19 pandemic or inability to access hospital and other clinical sites. The extent to which the COVID-19 pandemic and
global efforts to contain its spread will impact our operations will depend on future developments, which are highly uncertain
and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain
or treat the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
planned LungFit&trade; COVID-19 program may never be approved.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
response to the global outbreak of COVID-19, we have applied and received approval to study our LungFit<SUP>TM</SUP> system as
a treatment option for patients with COVID-19 from both the FDA and Health Canada. If the outbreak is effectively contained or
the risk of COVID-19 infection is diminished or eliminated, including if other parties are successful in producing an effective
vaccine or other treatment for COVID-19, before we can successfully test our LungFit<SUP>TM</SUP> system on patients with COVID-19,
the commercial viability of such product candidate for this indication may be significantly diminished. We are also committing
financial resources and personnel to this study which may cause delays in or otherwise negatively impact our other development
programs, despite uncertainties surrounding the longevity and extent of COVID-19 as a global health concern. Our business could
be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly
dissipate or against which our LungFit<SUP>TM</SUP> system may not be effective. Even if clinical testing shows that our LungFit&trade;
system is an effective treatment option for patients with COVID-19 and we receive clearance from FDA, other parties may produce
a more effective or more cost-effective treatment for COVID-19, which may lead to our LungFit&trade; system not being adopted
in the marketplace or not receiving insurance or government reimbursement. It may also lead to the diversion of governmental and
quasi-governmental funding away from us and toward other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Ownership of our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&rsquo; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for (A) any derivative
action or proceeding brought on behalf of us; (B) any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or other employees to us or our stockholders; (C) any action </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">asserting
a claim against us arising pursuant to any provision of the Delaware General Corporation Law, our Amended and Restated Certificate
of Incorporation or our Bylaws; or (D) any action asserting a claim against us governed by the internal affairs doctrine. Section
27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits
brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive
jurisdiction. In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over
all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As a
result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Securities
Act or any other claim for which the federal and state courts have concurrent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could adversely affect our business and financial condition.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
trading in our common stock has been volatile and may continue to be volatile in the future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has recently experienced extreme volatility. During the last six months, our common stock has closed as low as $3.94
per share and as high as $10.93 per share, with heavy daily trading volume. &nbsp;Our common stock may continue to be volatile
and could materially fall for a number of reasons including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcements
    by competitors that they have successfully produced an effective vaccine or other treatment option for COVID-19;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    announcement that the rapid spread of COVID-19 has receded;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcements
    by us of results from future clinical trials, if any, showing that the use of our LungFit<SUP>TM</SUP> system is not an effective
    treatment option for patients with COVID-19;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    termination of any other factors which may have created volatility and spike in volume; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    possible reasons for volatility which we have disclosed in this &ldquo;Risk Factors&rdquo; section and elsewhere
    in this Annual Report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product
    candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated adverse results or delays in our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our product candidates, if approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to the use of any of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key scientific or management personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for
    approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our
    product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on third parties, including CROs as well as our potential partners that provide us with companion diagnostic products;
    failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the
    public;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in quarterly operating results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed the estimates and projections of the investment community;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance
    of our competitors, including changes in market valuations of similar companies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the biotechnology and biopharmaceutical industries;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
    of new products offered by us or our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain an adequate rate of growth and manage such growth;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuances
    of debt or equity securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our stockholders in the future, or the perception that such sales could occur;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock; ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    political and economic conditions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects
    of natural or man- made catastrophic events; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that our stock price and volume will remain at current levels in which case investors may sustain large losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the stocks of small-cap biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these
&ldquo;Risk Factors,&rdquo; could have a dramatic and material adverse impact on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our
stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
trading market for our common stock that may develop will depend in part on the research and reports that securities or
industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish
research on us or our business. If no securities or industry analysts commence coverage of our company, the trading price for
our stock would be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts
downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If
one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could
decrease, which might cause our stock price and trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
incur increased costs associated with, and our management currently do and, in the future, will need to devote substantial time
and effort to, compliance with public company reporting and other requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, and particularly if and after we cease to be an &ldquo;emerging growth company&rdquo; or a &ldquo;smaller reporting
company,&rdquo; we incur significant legal, accounting and other expenses. In addition, the rules and regulations of the SEC and
national securities exchanges impose numerous requirements on public companies, including requirements relating to our corporate
governance practices, with which we now need to comply. Since becoming subject to the Exchange Act, we have been required to,
among other things, file annual, quarterly and current reports with respect to our business and operating results. Our management
and other personnel currently do and, in the future, will need to devote substantial time to gaining expertise regarding operations
as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those
requirements could be expensive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies
will make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may
choose to take advantage of certain exemptions from various reporting requirements applicable to other public companies, including,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports and proxy statements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from the requirements of holding non-binding stockholder votes on executive compensation arrangements; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption
    from any rules requiring mandatory audit firm rotation and auditor discussion and analysis and, unless the SEC otherwise determines,
    any future audit rules that may be adopted by the Public Company Accounting Oversight Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be an emerging growth company until the earliest of (i) December 31, 2021, (ii) the last day of the fiscal year during which
we have total annual gross revenues of $1.07 billion or more, (iii) the date on which we have, during the previous three-year
period, issued more than $1 billion in non-convertible debt and (iv) the date on which we are deemed to be a large accelerated
filer under the federal securities laws. We will qualify as a large accelerated filer as of the first day of the first fiscal
year after we (i) have more than $700 million in aggregate market value of outstanding common equity held by our non-affiliates
as of the last day of our second fiscal quarter, (ii) have been public for at least 12 months and (iii) have filed at least one
annual report pursuant to the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive if we rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock
and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Antidilution
provisions in certain of our outstanding warrants may affect the interests of our common stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants we issued in our January 2017 and March 2017 financing transactions, or the 2017 Warrants, contain price protection provisions
that could be triggered by our issuance of common stock in the future, if the offering price for any such future issuance is less
than the then-applicable warrant exercise price. The 2017 Warrants had an original exercise price of $6.90 per share. As a result
of our February 2018 financing transaction, we adjusted the exercise price down to $4.25 per share pursuant to the terms of the
2017 Warrants. As of result of the December 2019 equity offering, adjusted the exercise price down to $3.66 per share pursuant
to the terms of the 2017 Warrants. As of the June 19, 2020 there are 3,136,436 Warrants outstanding at a current
exercise price of $3.66 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, &ldquo;Empery&rdquo;),
filed a complaint in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price
of and the number of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as
a result of certain circumstances in connection with our February 2018 offering, the 166,672 warrants issued to Empery in January
2017 provide for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise.
Empery seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on
mutual mistake. While the Company believes that it has</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> complied
with the applicable protective features of the 2017 Warrants and properly adjusted the exercise price, if Empery were to prevail
on all claims, the new adjusted total number of warrant shares could be as follows: 319,967 warrant shares for Empery Master,
159,869 warrant shares for Empery I and 252,672 warrant shares for Empery II and the exercise price could be reduced from $3.66
to $1.57 per share. While the Company has several meritorious defenses against the claims, the ultimate resolution of the matter,
if unfavorable, could result in a material loss. On March 9, 2020, we filed a motion for summary judgment, which remains pending.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to Empery, there are 1,139,220 warrants outstanding held by investors in the 2017 Warrants who did not participate in
the February 2018 financing transaction. Any further adjustments to these 2017 Warrants pursuant to the antidilution provisions
may result in additional dilution to the interests of our stockholders and may adversely affect the market price of our common
stock. The antidilution provisions may also limit our ability to obtain additional financing on terms favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive
plans or otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to
fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that&nbsp;additional capital will be needed in the future to continue our planned operations. To raise capital, we may
sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner
we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than
one transaction, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales
may result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges
senior to those of holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions in our amended and restated certificate of incorporation and our amended and restated bylaws, as well as provisions
of Delaware law, might discourage, delay or prevent a change in control of our company or changes in our Board of Directors or
management and, therefore, depress the trading price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may depress
the market price of our common stock by acting to discourage, delay or prevent a merger, acquisition or other change in
control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove
members of our Board of Directors or our management. Our corporate governance documents include provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    that directors may be removed by stockholders with or without cause;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the ability of our stockholders to call and bring business before special meetings and to take action by written consent in
    lieu of a meeting;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of
    candidates for election to our Board of Directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common
    stock; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
    the liability of, and providing indemnification to, our directors and officers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation
Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock from engaging in certain
business combinations with us. Any provision of our amended and restated certificate of incorporation, amended and restated bylaws
or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders
to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing
to pay for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay
in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing
the likelihood that you could receive a premium for your common stock in an acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights
held by our directors, officers and employees may result in substantial expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation and our Bylaws eliminate the personal liability of our directors and officers
to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware
law. Further, our Amended and Restated Certificate of Incorporation and our Bylaws and individual indemnification agreements we
have entered with each of our directors and executive officers provide that we are obligated to indemnify each of our directors
or officers to the fullest extent authorized by the Delaware law and, subject to certain conditions, advance the expenses incurred
by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations
could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers,
which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from bringing
a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions
might otherwise benefit our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not intend to pay cash dividends on our capital stock in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the cash dividend paid in connection with the Merger, we have never declared or paid any dividends on our common stock
and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends in the future would
depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations,
anticipated cash requirements and other factors and will be at the discretion of our Board of Directors. Our stockholders should
not expect that we will ever pay cash or other dividends on our outstanding capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could be subject to securities class action litigation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s
attention and resources, which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to certain claims by Circassia.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the termination of our license agreement with Circassia, we may be subject to certain claims by Circassia. Adverse
outcomes in some or all of these claims may negatively affect our ability to conduct our business. However, as of the date of
this Annual Report, we cannot estimate the likelihood that we will be subject to any claims or the effects thereof on our
business and operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>ITEM
1B. UNRESOLVED STAFF COMMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>ITEM
2. PROPERTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive office is located at 825 East Gate Boulevard, Suite 320, Garden City, New York 11530 under a lease that expires in June
2023. We also lease office space at 12 Eli Horovitz Street, Rehovot, 7414002 Israel and that lease expires on March 2021. The
Company has a research and development facility in Madison, Wisconsin under a lease that expires on May 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>ITEM
3. LEGAL PROCEEDINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (filed a complaint
in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price of and the number
of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as a result of
certain circumstances in connection with our February 2018 offering, the 166,672 warrants issued to Empery in January 2017
provide for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise.
Empery seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on
mutual mistake. While the Company believes that it has complied with the applicable protective features
of the 2017 Warrants and properly adjusted the exercise price, if Empery were to prevail on all claims, the new
adjusted total number of warrant shares could be as follows: 319,967 warrant shares for Empery Master, 159,869 warrant shares
for Empery I and 252,672 warrant shares for Empery II and the exercise price could be reduced from $3.66 to $1.57 per
share. While the Company has several meritorious defenses against the claims, the ultimate resolution of the matter, if unfavorable,
could result in a material loss. On March 9, 2020, we filed a motion for summary judgment, which remains pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>ITEM
4. MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>PART
II </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>ITEM
5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock has been listed under the symbol &ldquo;XAIR&rdquo; on the Nasdaq Capital Market since May 7, 2019. From August 28,
2018 until May 6, 2019, our common stock was quoted on the OTC Pink.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 19, 2020, there were approximately 108 holders of record for shares of our common stock. This does not reflect
beneficial stockholders who held their common stock in &ldquo;street&rdquo; or nominee name through brokerage firms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
Authorized for Issuance Under Equity Compensation Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
regarding securities authorized for issuance under the Company&rsquo;s equity compensation plans is contained in Part III, Item
11 of this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any
future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash
dividends on our common stock for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unregistered
Sales of Equity Securities </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>ITEM
6. SELECTED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required for smaller reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>ITEM
7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with &ldquo;Item
6. Selected Consolidated Financial Data&rdquo; and our consolidated financial statements and related notes appearing elsewhere
in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking
statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions
and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, those discussed in Item 1A &ldquo;Risk Factors.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introduction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging medical device and biopharmaceutical company developing a nitric oxide (&ldquo;NO&rdquo;) generator and delivery
system (the &ldquo;LungFit&trade; system&rdquo;) that is capable of generating NO from ambient air. LungFit&trade; can generate
NO up to 400 parts per million (&ldquo;ppm&rdquo;) for delivery to a patient&rsquo;s lungs. LungFit&trade; can deliver NO either
continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand or maintain
a constant dose. We believe that LungFit&trade; can be used to treat patients on ventilators that require NO, as well as patients
with chronic lung disease or acute severe lung infections via delivery through a breathing mask or similar apparatus. Furthermore,
we believe that there is a high unmet medical need for patients suffering from certain severe lung infections that LungFit&trade;
can potentially address. Our current areas of focus with the LungFit&trade; are persistent pulmonary hypertension of the newborn
(&ldquo;PPHN&rdquo;), severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), bronchiolitis (&ldquo;BRO&rdquo;) and nontuberculous
mycobacteria (&ldquo;NTM&rdquo;)<I>.</I> Our current product candidates will be subject to premarket reviews and approvals by
the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If approved,
our system will be marketed as a medical device in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
additional focus of the Company is solid tumors. For this indication the LungFit&trade; system is not utilized due to the ultra-high
concentrations of NO used. We have developed a delivery system that can safely delivery NO concentrations in excess of 10,000
ppm directly to a solid tumor. This program is in pre-clinical development and will require FDA, or similar agency in another
country, approval to enter human studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to PPHN, our novel LungFit&trade; is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines
for delivery of 20 ppm NO with a range of 0.5 ppm &ndash; 80 ppm (low-concentration NO). We believe LungFit&trade; has many competitive
advantages over the current approved NO delivery systems in the U.S., European Union, Japan and other markets. For example, LungFit&trade;
does not require the use of a high-pressure cylinder, utilizes less space than other similar devices, does not require cumbersome
purging procedures and places less burden on hospital staff in carrying out safety procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
novel LungFit&trade; can also deliver a high concentration of NO to the lungs, which we believe has the potential to eliminate
microbial infections, including bacteria, fungi and viruses, among other benefits. We believe current FDA-approved NO vasodilation
treatments would have limited success in treating microbial infections given the low concentrations of NO being delivered. Given
that NO is produced naturally by the body as an innate immunity mechanism at a concentration of 200 ppm, supplemental high dose
NO should aid in the body&rsquo;s fight against infection. Based on our clinical studies, we believe that 150 ppm is the minimum
therapeutic dose to achieve the desired pulmonary antimicrobial effect of NO. To date, neither the FDA nor equivalent regulatory
agencies in other countries or regions have approved any NO formulation and/or delivery system for the delivery of a dosage of
NO at 150 ppm or higher to the lungs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have conducted the following studies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form10-k_004.jpg" ALT="" STYLE="height: 159; width: 630"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
active pipeline of product candidates is shown in the table below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form10-k_006.jpg" ALT="" STYLE="height: 265; width: 630"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><SUP>&dagger;</SUP>Caution
- LungFit&trade; is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
All dates are based on projections and appropriate financing, anticipated first launch on a global basis pending appropriate regulatory
approvals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
All figures are Company estimates for peak year sales: Global sales potential includes US sales potential</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
plan to submit for premarket approval or (&ldquo;PMA&rdquo;) to the FDA towards the end of the third quarter of 2020 for
the use of the LungFit&trade; in PPHN. We also expect to make certain regulatory filings outside of the U.S. later in 2020. According
to the 2019 year-end report from Mallinckrodt Pharmaceuticals, aggregate sales of low concentration NO in the U.S. were in excess
of $540 million in 2019, while sales outside of the U.S., where there are multiple market participants, sales were considerably
lower than in the U.S. We believe the U.S. sales potential of LungFit&trade; in PPHN to be greater than $300 million and worldwide
sales potential to be greater than $600 million. If regulatory approval is obtained, we anticipate a product launch in both the
U.S. and Israel in 2021 and will continue to launch globally throughout 2021 and beyond.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SARS
CoV-2 is a global pandemic with a widespread impact across many countries. We have received approval from the FDA to run a study
in COVID-19 (the disease caused by SARS CoV-2 infections) patients using our LungFit<SUP>TM</SUP> system. We have also received
approval from Health Canada to run a similar study to the one approved by the FDA. We look forward to results from both of these
studies in the summer/fall of 2020. The fact that our system does not need cylinders allows for us to potentially provide a practical
solution to this crisis. We have applied for grants related to COVID-19 in the United States and other countries. However, no
funding is required to perform the clinical studies recently approved by FDA and Health Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to bronchiolitis, we initiated a randomized, double blind, controlled trial with three arms randomized 89 subjects 1:1:1
to standard supportive therapy (SST), SST plus 85 ppm NO and SST plus 150 ppm NO for infants hospitalized due to bronchiolitis
in the fourth quarter of 2019. The trial is complete and we recently released top line data. These data were consistent on safety
with no SAE&rsquo;s related to NO therapy. With respect to efficacy, the 150 ppm arm was statistically significant when compared
to both the control arm and the 85 ppm arm on the Primary endpoint of fit for discharge from the hospital and the key secondary
endpoint of hospital length of stay. The 85 ppm was no different from control on both endpoints. This is an exceptional result
given the low number of patients and provides clear evidence of the need for 150 ppm to achieve the desired efficacy. The pivotal
study for bronchiolitis was originally set to be performed in the 2020/21 winter, but due to the SARS CoV-2 pandemic, hospitals
will not be considering any new study proposals not related to SARS CoV-2 or COVID-19. At this time, we anticipate commencing
a pivotal study in the United States in the fourth quarter of 2021 and complete it late in the second quarter of 2022.
We would submit a PMA to the FDA about 6 months after trial completion. Regulatory filings outside of the U.S., as long
as no additional trials are required, would begin after our review process is completed in the U.S. For this indication, we believe
U.S. sales potential to be greater than $500 million and worldwide sales potential to be greater than $1.2 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Over
3 million new cases of bronchiolitis are reported worldwide each year. In the U.S., there are approximately 130,000 annual bronchiolitis
hospitalizations among children two years of age or younger and approximately 177,000 annual hospitalizations among the elderly
population related to RSV infection only with the number rising higher due to other viruses similar to those that cause bronchiolitis
in very young children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Currently,
there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants
is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow
of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe these treatments do not successfully reduce hospital length
of stay.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
nontuberculous mycobacteria (NTM) program has produced data from four compassionate use subjects and nine patients from a multi-center
pilot study completed in 2018. All patients suffered from NTM <I>abscessus</I> infection and had underlying cystic fibrosis. One
compassion patient was treated with our nitric oxide generator at the National Heart, Lung and Blood Institute (&ldquo;NHLBI&rdquo;).
The rest were treated with our NO cylinder-based delivery system. All patients were treated with 160 ppm NO at intermittent 30-minute
dosing over 21 days, except one patient who was treated over 26 days and another patient who was treated with 250 ppm NO over
28 days. We expected to begin a study by the end of 2020 (delayed about 6 months by the COVID-19 pandemic) where patients would
self-administer high concentration NO at home over a period of 12 weeks with LungFit&trade;. We now anticipate preliminary data
for this study will be available during the first half of 2021 and that a full dataset will be available in the second half of
2021. If the trial is successful, we would commence a pivotal study in 2022. For this indication, we believe U.S. sales potential
to be greater than $1 billion and worldwide sales potential to be greater than $2.5 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NTM
lung infection is a rare and serious pulmonary disease associated with increased morbidity and mortality. There is an increasing
rate of lung disease caused by NTM, which is an emerging public health concern worldwide. There are approximately 50,000 patients
diagnosed with NTM in the U.S., and there are an estimated additional 100,000 patients in the U.S. that have not yet been diagnosed.
In Asia, the number of patients suffering from NTM surpasses what is seen in the U.S. To date we have treated only the <I>abscessus
</I>form of NTM which comprises approximately 20-25% of all NTM. We will be treating both the <I>abscessus and mycobacterium avium
complex (MAC) </I>forms of NTM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with NTM lung disease may experience a multitude of symptoms such as fever, weight loss, cough, lack of appetite, night sweats,
blood in the sputum and fatigue. Patients with NTM lung disease, specifically <I>abscessus</I> and other forms of NTM that are
refractory to antibiotic therapy<I>,</I> frequently require lengthy and repeated hospital stays to manage their condition. There
are no treatments specifically indicated for the treatment of NTM <I>abscessus </I>lung disease in North America, Europe or Japan.
There is one inhaled antibiotic approved in the U.S. for the treatment of refractory NTM MAC. Current guideline-based approaches
to treat NTM lung disease involve multi-drug regimens of anti-biotics that may cause severe, long lasting side effects, and treatment
can be as long as 18 months or more. Median survival for NTM MAC patients is approximately 13 years while median survival for
patients with other variations of NTM is typically 4.6 years. The prevalence of human disease attributable to NTM has increased
over the past two decades. In a study conducted between 1997 and 2007, researchers found that the prevalence of NTM in the U.S.
is increasing at approximately 8% per year and that NTM patients on Medicare over the age of 65 are 40% more likely to die over
the period of the study than those who did not have the disease (Adjemian et al., 2012). NTM <I>abscessus</I> treatment costs
are estimated to be more than double that of NTM MAC. In total, a 2015 publication from co-authors from several U.S. government
departments stated that prior year statistics led to a projected 181,037 national annual cases in 2014 costing the U.S. healthcare
system approximately $1.7 billion (Strollo et al., 2015).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the solid tumor program, we have just released pre-clinical data at the virtual American Academy of Cancer Research (AACR) which
showed the promise of delivering NO at concentrations of 25,000 ppm &ndash; 200,000 ppm directly to tumors. Results showed local
tumor ablation with complete eradication in 5 of 30 mice. Additionally, regardless of whether the tumor was completely or partially
cleared, all colon tumor bearing mice were resistant to a second challenge of colon cancer. Breast tumor bearing mice a 7-10 day
delay in the uptake of breast cancer post challenge. Pre-clinical work will continue throughout the rest of 2020 and most of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
program in chronic obstructive pulmonary disease is in the pre-clinical stage and will remain there, subject to our obtaining
additional financing.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
3 million new cases of bronchiolitis are reported worldwide each year. In the U.S., there are approximately 130,000 annual bronchiolitis
hospitalizations among children two years of age or younger and approximately 177,000 annual hospitalizations among the elderly
population related to RSV infection only with the number rising higher due to other viruses similar to those that cause bronchiolitis
in very young children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there is no approved treatment for bronchiolitis. The treatment for acute viral lung infections that cause bronchiolitis in infants
is largely supportive care and is based primarily on prolonged hospitalization during which the infant receives a constant flow
of oxygen to treat hypoxemia, a reduced concentration of oxygen in the blood. In addition, systemic steroids and inhalation with
bronchodilators are sometimes utilized until recovery, but we believe these treatments do not successfully reduce hospital length
of stay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not generated
revenues from royalties or sales of any product and will not until we obtain marketing approval of, and commercialize, our product
candidates. As of March 31, 2020, we had an accumulated deficit of $57.6 million. Our financing activities are described
below under &ldquo;Liquidity and Capital Resources.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
impact of COVID-19 on the Company is unknown at this time. The financial consequences of this situation cause uncertainty as to
the future and its effects on the economy and the Company.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Operations Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Estimates and Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the years
ended March 31, 2020 and March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. On an ongoing basis, the Company&rsquo;s evaluates its significant estimates including accruals for expenses under
consulting, licensing agreements, and clinical trials, stock-based compensation, warrant fair value determination and associated
debt discount and classification within stockholders&rsquo; equity, assumptions associated with revenue recognition, and the determination
of deferred tax attributes and the valuation allowance thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when we transfer promised goods or services to customers in an amount that reflects the consideration
to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with
customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s)
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in
the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess
the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those
that are performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above
and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction
price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract
for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other
variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated
to each performance obligation on an estimated stand-alone selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statement of operations and comprehensive loss as incurred. Research and development
expenses include salaries, costs incurred by outside laboratories, manufacturer&rsquo;s, consultants, accredited facilities in
connection with clinical trials and preclinical studies and stock based-compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures the cost of employee
and non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.
Fair value for restricted stock awards is valued using the closing price of the Company&rsquo;s stock on the date of grant. That
cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite
service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model.
The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity
instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception
and does not anticipate paying dividends in the foreseeable future. The Company started to blend its trading activity with it
traded peer group to obtain expected volatility. Due to the Company&rsquo;s limited trading history, the Company utilizes an implied
volatility based on an aggregate of guideline companies. In 2020, the Company began to blend its historical volatility with the
peer group in order to obtain expected volatility. The peer companies were based similar publicly traded peer companies. The Company
routinely reviews its calculation of volatility based on, the Company&rsquo;s life cycle, its peer group, and other factors. The
Company uses the simplified method for share-based compensation to estimate the expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the
fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The
expense was previously adjusted to fair value at the end of each reporting period until such awards vested, and the fair value
of such instruments, as adjusted, was expensed over the related vesting period. Adjustments to fair value at each reporting date
resulted in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment.
In June 2018, the FASB issued ASU No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting,
which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance
on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee
equity awards is fixed on the grant date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value
of all non-employee awards became fixed at the start of the fourth quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
in Marketable Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity marketable securities classified available-for-sale are carried at fair value with the changes in unrealized gains and
losses recognized in the Company&rsquo;s results in operations. Realized gains and (losses) from the sale of marketable securities
are recognized in the statement of operations using the specific identification method on a trade date basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed
Right to Use Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed
right to use technology that is considered platform technology is recorded as an intangible asset which resulted from the NitricGen
transaction, see Note 11. The intangible asset was valued based upon the fair value of the options issued to NitricGen and the
cash paid for this transaction. The license also contains two future milestone additional payments aggregating $1,800,000. The
intangible asset is being amortized on a straight-line method over its estimated useful life of thirteen years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assess the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant underperformance
    relative to expected historical or projected future operating results,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant changes
    in the manner of our use of the acquired assets or the strategy for our overall business,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant negative
    regulatory or economic trends, and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant technological
    changes, which would render equipment and manufacturing processes obsolete.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability
of assets that will continue to be used in our operations is measured by comparing the carrying value to the future net undiscounted
cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues,
driven by market growth rates, and estimated future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded
a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit does
not meet the more likely than not threshold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files a U.S. Federal, various state, and International income tax returns. Uncertain tax positions are reviewed on an
ongoing basis and are adjusted in light of changing facts and circumstances. Such adjustment is reflected in the tax provision
when appropriate<B>. </B>The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in income
taxes in the statements of operations. The Company has recorded a liability in accrued expenses $154,300 for uncertain tax positions
as of March 31, 2019 and reversed this accrual for the year ended March 31, 2020 which resulted in income. Tax years 2016 through
2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax
years 2014 through 2020 remain open.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Commitments</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 22, 2013, the Company entered into a patent license agreement with CareFusion, pursuant to which it agreed to pay to the
third party a non-refundable upfront fee of $150,000 and is obligated to pay 5% royalties of any licensed product net sales, but
at least $50,000 per annum through the term of the agreement and the advance is credited against future royalties payments. As
of December 31, 2019, the Company did not pay any royalties since the Company did not have any revenues from this license. The
term of the agreement extends through the life of applicable patents and may be terminated by either party with 60 days&rsquo;
prior written notice in the event of a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days&rsquo;
prior written notice in the event that we do not meet certain milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, BA Ltd. entered into an Option Agreement (the &ldquo;Option Agreement&rdquo;) with Pulmonox whereby BA Ltd. acquired
the option to purchase certain intellectual property assets and rights (the &ldquo;Option&rdquo;) on September 7, 2016 for $25,000.
On January 13, 2017, the Company exercised the Option and paid $500,000. The Company becomes obligated to make certain one-time
development and sales milestone payments to Pulmonox, commencing with the date on which we receive regulatory approval for the
commercial sale of the first product candidate qualifying under the agreement. These milestone payments are capped at a total
of $87 million across three separate and distinct indications that fall under the agreement, with the majority of them, approximately
$83 million, being sales related based on cumulative sales milestones for each of the three products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018 the Company entered into an agreement (&ldquo;Agreement&rdquo;) with NitricGen, Inc. (&ldquo;NitricGen&rdquo;)
acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets
and confidential information from NitricGen related to LungFit&trade;. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $2,000,000 in future payments based upon achieving certain milestones, as defined in the
Agreement, and royalties on sales LungFit&trade;. The Company paid NitricGen $100,000 upon the execution agreement, $100,000 upon
achieving the next milestone and issued 100,000 options to purchase the Company&rsquo;s stock valued at $295,000 upon executing
the agreement. The remaining future milestone payments are $1,800,000 of which $1,500,000 in due after six months after the first
approval of LungFit&trade; by the Food and Drug Administration or the European Medicine Evaluation Agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 18, 2019, the Company entered into an agreement with a contract research organization to perform a pilot study for bronchiolitis.
As of March 31, 2020, the remaining cash commitment under this agreement is approximately $303,000. The Company recorded $754,000
expense for the year ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
officer agreements contain a change of control provision for payment of severance arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Contingencies</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, filed a complaint in the
Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price of and the number of warrant
shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as a result of certain circumstances
in connection with our February 2018 offering, the 166,672 warrants issued to Empery in January 2017 provide for adjustments to
both the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery seeks monetary damages
and declaratory relief under theories of breach of contract or contract reformation predicated on mutual mistake. While the Company&nbsp;
believes that it has&nbsp; complied with the applicable protective features of the 2017 Warrants and properly adjusted the exercise
price, if Empery were to prevail on all claims, the new adjusted total number of warrant shares could be as follows: 319,967
warrant shares for Empery Master, 159,869 warrant shares for Empery I and 252,672 warrant shares for Empery II and the exercise
price could be reduced from $3.66 to $1.57 per share. While the Company has several meritorious defenses against the claims, the
ultimate resolution of the matter, if unfavorable, could result in a material loss. On March 9, 2020, we filed a motion for summary
judgment, which remains pending.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
for the year ended March 31, 2020 to the year ended March 31, 2019.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended <BR> March 31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">License
    revenue</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,390,104</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,724,001</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10,648,920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,929,558</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and
    administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,883,119</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,852,988</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,141,935</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,058,545</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (loss)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Realized and unrealized loss on available
    for sale marketable securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,075,602</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,581,193</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend income</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">115,716</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">86,748</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30,543</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,506</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign exchange gain (loss)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,560</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,034</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total other
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,954,869</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,499,905</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss before income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,096,804</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,588,450</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Benefit for
    income taxes</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,300</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,942,504</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,558,450</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deemed dividend
    from warrant modification</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(522,478</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss attributed
    to common shareholders</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,464,982</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,558,450</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss per
    share &ndash; basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.78</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.77</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average
    number of common shares outstanding &ndash; basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,506,212</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,498,525</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
revenue for the year ended March 31, 2020 was $1,390,104 and for the year ended March 31, 2019 was $7,724,000,
respectively. On January 23, 2019, the Company entered into an agreement for commercial rights (the &ldquo;License
Agreement&rdquo;) with Circassia Limited and its affiliates (collectively, &ldquo;Circassia&rdquo;) for persistent pulmonary
hypertension of the newborn (&ldquo;PPHN&rdquo;) and future related indications at concentrations of <U>&lt;</U> 80 ppm in
the hospital setting in the United States and China. On December 18, 2019, the Company terminated the License Agreement, see
Note 13. The Company would have received payments up to $32.55 million in up front and regulatory milestones, of which $31.5
million was associated with the U.S. market. All such payments were payable in cash or ordinary shares of Circassia, at the
discretion of Circassia, with payments in cash discounted by approximately 5%. Royalties are payable only in cash. In
consideration of the rights and licenses granted to Circassia by the Company, there were five milestone that were associated
with Agreement. Due to the consideration constraints associated with milestones 3, 4, and 5, only the amounts associated with
milestone 1 and 2 have been allocated. During the year ended March 31, 2019, the Company met the first two milestones under
the license agreement and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to the
first two performance obligations. one being the transfer of the intellectual property to Circassia, which was recognized at
a point in time and was valued at $7,116,232 and the other being the ongoing support associated with the PMA submission and
regulatory approval by the FDA, which was valued at $2,871,063 and recorded as deferred revenue to be recognized over a
period of time from the commencement of the agreement to when management expects to submit the PMA. For the year ended March
31, 2020 and March 31,2019, $1,390,1049 and $607,769, respectively of such revenue associated with this second performance
obligation has been recognized. As of March 31, 2020, and March 31, 2019, deferred revenue was $873,190 and
$2,263,294, respectively. On December 18, 2019, the Company terminated the License Agreement with Circassia pursuant to
which the Company had granted Circassia an exclusive royalty-bearing license to distribute, market and sell the
Company&rsquo;s nitric oxide generator and delivery system in the United States and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development for the year ended March 31, 2020 was $10,648,920, as compared to $3,929,558 for the year ended March 31,
2019. The increase of $6,719,362 was primarily attributed an increase in the development of the LungFit System for PPHN
and an increase in pre-clinical studies for bronchiolitis, an increase in salaries and employee benefits and an increase
in stock-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expense for the year ended March 31, 2020 and March 31, 2019 was $8,883,119, as compared to $6,852,988,
respectively. The increase of $2,030,131 was primarily attributed to an increase in non-cash stock-based compensation
expense, an increase in professional fees and an increase of insurance expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income (Loss)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
loss for the year ended March 31, 2019 was $1,954,869 as compared to $3,499,905 for the year ended March 31, 2020. For
the year ended March 31, 2019, $3,581,193 was primarily from for the unrealized loss and realized loss on available for sale securities
and realized loss primarily related to Circassia Pharmaceuticals plc stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Loss Attributed to Common Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the year ended March 31, 2020, the Company recorded a non-cash deemed dividend of $522,478 that represented a warrant modification.
This increased the loss to the common shareholders.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">As
a result of the foregoing, our net loss attributed to common shareholders for the year ended March 31, 2020, was $20,464.982
or $1.78 per share, basic and diluted, as compared to a net loss for the year ended March 31, 2019 of $6,558,450
or $0.77 per share, basic and diluted.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview
Update</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses and generated negative cash flows from operations since inception. To date, we have not generated any
revenue from the sale of products, and we do not expect to generate revenue from sale of our products until regulatory
approval is received for our product candidates. Since the time the Company became public through March 31, 2020,
we have funded our operations principally through the issuance of equity securities. As shown in the accompanying financial
statements, the Company has an operating cash flow decrease of $15.3 million for the year March 31, 2020
and has accumulated losses of $57.6 million since inception through March 31, 2020. The Company has cash, cash
equivalent and restricted cash of $25.5 million as of March 31, 2020. The Company estimates that it has enough cash and
liquidity to execute its current business plan for at least one year from the date of the filing of this
annual report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2020, the Company entered into a facility agreement (the &ldquo;Facility Agreement&rdquo;) with certain lenders
pursuant to which the lenders shall loan to up to $25,000,000 in five tranches of $5,000,000 per tranche at the option of the
Company (&ldquo;Tranches&rdquo;), provided however that the Company may only utilize tranches three through five following
FDA approval of our LungFit&trade; PH product. The loan(s) are unsecured with an interest rate of 10% per annum
which is paid quarterly, and may be prepaid with certain prepayment penalties. The effective interest rate for this loan is
13.3% per year. Each tranche shall be repaid in installments commencing June 15, 2023 with all remaining amounts
outstanding under any tranche due on March 17, 2025. Beyond Air has the ability to draw down on a $5 million tranche
prior to FDA approval of the LungFit&trade; PH product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2020, Beyond Air, Inc. entered into an At-The-Market Equity Offering for $50 million and utilized the Company&rsquo;s
shelf registration statement. The Company may sell shares of our common stock having aggregate sales proceeds of up to $50,000,000
from time to time in this offering. If shares are sold, there is a three 3 percent fee paid to the sales agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2020, the Company entered into a $40 million New Purchase Agreement with LPC, that replaced the existing $20 million purchase
agreement. The New Purchase Agreement provides for the issuance of up to $40 million of the Company&rsquo;s common stock which
we may sell from time to time in our sole discretion to Lincoln Park over the next 36 months, subject to the conditions and limitations
in the New Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue to operate is dependent upon the filing of our PMA, expected timing of the Company&rsquo;s launch of our product,
obtaining Partners in other parts of the world, timing of future milestones and royalties, raising additional funds to finance
our activities. There are no assurances that we will be successful in obtaining an adequate level of financing for the development
and commercialization of our product candidates. The Company&rsquo;s ability to continue to operate is dependent upon raising
additional funds to finance its activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous risks and uncertainties associated with the development of our NO delivery system, we are unable to estimate the
amounts of increased capital outlays and operating expenses associated with completing the research and development of our product
candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    progress and costs of our preclinical studies, clinical trials and other research and development activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other research and development programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of obtaining regulatory approval for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our
    product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential costs of contracting with third parties to provide marketing and distribution services for us or for building such
    capacities internally;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications
    of our product candidate;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    magnitude of our general and administrative expenses; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    cost that we may incur under current and future in-and out-licensing arrangements relating to our product candidate.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
Flows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a summary of the statements of cash flows for the Years Ended March 31, 2020 and March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
    The Year Ended <BR> March 31, 2020</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
    The Year Ended <BR> March 31, 2019</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by (used in):</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating activities</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 21%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(15,250,049</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 21%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,341,052</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,423,433</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,793,639</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing activities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">34,934,590</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,071,490</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net increase in cash, cash equivalents
    and restricted stock</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,107,974</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">618,903</FONT></TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
between March 31, 2020 and March 31, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the year ended March 31, 2020, net cash used by operating activities was $15,250,049 which was primarily due to our net
loss of $19,942,504, a decrease in current assets prepaid expenses, accrued expenses and deferred revenue and operating
lease payments of $2,180,374 and was offset by an increase in unrealized and realized loss in available for
sale securities of $2,075,602 an increase in operating lease expense, accounts payable of $1,154,433 and non-cash
expense of $3,741,704. For the year ended March 31, 2019, net cash provided by in operating activities was $1,341,052 which
was primarily due to the net loss of $6,558,450, a use of cash $729,159 for other current assets and prepaid expenses which was
offset by unrealized and realized loss marketable securities of $3,498,883, a source of cash for accounts payable, accrued expenses
and deferred revenue of $2,862,684 and non-cash expense of $2,464,108.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2020, cash provided by investing activities was $4,423,433 which was from the net purchases of
available for sale marketable securities of $4,467,064 and $43,631 purchase of property and equipment. For the year ended March
31, 2019, the Company used in activities $1,793,639 which was from the net purchases of available for sale marketable securities
of $1,737,164 and $56,475 purchase of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financing
Activities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2020, net cash provided by financing activities was $34,934,590  was primarily
from the net proceeds an underwritten offering and private placement of $10,169,300, net proceeds from a private placement of
$7,839,500, and the issuance and sales of $7,740,000 of common stock to Lincoln Park Financial Corporation (&ldquo;LPC&rdquo;),
proceeds from the issuance of common stock from warrant exercises of $3,968,900 and proceeds from the issuance of common stock
from the exercise of options for $210,700. For the year ended March 31, 2019, net cash provided by financing activities was $1,071,490
which was primarily from the net proceeds of $799,156 from the sale of stock to LPC and a bank loan of $292,250.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables sets forth our contractual obligations for the next five years and thereafter for the year ended March 31,
2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%">Rent</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">90,100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">65,400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">64,700</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">16,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">236,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Facility loan agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">335,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CRO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">728,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">65,400</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,564,700</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">2,766,300</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">750,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">5,874,400</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>Quantitative
and Qualitative Disclosure about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our
financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result
of foreign currency exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Currency Exchange Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Certain of
our expenses are denominated in New Israeli Shekels (&ldquo;NIS&rdquo;). Our results of operations and cash flow are, therefore,
subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes
in foreign exchange rates. We do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency
hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating
currencies. These measures, however, may not adequately protect us from significant changes in such fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements together with the report of our independent registered public accounting firm, required to be filed pursuant
to this Item 8 are appended to this Annual Report on Form 10-K. An index of those consolidated financial statements is found in
Item 15 of this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_014"></A><FONT STYLE="font-size: 10pt"><B>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>ITEM
9A. CONTROLS AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Controls and Procedures </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information
required to be disclosed in this Annual Report and filed with the SEC is recorded, processed, summarized and reported timely
within the time period specified in the SEC&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files
or submits under the Exchange Act, is accumulated and communicated to the issuer&rsquo;s management, including its principal executive
and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding
required disclosure. There can be no assurance that our disclosure controls and procedures will detect or uncover all failures
of persons within our Company to disclose information otherwise required to be set forth in our reports. Nevertheless, our disclosure
controls and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Based on our
evaluation, our principal executive officer and principal financial officer, have concluded that our disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15(d)-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report
are effective at such reasonable assurance level.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s
    Annual Report on Internal Control over Financial Reporting</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules
13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2020,
based on the framework in Internal Control&mdash;Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (2013 framework). Based on this evaluation, management concluded that our internal control over financial
reporting was effective as of March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attestation
    Report of Registered Public Accounting Firm</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report does not include an attestation report of our registered public accounting firm as we are not an accelerated filer or a
large accelerated filer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in Internal Controls over Financial Reporting</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no other changes in our internal control over financial reporting that occurred during the year ended March 31, 2020
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>ITEM
9B. OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_018"></A><FONT STYLE="font-size: 10pt"><B>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the name, age and position of each of our directors and executive officers and as of the date of this Annual
Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Lisi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Avniel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Operating Officer and Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Beck, CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
    Bentsur</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
    J. Lucera</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori
    Lee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    William Forbes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    F. Carey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Steven
A. Lisi, Chief Executive Officer and Chairman of the Board</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
Lisi has served on our Board since January 13, 2017, and has served on the Board of AIT Ltd., our wholly-owned subsidiary, since
June 2016. Mr. Lisi has served as our Chief Executive Officer since June 14, 2017. Mr. Lisi was previously Senior Vice President
of Business and Corporate Development at Avadel Technologies (AVDL), where he was instrumental in restructuring the company and
transforming it from $100,000,000 in enterprise value to $1 billion in three years. Mr. Lisi raised $121 million in equity, led
the sale of Flamel&rsquo;s contract manufacturing facility, rationalized the product pipeline, refocused the business development
effort, transformed the investor base and established Flamel&rsquo;s presence in Ireland. Prior to his position with Flamel, Mr.
Lisi spent 18 years investing in healthcare companies on a global basis at Mehta and Isaly (now OrbiMed), SAC Capital (portfolio
manager), Millennium Partners (portfolio manager), Panacea Asset Management (co-owner) and Deerfield Management (Partner). Mr.
Lisi serves on the Board of Mico Innovations, a next generation coronary and neurovascular stent company. Mr. Lisi received his
Masters in International Business from Pepperdine University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Amir
Avniel, President, Chief Operating Officer and Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
Avniel has served on AIT Ltd.&rsquo;s Board since 2011 and became AIT Ltd.&rsquo;s Chief Executive Officer in August 2014. He
has served on our Board and served as our Chief Executive Officer from January 13, 2017 to June 14, 2017. He has more than ten
years of management experience in the biotechnology industry. From 2013 through 2014, Mr. Avniel served as Strategy and Business
Development of A.B. Seeds, a wholly owned subsidiary of Monsanto Company. Mr. Avniel served as the Chief Executive Officer of
Rosetta Green Ltd. from 2010 through 2013 and led Rosetta Green in its acquisition by Monsanto. He also served as the president
and the Chief Executive Officer of Rosetta Genomics from 2006 to 2009, and Mr. Avniel is a named inventor in over 20 patent applications.
He studied computer science at the Academic College of Tel Aviv - Jaffa Israel and earned a Bachelor&rsquo;s degree in Social
Sciences and Humanities - from Open University in Israel. Prior to his academic studies, he served as an officer in the Israel
Defense Force, where he was awarded four commendations for excellence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Douglas
Beck, CPA, Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
Beck has been our Chief Financial Officer since November 1, 2018. He was the Chief Financial officer of JLM Couture Inc, from
February 16 until October 31, 2018, the Chief Financial Officer of Relmada Therapeutics, Inc. from December 2013 and was the Chief
Financial Officer for iBio, Inc. from January 2011 to March 2013. In addition, Mr. Beck serves on the New York State Society of
CPAs Chief Financial Officer and SEC committee<FONT STYLE="background-color: white">. </FONT>Mr. Beck is a graduate of Fairleigh
Dickinson University and is a licensed certified public accountant in New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ron
Bentsur, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
Bentsur joined AIT Ltd. in August 2015 and serves as a director. Mr. Bentsur has served as Chief Executive Officer and Director
of UroGen Pharma, Ltd. since August 2015. From 2009 through April 2015, Mr. Bentsur served as Chief Executive Officer and Director
of Keryx Biopharmaceuticals, Inc. Mr. Bentsur&rsquo;s tenure as CEO of Keryx Biopharmaceuticals culminated in the September 2014
FDA approval of Auryxia <SUP>TM</SUP> (ferric citrate) and its December 2014 U.S. launch. Prior to joining Keryx Biopharmaceuticals,
Inc., from 2006 to 2009, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Ltd. Prior to that, Mr. Bentsur
served as Vice President Finance and Chief Financial Officer of Keryx Biopharmaceuticals, Inc., as Director of Technology Investment
Banking at Leumi Underwriters, where he was responsible for all technology and biotechnology private placement and advisory transactions,
and as a New York City-based investment banker, primarily at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and
Business Administration with distinction from the Hebrew University of Jerusalem and an M.B.A., magna cum laude, from New York
University&rsquo;s Stern Graduate School of Business. Mr. Bentsur also serves as Director of Stemline Therapeutics, Inc. Ron&rsquo;s
vast industry experience is invaluable to our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Yoori
Lee, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Yoori Lee joined Beyond Air&rsquo;s Board of Directors in January 2018. She has served as Co-founder and President of Trio Health
Advisory Group, Inc. since 2013. Trio Health&rsquo;s mission is to improve the quality of care in patient outcomes through coordinating
the efforts of all patient care stakeholders. Prior to Trio Health, Ms. Lee spent over 15 years at Leerink Partners LLC, a leading
healthcare investment bank, where she was Managing Director, and Director of MEDACorp Services. Additionally, she helped found
the MEDACorp network, a cadre of experts including more than 35,000 healthcare professionals in diverse areas of practice such
as clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information
technology. Yoori&rsquo;s perspective on the industry is unique and provides Beyond Air with a distinct advantage over other companies
of our size and stage of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dr.
William Forbes, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
William Forbes joined Beyond Air&rsquo;s board of Director in August 2018. He brings to the Beyond Air Board more than 30 years
of pharmaceutical product development experience and, working with health authorities in the US and Europe, has contributed to
numerous marketing approvals spanning a diverse range of therapeutic areas. Dr. Forbes currently serves as the founder, President
and Chief Executive Officer of Vivelix Pharmaceuticals, Ltd., a clinical-stage pharmaceutical company focused on gastrointestinal
diseases since 2016. Prior to founding Vivelix, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also
Head of Medical and R&amp;D. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development &amp; Regulatory Affairs and Clinical
Research at a number of global pharmaceutical companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Robert
F. Carey</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mr.
Carey joined Beyond Air&rsquo;s Board of Directors in February 2019. He has an extensive track record of accomplishment within
the healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion
in initial public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor
on mergers, acquisitions, and strategic alliance transactions with a total deal value of more than $10 billion. Mr. Carey served
as executive vice president and chief business officer at Horizon Therapeutics plc from March 2014 to September 2019, during which
Horizon Therapeutics deployed in excess of $3 billion to acquire or license eight commercial products and three products in
development and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of
75%. Before Horizon, he spent more than 11 years as managing director and head of the life sciences investment banking group at
JMP Securities. Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities
for a total of 14 years. He received his B.B.A. in Accounting from the University of Notre Dame. Mr. Carey currently serves on
the board of Sangamo Therapeutics, Inc.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Erick
J. Lucera, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Erick
J. Lucera joined Beyond Air&rsquo;s Board of Directors in August 2017 and serves on our Audit Committee. He was appointed Chief
Financial Officer for AVEO Oncology, a NASDAQ traded biopharmaceutical company focused on targeted medicines for oncology and
other unmet medical needs in 2020. Erick was the Chief Financial Officer of Valeritas, a U.S. NASDAQ traded commercial stage
company developing new technology for diabetes from 2016 to 2019. Mr. Lucera served as Chief Financial Officer, Treasurer
and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary
biopharmaceutical company. While at Aratana, he helped grow the company&rsquo;s product pipeline through a series of acquisitions
and in licensing transactions financed through five public and private offerings of nearly $250 million. Before his career as
a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance,
the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital and as head of the healthcare research team at Independence
Investments. He holds a Certificate in Public Health from Harvard University, an MS in quantitative finance from Boston College,
an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera has obtained CFA,
CMA, and CPA designations. Erick&rsquo;s financial and industry background serve us well on many fronts, including our audit committee.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
of Office of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected at each annual meeting of stockholders for a term of one year. Each director shall serve until his successor
is duly elected and qualified or until his earlier death, resignation or removal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our current or former directors or executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors, executive officers, significant employees, promoters or control persons has been involved in any legal proceeding
in the past ten years that would require disclosure under Item 401(f) of Regulation S-K promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Committees </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has established three standing committees: the audit committee, the compensation committee and the nominating
committee. The current members of our audit committee are Erick Lucera, Ron Bentsur and Robert F. Carey with Erick Lucera serving
as chairperson. The current members of our compensation committee are Yoori Lee, Erick J. Lucera, and Ron Bentsur with Yoori Lee
serving as chairperson. The current members of our nominating committee are Erick Lucera, Yoori Lee and Dr. William Forbes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that Erick Lucera, Ron Bentsur and Robert F. Carey meet the additional test for independence
for audit committee members imposed by Securities and Exchange Commission (&ldquo;SEC&rdquo;) regulations and Section 5605(c)(2)(A)
of the NASDAQ Stock Market listing rules and that Erick J. Lucera, Yoori Lee and Ari Raved meet the additional test for independence
for compensation committee members imposed by Section 5605(d)(2)(A) of the NASDAQ Stock Market listing rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Audit
Committee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our audit committee is to assist the Board of Directors in the oversight of the integrity of our accounting
and financial reporting process, the audits of our consolidated financial statements, and our compliance with legal and regulatory
requirements. Our audit committee met four times during the year period ended March 31, 2019. The functions of our audit committee
include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hiring
    the independent registered public accounting firm to conduct the annual audit of our consolidated financial statements and
    monitoring its independence and performance; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the planned scope of the annual audit and the results of the annual audit; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    all audit services and permissible non-audit services provided by our independent registered public accounting firm; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the significant accounting and reporting principles to understand their impact on our consolidated financial statements; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our internal financial, operating and accounting controls with management, our independent registered public accounting firm
    and our internal audit provider; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements
    and our compliance with legal and regulatory requirements; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
    reviewing and discussing with management the effectiveness and adequacy of our system of internal controls; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    consultation with management and the independent auditors, reviewing the integrity of our financial reporting process and
    adequacy of disclosure controls; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    potential conflicts of interest under and violations of our code of conduct; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters
    and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving related-party transactions; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating, at least annually, our audit committee&rsquo;s charter. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to reviewing and approving related-party transactions, our audit committee will review related-party transactions for
potential conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to
which we are or may be a party in which the amount involved exceeds the lesser of $120,000 or 1% of total assets, and in which
any of our directors or executive officers or any other related person had or will have a direct or indirect material interest,
excluding, among other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit
committee could approve a related-party transaction if it determines that the transaction is in our best interests. Our directors
are required to disclose to this committee or the full Board of Directors any potential conflict of interest, or personal interest
in a transaction that our Board of Directors is considering. Our executive officers are required to disclose any related-party
transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party transactions and
their service as an officer or director of other entities. Any director involved in a related-party transaction that is being
reviewed or approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible,
the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as
practical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial literacy requirements of the SEC require that each member of our audit committee be able to read and understand fundamental
financial statements. In addition, at least one member of our audit committee must qualify as an audit committee financial expert,
as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act, and have financial sophistication in accordance
with the NASDAQ Stock Market listing rules. Our Board of Directors has determined that Erick Lucera qualifies as an audit committee
financial expert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
our independent registered public accounting firm and management periodically will meet privately with our audit committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation
Committee </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compensation committee is to assist our Board of Directors in exercising its responsibilities relating
to compensation of our executive officers and employees and to administer our equity compensation and other benefit plans. In
carrying out these responsibilities, this committee reviews all components of executive officer and employee compensation for
consistency with its compensation philosophy, as in effect from time to time. The functions of our compensation committee include,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designing
    and implementing competitive compensation, retention and severance policies to attract and retain key personnel; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and formulating policy and determining the compensation of our Chief Executive Officer, our other executive officers and employees;
    </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to our Board of Directors the compensation of our non-employee directors; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating our compensation risk policies and procedures; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity incentive plans and granting equity awards to our employees, consultants and directors under these plans; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our performance bonus plans and granting bonus opportunities to our employees, consultants and non-employee directors under
    these plans; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    required from time to time, preparing the analysis or reports on executive officer compensation required to be included in
    our annual proxy statement; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
    compensation consultants or other advisors it deems appropriate to assist with its duties; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating, at least annually, our compensation committee&rsquo;s charter. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee retains sole authority to hire any compensation consultant, approve such consultant&rsquo;s compensation,
determine the nature and scope of its services, evaluate its performance, and terminate its engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee will review our compensation policies and practices for all employees, including our named executive officers,
as they relate to risk management practices and risk-taking incentives to assess and determine that there are no risks arising
from these policies and practices that are reasonably likely to have a material adverse effect on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominating
committee </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our nominating committee is to assist our Board of Directors in promoting the best interest of our company
and our stockholders through the implementation of sound corporate governance principles and practices. The functions of our nominating
committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing and evaluating candidates to serve on our Board of Directors; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
    the minimum qualifications for service on our Board of Directors; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to our Board of Directors an annual self-evaluation process for our Board of Directors and overseeing the
    annual self-evaluation process; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing,
    as appropriate, a set of corporate governance principles, and reviewing and recommending to our Board of Directors any changes
    to such principles; and </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">periodically
    reviewing and evaluating our nominating committee&rsquo;s charter. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has a critical role in guiding our strategic direction and overseeing the management of our business, and accordingly,
we seek to attract and retain highly qualified directors who have sufficient time to engage in the activities of our Board of
Directors and to understand and enhance their knowledge of our industry and business plans. In evaluating the suitability of individual
candidates, the Board, in approving (and, in the case of vacancies, appointing) such candidates, may take into account many factors,
including: personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer
or former officer of a publicly held company; strong finance experience; experience relevant to our industry; experience as a
board member or executive officer of another publicly held company; relevant academic expertise or other proficiency in an area
of our operations; diversity of expertise and experience in substantive matters pertaining to our business relative to other board
members; diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence
and specialized experience; practical and mature business judgment, including, but not limited to, the ability to make independent
analytical inquiries; and any other relevant qualifications, attributes or skills. The Board evaluates each individual in the
context of the Board as a whole, with the objective of assembling a group that can best perpetuate the success of the business
and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various
areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholder
Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not have a formal policy regarding stockholder communications with our Board of Directors, stockholders may communicate
with our Board of Directors, or any individual director on our Board of Directors, by writing to us at the address of our principal
executive offices, addressing the communication to the attention of our Chief Executive Officer, and specifying the Board of Directors
or, if applicable, the individual member thereof as the intended recipient of the communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Leadership Structure and Role in Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board does not have a formal policy on whether or not the roles of Chairman of the Board and Chief Executive Officer should be
separate and believes that it should retain the flexibility to make this determination in the manner it believes will provide
the most appropriate leadership for our company from time to time. Currently, Steven A. Lisi serves as Chairman of the Board and
Chief Executive Officer, working closely with former CEO and present COO and President, Amir Avniel. Mr. Lisi sets the strategic
direction for the company and provides day-to-day leadership. As Chairman of the board of directors, Mr. Lisi further oversees
the agenda for board meetings in collaboration with the other board members</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors oversees our exposure to risk through its interaction with management and receipt from management of periodic
reports outlining matters related to financial, operational, regulatory, legal and strategic risks. Risk assessment and oversight
are an integral part of our governance and management processes. Our board of directors encourages management to promote a culture
that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic
and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the
year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these
risks with the board of directors at regular board meetings as part of management presentations that focus on particular business
functions, operations or strategies and presents the steps taken by management to mitigate or eliminate such risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of business conduct and ethics that applies to all our directors, officers (including our Chief Executive
Officer, Chief Financial Officer and any person performing similar functions) and employees. We have made our Code of Ethics available
on our website at www.beyondair.net.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delinquent
Section 16(a) Reports </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filer</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Late Reports </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Transactions not Reported Timely</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Carey</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one Form 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Lisi </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one Form 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Forbes
    </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one Form 3; one
    Form 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori Lee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one Form 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir Avniel</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one Form 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas Beck</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">two Form 4s </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">two</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_019"></A>ITEM
11. EXECUTIVE COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the compensation earned by our named executive officers for the years ended
March 31, 2020 and March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
                                         and</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
        Position</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary
    Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
    Stock Awards (A)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
    Awards (A)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Lisi.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">546,535</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,300</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-
    </FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,268,835</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer and Chairman of the Board</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">462,007</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,927,657</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,839,664</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Avniel </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">400,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">264,115</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,600</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">819,715</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>President,
                                         Chief Operating Officer </I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>and
        Director</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">400,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">220,200</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">727,790
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,347,990</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Beck, CPA (1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,800
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">406,250
    </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Financial Officer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104,167</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,012</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">404,179</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
                                         Newman</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">237,965</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155,600</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">643,565</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inhouse
    Counsel</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">229,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">492,493</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">971,993</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duncan
                                         Fatkin (2)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,150
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">516,900</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Commercial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104,167</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">312,934
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,101</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    column represents the grant date fair value of the award in accordance with stock-based compensation rules under Accounting
    Standards Codification Topic 718</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Beck was appointed as the Company&rsquo;s Chief Financial Officer on November 1, 2018.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Fatkin was appointed as the Company&rsquo;s Chief Commercial Officer on January 14, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
and Service Agreements with Executive Officers; Consulting and Directorship Services with Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employment and service agreements with our Executive Officers and Directors contain provisions standard for a company in our industry
regarding non-competition, confidentiality of information and assignment of inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Directors
Agreement with Steven A. Lisi</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2016, the board of directors of AIT Ltd., appointed Steven Lisi to serve as a Member of its Board of Directors, effective
as of June 24, 2016, and concurrently entered into an agreement with Mr. Lisi to serve as a member of the Board of Directors pursuant
to which, among other things, the Company agreed to pay as compensation and benefits upon consummation of a financing round in
the United States (&ldquo;Financing Round&rdquo;) (i) an annual retainer of $40,000 to be paid on equal monthly installments;
(ii) one-time bonus amounted to $150,000 with 30 days from completion of the Financing Round (&ldquo;One-Time Bonus&rdquo;) and
(iii) restricted shares equal to 3% of all issued and outstanding fully diluted shares of the Company after the completion of
the Financing Round (including any green shoe or similar) with vesting schedule of 33.33% of such shares to be vested immediately
upon the completion of a Financing Round, 33.33% of such shares to be vested after 6 month anniversary of the completion of a
Financing Round and the remaining 33.33% of such shares after 12 month anniversary of the completion of a Financing Round. Upon
the closing of a change of control transaction, as defined in the agreement, the unvested options shall be accelerated and vested
immediately. The One-Time Payment was paid on January 27, 2017. The Board of AIT Ltd. determined to issue to Mr. Lisi an aggregate
of 364,286 ordinary shares issuable under this agreement in connection with financing transactions contemplated immediately prior
to the Merger. The shares were exchanged for shares of our common stock in connection with the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the board of directors approved a consulting fee payable to Mr. Lisi in an amount equal to $18,000 per month which
terminated upon his acceptance of the CEO position in June, 2017 at which time, the Board of Directors approved a salary of $260,000
per annum to Mr. Lisi. In March 2018, the board of directors approved a salary of $450,000 per annum to Mr. Lisi pursuant to an
employment agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 1, 2018, we entered into an employment agreement with Mr. Lisi with an annual salary of $450,000. Pursuant to the terms
and conditions of employment, Mr. Lisi will receive 400,000 options to purchase common stock vesting over a period of three years.
In the event of termination without cause, Mr. Lisi will be entitled to severance equal to twenty-four months of base salary,
a lump sum payment 1.5 times that of the most recent earned short term incentive award and all outstanding options would
automatically vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Amir Avniel </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2014, we entered into a service agreement with Amir Avniel, employing him to provide the Company with professional
Chief Executive Officer services, effective as of October 1, 2014. As thereafter amended in September, 2015, Mr. Avniel was entitled
to a base salary of $15,800 per month. If Mr. Avniel is terminated without cause, he shall be entitled to a salary continuation
at the rate then in effect for a period of 90 days from the effective date of termination. In the event Mr. Avniel is terminated
within two (2) years following the closing of a change of control of the Company, he <FONT STYLE="background-color: white">shall
be entitled to a salary continuation at the rate then in effect for a period of seven (7) months following the effective date
of termination.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2016, Mr. Avniel waived the accrued but unpaid salary owed by the Company to him in the total aggregate amount of
$304,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February, 2017, the Board of Directors approved a salary to Mr. Avniel of $260,000 per annum, which was thereafter confirmed by
the Board of Directors in June 2017 when Mr. Avniel resigned from the position of CEO and assumed the position of COO. In March
2018, the board of directors increased Mr. Avniel&rsquo;s annual salary to $400,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 1, 2018, we entered into an employment agreement with Mr. Avniel with an annual salary of $400,000. Pursuant to the terms
and conditions of employment, Mr. Avniel will receive 250,000 options to purchase common stock vesting over a period of three
years. In the event of termination without cause, Mr. Avniel will be entitled to severance equal to twenty-four months of base
salary, a lump sum payment equal to 1.5 times that of the most recent earned short-term incentive award and all outstanding options
would automatically vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Offer
Letter Agreement with Douglas Beck</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an employment offer letter agreement between the Company and Mr. Beck dated October 17, 2018. Mr. Beck will be
paid an annual salary of $250,000 per year. The Company issued Mr. Beck options to purchase 85,000 shares of common stock of the
Company at an exercise price of $4.25 per share. Under Mr. Beck&rsquo;s offer letter his employment is at will. In the event of
termination without cause he will be entitled to a severance equal to one month&rsquo;s base salary for every six months employed
by the Company not to exceed six months of base salary and the options will automatically vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement with Adam Newman</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 1, 2018 we entered into an employment agreement with Mr. Newman with an annual salary of $450,000. Pursuant to the terms
and conditions of employment, Mr. Newman will receive 150,000 options to purchase common stock vesting over a period of three
years. In the event of termination without cause, Mr. Newman will be entitled to severance equal to twenty-four months of base
salary, a lump sum payment equal to 1.5 times that of the most recent earned short term incentive award and all outstanding options
would automatically vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Offer
Letter Agreement with Duncan Fatkin</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an employment offer letter agreement between the Company and Mr. Fatkin December 20, 2018, Mr. Fatkin will be
paid an annual salary of $250,000 per year. The Company issued Mr. Fatkin options to purchase 85,000 shares of common stock of
the Company at an exercise price of $4.25 per share. Under Mr. Fatkin&rsquo;s offer letter his employment is at will. In the event
of termination without cause he will be entitled to a severance equal to one month&rsquo;s base salary for every six months employed
by the Company not to exceed six months of base salary. In the event of a change of control of the Company, he will receive severance
payments equal to six (6) months&rsquo; base salary and the options will automatically vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Compensation Plan Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain the Second</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Amended and Restated 2013 Equity Incentive
Plan (the &ldquo;2013 Plan&rdquo;). <FONT STYLE="background-color: white">The 2013 Plan provides for the grant of incentive stock
options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance
share awards, and other stock-based awards (collectively, the &ldquo;stock awards&rdquo;). Stock awards may be granted under the
2013 Plan to our employees, directors and consultants, other than incentive stock options which may only be granted to employees
of the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
maximum number of shares of common stock available for issuance under the 2013 Plan is 4,100,000 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2013 Plan is scheduled to terminate on August 13, 2028. No stock awards shall be granted pursuant to the 2013 Plan after such
date, but Awards theretofore granted may extend beyond that date. The Board may suspend or terminate the Plan at any earlier date
pursuant to the 2013 Plan. No stock awards may be granted under the Plan while the Plan is suspended or after it is terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the total number of outstanding options and shares available for other future issuances of options
under the 2013 Plan as of March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan
    Category</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares<BR>
    to be Issued Upon<BR> Exercise of<BR> Outstanding<BR> Options,<BR>
    Warrants<BR> and Rights</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-Average<BR>
    Exercise Price of<BR> Outstanding<BR>
    Options,<BR> Warrants<BR>
    and Rights</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares<BR> Remaining<BR>
    Available for<BR>
    Future Issuance<BR> Under the Equity<BR> Compensation<BR>
    Plan<BR> (Excluding Shares<BR> in First Column)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity compensation plans
    approved by stockholders -</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">785,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.54</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">221,047</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity compensation
    plans not approved by stockholders</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,268,589</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.50</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,053,589</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.77</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">221,047</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards as of March 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="23" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
    awards</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    of Grant</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of securities underlying unexercised options (#) exercisable</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of securities underlying unexercised options (#)<BR>
    unexcercisable</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
    incentive plan awards: Number of securities underlying unexercised unearned<BR>
    options (#)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
    exercise<BR>
    price ($)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
    expiration<BR>
    date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of<BR>
    shares or<BR>
    units of<BR>
    stock that<BR>
    have not<BR>
    vested (#)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Lisi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/13/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">187,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,600</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Avniel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/13/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">140,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,600</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/20/2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/20/2027</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Beck,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/01/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,250</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/01/2028</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">CPA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,250</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam
    Newman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/13/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,400</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/01/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,600</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45,500</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/30/2017
    (1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/20/2027</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duncan
    Fatkin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,250</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,750</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.05</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/14/2029</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,000
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.32</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/11/2030</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Received
    for performing legal services for the Company prior to being employed by the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
serving as both an Officer and a Director of the Company are only included in the Executive Compensation Table above for the year
ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    earned or paid in cash <BR>($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    awards <BR>($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option
    awards<BR> ($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-equity
    incentive plan compensation<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonqualified
    deferred compensation earnings <BR>($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    Other Compensation <BR>($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    <BR>($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 27%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
    William Forbes</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ron Bentsur</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Erick J. Lucera</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoori Lee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert F. Carey</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">97,250</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2020, the Board of Directors received options to purchase 25,000 shares of common and each option
expires in ten year from the date of grant. Compensation expense was based upon the grant date fair value of the award in accordance
with stock-based compensation rules under Accounting Standards Codification Topic 718.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_020"></A>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of our common stock by each person known by us
to beneficially own more than 5.0% of any class of our voting securities together with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of our directors and executive officers as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination
of beneficial ownership of securities. Except as indicated in the footnotes to this table, each beneficial owner named in the
table below has sole voting and sole investment power with respect to all shares beneficially owned. Percentage computations are
based on 16,841,555 shares of our common stock outstanding as of June 19, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the warrants issued by the Company to the holders listed below, no holder may exercise a warrant to the extent such
exercise would cause such holder, together with its affiliates and any other persons acting as a group with such holder or any
of its affiliates, to have acquired a number of shares of common stock which would exceed 4.99%, or, in the case of certain holders
indicated below, 9.985%, (subject to an increase of such percentage to 9.99% on 61 days&rsquo; notice by the holder to the Company)
of our then outstanding common stock, excluding for purposes of such determination shares of common stock issuable upon exercise
of warrants that have not been exercised. We refer to the foregoing limitation applicable to each individual holder or group as
the &ldquo;Ownership Cap.&rdquo; The share numbers in the table below do not reflect the Ownership Cap, but the figures contained
in the &ldquo;Percentage of Outstanding Shares&rdquo; column reflect the Ownership Cap applicable to each holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    and Address of Beneficial Owner (1)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of <BR>
    Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage
    of Outstanding<BR>
    Shares (2)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">5% Owners</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 12pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 59%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Charles Mosseri Marlio</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,524,214</FONT></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deerfield Partners, L.P.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">856,863</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%(4)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Executive Officers and Directors</I></B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Steven A. Lisi</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,389,709</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%(4)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amir Avniel</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">835,218</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%(4)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ron Bentsur</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">362,918</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. William Forbes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert F. Carey</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,668</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(10)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Erick Lucera</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,842</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(11)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoori Lee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,789</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(12)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Douglas Beck,
    CPA</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,460</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive
    Officers and Directors as a Group (Eight persons)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,721,709</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.2</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than one percent (1.0%).</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    address of these persons, unless otherwise noted, is c/o Beyond Air, Inc., 825 East Gate Boulevard, Suite 320 Garden City,
    New York, 11530.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of common stock beneficially owned and, except as limited by the Ownership Cap, the respective percentages of beneficial ownership
    of common stock includes for each person or entity shares issuable on the exercise of all options and warrants and the conversion
    of other convertible securities beneficially owned by such person or entity that are currently exercisable or will become
    exercisable or convertible within 60 days following June 19, 2020. Such shares, however, are not included for the purpose
    of computing the percentage ownership of any other person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based,
    in part, on information provided on Schedule 13G/A filed with the SEC on March 13, 2020. Includes 108,816 shares of common
    stock issuable upon exercise of the warrants issued to Mr. Mosseri Marlio in connection with Facility Loan Agreement
    in March 2020.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based,
in part, on information provided on Schedule 13G/A filed with the SEC on January 23, 2020 by Deerfield Mgmt, L.P.,
Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P. and James E. Flynn.
Includes 856,863 shares of common stock issuable upon exercise of the warrants issued to Deerfield Special Situations Fund, L.P.
in the Company&rsquo;s 2017 and 2018 offerings and now held by Deerfield Partners, L.P. James E. Flynn is the President
of J.E. Flynn Capital, LLC, which is the general partner of Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P.
and Deerfield Mgmt, L.P., which is the general partner of Deerfield Special Situations Fund, L.P. and Deerfield Partners
L.P. Flynn Management LLC is the general partner of Deerfield Management Company, L.P.. The reporting persons&rsquo; business
address is 780 Third Avenue, 37th Floor, New York, NY 10017.</FONT></P>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    provisions of the warrants issued by the Company in its 2017 and 2018 offerings beneficially owned by the holder restrict
    the exercise of such warrants to the extent that, upon such exercise, the number of shares then beneficially owned by the
    holder and any other person or entities with which such holder would constitute a Section 13(d) &ldquo;group&rdquo; would
    exceed 4.99% (subject to an increase of such percentage to 9.99%) of the total number of our then-outstanding shares of common
    stock.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    200,446 shares of common stock issuable upon exercise of the warrants issued to Mr. Lisi in the Company&rsquo;s 2017 and 2018
    offerings. Includes 362,5000 vested options to purchase shares of common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    45,676 shares of common stock issuable upon exercise of the warrants issued to Mr. Avniel in the Company&rsquo;s 2017 and
    2018 offerings. Includes 275,000 vested options to purchase common stock and 32,666 shares of common stock held by Dandelion
    Investments Ltd., over which Mr. Avniel has sole voting and dispositive power. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    73,419 shares of common stock issuable upon exercise of the warrants issued to Mr. Bentsur in the Company&rsquo;s 2017 and
    2018 offerings. Includes 362,5000 vested options to purchase shares of common stock.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    8,250 vested options to purchase common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    6,250 vested options to purchase common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,171 shares of common stock issuable upon exercise of the warrants issued to Mr. Lucera in the Company&rsquo;s 2018 offering,
    and 17,500 vested options to purchase common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,342 shares of common stock issuable upon exercise of the warrants issued to Ms. Lee in the Company&rsquo;s 2018 offering
    and 16,250 vested options to purchase common stock. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    25,000 vested options to purchase common stock. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_021"></A><FONT STYLE="font-size: 10pt"><B>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
with Related Persons</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to reviewing and approving related-party transactions, our audit committee will review related-party transactions for
potential conflicts of interests or other improprieties. Under SEC rules, related-party transactions are those transactions to
which we are or may be a party in which the amount involved exceeds the lesser of $120,000 or 1% of total assets, and in which
any of our directors or executive officers or any other related person had or will have a direct or indirect material interest,
excluding, among other things, compensation arrangements with respect to employment and Board of Directors membership. Our audit
committee could approve a related-party transaction if it determines that the transaction is in our best interests. Our directors
are required to disclose to this committee or the full Board of Directors any potential conflict of interest, or personal interest
in a transaction that our Board of Directors is considering. Our executive officers are required to disclose any related-party
transaction to the audit committee. We also poll our directors on an annual basis with respect to related-party transactions and
their service as an officer or director of other entities. Any director involved in a related-party transaction that is being
reviewed or approved must recuse himself or herself from participation in any related deliberation or decision. Whenever possible,
the transaction should be approved in advance and if not approved in advance, must be submitted for ratification as promptly as
practical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has determined that each of Ron Bentsur, Erick Lucera, Yoori Lee, William Forbes and Robert F. Carey is independent
within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules and the rules and regulations promulgated by the SEC. In making
its independence determinations, the board of directors sought to identify and analyze all of the facts and circumstances related
to any relationship between a director, his immediate family and our company and our affiliates and did not rely on categorical
standards other than those contained in the NASDAQ rule referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchases
of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2019, Steven Lisi purchased 58,252 shares of our common stock at a purchase price of $5.15 per share, or $300,000. On
December 12, 2019, Mr. Lisi purchased 190,437 shares of our common stock at a purchase price of $3.66 per share, or $697,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 3, 2019, Charles Mosseri-Marlio purchased 385,000 shares of common stock at a purchase price of $5.00 per share or $1,925,000.
On December 12, 2019, Mr. Mosseri-Marlio purchased 150,273 shares of our common stock at a purchase price of $3.66 per share,
or $500,000. On March 17, 2020, Mr. Mosseri-Marlio loaned us $3,160,000 pursuant to the terms of the Facility Agreement and we
issued him warrants to purchase 108,816 shares of common stock at an exercise price of $7.26 per share.</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_022"></A>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
Fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
aggregate fees billed for the fiscal year ended March 31, 2019 for professional services rendered by Kost Forer Gabbay
&amp; Kasierer, a Member of Ernst &amp; Young Global for quarterly reviews of our interim financial statements and services normally
provided by the independent accountant in connection with statutory and regulatory filings or engagements for this fiscal
period were as follows:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended<BR> March 31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Fees</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Related Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,870</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,870</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fees billed for the fiscal year ended March 31, 2019 for professional services rendered by Marcum LLP for quarterly
reviews of our interim financial statements and services normally provided by the independent accountant in connection with statutory
and regulatory filings or engagements for this fiscal period were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Fees</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,900</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Related Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,900</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fees billed for the fiscal year ended March 31, 2020 and March 31, 2019 for professional services rendered by Friedman
LLP for the audit of our annual financial statements provided by the independent accountant in connection with statutory and regulatory
filings or engagements for this fiscal period were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended<BR>
                                         </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended<BR>
                                         </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                31, 2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Fees</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">207,250</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92,037</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Related Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other Fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">207,250</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92,037</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the above table, &ldquo;audit fees&rdquo; are fees billed by our company&rsquo;s external auditor for services provided in auditing
our company&rsquo;s annual financial statements for the subject year. Audit fees also include professional services performed
for filing of the Company&rsquo;s registration statement on Form S-1 and S-3 for equity offerings, Form S-8 for registering restricted
stock and stock options and other filings. &ldquo;Audit-related fees&rdquo; are fees not included in audit fees that are billed
by the auditor for assurance and related services that are reasonably related to the performance of the audit review of our company&rsquo;s
financial statements. &ldquo;Tax fees&rdquo; are fees billed by the auditor for professional services rendered for tax compliance,
tax advice and tax planning. &ldquo;All other fees&rdquo; are fees billed by the auditor for products and services not included
in the foregoing categories.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Policy
on Pre-Approval by Audit Committee of Services Performed by Independent Auditors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed
and approved by the audit committee before the respective services were rendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors has considered the nature and amount of fees billed by each of Kost Forer Gabbay &amp; Kasierer, a Member of
Ernst &amp; Young Global, Marcum LLP and Friedman LLP, respectively, and believes that the provision of services for activities
unrelated to the audit, if any, is compatible with maintaining such auditors&rsquo; independence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_023"></A>PART
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_024"></A><FONT STYLE="font-size: 10pt"><B>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Financial Statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">See
Index to Consolidated Financial Statements on page F-1. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Finance Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Agreement
    and Plan of Merger and Reorganization, dated as of December 29, 2016, by and among AIT Therapeutics, Inc. and Advanced Inhalation
    Therapies Ltd., filed as Exhibit 2.1 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017
    and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">First
    Amendment to Agreement and Plan of Merger and Reorganization, dated as of January 12, 2017, by and among AIT Therapeutics,
    Inc. and Advanced Inhalation Therapies Ltd., filed as Exhibit 2.2 to our Current Report on Form 8-K, as amended and filed
    with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_2-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Merger
    Completion Certificate, dated December 29, 2016, by and among Red Maple Ltd. and Advance Inhalation (AIT) Ltd., filed as Exhibit
    2.3 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Certificate of Incorporation of AIT Therapeutics, Inc., filed as Exhibit 3.1 to our Current Report on Form 8-K,
    as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Bylaws of AIT Therapeutics, Inc. filed as Exhibit 3.2 to our Current Report on Form 8-K, as amended and filed
    with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315219009826/ex3-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Amended and Restated Certificate of Incorporation, dated June 25, 2019, filed as Exhibit 3.3 to our Annual
    Report on Form 10-K filed with the SEC on June 28, 2019 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Common Stock certificate, filed as Exhibit 4.1 to our Current Report on Form 8-K, as amended and filed with the SEC on
    March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant
    to Purchase Common Stock, by and among AIT Therapeutics, Inc. and the Holders party thereto, filed as Exhibit 10.3 to our
    Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317001048/exhibit_4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant
    to Purchase Common Stock, by and among AIT Therapeutics, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current
    Report on Form 8-K, as amended and filed with the SEC on April 4, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891318000674/exhibit_4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant
    to Purchase Common Stock, by and among AIT Therapeutics, Inc. and the Holders party thereto, filed as Exhibit 4.1 to our Current
    Report on Form 8-K, as amended and filed with the SEC on February 22, 2018 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315220000738/formdef14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Beyond
    Air, Inc. Second Amended and Restated 2013 Equity Incentive Plan (included in Appendix A to our Definitive Proxy Statement
    filed on January 17, 2020 and incorporated herein by reference).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315220004447/ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant
    to Purchase Common Stock, filed as exhibit 4.1 to our Current Report on Form 8-K filed on March 17, 2020 and incorporated
    herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex4-7.htm"><FONT STYLE="font-size: 10pt">Description
    of the Company&rsquo;s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as amended.</FONT></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Agreement for the Transfer and Assumption of Obligations Under the Securities Purchase and Registration Rights
    Agreements, dated as of January 12, 2017, by and among AIT Therapeutics, Inc. and Advanced Inhalation Therapies Ltd., filed
    as Exhibit 10.1 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein
    by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Securities
    Purchase and Registration Rights Agreement, by and among Advanced Inhalation Therapies Ltd. and the Investors party thereto,
    filed as Exhibit 10.2 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated
    herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-10.htm" STYLE="-sec-extract: exhibit">License
    Agreement, dated as of November 1, 2011, by and between Advanced Inhalation Therapies Ltd. and The UBC, filed as Exhibit 10.10
    to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.4^</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000132/exhibit_10-8.htm" STYLE="-sec-extract: exhibit">Non-Exclusive
    Patent License Agreement, dated as of October 22, 2013, by and between Advanced Inhalation Therapies Ltd. and SensorMedics
    Corporation, filed as Exhibit 10.9 to our Registration Statement on Form S-1(File No. 333-216287), and incorporated herein
    by reference.</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Option
    Agreement, dated as of August 31, 2015, by and between Advanced Inhalation Therapies Ltd. and Pulmonox Technologies Corporation,
    filed as Exhibit 10.13 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated
    herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Tenth
    Amendment to Option Agreement, dated as of December 31, 2016, by and between Advanced Inhalation Therapies Ltd. and Pulmonox
    Technologies Corporation, filed as Exhibit 10.14 to our Current Report on Form 8-K, as amended and filed with the SEC on March
    15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000777/exhibit_10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated as of June 24, 2016, by and between Advanced Inhalation Therapies Ltd. and Steven Lisi, filed as Exhibit
    10.15 to our Current Report on Form 8-K, as amended and filed with the SEC on March 15, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000658/exhibit_10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated as of October 1, 2014, by and between Advanced Inhalation Therapies Ltd. and Amir Avniel, filed as Exhibit
    10.17 to our Registration Statement on Form S-1 (File No. 333-216287), and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000658/exhibit_10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated as of September 17, 2015, by and between Advanced Inhalation Therapies Ltd. and Amir Avniel, filed as Exhibit
    10.18 to our Registration Statement on Form S-1 (File No. 333-216287), and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317000658/exhibit_10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Waiver
    of the back salary, dated as of October 31, 2016, by and between Advanced inhalation Therapies Ltd. and Amir Avniel, filed
    as Exhibit 10.19 to our Registration Statement on Form S-1 (File No. 333-216287), and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317001048/exhibit_10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Stock
    Purchase and Registration Rights Agreement, dated March 31, 2017, by and among the Company and the Investors party thereto,
    filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on April 4, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000117891317001048/exhibit_10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Subscription Agreement, dated March 31, 2017, by and among the Company and the Investors party thereto, filed as Exhibit
    10.2 to our Current Report on Form 8-K, filed with the SEC on April 4, 2017 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000117891318000674/exhibit_10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement, by and among AIT Therapeutics, Inc. and the Investors party thereto, filed as Exhibit 10.1 to our Current
    Report on Form 8-K, as amended and filed with the SEC on February 22, 2018 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000117891318000674/exhibit_10-2.htm" STYLE="-sec-extract: exhibit">Registration
    Rights Agreement, by and among AIT Therapeutics, Inc. and the Investors party thereto, filed as Exhibit 10.2 to our Current
    Report on Form 8-K, as amended and filed with the SEC on February 22, 2018 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315218011511/ex10-1.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement, dated as of August 10, 2018, by and between AIT Therapeutics, Inc. and Lincoln Park Capital Fund, LLC.,
    filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on August 13, 2018 and incorporated herein by
    reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315218011511/ex10-2.htm" STYLE="-sec-extract: exhibit">Registration
    Rights Agreement, dated as of August 10, 2018, by and between AIT Therapeutics, Inc. and Lincoln Park Capital Fund, LLC, filed
    as Exhibit 10.2 to our Current Report on Form 8-K, filed with the SEC on August 13, 2018 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315218015100/ex10-1.htm" STYLE="-sec-extract: exhibit">Offer
    letter between AIT Therapeutics, Inc. and Douglas J. Beck, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed
    with the SEC on November 1, 2018 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18 </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315219008872/ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Subscription Agreement, dated as of June 3, 2019, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the
    SEC on June 7, 2019 and incorporated herein by reference.</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19^</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315219002083/ex10-1.htm" STYLE="-sec-extract: exhibit">License,
    Development and Commercialization Agreement, dated January 23, 2019, by and between AIT Therapeutics, Inc. and Circassia Limited,
    filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q on February 14, 2019 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.20</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315219019117/ex1-1.htm" STYLE="-sec-extract: exhibit">Underwriting
    Agreement, dated December 10, 2019, by and between Beyond Air, Inc. and SunTrust Robinson Humphrey, Inc., filed as Exhibit
    1.1 to our Current Report on Form 8-K, filed with the SEC on December 10, 2019 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.21</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315219019117/ex10-1.htm" STYLE="-sec-extract: exhibit">Form
    of Purchase Agreement with U.S. Investors, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on
    December 10, 2019 and incorporated herein by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.22</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315219019117/ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Purchase Agreement with Foreign Investors, filed as Exhibit 10.2 to our Current Report on Form 8-K, filed with the SEC
    on December 10, 2019 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.23</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315220004447/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Facility
    Agreement, dated March 17, 2020, filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on March 17,
    2020 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.24</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1641631/000149315220005739/ex1-1.htm" STYLE="-sec-extract: exhibit">At-The-Market
    Equity Offering Sales Agreement, dated April 2, 2020, by and among the Company, SunTrust Robinson Humphrey, Inc. and Oppenheimer
    &amp; Co., filed as Exhibit 1.1 to our Current Report on Form 8-K, filed with the SEC on April 3, 2020 and incorporated herein
    by reference.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.25</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315220009517/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Purchase
    Agreement, dated May 14, 2020, by and between Beyond Air, Inc. and Lincoln Park Capital Fund, LLC, filed as Exhibit 10.1 to
    our Current Report on Form 8-K, filed with the SEC on May 14, 2020 and incorporated herein by reference.</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></P></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1641631/000149315220009517/ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Registration
        Rights Agreement, dated May 14, 2020, by and between Beyond Air, Inc. and Lincoln Park Capital Fund, LLC, filed as Exhibit
        4.1 to our Current Report on Form 8-K, filed with the SEC on May 14, 2020 and incorporated herein by reference.</FONT></A></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex21-1.htm"><FONT STYLE="font-size: 10pt">List
    of subsidiaries of Beyond Air, Inc. </FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex23-1.htm"><FONT STYLE="font-size: 10pt">Consent
    of Friedman LLP</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex31-1.htm"><FONT STYLE="font-size: 10pt">Rule
    13a-14(a) / 15d-14(a) Certification of Principal Executive Officer</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex31-2.htm"><FONT STYLE="font-size: 10pt">Rule
    13a-14(a) / 15d-14(a) Certification of Principal Financial Officer</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex32-1.htm"><FONT STYLE="font-size: 10pt">Section
    1350 Certification of Principal Executive Officer</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex32-2.htm"><FONT STYLE="font-size: 10pt">Section
    1350 Certification of Principal Financial Officer</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy
    Extension Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy
    Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy
    Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy
    Extension Labels Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy
    Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>



<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Management contract or compensation plan arrangement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">^
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>Item
16. Form 10-K Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
with respect to this item is not required and has been omitted at the Company&rsquo;s option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_026"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following
persons on behalf of the Registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
June 23, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
    AIR, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Steven Lisi</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
                                         Lisi</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chairman
        and Chief Executive Officer </I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
        Executive Officer)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Steven Lisi</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Lisi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Douglas Beck</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas
    Beck</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Amir Avniel</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir
    Avniel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Erick Lucera</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erick
    Lucera</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yoori Lee</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoori
    Lee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    William Forbes</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Forbes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ron Bentsur</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
    Bentsur</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Carey</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Carey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: split_01 -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
OF MARCH 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_027"><FONT STYLE="font-size: 10pt"><B>Reports
    of Independent Registered Public Accounting Firm</B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-2</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_028"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Balance Sheets</B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-3</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_029"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Operations </B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-4</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_030"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Changes in Shareholders&rsquo; Equity </B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-5
    - F-6</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_032"><FONT STYLE="font-size: 10pt"><B>Consolidated
    Statements of Cash Flows</B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-7</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_033"><FONT STYLE="font-size: 10pt"><B>Notes
    to Consolidated Financial Statements</B></FONT></A></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F-8
    - F-30</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_027"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.) and Subsidiaries</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheet of Beyond Air, Inc. (formerly: AIT Therapeutics, Inc.) and Subsidiaries
(the &ldquo;Company&rdquo;) as of March 31, 2020 and 2019, and the related consolidated statements of operations, stockholders&rsquo;
equity and cash flows for each of the years in the two year period ended March 31, 2020, and the related notes (collectively referred
to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of March 31, 2020 and 2019, and the results of its operations and its cash flows for
each of the years in the two-year period ended March 31, 2020, in conformity with accounting principles generally accepted in
the United States of America.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but
not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provides a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
        Friedman LLP</I></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
        have served as the Company&rsquo;s auditor since 2019.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
    Hanover, New Jersey</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 96; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_028"></A><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 0 0 auto; width: 100%"><DIV STYLE="margin-top: 0; font-size: 1pt; border-top: Black 1.5pt solid; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
    31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
    31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,829,275</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,340,203</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,635,836</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,934</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
    securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,542,667</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current assets and prepaid expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,149,806</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">788,409</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,970</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,681,887</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,688,213</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensing
    right to use technology</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">412,763</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">495,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,757</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,337</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">244,872</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    ASSETS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,434,744</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,428,085</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND SHAREHOLDERS&rsquo; EQUITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,256,229</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,164,672</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,097,534</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,567,638</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">873,190</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,263,294</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    to be issued to a vendor</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,342</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    payable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">335,358</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">263,604</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,871,653</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,403,208</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,581</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facility
    Agreement loan, net </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,339,065</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,342,299</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,403,208</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&rsquo;
    equity</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.0001 par value per share: 100,000,000 shares authorized, 16,056,360 and 8,714,815 shares issued and outstanding
    as of March 31, 2020 and March 31, 2019, respectively</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,606</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">871</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury
    stock </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,702,915</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,693,578</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57,587,076</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,644,572</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    shareholders&rsquo; equity</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,092,445</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,024,877</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,434,744</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,428,085</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_029"></A><FONT STYLE="font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
        31, 2020</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    Ended <BR>
    March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    revenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,390,104</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,724,001</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,648,920</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,929,558</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,883,119</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,852,988</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,141,935</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,058,545</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income (loss)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Realized
    and unrealized loss on available for sale marketable securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,075,602</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,581,193</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    income</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,716</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,748</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,543</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,506</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    exchange gain (loss)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,560</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(920</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other loss</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,954,869</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,499,905</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss before income taxes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,096,804</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,588,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit
    for income taxes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">154,300</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,942,504</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,558,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
    dividend from warrant modification</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(522,478</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributed to common shareholder</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,464,982</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,558,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share &ndash; basic and diluted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.78</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.77</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding &ndash; basic and diluted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,506,212</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,498,525</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_030"></A>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY<BR>
FOR THE YEAR ENDED MARCH 31, 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Treasury</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Paid-in</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Comprehensive</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shareholders&rsquo;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income
    (Loss)</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of April 1, 2018</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,397,056</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">840</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">32,141,110</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(30,569,764</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,986</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,544,200</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Adjustment
    due to adoption of ASU-2017 (1)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,194,292</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(516,358</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,677,934</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Adjustment
    due to adoption of ASU 2016-01 </FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,986</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,986</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">At
    the market stock issuance of common stock, net,</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">297,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">29</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">799,156</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">799,185</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon exercise of options</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">20,759</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,699</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,701</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,550,321</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,550,321</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,558,450</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,558,450</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of March 31, 2019</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,714,815</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">871</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">41,693,578</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(37,644,572</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,024,877</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company elected to adopt Accounting Standards Update 2017-11 retrospective to outstanding financial instruments with down
    round feature by means of cumulative-effect adjustment to the beginning additional paid-in capital of $6,194,292 and accumulated
    deficit of $(516,358) as of April 1, 2018. This ASU affects all entities that issue financial instruments (for example, warrants
    or convertible instruments) that include down round features.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY<BR>
FOR THE YEAR ENDED MARCH 31, 2020 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Common
    Stock</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Treasury</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Additional
    Paid-in</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Accumulated</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total
    Shareholders&rsquo;</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Stock</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Capital</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Equity</B></FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of April 1, 2019</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,714,815</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">871</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,000</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">41,693,578</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(37,644,572</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,024,877</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock pursuant to an underwritten offering and a private placement, net </FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,152,985</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">315</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,169,028</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,169,343</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock pursuant to Purchase Agreement, net</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,420,000</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">142</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,744,870</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,745,012</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Incremental
    value of warrants due to a modification</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">522,478</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">522,478</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deemed
    dividend due to a warrant modification</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,478</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,478</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock pursuant to a private placement, net </FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,583,743</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">159</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,839,336</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,839,495</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Warrant
    issued</FONT><FONT STYLE="font: 8pt Times New Roman, Times, Serif"> with debt issuance</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">594,979</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">594,979</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon exercise of options</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">58,662</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">210,644</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">210,650</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon the exercise of warrants</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">985,694</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">99</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,968,845</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,968,944</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock upon cashless excise of warrants</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">73,461</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Vested
    restricted stock</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">67,000</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(7</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,481,649</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,478,649</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(19,942,504</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(19,942,504</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of March 31 2020</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">16,056,360</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,606</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,000</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">75,702,915</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(57,587,076</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 8pt Times New Roman, Times, Serif">18,092,445</P>


</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_032"></A>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 0 0 auto; width: 100%"><DIV STYLE="margin-top: 0; font-size: 1pt; border-top: Black 1.5pt solid; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    The Year<BR>
    Ended March 31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    The Year <BR>
    Ended March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
    flows from operating activities</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19,942,504</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,558,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash (used in) provided by operating activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">159,403</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,787</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,577,649</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,399,321</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    lease expense</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,875</FONT></P>


</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Payment of operating lease liability</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(57,679</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized
    and realized loss on marketable securities to available for sale marketable securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,075,602</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,498,883</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    of management&rsquo;s assessment of prior year research and development to licensing right to use technology</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(200,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adoption
    of ASU 2016-01</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,986</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of debt issuance cost and deferred financing fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,652</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current assets and prepaid expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(361,395</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(729,159</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,091,557</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">322,633</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(470,105</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,757</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,390,104</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,263,294</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash (used in) provided by operating activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,250,049</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,341,052</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from investing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in available for sale marketable securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,320,235</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,222,774</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from redemption of marketable securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,787,299</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,485,610</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of property and equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43,631</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,475</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by (used in) investing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,423,433</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,793,639</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows provided by from financing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in an underwritten offering and private placement, net of offering costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,169,343</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in private placement, net of offering costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,839,495</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock related to at the market offerings, net of offering costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,745,012</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock, net of offering cost</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">799,185</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from credit facility loan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from loan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">375,570</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">292,250</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of loan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(303,806</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,646</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from the exercise of warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,968,944</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of debt issuance costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70,618</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from the exercise of stock options</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">210,650</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,701</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,934,590</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,071,490</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in cash, cash equivalents and restricted cash</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,107,974</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">618,903</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents and restricted cash at beginning of period</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,357,137</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">738,234</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents and restricted cash at end of period</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,465,111</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,357,137</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of non-cash financing and investing activities:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">258,605</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">264,570</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
    dividend as a result of a warrant modification</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">522,478</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    market value of warrants allocated to debt discount and stockholders&rsquo; equity</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">594,979</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    market value of options issued to NitricGen for the licensing right to use technology</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">295,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of cash flow items:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,112</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    taxes paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_033"></A>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 ORGANIZATION AND BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Inc. (&ldquo;Beyond Air&rdquo; or the &ldquo;Company&rdquo;) was incorporated on April 24, 2015. On June 25, 2019, the Company&rsquo;s
name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc. The Company has the following wholly-owned subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air, Ltd was incorporated in Israel on May 1, 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Inhalation Therapies (AIT), a
wholly owned subsidiary of Beyond Air, Ltd was incorporated on August 29, 2014, in Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air Australia Pty Ltd was incorporated on December 17, 2019 in Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air Ireland Limited was incorporated on March 5, 2020 in Ireland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for
the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous
NO for the treatment of solid tumors. S<FONT STYLE="background-color: white">ince its inception, the Company has devoted substantially
all of its efforts to research and development.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing a nitric oxide (&ldquo;NO&rdquo;) generator and delivery system (the &ldquo;LungFit&trade; system&rdquo;)
that is capable of generating NO from ambient air. LungFit&trade; can generate NO up to 400 parts per million (&ldquo;ppm&rdquo;)
for delivery to a patient&rsquo;s lungs. LungFit&trade; can deliver NO either continuously or for a fixed amount of time at various
flow rates and has the ability to either titrate dose on demand or maintain a constant dose. Our current areas of focus with the
LungFit&trade; are persistent pulmonary hypertension of the newborn (&ldquo;PPHN&rdquo;), severe acute respiratory syndrome coronavirus
2 (SARS CoV-2), bronchiolitis (&ldquo;BRO&rdquo;) and nontuberculous mycobacteria (&ldquo;NTM&rdquo;). The Company&rsquo;s current
product candidates will be subject to premarket reviews and approvals by the U.S. Food and Drug Administration, or the FDA, as
well as similar regulatory agencies in other countries or regions. If approved, our system will be marketed as a medical device
in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
Risks and Uncertainty</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Company has incurred cash used in operating activities of $15.3
million for the year ended March 31, 2020, and has accumulated losses of $57.6 million. The Company has cash,
cash equivalents and restricted cash of $25.5 million as of March 31, 2020. Based on management&rsquo;s current
business plan, the Company estimates it will have enough cash for at least one year from the date of filing these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s future capital needs and the adequacy of its available funds beyond one year will depend on many factors, including,
but not necessarily limited to, the actual cost and time necessary for clinical studies and other actions needed to obtain regulatory
approval of our medical devices in development as well as the cost to launch our first product for PPHN, assuming approval of
our Premarketing Application (&ldquo;PMA&rdquo;) which is expected to be filed in the third quarter of calendar 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be required to raise additional funds through sale of equity or debt securities or through strategic collaboration
and/or licensing agreements, to fund operations and continue our clinical trials until we are able to generate enough product
or royalty revenues, if any. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when
needed could have a material adverse effect on our growth plans, our results of operations and our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2020, Beyond Air, Inc. entered into an At-The-Market Equity Offering for $50 million and utilized the Company&rsquo;s
shelf registration statement, see Note 14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2020, the Company entered into a $25 million unsecured loan facility agreement (the &ldquo;Facility Agreement&rdquo;)
with certain lenders that is unsecured. As of March 31, 2020, the Company has drawn down of the first of five tranches of $5
million which is include in restricted cash. The Company has the ability to drawn down on an additional $5 million
tranche prior to the PMA filing, see Note 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2020, the Company entered into a $40 million purchase agreement (&ldquo;New Purchase Agreement&rdquo;) with Lincoln Park
Capital Fund, LLC (&ldquo;LPC&rdquo;), that replaces the existing $20 million purchase agreement. The New Purchase Agreement provides
for the issuance of up to $40 million of the Company&rsquo;s common stock through May 2023 at the Company&rsquo;s discretion.,
The Company utilized the shelf registration statement, see Note 14.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles
of Consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements include the accounts of the Company and the accounts of its wholly owned subsidiaries. All intercompany
balances and transactions have been eliminated in the accompanying financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those
estimates. On an ongoing basis, the Company&rsquo;s evaluates its significant estimates including accruals for expenses under
consulting, licensing agreements, and clinical trials, stock-based compensation, warrant fair value determination and associated
debt discount and classification within stockholders&rsquo; equity, assumptions associated with revenue recognition, and the determination
of deferred tax attributes and the valuation allowance thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Risks and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence
on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty
of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third party
suppliers, in some cases single-source suppliers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the Company&rsquo;s product will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics,
or that such products will be successfully marketed, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s products require approval or clearance from the U.S. Food and Drug Administration prior to commencing commercial
sales in the United States. There can be no assurance that the Company&rsquo;s products will receive all of the required approvals
or clearances. Approvals or clearances are also required in foreign jurisdictions in which the Company may license or sell its
products. If the Company is denied such approvals or clearances or such approvals or clearances are delayed, it may have a material
adverse impact on the Company&rsquo;s results of operations, financial position and liquidity.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
development of our product candidates could be further disrupted and adversely affected by the recent outbreak of COVID-19. The
spread of SARS CoV-2 from China to other countries has resulted in the Director General of the World Health Organization declaring
COVID-19 a pandemic on March 11, 2020. We have addressed the impact COVID-19 may have on our business plans and our ability to
conduct the preclinical studies and clinical trials as well as on our reliance on third-party manufacturing and our supply chain.
However, there can be no assurance that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19
or its consequences. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact our operations
will depend on future developments, which are still uncertain and cannot be predicted at this time.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentrations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s license revenue was from two milestone payments from a terminated license for sales and marketing rights
agreement, see Note 9. The Company is seeking additional partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company relies on two vendors to manufacture its delivery system. The Company is reliant on the vendors for commercial manufacturing
of our LungFit&trade; generator and delivery systems and nitrogen dioxide filters for both clinical studies and commercial supply,
if regulatory approval is received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents
and marketable securities. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts
in major banks in Israel and the U.S., the balances of which, at times, may exceed federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign
hedging arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Cash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020, restricted cash includes $5,000,000 of cash in an escrow account from the lenders of the facility agreement
loan, See Note 10. Subsequent to March 31, 2020, the Company received the funds from the escrow account into a cash operating
cash. In addition, as</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> of March 31, 2020, restricted cash includes
$619,000 of cash that is designated for a contract manufacturer. This cash is expected be used for material and parts that require
a long lead time. Collateral for vehicle leases are invested in bank deposit accounts which is restricted and as of March 31,
2020 was $16,836 and as of March 31, 2019 was $16,934, respectively.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months
or less at acquisition. Restricted cash is collateral for vehicle leases and invested in bank deposit accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table is the reconciliation of the presentation and disclosure of financial instruments as shown on the Company&rsquo;s
consolidated statements of cash flows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                         The Year Ended </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                               31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                         The Year Ended</B></FONT></P> <P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,829,275</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,340,203</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted cash</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,635,836</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,934</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents and restricted cash</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,465,111</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,357,137</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when we transfer promised goods or services to customers in an amount that reflects the consideration
to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with
customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s)
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in
the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess
the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those
that are performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above
and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction
price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract
for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other
variable consideration, except for royalties, should be included in the transaction price. The transaction price is allocated
to each performance obligation on an estimated stand-alone selling price basis, for which the Company recognizes revenue as or
when the performance obligations under the contract are satisfied, see, Note 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under
the terms of a license arrangement, they are recorded as contract liabilities and recognized as revenue when (or as) the underlying
performance obligation is satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment
reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we
have viewed our operations and managed our business as one segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statement of operations as incurred. Research and development expenses include salaries,
costs incurred by outside laboratories, manufacturer&rsquo;s, consultants, accredited facilities in connection with clinical trials
and preclinical studies and stock based-compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Exchange Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BA
Ltd.&rsquo;s operations are in Israel and Beyond Air&rsquo;s operations are in the United States. The Company&rsquo;s management
believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to
continue to operate in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar.
The Company&rsquo;s transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar
transactions and balances have been re-measured to U.S. dollars in accordance with the Accounting Standards Board Codification
Topic 830, &ldquo;Foreign Currency Matters&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company measures the cost of employee and non-employee services received in exchange for an award of equity instruments
based on the grant-date fair value of the award. Fair value for restricted stock awards is valued using the closing price of the
Company&rsquo;s stock on the date of grant. That cost is recognized over the period during which an employee is required to provide
service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated
using the Black-Scholes option pricing model. The risk-free interest rate assumptions were based upon the observed interest rates
appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company
has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Due to the
Company&rsquo;s limited trading history, the Company utilizes an implied volatility based on an aggregate of guideline companies.
In 2020, the Company began to blend its historical volatility with the peer group in order to obtain
expected volatility. The peer companies were based similar publicly traded peer companies. The Company routinely reviews
its calculation of volatility based on, the Company&rsquo;s life cycle, its peer group, and other factors. The Company uses the
simplified method for share-based compensation to estimate the expected term.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the
fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The
expense was previously adjusted to fair value at the end of each reporting period until such awards vested, and the fair value
of such instruments, as adjusted, was expensed over the related vesting period. Adjustments to fair value at each reporting date
resulted in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment.
In June 2018, the FASB issued ASU No. 2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting,
which amends the existing accounting standards for share-based payments to nonemployees. This ASU aligns much of the guidance
on measuring and classifying nonemployee awards with that of awards to employees. Under the new guidance, the measurement of nonemployee
equity awards is fixed on the grant date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value
of all non-employee awards became fixed at the start of the fourth quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
in Marketable Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investments
in equity marketable securities classified available-for-sale are carried at fair value with the changes in unrealized gains and
losses recognized in the Company&rsquo;s results in operations. Realized gains and (losses) from the sale of marketable securities
are recognized in the statement of operations using the specific identification method on a trade date basis.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and accumulated amortization. Depreciation and amortization is
calculated using the straight-line method over the estimated useful life of the assets as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    equipment </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    years</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven
    years</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    and medical equipment </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifteen
    years</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter
    of term of lease or estimated useful life of the asset</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed
Right to Use Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Licensed
right to use technology that is considered platform technology is recorded as an intangible asset which resulted
from the NitricGen transaction, see Note 11. The intangible asset was valued based upon the fair value of the options issued to
NitricGen and the cash paid for this transaction. The license also contains two future milestone additional payments aggregating
$1,800,000. The intangible asset is being amortized on a straight-line method over its estimated useful life of thirteen years.
The expected amortization expense for the next five year and thereafter is as follows for the year ended March 31,:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,077</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">222,378</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">412,763</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assess the impairment of long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate
that the carrying value may not be recoverable. Factors we consider that could trigger an impairment review include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    underperformance relative to expected historical or projected future operating results,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    changes in the manner of our use of the acquired assets or the strategy for our overall business,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    negative regulatory or economic trends, and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    technological changes, which would render equipment and manufacturing processes obsolete.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recoverability
of assets that will continue to be used in our operations is measured by comparing the carrying value to the future net undiscounted
cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues,
driven by market growth rates, and estimated future costs. There were no events during the reporting periods that were deemed
to be a triggering event that would require an impairment assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change
is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established
when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to
realize the benefit, or that future deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded
a valuation allowance to the full extent of our net deferred tax assets since the likelihood of realization of the benefit does
not meet the more likely than not threshold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company files a U.S. Federal, various state, and International income tax returns. Uncertain tax positions are reviewed on an
ongoing basis and are adjusted in light of changing facts and circumstances. Such adjustment is reflected in the tax provision
when appropriate<B>. </B>The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in income
taxes in the statements of operations. The Company has recorded a liability in accrued expenses of $0 and $154,300 for
uncertain tax positions as of March 31, 2020 and March 31, 2019 and reversed this accrual for the year ended March 31,
2020 which resulted in income, respectively. Tax years 2016 through 2020 remain open to examination by federal and state tax
jurisdictions. The Company files tax returns in Israel for which tax years 2014 through 2020 remain open.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Income (Loss) Per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
and diluted net loss per share attributable to common stockholders is computed by dividing the net loss and a deemed dividend
from a warrant modification attributable to common stockholders by the weighted average number of common shares outstanding for
the period. The dilutive effect of outstanding options, warrants, restricted stock and other stock-based compensation awards is
reflected in diluted net income (loss) per share by application of the treasury stock method. The calculation of diluted net income
(loss) attributed to common shareholders per share excludes all anti-dilutive common shares. For periods in which the Company
has reported net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share
attributable to common stockholders, because such common shares are not assumed to have been issued if their effect is anti-dilutive,
see Note 8.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Adopted Accounting Standards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and
Derivatives and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all
entities that issue financial instruments (for example, warrants or convertible instruments) that include down round features.
This ASU relates to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments
that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260.
The Company elected to adopt Update ASU 2017-11 during the third quarter of 2018, retrospective to outstanding financial
instruments with down round feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital
by $6,194,292 and decreasing accumulated deficit by $516,358 as of April 1, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Adopted Accounting Pronouncements (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which
generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use assets on the
balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing
arrangements. The Company early adopted the new guidance using the modified retrospective transition approach and practical expedients
to all leases existing at the date of initial application and not restating comparative periods. See Note 11. As of April 1, 2019,
the adoption date, the Company has identified three operating lease arrangements. The adoption of ASC 842 resulted in the recognition
of operating lease liabilities and right-of-use assets of approximately of $264,570 and $258,605, respectively.
The right-of use assets and operating lease liability is as follows as of March 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
    31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use asset short-term</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,970</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use asset long-term</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,757</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,727</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability short-term</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,342</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability long-term</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,581</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,923</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the
expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued
rent. The interest rate implicit in our leases is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease
payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized
the remaining lease term of its leases in determining the appropriate incremental borrowing rates. The weighted average discount
rate and remaining term on lease obligation is approximately 8.3% and 3.0 years. Operating lease expense is recognized on a straight-line
basis over the lease term and is included in general and administrative expenses. Amortization expense for finance (capital) leases
is recognized on a straight-line basis over the lease term and is included in general and administrative expenses and research
and development expenses, while interest expense for finance leases is recognized using the effective interest method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB <FONT STYLE="background-color: white">issued ASU 2018-13, &ldquo;</FONT>Fair Value Measurement (Topic 820):
Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&rdquo;, which adds disclosure requirements
to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements.
The guidance is effective for the Company&rsquo;s interim and annual reporting periods beginning with the Company&rsquo;s fiscal
year ended March 31, 2021, and early adoption is permitted. The Company is evaluating the impact of this accounting standard update
on the Company&rsquo;s consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recently
Issued Accounting Standards Not Yet Adopted</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU No. 2019-12, &ldquo;Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes.&rdquo; as part of its initiative to reduce complexity in the accounting standards.
The standard eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating
income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The standard
also clarifies and simplifies other aspects of the accounting for income taxes. The standard is effective for fiscal years, and
interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Company does not
anticipate the adoption of this guidance to have a material impact on its consolidated financial statements and related disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 FAIR VALUE MEASUREMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s financial instruments primarily include cash, cash equivalents, restricted cash, marketable securities,
accounts payable, loan payable and credit facility loan. Due to the short-term nature of cash and accounts payable, the
carrying amounts of these assets and liabilities approximate their fair value. Fair value is defined as the price that would be
received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the
valuation methodologies in measuring fair value. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable
inputs. The fair value hierarchy is as follows:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 -</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices in active markets for identical assets or liabilities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar
    assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other
    inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets
    or liabilities; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 -</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unobservable
    inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 FAIR VALUE MEASUREMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company does not have any marketable securities as of March 31, 2020. As of March 31, 2019, the fair value of the Company&rsquo;s
marketable securities was as follows:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of March 31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Marketable securities -</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Circassia
    Pharmaceuticals plc (Note 9)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,649,486</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,649,486</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mutual
    funds</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">893,181</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">893,181</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,542,667</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,542,667</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 PROPERTY AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consist of the following as of March 31, 2020 and March 31, 2019, respectively:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical and medical equipment</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">357,795</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">357,795</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Computer equipment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">73,982</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,782</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture and fixtures</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53,895</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,464</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leasehold improvements</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,336</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,336</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">491,008</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">447,377</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated depreciation
    and amortization</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(279,671</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(202,505</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">211,337</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">244,872</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense for the year ended March 31, 2020 and March 31, 2019 was $77,166 and $64,787 respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 SHAREHOLDER&rsquo;S EQUITY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 10, 2018 the Company entered into a Purchase Agreement with Lincoln Park Financial Corporation (&ldquo;LPC&rdquo;).
The Company may sell and issue LPC and LPC is obligated to purchase up to $20 million in value of shares of common stock from
time to time over three years. The Company also entered into a registration rights agreement with LPC whereby the Company filed
a registration statement with the SEC and the shares of the Company&rsquo;s common stock that may be issued to LPC under the terms
of the Purchase Agreement. The Company may direct LPC, at its sole discretion, and subject to certain conditions, to purchase
up to 10,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent
purchase. The amount of a purchase may be increased under certain circumstances provided, however that LPC cannot make any single
purchase that exceeds $750,000. The purchase price of shares of common stock related to the future funding will be based on the
then prevailing market prices of such shares at the time of sales as described in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
the execution of the Purchase Agreement on August 10, 2018 to March 31, 2019, the Company issued and sold to LPC 297,000 shares
of common stock at an average price of $4.53 per shares for net proceeds of $1,344,185. Net proceeds after offering
costs for these transactions were $799,185. For the year ended March 31, 2020 the Company issued and sold to LPC 1,420,000
shares of common stock at an average price of $5.45 per shares for net proceeds of $7,745,012. There is $10,910,804 remaining
on the Purchase Agreement. This agreement was replaced in May 2020, see Note 14.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2019, the SEC declared effective, the Company&rsquo;s Form S-3 shelf registration statement which allows the Company to
sell up to $100 million of equity securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2019, the Company entered into a purchase agreement with investors for the issuance of 1,583,743 shares of common stock,
resulting in net proceeds of $7,839,495. The Company&rsquo;s CEO invested $300,000 and received 58,253 shares of common stock
at $5.15 per share. In addition, certain directors and employees invested $610,000 for an aggregate of 118,254 shares of common
stock, representing a purchase price of $5.15 per share. The Company registered the shares sold in June 2019 in a registration
statement on Form S-3 that was declared effective in September 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 12, 2019, the Company closed on an underwritten offering and concurrent private placement of 3,152,985 shares of common
stock at $3.66 per share for net proceeds of $10,169,343. The underwritten offering shares were registered under the Company&rsquo;s
Form S-3 shelf registration statement. There were 532,786 common stock that were sold in a private placement and subsequently
registered under an effective Form S-1 on January 23, 2020. In addition, the Company&rsquo;s CEO invested $699,999 for
190,437 shares of common stock at $3.66 per share. In addition, certain employees participated in this offering by investing $475,000
and receiving 129,781 shares of common stock at $3.66 per share.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
to be Issued to a Vendor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020, and March 31, 2019, the Company was obligated to issue 30,000 shares to a vendor for services related
to investor relations. For the year ended March 31, 2020 and March 31, 2019, the Company recorded the fair market value of the
shares to be issued and recorded stock-based compensation of $96,000 and $144,000, respectively. The fair market value
of the liability as of March 31, 2020 and March 31, 2019 was $240,000 and $144,000, respectively.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 SHAREHOLDER&rsquo;S EQUITY (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuance
of Restricted Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 26, 2018, and December 31, 2019, the Board of directors approved the issuance of 340,000 and 390,000, shares of restricted
stock, respectively, to officers, employees and consultants and the fair value for the restricted stock awards was valued at the
closing price of the Company&rsquo;s stock on the date of grant. Restricted stock vests annually over five years. The fair market
value of the restricted shares for stock-based expense is equal to the closing pricing of the Company&rsquo;s stock at the date
of grant. Stock based compensation for the year ended March 31, 2020 and March 31, 2019 was $895,040 and $147,719,
respectively.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Of
                                         Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                         Date</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
                                         Value</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unvested as of April 1, 2019</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">340,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.62</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">390,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.23</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested (a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(67,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.62</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(16,200</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.65</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of March 31 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">646,800</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.99</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Option Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an amended and restated Equity Incentive Option Plan (the &ldquo;2013 Plan&rdquo;), pursuant to which the Company
may award officers, directors, employees, and non-employees with stock options, restricted stock units and restricted shares of
the Company&rsquo;s common stock. The vesting terms of the options issued under the 2013 Plan are generally between two to four
years and expire up to ten years after the grant date. On December 26, 2018 and February 13, 2019, the Board of Directors authorized
the increase of an additional 600,000 and 1,000,000 under the 2013 Plan, respectively. On March 4, 2020, the shareholders approved
1,000,000 shares of common stock authorized, resulting in a total of 4,100,000 shares eligible for issuance under the 2013 Plan.
As of March 31, 2020, there are 191,067 shares available under the 2013 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 SHAREHOLDER&rsquo;S EQUITY (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&rsquo;s options for the year ended March 31, 2020 and March 31, 2019 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Of
                                         Options</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted<BR>
                                         Average<BR> Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
                                         - Options</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> Average <BR> Remaining <BR> Contractual <BR> Life- Options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic<BR> Value</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options outstanding as of April 1, 2018</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">510,904</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.32</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,919,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.54</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,759</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.42</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(33,333</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.25</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of March 31, 2019</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,375,812</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.48</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,952,643</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">815,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.51</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,027,240</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(58,662</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.59</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(101,619</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(78,561</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.03</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,053,589</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.77</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,878,264</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable as of March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,235,674</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.39</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.8</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,673,690</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020, the Company has unrecognized stock-based compensation expense of approximately $4,899,000, related to
unvested stock options and is expected to be expensed over the weighted average remaining service period of 2.7 years.
The weighted average fair value of options granted during the year ended March 31, 2020 ad March 31, 2019 was approximately $4.03
and $3.11 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following assumption:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended <BR>
    March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended <BR>
    March 31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk -free interest rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5%
                                         - 3.2 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5%
                                         - 3.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected volatility</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80.7%
                                         - 87.5 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80.7%
                                         - 84.5 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend yield</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected terms (in years)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the components of stock-based compensation expense which includes common stock, stock options, warrants and
restricted stock in the consolidated statements of operations for the year ended March 31, 2020 and March 31, 2019, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 SHAREHOLDERS&rsquo; EQUITY (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    Ended<BR>
    March 31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    Ended March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">687,674</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">572,918</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,889,975</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,977,403</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation expense</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,577,649</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,550,321</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
modification of the exercise price to the January 2017 and March 2017 investor warrants from $4.25 per share to $3.66 per share
was triggered by the December 2019 equity offering described above. As a result, the Company recognized the incremental value
of $522,478, as a deemed dividend using the Black-Scholes pricing model with the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term in years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&rsquo;s outstanding warrants as of March 31, 2020 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
    Holders</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    Of Warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
    <BR>
    Price</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
    Of<BR>
    Expiration</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2017 offering - investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,531,782</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2022 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2017 offering - investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,531,782</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    2022 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2017 offering - investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,662</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2017 offering - placement agent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,541</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2021 </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2018 offering - investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,645,437</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    license agreement</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">208,333</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2020 loan (see Note 10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,187</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.26</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,173,724</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    warrants have down round protection.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the year ended March 31, 2020, there were 985,694 warrants exercised for $3,968,944 and 985,694 common stock were issued
at an average price per share of $4.03 per share. Warrant holders exercised 156,154 warrants on a cashless basis and the Company
issued 73,461 common stock to the warrant holders. For the year ended March 31, 2019, no warrants were exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 CURRENT ASSETS AND PREPAID EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
summary of current assets and prepaid expenses as of March 31, 2020 and March 31, 2019 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">266,510</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">324,063</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Insurance</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">471,182</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">297,945</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">156,259</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Value added tax receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">124,127</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,889</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">131,728</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">118,512</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,149,806</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">788,409</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 ACCRUED EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the accrued expenses as of March 31, 2020 and March 31, 2019 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
                                         of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
        31, 2020</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    of<BR>
    March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vendors
    &ndash; research and development</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">484,756</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103,320</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    fees</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">476,638</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">780,127</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    taxes payable</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">154,300</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    salaries and benefits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,066</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">183,271</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,074</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,084</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,534</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,283,102</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities were not included in the calculation of diluted net income (loss) per share attributable
to common stockholders because their effect would have been anti-dilutive for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31, 2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock warrants</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,173,724</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,143,405</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock options</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,053,589</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,375,812</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">646,800</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">340,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,874,113</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,859,217</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 LICENSE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2019, the Company entered into an agreement for commercial rights (the &ldquo;License Agreement&rdquo;) with Circassia
Limited and its affiliates (collectively, &ldquo;Circassia&rdquo;) for persistent pulmonary hypertension of the newborn (&ldquo;PPHN&rdquo;)
and future related indications at concentrations of <U>&lt;</U> 80 ppm in the hospital setting in the United States and China.
On December 18, 2019, the Company terminated the License Agreement, see Note 13. The Company would have received payments up to
$32.55 million in up front and regulatory milestones, of which $31.5 million was associated with the U.S. market. All such payments
were payable in cash or ordinary shares of Circassia, at the discretion of Circassia, with payments in cash discounted by approximately
5%. Royalties are payable only in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
contract was evaluated under ASC 606, which was adopted by the Company during fiscal 2019. Based upon the evaluation, it was determined
that the contract consists of five performance obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    Obligation 1: non-exclusive transfer of functional intellectual property rights to Circassia, which includes:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consummation of the License Agreement, which included significant pre-agreement negotiation, product specification, and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful completion of the pre-submission meeting with the FDA. At this meeting the FDA reinforced their assessment of LungFit&trade;
    PH as a medical device and the requirements for approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    Obligation 2: ongoing support associated with the PMA submission and regulatory approval by the FDA. This also includes development
    activities including manufacturing readiness process ahead of the approval. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    Obligation 3: launch of the approved product in the field in the USA upon FDA regulatory approval </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    obligation 4: FDA approval of the product in the field for use in cardiac surgery</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    obligation 5: regulatory approval in China for marketing and sale of the product in China for any indication </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 LICENSE AGREEMENT (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the rights and licenses granted to Circassia by the Company, five milestones were included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$7.35
    million upon signing or 12,300,971 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31, 2019);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.15
    million payable within five (5) business days following the successful completion of a Food and Drug Administration (the &ldquo;FDA&rdquo;)
    pre-submission meeting or 5,271,844 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31,
    2019);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$12.6
    million payable on the sooner of ninety (90) days post FDA approval of the Product or the launch of the Product in the United
    States,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8.4
    million payable within five (5) business days following the approval by the FDA of the Product in certain hospital and clinic
    settings for use in cardiac surgery; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.05
    million payable within five (5) business days following approval by the FDA equivalent in China for marketing and sale of
    the Product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Circassia shall pay the Company the following royalty amounts until expiration of all of the applicable patents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    one-time 5% royalty on the first cumulative $50 million in gross profit in the United States;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    one-time 5% royalty on the first cumulative $20 million in gross profit in China;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
running royalty amounts of 15% of annual gross profit (United States &amp; China combined) up to and including $100 million and
20% of annual gross profit (United States &amp; China combined) exceeding $100 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
expiration of the patents, Circassia shall pay the Company a 14% royalty on annual gross profits up to and including $100 million
and a 19% royalty on annual gross profits exceeding $100 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the consideration constraints associated with milestones 3, 4, and 5, only the amounts associated with milestone 1 and 2 have
been allocated. During the three months ended March 31, 2019, the Company met the first two milestones under the license agreement
and received 17,572,815 ordinary shares valued at $9,987,295. This consideration was allocated to the first two performance obligations.
one being the transfer of the intellectual property to Circassia, which was recognized at a point in time and was valued at $7,116,232
and the other being the ongoing support associated with the PMA submission and regulatory approval by the FDA, which was valued
at $2,871,063 and recorded as deferred revenue to be recognized over a period of time from the commencement of the agreement to
when management expects to submit the PMA. For the year ended March 31, 2020 and March 31, 2019, $1,390,104 and $607,769, respectively
of such revenue associated with this second performance obligation has been recognized. As of March 31, 2020, and March
31, 2019, deferred revenue was $873,190 and $2,263,294, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
10 FACILITY AGREEMENT LOAN </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 17, 2020, the Company entered into a facility agreement with certain lenders pursuant to which the lenders shall loan to
up to $25,000,000 in five tranches of $5,000,000 per tranche at the option of the Company (&ldquo;Tranches&rdquo;), provided however
that the Company may only utilize tranches three through five following FDA approval of our LungFit&trade; PH product. The loan(s)
are unsecured with interest at 10% per year which is to be paid quarterly. The loans may be prepaid with certain prepayment penalties.
The effective interest rate for this loan is 13.3% per year. Each tranche shall be repaid in installments commencing June 15,
2023 with all amounts outstanding under any tranche due on March 17, 2025. The first tranche was executed on March 17, 2020 and
because the funds were held in escrow as of March 31, 2020 they are classified as restricted cash in the consolidated balance
sheet. In connection with this utilization of the first tranche, the Company issued, in March 2020, warrants to the lender for
the purchase of 172,826 shares of the Company&rsquo;s common stock at $7.26 per share. The warrants expire in five years. There
are additional warrant issuances associated with each tranche. If the second tranche of $ 5 million is utilized by the Company,
the warrants that will be issued is up to twenty five percentage of its commitment value <FONT STYLE="background-color: white">divided
by the five day the volume weighed average price &ldquo;(VWAP&rdquo;) prior to utilization date. For tranches three to five, if
any of these tranches are </FONT>utilized by the Company, the warrants that will be issued is up to ten percentage of its commitment
value <FONT STYLE="background-color: white">divided by the five day the VWAP.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a result, the Company allocated the fair market value at the date of grant of the warrant to stockholders&rsquo; equity and debt
discount valued at $594,979. The Black-Scholes pricing model was used with the following assumptions:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected term in years</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Volatility</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend yield</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free interest rate</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
summary of the facility agreement loan balance as of March 31, 2020 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Face value of loan</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt discount</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(594,979</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accretion of interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,562</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred offering
    costs</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(70,518</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facility
    agreement loan balance </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash; March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,339,065</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Maturity
    of Facility Agreement Loan</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,500,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,750,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2025</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">750,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
11 LOAN PAYABLE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> March 31, 2020, and March 31, 2019, in connection
with the Company&rsquo;s insurance policy, a loan of $374,570 and $292,500, respectively was used to finance part of the premium.
For the year ended March 31, 2020 and March 31, 2019, the loan consists of nine payments of $42,366 and ten payment
of $29,687 bearing interest at 4.3% and 3.3% per annum, respectively. The outstanding balance as of March 31, 2020 and March 31,
2019 was $335,358 and $263,604, respectively.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
12 INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s foreign subsidiary is in Israel and subject to a corporate tax rate as follow: 2019 and 2018 &ndash; 23%24%. December
2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for
the 2017 and 2018 Budget Years), which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1,
2017 and to 23% effective from January 1, 2018. As of March 31, 2010, there is a net operating loss carry forward of approximately
$15,726,000 which offset taxable income for an indefinite period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, changes in the Company&rsquo;s ownership may limit the amount
of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation
would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period.
The Company has not performed a study to assess whether an ownership change for purposes of Section&nbsp;382 has occurred, or
whether there have been multiple ownership changes since the Company&rsquo;s inception, due to the significant costs and complexities
associated with such study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 31, 2020, the Company has approximately $19,400,000 of unused NOL carryforwards for federal tax purposes. Net operating
loss carryforwards of approximately $1,375,000, which were generated prior to March 2018 expire through 2037. The net operating
loss of approximately $18,025,000 can be carried forward indefinitely. The Company also has state net operating losses in the
amount of approximately $20,187,000 expiring during the years 2035 to 2020. Under Section&nbsp;382 of the Internal Revenue Code
of 1986, as amended, changes in the Company&rsquo;s ownership may limit the amount of its net operating loss carryforwards that
could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative
change in ownership of the Company of more than 50% within a three-year period. The Company has not performed a study to assess
whether an ownership change for purposes of Section&nbsp;382 has occurred, or whether there have been multiple ownership changes
since the Company&rsquo;s inception, due to the significant costs and complexities associated with such study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of net loss income before the provision for income taxes are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Year Ended<BR>
    March 31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the Year Ended<BR>
    March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Domestic</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,685,568</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,475,659</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,411,236</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,082,791</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,096,804</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,558,450</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation
allowance against its net deferred tax assets. The valuation allowance increased by approximately $6,166,000 during the
year ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
12 INCOME TAXES (continued</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></P>

<P STYLE="margin-right: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
    March 31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
    March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carry forward</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,017,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,201,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development tax credits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">524,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserves
    and allowances - foreign</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">880,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">608,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
    loss carry forward</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,571,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">966,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development - foreign</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">241,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    asset</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(56,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,860,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,694,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,860,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,694,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax asset</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
    31, 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
    March 31, 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    income tax at statutory rate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21.00</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,00</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax, net of federal benefit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7.08</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6.62</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    items</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.67</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development tax credits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.39</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.71</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.69</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.77</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    income tax expense rate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.00</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2020 and 2019 the main reconciling item between the effective tax rate is the recognition of valuation
allowances in respect to deferred taxes related to accumulated operating net operating losses carried forward due to the uncertainty
of the realization of such deferred taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
years 2016 through 2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel
for which tax years 2014 through 2020 remain open.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;) was enacted in response to the
COVID-19 pandemic. The CARES Act made various tax law changes including, among other things, (i) increasing the limitation under
IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest, (ii) enacting a technical correction so that
qualified improvement property can be immediately expenses under IRC Section 168(k) and (iii) making modification to the federal
net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back
to the five preceding taxable years in order to generate a refund of previously paid income taxes. The income tax provisions of
the CARES Act had limited applicability to the Company as of March 31,2020, and therefore, the enactment of the CARES Act did
not have any impact on the Company&rsquo;s consolidated financial statements as of March 31,2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2020 and March
31, 2019 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                         ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                         31,2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Ended <BR> March 31, 2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance at beginning of
    period</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,300</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 23%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,300</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decreases for
    the current year&rsquo;s tax position</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(154,300</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance at the
    end of period</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">154,300</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded a federal tax benefit in the amount of $154,300 related to the reversal of uncertain tax positions due to expiration
of statute of limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
13 COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 22, 2013, the Company entered into a patent license agreement with CareFusion, pursuant to which it agreed to pay to the
third party a non-refundable upfront fee of $150,000 and is obligated to pay 5% royalties of any licensed product net sales, but
at least $50,000 per annum through the term of the agreement and the advance is credited against future royalties payments. As
of December 31, 2019, the Company did not pay any royalties since the Company did not have any revenues from this license. The
term of the agreement extends through the life of applicable patents and may be terminated by either party with 60 days&rsquo;
prior written notice in the event of a breach of the agreement, and may be terminated unilaterally by CareFusion with 30 days&rsquo;
prior written notice in the event that we do not meet certain milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, BA Ltd. entered into an Option Agreement (the &ldquo;Option Agreement&rdquo;) with Pulmonox whereby BA Ltd. acquired
the option to purchase certain intellectual property assets and rights (the &ldquo;Option&rdquo;) on September 7, 2016 for $25,000.
On January 13, 2017, the Company exercised the Option and paid $500,000. The Company becomes obligated to make certain one-time
development and sales milestone payments to Pulmonox, commencing with the date on which we receive regulatory approval for the
commercial sale of the first product candidate qualifying under the agreement. These milestone payments are capped at a total
of $87 million across three separate and distinct indications that fall under the agreement, with the majority of them, approximately
$83 million, being sales related based on cumulative sales milestones for each of the three products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2018 the Company entered into an agreement (&ldquo;Agreement&rdquo;) with NitricGen, Inc. (&ldquo;NitricGen&rdquo;)
acquire a global, exclusive, transferable license and associated assets including intellectual property, know-how, trade secrets
and confidential information from NitricGen related to LungFit&trade;. The Company acquired the licensing right to use the technology
and agreed to pay NitricGen a total of $2,000,000 in future payments based upon achieving certain milestones, as defined in the
Agreement, and royalties on sales LungFit&trade;. The Company paid NitricGen $100,000 upon the execution agreement, $100,000 upon
achieving the next milestone and issued 100,000 options to purchase the Company&rsquo;s stock valued at $295,000 upon executing
the agreement. The remaining future milestone payments are $1,800,000 of which $1,500,000 in due after six months after
the first approval of LungFit&trade; by the Food and Drug Administration or the European Medicine Evaluation Agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
September 18, 2019, the Company entered into an agreement with a contract research organization to perform a pilot study for bronchiolitis.
As of March 31, 2020, the remaining cash commitment under this agreement is approximately $303,000. The Company
recorded $754,000 expense for the year ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
officer agreements contain a change of control provision for payment of severance arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none; letter-spacing: normal; word-spacing: 0px"><B>NOTE
13 COMMITMENTS AND CONTINGENCIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2018, the Company entered into an operating lease for office space in Madison, Wisconsin. The lease commenced in March 2018.
The lease agreement expires in April 2021, at which point the Company has the option to renew the lease for one additional five-year
term. The renewal period was not included the lease term for purposes of determining the lease liability or right-of-use asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company entered into an operating lease for office space in Garden City, New York. The lease commenced in July 2018.
The lease agreement expires in June 2023, at which point the Company has the option to renew the lease for one additional three-year
term. The renewal period was not included the lease term for purposes of determining the lease liability or right-of-use asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has other operating lease agreements with commitments of less than one year or that are not significant. The Company elected
the practical expedient option and as such these lease payments are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other Information For The Year Ended
    March 31, 2020</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash paid for amounts included in the
    measurement of lease liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 80%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash paid</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81,001</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Right-of-use assets obtained in exchange
    for new operating lease liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term
    &mdash; operating leases</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0
                                         years</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-average discount rate &mdash;
    operating leases</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Maturity
    of Lease Liabilities</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    of<BR> March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    Leases</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,117</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,826</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2024</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,279</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">228,915</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(27,992</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present
    value of lease liabilities</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">200,923</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Contingencies</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 16, 2018, Empery Asset Master, Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, &ldquo;Empery&rdquo;),
filed a complaint in the Supreme Court of the State of New York, relating to the notice of adjustment of both the exercise price
of and the number of warrant shares issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as
a result of certain circumstances in connection with our February 2018 offering, the 166,672 warrants issued to Empery in January
2017 provide for adjustments to both the exercise price of the warrants and the number of warrant shares issuable upon such exercise.
Empery seeks monetary damages and declaratory relief under theories of breach of contract or contract reformation predicated on
mutual mistake. While the Company&nbsp; believes that it has&nbsp; complied with the applicable protective
features of the 2017 Warrants and properly adjusted the exercise price, if Empery were to prevail on all claims, the new adjusted total number of warrant shares could be as follows: 319,967 warrant shares for Empery Master, 159,869 warrant
shares for Empery I and 252,672 warrant shares for Empery II and the exercise price could be reduced from $3.66 to $1.57
per share. <FONT STYLE="font-size: 10pt">While the Company has several meritorious defenses against the claims, the ultimate
resolution of the matter, if unfavorable, could result in a material loss. On March 9, 2020, we filed a motion for summary judgment,
which remains pending.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BEYOND
AIR, INC. AND ITS SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2019, the Company terminated the License Agreement with Circassia pursuant to which the Company had granted Circassia
an exclusive royalty-bearing license to distribute, market and sell the Company&rsquo;s nitric oxide generator and delivery system
in the United States and China. As previously described in Note 9, Circassia had agreed to pay the Company certain milestone and
royalty payments, with the remaining milestone and royalty payments payable in cash or ordinary shares of Circassia at Circassia&rsquo;s
option. The Company terminated the Agreement pursuant to section 13.3(b) of the Agreement, which provides for termination by either
party upon the other party&rsquo;s material breach or default. The Company is evaluating other options for the commercialization
of its generator and delivery system. In connection the termination of the license with Circassia, we may be subject to a variety
of claims. Adverse outcomes in some or all of these claims, if filed, may adversely affect our ability to conduct business
and our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
14 SUBSEQUENT EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2020, Beyond Air, Inc. entered into an At-The-Market Equity Offering for $50 million and utilized the Company&rsquo;s
shelf registration statement. The Company may sell shares of our common stock having aggregate sales proceeds of up to $50,000,000
from time to time in this offering. If shares are sold, there is a three 3 percent fee paid to the sales agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2020, the Company entered into a $40 million New Purchase Agreement with LPC, that replaced the existing $20 million purchase
agreement. The New Purchase Agreement provides for the issuance of up to $40 million of the Company&rsquo;s common stock which
we may sell from time to time in our sole discretion to Lincoln Park over the next 36 months, subject to the conditions and limitations
in the New Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Initial Purchase from time to time on any trading day the Company selects that the closing sale price of our common
stock is at least $0.25, we have the right, in our sole discretion, subject to the conditions and limitations in the Purchase
Agreement, to direct LPC to purchase up to 80,000 shares of our common stock (each such purchase, a &ldquo;Regular Purchase&rdquo;)
over the 36-month term of the New Purchase Agreement; provided, however, that such limit may be increased to up to 100,000
shares if the last closing sale price of our common stock is at least $5.00 on the purchase date, may be increased to up to 120,000
shares if the last closing sale price of our common stock is at least $7.50 on the purchase date, and may be increased to up to
140,000 shares if the last closing sale price of our common stock is at least $10.00 on the purchase date (each subject to adjustment
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as
provided in the Purchase Agreement). The purchase price for shares of common stock to be purchased by Lincoln Park will be the
equal to lesser of (i) the lowest sale price on the purchase date, as reported by Nasdaq, or (ii) the arithmetic average of the
three lowest closing sale prices for our common stock during the ten trading days prior to the purchase date. Lincoln Park&rsquo;s
obligation under each Regular Purchase shall not exceed $2,000,000. The amount of the regular purchases can be modified upon the
mutual agreement of the Company and LPC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
Air can also direct LPC to purchase additional amounts as accelerated purchases and additional accelerated purchases, under certain
circumstances and provided the last closing sale price of our common stock is at least $1.00 per share, in an amount up to the
lesser of (i) three times the number of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the trading
volume on such accelerated purchase date. The purchase price for the additional shares is the lower of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    closing sale price for the common stock on the date of sale; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ninety-five
    percent (95%) of the volume weighted average price of the common stock on the Nasdaq Capital Market on the date of sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no upper or lower limit on the price per share that Lincoln Park must pay for our common stock under the New Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, there are no trading volume requirements or restrictions under the New Purchase Agreement. We will control
the timing and amount of any sales of our common stock to Lincoln Park. We may at any time, in our sole discretion terminate the
New Purchase Agreement without fee, penalty or cost, upon one trading day written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 124; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>ex4-7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES<BR>
REGISTERED PURSUANT TO SECTION 12 OF THE<BR>
SECURITIES ACT OF 1934 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description sets forth certain material terms and provisions of our securities that are registered under Section 12
of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock are entitled to one vote per share on all matters submitted to vote of our stockholders, including
the election of directors. Holders of our common stock are not entitled to cumulate their votes for the election of directors.
Except as otherwise required by law, or as otherwise fixed by resolution or resolutions of our Board of Directors with respect
to one or more series of our preferred stock, the entire voting power and all voting rights is vested exclusively in our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are not entitled to receive dividends except if declared by our Board of Directors and are not be entitled
to a liquidation preference in respect of their shares of common stock. Upon liquidation, dissolution or winding up of our company,
the holders of our common stock would be entitled to receive pro rata all assets remaining for distribution to stockholders after
the payment of all of our liabilities and of all preferential amounts to which any series of our preferred stock may be entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no preemptive or subscription rights, and have no rights to convert their common stock into any other
securities. The common stock is not subject to call or redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 21.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of<BR>
    Incorporation </B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond Air Ltd.</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Inhalation Therapies Inc.</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond Air Ireland Limited </FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ireland</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond Air Australia Pty. Ltd.</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-231416, 333-233283, and 333-237958)
and Form S-8 (No. 333-227697 and 333-238239) of Beyond Air, Inc. (formerly AIT Therapeutics, Inc.) and Subsidiaries of our report
dated June 23, 2020 relating to the consolidated financial statements of Beyond Air, Inc., which appear in this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Friedman LLP</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
    Hanover, NJ</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 23,
    2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 0; margin-bottom: 0; margin-right: 0"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 63pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Steven A. Lisi, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this Annual Report on Form 10-K of Beyond Air, Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Steven A. Lisi</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steven
    A. Lisi</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chairman
        and Chief Executive Officer</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Principal
        Executive Officer)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Douglas Beck, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this Annual Report on Form 10-K of Beyond Air, Inc.;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
    internal control over financial reporting; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Douglas Beck </I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Douglas
    Beck </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief
        Financial Officer</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Principal
        Financial Officer and Principal Accounting Officer)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 63pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Steven A. Lisi, Chairman and Chief Executive Officer of Beyond Air, Inc. (the &ldquo;Company&rdquo;), hereby certify, pursuant
to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    Annual Report on Form 10-K of the Company for the year ended March 31, 2020 (the &ldquo;Report&rdquo;) fully complies with
    the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Steven A. Lisi</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steven
    A. Lisi</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chairman
        and Chief Executive Officer</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Principal
        Financial Officer and Principal Accounting Officer)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 63pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Douglas Beck, Chief Financial Officer of Beyond Air, Inc. (the &ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. &sect;1350,
as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    Annual Report on Form 10-K of the Company for the year ended March 31, 2020 (the &ldquo;Report&rdquo;) fully complies with
    the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Douglas Beck</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Douglas
    Beck</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief
        Financial Officer</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Principal
        Financial Officer and Principal Accounting Officer)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ ,@ R  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? G8# 2(  A$! Q$!_\0
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MW!O#?7ZN34_KD%B%2Q4,T59R=58REA:7/6A['XJ_:I_X*#>"+WQ!8>*/B?\
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MH_X;P_;*_P"C@?B+_P!_M/\ _E=7R+Y$_P#SQB_\=_\ BJ/(G_YXQ?\ CO\
M\57T/_$./#S_ *(7@G_Q%N&?_G2?.?\ $7O&#_HYOBC_ .)[QI_\_3ZZ_P"&
M\/VRO^C@?B+_ -_M/_\ E=1_PWA^V5_T<#\1?^_VG_\ RNKY%\B?_GC%_P".
M_P#Q5'D3_P#/&+_QW_XJC_B''AY_T0O!/_B+<,__ #I#_B+WC!_T<WQ1_P#$
M]XT_^?I]=?\ #>'[97_1P/Q%_P"_VG__ "NH_P"&\/VRO^C@?B+_ -_M/_\
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M:332;U:2;U;/R1>+OC$E:7B=XH.2TDUQ[QI9R6DFO^%Q:.2;6BT:T6R^NO\
MAO#]LK_HX'XB_P#?[3__ )74?\-X?ME?]' _$7_O]I__ ,KJ^1?(G_YXQ?\
MCO\ \51Y$_\ SQB_\=_^*H_XAQX>?]$+P3_XBW#/_P Z0_XB]XP?]'-\4?\
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MB^1/_P \8O\ QW_XJCR)_P#GC%_X[_\ %4?\0X\//^B%X)_\1;AG_P"=(?\
M$7O&#_HYOBC_ .)[QI_\_3ZZ_P"&\/VRO^C@?B+_ -_M/_\ E=1_PWA^V5_T
M<#\1?^_VG_\ RNKY%\B?_GC%_P"._P#Q5'D3_P#/&+_QW_XJC_B''AY_T0O!
M/_B+<,__ #I#_B+WC!_T<WQ1_P#$]XT_^?I_0+_P2I_:"^-OQR^*GQ0T/XO_
M !%\3^/-)T3X?V&JZ19>('M7M[+49?$=K:2W5MY%K XF:V=H7RQ4HXRI(4@K
MQG_@BF#%\:/C+YRQ1@_"_2P"-H+$>*[0CH3G;ENN"N[C(8X*_P HOI993D.4
M>->=8#+<MR/+,)2R+A24,'@L-@L!AZ<ZN45JE24<+@Z>&P\)5)OVDW"C%SD^
M>;E)MG^ZOT%,^XDS[Z./#6:9_G6>9UF5?B3C>-3,,YS',<RS"I1H9_1HT*=7
M&X[$8G%5X481E3I.K6FX4_W4.6G3A%?T%_$KQ&? O@3Q/XJLY?!VGR:#HUYJ
M:3>.-?F\(>#8VM4C"R>(?$-AH?B&^TNPB7&Z6ST34;B4B.SBMF:=&3\Y]8_X
M*%?$?2/"'Q*\1WW[-T.G:I\/?@%XN^*^H>#M>^*MYX7U^S\:_#/X(_ #XX_$
M_P"'_B=-1^%TE]X1T_2/#O[0%CHWA[7[S2)M?O/$O@O5+?Q'X.\,VVO:9-;_
M &S\1-'UOX@:9K'@CQ7\%/AO\4/ .JR6(N-%\>>*K:^TK7!IM[8ZS87&J^$=
M9^'&MZ9Y^FZU8V6IV DFOC97^FV.I6LD-Y;PO'YW8?"70]$AUB'2_P!D7]GO
M2[?7_!%O\+_$$5C?>';6+7?AQ8Z7!I%M\/=9CA^#R+JW@NWT:SM=*C\*WJW&
MB+IEE:6'V'[+:6\,?XI/,,/3DZ;PN82<'R)4LHQ]:*44HI1=.AR*-DE'EM&R
M2BE%)+^HWCJ,93C[#'<T9R4W#+,=).7,VY<\:%I<TG*7-=MN3DVW)M^G>"/B
MAJ_B?XU?&GX2:SX1M-'MOA9H_P *_$.@^(H?$PUR3QAI'Q)MO&:BZO\ 0!H&
MFQ^$+S2-7\#:O:Q62:OXB.HV$]CJ+W>G/+_9-K[GY<>-OEIMW;L;%QNW;]V,
M8W;_ )L]=WS9SS7@]K<?$*TUG4_$-E\&? %IX@U^TTRTUG7+;XBBWUC6K'0F
MOQHMMJFIQ?#!+S4;32#JNI_V3#=S316 U&]%HL(NIP^LWBCXOJ"3\,_"^ P4
MD?%2\(!8@#)'PU. 2>IXX)S@$UG_ &EA&[_4LTYN_P#8.9<UM>OU>]KWZ]_,
M3Q]'6^'Q]WH[Y5C[M;6?^SZK2VMU9=K'L850,!5 ] !CICT] !]!BEVKZ#\A
M7C0\4_%XY_XMGX6XR&S\5+S"D$J0Q_X5K\IRK @X(Q\P&5R\>)?C <X^&?A;
M@X(/Q5NU(/!P0WPV!'!'44?VGA5=_4\U7=_V%F2O?O\ N-;A_:%'_H'S"RZ?
MV7F&GR]AI]WW'L6!Z#\A7AG[2'Q8G^!?P7\?_%FUTK3]:G\&:/:7\>FZOJFH
MZ+H\S7FL:?I(GU74]&T/Q/K%GI]@+]M0OGT?PYK.JS6EK-!I^F:A>/;P#2_X
M23XP_P#1,_"O_AU[K_YVU9&MW'Q#\26$VC^(_@SX \0:7<FW>XTO6OB(-6TZ
MY:UN[>]M3/8WWPPN+6<VU_:VEY;^9$_DWEO:W"!9HH7!_:F%Z83-7_W0LR_^
M4!_:%'_GQC__  UYA_\ *#Y.\!_\%!2;G5]/^,?P9\8> +FWD32=!U*QGL1X
M;\1^,Y?"'BSQOH?@FSO/B;)\*O$^E>(/B;X6\&:KXL^&$'C'P=X2L[C1]0\.
MZ#XRO/"'C;7=&\/:MK7/_!3/X"V_A_2]>B\&_&O4+CQ'H_A#5_!WA'3? FFW
MOC_QR?%'P]\5?$_4K/P;X'B\4?\ "2:\O@;PIX%\:CQ9XAM=/_X0R?Q1X5UK
MP'X.\3^+O'-J/#LGM?BGP1-XYAU*+QK^S'\%?%\6KWEMJ&L+XI\0Z5KYU34;
M+1;[PW97^I?VM\);N2]O['P_J&I:!975R9+JTT>\O-,MWCLII86XYO@'X%^P
M/I+?L4_LQ)I,D'AVWDTXQ>#8]->U\)PFU\*6IM?^%+K;&U\/6H:VT&W5/(TN
MU9[6S2"%S$Q_:>&_Z \U_P##%F7_ ,H#^T*/_0/F'G_PE8__ .4_(]=?XLZO
M;_M!^'?@W/X2B7PYXK^"OC7XM:3X\/B&:._%[X+\;?#OPQJ?A:^\"W&@))8Q
M?8OB3HFKP:]/XE^T22VNH:8WANS""8?-'A?]O32[5_#^B_%[P)J'@CXA^)?B
MO9?"ZX^%_AG43XD\7?#C5O$.K?#GPSX3M_BA9^++/X<WRQ:]XN^*7A#P_9>.
M/AA8_$?X07P\0Z)XCTGXB7G@^Y'B!_IAY?B#/KEGXFE^"WP^D\2Z;I.I:!I_
MB&7XAJVNZ=H6L7ND:AJ^AV6K/\,#J%EI.IZAH&@W^HZ7;SQ6EY>Z+I%U=027
M&FV;P>1:9\ ? FAW&@W>C_L3?LO:1=>%O$4_B_PO=:=;^"K*X\.>+)+[PYJD
M_B?0+BW^"L<FD:^VH^#O"-^VL:>]O?B[\)^&[C[0)= TQK0_M3"[?4\U_P##
M%F7_ ,H#^T*/_/C,/_#5F'_R@\+^&'_!2K3?&OP^^&>IS_ WXKZS\1/%^G?L
MX2^+]#\)6'AQ/ ?@OQ'^T<_P)U:U\$?\+/\ $?B^P\+:MXE\!^%/VB_AYK.H
M0QZA8V_C*-M63P>C7.B^)],\*>O:O^W9\-T^$FG?&KPWH/B_6_ <^I:@]W?S
MZ8MA?3>'?#7[-^J_M0>-]1\/6%O)JDFN:QX<\):#JW@&?PU(VF74'Q=TW7/
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MO-N#G!+?\*UP!QU) 'K3_M3"_P#0)FO_ (8LS_\ E ?7Z/\ T#X__P ->/\
M_E!['@>@_(48'H/R%>.)XF^,#J&7X9^%L'.-WQ5O$/!QRK_#56'T(!!X(!!%
M._X23XP_]$S\*_\ AU[K_P"=M2_M3"?] F:?^&+,O_E ?7Z/_0/C_P#PUX__
M .4'L.!Z#\A1@>@_(5X]_P ))\8?^B9^%?\ PZ]U_P#.VH_X23XP_P#1,_"O
M_AU[K_YVU']J83_H%S3_ ,,69?\ R@/K]'_H'Q__ (:\?_\ *#V' ]!^0HP/
M0?D*\>_X23XP_P#1,_"O_AU[K_YVU'_"2?&'_HF?A7_PZ]U_\[:C^U,)_P!
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M7 &3_P 76NL] >G_  K;.<$<8S3_ +4PO_0)FO\ X8LS_P#E _K]'_H'Q_\
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ME<LHSD@4H\4?%\\CX9^%B,D;A\5;LKD':5R/AL1N#<%?O \$ @@/^T\+_P!
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M *!**7;Z[0M_ZK?DK6MZ-I_/N@_#G]N ZO\ MI>-+O4M>TKXD^+?@KH/@/\
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MP?%22&6*5=Z/%(/&.V2)E.8Y5.)4Q*%1'059_P"%2>%O^@I\1O\ P[OQ4_\
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M #M#VN-_Z Z/_A=2_P#G<=]Y,7_//_QZ3_"CR8O^>?\ X])_A7 _\*D\+?\
M04^(W_AW?BI_\V-'_"I/"W_04^(W_AW?BI_\V-'/C?\ H7T/_"^A_P#.T/:X
MW_H#H_\ A=2_^=QWWDQ?\\__ !Z3_"CR8O\ GG_X])_A7 _\*D\+?]!3XC?^
M'=^*G_S8T?\ "I/"W_04^(W_ (=WXJ?_ #8T<^-_Z%]#_P +Z'_SM#VN-_Z
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M-_IO@;XL>-M)O=6N-)^(GP\UJVMO#^MZVKZ9X\\(S2212ZS! 'SXW_H7T/\
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M?P*\5:=%\0K7XGZUX.T+7KSPSXEU#X9:II!U35_#OC2&S\+Z?Y1KU]_P4A\
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M !6QD*5''_"98Q@GC&"?F(+ $'_"I/"W_04^(W_AW?BI_P#-C1SXW_H7T/\
MPX47^>7/R#VN-_Z Z/G_ +;16ORRX[[R8O\ GG_X])_A1Y,7_//_ ,>D_P *
MX'_A4GA;_H*?$;_P[OQ4_P#FQH_X5)X6_P"@I\1O_#N_%3_YL:7/C?\ H7T/
M_"^A_P#.T/:XW_H#H_\ A=2_^=QZ'$8H0W\&[']]LXSV([9Y(]1GM17->'_
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M?AO177LLU_Z#\/\ ^&N'S_YC.GZA['-/^@ZAO_T*X>?_ %&K;;YGI7@SX+_
M3PGINE:?<:5\8==31->U+5-+%Y\,?C38P1:5_P *S\5? WPOX>GM[#P7&\]G
MX3^"?B5/A_:7?GQ76I'2+'Q/=N=:=KDU?B'\$O@+X[TW1]+BT_XO>&(?#'A'
MQ_X2\&#3/A%\5+\>$I?B=I/BGP]XK\3Z5=ZK\.[KQ%+XADT'QIXHL]/@U'Q#
M?>$;6\U"QUZ\\*7^L>&O#M_I?@,?[>?[1M[IEYKVE?LC_$74K6UT'Q1/IWAR
MV^%/QKMO%7B'Q1H?[*OP=^,ZZ=+9^(]!\,W/A[PI:?%?QE\2_A)/XITG2_B'
MK&L^+? .G?#S3/!MMXEUNYUW3O0_B'\6_P!IC5?A3\./%.EP2?#K7_$/PR^,
M&N>*=5\+?#WQ_P")M M-3\*_%WX/Z'\/[QH;KX0?%3QI\.];\??#35O'%_I4
M-Y\.OBSH_P .-6U[4_$-_HOQL\*?#5M7UEJCFKEKC\.O^Z5"WW+&:^BU^5V-
M4<T;L\=AU_W2X?IC+_=K^:^Y++XG>$=/MH+&RTCX@VUI:006MK;I\'?B^$AM
MK6%(;>) W@7<5AMTCBW9;'EA&<E#BT/BUX;/33OB&?I\'?B\>N<'CP+T.#@]
M\&OSJ_9S^*/[57B7]H#4+GQUH7QWL?@/J_@B&Q\">'?BSX"\*:/K3>+]/_9M
M_92^(]OIWB63PC\)O"&J>#/&.I^,?%?QTM]=\4:_XLN/AQJ/B?1/$/PXT3P=
MX-U_PYH.EUN_!+]I+]J+Q=86EQ'\&].^)VDZA\,!KWA76[0>(/AY)XU\;VWP
MM_93^(5ZDOBS7=+3X=Z#X?U/Q/\ '7XR> ='T8_\370[[X!7FFW.K>)O$$GC
MBQ\"#HYHE=9AAWZ95'S[XN^GZZ7L[#HYGTQ^'?IE4--7T>,OVTWUZV=OOC_A
M;?AK./[/^(6<XQ_PI[XN]>F/^1%ZYXQUSQUI?^%L^'/^@;\1/_#._%[_ .86
MOSO^*WQ^^-NB>*K9[>U\>?"CQ1X;^#MGXK\9_"C7/#6G^-_A+K/Q UKQU;6_
MPW^&GP_^*VE_"];;Q'\2/B%<Z>_A+QGJ1^*<>D>'M%\:^'O#WA7P5K'Q&\6C
MQ%X(_4[[+ O"M)M' _> \#@<DDGZDDGJ>:;HYHDK9AA]=_\ A*CI_P"7:OZK
M0'0S.R?]H8?7OE4=_P#PL5_D<#_PMGPY_P! SXB?^&<^+W_S"T?\+9\.?] S
MXB?^&<^+W_S"UWWV:+^])_WVM'V:+^])_P!]K4^RS3_H/P__ (:H?_-@O8YG
M_P!###_^&J/_ ,V' _\ "V?#G_0,^(G_ (9SXO?_ #"T?\+9\.?] SXB?^&<
M^+W_ ,PM=]]FB_O2?]]K1]FB_O2?]]K1[+-/^@_#_P#AJA_\V![',_\ H88?
M_P -4?\ YL.!_P"%L^'/^@9\1/\ PSGQ>_\ F%H_X6SX<_Z!GQ$_\,Y\7O\
MYA:[[[-%_>D_[[6C[-%_>D_[[6CV6:?]!^'_ /#5#_YL#V.9_P#0PP__ (:H
M_P#S8<#_ ,+9\.?] SXB?^&<^+W_ ,PM'_"V?#G_ $#/B)_X9SXO?_,+7??9
MHO[TG_?:T?9HO[TG_?:T>RS3_H/P_P#X:H?_ #8'L<S_ .AAA_\ PU1_^;#@
M?^%L^'/^@9\1/_#.?%[_ .86C_A;/AS_ *!GQ$_\,Y\7O_F%KOOLT7]Z3_OM
M:/LT7]Z3_OM:/99I_P!!^'_\-4/_ )L#V.9_]###_P#AJC_\V'S_ /%"^^&O
MQ9\'7_@OQ;IOQ;BTVZU#P_K=GJ/A_P"&?QLT+Q!H'B;PGXBT?Q7X/\4>']7T
M[P0ES8Z[X7\5:%HVNZ3,PGLWN[%+?5++4-*GO+"X^5-<_9M^$OCCQ!\3=3^)
M?B+XW>+[;Q_\-_AU\*[?4G^$OQ1L?'-KH'@OQ9?^.?$GB#4O$C?#V?3D\?>/
M?%=UX9@N?&/@GPOX(U[P;HGPI^$K>!-1T'Q#X&T/Q#I'T]^U?/\ %_3_ ()Z
MG_PH#6I_#OQ7U3Q_\#?#/A[Q%_PAP^(=EX?T[Q=\=?AMX6\8ZWKOA%8I)-3\
M*Z5X)UCQ'?>,)X)M-N=(\*P:QK5IKGA^ZTZ'7-.^ -?^)7[9/C/0O&OCW1I?
MVA/A#K'AOP;^VFMC\(=-^$_@GQ+H@^(7P<\(>$K?X8Z7%J'B#X-ZUXE^(6G:
MIX_U7QFOPWUGPIXCTG1?C=H.@Z'JVA&]L6N-.OJ5',^N88=>N51?;MC'8I4<
MRZYAA_7^RH_=_OO]?G]/V'P4^ NC>+[?Q]H<_P"T-HOB^S\9W7C+3-=L_!7Q
M:FN-/_M/Q=\:/&>N>%HH=2^&-_9WWA'7M7_:!^*4=]INKVVIWL%KK6EIH^IZ
M9=>%_"]UI%KX@?!+]F/XF1?$>/Q)X-^*Z7GQ7U_Q7XC\:ZSH7P\^-N@^(]1U
M+Q?^SSKO[+VJ)#XBTKP/;ZU:6=G\*/$6K66AVD-Z$T#7Y8_$&EFUO[6 Q^4?
M#?XY?M51:_\ $CQ)\5/AEX_/A/X2_LR>-K>Z\'^'_A/JDNI_%C]HKX':AIQ\
M<>//AI]EMUU77_#'QG;5GTGX%>![+5[:X\3:7X9U+6M/@NO[5MKC3O&_#7[8
MW[8=_P"(]>U.3X&:V(+WP)JD>C^$_%'P=^.OA;PN=2\ ZG^V-9W'Q0TWQ9#X
M9UC2?"_A[Q1%\)_@?J&K^ =;\5>+]:O--^*GA:'PEXEB_M7P;JWQ%7L<T_Z#
MZ&S?_(KAO?;_ 'N_G=[]-;H7L<S_ .@ZAM_T*X?_ #9==_/IJCZ:M_V=_P!G
MRREU+6;"X_:3T[Q_JOB*T\97/Q2T_P )?&"R\>1^,X;KXU/?^*;&XM_AC'X=
MT_4M9TO]H7XL>&KZUL_#<.BV7AWQ%:6'A_2M$D\.^';G2^:O/V0_V3[G2/%.
MAVV@_'/2=-\4:7=^'OL.E?#?XE6VF>'O#-U!X!L4T;PUH4OPEG\/Z?=V>E_#
M7PGIEGXXN=)OOB9'#I6G7TOC>;6M"\,ZIH?*>(OVS/VDK?P/>^(_#'[//B"3
MQ#/=_"G2-(\)^-?@U\:_#FK:+9^-?@P?B9=?$SQ[!H,WC"&V\.ZW\00OP#'@
M#X?W_P 0O$7PE\77<&O^-/%7BJXLM6\#V=GQ3^V/^TGH%YXULK+]G#Q#XAOO
M#'B?]IG0M+T[PU\*_B]KUMXGF^%O@6#Q3\)(_#_B 2:6^N^%O&EZ+S0?%'Q"
ML/#::W%\0XK7X:^%/@[JVAW</QC=>RS7_H/P_P#X:X?_ #83[+-/^@ZA_P"&
MNG_\VGO?C_P#\+OB#XIT[Q=<ZG\?/#.KZ1X<\+Z/HNL^&/AW\9K/Q1HFM^ ]
M2\2W?@3QAI/B35? >IW@UO2-)\?_ !/\+>(+37+?7M&\>>&_'^L:-XPTW5+#
M?;WT6G_#GX-Z/X@L?$>EV_Q7&MW/Q.\*_%CQUK>H_!_XI:EXG^)WBOP/\)[7
MX1^$&\6>(Y/A_;7,MEI&GZ3HGB1[>)8XYO$FF>=&VG:=J6HV=UYKI'[6?QE\
M4:G\0/[+^!GBB'1-(^%?[3'C+X;RW7PR^*]A<^*O$GP<^+OQ+\#_  ^M?%-[
MXLL_"#^$;#XI^$/"GA#Q=\/[32/#OC-_B3:^)M9U?3==\':3I7A.+Q_XY?\
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M^@_#_P#AJA_\V![',_\ H88?_P -4?\ YL.!_P"%L^'/^@9\1/\ PSGQ>_\
MF%KYI^-_PR^#/[0.I:=>^/[O]H);32/#_B[1-+T/P[X"^*^B:5IU_P"-?!?C
M/X>:OXKLGA^&$NL6GB1O"'C[Q/HD@M]6B\/:Q:W5JGB?P_KPTVP%O]J?9HO[
MTG_?:U^?7[2/Q?\ BK\(OC5HE_X=L?BSXW\"V_P9^(OB(?#7X6?"_6?%J3>.
M?#?A'XJ>);+6_'5\_P ++VV\7>&]930/"WA+0?#'@CX^_"7QMX;^(;^$+/5/
M#/CWP_\ %&WU+P0U1S1W_P"%##Z)_P#,JC_\UOT\AJCF>O\ M^'V;_Y%4?\
MYLZ[?GH<^_[(_P"R))HFB:&WA#XOS1Z!KZ^);"XO/A9\1]61=1GU3XWZEJZ?
MV!J_PGU#P?!8:['^T5\6-,NK*R\-6EOI6GZ]II\*KX>O_"_AF^TGNO'OP5^
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MQ/=^)=!^&V_L<T6GU_#^?_"5#3=?]!:7;;;:RL:NCF=_]_P^^O\ PEP\U?\
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M_O?RW#V.:?\ 0=03\\KAVO\ ]!OR]3"\'_L=?LI>!CI3Z#:?M'P/9>-_ 7Q
MUEG\*?&&,>-->^%GB7X.>,/AX?&4=G\,;2'58/#'B7X$^ M9$UO'8:IX@U%_
M&%[XOU+Q#=>/?&,VL_>J_%CPXH.-.^(IR<\_![XOG&<<#_BA>G?\<]Z_.6U_
M:Z_;!/AU_%'_  S-9>)=-T[X?W/B-M.\.>$_COIFO^,]<O\ 0/VL]4T33]%T
MW5?"-UJ7A6ZTO5/@5\)M%\4>%1I7Q UYO^%SVMSI%V]Z?!FC>,_-/#'[;/[5
M&B:K\0/#,?PEU3XY>)/#J^//'^A>';/X0?'?X>^(OB!X,U#Q=^U;IW@<^%VU
M'P??Z9\,?"EEI7P$\(WOAV#Q^WBKQ'\2;'QG+H?P\U/QGXBG\ S?$$]CFMF_
MK^'TZ?V7#;K_ ,Q=M/.WEJ'L<TLW]?P^G3^RX?/_ )C+:>J/UF_X6UX;SC^S
MOB'GT_X4[\7L\]./^$%H'Q:\-G.--^(9P<''P=^+QP?0_P#%"\&OS>UK]JG]
MK&WT[Q)K?A'X"W7CF;1/#>K:GI^JS?#WXW>%O!OQ!T[P5X3_ &MO&D5YX.\$
M:GHMSXU\':]\0]8^$/PK^&D$/B/5M>.DW_Q'T/Q)I-IXWT^]\":3\0O:?@=\
M=_CAKGQF?X6_$_P7</H=QXB_:.AM?&6B?!OXD>$K"PMO OQ^^)'A?X<:?XFU
M3Q+KTOA_1M-U?X3:)X&UOPOXNT9O&5C\6]1\3:A<2#X:+I?A=?B@>QS7_H/P
M_3_F5T_._P#S&=-NVNCW#V.9_P#0=0Z?\RNG\_\ F,6WK9WT>]OK@?%KPV>F
MF_$,^X^#OQ>(Z9ZCP+Z$'Z$&E_X6SX<_Z!GQ$_\ #.?%[_YA:_.SX;_M(_MB
M7]S\+8-3_9^$/A36-,^#$/BF?Q)X9^+J?$2R;7],_8NMOB&^H7\FAZ9X;76+
M'5?VG?BM?V\MYIVFV6BP?LN^.+;6K>X;6_&-[\%>&^&/[=?[5GQ+^'W@;XAZ
M5^SUI5QX4\3?"[1/B7J_C"S^'7[0ZZ78Q>,/#O[+ES_9GACPWJ/AJR\3^.+?
MX27WQY^(GB;Q3J>C1B\^+GA+X&ZYH?PXT'1/&EWXQL?AD>QS7_H.P]K_ /0K
MA_\ -B_1@Z.:?]!U#_PUT_/OC%O;K9]S]3/^%L^'/^@9\1/_  SGQ>_^86D_
MX6UX;SC^S?B'GT_X4[\7L\8SQ_P@ON/S'J*_.76/VR?VK]/T/6GM_P!E;5Y[
MK3H/#6J0>,$\$?%R7PS-X(\;^+]&^'/@GX@KX3FTS3O$TU[JVL>%?C5\1_&'
MPC.KVWCCX-_"L_!6]^*M_P"&W\?SZW;^I_ 'XU?M _%/]HRZT3XB^ M9^&?@
MO1?A5\1FUCP3'X(^)L>AZ)X[TCXC?#W0O"E_<?&#QKX*\*^%_B')XS\*#Q/X
MY\$VWA"#0;_1?!OB/^Q_&WA2+Q-HEQ>D5'-=?]OP^E_^97#I_P!SG]?-7%1S
M1W_V_#JW_4KA^F-_K[K_ &1_PMGPY_T#/B)_X9SXO?\ S"T?\+9\.?\ 0,^(
MG_AG/B]_\PM=]]FB_O2?]]K1]FB_O2?]]K2]EFG_ $'X?_PU0_\ FP/8YG_T
M,,/_ .&J/_S8<#_PMGPY_P! SXB?^&<^+W_S"T?\+9\.?] SXB?^&<^+W_S"
MUWWV:+^])_WVM'V:+^])_P!]K1[+-/\ H/P__AJA_P#-@>QS/_H88?\ \-4?
M_FPP/#WC;3O$MW/::=9>)X7M[?[1(VN^!?'/A2 KYJ1A8+WQ3X<T:QN9<ODV
MMO<2W>P&40^3'*ZE=3;1I'OVECG;G<P;INQC'3J:*[J*JQIQ5:I&K55^:I&D
MJ$9>\[6I*=10M&R?ORNTY:7LNVDJL:<56J1JU%?FJ0I*A&6K:M24ZBC:-D_?
ME=IRTO9<)J?A[XA3ZC<SZ1X]T;2M-=U^QV$_@;^T[BVC"*"D^HOXHM3=N9/,
M<2?9;?:C+'L)0R/1_P"$9^*G_13]"ZY_Y)PG7U_Y&[K[U7^.?C_3/A=\+?&'
MCO5_&?A?X>V7A_2O/_X2_P 9:%J_BKP]I-Y>7MGI>E+<^$O#NM>'O$GC&_U+
M5;^QTC0?!OAK6M/\1>+?$%_I?AW1)FU'4K>&7\N-2_;V^/NF^%?C#?+X8^ L
MOCGX5?LO>,/B[K'@J+5]9U5/#WCGX<?L_P#[-GQN\2:CK6O^%?&_B73=8^'O
MBZ[^//B#P;X,L]!N%M+?4O VEZA:_$_Q9!XHO'\.83P-*I.4Y5<:I2;;Y<PQ
ML(W?\L(U5&*\HI+R.>>!I5)RG*KC5*;<GRYAC81N^T(U5&*\HI+R/U/_ .$8
M^*> /^%G:#@=!_PK>/ SUQ_Q5W>D_P"$7^*?_13=!_\ #;Q__-=7G/PR\9?$
MW7OC[\=_!^J:Y\.]<^%?PSC\':-I$GA[P'XD\->,-$^(7BG3'\;ZGX'\1^(=
M2^)_BO2/%+^&OAOKOPW\2W6J:7X+\&P7;_$738X(5ETZ_@;Z:J?[/H_\_L?_
M .'+'_\ RXG^SZ/_ #^Q_P#X<L=_\N/*_P#A%_BG_P!%-T'_ ,-O'_\ -=1_
MPB_Q3_Z*;H/_ (;>/_YKJ]4HH_L^C_S^Q_\ X<L?_P#+@_L^C_S^Q_\ X<L=
M_P#+CRO_ (1?XI_]%-T'_P -O'_\UU9FKV7C[P_I^H:QK?Q<\*:1I&DV%WJN
MJZOJG@*ST_2]*TO3X)+K4=3U+4+SQI;VECI^G6L,EW?7=S/%!:VT<D\KK%'(
MZ>SUXG^T+\-U^+'PJ\2>"SXBT[PI*]QX6\4V&O:WIBZ[X:M-7^'OC+P]\1-&
MB\9^'WU30U\2> K_ %7PI9Z;X^\-#7-$;Q#X+O-?T<:WHSWJ:A"?V?1_Y_8_
M_P .6/\ _EP?V?1_Y_8__P .6._^7&/X#UW6/BGX9L/&OPT_:!^&WQ"\&:L]
MTND^+_ _AS0?%_A?5GL+RXTZ_&F^(/#OCS4M(O7L-2M+O3[U+:[E>UO;6>VG
MV31.B]#=^ _'^H76E7U_X\\)7M[H5[+J.AWEW\*[.YNM&U"XTZ^T:YOM*GF\
M5/+I][<:-J>IZ3+=6CPS2:=J-]92.]K=3PR?''Q0_8Y^-/QM\1ZEXO\ %GQK
M\+^&];\0?#/Q/X.NKOP#HOQ!TZ?PP==^&'QP^&L.@^"+]OB/;O:>"]6NOBQX
M5^)?BB>2TM]:U+X@?"#PMJMM*MU#X&U+X5>$?$[]@3Q>;_3_  1\)_B5HEMH
MWC3X@^.[WQ9H^IW_ (I>V^&_A[4/!'[=C^ /%UAX9A^*.BZMK6J_"V+]HOX
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M9TAOCI\+M(LO['\*^/[[P[8Z?XAU77_%_C#Q!X9MKSQ%J.CW1_9]#_G[C_\
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M3Q%X/U.^_9'UJWTOQ--X=\,7?AU=3AO-8T&XCM?&%MX*/[/H?\_<?_X<L?\
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M(?\ !1[5C9_ NR\2VWA[Q;KFM^/VTO\ :9F^&GPR^(&M^$/@3X:U_P 0>"/
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M?\_<?_X<L=_\N#^SZ'_/['_^'+'?_+3[]_X1GXJ<_P#%S]"YZ_\ %N$Y^O\
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MRQ__ ,N#^SZ/_/['_P#ARQW_ ,N/OC_A&?BI_P!%.T+U_P"2<1]?7_D;J/\
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M+0O#/@B/Q7XCOO%>E>/_ (,> /!VB^#K;5?AWX-7QCX;^*O_  N&#XA>!_'
M&A6</PMM]-\=>.-/\&6=UKMMX;]6\(?&/]E'Q?X(^)/Q'MO@S96O@KP-XW^%
M_P /M%U*^^#?A_[;\3-?^,_A?X/:]\.]/\#: MF^N"ZU[7OC7X(\"-8>*K'P
MU/I'BR:=/$ TG3K:XOK1NIFR;7L,J;\L7CVOE:@_NW5U>W4=3-4VO894VNV+
MS!IZ]/\ 9^VW75-V/T.2Y7:N5.=JY^9<YP,YR['/KEF_WCU+OM*_W3_WTO\
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M]T_]]+_C7E7_  I3X2_]$O\ AG_X0OAC_P"5E'_"E/A+_P!$O^&?_A"^&/\
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MKG7Q:>.?!NNV37'ARSU>QM+-='O]6N]-B\4>&!K'OX^"OPE(S_PJ_P"&?/\
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M/A+_ -$O^&?_ (0OAC_Y64>US;_GQE/_ (5X_P#^9P]KFO\ T#Y5_P"%>/\
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MS]G'XS?%K3_A_P##WX)>'-0\*:E\.?'GCFR^)&M?"6W\*Z-JNH?#_P ;^"?
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M:?8^%-2A^/VM1WGQ7M?N[[3!_P ]!^3?X5'U;$?]#7&_^"L!_P#,)'U?$?\
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M ZOXLT*T^+5IX"T2P^*'A&1OAXG[/$FGVG@/Q)\4?@#?>!];^!NA^/=<N?\
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MPOHZR_!G4/@Y-I\WQ \-ZAXH\.?%KP[XD;3M/UOQ4?5J_P#T-<;_ ."\O_\
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M_0%W'[#$?]#3%_\ @G+_ /YB/N@>,/'K':/A/JQ/''_"9>"\\E@./[5YR58
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MK>F+XHT_Q3X9L?%"MXDN?'MYK.L-XHMO$46O'Q==WWQ5^*5\GC=M1/C&TO\
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MWX@\$7GA/QY/\*++2[32UU[Q?HUWXI^(!]6K_P#0UQO_ (+R_P#^8@]AB/\
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M-SXEU?Q^?5J__0UQG_@O+_\ YB#V&(_Z&F+_ /!.7?\ S$?I7_PEOQ W!?\
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MANXLP;":U=_>?M,'_/0?DW^%'U;$?]#7&_\ @K ?_,(>PQ'_ $-,7_X)R_\
M^83S#_A*_B%_T236/_"Q\&?_ "TKQ?XA_"GP=\6M5.L?$S]EO2O'.H'PQK7@
M]G\1^)?!FI6Q\.Z[I>LZ'JUH^FS:V=.-Q+H?B;Q)H\.K-9G6-/TCQ)X@T[3K
M^UL];U*"Z^M_M,'_ #T'Y-_A7YY?M)Z?^T3IGQJT'Q]\%/"/Q7^)$6F?!GXB
MV(\.6/Q$TSP/\,-&\66OA/XHWOA?6=(L[SXJ:3X3\3?$[Q'XCOO"G@V;0OC)
M\!/BSX0%G=>"?$_ACQ?\-)?"/Q F\3'U;$?]#7&_^"L O_=%!]7Q'_0TQ?\
MX)R]?^Z2/1(?@;\.H[&RT^U_9'T*V@T[5[77[*>SU[P9:ZC:ZW;:IXZUAM5B
MUFVUJ+5A?ZC>_%'XF?V]=+?&3Q)9?$7QUI?B%M3TSQ;K]E?S^+/@QX!\<>,_
M^%@>+OV4-#UWQNNI:'K2>)+W7_!8U2'Q)X9CM[?P]XJ@F@UF$6OC/1]+MX-
MT_QC"D7BBW\* ^$8]7_X1B:72'^&XO#'_!2RWN3\1K;6/%-G\0?$FE?#SX;Z
MG=ZIX<^!GC*V\+>$_!7BC]K2XL/%EE\*[7QIX%\,-JWQ$NIOV9]5^/S:/XUT
MJ]DT#7=6MOA['X0?0H#\/?:/C+I_[8%M^U]I7COX=:/\4[_X36FH?"CP==Z3
MX9\5>#Y?A^_PT77M%\3_ !+^(C^&?%WQ1TO2-1^(UU>3>(_A?J/A"?X3GQ%I
MG@B;3OBWX,^+TVL:./AC?'U:O_T-<;_X+P'_ ,Q>7X!]7Q'_ $-,9_X*R_\
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M^AKC'_W"R_\ ^8DOP/K=/@GX!319- N_V2M!U719=$B\.WEGXBUSP3XE2_\
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MZI80OI>IW>DQ6^H1V^IZ)JNFW&T1LTUF;JT6ZTRXLM0NO9O^%80_]#]\2O\
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M5A#_ -#]\2O_  H8_P#Y J]_PM#P=_?\3?\ AO/B%_\ ,?1_PM#P=_?\3?\
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M\2O_  H8_P#Y KQKQ!XE^'WAKXDCX7ZE\1_BPFO6?@2X^)OB;4AJ0A\)>!/
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M5>_X6AX.'\?B;_PWGQ"_^8^C_A:'@[^_XF_\-Y\0O_F/J?9<._SX7_PLQ_\
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M!HVIV=S<7ZZ;&]HDH%]#:.8A+XKI/['G[+ELWV_Q%XD^.OC3Q59ZW%XP\/\
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M_">_$DC)//B"(D-@+E2; E& &W<A5MI>-B8I9HY#_A6$/_0_?$K_ ,*&/_Y
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MO[_B;_PWGQ"_^8^C_A:'@X]'\3=2/^2>?$+J.H_Y$_J.]'L^'?Y\+_X6X_\
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M$FW?//++-(6DD=CY'_:7QE_Z%KX9?^%[XJ_^=E1_:7QE_P"A:^&7_A>^*O\
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M9 B[=)TJ\\0Z]=Z?81^5;6EUJM_,D3/=RM74UXU_:7QE_P"A:^&7_A>^*O\
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M?_M+XR_]"U\,O_"]\5?_ #LJ/[2^,O\ T+7PR_\ "]\5?_.RH_M5?]"[.?\
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MB7PKJMW:BQN]3\-R?\*BWZ%J-U9*MG<7NEFUN9[55MY96B4(#^U8?] &<_\
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MB+5["XAM6L= TQK6*>U^%,4L=NVF>%/"VG- C+$UAX:\/V90V^BZ;';8F@^
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%TO9?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ ,@ R  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $) G8# 2(  A$! Q$!_\0
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MC2@ZS<(N3<5[O-)<MOU6_P"'R7[9']_X1_\ A W'_P U='_#Y+]LC^_\(_\
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M(_\ P@;C_P":NORIY_O-_P!]-_C1S_>;_OIO\:K_ (@?X0?]&YX3_P##7_\
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M&X_^:NORHR>,,W7'WF/8Y!Y_3OT[T\'# *SE\D)R<!P<IN#9!#'( ^;[IW
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M$_\ PU__ (4,_P#B:7Z0W_1X_$#_ ,/D/_G0?JM_P^2_;(_O_"/_ ,(&X_\
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M$?\ X0-Q_P#-71_P^2_;(_O_  C_ /"!N/\ YJZ_*GG^\W_?3?XTF?\ :/\
MWVW^-/\ X@?X0?\ 1N>$_P#PU_\ X4'_ ,32_2&_Z/'X@?\ A\A_\Z#]5_\
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M.K"O]:JTZV#RVGF7*LP?K7_#Y']LG^_\(_\ P@;C_P":NC_A\E^V3_?^$?\
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M/Q4\1V/B*36/M&I^#-5LO@W,U_X1ALM'U,>(=7LG^%.N:9+X;%Q!JUWJ&O\
MAUK7&G2ZA>Z9\GGFG;W (WG#1F)N@S$65FC.!]UF52X&-^U=^X*,>%Q!DO\
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M.5).G@)5*%.I%4Z52G+#?J*R/PEH8;#<W'V/>.=/"5L96RG+JL*=:&,J9?\
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MM7]_>ZI?W^IZE<27>HZE>W5_?W<Q!FNKV\F>YNKB8C"M-/-(\LK*%5I'9E1
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MAM/L$-[=Q1K'<WD-CYUS]CBNIE>>*U%S<"!)%B6>8*)&N>1%_=H_XCYXT_\
M1Q^)/_!F5_\ SD%_Q*;]''_HSO!O_@.>?_1"?B[_ ,.0/V9/^BF_'3_P<> O
M_G>T?\.0/V9/^BF_'3_P<> O_G>U^T7D1?W:/(B_NT?\1\\:?^CC\2?^#,K_
M /G('_$IGT<?^C.\&_\ @.>?_1"?BT__  1$_9A3 ;XG?'7+ D :MX$8D J#
MPOP\/=U'N64#)(%*O_!$3]F)\[?B=\=3C&<ZOX#&,YQU^'@ZXS],'H17V?\
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M>C?$+Q9;ZEX4NM9^(&MS>#]&^+&IPZQHFL6%]J&@Z9X:U#Q3\/\ Q)K=R?\
M$?/&C_HX_$G_ (,ROY_\R07_ !*;]''_ *,YP;_X#GG_ -$".#_X<@?LR?\
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M#_:_@, X[C=\/!E2"&5AE64AE)4@G>\7V_[1EE\?/B]:JGQ*UGPSXO\ VC?
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M=T_PY\*=/\6G_$?/&G_HX_$G_@S*^_\ V).P_P#B4WZ-_P#T9S@[[L\_^?\
M^9CK_P $1?V86*A?B=\=3N7<O_$V\"8*@XSD_#S&/3)Y[9I__#D#]F3_ **;
M\=/_  <> O\ YWM?3_[ \WQ(O?#7B.?QQ=?&>]T^X\,?!ZYO9/CI;>/K;Q?!
M\<)/ <)_:%M=*A^(FFZ7J5IX1C\6'1)+'3O"]I!\,M-\1S>+-/\ AW::=HUI
M/I=A^@?D1?W:/^(^>-/_ $<?B3_P9E?_ ,Y!/Z)OT<.G@YP;;SCGC_\ ?@1^
M+O\ PY _9D_Z*;\=/_!QX"_^=[1_PY _9D_Z*;\=/_!QX"_^=[7[1>1%_=H\
MB+^[1_Q'SQI_Z./Q)_X,RO\ ^<@O^)3/HX_]&=X-_P# <\_^B$_%W_AR!^S)
M_P!%-^.G_@X\!?\ SO:8W_!$3]F%6"M\3_CIN;&%&L> BQW$A>!\/2?F8%5X
M^9@0N2"!^TC0(%)5 S $JI.T,0. 6P< G@G!QUP:_*G]JS6OV@M2_9$_:0NO
M'<VH?#2R\-M%=?#[Q;X<MOB1H/C[XH^#[.]GO=8\+^-_#G[/4OQ)\<?!G1=?
MMH=(T"R^+/@SQ?<>()'OM1USQO\ !_P/X<TJ]\#>.3_B/GC1U\1^)/E4RO\
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M<> O_G>U^T7D1?W:/(B_NT?\1\\:?^CC\2?^#,K_ /G('_$IGT<?^C.\&_\
M@.>?_1"?BX?^"(?[,:<GXG?'09XS_;'@(^__ $3TXZ?T[TQ/^")G[,"-\OQ1
M^.6[#':=5\ N0O"/E&^';8VDA7!&48@':^*_2?6M6^-"_&0^'M#\.V=Y\&[G
MPM)-XB\8:K;V6B:EX-\0+8ZDUH? ,]GJ7B+6/B;JMW<C1I-0\*:Q\/O"?A[1
M[.;4M3M/BMKVKV:?#>?\<?@OX[_: LO GP8T[2M"^./Q&\.^$/CK^TY8^)O$
M6J7G[9&F7?[1WQ,\*_&3X1/X'U>.XO;*T\:?"3PYXBTCQ)\9M/N/ _Q8U:W_
M &:_"GC?P%XPTKQ/IGBO1+"R\3:"?\1\\:/^CC\1]/MY7W3_ .A)?1I->:35
MFDT_^)3/HWV:?@WP:[^6>:Z?]C]]?/[CVG_AR-^S$6V?\+.^.FX@\'5/ 0.U
M=JDKGX=Y RHRRXW'=DDLVYR_\$1/V8V7*_$[XYE2,9&K^ <]"IY_X5YG."<]
M\\GYAD>8ZE?_ +1<N@7ZZIJ7[80T.?X1^&Y_&E[X;T[]H:#Q=;_\%!AX-^/K
M^(M(\*6EOI2^(].^!#^(U^%S:7IW@^-/V6+K6M/^&VG6AN-.\1>*[?Q/^@W[
M17Q"_:A\#Z9X;A^$FD>'[[7],_9V^-WQ<\7QZC\*?%?Q'T[Q'\1OA9=_ ^+P
MO\*M*F\(^+_#+Z!=_$63QKX_CT_R%U_7;RTT"XN_#6BZ@- O4EA^//C*W=^(
MG$+EMS2>4R>]_B>12EO[VDDW+WFW+WG?_$J'T<TK+P@X12;NUS9_9NUKV_UC
M2;LDKM-V23NM#Y'/_!$;]F0$K_PL[X[$G:<+JW@1CPI52-OP\)'!/3&<%CDJ
M2'?\.1_V9I<'_A9_QT.T\%=5\ 1MG&#ED^':,QQUW$G.2?F)SJ_%_P 7_M8Z
M[>W_ (6U#0O&=Q>>$=:\6Z8GCKX7^!_B[X(LO&-EI4OQ,@T/4+;0['Q/XHT.
M.WGTB7PZ9[G3Y+R]O]6M;;4K?6(=,N[/P_;]'HWQN_:D\)6^F:%9> ]>M'AU
M">/PQI^N_!CXV_$"\^-WB'3]<\*:$_P^O?'0U^;0/@&]UH'FWQ^)OBZ&'X=S
MZAXDO_'$.F6GACX5?$B'6:?CUXSMW?B-Q&W:UW+*GIR\MO\ D2-VY6XV>G+=
M6L]5_P 2H?1ST:\'N#[Q=T[Y[=.RC=?\9 K>[&,=W9)62LFN(/\ P1%_9F((
M_P"%F_'/#%B<:K\/P3N*,0"/AWD#*+@ @* 57"LP8'_!$3]F8 J/B=\=,';G
M.L> 2?D)9>3\/21R23@_-T;(XK[,_9I^)/[0GC'Q-X@L?C5HFE6FB:CX&TSQ
MOX3NM*^%_B_X>2:!J$WQ)^*?@^]\$ZO/XD\1>(X_$5\GA7PKX)\5&5(?#FJV
M[ZY>W\FDKHVLZ-:Z5]I^1%_=J5X\^,R5H^(G$*6ND7E,5[W/S7Y<BC?F]I.]
M[WYY_P TKC^BA]'1W3\(.$&GT;SYK7DOH^(FM?9T[Z*_LX7TA%+\8A_P1'_9
MG&"/B;\<."I'_$R^'9(V,7 !/PY)P6)WCI(/ED#H H8?^"(?[,I(8_$[XZ9&
M,8UCP",8Z  ?#T# [#&*_:#R(O[M'D1?W::\>?&9-M>(G$2;W?/E=WK?7_A$
M?5M^K8G]$_Z.<OB\(.$)6O;F?$$K7O>W-Q))*_-*]DOBE_-+F_%X_P#!$']F
M0DD_$WXZ$GK_ ,3CP#_\[VD_X<@?LR?]%-^.G_@X\!?_ #O:_:+R(O[M'D1?
MW:?_ !'SQI_Z.-Q'_P"#,K_^<A/_ !*9]'#_ *,[P;_X#GG_ -$)\;_LH_L=
M^ OV.=#\8>'?AMXA\8^)++QKK&G:WJ4OC:\T*XN+2XTVP:P@BL6T71="0021
MRO(XFAD?>3\Y7:%*^R1#&.@_D?RR./PHK\[SC/\ -^(,SQ><Y]B9YQF^85%6
MQV98R</K.*JQITZ,95G3I4H.4*-&C23A2IQY*<%&$4DC]MX6X;R+@C(,NX7X
M4R;*\EX?RFG5I9;E>&AC9X?!TZV(KXNK3HNOB\154)8C$UZBC*M-1=25FD[$
MM?'7Q!_:.T/X=^)O&_@>_P#">KSZ]HMK\(-1\*V37NE6:_$!OBWXUOO >FMI
MTUS*@L9?#'BC2KF+Q'<:F$^QZ?#!J8D\JX28_8M?/'Q ^ OP[^(WCKP/\1?%
MFF3:MXC^'-MXCL?#RM=RKI5[8^*=/73=1M-;TWR9;;68;-'>ZTL7 8:9?SW%
MU!LG^=7D>(X>P^/D^)<+C\7ET\'BE&GEDJBQ7UVFH8G 1:I5J+EA,3BL*L!C
MKRE*&&Q\ZV'@\71P\:OE\;8?C/$Y12CP)C\OR[.EF.!A6K9I357"RRG$3JX/
M,94HNC6_X4LMHXM9[E-*4'1Q^/RJGE&+M@\QK5*7$/\ M??LXQZ6=<;XHV,V
MCQ37-HMW!H/C*XN0NE^'H?&%QJ<>GVGAF2\?P\_@V[7Q99^+(+9O#NI^'!=Z
MW8:I>:/;3WL'B.I_'OX&?#_7_B]\0/ G@$3^-M&U7QCHOC37M0@U;0+GQ8/#
M_P &/$7[0UI;^!M=U/1-9M=2TW6/[)G,^EV<N@6EO<7A\<7EA<V&J^%KWQ)Z
MWI'[&'P.T7PQ:>#[2'Q4-"T_3_'&DV<;Z^6N['1_'G@%OAMJNF)?K8IJ-W:Z
M=X3,MIHMYJD]]J-K=S/?76I:C<2L6O:O^R%\(];?64OI?&2VGB&6X:\TR/Q/
M.=/CU.Y^".J?L\7^NVEM+;2-8:GJ'PPU"+1;V:WF^R3ZAI6B:DMK%,E]%?\
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M(;'3KN=UMN+E_8D^!9O/%E_)_P )Q'>>--#U#2;Z>/QCJ1?3A-XJ\$^,EO\
M0I"K266IZ9XG^'WAO4].OB)8;0?:-.>*31[FTTJTK6_[-_[._C34M=FTSQ'J
M_BFXU-M0US^SM.^)DVL67AJX\4_$+2?%OBSQ#X:T6VN[FWT6;QQ\1?ALI\0W
MR*]F^IZ)XCTO3UTRVG\06$^-+">%#IT\0\1QY*-"<,1F&(P>&HTJ-2=266/$
MTX4L1SX?!X?#U8XUX2IB*BE4A6:S"+AALNI5MWCOI&4*GLYT/"=SQ5.6'R^C
MCLPQ?+6EA:&9>SQ/-AIY1B,9B\;5I9/BL9AL!16$H3AB<)@X8>AC,WQ67?7>
M@+INOZ;;:S;/?-:ZC!!<P)>6%WI%P89X(+BW^V:3J=M;ZCI]RD<G[VQO[:UN
MK=I)8+NTCD#H.GM[:.U0I%NVDC&[!*A5"J@(4':H&%!SM'R@A0 .?\,ZMI&K
MZ3%JV@:AIFIZ/J#/<V6H:5>6U_IEU$J1PF2QO;&XN;2X@#QE3)!(R,^[)+[G
M?I(G+@DXXQR.A! .1DDX]#W':OSN49TYU:4XU*<HU:D:M.I=5:=2,I0Y<0I1
MIS=:$81I2E4IQG^[Y5"C#EH4?W["RC/#T)0KT\33E1IN&(H2J2PU6,H4DIX?
MGKUHJG6C1IU8*E4K4W3<94Z]:DX5\1)1114FX4444 %?#7[9OQX^+'P6C^&-
ME\'="L_$?B[Q]K?CC3K'1KCX1_$OXQW>O:EX5^'VK^+?#_@^TTOX8^(?#]UX
M#@\9:_86&BZC\6/&%U)X"\!P3PW_ (GB\J:R9?N6O*/'7B/X2^&O$OP^N_B%
MKO@#1?%NH>(Y_#WPID\7:KH6FZ[=>*?$L%MX?N=(\$_VD\=_=:OK$&I6NDW-
MGI#27=VFHV]B\;&\MHI #\])?VV/CIH^K^/]6U+P!9ZS\.O"?QMT;X4:G/I/
MP0^-.D77@N>^_;1^$7[.6F^'](\;:CKNI:!^TQXG\;?#_P ;?$7Q=:7GP4T*
MSL/AEXN^'<'AKQGINIW7BK2=-?;B_;I\7+\6;""Z\ 1Z9\#]'\8_&G2_B9K/
MB7PSXY\#_$CX?> _ =E^RA8>'_B9JN@>*6TR/2O#&@^)?VA+[6/BYJ/B+2M%
MLO#_ ,(M,?XCPW<.E^%]8/B7ZHG\?_LJ1:1X<T>[\9? >VT#X@>-_AWX^\*:
M7=>)O!$5EXO^(OQ)\4ZK\5_A1XM\/VC7PM_$?B?QUXP\$ZWX^\#:MI:WNIZ]
MK7A#5O$VASWYT:\O;'E;7XT_L+3KXP^(MK\5_P!EF>S@?4=(\>^-XO'GPPGM
M86^)]GI4>JZ?XLUO^TWMD@\?:-\'-*EOUU2Y-MXBT3X:6]Y*+K3/";SV@!YW
MJO[6/@^T_9O_ &5_C'\:OA]_PD>J_%SP7\(?BYJ'ACPC;Z#JEWX!U34-'\"Z
M]K?Q!TCPEXI\0VGBF\\+?#'Q%XUT9M1U[0[?7-6\+I=:9)?F"_O].M]0V/#O
M[<7AWQ-K4/A72?@I\9'\4:SXCM_#WP^\/3/\);2Y^(\!UCXW:3K&OZ)?R_%;
M^R?#^B^'K;]GSXB:]?P>-=2\-ZU=:"N@#0]+U;6]8_L*PV;ZQ_80UG2]*^&V
MK0_LO:QI'[+OAG7M*TWP3>7?PUOM-^!/@SX4Z=X9M/$VD1:'/.;?P+H/P]T[
M3/ [>(]*GMM/TWPM#I/A:\U2"S-EX>N9/;]5_9W^!/B6P.D:]\(/AQJNG0S6
MCQ6=YX/T26*"73O$>M^+=/EMR]GOAGL/$_B/Q'KUG=6[I+;:KXAUZY@>&;5=
M268 \,^&W[3VM^(?@E^RIXLU7X?^(?&/Q6_:/\ Z!XO7P3X"3PIHD&C$^$]-
M\5>.M<U"]\9^.-.\.:;H_A275K*Q.GV7BGQ#KVI:KJ-C'H0UBP.L:SIN(G[=
M_@N]^)%[\+M#^&_Q*\4Z_P#\)[X3\':3JWAVZ^&M[X/\2>'/%&A?M&>(HOB7
MHOC"7XAV^A7_ (1T:S_98^+]IK^GVUQ<>--+U73](T63PQ/X@U.[T?1/I^^^
M OP8U+P;X'^'E[\+_ DW@;X9R:++\.O"G_"+:,FA>!7\.Z=+H^AGPCIJ6:VG
MAU=-T>>XT:VBTF*T@71[J[T@Q'3;NYM9*7AK]G/X$>#/$%QXL\)?"'X;^&?%
M%UKD'B6X\1:'X-T+3=9DU^UC^($-GJQU"VLTN1>647Q8^)\5E*KK]CB^('C"
M.T$"Z_J/G@'Q/HO_  4 .J_%2QL]?\&ZO\.OA+XD^&/P5^)'@K4_'$7PW@U3
M6O#_ ,0_AI^WQ\7-0\7Z]XLM_C=#X7^'GA*_\%?LG^&[[2K[Q7;'4_#&IW.I
M:3XMT*PTS7YO%GP_]T^#O[76E?&[7-,\,>#OA%\6;?586\0+\28?$*>!]!A^
M$5IIGB[QIX(T>^\5&]\:QWVOP>.-;\"^))O#D?P]LO%]W%IEB-1\26^@-/80
M77HNF_LD?LPZ/#J5OI?[/WP;L(-9B,&K0VWPW\(PQZC;C0/B%X3CM+J--*6*
M2Q@\+?%KXI>&;6P\L6-IX>^(GC/1;2W@TWQ!J-M/M:%^S9\!/#%_X2U3P[\'
M_ASH6I> KSQ'J'@O4-(\(:)IU]X:O_&$\-YXLO=*O;2SBNX+OQ+?V\&J:]<F
M9YM6U:*/5;YYM1BAN8P#VF  1* "!S@'!(&XX!P2,^N">:EIJ*$4*"2!T).3
MC/\ 3H.P'  '%.H **** /AO]JSX]?&+X6_$CX-^ ?@]X8L/%^K^/O!_Q:\7
M-X;N/A9\2?']YXNU7X=>*/@?H&B^!H?&7@?Q!HWAOX$6'B>+XJ:PVH_&?XIV
MFL^ ?"D^E:8VKV3Q3R0W'SYH7[?GC_5T\+>$AX+\%CXHWG[7MQ\,/$.GB?6H
M-#3]D^;]I33/@IX?^._A^P&J7&JW&J:E<^,/"'PQ)U&:WT27XTZ-\5%TZTO/
M#?@/4; ?J;<^'=#N]>TOQ3<:5I\WB31=*UK0M(UV6S@DU;3-&\27F@ZAK^EV
M-\Z&XMK#6K[PMX:N]3M8G6&]N-!TF:='>Q@*>=#X _!01WL0^%7P\5=3BTB'
M4RG@WP]')J$.@>.]8^*6@Q7<T>GI/-%HOQ-\1>(?B%I4,DK16'C+7=6\1VR1
MZM?37; 'S-^RG^U)X2_:_F^/?@S44\"Z]HNBWUOJ/AS2="DFUJR\2?LZ_$^;
MQEX0\ :KX_M]2GN[:'Q7XSO_ (:_$F\UOPLEM;6UAX2N_![7=C'<:G*'^ZK7
M3[2SMK:TLXUM[.TMX+6UMH%1+>"VMH5@@@AC50L<,<*1HD2 1JJ#:HW/OYS2
M/A_X*T"\T+4-$\+>'M)O?"_A7_A!/#=UIVC:?8S:#X($VDSIX0T=[2"$Z?X;
MCET+1Y(M&MMEA$^FV;Q0(8$QV & !G. !D]3[GZT 84OA?P_-X@LO%<NDV,O
MB?3=%U3PYI_B&2U@DUFRT#6[S2-0UG1K74GC:[ATW5M0\/Z#?:C:)*(;R[T7
M2[B='ELK=DUQ H(.YS@8&6& .,87&T8VC! !X'/ Q/10!7%NH)/F3'I@>:P5
M<8X 7&5XSL;<O)  #$$%K&H"J7 &[HV/O#! &,* "<!0 #AL;E4K8HH @6!5
M! :0YQEBYW<*5SGCDAC]. NU41558%!)W2')).7(')R<A=H(W;FPP(!9@!@X
M$U% #$C6/)4<M@$\=%R . .!DX';.!@  /HHH *BF"-&PD?RTZEMX3;CG.X_
M=P>0<C! .>*EKYQ_:E\6:]X%^&>C>,-&U;4="TWP_P#&'X#7OCW6-/B,L>E_
M"M_C+X'M/B?J6NL+6[%EX/T[P/<ZY?>-]7E6"RT'PA;ZWKFIW^G:7IU[?6X!
M] LEJ2<W&"OWQ]HQQRQ#*6P."22 I"@ $*J@2-%&3EYG/)7!D ^8[CC( ;(!
M;:N<(.4"D9K\D-&^,7C:\^+7PB\2ZI\3/$7B_P '>._C7\4-(^'_ ,)/#GB[
M4/!WCK7?!&K_ !\U7PW\//C=X?\ "EIH;M\<_@-I7@^*WG\30:EJ.E^'/"'P
M<LY_C7X:O/%=MJ&GK-J_$S]J/XH?!'XM_%30M-T_5/$\>M?M2^!](\+Z#XG\
M+ZOJVAR_#&'X#?L76_C+PW\-];;QYX4.@:W_ &_\3?&WC6VM/#'ACXN75Q<Z
M7\0?$.H>!UTKPOXLUFR /U=\I,L=QR=PX(&W<<MC SSE 5)*D)'E<C)Q]6T'
M0=?TO5- UVSL]8T?6["[TO6-*U-(;RRU33-3BEM;W3[ZUG5X[FTO(9I()H95
M990S Y=G+?F5H7[8WQZ^(_B7PM\/? 'AWX<:+XJOX_A?X?\ 'FM^(_ GQ)\1
MZ#\,?B)K^E_MP3_$CPOKVC:;XL\*O<:KX-U?]FOX:Z:?#<_BG2=0L;;XB1ZM
MJ>I3:9XK\!W=QS]Q^TY\>/C'X/TYM%U#P?\ "#QM=>-/V%]2T;X6?\(S\0[_
M .(T'AKXI>*OV7?%?C_XB^)=2/BGPC+XD^#$3_$CQ_\ "O4/#FE>%-,M-3;P
M3KNE^(?B?H?B%?&7@SP0 ?I[X)^'_@7X::!;>$_A]X;T+P7X:M+B_O+;0?#=
MA9:3IJ7FHW<E[JE\;:TBC66^U'4+N:\U*^F\R[O;VY:>[FEF9&7JQ##N!\YF
M<;6!,BELX:-2..0P)7!RK%0=I8$GQ3X,^*?&7Q7^"^DZ[XN2'P9X\U&U\6^&
M=:O/#6ERV]G8^)/"_B+Q'X)G\6>&-&\9P:VUKIVI7FC'Q3X<TKQ OB"&WT^^
MLK#4;WQ):K)?7_YD7GQ7_;(T[X'>.;OP?-=^-?$&B_L%>,?$]_XH^('BO6/
M7BW2_B3I/B3XVZ7IWCKPWI'A/X'>,=(\8?$F[L?#OA^YN] =/ FFPS6.B#2[
M-++5V2P /VB @08^T *"6VF6,   ;AC P"#ES]X[BQ;+$ES)$=RM,2#@,IE
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MCQ//X4\,OH7AWP[#?^&-&\2:OKD5I>:D-:U^2^^W#6]?U*_24Q?3% !1110
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M (3+X:XPP)_X5MXLW$/DG<W_  MO<QW8;<26)4$DG)+?[!^+X!QXU^'(R%
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M_P">I1_8WQB_Z';X;?\ ALO$G_SU*/K=3_H S'_P7@O_ )X!];G_ - .8_\
M@G!__/ ].WGT'Z_XUX7\6?@=IOQ8\1_"SQ+<>*->\(ZC\+?'&F>-=/U'PI#I
M5EXBOUT_4]#U*]\,IXLFLYO$.A^&?%T&A)X8^(.CZ'?66G^._ VK:SX4\26M
M]:3V%QIW5+HWQ=VD/XU^')/8K\,_$07\0?BF2?KD>N.U']B_%O\ Z'3X=?\
MAL_$/_STZ?UNI_T 9C_X*P7_ ,\ ^MS_ .@',?\ P3@__G@?+/@']@SP3X(U
MGP=J^I_$GXB^.H?A]8>!O#?@_2_$%OX%TJ#2_ _PV^$7[1?P3\(>%&U#PAX0
M\/:O-);^#?VD_%AU/Q0;Y/$NH:KHVA7*ZC9V1U/3[_YZ\'_\$]O$7CRVNKCX
M[>*;R&;POIWPB\&?"W3M7M_A%\59+/P=\+/A_P#&;X;W-KXRT]OA#X3\!ZW%
MXET#XX^);:%5\,R:U;WNCV>N3ZM8Z9K.H?#VU_2O^Q?BW_T.GPZ_\-GXA_\
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MTK>?0?K_ (T;SZ#]?\:\U_L7XM_]#I\.O_#9^(?_ )Z=']B_%O\ Z'3X=?\
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MT?V+\6_^AT^'7_AL_$/_ ,].CZW/_H S+_P5@O\ YX!];G_T YC_ ."<'_\
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M &9?^"L%_P#/ /K<_P#H!S'_ ,$X/_YX'I6\^@_7_&C>?0?K_C7FO]B_%O\
MZ'3X=?\ AL_$/_STZ/[%^+?_ $.GPZ_\-GXA_P#GIT?6Y_\ 0!F7_@K!?_/
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MQ3\.QXDU.U\1:+X27]F&C1B&9$9E!"EE!*AL;@"02 V!G'7 ST%+@9#8&0"
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M)[_#GQA>_!74-?\ CU]O\(V_ACQ/^T)XK^)SZ=X;/[3.EZU_PCOQ,UME\/\
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MCHVI_%?3K+0M/UR76A;W>C?"7Q=X\@TZQ\-:0^O^)O$/B=_A]X*\4CP;X/\
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MPQ_X/M*_^2ZB_P"%=^"_^A.\,_\ @CTG_P"1J/\ A7?@O_H3O#/_ ((])_\
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MZULM)T"\O-;T&#4SFX@_DR/_ ,"SO_Y6%L]_ZD?_ (%G7_RL]_\ ^%C^ ?\
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M7D$\<<MMHB2VMRAU:=$T_=!*!<'8V#FX@_DR/_P+//\ Y6%L]_ZD?_@6=?\
MRLZ#_A8_@'_H<O#'_@^TK_Y+H_X6/X!_Z'+PQ_X/M*_^2ZY>?2_@_;1Q37-G
M\.[:*?39=9@EN(?#D$<^C06LE[-K$#S(BS:3%90S7LFIQ%K%+.&:Z,XMXI)%
MQ?&5Q\$O ?AOQ/XL\26/@NTTCP?X0\3>.]=2UT?2-2U2/PMX/T>'7O$6JV6C
M6-M<:IJ46G:5=6=S)'86=Q++_:.F)$"]_:+,<W$'\F1_^!9W_P#*PMGO_4C_
M / LZ_\ E9Z%_P +'\ _]#EX8_\ !]I7_P ET?\ "Q_ /_0Y>&/_  ?:5_\
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M9H.G:K;F]\ 6UC>>+;'4K^PLY[/1[[1X;^W66SU*>WN9)Y3 L/FQ%'LW]]\
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MK=GK%CJUOH<IAT.TT:YUB]TM]4NHK2WUJQL+K2Y2D\HNC%:73Q'-Q!_)D?\
MX%GG_P K'_PN_P#4C_\  LZ_^5GJ?_"Q_ /_ $.7AC_P?:5_\ET?\+'\ _\
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M** "BBB@"M>0_:+.[M\JOGVT\.YUWHOFQ.F67!W*-V67!R,C'-?B%HO_  3
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M5+/5$/[.J_\ 0VS7_P &8+_YWA]0J_\ 0US3_P #P7_SO/T!_M?XK?\ 1/\
MPK_X<>^_^8"C^U_BM_T3_P *_P#AQ[[_ .8"ODCXO_ML:C\.OBUXYTO2_ .H
M^*/A_P# WP'^T'XC^,D5GJWA+2];2S^#'A#]CWXKW_BWPQ<ZWKEDEX-,\!_M
M"ZYI=IX3N8K >(?$]C NJZ_X9TJ.SU6;8T_]O&W\1^*-4\,>$?@)\6M6+?&B
MZ^"'@_Q'K>BWW@;P;XI\2Z)XM^+'@;Q;>#Q9XPTC2M$%IX6UWX.^)=4O[7PO
M>>--4E\(ZEX=OH;+_A+;O4_ ^D']G5?^AMFO_@S!?_.\/J%7_H:YI_X'@O\
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M_P#0VS7_ ,&8+_YWA]0J_P#0US3_ ,#P7_SO/'O[7^*W_1/_  K_ .''OO\
MY@*/[7^*W_1/_"O_ (<>^_\ F KV' ]!^0HP/0?D*/[.J_\ 0VS7_P &8+_Y
MWA]0J_\ 0US3_P #P7_SO/'O[7^*W_1/_"O_ (<>^_\ F H_M?XK?]$_\*_^
M''OO_F KYX_:L^-/QR^'OQ/^#/P^^!N@Z-XEUGQ[X&^,7BN;P]J7PM\7>/9?
M$>J_#SQ7\!]$T/PW/XLT'XD> /#WP9\-ZO:_$_Q!_P )!\4/&5OXGTO0+FUT
M.ZAT+69+>7POXE\Z\*?ML>*=2\<>*_#NF>"D\?S7=FUUX"\/VMSX?^',J:9X
M+U7XQP_$75]<\0>)?$>K:9YS67@7P_:^%]&AO+G4-4U/5/[2OH] \+V_B_7?
M!I_9U7_H;9K_ .#,%_\ .\/J%7_H:YI_X'@O_G>?9G]K_%;_ *)_X5_\./??
M_,!1_:_Q6_Z)_P"%?_#CWW_S 5\S^"_VSKG5_A)^TY\=];^&[Q_#SX+WFD:Q
MX!L= \1Z;<>,_B'X$UWX"?"/XW:;<ZSIVO'1-#\'^++NT^)]K91Z7J/B&/2+
M)GBAU+5+**UN-6NN+U;]MWQ?HGQEL?"]_P#";4(/#_A5?''A/XRZ%IWB#PGK
M5[X7\4V/Q%_94T3PUXL\.>(4U&U7Q3H8\'?M(:1XAOO#5II>FZX3;>)]-NH+
M7Q+X<T'0_%Y_9U7_ *&V:_\ @S!?_.\/J%7_ *&N:?\ @>"_^=Y]F?VO\5O^
MB?\ A7_PX]]_\P%']K_%;_HG_A7_ ,./??\ S 5\M67[?_A74M<U'2-/^'FN
MW6E:9\1_AYX:N_B+]NN(?A3:?#SXHV_BJX\$_%:]\<3>'D@@\.^(9O!NKZ)H
M^K0V%U\.-0\3W_A?1H_B@B^((KVU]<_9D_:GTC]IVS\0ZSX?^&GQ/\&^&+.V
M\.ZWX/\ %/CKP5XE\,:%X_\ "OBH^(%TK4O#M]XBT31(M0U2S'AR:[\0Z;HC
M:]I6CZ=KOA*=/$E_=ZQ>V&CG]G5?^AMFO_@S!?\ SO#ZA5_Z&N:?^!X+_P"=
MYZ3_ &O\5O\ HG_A7_PX]]_\P%']K_%;_HG_ (5_\./??_,!7L.!Z#\A1@>@
M_(4?V=5_Z&V:_P#@S!?_ #O#ZA5_Z&N:?^!X+_YWGCW]K_%;_HG_ (5_\./?
M?_,!1_:_Q6_Z)_X5_P##CWW_ ,P%>PX'H/R%&!Z#\A1_9U7_ *&V:_\ @S!?
M_.\/J%7_ *&N:?\ @>"_^=YX]_:_Q6_Z)_X5_P##CWW_ ,P%']K_ !6_Z)_X
M5_\ #CWW_P P%>PX'H/R%&!Z#\A1_9U7_H;9K_X,P7_SO#ZA5_Z&N:?^!X+_
M .=YX]_:_P 5O^B?^%?_  X]]_\ ,!1_:_Q6_P"B?^%?_#CWW_S 5[#@>@_(
M5\^?M,?'#2O@'\*M4\:W4^BV^N7VH6/A+P,/$\]U8^$9/'7B'S[;P_/XUU>R
MCDN="\#:-)'+XB\;ZS;QS7]EX3TG5SH=CK?B"32M!U,_LZK_ -#;-?\ P9@O
M_G>'U"K_ -#7-/\ P/!?_.\Z+^U_BM_T3_PK_P"''OO_ )@*/[7^*W_1/_"O
M_AQ[[_Y@*_.WP'^V5\<_B#\([W]H#1-1^!-QX'\"67[,MIXH^'=EX,\7:GXV
M^*>I?&'X4? GXD:[??#KQ=9?%F/3?A]>^);WXX0^&/@IX+U#P1\4Y/$6K>&X
M(]1\97G_  F]JG@[:\<?M2?M%:%'XVA\+ZO\#;_0;2]^)VM?#WXO:[\(?B+H
M'@+Q%HGP<^%WB?QOX[\!VGAV;XXF\\636^KV>@Z9H_QPT7Q7I7@_5[*V^(XT
MSX<W!\"V>K>(S^SJO_0VS7_P9@O_ )WA]0J_]#7-/_ \%_\ .\^^/[7^*W_1
M/_"O_AQ[[_Y@*/[7^*W_ $3_ ,*_^''OO_F KR;XA?M*WW@*V^%]K'\--3EN
MOBKX*\0>(]-U7Q-K"^&/!FC>,(/#5IK?AOX5:GXK_LG4+>'Q_P"+]7U.'3-
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MA[:^,?#7C[PUK&G3:?KW@K4O$EOX=\!>-3^SJO\ T-LT_P# \%_\[P^H5?\
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MM9(O&>E3:E<:5XL#P:)&Q\1:7<:OJ<VFZLI2_P!/EO[N2SN86G^3N_"'PV\
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M_P \)?SA_P#BZ/:0_FC_ .!0_P#D@NNZ_P# H_\ R1KT5D?VF?\ GA+^</\
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M(+KNO_ H_P#R1KT5D?VF?^>$OYP__%T?VF?^>$OYP_\ Q='M(?S1_P# H?\
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M#7_$WBB^M+:&]\6^+/%/B:?5_$.I']EY=_T!8?\ \ G_ /-(?V9EW_0%A_\
MP&I_\TC/^%4>%O\ H)_$C_P\OQ?_ /FYH_X51X6_Z"?Q(_\ #R_%_P#^;FO1
MDFBE5'CECD21$DC9'5U=)!NC=&4D,CJ04920P.5)%24?V7EW_0%A_P#P"?\
M\TA_9F7?] 6'_P# :G_S2?'_ ,:_&7P1^ @T-_'NJ_'3RM;TWQ7KY?PIXH_:
M-\='1_"W@2UTR^\9^+=?C\)^)M4GTCPYX:L]8TZ;4[^>!G"W:&V@N3%.J=K'
M_P *'>[AL1\6[DWMSXFM_!5K9K^TKX]:ZN?&5U;SW5MX3@MQ\2S--XEN;:VN
M+BWT%(O[6E@M[B6.T>.)W$GQB_9S\ _&_P ;_#/Q-\1M/M?$_A_X=:9X^LF\
M"ZO937GAOQ1-XY'A.$GQ);K?V]EK.D:=!X:FCN/"VO:=K?AS7#J2RZI8"?3=
M/E'S-XA_X)\^%-?\1_#[79/%SM!X6^)/[17CGQ=H%UI_Q!T;PYX_T[]HG]HS
M0_VC]5LM1T[X8?%[X:0W/B7PMX@\*^%]#T[7/&G_  L'PAK>G:8MUXE^'6JW
M$.C0: ?V7EW_ $!8?_P"?_S2']F9=_T!8?\ \!J?_-)]0^,M,^$7@&WLY?%G
MCKQ7H<^JG4HM"TW4OCU\3K+5O$M[I.F76L7NE^&--O/B);7.OZO'IUG<7/\
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M?] 6'_\  )__ #2']F9=_P! 6'_\!J?_ #2>:_\ "J/"W_03^)'_ (>7XO\
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ME*?$=_<Z#XRT@Q6VDFYN9=0%Y9+;B2TDK2\-^)_V;/%_@3Q'\3/#OQIN-0\
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M=>%?&_[*?B'4M<?Q;XBFU.:^T_5M0^&/Q7UGP7X:$ZV?A*VN;2_LM.\(W_Q
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M_P#FD/[,R[_H"P__ (#4_P#FD\U_X51X6_Z"?Q(_\/+\7_\ YN:/^%4>%O\
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M'_!SQ[JVJ> X?"'A>ZB\":;HESI_B.ZTKX2?"G1YI-/UG6N_"/[:7B_QK?\
MAO67^(G@[X?6/Q1\1PZIXMT;XH^ =.E\8?#'6_VMO$GC;2QX6FT/5KCQEX=L
MM)_9FNO#W@B_O)K3PGXUTMI=6T3PM(-:TO1/'!OW'[3WQ#\ _ OX">)/%_BO
MX;:+?_%;XR_%#X9Q?&KX^QOX \+CX6^&=&^/GC#X0_&?QGX<T=?!.E0>(OB=
MX"^%OP_U?4M!M[GX:>'[J_\ 'MS?:=I_@^)=,\&VOS_XR_X**_%;7[#4-(\%
M:!X.^%7BQ/V?/ _QH\21_$;2KS6;CX#Z^]G^S)X\\;>'/B#I%YXL\)^*?$&@
M6_@7X[>(H5\3ZO\ #SX5:)H5QX&O-8AU[Q+>Q>)M)\$%X_SP_P# XKMOVW"\
M?YZ?_@R*[;]M_P"K&GX%\4?M#^'?VB/V>OA3\3?B#XSU_P"(Y\5_#X>*-#T3
MXL_##4]&3X$:-^RSXS3Q3/\ %OX5:%JS^+;OQKK/[06D2>+M6^*X\$6?A2[L
M]2^'/A[1/BK;7$FH_"J_]L\9?##]K2]^*_CKQ)X6\2>*=#\*6GCK4/%?@72?
M#GBWP=X>TCQ#<#Q+^RW#I?\ PF&E@"]U^Q;P)X>^/>AG2?$D\UA)INL7TM_8
MOXELOAG?^%?)K_\ X*"_%+0/$^O>$+'X:Z'XBM_#.F_M.>+)M6UWQ[X(T-O%
M^A_"SXV?M=^"=,_X02RU#Q7X6\7:Q9^"]%_9V\+ZEXCT;P;\.OBGJLGAOXDZ
M2^K^(/#C>'[/Q-\1KFM?MC?M#:!XZO+/7(_@%X<LO!7@SX]IK.@:[JU[X/\
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M-T7C_-#_ ,"07C_-#_P)$]%0>:W]P?\ ?3?_ !NCS6_N#_OIO_C=%X_S0_\
M D%X_P T/_ D3T5!YK?W!_WTW_QNCS6_N#_OIO\ XW1>/\T/_ D%X_S0_P#
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M_M :+J.H^(_A+\58++P]X%^'G[1>F?#GX2>'-<_X5G\,OBM?6EO\4/@T^O\
MQ'_X6=XI7X7^#=1U5?#&J:5XO\.^&4OM*\4OZK7_ .ACC_\ P9A/Q_V8?L*O
M_09F'_@W"_C?#?U]Q^@']L?&3(!^'_PU7)P ?BWXGR3Z ?\ "GN3[4IU?XS
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M_,Q]*?VO\9O^B>_#;_P[?B?_ .<]3AJ_QD(;_BW_ ,-MRC.T?%GQ.>XQN/\
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M7_Z&./\ _!F$7_NL'L*G_09F'_@W"?\ S-_7H?H1_;'QF_Z)[\-O_#M^)_\
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M_P#.>KUKR3ZC\A_\31Y)]1^0_P#B:/JU?_H89A_X'A/_ )F#V%7_ *#,P_\
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MTTW<HJG]OM?^>G_CK?X4?;[7_GI_XZW^%/FA_/3_ /!E+_Y:.Z_FA_X,I_\
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M)/<]:K?;[7_GI_XZW^%'V^U_YZ?^.M_A1S0_GI_^#*7_ ,M"Z_FA_P"#*?\
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MW^%'V^U_YZ?^.M_A1S0_GI_^#*7_ ,M"Z_FA_P"#*?\ \L+E%4_M]K_ST_\
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M^.]6@^''@SQ1\6O%FLZGXK^$?A2[\"?$'P_"?!ME/XGL#FA_/3Z_\O:73?\
MY?=.OR>S39S1_GI]?^7M+IO_ ,ONG7[]FF_V!)BW^64&1M RJXZ$\ G.%R 6
M"[=TFU6+[PLGE1]HT'RA>% ^48PO Z# P.@[5^=_Q"_:%\6^ _VD_$U]:)XJ
MU;X+Z5!\!OAGXWO3X&^(/B7PUX/\8:AX4_;%\;:[<:#%X>TJ96\2:CKLG[*W
MACQ)K%A!K6FQVWC;PEX>OF@UF_TN:R\$L_VQOVU8? ]]\0[GX2>'M7@F\,>%
M[33/ EG\)/BGI?B#1]?U7]E+]F_XY>)/'FNZG/XHOYM1\/\ A#QU\1/C!X3N
M?AS8>&M.U[5D\$V'A&T\9#QWINL6M\^:/\]/7_I[2_6LNS[;/L[%XZ+FA=ZI
M>TI7?WUEV>NVCUT=OUTN-'T"35].UZZTG2Y-<T:PU2PTG69K&UDU/3-.UR;3
M;G6K&POVC-U96FK3Z%H\^I6\,L4.H2Z3I\EPLSV$)AO,;4$[HE^16R2BG";6
M1SST3:A1F.%(')VJQ7\S/B?\9O%^L?L;>$_$7Q0UJ_T#XD?$;Q%K7A3PMXG^
M"?BGXC_#3P?#JK2?$2X^'OC_ ,6^,O#\5]XK\%> H_"/ARP\=>-;>TG\2Z9J
M/B&"S\#>%D^(D/B7PYI'B?PG5?BMXST/Q+X^U3XC>,OVA/&.C'P[X^TGXB6O
MA'6?B3\-?"MVM[\9/V;?#/['?B3P3XG\,V>E:/\ "73/B)X&UKX@>*OB+XO^
M&>I6>H1^'-3^+UWXQO=:N?AGH5IX:2E![3IZ*[_>T=N_\9::-WVLF]E<$XN]
MITW97?[VEHGL_P"-L^CV:NTVE<_:<K9JV/LZ!BJ# A4'"E61.@("'8^3B- !
M(S*%+"SY43 ?NUP0."F"!C@8(!7 XVX&!\I':OR.^ WBCXQ2?&3X1Z3KGQ6^
M(WQ)UNSN/".B^+=5%OXSM_A#XT_9G3]C.WUF[^+>GVMYHFG^")?&&K_MGK'H
M3^++I+;XI36K:AX?O-/M/"ZRZ?:?K0M];!5!D&0H!PK 9 P< @D#TR3QWHYH
M?ST]=5^\I;?^#6%X_P T._\ $I;?^#7W1:$40(*QHI "@JH&%&<*, 84$Y"]
M >0,\T]5"@*H"JH   P !P  .  *J?;[7_GI_P".M_A1]OM?^>G_ (ZW^%'-
M#^>G_P"#*7_RT+K^:'_@RG_\L+E%4_M]K_ST_P#'6_PH^WVO_/3_ ,=;_"CF
MA_/3_P#!E+_Y:%U_-#_P93_^6%PC((/0\&H_*CY&Q<'J,  \8Y'?(X.<Y'!X
MXJO]OM?^>G_CK?X4?;[7_GI_XZW^%'-#^>G_ .#*7_RT+K^:'_@RG_\ +"R8
MXV^\BMW&5!QR#QGIR >,<\]>:?5/[?:_\]/_ !UO\*/M]K_ST_\ '6_PHYH?
MST__  92_P#EH77\T/\ P93_ /EA<HJG]OM?^>G_ (ZW^%'V^U_YZ?\ CK?X
M4<T/YZ?_ (,I?_+0NOYH?^#*?_RPN453^WVO_/3_ ,=;_"C[?:_\]/\ QUO\
M*.:'\]/_ ,&4O_EH77\T/_!E/_Y87**I_;[7_GI_XZW^%'V^U_YZ?^.M_A1S
M0_GI_P#@RE_\M"Z_FA_X,I__ "PN453^WVO_ #T_\=;_  H^WVO_ #T_\=;_
M  HYH?ST_P#P92_^6A=?S0_\&4__ )87**I_;[7_ )Z?^.M_A1]OM?\ GI_X
MZW^%'-#^>G_X,I?_ "T+K^:'_@RG_P#+"SY:9SL7(.0<#.=Q?.>OWB3UZD^I
MI##$<DHI).22,DG;LR3UR%)4'L"0.IJO]OM?^>G_ (ZW^%'V^U_YZ?\ CK?X
M4<T/YZ?_ (,I?_+0NOYH?^#*?_RPMJJHH50%51@*H  '8 #@ =@.!VI:I_;[
M7_GI_P".M_A1]OM?^>G_ (ZW^%'-#^>G_P"#*7_RT+K^:'_@RG_\L+E%4_M]
MK_ST_P#'6_PH^WVO_/3_ ,=;_"CFA_/3_P#!E+_Y:%U_-#_P93_^6%RBJ?V^
MU_YZ?^.M_A1]OM?^>G_CK?X4<T/YZ?\ X,I?_+0NOYH?^#*?_P L+E%4_M]K
M_P ]/_'6_P */M]K_P ]/_'6_P *.:'\]/\ \&4O_EH77\T/_!E/_P"6%RBJ
M?V^U_P">G_CK?X4?;[7_ )Z?^.M_A1S0_GI_^#*7_P M"Z_FA_X,I_\ RPN4
M5'%*DR!XSE22 <$9(.#P<'K13YHO:2?HTU]Z;3^3:\Q_UHTU]Z;3^3:\SA=7
MA^(GVQSH/_"&_P!G>5%L_M>#66O_ #B#YP;[)*EOY0.WRN"^W(D9B,G)^S_&
M$\^9\-^?^F7B@?I]IX^E>J45R5<'[67,\9F%-+:-'&2IK\:%5M=EI\^G)5PC
MJRYGC,PI]HT<9*G'[O85&_OT[ZV/*_LWQA_YZ_#?_OUXH_\ DFC[-\8?^>OP
MW_[]>*/_ ))KU2BLO[.7_0PS;_PX/_YB,O[/_P"IAFW_ (<)?_,AY7]F^,/_
M #U^&_\ WZ\4?_)-'V;XP_\ /7X;_P#?KQ1_\DUZI11_9R_Z&&;?^'!__,0?
MV?\ ]3#-O_#A+_YD/*_LWQA_YZ_#?_OUXH_^2:/LWQA_YZ_#?_OUXH_^2:]4
MHH_LY?\ 0PS;_P .#_\ F(/[/_ZF&;?^'"7_ ,R'E?V;XP_\]?AO_P!^O%'_
M ,DT?9OC#_SU^&__ 'Z\4?\ R37JE%']G+_H89M_X<'_ /,0?V?_ -3#-O\
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M5_9OC#_SU^&__?KQ1_\ )-'V;XP_\]?AO_WZ\4?_ "37JE%']G+_ *&&;?\
MAP?_ ,Q!_9__ %,,V_\ #A+_ .9#RO[-\8?^>OPW_P"_7BC_ .2:/LWQA_YZ
M_#?_ +]>*/\ Y)KU2BC^SE_T,,V_\.#_ /F(/[/_ .IAFW_APE_\R'E?V;XP
M_P#/7X;_ /?KQ1_\DT?9OC#_ ,]?AO\ ]^O%'_R37JE%']G+_H89M_X<'_\
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M7JE%']G+_H89M_X<'_\ ,0?V?_U,,V_\.$O_ )D/*_LWQA_YZ_#?_OUXH_\
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<0C#FG/EBH\]27/4E96YISY8\TWO*7+&[ULC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Q G(# 2(  A$! Q$!_\0
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M%))H.J1300O9NLDX)C4D?-@9/XX[5/)6[/\ $7[SS*OVRX_Y[/\ G1]LN/\
MGL_YU<E\.ZO#')))8R*D:;V.1P/SYJK%I]U.EN\<19;B0Q1$$?,P[>U#C63L
MT_Q!\Z[C?MEQ_P ]G_.C[9<?\]G_ #J6;2;ZWLA>2V[+;EMH<D=>G].M2:1I
MRZE<RK)*T<,,332,B[FP.P'<\T*-5R4=;L+SO8K?;+C_ )[/^='VRX_Y[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "E'44E*.HI@9"?ZM?H**$_U:_045Q+8DOV7_'C;_[@IZ6\$<+0
MI!$L39W1J@"G/7(Z<]_6H++3I)+&!Q?W" H#M&W _2I_[+E_Z"-S_P"._P"%
M=,'+E6GY%#6L[5E56M8"JH8U!C4A4/!4<< ^G2AK.U<,&M8&#((V!B4Y0=%/
M'3VZ4[^RY?\ H(W/_CO^%']ER_\ 01N?_'?\*J\NWY ,-G:-,)C:VYF&,2&)
M=PQTYQGCMZ5E^(_#5OXA\.2:&)!9VLKQEQ%$,%5<,5 X SCK6O\ V7+_ -!&
MY_\ '?\ "C^RY?\ H(W/_CO^%%Y=OR DXZ 8'0#VJNEA91Q^7'96R1[Q)L6%
M0-PZ-C'7WZU)_9<O_01N?_'?\*/[+E_Z"-S_ .._X47EV_(!KV=K(DB/:P,D
MC[W5HE(=O[Q&.3P.363?>&+.^\0Z9JKB,)8Q7$9M?)4I-YNW);WRN>ASFMC^
MRY?^@C<_^._X4?V7+_T$;G_QW_"B\NWY )+:VTXC$UM#*(B&C#QAMA'<9''X
M4CVMM([/);0N[%2S-&"25^Z2<<X[>E._LN7_ *"-S_X[_A1_9<O_ $$;G_QW
M_"B\NWY ->SM9$D22U@=)6WR*T2D.WJPQR>!R?2I$BCC9VCC1&<[G*J 6/3)
M]3BF_P!ER_\ 01N?_'?\*/[+E_Z"-S_X[_A1>7;\@&_9+81B,6T&P/Y@7RQC
M?G.[&.N><]:%M+92A6VA4HY=2(P-K'JPXX)R<FG?V7+_ -!&Y_\ '?\ "C^R
MY?\ H(W/_CO^%%Y=OR C:PLG@6![*V:%6W+&T*E5/J!C /O4DT$-Q"T,\,<L
M3=8Y$#*?P/%']ER_]!&Y_P#'?\*/[+E_Z"-S_P"._P"%%Y=OR 3[-;FX6X-O
M#YZKM67RQO"^@/4#VISP0R2"1XHV=5*AF0$@'J ?0]Q2?V7+_P!!&Y_\=_PH
M_LN7_H(W/_CO^%%Y=OR :MI:JT++;0*81MB(C ,8]%XX'TIYBC,RS&-#*H*K
M)M&X ]0#UQ2?V7+_ -!&Y_\ '?\ "C^RY?\ H(W/_CO^%%Y=OR 8+&S6.:-;
M2W"3',JB)0)#_M#'/XU..  . .F.U1_V7+_T$;G_ ,=_PH_LN7_H(W/_ ([_
M (47EV_("(:?8A&06-J$8%640K@@G)!&.A/-2);6\<[SQP1),X >18P&8#H"
M>II?[+E_Z"-S_P"._P"%']ER_P#01N?_ !W_  HO+M^0#([&SAV>5:6\>QBZ
M;(E7:QX)&!P2.](UA9.BHUE;,BEF53"I"D]2!CC/?UJ3^RY?^@C<_P#CO^%'
M]ER_]!&Y_P#'?\*+R[?D!E>(?#5GX@T"]TEC]D%T$W30(H8%""N?[P& ,'MQ
M5+POX-M_#MKJ"W-R-2N-1E62ZDEMXXT?:-J@1J-H 'YFNB_LN7_H(W/_ ([_
M (4?V7+_ -!&Y_\ '?\ "B\NWY!J.CCCAC6.*-(XU&%1%"@#V Z4ZH_[+E_Z
M"-S_ .._X4?V7+_T$;G_ ,=_PHO+M^0$E%1_V7+_ -!&Y_\ '?\ "C^RY?\
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M^._X4?V7+_T$;G_QW_"B\NWY 245'_9<O_01N?\ QW_"C^RY?^@C<_\ CO\
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M]S_T$KG\E_PH^SW/_02N?R7_  HYW_+^07->BLC[/<_]!*Y_)?\ "C[/<_\
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M3/[*D_Z"-U^:_P"%']E2?]!&Z_-?\*+R[?B@'T4S^RI/^@C=?FO^%']E2?\
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MK_QW_"C[-<?]!&Z_\=_PHYY?R_D%S8HK'^S7'_01NO\ QW_"C[-<?]!&Z_\
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MZC- 'HNF:BU]+J,,D2QS65VUNR@YR,*RM^*L/QS6A6#HYW>+?%3+]SS[8?\
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M^R6_Z"%W_P!]+_A1>7;\4&HJ0PQ/(\4,<;2'+E$ +'U)'7\:C-E:&VDMOLL
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M=6T<[(#D*64'&?QJ]WKQF^U2ST_PO=P75TL,MYX6L%M48\S$"0$(.Y&Y<XZ
MY/%7;6">Y^)=Q//J.E6NH0:L0J2N_P!LDMM@VQHN=IC93GIC.3U% 'K-%%%
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M[3C-<5<0:[IN@:---X>FN((XM-BMI?M4<?EDSI(RE&.0S-L3I@;1[T >J?\
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M,^E5?L$O_01NO_'?\*/L$O\ T$;K_P =_P *.:7\OXH"]15'[!+_ -!&Z_\
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MFE_+^* O451^P2_]!&Z_\=_PH^P2_P#01NO_ !W_  HYI?R_B@+U%4?L$O\
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M_P"@C=?^._X4<TOY?Q0%ZBJ/V"7_ *"-U_X[_A1]@E_Z"-U_X[_A1S2_E_%
M7J*H_8)?^@C=?^._X4?8)?\ H(W7_CO^%'-+^7\4!>HJC]@E_P"@C=?^._X4
M?8)?^@C=?^._X4<TOY?Q0%QT26-HY%5T8896&01[BD6&)1&%B0",83"CY1C'
M'I53[!+_ -!&Z_\ '?\ "C[!+_T$;K_QW_"CFE_+^* MQ0Q0AA%$D89BS;%
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M_% 6#:V[)&A@B*1$-&I080CH1Z4\Q1F83&-/- VA]HR!Z9]*J?8)?^@C=?\
MCO\ A1]@E_Z"-U_X[_A1S2_E_% 63;0%W<PQEY%VNQ098>A]17-OX-+ZR]R=
M6N/[.DO$OVL/+3!G7;@[\;MN54[?;KCBMO[!+_T$;K_QW_"C[!+_ -!&Z_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ ,@ R  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "? G8# 2(  A$! Q$!_\0
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M_P"&\_VO_P#HX7X@_P#@;!_\37RG_96I?] R_P#_  !N?_C5']E:E_T#+_\
M\ ;G_P"-4?\ $//#[_HA^"O_ !%N&_\ YQ!_Q&#QH_Z.;XI?^)IQG_\ /H^K
M/^&\_P!K_P#Z.%^(/_@;!_\ $T?\-Y_M?_\ 1POQ!_\  V#_ .)KY3_LK4O^
M@9?_ /@#<_\ QJC^RM2_Z!E__P" -S_\:H_XAYX??]$/P5_XBW#?_P X@_XC
M!XT?]'-\4O\ Q-.,_P#Y]'U9_P -Y_M?_P#1POQ!_P# V#_XFC_AO/\ :_\
M^CA?B#_X&P?_ !-?*?\ 96I?] R__P# &Y_^-4?V5J7_ $#+_P#\ ;G_ .-4
M?\0\\/O^B'X*_P#$6X;_ /G$'_$8/&C_ *.;XI?^)IQG_P#/H^K/^&\_VO\
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M/_B'GA]_T0_!7_B+<-__ #B%_P 1@\:/^CF^*7_B:<9__/H^K/\ AO/]K_\
MZ.%^(/\ X&P?_$T?\-Y_M?\ _1POQ!_\#8/_ (FOE/\ LK4O^@9?_P#@#<__
M !JC^RM2_P"@9?\ _@#<_P#QJC_B'GA]_P!$/P5_XBW#?_SB#_B,'C1_T<WQ
M2_\ $TXS_P#GT?5G_#>?[7__ $<+\0?_  -@_P#B:/\ AO/]K_\ Z.%^(/\
MX&P?_$U\I_V5J7_0,O\ _P  ;G_XU1_96I?] R__ / &Y_\ C5'_ !#SP^_Z
M(?@K_P 1;AO_ .<0?\1@\:/^CF^*7_B:<9__ #Z/JS_AO/\ :_\ ^CA?B#_X
M&P?_ !-'_#>?[7__ $<+\0?_  -@_P#B:^4_[*U+_H&7_P#X W/_ ,:H_LK4
MO^@9?_\ @#<__&J/^(>>'W_1#\%?^(MPW_\ .(/^(P>-'_1S?%+_ ,33C/\
M^?1]6?\ #>?[7_\ T<+\0?\ P-@_^)H_X;S_ &O_ /HX7X@_^!L'_P 37RG_
M &5J7_0,O_\ P!N?_C5']E:E_P! R_\ _ &Y_P#C5'_$//#[_HA^"O\ Q%N&
M_P#YQ!_Q&#QH_P"CF^*7_B:<9_\ SZ/JS_AO/]K_ /Z.%^(/_@;!_P#$T?\
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MC/Q ^(>N:[X?\/7>E^%(9(-*\*Z5!IFI6EMI^AV4/[IH-.N9+I]-DUJ]>_\
M$FKV0GG2+6]8OI%E\R:?/E?]E:E_T#+_ /\  &Y_^-5]?E/ W!&.RS 8S'>'
M?!678S%82AB,1@'PUP_5E@ZE>G&L\-.=7)9S=6A&I"E73:C'$0Q$()4X0;^
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M&\_VO_\ HX7X@_\ @;!_\31_PWG^U_\ ]'"_$'_P-@_^)KY3_LK4O^@9?_\
M@#<__&J/[*U+_H&7_P#X W/_ ,:KZC_B'GA]_P!$/P5_XBW#?_SB/B?^(P>-
M'_1S?%+_ ,33C/\ ^?1]6?\ #>?[7_\ T<+\0?\ P-@_^)H_X;S_ &O_ /HX
M7X@_^!L'_P 37RG_ &5J7_0,O_\ P!N?_C5']E:E_P! R_\ _ &Y_P#C5'_$
M//#[_HA^"O\ Q%N&_P#YQ!_Q&#QH_P"CF^*7_B:<9_\ SZ/JS_AO/]K_ /Z.
M%^(/_@;!_P#$T?\ #>?[7_\ T<+\0?\ P-@_^)KY3_LK4O\ H&7_ /X W/\
M\:H_LK4O^@9?_P#@#<__ !JC_B'GA]_T0_!7_B+<-_\ SB#_ (C!XT?]'-\4
MO_$TXS_^?1]6?\-Y_M?_ /1POQ!_\#8/_B:/^&\_VO\ _HX7X@_^!L'_ ,37
MRG_96I?] R__ / &Y_\ C5']E:E_T#+_ /\  &Y_^-4?\0\\/O\ HA^"O_$6
MX;_^<0?\1@\:/^CF^*7_ (FG&?\ \^CZL_X;S_:__P"CA?B#_P"!L'_Q-'_#
M>?[7_P#T<+\0?_ V#_XFOE/^RM2_Z!E__P" -S_\:H_LK4O^@9?_ /@#<_\
MQJC_ (AYX??]$/P5_P"(MPW_ /.(/^(P>-'_ $<WQ2_\33C/_P"?1_5?_P $
MO/B9\0OC!^SIK'B[XF^+M:\;>)%^*/BC2(M9UJY66]CTJRT3PG<VE@L@&%MH
M9]0O)(85&%:65CG?17%?\$?(98/V3=6CN(987/QD\8,(YHI(W*_\([X*3>$D
M56*[XY$W 8WHZ9W*P!7^2OC%@<'@O%7Q"P>74L/@,!A>*\SH83!Y=3HX7!8>
MC".7VIX?#X>$:%*"G*JW&C"%-3<U&G"SA'_H*^CEFN8YAX">$&/SKZ_G&;8W
M@+)L5F&99KB\SQ>8XO$U:V=.57&8G%U:V)K5G"-%.=>K*<HJF[N+@Y??OQM\
M>:G\*?ACXD\:Z!I_A?5M8T2VM#I6B>+-=\1^'-+UR_O-1M-.LM TZ;P=X%^(
M_BO5/%/B&\O(-&\'>%?"_@;Q%X@\7^*K_2/#>C:=-J&I0(?C0?MV^-#9:UJK
M? ?2+6QMO$T.BZ58ZC\77BUZWM?"'[45O^R;\;D\8V^C_#7Q!HVA^(_"7Q!G
M;6?AAI.C:YXDT;XM>';35EU#Q/\ #C4M'N(9_I_XD^%=8^*&EW'@WX@_L_?"
M;XH>#3J]OJ=IHGC[Q:FK:;=W6BWYNM"UN;P_K/PIU>QM-4LI([>_M7CFN)M*
MO&9;>^F,2W4G/Z7\-6T<>(&T;]ECX$:6/%Q\)MXI?3/$NG6C>)F\!):IX%;7
MI;;X,1OK1\&BTLQX4?4'N?[ :VA.E&U>/C\7^O8*G^[^HYBW!**4,FQJIJ*;
MLJ?)@[6WU5UM:R9^X3S"A&4HSPV:3ES-N2RG'5%*3;3:FL/K>SUVV:LK'H'P
MG^)FM?$+Q/\ M >&-=\*:9X7N/@C\:E^%=E<Z5XKNO%,7B[1;[X/_"+XP:)X
MMO$N?"GA=O"^J7>F?%FVTG4O"<+>)K73+K1I+BW\6:M%?K':>S^2/4_D?_B:
M\2L)?B9I5WK5]I?P9^'>G7_B?4X-<\17MC\3+NTO/$6M0:)I'ANWU?6[FW^$
M\<FJZI%X<\.Z#H4-_?-/=1Z+H>DZ8DJV6FVD$.E_PD'QDP#_ ,*P\&X)VY'Q
M:U4C=_=R/A8<L>F!DYXQ4_VAA/\ H S+_P ,V8?_ #(1_:.&_P"@/-/EDN/\
MN^'[GK?DCU/Y'_XFCR1ZG\C_ /$UY'_PD/QD.,?#'P:<YQCXMZIDX(7@?\*L
MR>2 <?=)PV#3EU_XS,-R_"_P<RG."OQ;U0C()!Y_X5;V((/N#1_:&$_Z <R_
M\,V/_P#F0/[1PR_YA,T_\,N/_P#F<]:\D>I_(_\ Q-?/?[4?QFU/]GOX.7_Q
M,T7PUIWB_5H_'OP9\":?H6KZAXJTS39;GXN_&3P'\)EO[FX\$>!?B1XMF_L4
M>-3K,&FZ!X)UV_UBYL(=)6.QCO9-4LNK_MWXT?\ 1+?!_P#X=K5/_G6UF:K)
M\3M=MX+/7?@Q\/=8M+;4]'UJUM=5^)EWJ$%OK7A[5+37= U:WAN_A//%#J>A
MZUI]AK.D7Z(MUIFJ6-IJ%E-!=VT,R']H83_H S+_ ,,V/_\ F3O8/[2PW_0)
MFC\O[&QZ_%8>Z/CCPU_P48M(-&\42?%?X"?$WP!XPT71--UO1O!-K?\ P^>]
M\6:HGA;]GW5O&WPR\-W7Q!\<_#2[N?B=\/M=_:#\-:/J.B>*=%\"KXFBM[NW
M\'1ZSXKTGQ#X5TCM;;_@HG\%-3US0- \/^$/C7XKU'Q3KF@V_A_3O"GPZAU_
MQ+?> =8LO#U]<_&Z[\ V'B.3XD^'/A)I<?BOP^8M5\6>"] \4^+['41XC^&O
MA#QWX3L]0UZT]5\4?#-?&JW(\9?LK? /Q9'?:A=ZE?IXEU_2M<34-4OKGPS=
M7][>C5?@K=?:KV]N_!'@ZXO;B4M<74_A+PX]S)(VAZ;]FQH/@CH%G<Z=-:_L
M?_LX6EUI.OZ-XLTN2WU30(;C3O$OAVTFT_0/$&GR+\$1-8ZMHMG/<VNDWUDT
M%Q803W$=F\4<T@>O[1P7_0OS+_PSYA_\R*_W+;S'_:.&ZX/-?ED^/_7#]W\D
MMNW=P?&+Q;/\8_CW\)(?AM:7]Q\)?@[\'_BUX+O=*\=02:K\3G^*U_\ ';0A
MX3O-*UOPUX?T'P#?Z9XE^!E_IFG:I=>,O$NG:K9>([+5M5/AA;":RN/D#Q'_
M ,%*]&\%_# :SXA^%VH:M\9+CX<_&_Q='\*_!7B&W^S^&O&?PD^'OQH^)FF_
M"OXEM\5K+X0_%;X=^(/&7ASX#_$-=&\3^*O@YI/@#5;SPYJ@T'Q3JELVD3ZK
M]EW5GXZO;W7=1O?@7\+[K4_%7AZP\(^)K^Y^(;SWWB/PMI$WB*;2O#.NW,WP
MCDEU?0-*N/%_BR;3]$OWN-/LI?$_B%X;5&UK4C<^3V/[/G@?35T>#3?V*/V6
M;$>'=#UGPYH$-F?"EM_8GAKQ':^+;+Q%H6E1P_ M/L&B:]9?$3Q]::U8VJQ6
MFI6OC[QG:WHF@\6:Y%?BS'!J]\OS)]E_8^8?/7ZHGYK[F@_M+#-:X/->EK9/
MC]>__,/_ %Y,\PU'_@HAH7A]+>VNO@7\??%QT#QGXI^'7C[Q;X;\ Z'H7A&X
M\2?#'X6_M$>-/BW=?#!=?\?W4GQ$D\#>,_V9/B+\-M7\%>&]7UCQ5#K$NC:M
MH;>+O"^K>&_$/BCUKQ+^V/X.TC3_  1KV@>%/$_C/P_XTUWX@:3IMQHK:1#J
M>NV_@GXV> ?V<-.U'P/;7FHQZ'XDL/&_Q=^*7@;_ (176-6\2^%/#EY\.;W4
M?'\FM16EOINGZM9U?X/3WX\3:CI_[.'P:\+^+_$VN+XQG^(N@>(O#,?CG3OB
M1:Z-K6A:!\4K#5M6^ NK6D_Q$\,6GB/6_P#A'_$>LZ;K$D#ZMJEO<P7UEK&K
MV6H.T;X._P#".^&OA!X-TC]G#X:6?A?X#^'M \)?";0?^%KZY/IWA'PUX4TS
MP[IGAS0[2UN?AC-'?Z;H2^#O!^J:7;ZJM^MAXD\(^%O%<!B\1^'=&U6R/[1P
M7_0OS+S_ .$?,=?_ "T_R[:!_:6&_P"@/-?_  SX_P#^9_FM^VYI>#OVNOA/
MX]U?P?X&T"\O=.^+WCWP7J7BSPY\*_%]I=:1J]M>Z0/%EGJOAOQ1X@T&V\6>
M%M+O]$\0^"/%/A[6]0T+5?%FBK<:+<ZCX;O_ !5I-UI-[J7S/IG_  4.\0ZA
MX/\ AU\0I?@EHUMX2\2>$OA[J'C@6?Q5O-2\0^$?%_B;]G75OVM?&&G>'M+N
M_AIH5OXP\#>%_@9X:\00^&_&E]?>$=?\;?%/^RO!]Q\/O"F@'5O&6F_:VDS_
M !,\.Z?'I>@_!OX>Z%I4<]W=1:=I/Q/O-,T^.ZU2_N-3O[F.TLOA1;VL=QJ.
MJ7=WJ%Y*(UDO+^[N+J9I9YW=O+M1^#=AJKZ>\_[+/P2ANM*\*^&_ >FWVD>-
MAH6J67P]\)^*-.\8Z'\.H-3T/X1:=J*?#F#Q!IEI<W/@+[0?"&I0->:9J&CW
M6FZGJMG>+^T<'_T+\R\K91F+OOWP>GWZ=&"S+#]<'FGE;)\??K:_^S+]5?4^
MOO*'/)."RYP1DJ2IXP>X/<_6CR1ZG\C_ /$UY)_PD/QD.,_##P?R2H)^+6J_
M,P!+#)^%@!( )..@5B<;'VM_X2+XQ<_\6R\&?+G/_%V]4XP"Q!_XM9P0%8X;
M' )Z FE_:&%_Z <R_P##-F'_ ,R"_M'#_P#0)FG_ (9L?^N'/7?)'J?R/_Q-
M'DCU/Y'_ .)KR3_A(/C(2!_PK#P;DDC'_"VM5SD'&,'X69SGC'7/&,\4G_"1
M?&/C_BV/@SDJ!_Q=O5.2P)7I\+3PP!VD\-V-']H83_H!S+_PS8__ .9 _M'#
M?] >:?\ AEQW_P SGKGDCU/Y'_XFCR1ZG\C_ /$UY*-?^,S9V_"_P<V,=/BU
MJAZC(_YI9G)&#@\X(XYII\0_&,#)^&/@S&<9/Q;U0#(3S,$GX6 #]V"_^X-W
M3&3^T,)_T YE_P"&;'__ #(']HX?_H$S73_J2X__ .9SUSR1ZG\C_P#$T>2/
M4_D?_B:\E&O?&<YQ\+O!YQP?^+M:H"._(/PL!'!!P0#@BE_MWXT?]$M\'_\
MAVM4_P#G6TO[0PG_ $ YE_X9L?\ _,@?VEAO^@3-?_#+C_\ YG/6?)'J?R/_
M ,31Y(]3^1_^)KR;^W?C1_T2WP?_ .':U3_YUM']N_&C_HEO@_\ \.UJG_SK
M:/[0PG_0#F7_ (9L?_\ ,@?VEAO^@3-?_#+C_P#YG/6?)'J?R/\ \31Y(]3^
M1_\ B:\F_MWXT?\ 1+?!_P#X=K5/_G6T?V[\:/\ HEO@_P#\.UJG_P ZVC^T
M,)_T YE_X9L?_P#,@?VEAO\ H$S7_P ,N/\ _F<]9\D>I_(__$T>2/4_D?\
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M'<JRD9##*_M#"?\ 0#F7_AFQ_P#\R!_:.&_Z!,T_\,N/_P#F<]<\D>I_(_\
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M_P")KR3_ (2#XR_]$P\'="?^2M:KP!U)Q\+#@#H2<#T)I!XA^,9R!\,?!A(
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M&/P]UC7M.D\ Z#XDBF\/:?XRT.;76=-+>6]M[J;2[[TW_A3_ (8_Z"'Q,_\
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MX3_$GX(ZOXKU3XB:9XV\$ZA\1?@OXI^+6HZ;XE^$'C71--UV#Q_X^\;?%WP
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M>)+?Q#J</Q-,MA=2V7Q6\+^(-'F6SGTK5?#9O-8M]36T.GR7Q[?,O^A;A_\
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M(?V>_#7PG\&:#>WWBJ[^)WAC3_AJ/A/J?ZX?\*@\,?\ 00^)G_A[/C'_ //
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M\3/_  ]GQC_^>!1]8S/_ *%V'_\ #M2_^= >WS/_ *%V'_\ #O0_^=!\A_\
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ML^(].\1ZN=5AB\'/^T%\4]3\6VFI>'-;\6^%?%FD7FB^&_B3KLAO_"GB_P
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MCK.BPP6]U)-I>LZ9J-X+&SU;2)M0^BO^%0^&<%?[0^)F"02/^%V?&/J 0/\
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MS_A3_AC_ *"'Q,_\/9\8_P#YX%'_  I_PQ_T$/B9_P"'L^,?_P \"CZQF?\
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MJW]G@Z'XW\.KX/\ C/;:3\0/"'Q4\"^(K2W^&GQS5&\-_&3X@>+/B9XVM-,
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MCN+?QUX6\<7O@RY\6>!?'"+\/=_B?PYK]I\/_"6CZ]/J<UUXM\1:7IU^-?\
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M6FNK6E^P+#YB[_[=37_=*HV[[_VA9::Z]#[&_P"%O>%O^@+\4?\ PRGQB_\
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M/_AE/C%_\PM'_"WO"W_0%^*/_AE/C%_\PM=KL;_GLO\ WV/_ (FC8W_/9?\
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M)K=Y!;I86^I:EK/AW3[ZYU>WL(T6.PMM9>8ZM;V$8$=E#>I:QY2%2?7MC?\
M/9?^^Q_\34^QS+_H8T?_  UTO_FX/89C_P!!U/\ \-5+_P">!Q7_  M[PM_T
M!?BC_P"&4^,7_P PM'_"WO"W_0%^*/\ X93XQ?\ S"UVNQO^>R_]]C_XFC8W
M_/9?^^Q_\31[',O^AC1_\-=+_P";@^KYC_T'4_\ PU4O_G@<5_PM[PM_T!?B
MC_X93XQ?_,+1_P +>\+?] 7XH_\ AE/C%_\ ,+7:[&_Y[+_WV/\ XFC8W_/9
M?^^Q_P#$T>QS+_H8T?\ PUTO_FX/J^8_]!U/_P -5+_YX'$/\7/"S(Z_V+\4
M3N4J1_PI3XP\@C! W>!@N2#QN(7/7C-?&WQD_9Z_9W^//B3Q-XH^),/[2NKW
MWB/0[;PM!;6_@'XP6>D>&_"QO_#FJ:YX9T72A\,9;:^T/Q'JGA?3-7N]/\7#
MQ/#X?UQKO7O !\':S>3WZ_?S*55F,Z@ 9)WCCL#]WUQ@=">#G.*_+;XV_M*_
MM _!SXF_M'Q^&M ^*OQ?@TW1?",_P:\+^'/@;XS\1_"KP9=?V/\ #R/5M \=
MW>D?#3P7XPUWQ?XPUW5_$&H^%/%G@'XV_%?PW=:3<:SHM_\ #WPCXE\!6NE^
M-FJ&9-V_M&@O-Y51MNE_T'[W:^_J] ]AF-[/'TUYO*Z77_NH>GWJU]CUOP_\
M!OV9?#'COP+\1=%\$_&*#Q)\/X]2M](FO?A+\6==CN['4+Z+6+6QOSX@^&>J
MW4'_  CGB"-]=\/:EH-WH6LVEW>ZI93ZE=:-J>HZ9?6_"GP:^ G@KXQ:?\</
M#]E^T7:^,=&NOB<-'M)/ /QFN/#=GH7QE\3:E\0/B5X3DT6?X</'J&A^(?B=
MJDWQ$M+C6IM6\2^%-?B?3/!7B+PUX*U37_".L^/_  R^/_[7#?&?P_X5\4?#
MJ[U#P=\7/BGXY\1)JGB[P9\2/"5K\-_AAIQ\(^&=#^&OA[5-*\,ZQIEIXL\'
M:5;ZE\1M<UOXCV^CZ?\ %6^U:\TGPF/#4-CXIU?P-K?!_P#:#_:%U;]KKQ;\
M,_'6A>-8?A?XG\<>.[/PA<:[\(?'.G^'? ?AOX63_$K1AHEQX\T[X;>'/#^E
M^-/B^[?#;Q[\.AK?CCXJ^#O%WPK\*>/?%5KXO\$>*?%7@KP#>MX?,E;_ (4:
M&UW_ ,)5'3_R_P!=>P.AF*M_M]+7?_A*I:?^9#76RT[HZWPE^SM^S?X1\/3^
M%+?3?VA]3T#[+\0=-TNQO_AC\4;,Z%HWQ,UOX?>(?$^DV=WX<^%&@7VIB75?
MAGX6N;35_%%QXA\2VR07UJVNS6UXT0^S1\7O"^.=%^*.>^/@G\8L9_\ "%K\
M:;/XI_M]^-_A7#?>&_B!\0M$\;P^'?VFKSQ0FN?!74_$%]I'B_3K[X)>#?AA
MH>F:=9? SX!PZ.FD:9X]^)OC#PWX6*_%]+_5O#]AK-Q\6/'NG^%]3TNW_<E(
M#%''$+IYA%'''YTTJO--Y:*GG3.J*KRRX\R1E559V)55! ">'S)?\S&C_P"&
MJC_\W_\ #Z^@>PS'_H.I_P#AJH__ #P_X<XS_A;WA;_H"_%'_P ,I\8O_F%H
M_P"%O>%O^@+\4?\ PRGQB_\ F%KM=C?\]E_[['_Q-&QO^>R_]]C_ .)I>QS+
M_H8T?_#72_\ FX/J^8_]!U/_ ,-5+_YX'#/\6_"SL =&^)^"C [O@G\82.>.
M5_X04L1SSA<8R"<XK*TCX@> =$?5)=-\)_$"PEUG46U759K#X"_%FRDU34FM
M;6R;4=1>W\!H]]?-:65I;->76^X:WMK> N8X(U7TTQN<_O%=<$%200WMG:3G
MCC"GK7+>&I_%ES<^*8_$FC:7HEC9^(Y+7PA<:?XCEUR3Q!X8&EZ7-#K>I6TV
MDZ:/#VH/JDVJ:>^B1S:HL<&GP7W]HR_;0JX3AC/;482Q=*59RJ^RJK)*-7V5
MJ2E44JOUU_5(3A:$9N2>(G>CR62;QE3QBJTH2Q5.=24JJI5%DM&JZ/+24I\U
M7Z^_JD*D/=C+F7UB?[GDT3?S%\5OAE^SS\9/$MUXO\:^#_C1<^(IKOX#7]KJ
MVG?#7XZZ1=Z/??LZ^/?B!\0?A_<Z')I_@N*33)+F^^*/CSPYXW2!E@\=^ ?%
M&K^!/$:7OAR_O;&>EX,^&/P9^'O@WQ1X.\%O^TGX=7Q'X<\'^"-/\0P> _C)
MJGB+P-\/_AP;_P#X5Q\//!5WK_PUU>RMO!?@>/6=>AT?1]>TO7SJ<'B#78?%
MUSXA&I7(E\Z_:.^*7[5?@'X[:Y%\-]+\5^(O@HW@+]D_PY/:>'/A@WBK4_"G
MQ#^+O[0?Q;\+>*?B3H&J6>D7E]XJT30O"GA?P;X5^,7A5H]6A^&GACQMX2^-
M4UQX(\-^'?&6I>)C2OV@?V@_B)\"/C;XEF\-WWP8\9^&])\ ZKX9U-_A?\7?
M/\*ZQXFO5E\=_!N]TCQ!\,_B%KWBGQK\,[2P?0-7_: \%_";XB?"2*?QEI'C
MFV^&/B"S\ ^,O!UUT_5\RM?^T:'2R_LJCL^O^_Z?/Y)[&WL,Q_Z#J=^B_LNE
M=_=F'Y_*YSUU^Q/^Q!-X6U#PY;_"?XMV6H:EX1\0> ;CQU;_  L^-$GQ%/@?
MQ)^S[J'[,M[X'?QC??#Z^O[GP):?"^_4:1X'O8KOPAIGB[3=$\96^@#7-(L9
M[?V#P/\ #;X:?#WX@:)\2/#VM_M%MXCL-#TWPCX@EO/@MXNL[#QIX,TC3=;B
MT_PYXBT?PK\%O"^DW(L=>U#1_$FD:O\ V?\ VOX:D\.OH'A&\\-^&?&?Q!TK
MQ1\>>.OVI_VPU\*^/]=\$_"3]J31_#*_L?\ Q%T+P'XD\7_![P%/XIMOVK/#
MW[.=_P#'SPWX[U_1=+\+3^/K:\NKJSU?X07-G+^S1<?!S4?BW8>&_#NCZ3>>
M*O$,/PZN_I_X)?M!_$+5OB/X8^%/C6_G;2M7\+^$KKPM\0?$O@WQC/<_$+Q!
M<:!XB\0>-/#$_CBY\"_L]^'[/Q_8V^B:QJ?A_P .6?P"T;3;_P"'W@O7/%DV
MJ76MKXE\*>"#ZMF?7,:*T37_  E4G>^W_,?N^B>H?5\QZXZFNJ_X2J3O?;_F
M8?@5-(_9U_9]TM_#XN9?VGO$%AX8U>*\TO0M?\"_%RXT*?P[IOCW1/BGX8^'
MVMV>G_"K3)?$'@CPA\2/#FF>+- MM:GOO$,<LVM:!J7B+5/"'B/Q%X=U7E-#
M_8Q_8O\ #$/AQ-!^'GQO@N_#.K_#[6+/4]7^''QJ\77=Y=?#SP9XI^']F=8B
M\:?#WQ'I^K'Q#X6\;^*X/%5W=6#:KJ>L:K'XHL]2TGQ5I>BZYI?%>(?VHOVK
M'TKPU\1=$^%/C34[R/X??'G7-=^">D?#+XIZ)%X1^('@O0=#\2>!?A=\0?$N
MH>%->U3QCXFM]2MM4\"ZAXN^'MMI7@?X@3ZS+J?P^TO5(],TN>]]+TW]H7]I
M6T^*0\&^,/AW+HFFMXN\"^!-7^)5G\-/C'K_ ,+U@F\?_M<V4^M^&_#&F6SZ
MW::EXO\ #WPP^#ND-X@U?QI>>!O#.I_$;0-3U74;U)_!GA_Q^_JV96O_ &E0
MM_V*J6OI_M__  =M[C^KYAO]?I6Z?\)5/73I_P *&OY]DTRW<_LP_LLRZA::
MK9^$?CGI>I6'@+PCX$T[5=/^&/Q<_MW26^'6O:UXD^&?C31O$6H?#._\0Z)X
MZ^'VM>(-3O='U;1]7M-+U<26<'B[0O$\7A[PQ#I.UXE^ /[.OBKX?>'_ (9Z
MS8?M+7_AK2+_ .,L^L>9X3^/(U3QWI?[0VL^(=:^-_AWQUJ3>!3-KVA_$>3Q
M7XAL=1M8SIMYH=OJ2W/@_4O#&KZ3H>L:9XYX$_:N_:=^(5A\4O&=Q\'?BGX/
MT_P/\'/VF=2\%^&I_@=X\T/5O&GBS0O"7[*WCSX/W%QX,\3PZQJ]WXYTFY^)
M7Q0^&L_@WPWXIUBT\9^(? GCBWTS3!K^C:GX4\(VOA;^T[^TI!^SO\;->\4>
M&-:\7?%'X,7GA73]$NO$WPI^)>E'XJZ=XJ\<7<]YXU\"0VOP_P#@[IOQ:\.:
M7X%UG2_#/@B33/#7P17Q5\1? 7B=/B1??"?P1KNG?$>S3P^9)V_M&AT7_(JI
M;OR^OWMW?3MM<]AF-TOKU/M?^RJ>_P#X</O?3MM?TOP/^SK^SG\.?&M]\0O"
M.G_M(:;XPU?6O$=_KVNMX)^--[<^)=!\6S:;<^(_ WB5;_X9SIK?AS6YM"\,
MOJVKZBMQ\0=0NO"VDZU>^-;K7KS7]2UB+P%^S3^S!\.=?L?$V@^&OCQ=:S97
MGPLU0ZEK?PN^*FH:I=ZY\(O!W@+P!X7UN_UY/A9;>);V6[\)?"WX>Z5K^B/K
M:>%=2G\,QZZN@6_B/7?%6K:YR%]^V)^T9JFLZ?X;\$_L\^)%U.UUWQPGC"]\
M<?"GXZZ)I^B>&_#US\=/$G@XV;GP_;Z3J/B;XA_#?X:_#E[;3;+Q1J%MX5\8
M_%[P_IVLRR2W&BZ%K5.+]K/]JZVUE?#FM? Z,:G';?#BT\07?A[X0?M#:WI?
M@>#QI;?L_7FJ_%6>1+&'_A8?@G0+OXO_ !!\(GX>^%;O3?&<6J? KQ3XDU_Q
M#H&DQ?$S3/@@?5\RM?\ M+#VZ?\ "71V_P#"_P#5].ZNO89A:_U^DD]G_95+
M;O?^T+6MKN^G=7[KX9_LQ_LK_"GQWX7^(WA?PM^T%_PDO@NWT&R\,2ZQX'^.
MFKPZ7I_A[P/'X!L;!VG\!"\UBR30UE%M!K]WJG]D-/\ 8?#W]B:#:V&BV<&M
M?LP?LP:Q#JEK_8_[2%EIVK>)+CQ[)HMIX.^.3Z);?%"XACTIOB>ND:G\/-1T
M_4_$S>$(H_A[J6B^(;?6OA]XE^';:AX.\6>"M?TG7O$$6J^#>"_V[_VFOBFO
MPQF\,_!K4?#FA>+_  9^S+X_\1>-;KX&?&S7O#5A:^.?B)^Q_8_%'0/#6H&_
ML8-<T;6? '[2'C?4_#OBW4XO#6H_#&7X'?$J[\4^'?%&E>'O$FN^#?7M)_:N
M_:?O_P!E*_\ C9JGP C\/_$N[^(GA+PWIO@9O#GQBU+_ (0'PGXJB\(OK?B'
MXH^";GPKH7C_ %";X4:QK^O^#O%T_@?[5X;U.?PS'X[OM8\!>&)/%>G^!7]6
MS);YC0W2O_95+JVO^@_HUKZ]]!^PS"_^_P!*VFO]E4[:MK_H8=']]].QW/P8
M^ '[-7P%\4^%O%'PY\/_ +0FDCP?X>O] T/PY?>"OCQK/A:U;5O"/P]\!ZOK
M\FEWO@1VN_$>I^$OA-\.=%FO;JYEM;&+P[/>Z/9Z?JOBCQI?^(_L'_A;WA;_
M * OQ1_\,I\8O_F%K\]]9_:I_:RTB&U&O? _2?#$/BK4/$NC6>N:+X&_:"^)
M5A\*+GP;J::7=:GXPTK1/!>D>+/B+IOQ&U74='\.?#27P[X4\$WUF]Y#XT\0
M:;?:&FKZ+HGDOPJ_;<_:BU3P=X2TK6OAQ=W^IZ?X<T[PQ\2OB1JWP,_:"URX
M^$WC3PS:>#]+O]>^*'A/P9X8T?\ X63J_P 3]=U/Q+IA\&?!R/0G^$OB3P[J
M#^.[NVTV'6[#PH?5LR_Z&6'Z?\RNEU],<]=;>?2[:N?5\P_Z&%+I_P RJE:[
MM9:9@][Z=^B;:3_6+_A;WA;_ * OQ1_\,I\8O_F%H_X6]X6_Z OQ1_\ #*?&
M+_YA:_-.Y_:@_;5O?#/C"^\/_L^:GX6U:'P-;ZY8:1XU\'_$KQKXAT_XB?$%
MOVE=+T/PQH?]BZ;X6T;6M"^$^N_"GX7ZCXGL76>]\2^'_B'%;KJ?A8ZSX6UC
M5?8_"'[0?QE\8>!_C3+J'@O7W\0>!S\('\&:CX5^&GQ(\%Z9XVTCQP-*_MG4
M="N/&QUCQ#-XCTY8]3UCQ7X*E\%:7/\ "_3M2T/3KS5/'^B:GI?Q#UL>&S)?
M\S*@UIME=)[OHOKVNFN^JV!X?,?^@^FU9/3*J75_]C#73WE;=;:GV3_PM[PM
M_P! 7XH_^&4^,7_S"T?\+>\+?] 7XH_^&4^,7_S"U^:>H?MB_M:^$_#5EXO\
M>_!3PGH.@Z[>?!C1K:6+P5\>GN_"6K_&6]_9TB23Q-IYTNZU#6!X+G^+WC?P
M?>>&?#UG;^(?$OCCP796%DND7QU_0-*>/VP_VO8?#6M^*;[]GA5T_3->OO#_
M (6@M/A5^T#<ZU\4;SPU\,=$\=Z7-IGAQ-,.N_#C3?VC]2UR'P]\+=6\9V=]
MIOP2U.PUCPS\8+GQ#\0[6R\%ZB/#9DO^9GA__#72_7'+_AM=M0>'S!?\S"E_
MX:J?ZX_^M]M3]*?^%O>%O^@+\4?_  RGQB_^86C_ (6]X6_Z OQ1_P##*?&+
M_P"86OSQU/\ :^_:S@\3^$- T_\ 94OI(9?&/Q%\$>);_5-,^*EA8>*];^#U
M]\.M'\4-\.]7MO"5_9Z%H'Q1NO&_C#6_@+XI\?6ZZ#XHT3X(^*I]0O!X>\5V
MWC?P7[]^QO\ $KXN_%?1OC9XD^+"ZA:B'XPZ#9?#VWNOAA\0OA+I=KX)NOV<
M/V??$.JV'AO0/BGH>B^-]4TO2OBIKOQ+TG4=?UJ.ZEG\66/B32D.DKI'_",Z
M"GA\R2O_ &E0?DLKHOJU_P!!_E^-K7O8^KYCTQ]-_P#=*I=VO^AAY?C;>Y](
M?\+>\+?] 7XH_P#AE/C%_P#,+1_PM[PM_P! 7XH_^&4^,7_S"UVNQO\ GLO_
M 'V/_B:-C?\ /9?^^Q_\34^QS+_H8T?_  UTO_FX7U?,?^@ZG_X:J7_SP.*_
MX6]X6_Z OQ1_\,I\8O\ YA:/^%O>%O\ H"_%'_PRGQB_^86NUV-_SV7_ +['
M_P 31L;_ )[+_P!]C_XFCV.9?]#&C_X:Z7_S<'U?,?\ H.I_^&JE_P#/ B\/
M^)M.\36<E[I]MKUK%%</;-%XA\+^)/"=\9(TC=G33?%.E:/J,EN1*H2[CM6M
M97#I',[Q2JA6C$I6,  %LDE@?O#/'S9&?P_PHKK@JT(QC4O6FDN:I"G&E&3W
MNJ:J34?12DO,Z8*K&*C4O4FOBG"FH1EY\BJ247WBI22>BD]SSJY\*?$I[R>>
MR^(/AZSMS-*UG;S^ [V^GM;=G8QPO>?\)Q:^?(L>Q)IUMK=9V3>((@0@C/AK
MXLL<GXA>$2>>OP\OSUX/_,\]QP?;CI7)_M0?%.Y^#GP?\2>-]-\7>$_!FO6D
MFDZ;X6O_ !GX5O?'.D:OXJUG6++3=!\(6WA#3/B#\++[6]<\7WUPF@Z-CQYX
M<T_2+R[77]=OE\/Z3JJ/\*6G[<_QENXO%NHVWA7X0LNB^)_#FF:KX3M]5\37
MVI_":QTW]J:T_9M\51>,?$EGJLT7CJ?XS:8]Q\6_V>M7M_"7PHT]?!\%S+>0
M>/+'38M8UWDGEM"I)RE7S*[Z1S;,817I&-517RZ:')/+J-23E+$9E=](YMF$
M(KTC&HDOT6A^BP\,_%@$$?$'P@"!@$?#R_! SG QXY&!G)QTR2>I-._X1SXM
M_P#11/"?_AOM0_\ FZKSCX%>,_BQXN\;?'RU\:^(?AUXE\"^!OB5%X"^'.J>
M"_A[XD\"ZE=7>F:?#K?C>WUN[USXL_%&P\86_A>3Q'X=^'S>(M*MO LTGQ \
M%_$NWN_"6GV!T%$^GZG^RL/_ -!&:?\ AYS/_P"7$?V7A_\ H(S3_P /.9__
M "T\G_X1SXM_]%$\)_\ AOM0_P#FZH_X1SXM_P#11/"?_AOM0_\ FZKUBBC^
MRL/_ -!&:?\ AYS/_P"7!_9=#_H(S7_P\YG_ /+3R?\ X1SXM_\ 11/"?_AO
MM0_^;JN>\63^,_ _AW5_%WC;XR?#7PIX4\/V<NIZ[XD\3^%%T+P]HFGVXW3Z
MCK&M:S\0[/2M+L;<?-->7]W;P1<9D#%0?>:\#_:,^'>J_$7P3H$/A[Q'X;\.
M>)?!?Q+^'/Q(\,R>.='N?$7@#5_$7@KQ18ZKI&A^,M!L]7T&ZO;2^O%B?PSJ
M5IJD>H>#?B#;^#O'VEZ=XBU7PI9>&=9/[*P__01FG_AYS/\ ^7!_9>'_ .@C
M-/\ P\YG_P#+1WA>7QEXV\/Z/XK\%_&'X;>+?"?B'3X-6\/>)_#'A :]X<US
M2KQ%>UU/1=:TGXA7>F:G87<)#V]Y87,]O/%AHY&0@U?E\#?$2?5;/7)O%W@&
M?6].T[5-*T_69OA9-)JMAI.NW.DWNMZ79:E)XS-W:Z?K-[X?T&[U:PMYT@U&
MZT71[B]AFETVR>#Y%\3?L4?$WX@_$C5/'OCCXN>')K?Q1XA^$WB/Q;I6A^'O
M'%F-;T/P=XM_9XU_Q1\#KJ/4?B'?Z9/\$[V+X*^,[S2M!N=*:>]UOXW>,EUN
MV72+WXB6/Q<\%TK]@KXD>&O%'P:\$^&_C/:ZWX:\)^!+B3QUXKUCQ!X\UGQ1
MX?\ BEX2T_\ 8JT"Y^(7A?3;SXMRZW-\4?&TWPF\?^)K/Q3XCB\1:5X=O?&V
MLW'B^35KKQ?JUAX^/[*PW_/_ #3_ ,/&9_\ RT/[*P__ $$9I_X>,S_^6GZB
M?\(Y\62<_P#"PO"9/!W'X=ZCN&<X.3XYW9Y/3D9;..:S=/L_B-J<VJPZ=\3O
M!MS/HNIG1]7B@^'NH/)8ZF+*QU(6=T$\<L4G.GZGI]X$;YE@NX&8*6*K^=WA
MW_@G;\=;'3[A?%'[1NF>*=2U*_\ C+>ZH]AX7NO!^DP6'Q1_9]^%?PIO=%\%
M:/IMQ?V7PTU/7?B?X"\0_&_4O'?@J#3-7L9O'WBWP'XPT?XRVWC'Q_XI\7]4
M_P"P+\9I[W2[Z^_:(TNYU&*S^'<$>MZ7X.\0^#9_AY=^!_#WP[T[Q/=?!OPY
MX2\<Z9X2\$V/QMB\':OX%^*6@6VDII(^&NLV&C>%8M&AM/$6E>+S^RL-_P _
M\T_\/&9__+0_LK#_ /01FG_AXS/_ .6GWI/H/Q3M8)YY_B+X.@MH(9)IY9?A
M]>0P10PJ\KR32R>.TBCAC7>[O(RI$N]W*C<:D'A[XL$*5^(?A,@Y92OP[U#:
M=QW%U*^.L'=G=D'<W7!K\Z_&'_!-;QQXC72?!>G_ !WL-+^#=KI_C.PNO!E_
MX,U3Q1J0M?B)\!=(^#?Q%TH:YXA\7W^LWVA?$76_^$A^(WBC1FUK3=)O=>U3
M6KCQ#IWC#Q)XHA\7^#_1_ _[#OQ#\/:!^T=87WQDATO6OC3\(;GX<>"+WPC:
M^*-+\.?"22_\&V>B:1IVE^$-/\2:#;:MX7^$>KV*V_PKD74M*\2:=X'O+OPY
M::GX:U*]\3Z_XM/[*P__ $$9I_X><S_^6A_96'_Z",T_\/&9_P#RT^SO^$<^
M+/ _X6%X3X.X8^'>I8#,>6&/'& 23ECU/))ZFN/UG7M:\.:C?:+XA^._PCT+
M5M,\*:GX[U'2=9\/V>E:A8>!M)N([+5_&E[87_Q'M[FT\):;>7,5AJ7B2XAC
MT>SN[A+6ZO(Y)E5OB;Q%^P7^T%XG37+Z^_:(T"UUGQ-9^,IO%,,7A;6-:T;Q
M#9^)/VR?%G[3MA\*K5?%>KZ]J?A'X>1> O$1^ OC.[T:]N=)^)OAPV.J>,OA
MA?:;X*\$^$]+[7XV?\$^M0^*?AJVM]%^+$OAKQUX?_9C\-?LZ>%/'NMZ7KWC
MG6_[+%KXMT#XIVWC74M<\7+KOCOPG\7?!WBI;#Q%HOB+6;R]@\;^'/!'Q9DU
M'4O'O@#P=J6DG]E8?_G_ )I_X>,S_P#EH?V5A_\ H(S3_P /&9__ "T^NM:7
MQ_X>L;G4M=^*7@G2[&SM+J_N+B^\!74*Q6-C&'O+LK)X]#M;VL3A[ET1OL\;
M!I@B."=>+PO\588HX8?'OA"&*)4BCAB^'-]''%'$HCC2..+QSY:1QQHB1H@"
MHBJBJ H%?GU+_P $\_BEJ7COQK\1/$'QH\&:QXF\1>*OC+JWA:_C^'=UHMQ\
M-H?B[X$\9^#M7\0>"9M%U^Q.D>,-22Y^'MGX@OD5[K6?#?AJYTS7M<\1:A%I
MVK#1LO\ @GGXZG75G\0?'!YKJ+POXBLO#MSH:_$C2FNOBR;;/A;]IWQ6/^%F
M2F]^.<NJ&RUCQ9J>GM;:4^I>%_"5]X:@T6YTN-XS^RL/_P _\T_\/&9__+0_
MLK#_ /01FG_AXS/_ .6GVQJ3>,M,U:QT35OBY\.;'6KC1O$'BO3=.U'P2UM?
M2:%X7?1]/\4^(;.&Y\?I*NFZ"_BS1+/6]3B"P6'_  D-A#>31KJ**^O8Z7\3
MM3LK/4=-^)W@O4-.U"UM[W3[^Q\"W=W97UE=PI<6MY9W=OX]D@N;6Y@D2:WN
M(9'BGB9)(G='1F^0/@[^Q+\3?!/C/XD^-_B'\:]$\=ZEX^\+_'C0$L]-\!_\
M(OI.F:G\:+7X%VNH^(K72M/UE=,M%U._^#-QXGUW1X+&2]FO?%<%CJOBGQ9K
MF@ZEX]\8\C?_ /!/7QU9Z-I,?A#XV0:;XF6._B\0:IK&C^)-?\-:W=:=XR^%
M6N_"B_UKX?:YXLUGP9XJT/X/:)X-\=Z1H/P^UO2$T2Y;XG:_J?AC5OASXS,/
MCN _LK#_ /01FG_AYS/_ .6A_9>'_P"@C-/_  \YG_\ +3[:MI/'EYJ4VCVW
MQ9\"S:I!!9W+Z>G@BY>Z\F_FURVM'6-?'S;S+<>&?$4(2,NZ2:'JJR*GV*4C
M432/BE).]JGQ*\(-=1107$UJO@"_:XAM[I[B*UN)81X[+QV]S):74<$[@13-
M:W*QNYMY0GY\:G_P37UQ[""Q\->//A[X2_X1Z+XQZ;\.9=+\ :XD/PV'Q6TO
M]M"PF\<^$K.Q\9:4^B_$&>X_:5^&]SXPOM#OM%_X2R#X2W]DVHZ:WB#0KSPA
ME^,_^"<7Q6\:W?B'Q)J/QH\*67B_X@7TMS\1[_0?#GBO1+OQ!X=C^+_[7WQ%
M\/?#0^+6\5:IXJ'@WP+!^U-X8U;PC=6MQI6HZ-\0?V<_ ?B+P]!X9CUS38_A
MN?V5A_\ H(S3_P /.9__ "X/[+H?]!&:?^'G,_\ Y:?H+XJN/''@?P[K?B_Q
MA\7O /AKPMX:TN\UOQ!XAUGP5<Z?I&C:3I\+W%]J&HWUSX^C@MK:V@C>6621
MQ\HPH9R%-6?5O%%K<R65W\;_ (8V=["WA59[*\\,I:WENWCK4IM%\$)<6D_Q
M%CN8)/&.M6USHWA:*6%)/$&JVMQI^E+=W<,D2_+_ ,:?V$=<^,_C_P ?:OX@
M^(VDZCX(\8P^'Q#I'B?0_$OB76X-'T3POX&T!/A3JOV[QB/"VJ_"J'Q9X-N/
MCE96@\/6NNP_&/Q!<:T+V."WU%_$/:_'']BZY^,/Q3\1?%*S^+/C#P3J6IV?
M[+MGHEAH&L^*+;1='D_9Z^+_ (]^)]]JVH^%;;Q):^#?%>M:W'XTM[7PS>^(
M_#U^/">M:#INL/'JUO#%IJ']E8?_ *",T_\ #SF?_P N#^RZ'_01FG_AYS/_
M .6GOVO1_$#PMH>M>)O$OQ9\":#X=\.:5J&NZ_KFK^"+O3]*T;1=)M)M0U35
MM3O[KQ[%;6>GZ=8V\]Y>W4\L<-O;PR2RNJ(2(+&7QSJ>M:GX<T[XO_#^]U_1
M=/TW5M7T:U\&S7&I:9I>L:GXDT32M0OK.'X@23VMIJ&L^#O%FDVDTZ1K-J/A
MO6[-?](TV[CB_-^__P""9_QJU+P;X,\$R?M*:9;:5HO@3XK>'O$:/X/UC5I-
M8\2?$[X7_$[X5>*-4L+R^\3)JNC>%?'\?C#P-\1?$_@'1-1T;PU8^/O &N:[
MK=I\3?&WQ$@^)'@+U/0/V"_$/PP\;ZO\7_AYKO@=/&OA[Q5XI\6?#GP[::?X
MB\$^&[Z/7?B=^VK\4;GPOXLN=)UF]M;2Q\6W_P"UCH6A^.-3M_#^M)?_ /"L
M[;Q3%HL^IW'AO3/")_96'_Z",T_\/.9__+@_LNA_T$9I_P"'G,__ ):?6^K^
M(]<\/C4FU[X]?";18]%U"[TG6)M6T2RTZ+2=4T_P;)\1=0T[4WO/B5 +"_L?
MA_#-XYN[*\\B[M_!\$_BB6%="ADU!=#PC?>+O'_AS1_&/@7XU_#+QGX2\0V:
MW^@^*?"?AE/$GAO6[)GDC%WH^NZ+\1+[2M3M3)%+']HLKN>+S(W7?E:^=/BY
M^QUXO^)_CGXA7TGBOX>7WPP\:^,];^+Y\%>)O"/C)=>N?B5J7[)MY^R*- U7
MQ=X7^(&@7-GX"?PI+:^-(=7\,V>A_$#0O%5LHTC5XQ':WEK]7?!/P9XZ\!?#
M;PSX6^(_CM_B+XKTA-9CO/$TD%\DITV\\0:IJ'A?PZVH:K?ZGKOB,>"/"UWH
M_@D^,O$]]>^+?'C>'AXW\77+^*/$&L%C^RL/_P!!&:?^'G,__EP_[+H?]!&:
M?^'G,_\ Y:+_ ,(Y\6_^BB>$_P#PWVH?_-U1_P (Y\6_^BB>$_\ PWVH?_-U
M7K%%']E8?_H(S3_P\YG_ /+A?V70_P"@C-?_  \YG_\ +3R5O#/Q8<%7^(/A
M!U(*E7^'E^ZE3U!5O')!!P,@C!Q3O^$;^+?_ $4/PD,G/'P]U <XQV\=>@Q]
M..E>1?M9?''X@? V#X$7W@#P-;_$?_A._C9/X.\<>$[>'6;KQE>_#;1/@C\:
MOBYXRO/A;I^BF:76_BAI&G_"U=4\)>%KC3-4C\;S6EUX'M%T;5O$FG>*= ^#
MKC]NO]I76O!$_P 8OA;)^SK\3?".N_#7]EKX@?#3X=Z+X.\:V^J_$ _M#?M/
MR? JUM-'^,\7QOO_  S=6VO:!HM]JO@+58?A5]@NM6\5^'5OKR\T70KP^)#^
MRL/_ ,_\T_\ #QF?_P M#^R\/_T$9I_X><S_ /EI^IG_  C/Q8( /Q!\($ A
M@#\/+_"L#D,H_P"$YP&!Y!&"#R#1_P (S\6<Y_X6%X1W<_-_PKR_W<A0?F_X
M3G/(1 >>0JCHHQ\4>"/^"@>D^)/!?[1OQ@ATGP_??!SP;XI^$VE?L[:G#>>(
M-+USXK^'/BDVC>!_#?B#Q#YVF:[<Z3:>-/BPVNCX>G1/#VISZK\+KCP9XM>P
MGU/Q'/I%CY-X0_X*P>'=4TWQCXDNO ,=_P"%7T'3_B=X,O[7Q9X=LK[PM\+I
M_"G[(7B/6[WXS:)INL^-O$'AJ;PWIW[66@>(FU?PSHOB&/6] \+^+;RV\-Z=
MI.G^&]?\;']E8?\ Y_YI_P"'C,__ ):']E8?_H(S3_P\9G_\M/TQ/AKXLDY/
MQ"\(DXVY/P]O\[2<E<_\)SG:3SC.,\XS0/#?Q:' ^(?A(#T'P]U#'IT_X3K'
M3C'IQ7R+<?\ !0OPZOBKX;>&-,^%OB#Q%-\5/B9\0O!GAM=#\7^#)]0TSPS\
M+?B5\.?A#XQ\4>-;6]U#3],\&^(;3QA\3M"UFU^&^LZY%XB;X?:=X@U;4Y])
M\>V%K\,M0QO!?_!2SX?>)KOP)!K/@VX\)0>-M(\*7;7.I^*K';HVM>(/V@;/
M]GKQ#X<OI+K2M-L;>_\ A;XMU70K?XCKJU_HUS#JGB#1;+P+9>/-"OE\5J?V
M5A_^?^:?^'C,_P#Y:']E8?\ Z",T_P##QF?_ ,M/M!_"WQ6DC:&3Q_X.DA>-
MHGA?X=7KQ/$ZE&B>-O'!1XV0E&1E*E#M(V\4K>%_BNZ-&_Q \'M&Z&-XV^'5
M\T;QL"&C=#XY*LC!F#(P*D,V0=QS\>_#/_@H%H?QQ^']WXG\!>$T\/:GJGAO
M]BGQ+X/M/%FL1:JU]X?_ &VV^'T/@SQI<VGAMH=-U+PIX6O?'LNFW$6C>,3J
MGB/6/!WB73IH_"EE<>'=:UOSCPI^UO\ 'CX@G]G&Z\&^+?@+J,_[1/CW1(]7
M^'_A7X6>)?B%XO\ V;?!4O@?QMXJ\0^"?BY?#]J+P(UYXZT?4]!@\,Z]XS3P
MAX+'@K6?!_C;2?\ A3?BV[DC3PR?V5A_^?\ FG_AXS/_ .6A_96'_P"@C-/_
M  \9G_\ +3]"QX:^+2@*OQ#\)*J@!57X>WZJH P JCQT  !P   !P!BE_P"$
M<^+?_11/"?\ X;[4/_FZJ;X(>/;OXI?!SX7_ !'O["UTO4?&_@/POXFU+3K"
M22;3K/4M7T>TO-0M]+N)F::YTJ.]EG&EW4Q\ZZT_[-<3*LDC*/4J/[*P_P#T
M$9I_X><S_P#EP?V7A_\ H(S7_P /.9__ "T\G_X1SXM_]%$\)_\ AOM0_P#F
MZH_X1SXM_P#11/"?_AOM0_\ FZKUBBC^RL/_ -!&:?\ AYS/_P"7!_9=#_H(
MS7_P\YG_ /+3R?\ X1SXM_\ 11/"?_AOM0_^;JC_ (1SXM_]%$\)_P#AOM0_
M^;JO6**/[*P__01FG_AYS/\ ^7!_9=#_ *",U_\ #SF?_P M/)SX;^+9!!^(
M?A(@C!!^'NH$$'J"#XZP0>X/!I/^$:^+0Y_X6'X2R,X/_"O=0R-QW-@_\)UD
M;FY;U."<D5ZK,<1N<A<*<$XP/KGC'KD$'IM;H?S ^-'[>\O[/WQ-_:"T?XE7
M7@.]T'P#H.@:I\(/AMX<1Y_'?Q!LXM'\!WWCO5?$'Q#TSQWXJM?">M>'-1\8
MW=K'\,/%GP7\#ZM<:#'H/CG0_'/BSPQ/XIN_!Y_96'_Z",T_\/.9_P#RX/[+
MP_\ T$9I_P"'G,__ ):?=)\,?%@DD_$#P>2>I/P[OB3RI.<^.><E$)SG)1">
M57"CPU\6@ !\0_"( & !\/;\<9SV\=>H!^H'H*^%?A9^WQKWBSXN:=\.O$'P
MUEU.#XF_$[Q=#\-;KP7>6ENWA?X):)<>$_"F@^*/&UYXDU:UM/%'BV]\7:EK
M7B/QKHOA*6QA\ ^#M0T73[:/Q1XAF\.KXVV/@_\ MP:IX_\ VKO&'[/FLZ9X
M1BL-1\5>/=,^%$MCJ-IH_B6\\*?!35?B)X-^,GBK4+>[\6^()_$%QX?^(>@?
M#KPM'X9U+PC\(O&<5UXV\1^(/#_A'X@_"[P/<?%76C^RL/\ \_\ -/\ P\9G
M_P#+0_LK#_\ 01FG_AXS/_Y:?:1\-_%H]?B'X2_\-[J'O_U/7N?S/J:4>&_B
MV!@?$3PF . !\/M0P!Z?\CU7Y'_\-]?M5:O\)].\<>"]+^ NO:SJ7AO]IKQ7
M);ZQX=UWPEIGAY/A;>_!CP5\/_#XM]'^.OQ1NO%%N/%7QBE\3>*?%5]??#;5
MO$^B^$XO#,'PX\ 7.O#Q-9_N%;I+';P1SR)-.D,2331Q&".65459)(X#),84
M=PS+$9I3&I"&1R-Q/[*P_P#T$9I_X><S_P#EH?V7A_\ H(S3_P /.9__ "T\
MM_X1SXM_]%$\)_\ AOM0_P#FZH_X1SXM_P#11/"?_AOM0_\ FZKUBBC^RL/_
M -!&:?\ AYS/_P"7!_9=#_H(S7_P\YG_ /+3R5O#'Q9D^]\2/"R8Z!/AW>L#
MGKG?XZX]..H)S2KX8^+*?=^(_A5\\DO\/+Y3GT^3QU@COD\Y)KU9WV@G!8@$
MX! )'L20,D\#) ]2!S7*^%_%%WXCN?%5M<^%/$GAE?#/B.3P_;76OP:?%:^*
M8(]*TK4QXB\,O8ZC?277A^234Y-+CN+^+3KTZGIFIP/8I'!'--$L!A(3I4I8
MC-5*LY^S2S7-FFZ<>>=YQJRA"T7=>T<.;X8<TM!2P.&BZ=)XG-+U'-0MFN:N
M[IQ]I)2J1FXPM%W7M)0YOACS-<IR?_"-?%HG/_"P_"6<$9_X5[J&<'J,_P#"
M=9Q[=*3_ (1GXL[@W_"PO".Y1A6/P\ORRCC(!/CG(!P,@'!P,C@5\<?M'?MD
M>/\ X'?'O6_A\OA;P?<_#.+P#^RPNG>-M0F\0+J'A[XO?M'_ !\^+/PO\/Z%
MXSALKR+38O!?C'2?AI+X?\$:S%)I5_!\8K_PIX)G'B7_ (6/I5OH&CHO[;&H
M?%+X)?%KQY\*/!^C:3XE\'Z!\-?%'A<>.?&'@74?#EWX=^+%UG08_$MT/'W@
M'PKHGQBT31[74[K7O@'XO^)OPYEM_$=QX(\-ZQ\4O"NA>/M+\=:=?]E8?_G_
M )I_X>,S_P#EH_[+P_\ T$9I_P"'G,__ ):?6P\,_%D<CXA>$01P,?#R_&/I
MCQSQT X[ #IQ2MX9^++$%OB%X08J<J6^'E^Q4@$ J6\<DJ0"0""" 2.YK\M/
M&7_!3FZT+PWX]UGPA-X?\6Z/X>_9!\>_$+PI\3;_ .#?QA\+> ?%?[4W@G]G
MR\_:@/@4?VKXFN/!%MH.H_!RWU#QE<_#&[^->G_$SPY<>$/%.D:MXF:W>'Q)
M:_8OP3_:FU/QMXVTGX.>)[#0+WQU!X,\+>+M1\36<MAX)TSQ98:S;RS:_JG@
MWP7:^./C58Q6_@[4;O1/"VN^'Y/C/XC\5V^LW5QJTMA;^#[SPIXB\3']E8?_
M )_YI_X>,S_^6A_96'_Z",T_\/&9]-O^7O0^AO\ A&_BU@#_ (6'X2P  %_X
M5[J&T <  ?\ "=8P!P!C '&*/^$:^+0Q_P 7#\(\# _XM[?X QC '_"=8 QQ
MQVKX,T;_ (*.W]O8V#ZW\%-3UNSL1K)\8>+/"_B_PEINCZ0OAW3;'QKKXTWP
MYXBUQO$VI/I/PWO_ .T;>%"9=9\66J>'85T_3K[^WK""/_@J5X3EN-3@MO@W
MXEU1-'\ Z]\6=6O=#^(?PPU32]#^'>A6GC6&XD\0ZLOB&#3-'\>6?B'P'J-A
MXG\"SW<C^ _#_B/P5XN\:ZYH>GZAXIMO!A_96'_Y_P":?^'C,_\ Y:']EX?_
M *",T_\ #SF?_P M/OH^&?BRWWOB%X1;D'#?#R_8$K@@D'QR02" 1Z$ CH*0
M>&?BR&+#XA>$ S-O+#X>7X8MM"[BW_"<Y+%552V<E55<X  ^%-:_X*A>!O#M
MC?VVJ?"[Q/+XNT^=5;2M#\1:!K_A>^TAOCK=?LJGQQI'C331(FH> ;;]H^3P
M_P"#]1U1=#B\3:;X'\1P_$J[\'1VFCZ]H.G:.F?\%(K2_P#%7A70KK]G_P ?
M:1I?B/6/A[HEWJE[XM^']UJ>A7?C34OV2/#VJ+<>'-&UK5+G4G\.^)/VUO@[
M96\&C7M]/XCT_1?B7J-A'!<Z1X!TOXF']E8?_G_FG_AXS/\ ^6A_9>'_ .@C
M-/\ P\YG_P#+3[;'AKXM 8'Q#\) 98X'P]U #+$LQP/'75F)9CU9B2<DDUS/
MB[X2^)_B!X;U3P;X]U3X4^./"&N+"NM>%/&/P<M_$_AK6%M[NWO[<:KH.M^+
MK[2M0$%]:6M["+NTF\J[MK>Y3;-!$Z_&_@7_ (*:6'Q&\+>"O%_AWX >.(-$
M\<6GA;5-.OM<\8^!K"!-%^*'B3X7^"OA#J1M[2_U36;A?$WC#XR>#="\56\.
MCF7PC_8OQ#U+2O\ A---TGP#<_$_H?AO^W?:?$7X9^-_$USX:TSP;XN\$_!O
M]GGXKSV>F>(8OB'H^MV'QX\%^'/%,NK^$IU3P9IVO^#- U;7+CP;;:G>^(-'
M\1ZCK/AS5+[5?"WAO1)_!VI^,S^RL-_S_P T_P##QF?_ ,N#^RL.]Z^:?^'C
M,_\ Y:?8.G^"OB5I.GV&DZ3XT\"Z7I6E65KINEZ9IOPRN+'3M-TZRMTM+*PT
M^QM?&T5K96-I:Q1VUK:6T45O;V\<<,4:1HJBV?#/Q9)!/Q"\(DK@J3\/+\E2
M,8()\<Y&-JD8Q@JI'*C'RQH/[=^D:E\*O%/Q'U'X6ZWX:N+!OV>;GPOH.L>,
M_!7V+7=#_:C\2:-X&^$^O:]XJL[ZYT7P3I\7BO4+R/QW#?+J5YX8\/Z9+J^F
MVWB74KVR\.R^-:O_ ,%%]0\"S_$C_A*OAZ?&A\#Q_$/Q-=:?\/\ 5M$T>WT?
MX??#C6OVO+_7]9C\0>*?%3IXNUP^!/V7[NPTC2[+1?#NF:SXQU?0[F34]$\*
MZ_KFI_#P_LK#_P#/_-/_  \9G_\ +0_LK#_]!&:?^'G,_P#Y:?H;_P (S\61
MT^(7A$<8_P"2>ZAT]/\ D>NG)X]ZSM-\!?$/1H[J+1_%OP^TF*^U+4=9OH],
M^%LFGI>ZQJ]R][JVK7B6GC2%;K4]4O))+O4K^<27=]=.]Q=32RLSGX^U3_@H
M3H/ACP]\7]0U7PYIFH2?"+Q1J7@B=-1\5Z9X2UKQ=XVG^)^H>$?#FB^'/!5F
M_C_Q(WA9M MOM-U\3[LPZ'?^(M*UO2;'3+>?2O$4?AFII?\ P4,T^#X4_#?X
MGS> /$/C8_&KXU>-O GPU\.>%H]+T/4AX2T33]<\::8VOWFO>(+OP[!XX'@'
M1I!'I$GB"PTG7_%1>,ZEX9\,6NI^(-&/[*PW_/\ S3_P\9G_ /+0_LK#_P#/
M_-/_  \9G_\ +3[='AGXLC@?$+PB!SP/A[?@?,<L>/'75CRQ[GDY-+_PC?Q;
MSG_A8GA+/<_\*^U#)Y)Y/_"=<\DGGU-?G/\ %;_@IW-X:^'OC2\\/?"NW\,?
M$&+X1ZO\:/AZWQ+\=^";7P7JG@#[+XZTWPUKFH36_B32;G4_&FK>,/A_K\-E
M\%-*U&U\6ZYX6M)-:LM?L;VR\1Z7X:W[W_@J/X$M)?$5LWPQUF<^&-*UOQK<
M2VOQ#^'=Q;7_ (#\+ZA\0-&UW2-/O(-7DM+K]H*>\^'&N7'A;]G19E\6^(M'
MU+0]8;5])BM/'">!S^RL/_S_ ,T_\/&9_P#RT/[+P_\ T$9I_P"'G,__ ):?
M<^I^ _B)K=M'9:UXN\ :Q9PZAI&K16>J_"^74;6+5= U:RU_0=3CMKSQI-"F
MHZ)KNF:;K>CWJH+G3-7T^QU.RE@O;2WGCT1X:^+()(^(7A$$YR1\/+\%L\G<
M1XYR<DDG.<DGUKX!UO\ X*):MI6E:Q)I'PIAU^XTKQS8?#^'Q=XM\>^&_AOX
M(O?$+ZI\)];UM-5AL9?B-KOA;0/#?PR^)MQXCD\53V&H6=WK7A+4=/NK'2[#
M4!?Z?]O? #XZZ9\>-&\>:G8Z)-X:O?A]\4?%?POUWP_>ZG#J>L:7J/ARWT?5
M+%]:DLK9=(AN]>\->(- \4V*>']5\4^'[G0==T?4M)\5:U:7R3J?V5AO^?\
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M_P#"'\-?_*ZE?-O^?66?^%.:?_,0N;-O^?.5?^%.;?\ S&>B?VA!_P ](/\
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M3_"ORO\ !?[2?P0UGXAS_#+QS^RQX?\ ASXDC\7:#H]L+S2/!GB*VU;PK/\
MLH+^TAX[\7Z!_8_AG[;X@N/A1XH@N/@WX]\+:+97VJ:7J6N_"_QHTR:1\6O!
M6F7SO&O[3?[.^GWGPZE^&?[.&D?$OPQ\0[J;P_IGB34/ACKWPWCN_'.H^+]
M^'GA3P?H=CXG^#TYGN7\8>*-!G\=:IXOO? NG>%/ U^?%WAB3XBW5CJ7ARR=
M\V_Y]Y7_ .%.:_\ S"/FS;_GUE7_ (4YO_\ ,1^IW]H0?\](/_ A/\*/[0@_
MYZ0?^!"?X5XMX+^'WP.\>^#O"?CKP_\ #;P')H/C3PUH7BS0Y+KP#X;MKF31
M_$>EVNL:8]Q;/I[-;SO97D#30,S-#(6C+,5R>E_X4E\)?^B9_#S_ ,(?PU_\
MKJ5\V_Y]99_X4YI_\Q"YLV_Y\Y5_X4YM_P#,9Z)_:$'_ #T@_P# A/\ "C^T
M(/\ GI!_X$)_A7G?_"DOA+_T3/X>?^$/X:_^5U'_  I+X2_]$S^'G_A#^&O_
M )747S;_ )]99_X4YI_\Q!S9M_SYRK_PIS;_ .8ST3^T(/\ GI!_X$)_A1_:
M$'_/2#_P(3_"O._^%)?"7_HF?P\_\(?PU_\ *ZC_ (4E\)?^B9_#S_PA_#7_
M ,KJ+YM_SZRS_P *<T_^8@YLV_Y\Y5_X4YM_\QGHG]H0?\](/_ A/\*/[0@_
MYZ0?^!"?X5YW_P *2^$O_1,_AY_X0_AK_P"5U'_"DOA+_P!$S^'G_A#^&O\
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M$%K:6L")#!!%'%$BHBJ-7^T(/^>D'_@0G^%>=_\ "DOA+_T3/X>?^$/X:_\
ME=1_PI+X2_\ 1,_AY_X0_AK_ .5U*^;?\^LL_P#"G-/_ )B#FS;_ )\Y5_X4
MYM_\QGHG]H0?\](/_ A/\*/[0@_YZ0?^!"?X5YW_ ,*2^$O_ $3/X>?^$/X:
M_P#E=1_PI+X2_P#1,_AY_P"$/X:_^5U%\V_Y]99_X4YI_P#,0<V;?\^<J_\
M"G-O_F,]$_M"#_GI!_X$)_A1_:$'_/2#_P "$_PKSO\ X4E\)?\ HF?P\_\
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MOEGQA-\,M%\._P#"027O@^&]F\3^'O$^G:,7S;_GUE?_ (4YK_\ ,0<V;?\
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MMK^H^,?C_P"%?$@\2Z%J?AK3M"\-^&/"UO\ L]^+M=F\57'BNYLM2L?L<%G
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M?PIHMGXV?X7#Q-I;>*_$4L>@:#_9\MQJ-E=S#1?%5OX;?-FW_/K+/_"G-?\
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MO;756>C;27U+%],UQ5M-\-ERZ*__ # OK=?(\X_X3?Q[_P!$B\0_^%+X _\
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MQ#\6O0?B/JW[?>C_ !,L!X$\,:AXH\&:Q\>[Z&*.!?@OI_A7PG\"-)USX(Z
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M-? YY_X2;X?_ ,)*M_S-W\+ J?0@@\BE_P"$Y\>'./A)X@. "?\ BIOA_P
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MOBR\O;GX,6&J)\+M \::ZWP]M?C!H$RKX4&K_$#X81Z'=?$UOA!J_@:Y\/\
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MW<.CS2>//^*9MM?T_1K#3/&-OX:&D6WC?3[&+3_&$6N6<;0'[*>,;&P QQP
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MX&\7ZCXL^(?Q"TQ_5L5K_P *^)T2:_=Y0]-VW;!NR6JLN:3:7NZW1]3Q>O\
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M*K_PWX3M?"^N:W8Z7J"V/BZPT/Q%K'BC1OB,?'?C7]H'XRW%KKLNE:OK<'Q
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MUU>C^4OJO_?1H\I?5?\ OHU'L<3_ -#?%?\ @G*__F,?U+&?]#3%?^$^7?\
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MTV[UWPOI]IKFG+K_ (2\3Z4FHZ1->VLEQI$SK+]DN=/NKOV?_A5__50_B?\
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M&G^*K[X>^)?#\6IZ#KNJ:=IOBY-.\):Q=:?XBU?3--N?<U^&&54_\+"^* R
M<'Q4F1D9P?\ B6CFOF37O ?PAU+Q3I?B/2M>\>Z+#%'^SEHFL:.?A[\1=7L[
M[P=^RSXR^(WQ,^%>C:;<ZAX:&I:5J0^('CV&\\4Z_?WGB.XUOP_X?MM&BL["
M^U&XURV^DQ\7/!X 'V[Q3P /^2;_ ! '0>@\(X'T' HOPY_T%87_ ,..,_\
MGF'-P[_T$X+7_J-K_=_R,"P/A<HZ?$+XH#(&<^+ V2.^7T]B">X! ] !2_\
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MH?Q/_P#"J3_Y6T?\*O\ ^JA_$_\ \*I/_E;5?_A;O@__ )_O%/\ X;CX@?\
MS(T?\+=\'_\ /]XI_P##<?$#_P"9&B_#G_05A?\ PXXS_P">8<W#O_03@_\
MPMK_ /SP/+?BKK_PW^"US\++;XC_ !@^*OA__A<OQ7\._!+P%<C4=:U2QO\
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M?U"V\)16HL[GP7\8;7XS>"M4N=%L_@);>&=7M_ &J6\W@?X8>"M;T/4_AO\
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MDGC/XI_!3P!\3-:^#_BGXV_%K3?B'H7PX\&?%J\T!6\47OVCP'X\^)%[\)-
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M3%_8(35;">Y[S1/$/PKUBUUB2Z^.?CCPMJOAGPO_ ,)OXS\*^-?'MEX0\9^
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M&-=TNU\$?LU>'=(O1H6L> ?"-EIO@#7=.U;X.PZ9H\:R_#>?49GU(%^&]?\
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M6[X/_P"?[Q3_ .&X^('_ ,R-*_#G_05A?_#CC/\ YYAS<._]!.#_ /"VO_\
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MZ_)XFM;KQ?H'B6S\;^([WX>_"W0M-@\5_%#PI<3G];O_ #'=]W][_P S[/\
M*C_N_JW^-'E1_P!W]6_QK\9[;_@HQ\38? ,WC'SO@5X\\0>&?#?Q%^(&O> ?
M!,'BC31XY^'&C?LH^$/VB]'\3>$?&=[X[UQ/"D'A'QOXSM?@/JL3>$/B1K?Q
M:\0Z/J_B7POH/PY@TWQAX>\!_HM^S7\3?%'Q3^'MUK?BZ[\(ZSK&B?$/XH^
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M=>(;I]??4X]%\1'];O\ S"[[O[W_ )G[+^5'_=_5O\:/*C_N_JW^-?E1??\
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M^8KON_O?_P D<UH'_!3?5/&FJVWA_P '? BQO/$VM:=)<Z;X7UWXRVVC^(?
MNH6EOX-OGTC]H+1],^&'B2_^"^I^)K+QC/=?#6R>#QI?>/+/X?\ Q+NH=/T6
M'PO')K'LVF_MC^,-?^$/AOXF6_PW\(^#+R?]H?\ 9]^$OB_2_''Q)NCH&B^"
MOCLGPCU[3O$^F>+--\$017OBV#PM\9_".DP>&M1TW2M";XEG4_"MGXKU[38=
M$USQ'6^%'[5OA5?C3_PH[0OAAJ>GKXS^-GQ:\/ZGX[TV[T#2]$A\>GQK^V5+
M$UYX7G\7Z]K^H/J.E?L<>/;OQ'XAMI[*.XUGQ+X%N]/\+65MJOC+2OAKY?J?
M_!3G0K^P\:6WA[X6^(%U?PY\.?BK\3QK8\6?#CQ9H_A[P;\-M"^*=Q>ZWXDT
M[2O&NAROXK@UWX3:Q:W?PGM]<TSQ):6NN>"[C5]=\*6^J^)9_!A_6[_S"[[O
M[W_\D<YX:_X*G7FK^&6UWQ#\#O#G@&\7X5?"#X@M9>+_ -HGPEIMI;ZY\=[/
MX-:U\-=#U-)_!$7C.Q^'VJ:5\;=#\-:E\=(_ UY\,]"^,WA'X@_#'4]3@T_0
M;#QOK5WP=_P4E\=^-;_28?#7P/\ !^O1>,]=^'-QX8L+CXS77A_7?"7@KXK:
M#^P-)X%;XGV=O\+/$ZZ?XPO/$/[<VFW^OZ7HPGTG3? GP^US4?#FJ>,-:?3[
M/7?1KK_@HOH.FZEJX\4_"3Q5X3\-VPU:#0/%^I^,/!%_8>(+Z\T[XRZCX"TR
MZTC0[G5O$6E3>.)O@%\2=.-M_8NJW>BW=QX!LH].UG4O%&LV?@V#X>?\%*?#
M/Q&T[1==T[X.^.[;PYXH\9^"?A!X5UN7Q+X,G&O?'[QY\/? /Q.TKX4PZ9!J
MG]HV%M;^&/'%Y=2^-]<L['0MGA/5V:&$W&FQRG];O_,/F_O?_P D<WX-_P""
MD7B3X@ZO_P ([X0_9YA?7)-+^!D,-KXL^.G@SPU-;>+?C='\ +VQLM;\-67A
MSQ'\2K+P!I6F_'>Y;2OBSI?@'6O#OBC5/A7XYT*6PT'6[WP;I_B3I_#O[?6J
M:C^SU\<_VA=7\"^ M+TKX8^(?@E+HGA&]^+<&A:O9^ ?C-\+OV?_ (C1:W\3
MM3U7PG,NAZ_X>LOC%K-_;>&? ^A>/M=^(=KX:M?#/POT+Q?XWUK0]'UOKOB#
M^WIX3\&_'OQ3^SMX=\ :SX^^(.C1^'-/T>+2/%&AZ+IFHZ_JGC']GOP?K&BZ
MWJ&OPV$6A+X5;]J/X7^([B73)O%-P=!D\0F#2K37(?#NA^*N5^%7[>R_'3XG
M>'?#7P_\+Z7H?@G6OV9/C-\:89_%VK^'+OX@)XF^'@_92U#PS8:CX9\/>*W?
MPMX6MK+]H+6K2_EU:WNX_&4FGZ9K_A?6](\+2:=?>,3^MW_F'S?WO_Y(\^D_
MX*,^+?!6A^(KKQW\._!$JW'Q!^,=I\/O&6O_ !4;X8>![WP5X-^,'[5'AC0;
M7XA:EK'P[U67X>^)+GP]\!- \,>#K9;;Q3+\1O&7C30+?5E^'FH7=]IME<U_
M_@J)8Z'>>,=/D^ 7C*RU'PIJ]]HUU;>,?%VB^"+.PFT;XIZ=\+_%.J^)]4U?
M139^#?"_@1OB?^S'XU\=^(=>D6TT#P5\=;O4X4U&[^&VLV6LYOPF_P""JOA[
MX@>$/AEKDWPB\:ZO?Z[\$-*^,OQ.U+P[+X=TFS\#>'8+'XF2>(M5N_"WB/79
M/$FE3Z=>?!'XIWUS\-=3OY_BMX8MYOASHVN>&E\4^)_%^G^ OH#XE?MX^!?A
M;\._A=\5O$_A#Q8G@#XI>!?BS\3='UBUO-,O[N7P9\//",_CSPC;V&D60OY+
MOQG\8?!3V7B+P;X>U9] TFR9K_PWXK\6:7XO30_#/B4_K=_YAKW?WO\ ^2/+
M_AG^WMXG^)GQSB\$_P#"$^#?">B>'?V8/C5\7?&7@:;XP> ?$GQ!M_&G@K2O
MV-_%7AF#6-5TP0?#_P )> M3TCX]^+[3P;\0F\=:QX3^).CVEK\0(+G0_#4%
MHTWF>K_\%7;3PKX9U/QYXD\$?#&?P[-X<^&NO^$O#.A?&/6H_&?B&/6-'_:&
MU/XG0:7<^*_A3X9\/^(+OP_=?L_>)=#^&3VEQI/AGXM:UINN6_AGQ?<1)HLF
MK>XZ7_P4&TG4-&O=2O/A3K6@WVD:'\/Y]6TSQ+X_\!:9<C7OBQ\?/$_[._PU
M.E^9/)=:C\-]2\1^'-0\7^+_ (GWNGZ19^#_  5J=A'%X?USQWI7C?P)X,Q[
M7_@I1X6N;<ZB?A'XKL-!G\2>&OAGHNOW7C3X>C0M2^+'BJW^ SZ1X>DO;'5[
MXV7P[B/Q^T&_F^+4*WWAR;P[X9UKQ-HVFZQIFI^&/^$@/ZW?^8:]W][_ /DC
M#T'_ (* ^*8?%6G^%?%GA#X</XEU_P"(C?"9;?1?BM=R^#M!\7M\>/VD/@MX
M=TBTCM/A7JWQ1UWQEK6M_"CPGI/C/28/"-WH'@2XUO\ MOQ)J?@O0;.[O-2P
MOAE_P4LCU?PD_B;QSI?PWTU8OA&WQCUS59?BN;'P?=VNG_LI?!#X[:YX8^ X
MTSX9ZYXG^+G]B:K\1=4F\91SVL>K?#_PK&/%.I7FM07VB>&8J7P]_P""I^E^
M([7P7X;U#X=KXQ^*OBO1_#T]K8?#KQ+X?LO"<7BCQC\=_@E\'-+\,W6M:WJN
MJ:1$-'T/]I?X/^.=3\0:%XA\6P:IX?NM?U'2])B%YX+TWQ9[OJ7[?WA>S^ ^
MH?')/A=\03%!\4?#_P &-.\)75QHJ:G+\5=2T31)O&_A?4M7L)=7T/06^%/C
MR]\7_!;QC>7$UR(_BU\//$WA.PCO+B72IM3/ZW?^87?=_>__ )(^=?#O_!2K
MQ'?:^_Q$U[PMI.F? [0_!'C36_B%I>C:M9>+;OP=:_#KX[6OP0\>?$G1_'NB
MZ>UGX\\">'&T_P 1_$&R:PTG2)=>\ Q0:O%]FO@NF2?0'Q4_;5UKX;^+/ ?P
M]\2_#:;P_P",O%?P\_9^^)-]X8T'QOHWC'X@6NH_$/\ :'^'GPC\=_#BP\&V
M/A348Y;/PE!XK%O<>.?%6H^ H?'M]J<>@_!ZU\1Z]HOC/5/ 'E_Q5_;M\&>(
M?",VB>+/@3XBM;7Q+J_CEOAOI_Q"^(_@#POX1\2>(/V=O&/BVU\>6WQ1OM(\
M:II/A;1/#?B'X<PQ1:#X@U37- ^(VH:E9>$)U%G=RSK'X+_X*?Z+KVA>"+#4
M_AXDOC?QSI5[8Z?>67Q#^'WAGP./%7@RU;_A8T_CK5]3\1ZS<? CPW>W*RR?
M"9_B%>7>K?$*1HM'L(X=15[F\/ZW?^8[ON_O?_R0[P)_P4MO_']_IEKHWPE\
M(:QH\GCSX=^"?$GC+P#\>M.\?>']&A^+.H?LE>'_  MJ7AF\B^&&C6'C#5]$
M\0_M<>';;QGH%U=>&['0++X?>-+B#Q%KM_)H6D:QRW@/]OKXE6C1:W\1-.\'
MP:3X\N=(B^'DWBKX@Z+\._AEX)\-R_##]FSQ0OB3XY_$Z;X527/@S4];U?XF
M^)["&XTG1?$GAZY\<Z]X)^&NDZ9;SZW8>(-/S?#7[=W@;X2_"_XAZK\(O@9X
MRUVWA\(^-?C0=<\>>-9++Q%K_BV]\&?M*W_PXT'XK^(?''C3XK?%;Q%XEU&P
M_9)N?AWXE\7:A<ZU?^$-,OO .B:)X>;PYX;O]%\)?HE\#OV@M)^-'B#XH>$F
MT6VT37?A=J?AC3]8L%\0VOBB/5]-\3Z;?7&D^+-*U&QTRVTC4O!>NZEH^OV_
MA/6M.U"^?4X-'O%U[3_"7BNQU[P=HA_6[_S"[[O[W_\ )'QH_P#P4Q@OO%?Q
M<\-^$?A'IOC"S^#FK^/KSQ)KMC\6$M!)X ^&MWX]LO%5T-'N?AQ_;&C_ !:L
MKSX9^*M._P"%1^)K31K9=2?0/M'C^'1M7EUO3_M[]FWXH>(?C#\,+7QAXOT_
MP7I/B:+QO\5O!6NZ/X%\2ZEXGT32M1^''Q-\7^ GTZ;4-7T3P]JEMX@MH_#2
MIXHT.^TN&?0]=%]IK2S+;+++] [%XXZ9/4\DC!)YY.!U.2.QH"*#NQSZ\D],
M G/4@< GD G'WCD_K=_YBU[O[W_\D-\J/^[^I]_?W/\ D"BI**5EV7W 8^N^
M'?#_ (HT^32?$VA:/XBTJ5HWETS7=,LM7T^5X9$FB>2RU""XMG>*6..6-FB+
M1R(KH0R@B.S\,^&]/%T+#P]H=B+X:8MZ+/2;"V%XNBVT%GHPNA#;I]H&DVEK
M:VNF"7>+"VMH(+7RHH8U7A;C5OBFES<K8>$_ EW:+/(+2:[^)7B*PN9K4,/*
MEN+2+X3ZC%:SNGS2V\5]>)"Y*)=3J Y@_M?XM_\ 0F_#S_PZGB?_ .<U7&\=
M%2<7A,SO%V;658]Q>_PRY+26FZ7;NCD>+M*4?J>9MQ=FUE>.<7O\,N5*2T>J
M7;NCTK3]%T?2%NTTK2=-TQ+^_N]5ODT^QM;)+S5+^19K[4[M;:*);C4+R55E
MN[V8/<W$BJ\TKL 13U?PIX6U^[T>_P!>\-Z!K=]X>OEU/P_>:OH^GZE=:%J2
M2V\Z:AHUQ>V\\VEWJ3VEI,MU8O!.LMK;R"0/!$5X'^U_BW_T)OP\_P##J>)_
M_G-4?VO\6_\ H3?AY_X=3Q/_ /.:I?7H_P#0)FG_ (:L?_\ ("^M_P#4'FG_
M (:\=_\ (G8+X!\")>:3J*>"O"2:AH,]]<Z'?KX<T=;S1KG5+VXU+4[C2;H6
M8GTZ?4=1N[J_OI;-X9+N]N;BZN&DGFDD;?TW2]-T:PL]+T?3['2M,T^!+6PT
MW3;6"QL+&UB4)%;6=G:QQ6UK;QJ L<,$:1H!A5 KS#^U_BW_ -";\//_  ZG
MB?\ ^<U1_:_Q;_Z$WX>?^'4\3_\ SFJ/KT?^@3-/_#5C_P#Y /K?_4'FG_AK
MQW_R)Z[4,]M;W2+'=6\-S&LL,ZQSQ1S(LUO*D]O,JR*RB6":-)H9  \4J)(A
M5U!'E']K_%O_ *$WX>?^'4\3_P#SFJ/[7^+?_0F_#S_PZGB?_P"<U1]>C_T"
M9I_X:L?_ /(!];_Z@\T_\->._P#D3T*]\,^'-2BN(-1\/Z)J$%W-:7-U#?:5
M87<5U<:?=17MA/<1W$$B3S65[##=VDLH:2VNHHKB%DEC5Q:M='TBRO;[4K/2
M].M-1U1TDU/4+:QMH+W49(HHH(WO[N*)9[QXX((84:XDD9(H8HU(2- /,_[7
M^+?_ $)OP\_\.IXG_P#G-4?VO\6_^A-^'G_AU/$__P YJCZ]'_H$S3_PU8__
M .0#ZW_U!YI_X:\=_P#(G<OX-\(2/=R2>%?#DDE_JMGKU\[Z'ICO>ZYITPN-
M/UJ[9K4M<ZM8SJL]GJ,Q>\M9@)()D<;J;/X*\&W,ES+<^$O#-Q+>:I::Y>23
MZ#I<LEWK5@TC6&L7+R6K-/JEDTLK6FH2E[NV:20PS(7;/$?VO\6_^A-^'G_A
MU/$__P YJC^U_BW_ -";\//_  ZGB?\ ^<U1]>C_ - F:?\ AJQ__P @'UO_
M *@\T_\ #7CO_D3T9/#^@Q:F-:BT32(]96TN+!=6CTVS34UL;N^;4[JR6_6$
M7:VESJ3OJ$]NLHAFOG:[D1KAC(:UKX3\*V,4D-EX9\/V<,MU-?2Q6NC:=;Q2
MWMR]G)<7DD<5LBO=3OI]@\UPP,LKV-FSNQMH2G!?VO\ %O\ Z$WX>?\ AU/$
M_P#\YJC^U_BW_P!";\//_#J>)_\ YS5'UZ/_ $"9I_X:L?\ _(!];_Z@\T_\
M->._^1/0)/"_AF:ZLKZ7P[H<M[IL_P!JTZ\DTFP>ZL+K[-967VFRN&MS-:7'
MV/3=.M/.@>.3[+865ON\JTMTC?<>&_#MY<VE[=Z!HMU>6%U<7UC=W.EV,]S9
MWUXL:7=Y:SRP/+;W=TD,*7-Q"Z33K%&LKL$4#SS^U_BW_P!";\//_#J>)_\
MYS5']K_%O_H3?AY_X=3Q/_\ .:H^O1_Z!,T_\-6/_P#D ^M_]0>:?^&O'?\
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MU1_:_P 6_P#H3?AY_P"'4\3_ /SFJ/KT?^@3-/\ PU8__P"0#ZW_ -0>:?\
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M3'3716LO)901P_\ :_Q;_P"A-^'G_AU/$_\ \YJC^U_BW_T)OP\_\.IXG_\
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M\6_^A-^'G_AU/$__ ,YJC^U_BW_T)OP\_P##J>)__G-4?7H_] F:?^&K'_\
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M>*,NQ.9/\-([G0YO#%Q^SK^S?/X:N+'^R[CPY-JZ2Z#<:;]@\/Z7_9\^D2?
M1M/DL3IGA+PIIIM'MV@-AX8\.VGE_9]%TV.U/KT/^@7-/_#3C_\ Y$/K:_Z
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M>)__ )S5']K_ !;_ .A-^'G_ (=3Q/\ _.:H^O1_Z!,T_P##5C__ ) /K?\
MU!YI_P"&O'?_ ")Z[17D7]K_ !;_ .A-^'G_ (=3Q/\ _.:H_M?XM_\ 0F_#
MS_PZGB?_ .<U1]>C_P! F:?^&K'_ /R ?6_^H/-/_#7CO_D3UVBN5\/7/B:Y
MM'D\2Z7HNEW@E=8[;1/$%]XAM7M]L9BF>_U#PYX8F29F\U7MQIKHBA&6Y<LR
M*5T0KPG%2Y:L;_9G1G":\I0E[T6NL96:>C29M&M&45+EJQOO&I2G"<7U4H2]
+Z,EUC+5/1I-,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ ,@ R  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $) G8# 2(  A$! Q$!_\0
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M&9-:CT ^+KWP&?$6H>#K?67\8Z=X;'C'3[CPT/$5]H%OI#:P(;072O-#YGF
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M4ZV'JSJ4Z5:FO]8/>IU)T:L(2CS*4J<HIN2<5]>_\-X?ME_]'(?%'_PI3_\
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MTJUU8V\W]G7&J:5:Z==ZEIT-T$,4M]I]IJ^E7%W;1LTUM#JFGR31A+N$M,^
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M/XAT/3= U;4K-;02F[Q%9^)]&87!@%K++=&VBG:YBDB& 2V<8+.=N%!)+9)
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M_P"&\/VR_P#HY#XH_P#A2G_XY7R$98P#F1!@E<EEX;@8).WG++C(4_,H(!8
M]#'X:UF2QAU-K-;'2[K3-1U6QU'5;B'2K+6(-(GAM-1@T6YOY((=:U""[E^S
MKIVFO<W\LR2P1VIF@D2NC$<$^'^%4)8CA+@K#JI)PINOPYPY252:2DX4^;(H
MN<U&2DX04Y*/O.,8WFN&EXI^+5=RC2\0_$J?)!U)M<;\7*$*:<5SSG+/XPA&
M4IPA"4ZD(SJ3A3A*<YTX5/IS_AO#]LO_ *./^*/_ (4I/?'_ #T]>/KQUH_X
M;P_;+_Z.0^*/_A2G_P".5\[>$_!/B?QO+J</AK3WU2?2H]!DNX+:ZL[:0'Q1
MXP\,^"]%BA%[/;K/+<^*_%WAO3WC0@V<5]_:-X8+&SN9D=?>!->LO#L'BI!I
M=_H,IB4:EI&O:7JJ*\DZVDPDM[.Y>ZC33[J6SL]3E>(0V-YJ>F6\DS2796/F
MEPMX:0Q,<#4X:X$IXUU*5%X9\/\ #E2I"I7A*I0C-4>'I<GMH0G*GS6=1)\B
MERSY?0CX@>,L\(L=#COQ2E@^2O5EB_\ 7#C%X54<-.-/$5X5X\1<E:GAZDHT
MZ_L5.5&<HQG%-M1^A_\ AO#]LO\ Z.0^*/\ X4I_^.4?\-X?ME_]'(?%'_PI
M3_\ '*^11T';@4M>A_J!P-_T1?"'_B,</?\ S@/'_P"(N^*/_1R?$7_Q.^+/
M_HA/KG_AO#]LO_HY#XH_^%*?_CE'_#>'[9?_ $<A\4?_  I3_P#'*^1O\_U_
M0<GT&2>*.<$X.!C)P<#<,KDXP-PY7/WAR,BD^ >!EOP9P>O7ACAU?GD*'_Q%
MWQ2:O_Q$GQ&MW_UZXMM]_P#K!;\3ZX/[>/[92@L?VD?B@ H))/B8@  9)),F
M   22> .333^WK^V,.#^TK\3!\@DY\4J/W9P _,OW"2,-]TY&#R,_+6D:IJF
M@:MI6NZ/*UGJVDZA9ZKI-X2T7V?4=/N([NQN5DVDJ8+F&*7<@=AM^5=V"/U.
MNO%_PCT>35'\/:_X%<^#I]4_;U\&Q&XTD.WC_P 6P>)X?"_P%B.]H+S5-+-_
M^SL^M>% 'FTX^$?'<ES9VUO8ZE%>_'\493PAPY6P<*7A?PYFU/%T<14=3"<,
MY"EAIX>I2A-8IKA;$1H49/,,F]E7FE[3ZYC.2$XY5BI+]%X'XC\0^+\-F&(Q
M?CCQKP^LNQ&'IU88[CCB&3K8?$8?$XA5\,J_'.75*TZ4,IX@]M2ITJD:7]GX
M"-2M3GG6#B?+?_#=W[9O_1QWQ2ZJ/^1E;@L=J@_O."S?*H/+'A<FG?\ #=7[
M:.Z%/^&B_BKON%C:W3_A(I-\ZS2&*)H5W[I5EE5HHS&&#R HN6&*] A^'?[/
M5GJ$+:Q8^![OPO97_P!J\!ZU9?&;77\2?&#PU:?!#XM>+/$.K?$BP@\;WLG@
M37+/XA^'_AK9:5:Z5HGP\:UU?Q7JG@?4-)\8W<%Q/I_7_#.7X>:UKO[/_C&:
MT^&&J>(?";_L]VUWX;USXK7W@C0/AOX'N/BA\7==\;>(M,N[_P")VD:]J.I^
M"Y8/!]C;6_BSQ#X^GTG1=3M[OQ/X:\7WFMQ:K:>'B<7P'2PKQ5'PGRJI&%'%
MRFJW"_#&&C+%4L)B:V$P<)RX:DJ<JM?#2IX^MB(>RRJ5\OQ'UC-W2IUOJ<%@
MO%NOBH8/$^.G$V'Q%6KE\(0I<?<78E4Z5?-L'EV/Q-6;XLP\*E'"T\4\5@7A
M*U19O0I2Q^#J_P!D?[;+PUOV[_VRU+*W[2'Q15D)5E;Q,0596*,&!D!4JX*,
M#C:P*G!!%2_\-T?MI><MO_PT5\5OM#*'6#_A(I//9&C\U76'?YC*8OWH8*08
M_G!V\UWUEX$_9SU7P\WC#6M7T%M;U/P[J/Q!NO#S?$.Y@F23X+:CJ6@>/_ U
M]'!JR7K:M^T8;W0O&W@98)X9] BTW4=&\*IIEK+%%:=GX.TOX<:!XAL_%ND7
M?@7Q)?Q:5KFF^+/$GC/XV7UIKO@.TL_V6/ DW@R3PGI]_P#$+3AXED\3_$'Q
M#\1/#=Y:ZSI?Q&M+27P[I_@'0K#P!)H*/<9XO'^']"EB71\+,KJXC#1Q%%T:
M_!648*E4Q].E4JT:-+$UN%:D:N&K?5\5"%>E0<\35IT,/@H2Q&+HVG!83Q:Q
M&(HQK>.O$$,+B/8XBGB*'B7Q+B*ZRZK*7[Z6!7%7UAXN-/$996JX52A#!4L1
MC*N8U</2R[$3CX3_ ,-W_ME\G_AI#XHX R3_ ,),>!DKD_O.!N!7)P-P(Z@@
M)_PWA^V7_P!'(?%'_P *4_\ QRJ'QV\*_!?PQX'\$/\ #1KR_P!6U&/PY-%X
MJCUS0KFW\1:-?>"+34O%0\0:+'\9_'.MV.OZ?X[G2.QBA^%7P:L-"LY=2\-:
MUIGB/Q!;-JJ_+$ORR<@CY(\ @Y " <CD@ALAAV(P><U]OD?#?A_GN!CF%#@'
MA_!4:F(QV'IT<SX/X?P6+E]2K^Q>(EAJN01G3P]>TW2YTJT9TZE.K!.G.;_-
M^*>./%?A7-)95B/%GC3,:JPF"Q?UC+/$+BW$86V-PE#%?5U6>?04Z^']NH5O
M9\]!KDJ4JU2%2#/K;_AO#]LO_HY#XH_^%*?_ (Y1_P -X?ME_P#1R'Q1_P#"
ME/\ \<KY&HKVO]0.!O\ HB^$/_$8X>_^<!\T_%WQ16C\2?$5/L^.N+$_N?$"
M/ZK_ /@D?\6OB?\ &OX+?%'Q#\6/'OB3QUKFE_%I]&TW5/$-^-0N[/28_!/A
M.^&GVTS9\JT^VWUU<&$,Q-Q+*[$ HBE<!_P0W_Y-\^,/_9;I_P#U7W@>BO\
M*SQQP^$RGQ<X^R_+L)A<OP.&SU1P^#P&&P^$PE"$\IR*K*-'#T:5*C24JM6K
M4DJ5*E!SJ3<:<+V/]Z/HN8C%Y]]'WPJS?.<;CLVS/&\-2J8O,<SS#,\=C\5-
M9UQ#3C/$XO$X^K7KS5.%."G5J5)<L(QYG&,4OP]_;D_Y/#_:5_[+%XM_].,U
M?*"]!]!_*OJ_]N/G]L+]I4Y7 ^,'BY^70'8-3E0M@L#C<0!QE@<KD<U\G@@
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M.)\6/_F]H_X=<_L*_P#1![?_ ,.)\6/_ )O:_0*BOB?^(H^)_P#T<GC_ /\
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MC_XS:#JUU:?;_@_X:F\+?$70/%GA7PY8:SJFJ6-C/JFN_#7QGJU[X*O-%/\
MB*/B?_T<GC__ ,3'B/\ ^>H?\0.\%O\ HT7AC_X@/"?_ ,Y3W3_AU_\ L'[M
MG_"B[4L#M*CXA_%LD-C.T@>.N& (R#R-RY W+EI_X)@_L'#=GX&6OR.(W(^(
M?Q;8(Y"ML9E\=%0P5E<@G(0ASA>:\#^(5_\ M8:+XR7PGJ:?M':AH_CW]HCX
MOS^%7^'?CKX#^#?B/XV\ 6WPN^*FN^%-!\/V'BGQAKG@'P)X+^&^KV/P_CT;
M5_\ A,_"/B7XCQ:9#X@\:?#O29CX]T;Q]!-\)OVT/#WC!?B5K>B^*?'7CYOA
MY\3_  +K4WPN^(7@SP+X#GUWQ=I7[(=OK/C_ $WPK=>)O 4NL:G<OX1^/&J^
M I=:GTCQ++?^&_"'A#7/%_PTTN[\+^*-&/\ B*/B?_T<GC__ ,3'B/\ ^>H?
M\0.\%O\ HT7AC_X@/"?_ ,Y3WR/_ ()E_L"2W5S8Q?!739+VRCMIKRS3XD_%
M=KJTAO3<"SFN;<>/3-!#=FTN_LLLJ+'<?9KCRF?R9-M@?\$O_P!@]CM'P+ML
MX+8/Q"^+BDJ"H)&[QT-V&=58+DJS!6 ;('EOPR^&_P"V+X;\"_$KQGXHT[7[
M_P"-&H> OV:M,AO(=<^&]MXP\>VWP;^/'QBUCQ9X5CN$\4ZQX1T[Q1XC^"6L
M^'=#2YU[Q6=%O?$'BJ:*]\=RWB:WX@L\37],_P""B-XWB75O!]EXYTCQ%KO@
MG]IZ/PAIGBS7O@P/#/PMO=6^+G[0'B#X)ZH(M ^(]_8?$WXBZA\-)O@?X(TS
MP+XNTJQ\!_#]=-TSQ-_PN>$VGQ.\&^,#_B*/B?\ ]')X_P#_ !,>(_\ YZA_
MQ [P6_Z-%X8_^(#PG_\ .4]@U7_@FG_P3\T+3KK6-;^#NC:-I%C"UQ?:KJOQ
M/^*6G:996ZLJ-/=ZA>>/X;2VB#.B^9/,B990#DBKW_#K_P#8/!"GX%VH)!.#
M\0_BV.!UZ^.Q@CH0>00P(RK8R+_X&_&3XA_LU?!SP5\3-:\>>*_&FA?M)?"#
MXDZZ-:;P[\/_ !-:_#WP;\?M+\90Z#XLC\/_ !9^+.G^(K/P7X,L+:YM9KKX
MG>*?%/B230="UC6)KGQI!<VM<'\,? ?[<&LW/PZTSXB^*OC%X7TZ3Q!\)IOC
MUJUQXT^#,TFN^,-)\"_&Y_C/KOP=N/#,NN:CX;^!'C+QO)\%],T/PQ/:^'?%
MMEI<$=UH/@WX?:O%XTU75C_B*/B?_P!')X__ /$QXC_^>H?\0.\%O^C1>&/_
M (@/"?\ \Y3U?_AUS^PK_P!$'M__  XGQ8_^;VC_ (=<_L*_]$'M_P#PXGQ8
M_P#F]K] J*/^(H^)_P#T<GC_ /\ $QXC_P#GJ+_B!W@O_P!&C\,?_$!X3_\
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MVJ^9*R)&FYO'87<[R(JKG)+ "GG_ ()>_L( @'X%6PSD\_$+XMC  !))/CK
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M[7=,TK2/AC=>$3_B*/B?_P!')X__ /$QXC_^>H?\0.\%O^C1>&/_ (@/"?\
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M\2="\=^*?#7PJT/XDZ#K/C'Q[IGAKPOJVG>'/AOXEA\<G_$4?$__ *.3Q_\
M^)CQ'_\ /4/^('>"W_1HO#'_ ,0'A/\ ^<I]=K_P2_\ V#W?8OP+MF?Y^!\0
MOBWSY;^7)M)\=A6\M_DDP3L<A6PS*#)_PZY_85_Z(/;_ /AQ/BQ_\WM>B?LA
M?"^^^&>@_% Q_"N'X%>#?&WQ6'B_X<?!. >!K:/X8^&8/A!\(? VLZ2-(^&>
MO^)OAYHK>)?B/X)\?_$(VOA'7-1M[[_A-#K^NM9^+=:\0V-M]?4?\11\3_\
MHY/'_P#XF/$?_P ]0_X@=X+?]&B\,?\ Q >$_P#YS'Y^_P##KG]A7_H@]O\
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M@+7-?O\ P_%!I=_KVL> ;;PSJ>MW]O;64U[JMW=W-]I]A?RW=G ?\11\3_\
MHY/'_P#XF/$?_P ]0_X@=X+?]&B\,?\ Q >$_P#YS'S-_P .N?V%?^B#V_\
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M_$W_  BEU9'_ !%'Q/\ ^CD\?_\ B8\1_P#SU#_B!W@M_P!&B\,?_$!X3_\
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M[YQ4E?,7[2-MXKL=6_9S^(7ASPMXL\9Z3\)OCM=^,?'GA_P.EK?>*)_!VO?
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MH22.33Z* &>6G]T?E[J?RRJ\=/E'I3?)BSD( >.02.G Z$=,#\50]8T*RT4
M1&&(YRB_,"#VX("D#'W00,$+C//J<R!0.@QV'L,YP/0>@' & . !2T4 %%%%
M !1110 4444 (0""" 01@@]"*:8HSC*@XQC//(!&?<X)&3SS3Z* (Q%&HP%
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MVAZLWAJT^CO^%=^(_P#HL7Q*_P# /X3_ /SJJ/\ A7?B/_HL7Q*_\ _A/_\
M.JH^LX[_ *%E7_PMRW_Y<'M\;_T+:G_A;EW_ ,N/*K7]FKPE8?$;X ^)M.?3
M;#P1^S1X+\8Z#\*_!R6NLW>N:=X@\9Z;8>%[O5[_ ,9ZAXFNCJ.@Z?X+L9=+
MM?#E[H-U>7&N:@/$EWXA:?2-,LU^GUN8U &1QZ,H'Y#@?0=.E>:_\*[\1_\
M18OB5_X!_"?_ .=51_PKOQ'_ -%B^)7_ (!_"?\ ^=51]9QO_0LJ_P#A;EO_
M ,N#ZQC?^A;4_P#"W+O_ )<>E_:H_4?]]+_C1]JC]1_WTO\ C7FG_"N_$?\
MT6+XE?\ @'\)_P#YU5'_  KOQ'_T6+XE?^ ?PG_^=51]9QO_ $+*O_A;EO\
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M^A=4_P#"W+O_ ):>E_:H_4?]]+_C1]JC]1_WTO\ C7FG_"N_$?\ T6+XE?\
M@'\)_P#YU5'_  KOQ'_T6+XE?^ ?PG_^=51]9QO_ $+*O_A;EO\ \N#V^-_Z
M%U3_ ,+<N_\ EIZ7]JC]1_WTO^-'VJ/U'_?2_P"->:?\*[\1_P#18OB5_P"
M?PG_ /G54?\ "N_$?_18OB5_X!_"?_YU5'UG&_\ 0LJ_^%N6_P#RX/;XW_H7
M5/\ PMR[_P"6GI?VJ/U'_?2_XT?:H_4?]]+_ (UYI_PKOQ'_ -%B^)7_ (!_
M"?\ ^=51_P *[\1_]%B^)7_@'\)__G54?6<;_P!"RK_X6Y;_ /+@]OC?^A=4
M_P#"W+O_ ):>E_:H_4?]]+_C1]JC]1_WTO\ C7FG_"N_$?\ T6+XE?\ @'\)
M_P#YU5'_  KOQ'_T6+XE?^ ?PG_^=51]9QO_ $+*O_A;EO\ \N#V^-_Z%U3_
M ,+<N_\ EIZ7]JC]1_WTO^-(;B)L;@IP<C)4X.",C/0X)&?0D=Z\U_X5WXC_
M .BQ?$K_ , _A/\ _.JH_P"%=^(_^BQ?$K_P#^$__P ZJCZSC?\ H65?_"W+
M?_EP>WQO_0NJ?^%N7?\ RT](\ZWP%V1[0<@?)@'&,@= <$CCL<=*/.@!R$C!
MSG/R9SSSGKGYFYZ\GU->;_\ "N_$?_18OB5_X!_"?_YU5'_"N_$?_18OB5_X
M!_"?_P"=51]9QO\ T+*O_A;EO_RX/;XW_H75/_"W+O\ Y:>D>=;XV[(]N-NW
MY,;<;=N.F,<8Z8XZ4"6W P$C ] (P.1M/'NH ^@QTKS?_A7?B/\ Z+%\2O\
MP#^$_P#\ZJC_ (5WXC_Z+%\2O_ /X3__ #JJ/K.-_P"A95_\+<M_^7![?&_]
M"ZI_X6Y=_P#+3TH7$0& % ] 5QTQT^G'TI//A_NIZ]4Z^M>;?\*[\1_]%B^)
M7_@'\)__ )U5'_"N_$?_ $6+XE?^ ?PG_P#G54?6<;_T+*O_ (6Y;_\ +@]O
MC?\ H75/_"W+O_EIZ29X#@%4('0'8<<$<9Z<$CZ$CH://@X^5.,X^YQDDG'I
MDDD^Y)KS;_A7?B/_ *+%\2O_  #^$_\ \ZJC_A7?B/\ Z+%\2O\ P#^$_P#\
MZJCZSC?^A95_\+<M_P#EP>WQO_0NJ?\ A;EW_P M/2A<0CD! <YR"HYP!GZX
M 'T '04OVJ/U'_?2_P"->:?\*[\1_P#18OB5_P" ?PG_ /G54?\ "N_$?_18
MOB5_X!_"?_YU5'UG&_\ 0LJ_^%N6_P#RX/;XW_H75/\ PMR[_P"6GI?VJ/U'
M_?2_XT?:H_4?]]+_ (UYI_PKOQ'_ -%B^)7_ (!_"?\ ^=51_P *[\1_]%B^
M)7_@'\)__G54?6<;_P!"RK_X6Y;_ /+@]OC?^A=4_P#"W+O_ ):>E_:H_4?]
M]+_C1]JC]1_WTO\ C7FG_"N_$?\ T6+XE?\ @'\)_P#YU5'_  KOQ'_T6+XE
M?^ ?PG_^=51]9QO_ $+*O_A;EO\ \N#V^-_Z%U3_ ,+<N_\ EIZ7]JC]1_WT
MO^-'VJ/U'_?2_P"->:?\*[\1_P#18OB5_P" ?PG_ /G54?\ "N_$?_18OB5_
MX!_"?_YU5'UG&_\ 0LJ_^%N6_P#RX/;XW_H75/\ PMR[_P"6GI?VJ/U'_?2_
MXT?:H_4?]]+_ (UYI_PKOQ'_ -%B^)7_ (!_"?\ ^=51_P *[\1_]%B^)7_@
M'\)__G54?6<;_P!"RK_X6Y;_ /+@]OC?^A=4_P#"W+O_ ):>E_:H_4?]]+_C
M1]JC]1_WTO\ C7FG_"N_$?\ T6+XE?\ @'\)_P#YU5'_  KOQ'_T6+XE?^ ?
MPG_^=51]9QO_ $+*O_A;EO\ \N#V^-_Z%U3_ ,+<N_\ EIZ7]JC]1_WTO^-'
MVJ/U'_?2_P"->:?\*[\1_P#18OB5_P" ?PG_ /G54?\ "N_$?_18OB5_X!_"
M?_YU5'UG&_\ 0LJ_^%N6_P#RX/;XW_H75/\ PMR[_P"6GI?VJ/U'_?2_XT?:
MH_4?]]+_ (UYI_PKOQ'_ -%B^)7_ (!_"?\ ^=51_P *[\1_]%B^)7_@'\)_
M_G54?6<;_P!"RK_X6Y;_ /+@]OC?^A=4_P#"W+O_ ):>E_:H_4?]]+_C1]JC
M]1_WTO\ C7FG_"N_$?\ T6+XE?\ @'\)_P#YU5'_  KOQ'_T6+XE?^ ?PG_^
M=51]9QO_ $+*O_A;EO\ \N#V^-_Z%U3_ ,+<N_\ EIZ7]JC]1_WTO^-'VJ/U
M'_?2_P"->:?\*[\1_P#18OB5_P" ?PG_ /G54?\ "N_$?_18OB5_X!_"?_YU
M5'UG&_\ 0LJ_^%N6_P#RX/;XW_H75/\ PMR[_P"6GI?VJ/U'_?2_XT?:H_4?
M]]+_ (UYI_PKOQ'_ -%B^)7_ (!_"?\ ^=51_P *[\1_]%B^)7_@'\)__G54
M?6<;_P!"RK_X6Y;_ /+@]OC?^A=4_P#"W+O_ ):>E_:H_4?]]+_C1]JC]1_W
MTO\ C7FG_"N_$?\ T6+XE?\ @'\)_P#YU5'_  KOQ'_T6+XE?^ ?PG_^=51]
M9QO_ $+*O_A;EO\ \N#V^-_Z%U3_ ,+<N_\ EIZ7]JC]1_WTO^-'VJ/U'_?2
M_P"->:?\*[\1_P#18OB5_P" ?PG_ /G54?\ "N_$?_18OB5_X!_"?_YU5'UG
M&_\ 0LJ_^%N6_P#RX/;XW_H75/\ PMR[_P"6GI?VJ/U'_?2_XT?:H_4?]]+_
M (UYI_PKOQ'_ -%B^)7_ (!_"?\ ^=51_P *[\1_]%B^)7_@'\)__G54?6<;
M_P!"RK_X6Y;_ /+@]OC?^A=4_P#"W+O_ ):>E_:H_4?]]+_C1]JC]1_WTO\
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M-T[0_%OQ%TF/4--\-?M:ZKX@\)^'-+^(/Z_44 ?E]\=K/]M >-?CQ<?!2_\
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MQ/8YU_T'Y=_X:Z__ ,] ]CG'_0?@/_#95_\ GH>S?\+R\!_\]O%7_AL_B?\
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ML<X_Z#\!_P"&RK_\]#R;_A>7@/\ Y[>*O_#9_$__ .8^C_A>7@/_ )[>*O\
MPV?Q/_\ F/KUG[)#Z'\Q_A1]DA]#^8_PH]CG7_0?EW_AKK__ #T#V.<?]!^
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MZA:KJ?A[6=$\3:)<3VL=MKWA77M \4Z++?>']=TG4;P]CG7_ $'Y=_X:Z_\
M\] ]CG'_ $'X#_PV5?\ YZ&'_P +R\!_\]O%7_AL_B?_ /,?7"^/O$?[/?Q5
MT>#P_P#$[P-9_$70K74(]6M=%\>? ?Q?XQTBVU2*VNK*/4K?3?$?P^U*RAOT
MLKZ]LTO(H$N4M;RZ@258[B57^D_LD/H?S'^%>$_'KXRVOP.TCP7?)X(\0>/M
M3\<^,KSP=H^AZ!K?@/PV\4VE?#KX@?%'5]3U37_B/XL\%^%-)TNP\+?#;Q [
M7-_KD DOWT^T;R(+F>_LSV.=?]!^7?\ AKK_ /ST#V.<?]!^ _\ #95_^>AQ
M&JC]ES7K3Q#I^N_"SP[K>G>+1X:7Q5IVK_LZ>(-2L?$R^"[5;'P<OB"VO/AK
M-%K2^$K)([/PPNI"Y&@6L:6VDBT@41C9T'Q)\ /"M[;:EX7\'1^&M1LO"^D>
M![34/#WP+\8:+?6W@GP_--/H'@Z"\TWX>VMS!X4T26XGDTCP[#+'H^G/-,]G
M90M(Y,?PY_:G^"/Q$T*WU^V\7Z9H<-Y;?":[M-.\07MC8:X8/C>?!]G\-8M0
MTF*YNY=*U?Q#XC\<:!X130;F5M3M?$-]I]O<Q1P:QH]Q?9UM^V'^SIJNL?#?
M1/#7CF3Q=<?%+Q_!\.O#-UX5\.^(]<TY-5O_ (?^)_B9H6N:O?6FD_9M,\!^
M*_"'A/4]5\&?$*5Y/!_BZS:'5O#NKZGH$&IZMIY['.O^@_+O_#97_P#GH'L<
MX_Z#\!_X;*O_ ,]#U#_A>7@/_GMXJ_\ #9_$_P#^8^C_ (7EX#_Y[>*O_#9_
M$_\ ^8^N5\(?M#?#OX@?$/P]X \$R7>NOKG@SXD>*[O56MKO19?#=[\-/$7P
MJT+4_"OB7PUK]EI?BC0]>U*U^+7AWQ+I4&JZ59?:_#,MEKD"SZ3KNB7][@6G
M[6WP'U3Q3X.\+:)XBUW73X[\"?$_XD^&?$>B>!?&NJ>$-5\(?"5O +>)-6L/
M$5IH#V6I66K67Q)\,:IX(U32?[2T;QQI]W%/X8U'4FU#0H=:/8YU_P!!^7?^
M&NO_ //0/8YQ_P!!^ _\-E7_ .>AZ3_PO+P'_P ]O%7_ (;/XG__ #'T?\+R
M\!_\]O%7_AL_B?\ _,?7D'C']M7]F?P;X?N?$,_Q"/B!;'PSX;\8W^A>#/#?
MB;Q=XLTWPUXJ^)5W\'])U36?"^BZ1<:SH*/\2M,U[P9=6>OVND:E8>(?"WBO
M2+FS&I>'-8M++V+2/C!\*=;\/>.O%-CXVT=/#'PU?Q!'XV\6ZB+K1?"N@)X4
M343XIO;CQ#K5MI^BW6F>%9]&US3_ !/JNGW]WIF@ZQX?\0Z)JMU9:QH6KV%B
M>QSK_H/R[_PUU_\ YZ!['./^@_ ?^&RK_P#/09_PO+P'_P ]O%7_ (;/XG__
M #'T?\+R\!_\]O%7_AL_B?\ _,?7S!8?MV>&M>\*R^*_"GP%^/WB.W\/>!-1
M^)OQ0T:'0O >B>*OA1X,L?&GQ0\#Q'Q-X9\4_$'0M7USQE?:E\'?B#>I\.?
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ML_B?_P#,?7K/V2'T/YC_  H^R0^A_,?X4>QSK_H/R[_PUU__ )Z!['./^@_
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MO/%'A:UU3UJP_:C_ &<M4UCP?X=LOBQX6DU[QR;&/P_I4DUY;7QN]2\3^)_
MMGIFMV]S8POX4UF7X@>#/%/PX;1/%BZ'K$7Q(T2]^'L]C%XT6/0I#V.=?]!^
M7?\ AKK_ /ST#V.<?]!^ _\ #95_^>AUO_"\O ?_ #V\5?\ AL_B?_\ ,?1_
MPO+P'_SV\5?^&S^)_P#\Q]>L"UA(!(/0>G_Q(_D/I2_9(?0_F/\ "CV.=?\
M0?EW_AKK_P#ST#V.<?\ 0?@/_#95_P#GH>3?\+R\!_\ /;Q5_P"&S^)__P Q
M]'_"\O ?_/;Q5_X;/XG_ /S'UZS]DA]#^8_PH^R0^A_,?X4>QSK_ *#\N_\
M#77_ /GH'L<X_P"@_ ?^&RK_ //0\F_X7EX#_P">WBK_ ,-G\3__ )CZ/^%Y
M> _^>WBK_P -G\3_ /YCZ]9^R0^A_,?X4?9(?0_F/\*/8YU_T'Y=_P"&NO\
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MT*X;PWXI\9^$_"FL3Z3JVIZ=#XC\2^'M(M;^\N==T?[> >0>'?V*?AYX:O\
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MC4H_"6@Z1>>-_&$,/B-]!E\;>,;G4=87PSH^B:39FT,6M76O?0U%% !1110
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M*OBCX\\87M^]U<?M,Z#\4? ,NAZ/X>\'>.9'M],/A]O!SZ3X"T'XD^+]?\-
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M?\0^%](U3P'9-8>'?#Z>%],\-Z)HUS;^&_\ A-/& !]O4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >875O\ $A[NY?3_ !CX(ALW
ME8VMO>?#[Q#?W-O!_P LX[F\A^*MA!=3KN(DN8=/LDE&S%K%L&8OL'Q5_P"A
MW^'?_AM/$_\ \^"O43'&>L:'ZJI_I1Y<?_/-/^^5_P *\^67TYR<I8K,EV5/
M,:]->=U&C*_EM9'&\'%R;]OC]>BS'$02WZ0I6Z_+H>7?8/BK_P!#O\.__#:>
M)O\ Y\%'V#XJ_P#0[_#O_P -IXF_^?!7J/EQ_P#/-/\ OE?\*/+C_P">:?\
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M_9='_H+S?_PZXC_YG#ZE'_H(S'_PZXS_ .5'ZN?V=\6?^AX^'/\ X;3Q3_\
M/BH_L_XL_P#0\?#G_P -IXI_^?%7Q9H7[;1\7_&_PAX/\*W7PTUKX4^*_C-X
MV^&GA_QEX8U,>,?$7CNU\/?#+X4^+='U/PKH>G^+-&O)_"LFL>/-?A\0?%GP
MAHOQ0\#^'K7PQ96/BO3O!VG:Y)XXTS]*/+C_ .>:?]\K_A1_9='_ *"\W_\
M#KB/_F8/J4/^@C,O_#KB_P#Y2>5?V?\ %G_H>/AS_P"&T\4__/BH_L_XL_\
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M5W\.C^RZ/_07F_\ X=:__P SA]2ATQ&8_P#AUQG_ ,J/U6_L[XL_]#Q\.?\
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M/+C_ .>:?]\K_A1_9='_ *"\V_\ #KB/_F8/J4/^@C,O_#KB_P#Y2>5?V?\
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M_9A_;&,7Q*\#VGQ>\"_&?Q]\,_".I^'? FO:/J?P]\#3>-_#EAX<AUW1-/\
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M$,GP_F\,>(+36432(M?\+:]X;UU;6[_M1=:UKZG\N/\ YYI_WRO^%']ET?\
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M^GVE_KEAX-U[X?:WXB/@WQG=^+"?V71_Z"\W_P##KB/_ )G#ZE#_ *",R_\
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M)O#Z>*O&MK8R^')FT#1[/P]IGAG1T7Q3X:LSXE\;^&K'5O$>@Z&;[Q!'Z_\
M";]K7XQ>/?B/\+K#5_AYX(TKP-XM\5^%? .O36:^-9=>GU+Q5\#_ (P?%6S^
M(?A.]U6+3=/3X?WMU\,=!7P]IFNZ#%KFM^%/B79:QJ=_X<USPA'X?\8G]ET?
M^@O-_P#PZXC_ .9@^I0_Z",R_P##KC/_ )4?:_\ 9OQ6R3_PFOPVR<9/_"L?
M$^3CIG_B\/..WI2_V=\6,Y_X3?X;YZ9_X5GXH! ] ?\ A<.0/85ZHJ1L ?*4
M9YP57/L>,CGJ.^#R <@+Y<?_ #S3_OE?\*/[+H_]!>;?^'7$?_,P?4H?]!&9
M?^'7%_\ RD\J_L_XL_\ 0\?#G_PVGBG_ .?%1_9_Q9_Z'CX<_P#AM/%/_P ^
M*O5?+C_YYI_WRO\ A1Y<?_/-/^^5_P */[+H_P#07FW_ (=<1_\ ,P?4H?\
M01F7_AUQ?_RD\J_L_P"+/_0\?#G_ ,-IXI_^?%1_9_Q9_P"AX^'/_AM/%/\
M\^*O5?+C_P">:?\ ?*_X4>7'_P \T_[Y7_"C^RZ/_07FW_AUQ'_S,'U*'_01
MF7_AUQ?_ ,I/*O[/^+/_ $/'PY_\-IXI_P#GQ4?V?\6?^AX^'/\ X;3Q3_\
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M4/\ H(S+_P .N+_^4GE7]G_%G_H>/AS_ .&T\4__ #XJ/[/^+/\ T/'PY_\
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MWOK>YLY9[>3IP,  DD@ $GJ<=SCC)Z\4M% !1110 4444 %%%% !1110 4G
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MD?\ 02L_^_Z?XT?6<-_T$X;_ ,*<-_\ - <\/YZ?_@RE_P#+34HK+_MO2/\
MH)6?_?\ 3_&C^V](_P"@E9_]_P!/\:/K.&_Z"<-_X4X;_P": YX?ST__  92
M_P#EIJ45E_VWI'_02L_^_P"G^-']MZ1_T$K/_O\ I_C1]9PW_03AO_"G#?\
MS0'/#^>G_P"#*7_RTU**R_[;TC_H)6?_ '_3_&C^V](_Z"5G_P!_T_QH^LX;
M_H)PW_A3AO\ YH#GA_/3_P#!E+_Y::E%9?\ ;>D?]!*S_P"_Z?XT?VWI'_02
ML_\ O^G^-'UG#?\ 03AO_"G#?_- <\/YZ?\ X,I?_+34HK+_ +;TC_H)6?\
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M;>,==FEMI_%?B[6KJVM);1? 7['?[//PJU_PMI.@(MC-IOCSQ'\3?!7@^8>
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M^A=EW_AMRW_YWB_LW ?] .!_\(,!_P#,)^?7QO\ BQ\&O@K\7OAO\*;[X&^
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M=G1CX9OY?#?B'PWIGCCQ$ND:OX.O_#JWTLNE#Q;9>*+?P[H%OIE&;]C;X1W
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M:NU'P[^#/PO^!'AX)=-#"P'_  @OPA\(_;MPD>\UD:IJSO&^I-9VA_9F6?\
M0MRV_?\ L[+OR_L^P?V=E_\ T 8#_P (,!_\PG4_\*D^&'_1-_ 7_A%^&_\
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M-X>^,_A4Z'H7B#0_BA9^,;2Y\2W3_LS+/^A;EW_ANR[_ .=^GR8?V=@/^@#
M?^$& _\ F$X7X??&7]D/XAZ=KM[:>$=%\-3^'_B-J?PPOM)\;_!&^\)ZPWB"
MU^/VL_LSZ->6-AJWA&%]0T'Q=\6]'ET'P[J]H9H 9C#KBZ/?Z7KUII?.>%OV
MA?V/_%OQ)U_P/8^&? =GH6F^!?A_XW\/_$'5_AO)HGAGQS;>.+3]H[7WD\)7
M.N>!M,L]<\)6'@?]FCQOXWT?XE:1J>I>!O&VBI=R>%-6OQH]PT_?7G[$?PSN
MO$,.OIXD^)]F@^)-S\3K_0++Q/HD6@:YJ+?M!6'[5&G^&-967PQ-K%UX1T;X
M[0Z[XSTRU35H=92T\:^*?!%[K>H?#Z?2/"^C>=>)/^"?OA&3PW8>!_#FO^*M
M4\,ZM)^S[X"U^3Q[XTN[^Y\"?L\_LZ>*/B)XM\+_  M^&FGZ%X?TN35'\1:/
M\0_%OP/\3:[XO\0+XLUKX6>.-3U+QIXT\?:AX8L/#7B _LS+/^A;EW_ANR[3
M_P QX?V=E_\ T 8#_P (,!_\PGI/COXA?LJ> +!;O4_!FD:O?3_";Q'\;;;P
M_P"$?@5K/BWQ"/ASX9T&]\0W.OZMIFA>![Y_"::I!87&E^&K?QG)X<F\3>)8
MW\+:(E[XACETY.=F^-O[&FF:7IFI^)M T/P4NK_#31?BS8V_C?X ^*O"\\W@
M[7-2\$Z+'-:MJOPYM;;5-8TC6OB-X(TGQ+X;T>XU'Q%X7O/$VDC7]*T^*[CF
M;VOXL_LX^!OC+XS\#^,/&TVOWP\ Z?XNL-'T'3[C0M*L+@>.?#.M^#?$4EUX
MAM=!3XC6,-]X<U^_L+[1?#WCG1/#.OJFG2>)]#UN;1='>T\2TS_@GY\'+/QH
MGC_4M=^)GB7Q7_8?A+1)M:U[7_"W]H70\(ZG\!]4@U"^O]%\&Z/J-[-J=W^S
MA\,I[G2+B\E\*Z2UOXD_X1'P_P"%Y/%WB"2^/[,RS_H6Y=_X;LN[_P#8O[:?
MCN']G9?_ - & _\ "# ?_,)T7@GQ5\%/BC!\9H?AO\#)M7\0?!CQ':>#=0T#
MQ?\ !4?"I_$WB?4O 'A+X@Z9::#J'Q(\*^&[9K:73O&6DV.IW5RD5QHM\L_V
M[3(X+C1I=6^9S^VG^R%I'@SQ[XE\>?#SX7_#W6_!/PEUWXG:;X0\6:A\%M(U
M#XGW?A?XC?'OX5ZQX:^$5WJ5Y8Q^/[2_\3? /4-3\&^+=.M;?3/%GA'X@?#G
M6H+.QN-<ETZW^W?$W[.?AKQ'H?[0'A\^)/'.C:9^T?>VNJ>-H=#U?1+>71M6
MC\#>%_AYJ-_X1FO_  ]J+6:>(O"_@SPYI_B/1==_X2+PUJ!L[R6+1;8:YX@C
MU;&B_99\'2>$_B%X4\0Z_P"-O&(^*/P5TSX ^+=;U.?P5X?U)OASH6H_%>]\
M/V6C:;\/?!W@CPAX:O=$M?C'XFT6QG\/^%K.WBT;3/#4<EI=7FE37.H+^S,L
M_P"A;EW_ (;LN_\ G?\ (?\ 9V7_ /0!@/\ P@P'_P P?U\SPKXB_&#X<?"]
M?VD_^$@_9.75I_V=OAGI_P 8I['PAIOP4UF_\7?#C4=1^(.G1:VW]IZSX>TW
MP9?K!\-/$OBD:)XCU);Z_P#!J6UUHB:KXL36/!NC?9H^$GPRP-WPW\ [N^/!
MGALC/L?[+&1[X&?0=*\>M_V4_#D?AS]H#P7J/C[XE>(?!/[2"?$P>.O#6KR?
M#F'^SIOBPNIV?B>]\/\ B?0OA[H?CNZOK30M3B\*^&9O&_BWQG%X4\(Z#X9\
M+Z%;P:/H&E06GU2N[:-X ;'S!22H/H"0"0.@)"D]=JYV@_LS+?\ H79=_P"&
MW+?_ )WB>78!_P#,#@/_  @P'_S"><?\*D^&'_1-_ 7_ (1?AO\ ^5E'_"I/
MAA_T3?P%_P"$7X;_ /E97I-%+^R\M_Z%V7?^&W+?_G>+^S<!_P! .!_\(,!_
M\PGFK?";X7JI9OASX!55!9F;P9X;"JH&223IN  .23P!R:\?^+NL_LT?!+PS
MH'BWQYX3\'V^E^*?%OAGP/X6M?#?PH/CKQ#XK\3^+I7&CZ5X4\)>"/"OB+Q5
MXGNAI]OJ'B&_3P_H^HMIGA31?$'B:]1=(T2_N(?JAPQ1PA4.58*70N@8@A2Z
M!XRZ@X+('0L,@.N<C\X/B[^PSJNK_L\S_"7X5^*],M_&%Y\8OA]\5--\8^-;
M35].T[X4:]HVOZ4=4\5_ +PO\*M=^'>E_!/5/#FF17VJZ1HOPY/AZ'QBU]XS
MTCQMK6IZ_P#$_P 6>/W:RS+?^A=ES\O[-RW_ .=X_P"S<!_T X'_ ,(,!_\
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MF\.?%C0_A_\ !W6=5^)EKJ+6D]CHGB;X=ZU<?$RQ\86<'@'XCW/A3PWI6C>
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M "LH_P"%2?##_HF_@+_PB_#?_P K*])HI?V7EO\ T+LN_P##;EO_ ,[P_LW
M?] .!_\ "# ?_,)YM_PJ3X8?]$W\!?\ A%^&_P#Y64?\*D^&'_1-_ 7_ (1?
MAO\ ^5E>DT4?V7EO_0NR[_PVY;_\[P_LW ?] .!_\(,!_P#,)YM_PJ3X8?\
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MWFO_  */^9/14'GG_GC/_P!\#_XJCSS_ ,\9_P#O@?\ Q5'S7WK_ #"WFO\
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M?'>H6MQX7@\0P> O$\UA<> / FK6GB:]\8W^@ZSK/@74XS3NO_ E_F+YQ_\
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M>,__ 'P/_BJ/FOO7^86\U_X%'_,GHJ#SS_SQG_[X'_Q5'GG_ )XS_P#? _\
MBJ/FOO7^86\U_P"!1_S)Z*@\\_\ /&?_ +X'_P 51YY_YXS_ /? _P#BJ/FO
MO7^86\U_X%'_ #)Z*@\\_P#/&?\ [X'_ ,51YY_YXS_]\#_XJCYK[U_F%O-?
M^!1_S)Z*@\\_\\9_^^!_\51YY_YXS_\ ? _^*H^:^]?YA;S7_@4?\R>BH///
M_/&?_O@?_%4>>?\ GC/_ -\#_P"*H^:^]?YA;S7_ (%'_,GHJ#SS_P \9_\
MO@?_ !5'GG_GC/\ ]\#_ .*H^:^]?YA;S7_@4?\ ,GHJ#SS_ ,\9_P#O@?\
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M (%'_,GHJ#SS_P \9_\ O@?_ !5'GG_GC/\ ]\#_ .*H^:^]?YA;S7_@4?\
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M_"-_&#_HH/P__P##8>(O_GL5Z2-24L1Y1 #A%;>3NR>&7"$%64@HP8AF^7(
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MS\0=<U*R^(FI']ET/^@C,_\ P[8__,/[,H?]!&9_^'7''V*GA[XP,2/^$^\
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MV@OA?X8TVYL/V@_!%AJOQ#&GV5Q\//$WA?QAHVLW'@SXYK9^)? VA']ET/\
MH(S/_P .V/\ \P_LVC_T$YI_X=L>?KO_ ,(W\8/^B@_#_P#\-AXB_P#GL4?\
M(W\8/^B@_#__ ,-AXB_^>Q7Q7^T\?V@/$'QM^''@GX477Q0CUJ?X#^)/$&FW
M7@_XA:!X*^'O@GXMP_$OX9Z?X9^)OQ=TB_U'2Y_B+X#\+V$WBJTU[P#I$7C.
M'Q)H^JWNF'X:>(K^ZT+Q+X'Y)_A%^VI9_$OX,7T7Q)^(D7@J3XG>,O&_Q(>W
MU[3O&NJ:6?\ A>[:IIN@ZS;:S\>OAGX3L?A=K_[.-CH_PQT+0_#GP[^.3>#[
MFY\3^.[CX?Q_&::R^)%T?V70_P"@C,__  [8_P#S#^S:/_03FG_AVQY^@/\
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M!]/Y<51^UR?W$_[^1?\ QVC[7)_<3_OY%_\ ':.:/>/_ ('2_P#EP<R[Q_\
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M>!?&O@3QIK&C?"WQ(VM?$*SNM5M-(T?P-XS^;_%'[/\ \6T3XM6]_P#LK_\
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MI_\ -X?V?A_Y\9_X<LS_ /F\\P_X0?QC_P!%=\5_^$U\-O\ YBZ/^$'\8_\
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M?^'+,_\ YO/,/^$'\8_]%=\5_P#A-?#;_P"8NC_A!_&/_17?%?\ X37PV_\
MF+KT^BC^SL/_ #XW_P .>:?_ #>']GX?^?&?^'+,_P#YO/,/^$'\8_\ 17?%
M?_A-?#;_ .8NC_A!_&/_ $5WQ7_X37PV_P#F+KT^BC^SL/\ SXW_ ,.>:?\
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MV_\ F+KT^BC^SL/_ #XW_P .>:?_ #>']GX?^?&?^'+,_P#YO/,/^$'\8_\
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5BK)RJU9R?G*=2K.<GWE*4F^K9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>14
<FILENAME>xair-20200331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:XAIR="http://beyondair.net/20200331">
    <link:schemaRef xlink:href="xair-20200331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-06to2016-09-07_custom_OptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:OptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-06</xbrli:startDate>
        <xbrli:endDate>2016-09-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-30to2018-01-31_custom_NitricGenIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:JanuaryTwoThousandandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:MarchTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:MarchTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-25to2018-12-26_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-25</xbrli:startDate>
        <xbrli:endDate>2018-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_custom_InvestorOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:JanuaryTwoThousandandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:InvestorOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">XAIR:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-30to2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:ExecutionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:NitricGenIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:ExecutionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-02</xbrli:startDate>
        <xbrli:endDate>2019-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_ClinicalAndMedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-11to2019-02-13_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-11</xbrli:startDate>
        <xbrli:endDate>2019-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MarchTwoThousandEighteenMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:MarchTwoThousandEighteenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ThirdPartyLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:ThirdPartyLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_InsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:InsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_InsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:InsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-30to2018-01-31_custom_ExecutionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:ExecutionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-30to2018-01-31_custom_AfterSixMonthsMember_custom_ExecutionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:ExecutionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:AfterSixMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-30</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-03-31_custom_LicenseAgreementMember_us-gaap_IntellectualPropertyMember_custom_FirstObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">XAIR:FirstObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_LicenseAgreementMember_custom_SecondObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">XAIR:SecondObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_CN">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_HospitalAndClinicSettingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">XAIR:HospitalAndClinicSettingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:UnitedStatesAndChinaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:UnitedStatesAndChinaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:UnitedStatesAndChinaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:UnitedStatesAndChinaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-12to2017-01-13_custom_OptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:OptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-12</xbrli:startDate>
        <xbrli:endDate>2017-01-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_ComputersEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ComputersEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_ClinicalAndMedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ClinicalAndMedicalEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">XAIR:ClinicalAndMedicalEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-08to2018-08-10_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-08</xbrli:startDate>
        <xbrli:endDate>2018-08-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-02</xbrli:startDate>
        <xbrli:endDate>2019-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-09to2018-08-10_custom_LincolnParkCapitalFundLLCMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-09</xbrli:startDate>
        <xbrli:endDate>2018-08-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_UnvestedStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:UnvestedStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_UnvestedStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:UnvestedStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_FoodAndDrugAdministrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:CircassiaPharmaceuticalsPLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">XAIR:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-17</xbrli:startDate>
        <xbrli:endDate>2019-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-21to2013-10-22_custom_PatentLicenseAgreementMember_custom_CareFusionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:PatentLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:CareFusionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-21</xbrli:startDate>
        <xbrli:endDate>2013-10-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_CommonStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:CommonStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_RestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:RestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_RestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">XAIR:RestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-11to2019-12-12_custom_ConcurrentPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">XAIR:ConcurrentPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-11</xbrli:startDate>
        <xbrli:endDate>2019-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-12_custom_ConcurrentPrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">XAIR:ConcurrentPrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ProfessionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ProfessionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-02_us-gaap_AccountingStandardsUpdate201602Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-25to2018-12-26_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:OfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-25</xbrli:startDate>
        <xbrli:endDate>2018-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-30to2019-12-31_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:OfficersEmployeesAndConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-30</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_ProfessionalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ProfessionalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2018-04-02_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2018-04-02_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_custom_DirectorsAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:DirectorsAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-02</xbrli:startDate>
        <xbrli:endDate>2019-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-03_custom_StockPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ValueAddedTaxReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ValueAddedTaxReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_ValueAddedTaxReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">XAIR:ValueAddedTaxReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ContractResearchOrganizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:ContractResearchOrganizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-17_custom_FacilityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FacilityAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NewPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-12</xbrli:startDate>
        <xbrli:endDate>2020-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-09to2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-09</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">XAIR:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-03to2020-03-04_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-03</xbrli:startDate>
        <xbrli:endDate>2020-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-04_custom_TwoThousandThirteenIncentiveOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">XAIR:TwoThousandThirteenIncentiveOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_UnvestedStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:UnvestedStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_WarrantMember_custom_WarrantHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:WarrantHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MarchTwoThousandTwentyMember_custom_LoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:MarchTwoThousandTwentyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">XAIR:LoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-16to2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:FiveTranchesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-16</xbrli:startDate>
        <xbrli:endDate>2020-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:FiveTranchesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_TranchesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:TranchesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-01to2019-03-31_custom_ILMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:ILMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-01to2018-03-31_custom_ILMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">XAIR:ILMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">XAIR:MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-30to2020-04-02_us-gaap_SubsequentEventMember_custom_AtTheMarketEquityOfferingMember_custom_BeyondAirIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">XAIR:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-30to2020-04-02_us-gaap_SubsequentEventMember_custom_AtTheMarketEquityOfferingMember_custom_SalesAgentMember_custom_BeyondAirIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">XAIR:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:SalesAgentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:BeyondAirIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NewPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCorporationLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-12</xbrli:startDate>
        <xbrli:endDate>2020-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NewPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCorporationLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-12to2020-05-13_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NewPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCorporationLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-12</xbrli:startDate>
        <xbrli:endDate>2020-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_LincolnParkCorporationLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCorporationLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-02_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-12to2020-05-13_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:NewPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-12</xbrli:startDate>
        <xbrli:endDate>2020-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ContractManufacturerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:ContractManufacturerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-03_custom_StockPurchaseAgreementMember_custom_DirectorsAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:DirectorsAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_WarrantMember_custom_WarrantHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:WarrantHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FacilityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-01_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_FacilityAgreementMember_custom_ShareBasedCompensationAwardFiveTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">XAIR:ShareBasedCompensationAwardFiveTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_SecondTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:SecondTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-16to2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_SecondTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">XAIR:FacilityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">XAIR:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">XAIR:SecondTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-16</xbrli:startDate>
        <xbrli:endDate>2020-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyAssetMasterLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandAndSeventeenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:EmperyAssetMasterLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyTaxEfficientLpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandAndSeventeenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:EmperyTaxEfficientLpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyTaxEfficientIILpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandAndSeventeenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">XAIR:EmperyTaxEfficientIILpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandAndSeventeenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001641631</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">XAIR:TwoThousandAndSeventeenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>XAIR:Number</xbrli:measure>
    </xbrli:unit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" unitRef="Shares" decimals="INF">58253</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-12-11to2019-12-12_custom_ConcurrentPrivatePlacementMember" unitRef="Shares" decimals="INF">3152985</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_custom_DirectorsAndEmployeesMember" unitRef="Shares" decimals="INF">118254</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-04-01to2020-03-31_srt_ChiefExecutiveOfficerMember" unitRef="Shares" decimals="INF">190437</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-04-01to2020-03-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">129781</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">297000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="Shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">58662</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">20759</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">58662</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20759</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensation contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">3577649</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2399321</us-gaap:ShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember" unitRef="USD" decimals="0">7839495</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">799185</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-12-11to2019-12-12_custom_ConcurrentPrivatePlacementMember" unitRef="USD" decimals="0">10169343</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember_custom_DirectorsAndEmployeesMember" unitRef="USD" decimals="0">610000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-04-01to2020-03-31_srt_ChiefExecutiveOfficerMember" unitRef="USD" decimals="0">699999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-04-01to2020-03-31_custom_EmployeesMember" unitRef="USD" decimals="0">475000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">40000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-08-09to2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">799185</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-04-01to2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">7745012</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="USD" decimals="0">40000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-05-12to2020-05-13_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="USD" decimals="0">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-05-12to2020-05-13_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">1544200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">4024877</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">18092445</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_TreasuryStockMember" unitRef="USD" decimals="0">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">41693578</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">75702915</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">32141110</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-37644572</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-57587076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-30569764</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-2986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1340203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">19829275</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">16934</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">5635836</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6542667</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">6542667</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member_custom_MutualFundsMember" unitRef="USD" decimals="0">893181</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member_custom_MutualFundsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member_custom_MutualFundsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_custom_MutualFundsMember" unitRef="USD" decimals="0">893181</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" decimals="0">5649486</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel1Member_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" decimals="0">5649486</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel2Member_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-03-31_us-gaap_FairValueInputsLevel3Member_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">8688213</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">26681887</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">244872</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">211337</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">9428085</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">27434744</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1164672</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">2256229</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1567638</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1097534</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-03-31_custom_ContractResearchOrganizationMember" unitRef="USD" decimals="0">265000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">5403208</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4871653</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">871</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1606</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">25000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">25000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">41693578</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">75702915</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-04-02" unitRef="USD" decimals="0">6194292</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">-37644572</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-57587076</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-04-02" unitRef="USD" decimals="0">516358</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">9428085</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">27434744</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Liabilities contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">5403208</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9342299</us-gaap:Liabilities>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-18141935</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-3058545</us-gaap:OperatingIncomeLoss>
    <us-gaap:DividendIncomeOperating contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">115716</us-gaap:DividendIncomeOperating>
    <us-gaap:DividendIncomeOperating contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">86748</us-gaap:DividendIncomeOperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-3034</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-1954869</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-3499905</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">159403</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">64787</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">361395</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">729159</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">1091557</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">322633</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-470105</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">276757</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-15250049</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1341052</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">37320235</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">12222774</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">41787299</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">10485610</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">43631</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">56475</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">4423433</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-1793639</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2263294</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2019-03-31_custom_LicenseAgreementMember" unitRef="USD" decimals="0">2263294</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2019-03-31_custom_LicenseAgreementMember_custom_SecondObligationsMember" unitRef="USD" decimals="0">2871063</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">873190</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2020-03-31_custom_LicenseAgreementMember" unitRef="USD" decimals="0">873190</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">263604</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">335358</us-gaap:LoansPayableCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">1390104</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">7724001</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2019-04-01to2020-03-31_custom_LicenseAgreementMember" unitRef="USD" decimals="0">13901049</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2018-04-01to2019-03-31_custom_LicenseAgreementMember" unitRef="USD" decimals="0">607769</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">8714815</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">16056360</us-gaap:CommonStockSharesOutstanding>
    <XAIR:FirstTwoMilestoneOrdinaryShares contextRef="From2019-01-01to2019-03-31_custom_LicenseAgreementMember" unitRef="Shares" decimals="INF">17572815</XAIR:FirstTwoMilestoneOrdinaryShares>
    <XAIR:FirstTwoMilestoneOrdinarySharesValue contextRef="From2019-01-01to2019-03-31_custom_LicenseAgreementMember" unitRef="USD" decimals="0">9987295</XAIR:FirstTwoMilestoneOrdinarySharesValue>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">42366</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">29687</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2019-03-31" unitRef="Pure" decimals="INF">0.033</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-03-31" unitRef="Pure" decimals="INF">0.043</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <XAIR:MilestonesPayment contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_srt_MaximumMember" unitRef="USD" decimals="0">32550000</XAIR:MilestonesPayment>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">8714815</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">16056360</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">-1.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">-0.77</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">11506212</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">8498525</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <XAIR:RevenueRecognitionMilestoneMethodRevenueRecognized1 contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember" unitRef="USD" decimals="0">31500000</XAIR:RevenueRecognitionMilestoneMethodRevenueRecognized1>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-1390104</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2263294</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:LoansPayable contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">292500</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">374570</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember" unitRef="USD" decimals="0">25000000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_TranchesMember" unitRef="USD" decimals="0">5000000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_SecondTrancheMember" unitRef="USD" decimals="0">5000000</us-gaap:LoansPayable>
    <XAIR:PaymentsInCashDiscountedPercentage contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember" unitRef="Pure" decimals="INF">0.05</XAIR:PaymentsInCashDiscountedPercentage>
    <XAIR:RevenueAllocatedToPerformanceObligations contextRef="From2019-01-01to2019-03-31_custom_LicenseAgreementMember_us-gaap_IntellectualPropertyMember_custom_FirstObligationsMember" unitRef="USD" decimals="0">7116232</XAIR:RevenueAllocatedToPerformanceObligations>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">144000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-03-31_custom_VendorMember" unitRef="USD" decimals="0">144000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">240000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-03-31_custom_VendorMember" unitRef="USD" decimals="0">240000</us-gaap:DueToRelatedPartiesCurrent>
    <XAIR:OnetimeRoyaltyPercentage contextRef="AsOf2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_US" unitRef="Pure" decimals="INF">0.05</XAIR:OnetimeRoyaltyPercentage>
    <XAIR:OnetimeRoyaltyPercentage contextRef="AsOf2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_CN" unitRef="Pure" decimals="INF">0.05</XAIR:OnetimeRoyaltyPercentage>
    <XAIR:RoyaltyGrossProfitAmount contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_US" unitRef="USD" decimals="0">50000000</XAIR:RoyaltyGrossProfitAmount>
    <XAIR:RoyaltyGrossProfitAmount contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_CN" unitRef="USD" decimals="0">20000000</XAIR:RoyaltyGrossProfitAmount>
    <us-gaap:PaymentsForRoyalties contextRef="From2018-01-30to2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember" unitRef="USD" decimals="0">100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_US" unitRef="USD" decimals="0">12600000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_country_CN" unitRef="USD" decimals="0">1050000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_HospitalAndClinicSettingsMember" unitRef="USD" decimals="0">8400000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2013-10-21to2013-10-22_custom_PatentLicenseAgreementMember_custom_CareFusionMember" unitRef="USD" decimals="0">50000</us-gaap:PaymentsForRoyalties>
    <XAIR:AnnualGrossProfitRoyaltyPercentage contextRef="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember" unitRef="Pure" decimals="INF">0.14</XAIR:AnnualGrossProfitRoyaltyPercentage>
    <XAIR:AnnualGrossProfitRoyaltyPercentage contextRef="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember" unitRef="Pure" decimals="INF">0.15</XAIR:AnnualGrossProfitRoyaltyPercentage>
    <XAIR:AnnualGrossProfitRoyaltyPercentage contextRef="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember_srt_MaximumMember" unitRef="Pure" decimals="INF">0.20</XAIR:AnnualGrossProfitRoyaltyPercentage>
    <XAIR:AnnualGrossProfitRoyaltyPercentage contextRef="AsOf2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_srt_MaximumMember" unitRef="Pure" decimals="INF">0.19</XAIR:AnnualGrossProfitRoyaltyPercentage>
    <XAIR:AnnualGrossProfitRoyaltyAmount contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" decimals="0">100000000</XAIR:AnnualGrossProfitRoyaltyAmount>
    <XAIR:AnnualGrossProfitRoyaltyAmount contextRef="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember_srt_MaximumMember" unitRef="USD" decimals="0">100000000</XAIR:AnnualGrossProfitRoyaltyAmount>
    <XAIR:AnnualGrossProfitRoyaltyAmount contextRef="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_UnitedStatesAndChinaMember" unitRef="USD" decimals="0">100000000</XAIR:AnnualGrossProfitRoyaltyAmount>
    <XAIR:AnnualGrossProfitRoyaltyAmount contextRef="From2019-04-01to2020-03-31_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_srt_MaximumMember" unitRef="USD" decimals="0">100000000</XAIR:AnnualGrossProfitRoyaltyAmount>
    <XAIR:PaymentOfMilestoneOrdinarySharesValue contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember" unitRef="USD" decimals="0">3150000</XAIR:PaymentOfMilestoneOrdinarySharesValue>
    <XAIR:PaymentOfMilestoneOrdinarySharesValue contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_FoodAndDrugAdministrationMember" unitRef="USD" decimals="0">7350000</XAIR:PaymentOfMilestoneOrdinarySharesValue>
    <XAIR:PaymentOfMilestoneOrdinaryShares contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember" unitRef="Shares" decimals="INF">5271844</XAIR:PaymentOfMilestoneOrdinaryShares>
    <XAIR:PaymentOfMilestoneOrdinaryShares contextRef="From2019-12-17to2019-12-18_custom_LicenseAgreementMember_custom_CircassiaPharmaceuticalsPLCMember_custom_FoodAndDrugAdministrationMember" unitRef="Shares" decimals="INF">12300971</XAIR:PaymentOfMilestoneOrdinaryShares>
    <dei:EntityRegistrantName contextRef="From2019-04-01to2020-03-31">Beyond Air, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-04-01to2020-03-31">0001641631</dei:EntityCentralIndexKey>
    <dei:DocumentPeriodEndDate contextRef="From2019-04-01to2020-03-31">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2019-04-01to2020-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-04-01to2020-03-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2019-04-01to2020-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-04-01to2020-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2019-04-01to2020-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2019-04-01to2020-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-04-01to2020-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2019-04-01to2020-03-31">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2019-04-01to2020-03-31">false</dei:EntityShellCompany>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-04-01to2020-03-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2019-04-01to2020-03-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">128757</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-04-02_us-gaap_AccountingStandardsUpdate201602Member" unitRef="USD" decimals="0">258605</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">69342</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">131581</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">7839495</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">23112</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">200923</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-04-02_us-gaap_AccountingStandardsUpdate201602Member" unitRef="USD" decimals="0">264570</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-03-31" unitRef="Pure" decimals="INF">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-04-02_us-gaap_AccountingStandardsUpdate201602Member" unitRef="Pure" decimals="INF">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-03-31">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-04-02_us-gaap_AccountingStandardsUpdate201602Member">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">738234</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1357137</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">25465111</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:LicensedRightToUseTechnology contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">495000</XAIR:LicensedRightToUseTechnology>
    <XAIR:LicensedRightToUseTechnology contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">412763</XAIR:LicensedRightToUseTechnology>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">8874113</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">8859217</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-04-01to2019-03-31_custom_CommonStockWarrantsMember" unitRef="Shares" decimals="INF">6143405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-04-01to2020-03-31_custom_CommonStockWarrantsMember" unitRef="Shares" decimals="INF">5173724</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-04-01to2019-03-31_custom_CommonStockOptionsMember" unitRef="Shares" decimals="INF">2375812</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-04-01to2020-03-31_custom_CommonStockOptionsMember" unitRef="Shares" decimals="INF">3053589</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-04-01to2019-03-31_custom_RestrictedSharesMember" unitRef="Shares" decimals="INF">340000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-04-01to2020-03-31_custom_RestrictedSharesMember" unitRef="Shares" decimals="INF">646800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">25500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NumberOfOperatingSegments contextRef="From2019-04-01to2020-03-31" unitRef="Integer" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2018-03-31" unitRef="USD" decimals="0">154300</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">154300</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
    <XAIR:IntangibleAssetsMilestonePayments contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">1800000</XAIR:IntangibleAssetsMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-04-01to2020-03-31">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <XAIR:NonrefundableUpfrontFee contextRef="From2013-10-21to2013-10-22_custom_PatentLicenseAgreementMember_custom_CareFusionMember" unitRef="USD" decimals="0">150000</XAIR:NonrefundableUpfrontFee>
    <XAIR:RoyaltyPercentage contextRef="From2013-10-21to2013-10-22_custom_PatentLicenseAgreementMember_custom_CareFusionMember" unitRef="Pure" decimals="INF">0.05</XAIR:RoyaltyPercentage>
    <us-gaap:AcquisitionCosts contextRef="From2016-09-06to2016-09-07_custom_OptionAgreementMember" unitRef="USD" decimals="0">25000</us-gaap:AcquisitionCosts>
    <XAIR:PaymentsForDevelopmentAndMilestonePayment contextRef="From2017-01-12to2017-01-13_custom_OptionAgreementMember" unitRef="USD" decimals="0">500000</XAIR:PaymentsForDevelopmentAndMilestonePayment>
    <XAIR:MilestonePayments contextRef="From2017-01-12to2017-01-13_custom_OptionAgreementMember" unitRef="USD" decimals="0">87000000</XAIR:MilestonePayments>
    <XAIR:SalesRelatedMilestonesPayments contextRef="From2017-01-12to2017-01-13_custom_OptionAgreementMember" unitRef="USD" decimals="0">83000000</XAIR:SalesRelatedMilestonesPayments>
    <XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized contextRef="From2018-01-30to2018-01-31_custom_NitricGenIncMember" unitRef="USD" decimals="0">2000000</XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized contextRef="From2018-01-30to2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember" unitRef="USD" decimals="0">100000</XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized contextRef="From2018-01-30to2018-01-31_custom_ExecutionAgreementMember" unitRef="USD" decimals="0">18000000</XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized contextRef="From2018-01-30to2018-01-31_custom_AfterSixMonthsMember_custom_ExecutionAgreementMember" unitRef="USD" decimals="0">1500000</XAIR:RevenueRecognitionMilestoneMethodRevenuesRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember" unitRef="Shares" decimals="INF">191067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-03-04_custom_TwoThousandThirteenIncentiveOptionPlanMember" unitRef="Shares" decimals="INF">4100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <XAIR:OptionsToPurchaseCommonStockValue contextRef="AsOf2018-01-31_custom_NitricGenIncMember_custom_ExecutionAgreementMember" unitRef="USD" decimals="0">295000</XAIR:OptionsToPurchaseCommonStockValue>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2018-03-31">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2018-07-31">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">81001</us-gaap:OperatingLeasePayments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">1357137</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">25465111</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2020-03-31_custom_ComputersEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2020-03-31_us-gaap_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2019-04-01to2020-03-31_custom_ClinicalAndMedicalEquipmentMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2019-04-01to2020-03-31_us-gaap_LeaseholdImprovementsMember">Shorter of term of lease or estimated useful life of the asset</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">77166</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">64787</us-gaap:DepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">42782</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">447377</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">41464</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">5336</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-03-31_custom_ClinicalAndMedicalEquipmentMember" unitRef="USD" decimals="0">357795</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">491008</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_custom_ClinicalAndMedicalEquipmentMember" unitRef="USD" decimals="0">357795</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember" unitRef="USD" decimals="0">73982</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" decimals="0">53895</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">5336</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">202505</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">279671</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2018-08-08to2018-08-10_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">20000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2018-08-09to2018-08-10_custom_LincolnParkCapitalFundLLCMember_srt_MinimumMember" unitRef="USD" decimals="0">10000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2019-04-01to2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">10910804</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2020-03-30to2020-04-02_us-gaap_SubsequentEventMember_custom_AtTheMarketEquityOfferingMember_custom_BeyondAirIncMember" unitRef="USD" decimals="0">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <XAIR:StockIssuancePeriodTerm contextRef="From2018-08-08to2018-08-10_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">P3Y</XAIR:StockIssuancePeriodTerm>
    <XAIR:StockPurchaseCommitment contextRef="AsOf2018-08-30_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember_srt_MaximumMember" unitRef="USD" decimals="0">750000</XAIR:StockPurchaseCommitment>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USDPShares" decimals="INF">4.53</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USDPShares" decimals="INF">5.45</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="USDPShares" decimals="INF">0.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_LincolnParkCorporationLLCMember" unitRef="USDPShares" decimals="INF">1.00</us-gaap:SaleOfStockPricePerShare>
    <XAIR:NumberOfUnregisteredSharesOfCommonStock contextRef="From2019-06-02to2019-06-03_custom_StockPurchaseAgreementMember" unitRef="Shares" decimals="INF">1583743</XAIR:NumberOfUnregisteredSharesOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-12-12_custom_ConcurrentPrivatePlacementMember" unitRef="USDPShares" decimals="INF">3.66</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-03-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">3.66</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-06-03_custom_StockPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" unitRef="USDPShares" decimals="INF">5.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-03-31_srt_ChiefExecutiveOfficerMember" unitRef="USDPShares" decimals="INF">3.66</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-06-03_custom_StockPurchaseAgreementMember_custom_DirectorsAndEmployeesMember" unitRef="USDPShares" decimals="INF">5.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-04-01to2019-03-31_custom_VendorMember" unitRef="Shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-04-01to2020-03-31_custom_VendorMember" unitRef="Shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-04-01to2019-03-31_custom_VendorMember" unitRef="USD" decimals="0">144000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">3577649</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2550321</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2020-03-31_custom_VendorMember" unitRef="USD" decimals="0">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2020-03-31_custom_ResearchAndDevelopmentExpensesMember" unitRef="USD" decimals="0">687674</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-04-01to2019-03-31_custom_ResearchAndDevelopmentExpensesMember" unitRef="USD" decimals="0">572918</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2020-03-31_custom_GeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">2889975</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-04-01to2019-03-31_custom_GeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">1977403</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-04-01to2020-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">895040</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-04-01to2019-03-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">147719</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2018-12-25to2018-12-26_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">340000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2019-12-30to2019-12-31_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">390000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember_srt_MinimumMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember_srt_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-12-25to2018-12-26_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-12-30to2019-12-31_custom_OfficersEmployeesAndConsultantsMember_us-gaap_RestrictedStockUnitsRSUMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2019-04-01to2020-03-31_custom_TwoThousandThirteenIncentiveOptionPlanMember">Expire up to ten years after the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2018-12-25to2018-12-26_custom_TwoThousandThirteenIncentiveOptionPlanMember" unitRef="Shares" decimals="INF">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2019-02-11to2019-02-13_custom_TwoThousandThirteenIncentiveOptionPlanMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2020-03-03to2020-03-04_custom_TwoThousandThirteenIncentiveOptionPlanMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">815000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">1919000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-03-31_custom_UnvestedStockOptionsMember" unitRef="USD" decimals="0">4899000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-04-01to2020-03-31">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-04-01to2019-03-31">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-04-01to2020-03-31_custom_UnvestedStockOptionsMember">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">4.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-04-01to2020-03-31_custom_UnvestedStockOptionsMember" unitRef="USDPShares" decimals="INF">4.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-04-01to2019-03-31_custom_UnvestedStockOptionsMember" unitRef="USDPShares" decimals="INF">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-03-31" unitRef="Shares" decimals="INF">510904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">2375812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">3053589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">78561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-04-01to2019-03-31" unitRef="Shares" decimals="INF">33333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">1235674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-03-31" unitRef="USDPShares" decimals="INF">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">4.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-04-01to2019-03-31" unitRef="USDPShares" decimals="INF">4.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">4.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-04-01to2020-03-31">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">7952643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9878264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">101619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">6673690</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-04-01to2019-03-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-04-01to2019-03-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-04-01to2020-03-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-04-01to2020-03-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-04-01to2019-03-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-04-01to2019-03-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-04-01to2020-03-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-04-01to2020-03-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-04-01to2019-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-04-01to2019-03-31_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-01to2020-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-01to2020-03-31_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_us-gaap_InvestorMember" unitRef="Shares" id="Foot-00-0" decimals="INF">1531782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_us-gaap_InvestorMember" unitRef="Shares" id="Foot-00-1" decimals="INF">76662</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_custom_PlacementAgentMember" unitRef="Shares" id="Foot-00-2" decimals="INF">7541</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_custom_InvestorOneMember" unitRef="Shares" id="Foot-00-3" decimals="INF">1531782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_MarchTwoThousandEighteenMember_us-gaap_InvestorMember" unitRef="Shares" decimals="INF">1645437</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_ThirdPartyLicenseAgreementMember" unitRef="Shares" decimals="INF">208333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">5173724</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_custom_MarchTwoThousandTwentyMember_custom_LoanMember" unitRef="Shares" decimals="INF">172187</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_us-gaap_InvestorMember" unitRef="USDPShares" id="Foot-00-4" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_us-gaap_InvestorMember" unitRef="USDPShares" id="Foot-00-5" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_custom_PlacementAgentMember" unitRef="USDPShares" id="Foot-00-6" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_custom_InvestorOneMember" unitRef="USDPShares" id="Foot-00-7" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_MarchTwoThousandEighteenMember_us-gaap_InvestorMember" unitRef="USDPShares" decimals="INF">4.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_ThirdPartyLicenseAgreementMember" unitRef="USDPShares" decimals="INF">4.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_MarchTwoThousandTwentyMember_custom_LoanMember" unitRef="USDPShares" decimals="INF">7.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">7.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-01-01_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_srt_MinimumMember" unitRef="USDPShares" decimals="INF">3.66</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_srt_MaximumMember" unitRef="USDPShares" decimals="INF">1.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">788409</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31_custom_ResearchAndDevelopmentExpensesMember" unitRef="USD" decimals="0">324063</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31_custom_ResearchAndDevelopmentExpensesMember" unitRef="USD" decimals="0">266510</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31_custom_InsuranceMember" unitRef="USD" decimals="0">297945</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31_custom_InsuranceMember" unitRef="USD" decimals="0">471982</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31_custom_OtherMember" unitRef="USD" decimals="0">118512</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31_custom_OtherMember" unitRef="USD" decimals="0">131728</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1110534</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31_custom_ProfessionalMember" unitRef="USD" decimals="0">156259</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31_custom_ProfessionalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31_custom_ValueAddedTaxReceivableMember" unitRef="USD" decimals="0">124517</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-03-31_custom_ValueAddedTaxReceivableMember" unitRef="USD" decimals="0">47889</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities contextRef="AsOf2019-07-02" unitRef="USD" decimals="0">100000000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-06-19" unitRef="Shares" decimals="INF">16841555</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentType contextRef="From2019-04-01to2020-03-31">10-K</dei:DocumentType>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">35560</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-920</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <XAIR:OperatingLeaseAgreementExpireDateDescription contextRef="From2018-03-01to2018-03-31">The lease agreement expires in April 2021</XAIR:OperatingLeaseAgreementExpireDateDescription>
    <XAIR:OperatingLeaseAgreementExpireDateDescription contextRef="From2018-07-01to2018-07-31">The lease agreement expires in June 2023</XAIR:OperatingLeaseAgreementExpireDateDescription>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_us-gaap_InvestorMember" id="Foot-00-8">2022-01-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_us-gaap_InvestorMember" id="Foot-00-9">2021-03-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_MarchTwoThousandSeventeenMember_custom_PlacementAgentMember" id="Foot-00-10">2021-03-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_JanuaryTwoThousandandSeventeenMember_custom_InvestorOneMember" id="Foot-00-11">2022-02-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_MarchTwoThousandEighteenMember_us-gaap_InvestorMember">2022-03-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_ThirdPartyLicenseAgreementMember">2024-01-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-03-31_custom_MarchTwoThousandTwentyMember_custom_LoanMember">2025-03-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2019-04-01to2020-03-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">532786</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2018-08-09to2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">297000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2019-04-01to2020-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="Shares" decimals="INF">1420000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="Shares" decimals="INF">80000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:RestrictedCash contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">16934</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">16836</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-03-31_custom_ContractManufacturerMember" unitRef="USD" decimals="0">619000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-03-31_custom_FacilityAgreementMember" unitRef="USD" decimals="0">5000000</us-gaap:RestrictedCash>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">10648920</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">3929558</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">883119</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">6852988</us-gaap:GeneralAndAdministrativeExpense>
    <XAIR:RightOfUseLeaseAssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:RightOfUseLeaseAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">66970</XAIR:RightOfUseLeaseAssetsCurrent>
    <XAIR:DeemedDividendAsResultOfWarrantModification contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-522478</XAIR:DeemedDividendAsResultOfWarrantModification>
    <XAIR:DeemedDividendAsResultOfWarrantModification contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8714815</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16056360</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8397056</us-gaap:SharesOutstanding>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31" unitRef="USD" id="Foot-01-0" decimals="0">5677934</XAIR:CumulativeAdjustment>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2018-04-02_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6194292</XAIR:CumulativeAdjustment>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2018-04-02_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-516358</XAIR:CumulativeAdjustment>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" id="Foot-01-1" xsi:nil="true" />
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" id="Foot-01-2" xsi:nil="true" />
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" id="Foot-01-3" decimals="0">6194292</XAIR:CumulativeAdjustment>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" id="Foot-01-4" decimals="0">-516358</XAIR:CumulativeAdjustment>
    <XAIR:CumulativeAdjustment contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" id="Foot-01-5" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">210650</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">8701</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">210644</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8699</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">3478649</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2550321</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3841649</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2550321</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">799185</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">29</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">799156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <XAIR:IncrementalValueOfWarrantsDueToModification contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">522478</XAIR:IncrementalValueOfWarrantsDueToModification>
    <XAIR:IncrementalValueOfWarrantsDueToModification contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:IncrementalValueOfWarrantsDueToModification contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:IncrementalValueOfWarrantsDueToModification contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">522478</XAIR:IncrementalValueOfWarrantsDueToModification>
    <XAIR:IncrementalValueOfWarrantsDueToModification contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-522478</XAIR:DeemedDividendDueToWarrantModification>
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-522478</XAIR:DeemedDividendDueToWarrantModification>
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:DeemedDividendDueToWarrantModification contextRef="From2019-04-01to2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">10169343</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-03-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">P2Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-03-31" unitRef="Shares" decimals="INF">340000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">646800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">67000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">16200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2019-03-31" unitRef="USDPShares" decimals="INF">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">4.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">5.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="From2019-04-01to2020-03-31" unitRef="USDPShares" decimals="INF">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">10169343</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">315</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10169028</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3152985</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:RemainingCommitmentUnderLicenseAgreement contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">754000</XAIR:RemainingCommitmentUnderLicenseAgreement>
    <XAIR:RemainingCommitmentUnderLicenseAgreement contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">303000</XAIR:RemainingCommitmentUnderLicenseAgreement>
    <XAIR:RightOfUseAssetCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">66970</XAIR:RightOfUseAssetCurrent>
    <XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">7839495</XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts>
    <XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">159</XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts>
    <XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7839336</XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts>
    <XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1583743</XAIR:IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares>
    <XAIR:FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">295000</XAIR:FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology>
    <XAIR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">2027240</XAIR:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2019-04-01to2020-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2019-04-01to2020-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityPublicFloat contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">32811314</dei:EntityPublicFloat>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-20096804</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-6588450</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">154300</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">2986</XAIR:CumulativeAdjustmentOne>
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:CumulativeAdjustmentOne contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">2986</XAIR:CumulativeAdjustmentOne>
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1420000</XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares>
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">7745012</XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue>
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">142</XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue>
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7744870</XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue>
    <XAIR:StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringExerciseOfWarrantsShares contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">985694</XAIR:StockIssuedDuringExerciseOfWarrantsShares>
    <XAIR:StockIssuedDuringExerciseOfWarrantsValue contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">3968944</XAIR:StockIssuedDuringExerciseOfWarrantsValue>
    <XAIR:StockIssuedDuringExerciseOfWarrantsValue contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">99</XAIR:StockIssuedDuringExerciseOfWarrantsValue>
    <XAIR:StockIssuedDuringExerciseOfWarrantsValue contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringExerciseOfWarrantsValue contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3968845</XAIR:StockIssuedDuringExerciseOfWarrantsValue>
    <XAIR:StockIssuedDuringExerciseOfWarrantsValue contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">73461</XAIR:StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants>
    <XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7</XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants>
    <XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7</XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants>
    <XAIR:StockIssuedDuringThePeriodValueCashlessExciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringThePeriodSharesVestedRestrictedStock contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">67000</XAIR:StockIssuedDuringThePeriodSharesVestedRestrictedStock>
    <XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7</XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock>
    <XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7</XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock>
    <XAIR:StockIssuedDuringThePeriodValueVestedRestrictedStock contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <XAIR:UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">2075602</XAIR:UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities>
    <XAIR:UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">3498883</XAIR:UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities>
    <XAIR:ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">200000</XAIR:ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology>
    <XAIR:AdoptionOfAccountingStandardsUpdate contextRef="From2019-04-01to2020-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:AdoptionOfAccountingStandardsUpdate contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-2986</XAIR:AdoptionOfAccountingStandardsUpdate>
    <XAIR:AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">4652</XAIR:AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts>
    <XAIR:AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:ProceedsfromIssuanceOfMarketOfferings contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">7745012</XAIR:ProceedsfromIssuanceOfMarketOfferings>
    <XAIR:ProceedsfromIssuanceOfMarketOfferings contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromBankDebt contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">375570</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">292250</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">210650</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">8701</us-gaap:ProceedsFromStockOptionsExercised>
    <XAIR:RightofuseAssets contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">258605</XAIR:RightofuseAssets>
    <XAIR:RightofuseAssets contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:OperatingLeaseLiabilities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">264570</XAIR:OperatingLeaseLiabilities>
    <XAIR:OperatingLeaseLiabilities contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">34934590</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1071490</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">24107974</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">618903</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <XAIR:AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">594979</XAIR:AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity>
    <XAIR:AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:UnsecuredDebt contextRef="AsOf2020-03-17_custom_FacilityAgreementMember" unitRef="USD" decimals="0">25000000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="AsOf2020-03-31_custom_FacilityAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="USD" decimals="0">5000000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="AsOf2020-03-31_custom_FacilityAgreementMember_custom_ShareBasedCompensationAwardFiveTrancheMember" unitRef="USD" decimals="0">5000000</us-gaap:UnsecuredDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">985694</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2019-03-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-03-31_us-gaap_WarrantMember_custom_WarrantHoldersMember" unitRef="Shares" decimals="INF">156154</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">172826</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyAssetMasterLtdMember" unitRef="Shares" decimals="INF">319967</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyTaxEfficientLpMember" unitRef="Shares" decimals="INF">159869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-03-16_custom_TwoThousandAndSeventeenWarrantsMember_custom_EmperyTaxEfficientIILpMember" unitRef="Shares" decimals="INF">252672</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <XAIR:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-04-01to2020-03-31">P9Y2M12D</XAIR:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <XAIR:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-04-01to2019-03-31">P9Y</XAIR:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <XAIR:VendorsResearchAndDevelopment contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">103320</XAIR:VendorsResearchAndDevelopment>
    <XAIR:VendorsResearchAndDevelopment contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">484756</XAIR:VendorsResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">780127</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">476638</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">154300</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">183271</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">71066</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">62084</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">65074</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">5000000</us-gaap:DebtInstrumentFaceAmount>
    <XAIR:AccretionOfInterestExpense contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4562</XAIR:AccretionOfInterestExpense>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember" unitRef="Pure" decimals="INF">0.133</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2019-04-01to2020-03-31_custom_FacilityAgreementMember_custom_LendersMember_us-gaap_WarrantMember" unitRef="USD" decimals="0">594979</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">83117</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">64826</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">64693</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">16279</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">228915</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">27992</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-04-01to2019-03-31_custom_ILMember" unitRef="Pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-04-01to2018-03-31_custom_ILMember" unitRef="Pure" decimals="INF">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2016-12-01to2016-12-31">The Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">18025000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-03-31_custom_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" unitRef="USD" decimals="0">1375000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-03-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">20187000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2010-03-31" unitRef="USD" decimals="0">15726000</us-gaap:OperatingLossCarryforwards>
    <XAIR:UnusedNetOperatingLossCarryforwards contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">19400000</XAIR:UnusedNetOperatingLossCarryforwards>
    <XAIR:OperatingLossCarryforwardsExpirationYears contextRef="From2019-04-01to2020-03-31">March 2018 expire through 2037</XAIR:OperatingLossCarryforwardsExpirationYears>
    <XAIR:OperatingLossCarryforwardsExpirationYears contextRef="From2019-04-01to2020-03-31_us-gaap_StateAndLocalJurisdictionMember">Expiring during the years 2035 to 2020</XAIR:OperatingLossCarryforwardsExpirationYears>
    <XAIR:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.0248</XAIR:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <XAIR:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.0000</XAIR:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.3067</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.3610</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">-0.0139</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">-0.0371</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">-0.0369</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">-0.0477</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">4201000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9017000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">243000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">524000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">120000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">71000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">608000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">880000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <XAIR:DeferredTaxAssetsResearchAndDevelopment contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">550000</XAIR:DeferredTaxAssetsResearchAndDevelopment>
    <XAIR:DeferredTaxAssetsResearchAndDevelopment contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">550000</XAIR:DeferredTaxAssetsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6694000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">12860000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">6694000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">12860000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">241000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <XAIR:DeferredTaxAssetsLeaseLiability contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:DeferredTaxAssetsLeaseLiability contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">56000</XAIR:DeferredTaxAssetsLeaseLiability>
    <XAIR:DeferredTaxAssetsRightofuseAsset contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:DeferredTaxAssetsRightofuseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-56000</XAIR:DeferredTaxAssetsRightofuseAsset>
    <XAIR:FeePecentage contextRef="From2020-03-30to2020-04-02_us-gaap_SubsequentEventMember_custom_AtTheMarketEquityOfferingMember_custom_SalesAgentMember_custom_BeyondAirIncMember" unitRef="Pure" decimals="INF">0.03</XAIR:FeePecentage>
    <XAIR:AgreementTermDescription contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember">Over the next 36 months</XAIR:AgreementTermDescription>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember" unitRef="Integer" decimals="INF">10</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <XAIR:PurchaseAgreementDescription contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">The Company entered into a $40 million purchase agreement ("New Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), that replaces the existing $20 million purchase agreement. The New Purchase Agreement provides for the issuance of up to $40 million of the Company's common stock through May 2023 at the Company's discretion.</XAIR:PurchaseAgreementDescription>
    <XAIR:PurchaseAgreementDescription contextRef="From2020-05-12to2020-05-14_us-gaap_SubsequentEventMember_custom_NewPurchaseAgreementMember_custom_LincolnParkCorporationLLCMember">The Purchase Agreement, to direct LPC to purchase up to 80,000 shares of our common stock (each such purchase, a "Regular Purchase") over the 36-month term of the Purchase Agreement; provided, however, that such limit may be increased to up to 100,000 shares if the last closing sale price of our common stock is at least $5.00 on the purchase date, may be increased to up to 120,000 shares if the last closing sale price of our common stock is at least $7.50 on the purchase date, and may be increased to up to 140,000 shares if the last closing sale price of our common stock is at least $10.00 on the purchase date (each subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement). The purchase price for shares of common stock to be purchased by Lincoln Park will be the equal to lesser of (i) the lowest sale price on the purchase date, as reported by Nasdaq, or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during the ten trading days prior to the purchase date. Lincoln Park's obligation under each Regular Purchase shall not exceed $2,000,000. The amount of the regular purchases can be modified upon the mutual agreement of the Company and LPC.</XAIR:PurchaseAgreementDescription>
    <XAIR:TradingVolumePecentage contextRef="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_LincolnParkCorporationLLCMember" unitRef="Pure" decimals="INF">0.30</XAIR:TradingVolumePecentage>
    <XAIR:WeightedAveragePricePecentage contextRef="AsOf2020-05-14_us-gaap_SubsequentEventMember_custom_LincolnParkCorporationLLCMember" unitRef="Pure" decimals="INF">-0.95</XAIR:WeightedAveragePricePecentage>
    <us-gaap:InterestExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">30543</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">1506</us-gaap:InterestExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2019-04-01to2020-03-31" unitRef="Pure" decimals="INF">0.0708</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2018-04-01to2019-03-31" unitRef="Pure" decimals="INF">0.0662</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">70618</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">594979</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">70518</us-gaap:DeferredOfferingCosts>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">154300</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">788409</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1149806</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LongTermLoansPayable contextRef="AsOf2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermLoansPayable contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4339065</us-gaap:LongTermLoansPayable>
    <XAIR:RealizedAndUnrealizedGainLossFromMarketableSecurities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-2075602</XAIR:RealizedAndUnrealizedGainLossFromMarketableSecurities>
    <XAIR:RealizedAndUnrealizedGainLossFromMarketableSecurities contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-3581193</XAIR:RealizedAndUnrealizedGainLossFromMarketableSecurities>
    <us-gaap:RepaymentsOfBankDebt contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">303806</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">28646</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">3968944</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2020-04-01to2020-04-02_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <XAIR:OperatingLeasesRightofuseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">195727</XAIR:OperatingLeasesRightofuseAsset>
    <XAIR:ProceedsFromIssuanceOfCommonStockGross contextRef="From2018-08-09to2019-03-31_custom_StockPurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" unitRef="USD" decimals="0">1344185</XAIR:ProceedsFromIssuanceOfCommonStockGross>
    <XAIR:NumberOfSharesIssuedForExerciseOfWarrants contextRef="From2019-04-01to2020-03-31" unitRef="Shares" decimals="INF">985694</XAIR:NumberOfSharesIssuedForExerciseOfWarrants>
    <XAIR:NumberOfSharesIssuedForExerciseOfWarrants contextRef="From2019-04-01to2020-03-31_us-gaap_WarrantMember_custom_WarrantHoldersMember" unitRef="Shares" decimals="INF">73461</XAIR:NumberOfSharesIssuedForExerciseOfWarrants>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">6166000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <XAIR:FederalTaxBenefitForReversalOfUncertainTaxPositions contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">154300</XAIR:FederalTaxBenefitForReversalOfUncertainTaxPositions>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-16685568</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-4475659</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-34112236</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-2082791</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">20464982</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-6558450</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">-19942504</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31" unitRef="USD" decimals="0">-6558450</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-19942504</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-6558450</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-04-01to2019-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">594979</XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance>
    <XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance contextRef="From2019-04-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance contextRef="From2019-04-01to2020-03-31_us-gaap_TreasuryStockMember" unitRef="USD" xsi:nil="true" />
    <XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance contextRef="From2019-04-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">594979</XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance>
    <XAIR:AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance contextRef="From2019-04-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2020-03-16to2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_FiveTranchesMember">Each tranche shall be repaid in installments commencing June 15, 2023 with all amounts outstanding under any tranche due on March 17, 2025. The first tranche was executed on March 17, 2020 and because the funds were held in escrow as of March 31, 2020 they are classified as restricted cash in the consolidated balance sheet.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-04-01to2020-03-31_us-gaap_MeasurementInputExpectedTermMember">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" unitRef="Pure" decimals="INF">87.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" unitRef="Pure" decimals="INF">87</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="AsOf2020-03-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" unitRef="Pure" decimals="INF">1.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2018-03-16_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">166672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:IncrementalValueOfWarrant contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">522478</XAIR:IncrementalValueOfWarrant>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include&#13;the accounts of the Company and the accounts of its wholly owned subsidiaries. All intercompany balances and transactions have&#13;been eliminated in the accompanying financial statements.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentrations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s license revenue was from&#13;two milestone payments from a terminated license for sales and marketing rights agreement, see Note 11. The Company is seeking&#13;additional partners.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company relies on two vendors to manufacture&#13;its delivery system. The Company is reliant on the vendors for commercial manufacturing of our LungFit&amp;#8482; generator and delivery&#13;systems and nitrogen dioxide filters for both clinical studies and commercial supply, if regulatory approval is received.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentrations of credit risk consist principally of cash and cash equivalents and marketable securities. The Company&#13;maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts in major banks in Israel and the U.S.,&#13;the balances of which, at times, may exceed federally insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has no off-balance-sheet concentration&#13;of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue when we transfer&#13;promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange&#13;for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps:&#13;(i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the&#13;transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue&#13;when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each&#13;contract, assess whether each promised good or service is distinct and identify those that are performance obligations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company must use judgment to determine:&#13;a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations&#13;are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone&#13;selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.&#13;The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included&#13;in the transaction price. The transaction price is allocated to each performance obligation on an estimated stand-alone selling&#13;price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied,&#13;see, Note 9.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Where a portion of non-refundable up-front&#13;fees or other payments received are allocated to continuing performance obligations under the terms of a license arrangement,&#13;they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are identified as components&#13;of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker&#13;in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed&#13;our business as one segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses are charged&#13;to the statement of operations as incurred. Research and development expenses include salaries, costs incurred by outside laboratories,&#13;manufacturer&amp;#8217;s, consultants, accredited facilities in connection with clinical trials and preclinical studies and stock&#13;based-compensation.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Foreign Exchange Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BA Ltd.&amp;#8217;s operations are in Israel and&#13;Beyond Air&amp;#8217;s operations are in the United States. The Company&amp;#8217;s management believes that the U.S. dollar is the currency&#13;of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.&#13;Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company&amp;#8217;s transactions and balances denominated&#13;in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to U.S. dollars&#13;in accordance with the Accounting Standards Board Codification Topic 830, &amp;#8220;Foreign Currency Matters&amp;#8221;.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures the cost of employee and&#13;non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&#13;Fair value for restricted stock awards is valued using the closing price of the Company&amp;#8217;s stock on the date of grant. That&#13;cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite&#13;service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model.&#13;The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity&#13;instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and&#13;does not anticipate paying dividends in the foreseeable future. Due to the Company&amp;#8217;s limited trading history, the Company&#13;utilizes an implied volatility based on an aggregate of guideline companies. In 2020, the Company began to blend its historical&#13;volatility with the peer group in order to obtain expected volatility. The peer companies were based similar publicly traded peer&#13;companies. The Company routinely reviews its calculation of volatility based on, the Company&amp;#8217;s life cycle, its peer group,&#13;and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation expense for options and warrants&#13;granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments&#13;issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to&#13;fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted, was&#13;expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense, depending&#13;upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued ASU No.&#13;2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing accounting&#13;standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee&#13;awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant&#13;date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all non-employee awards became&#13;fixed at the start of the fourth quarter.&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Investment in Marketable Securities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in equity marketable securities&#13;classified available-for-sale are carried at fair value with the changes in unrealized gains and losses recognized in the Company&amp;#8217;s&#13;results in operations. Realized gains and (losses) from the sale of marketable securities are recognized in the statement of operations&#13;using the specific identification method on a trade date basis.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes using&#13;the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences&#13;attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective&#13;tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#13;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities&#13;of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized&#13;when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not&#13;that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future&#13;deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded a valuation allowance to the full extent&#13;of our net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files a U.S. Federal, various state,&#13;and International income tax returns. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing&#13;facts and circumstances. Such adjustment is reflected in the tax provision when appropriate&lt;b&gt;. &lt;/b&gt;The Company will recognize&#13;interest and penalties, if any, related to unrecognized tax benefits in income taxes in the statements of operations. The Company&#13;has recorded a liability in accrued expenses of $0 and $154,300 for uncertain tax positions as of March 31, 2020 and March 31,&#13;2019 and reversed this accrual for the year ended March 31, 2020 which resulted in income, respectively. Tax years 2016 through&#13;2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years&#13;2014 through 2020 remain open.&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic and diluted net loss per share attributable&#13;to common stockholders is computed by dividing the net loss and a deemed dividend from a warrant modification attributable to&#13;common stockholders by the weighted average number of common shares outstanding for the period. The dilutive effect of outstanding&#13;options, warrants, restricted stock and other stock-based compensation awards is reflected in diluted net income (loss) per share&#13;by application of the treasury stock method. The calculation of diluted net income (loss) attributed to common shareholders per&#13;share excludes all anti-dilutive common shares. For periods in which the Company has reported net losses, diluted net loss per&#13;share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because&#13;such common shares are not assumed to have been issued if their effect is anti-dilutive, see Note 8.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2010-03-31" unitRef="Pure" decimals="INF">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">966000</XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward>
    <XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1571000</XAIR:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward>
    <XAIR:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table is the reconciliation of&#13;the presentation and disclosure of financial instruments as shown on the Company&amp;#8217;s consolidated statements of cash flows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended &lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,829,275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,635,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents and restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25,465,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,357,137&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</XAIR:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock>
    <XAIR:DeemedDividendFromWarrantModification contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">522478</XAIR:DeemedDividendFromWarrantModification>
    <XAIR:DeemedDividendFromWarrantModification contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <XAIR:WarrantsDescription contextRef="From2020-03-16to2020-03-17_custom_FacilityAgreementMember_custom_LendersMember_custom_SecondTrancheMember">The warrants that will be issued is up to twenty five percentage of its commitment value divided by the five day the volume weighed average price "(VWAP") prior to utilization date. For the tranches three to five, if any of these tranches are utilized by the Company, the warrants that will be issued is up to ten percentage of its commitment value divided by the five day the VWAP.</XAIR:WarrantsDescription>
    <us-gaap:UseOfEstimates contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and&#13;liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts&#13;of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the&#13;Company&amp;#8217;s evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and&#13;clinical trials, stock-based compensation, warrant fair value determination and associated debt discount and classification within&#13;stockholders&amp;#8217; equity, assumptions associated with revenue recognition, and the determination of deferred tax attributes&#13;and the valuation allowance thereon.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">62875</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38077</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38077</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38077</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38077</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">38077</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">222378</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less&#13;accumulated depreciation and accumulated amortization. Depreciation and amortization is calculated using the straight-line method&#13;over the estimated useful life of the assets as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Seven years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Clinical and medical equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fifteen years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shorter of term of lease or estimated useful life of the asset&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <XAIR:ScheduleOfUsefulLifeOfAssetsTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation and amortization is calculated&#13;using the straight-line method over the estimated useful life of the assets as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computers equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Three years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Seven years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Clinical and medical equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fifteen years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Shorter of term of lease or estimated useful life of the asset&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfUsefulLifeOfAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The expected amortization expense for the next&#13;five year and thereafter is as follows for the year ended March 31,:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;222,378&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;412,763&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <XAIR:LicensedRightToUseTechnologyPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Licensed Right&#13;to Use Technology&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Licensed right to use technology&amp;#160;that&#13;is considered platform technology is recorded as&amp;#160;an intangible asset&amp;#160;which resulted&amp;#160;from the NitricGen transaction,&#13;see Note 11. The intangible asset was valued based upon the fair value of the options issued to NitricGen and the cash paid for&#13;this transaction. The license&amp;#160;also&amp;#160;contains two future milestone additional payments aggregating $1,800,000. The intangible&#13;asset is being amortized on a straight-line method over its estimated useful life of thirteen years.&amp;#160;The expected amortization&#13;expense for the next five year and thereafter is as follows for the year ended March 31,:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;222,378&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;412,763&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:LicensedRightToUseTechnologyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Impairment of Long-Lived&#13;Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assess the impairment of long-lived&#13;assets on an ongoing basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.&#13;Factors we consider that could trigger an impairment review include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant underperformance relative to expected historical or projected future operating results,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant changes in the manner of our use of the acquired assets or the strategy for our overall business,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant negative regulatory or economic trends, and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant technological changes, which would render equipment and manufacturing processes obsolete.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"&gt;Recoverability of assets that will continue to be used in our&#13;operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the&#13;asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated&#13;future costs. There were no events during the reporting periods that were deemed to be a triggering event that would require an&#13;impairment assessment.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Standards&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In July&#13;2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives&#13;and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all entities that&#13;issue financial instruments (for example, warrants or convertible instruments) that include down round features. This ASU relates&#13;to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include&#13;down round features affect entities that present earnings per share in accordance with the guidance in Topic 260. The Company elected&#13;to adopt Update ASU&amp;#160;2017-11 during&amp;#160;the third quarter of 2018, retrospective to outstanding financial instruments with&#13;down round feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital by $6,194,292 and&#13;decreasing accumulated deficit by $516,358 as of April 1, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 1, 2019, the Company adopted Accounting&#13;Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which generally requires lessees to recognize operating&#13;and financing lease liabilities and corresponding right-of-use assets on the balance sheet and to provide enhanced disclosures&#13;surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The Company early adopted the new&#13;guidance using the modified retrospective transition approach and practical expedients to all leases existing at the date of initial&#13;application and not restating comparative periods. See Note 11. As of April 1, 2019, the adoption date, the Company has identified&#13;three operating lease arrangements. The adoption of ASC 842 resulted in the recognition of operating lease liabilities and right-of-use&#13;assets of approximately of&amp;#160;$264,570&amp;#160;and&amp;#160;$258,605,&amp;#160;respectively. The right-of use assets and operating lease&#13;liability is as follows as of March 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;66,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,757&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;195,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liability short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liability long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating lease liabilities and their corresponding&#13;right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments&#13;to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in our leases is&#13;typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed&#13;rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar&#13;term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases&#13;in determining the appropriate incremental borrowing rates. The weighted average discount rate and remaining term on lease obligation&#13;is approximately 8.3% and 3.0 years. Operating lease expense is recognized on a straight-line basis over the lease term and is&#13;included in general and administrative expenses. Amortization expense for finance (capital) leases is recognized on a straight-line&#13;basis over the lease term and is included in general and administrative expenses and research and development expenses, while interest&#13;expense for finance leases is recognized using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"&gt;In August 2018, the FASB&amp;#160;&lt;font style="background-color: white"&gt;issued&#13;ASU 2018-13, &amp;#8220;&lt;/font&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for&#13;Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average of significant&#13;unobservable inputs used to develop Level 3 fair value measurements. The guidance is effective for the Company&amp;#8217;s interim&#13;and annual reporting periods beginning with the Company&amp;#8217;s fiscal year ended March 31, 2021, and early adoption is permitted.&#13;The Company is evaluating the impact of this accounting standard update on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <XAIR:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Standards&amp;#160;Not&#13;Yet Adopted&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"&gt;In December 2019, the Financial Accounting Standards Board&#13;(&amp;#8220;FASB&amp;#8221;) issued ASU No. 2019-12, &amp;#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&amp;#8221;&#13;as part of its initiative to reduce complexity in the accounting standards. The standard eliminates certain exceptions related&#13;to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition&#13;of deferred tax liabilities for outside basis differences. The standard also clarifies and simplifies other aspects of the accounting&#13;for income taxes. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December&#13;15, 2020. Early adoption is permitted. The Company does not anticipate the adoption of this guidance to have a material impact&#13;on its consolidated financial statements and related disclosures.&lt;/p&gt;</XAIR:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock>
    <XAIR:ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The right-of use assets and operating lease&#13;liability is as follows as of March 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;66,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right of use asset long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,757&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;195,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liability short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;69,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating lease liability long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not have any marketable securities&#13;as of March 31, 2020.&amp;#160;As of March 31, 2019, the fair value of the Company&amp;#8217;s marketable securities was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Marketable securities -&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 42%; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Circassia Pharmaceuticals plc (Note 9)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,649,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,649,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Mutual funds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;893,181&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;893,181&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,542,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,542,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment consist of the following&#13;as of March 31, 2020 and March 31, 2019, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Clinical and medical equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;357,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;357,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,895&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;491,008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;447,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(279,671&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(202,505&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;211,337&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;244,872&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested as of April 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;390,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(67,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(16,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of March 31 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;646,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#8217;s options for&#13;the year ended March 31, 2020 and March 31, 2019 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;        Average&lt;br /&gt;&#13;        Exercise&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Price - Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Remaining&lt;br /&gt;&#13;Contractual&lt;br /&gt;&#13;Life- Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate Intrinsic&lt;br /&gt;&#13;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 47%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding as of April 1, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;510,904&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,919,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(20,759&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(33,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,375,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,952,643&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;815,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,027,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(58,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(101,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(78,561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding as of March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,053,589&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,878,264&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable as of March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,235,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,673,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value of options&#13;granted during the year ended March 31, 2020 ad March 31, 2019 was approximately $4.03 and $3.11 per share, respectively, on the&#13;date of grant using the Black-Scholes option pricing model with the following assumption:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the Year Ended &lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the Year Ended &lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk -free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.5% - 3.2 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.5% - 3.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80.7% - 87.5 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80.7% - 84.5 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;687,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;572,918&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,889,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,977,403&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,577,649&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,550,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <XAIR:ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result, the Company recognized the incremental&#13;value of $522,478, as a deemed dividend using the Black-Scholes pricing model with the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 80%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#8217;s outstanding&#13;warrants as of March 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrant Holders&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number Of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Date Of&lt;br /&gt;&#13;Expiration&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 51%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;January 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,531,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;January 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;January 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,531,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;February 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;76,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2017 offering - placement agent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,541&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2018 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,645,437&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Third-party license agreement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;208,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;January 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2020 loan&amp;#160;(see Note 10)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;172,187&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,173,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These warrants have down round protection.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <XAIR:ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of current assets and prepaid expenses&#13;as of March 31,&amp;#160;2020&amp;#160;and March 31,&amp;#160;2019&amp;#160;is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;266,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;324,063&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;297,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Professional&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,259&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value added tax receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;124,517&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,728&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;118,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following potentially dilutive securities&#13;were not included in the calculation of diluted net income (loss) per share attributable to common stockholders because their effect&#13;would have been anti-dilutive for the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,173,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,143,405&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,053,589&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,375,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;646,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,874,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,859,217&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <XAIR:ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result, the Company allocated the fair&#13;market value at the date of grant of the warrant to stockholders&amp;#8217; equity and debt discount valued at $594,979. The Black-Scholes&#13;pricing model was used with the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 80%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;87.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock>
    <XAIR:ScheduleOfFacilityAgreementLoanTabletextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the facility agreemetn loan balance&#13;as of March 31, 2020 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Face value of loan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Debt discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(594,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accretion of interest expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,562&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred offering costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(70,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Facility agreement loan balance&amp;#160;&amp;#8211; March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,339,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfFacilityAgreementLoanTabletextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The components of net loss income before the&#13;provision for income taxes are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Year Ended&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Year Ended&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 51%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Domestic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 21%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(16,685,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,475,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,411,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,082,791&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(20,096,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,558,450&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The tax effects of&#13;temporary differences that gave rise to significant portions of the deferred tax assets were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net operating loss carry forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,017,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,201,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;524,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;243,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Reserves and allowances - foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;880,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;608,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capital&amp;#160;loss&amp;#160;carry forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,571,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;966,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development - foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred Revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;241,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(56,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Lease liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,860,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,694,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(12,860,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,694,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal income tax at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21,00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State income tax, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent items&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective income tax expense rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;A reconciliation of&#13;the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2020 and 2019 as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year&amp;#160;Ended&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 22%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Decreases for the current year&amp;#8217;s tax position&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at the end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <XAIR:ScheduleOfLeaseOtherInformationTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company elected the practical expedient&#13;option and as such these lease payments are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other Information For The Year Ended March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 81%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;81,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average remaining lease term &amp;#8212; operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.0. years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average discount rate &amp;#8212; operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:ScheduleOfLeaseOtherInformationTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity of Lease Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 81%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;83,117&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,826&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;228,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(27,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 ORGANIZATION AND BUSINESS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beyond Air, Inc. (&amp;#8220;Beyond Air&amp;#8221;&#13;or the &amp;#8220;Company&amp;#8221;) was incorporated on April 24, 2015. On June 25, 2019, the Company&amp;#8217;s name was changed to Beyond&#13;Air, Inc. from AIT Therapeutics, Inc. The Company has the following wholly-owned subsidiaries.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beyond Air, Ltd was incorporated in Israel&#13;on May 1, 2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advanced Inhalation Therapies (AIT), a wholly&#13;owned subsidiary of Beyond Air, Ltd which was incorporated on August 29, 2014, in Delaware.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beyond Air Australia Pty Ltd was incorporated&#13;on December 17, 2019 in Australia.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beyond Air Ireland Limited was incorporated&#13;on March 5, 2020 in Ireland.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is an a clinical-stage medical&#13;device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory&#13;conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors. S&lt;font style="background-color: white"&gt;ince&#13;its inception, the Company has devoted substantially all of its efforts to research and development.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is developing a nitric oxide (&amp;#8220;NO&amp;#8221;)&#13;generator and delivery system (the &amp;#8220;LungFit&amp;#8482; system&amp;#8221;) that is capable of generating NO from ambient air. LungFit&amp;#8482;&#13;can generate NO up to 400 parts per million (&amp;#8220;ppm&amp;#8221;) for delivery to a patient&amp;#8217;s lungs. LungFit&amp;#8482; can deliver&#13;NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand&#13;or maintain a constant dose. Our current areas of focus with the LungFit&amp;#8482; are persistent pulmonary hypertension of the newborn&#13;(&amp;#8220;PPHN&amp;#8221;), severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), bronchiolitis (&amp;#8220;BRO&amp;#8221;) and nontuberculous&#13;mycobacteria (&amp;#8220;NTM&amp;#8221;). The Company&amp;#8217;s current product candidates will be subject to premarket reviews and approvals&#13;by the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If&#13;approved, our system will be marketed as a medical device in the United States.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Liquidity Risks and Uncertainty&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The&amp;#160;Company has incurred cash used in&#13;operating activities of&amp;#160;$15.2&amp;#160;million for the year ended March 31, 2020, and has accumulated losses of&amp;#160;$57.6&amp;#160;million.&#13;The Company has&amp;#160;cash,&amp;#160;cash equivalents&amp;#160;and restricted cash&amp;#160;of&amp;#160;$25.5&amp;#160;million as of March 31, 2020.&#13;Based on management&amp;#8217;s current business plan, the Company estimates it will have enough cash for at least one year from the&#13;date of filing these financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s future capital needs and&#13;the adequacy of its available funds beyond one year will depend on many factors, including, but not necessarily limited to, the&#13;actual cost and time necessary for clinical studies and other actions needed to obtain regulatory approval of our medical devices&#13;in development as well as the cost to launch our first product for PPHN, assuming approval of our Premarketing Application (&amp;#8220;PMA&amp;#8221;)&#13;which is expected to be filed in the third quarter of calendar 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company will be required to raise additional&#13;funds through sale of equity or debt securities or through strategic collaboration and/or licensing agreements, to fund operations&#13;and continue our clinical trials until we are able to generate enough product or royalty revenues, if any. Financing may not be&#13;available on acceptable terms, or at all, and our failure to raise capital when needed could have a material adverse effect on&#13;our growth plans, our results of operations and our financial condition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 2, 2020, Beyond Air, Inc. entered&#13;into an At-The-Market Equity Offering for $50 million and utilized the Company&amp;#8217;s shelf registration statement, see Note&amp;#160;14.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 17, 2020, the Company entered into&#13;a $25 million&amp;#160;unsecured&amp;#160;loan facility agreement (the &amp;#8220;Facility Agreement&amp;#8221;) with certain lenders that is unsecured.&amp;#160;As&#13;of March 31, 2020, the Company has drawn down of the first of five tranches of $5 million which is include in restricted cash.&amp;#160;The&#13;Company has the ability to drawn down on&amp;#160;an additional&amp;#160;$5 million tranche&amp;#160;prior to&amp;#160;the&amp;#160;PMA filing,&amp;#160;see&#13;Note 10.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 14, 2020, the Company entered into&#13;a $40 million purchase agreement (&amp;#8220;New Purchase Agreement&amp;#8221;) with Lincoln Park Capital Fund, LLC (&amp;#8220;LPC&amp;#8221;),&#13;that replaces the existing $20 million purchase agreement. The New Purchase Agreement provides for the issuance of up to $40 million&#13;of the Company&amp;#8217;s common stock through May 2023 at the Company&amp;#8217;s discretion., The Company utilized the shelf registration&#13;statement, see Note&amp;#160;14.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include&#13;the accounts of the Company and the accounts of its wholly owned subsidiaries. All intercompany balances and transactions have&#13;been eliminated in the accompanying financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and&#13;liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts&#13;of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company&amp;#8217;s&#13;evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and clinical trials,&#13;stock-based compensation, warrant fair value determination and associated debt discount and classification within stockholders&amp;#8217;&#13;equity, assumptions associated with revenue recognition, and the determination of deferred tax attributes and the valuation allowance&#13;thereon.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Other Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks common to medical&#13;device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary&#13;technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the potential&#13;need to obtain additional financing. The Company is dependent on third party suppliers, in some cases single-source suppliers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There can be no assurance that the Company&amp;#8217;s&#13;product will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured&#13;at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if&#13;at all.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s products require approval&#13;or clearance from the U.S. Food and Drug Administration prior to commencing commercial sales in the United States. There can be&#13;no assurance that the Company&amp;#8217;s products will receive all of the required approvals or clearances. Approvals or clearances&#13;are also required in foreign jurisdictions in which the Company may license or sell its products. If the Company is denied such&#13;approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact on the Company&amp;#8217;s&#13;results of operations, financial position and liquidity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The development of our product candidates could&#13;be further disrupted and adversely affected by the recent outbreak of COVID-19. The spread of SARS CoV-2 from China to other countries&#13;has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020. We have&#13;addressed the impact COVID-19 may have on our business plans and our ability to conduct the preclinical studies and clinical trials&#13;as well as on our reliance on third-party manufacturing and our supply chain. However, there can be no assurance that this analysis&#13;will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences. The extent to which the COVID-19&#13;pandemic and global efforts to contain its spread will impact our operations will depend on future developments, which are still&#13;uncertain and cannot be predicted at this time.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentrations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s license revenue was from&#13;two milestone payments from a terminated license for sales and marketing rights agreement, see Note 9. The Company is seeking additional&#13;partners.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company relies on two vendors to manufacture&#13;its delivery system. The Company is reliant on the vendors for commercial manufacturing of our LungFit&amp;#8482; generator and delivery&#13;systems and nitrogen dioxide filters for both clinical studies and commercial supply, if regulatory approval is received.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Financial Instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject&#13;the Company to concentrations of credit risk consist principally of cash and cash equivalents and marketable securities. The Company&#13;maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts in major banks in Israel and the U.S.,&#13;the balances of which, at times, may exceed federally insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has no off-balance-sheet concentration&#13;of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, restricted cash includes&#13;$5,000,000 of cash in an escrow account from the lenders of the facility agreement loan, See Note 10. Subsequent to March 31, 2020,&#13;the Company received the funds from the escrow account into a cash operating cash. In addition, as of March 31, 2020, restricted&#13;cash includes $619,000 of cash that is designated for a contract manufacturer. This cash is expected be used for material and parts&#13;that require a long lead time. Collateral for vehicle leases are invested in bank deposit accounts which is restricted and as of&#13;March 31, 2020 was $16,836 and as of March 31, 2019 was $16,934, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash equivalents are short-term highly liquid&#13;investments that are readily convertible to cash with original maturities of three months or less at acquisition. Restricted cash&#13;is collateral for vehicle leases and invested in bank deposit accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table is the reconciliation of&#13;the presentation and disclosure of financial instruments as shown on the Company&amp;#8217;s consolidated statements of cash flows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended &lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,829,275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,635,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents and restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25,465,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,357,137&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue when we transfer&#13;promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange&#13;for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps:&#13;(i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the&#13;transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue&#13;when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each&#13;contract, assess whether each promised good or service is distinct and identify those that are performance obligations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company must use judgment to determine:&#13;a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations&#13;are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone&#13;selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.&#13;The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included&#13;in the transaction price. The transaction price is allocated to each performance obligation on an estimated stand-alone selling&#13;price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied,&#13;see, Note 9.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Where a portion of non-refundable up-front&#13;fees or other payments received are allocated to continuing performance obligations under the terms of a license arrangement, they&#13;are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating segments are identified as components&#13;of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker&#13;in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed&#13;our business as one segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses are charged&#13;to the statement of operations as incurred. Research and development expenses include salaries, costs incurred by outside laboratories,&#13;manufacturer&amp;#8217;s, consultants, accredited facilities in connection with clinical trials and preclinical studies and stock based-compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Foreign Exchange Transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BA Ltd.&amp;#8217;s operations are in Israel and&#13;Beyond Air&amp;#8217;s operations are in the United States. The Company&amp;#8217;s management believes that the U.S. dollar is the currency&#13;of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.&#13;Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company&amp;#8217;s transactions and balances denominated&#13;in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to U.S. dollars&#13;in accordance with the Accounting Standards Board Codification Topic 830, &amp;#8220;Foreign Currency Matters&amp;#8221;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company measures the cost of employee and&#13;non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&#13;Fair value for restricted stock awards is valued using the closing price of the Company&amp;#8217;s stock on the date of grant. That&#13;cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite&#13;service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model.&#13;The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity&#13;instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and&#13;does not anticipate paying dividends in the foreseeable future. Due to the Company&amp;#8217;s limited trading history, the Company&#13;utilizes an implied volatility based on an aggregate of guideline companies. In 2020, the Company began to blend its historical&#13;volatility with the peer group in order to obtain expected volatility. The peer companies were based similar publicly traded peer&#13;companies. The Company routinely reviews its calculation of volatility based on, the Company&amp;#8217;s life cycle, its peer group,&#13;and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation expense for options and warrants&#13;granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments&#13;issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to&#13;fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted, was&#13;expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense, depending&#13;upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued ASU No.&#13;2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing accounting&#13;standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee&#13;awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant&#13;date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all non-employee awards became&#13;fixed at the start of the fourth quarter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Investment in Marketable Securities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in equity marketable securities&#13;classified available-for-sale are carried at fair value with the changes in unrealized gains and losses recognized in the Company&amp;#8217;s&#13;results in operations. Realized gains and (losses) from the sale of marketable securities are recognized in the statement of operations&#13;using the specific identification method on a trade date basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less&#13;accumulated depreciation and accumulated amortization. Depreciation and amortization is calculated using the straight-line method&#13;over the estimated useful life of the assets as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 35%"&gt;&lt;font style="font-size: 10pt"&gt;Computers equipment &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 65%"&gt;&lt;font style="font-size: 10pt"&gt;Three years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Furniture and fixtures &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Seven years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Clinical and medical equipment &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Fifteen years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Shorter of term of lease or estimated useful life of the asset&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Licensed Right&#13;to Use Technology&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Licensed right to use technology that is considered&#13;platform technology is recorded as an intangible asset which resulted from the NitricGen transaction, see Note 11. The intangible&#13;asset was valued based upon the fair value of the options issued to NitricGen and the cash paid for this transaction. The license&#13;also contains two future milestone additional payments aggregating $1,800,000. The intangible asset is being amortized on a straight-line&#13;method over its estimated useful life of thirteen years. The expected amortization expense for the next five year and thereafter&#13;is as follows for the year ended March 31,:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38,077&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;222,378&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;412,763&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Impairment of Long-Lived&#13;Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assess the impairment of long-lived&#13;assets on an ongoing basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.&#13;Factors we consider that could trigger an impairment review include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;significant underperformance relative to expected historical or projected future operating results,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;significant changes in the manner of our use of the acquired assets or the strategy for our overall business,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;significant negative regulatory or economic trends, and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;significant technological changes, which would render equipment and manufacturing processes obsolete.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Recoverability of assets that will continue&#13;to be used in our operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to&#13;be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market&#13;growth rates, and estimated future costs. There were no events during the reporting periods that were deemed to be a triggering&#13;event that would require an impairment assessment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes using&#13;the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences&#13;attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective&#13;tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#13;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities&#13;of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized&#13;when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not&#13;that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future&#13;deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded a valuation allowance to the full extent&#13;of our net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files a U.S. Federal, various state,&#13;and International income tax returns. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing&#13;facts and circumstances. Such adjustment is reflected in the tax provision when appropriate&lt;b&gt;. &lt;/b&gt;The Company will recognize&#13;interest and penalties, if any, related to unrecognized tax benefits in income taxes in the statements of operations. The Company&#13;has recorded a liability in accrued expenses of $0 and $154,300 for uncertain tax positions as of March 31, 2020 and March 31,&#13;2019 and reversed this accrual for the year ended March 31, 2020 which resulted in income, respectively. Tax years 2016 through&#13;2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years&#13;2014 through 2020 remain open.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Net Income (Loss) Per Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic and diluted net loss per share attributable&#13;to common stockholders is computed by dividing the net loss and a deemed dividend from a warrant modification attributable to common&#13;stockholders by the weighted average number of common shares outstanding for the period. The dilutive effect of outstanding options,&#13;warrants, restricted stock and other stock-based compensation awards is reflected in diluted net income (loss) per share by application&#13;of the treasury stock method. The calculation of diluted net income (loss) attributed to common shareholders per share excludes&#13;all anti-dilutive common shares. For periods in which the Company has reported net losses, diluted net loss per share attributable&#13;to common stockholders is the same as basic net loss per share attributable to common stockholders, because such common shares&#13;are not assumed to have been issued if their effect is anti-dilutive, see Note 8.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Standards&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In July&#13;2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives&#13;and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all entities that&#13;issue financial instruments (for example, warrants or convertible instruments) that include down round features. This ASU relates&#13;to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include&#13;down round features affect entities that present earnings per share in accordance with the guidance in Topic 260. The Company elected&#13;to adopt Update ASU 2017-11 during the third quarter of 2018, retrospective to outstanding financial instruments with down round&#13;feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital by $6,194,292 and decreasing&#13;accumulated deficit by $516,358 as of April 1, 2018.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 1, 2019, the Company adopted Accounting&#13;Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which generally requires lessees to recognize operating&#13;and financing lease liabilities and corresponding right-of-use assets on the balance sheet and to provide enhanced disclosures&#13;surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The Company early adopted the new&#13;guidance using the modified retrospective transition approach and practical expedients to all leases existing at the date of initial&#13;application and not restating comparative periods. See Note 11. As of April 1, 2019, the adoption date, the Company has identified&#13;three operating lease arrangements. The adoption of ASC 842 resulted in the recognition of operating lease liabilities and right-of-use&#13;assets of approximately of $264,570 and $258,605, respectively. The right-of use assets and operating lease liability is as follows&#13;as of March 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font-size: 10pt"&gt;Right of use asset short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;66,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Right of use asset long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;128,757&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;195,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Operating lease liability short-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Operating lease liability long-term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;131,581&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;200,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating lease liabilities and their corresponding&#13;right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments&#13;to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in our leases is&#13;typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed&#13;rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar&#13;term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases&#13;in determining the appropriate incremental borrowing rates. The weighted average discount rate and remaining term on lease obligation&#13;is approximately 8.3% and 3.0 years. Operating lease expense is recognized on a straight-line basis over the lease term and is&#13;included in general and administrative expenses. Amortization expense for finance (capital) leases is recognized on a straight-line&#13;basis over the lease term and is included in general and administrative expenses and research and development expenses, while interest&#13;expense for finance leases is recognized using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB &lt;font style="background-color: white"&gt;issued&#13;ASU 2018-13, &amp;#8220;&lt;/font&gt;Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for&#13;Fair Value Measurement&amp;#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average of significant&#13;unobservable inputs used to develop Level 3 fair value measurements. The guidance is effective for the Company&amp;#8217;s interim&#13;and annual reporting periods beginning with the Company&amp;#8217;s fiscal year ended March 31, 2021, and early adoption is permitted.&#13;The Company is evaluating the impact of this accounting standard update on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Standards Not&#13;Yet Adopted&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2019, the Financial Accounting&#13;Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2019-12, &amp;#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income&#13;Taxes.&amp;#8221; as part of its initiative to reduce complexity in the accounting standards. The standard eliminates certain exceptions&#13;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the&#13;recognition of deferred tax liabilities for outside basis differences. The standard also clarifies and simplifies other aspects&#13;of the accounting for income taxes. The standard is effective for fiscal years, and interim periods within those fiscal years,&#13;beginning after December 15, 2020. Early adoption is permitted. The Company does not anticipate the adoption of this guidance to&#13;have a material impact on its consolidated financial statements and related disclosures.&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 FAIR VALUE MEASUREMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial instruments primarily&#13;include cash, cash equivalents, restricted cash, marketable&amp;#160;securities,&amp;#160;accounts&amp;#160;payable, loan payable and credit&#13;facility loan.&amp;#160;Due to the short-term nature of cash and accounts payable, the carrying amounts of these assets and liabilities&#13;approximate their fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a&#13;liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance&#13;establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value.&#13;A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets&#13;for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 58px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 1 -&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 2 -&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 3 -&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company does not have any marketable securities&#13;as of March 31, 2020.&amp;#160;As of March 31, 2019, the fair value of the Company&amp;#8217;s marketable securities was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Marketable securities -&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 42%; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Circassia Pharmaceuticals plc (Note 9)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,649,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,649,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Mutual funds&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;893,181&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;893,181&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,542,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,542,667&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment consist of the following&#13;as of March 31, 2020 and March 31, 2019, respectively:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Clinical and medical equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;357,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;357,795&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;42,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,895&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,336&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;491,008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;447,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(279,671&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(202,505&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;211,337&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;244,872&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation and amortization expense for&#13;the year ended March 31, 2020 and March 31, 2019 was $77,166 and $64,787 respectively&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 SHAREHOLDER&amp;#8217;S EQUITY &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Common stock &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 10, 2018 the Company entered into&#13;a Purchase Agreement with Lincoln Park Financial Corporation (&amp;#8220;LPC&amp;#8221;). The Company may sell and issue LPC and LPC is&#13;obligated to purchase up to $20 million in value of shares of common stock from time to time over three years. The Company also&#13;entered into a registration rights agreement with LPC whereby the Company filed a registration statement with the SEC and the shares&#13;of the Company&amp;#8217;s common stock that may be issued to LPC under the terms of the Purchase Agreement. The Company may direct&#13;LPC, at its sole discretion, and subject to certain conditions, to purchase up to 10,000 shares of common stock on any business&#13;day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased&#13;under certain circumstances provided, however that LPC cannot make any single purchase that exceeds $750,000. The purchase price&#13;of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the&#13;time of sales as described in the Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From the execution of the Purchase Agreement&#13;on August 10, 2018 to March 31, 2019, the Company issued and sold to LPC 297,000 shares of common stock at an average price of&#13;$4.53 per shares for net proceeds of $1,344,185. Net proceeds after offering costs for these transactions were $799,185. For the&#13;year ended March 31, 2020 the Company issued and sold to LPC 1,420,000 shares of common stock at an average price of $5.45 per&#13;shares for net proceeds of $7,745,012. There is $10,910,804 remaining on the Purchase Agreement. This agreement was replaced in&#13;May 2020, see Note 14.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 2, 2019, the SEC declared effective,&#13;the Company&amp;#8217;s Form S-3 shelf registration statement which allows the Company to sell up to $100 million of equity securities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 3, 2019, the Company entered into a&#13;purchase agreement with investors for the issuance of 1,583,743 shares of common stock, resulting in net proceeds of $7,839,495.&#13;The Company&amp;#8217;s CEO invested $300,000 and received 58,253 shares of common stock at $5.15 per share. In addition, certain directors&#13;and employees invested $610,000 for an aggregate of 118,254 shares of common stock, representing a purchase price of $5.15 per&#13;share. The Company registered the shares sold in June 2019 in a registration statement on Form S-3 that was declared effective&#13;in September 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 12, 2019, the Company closed on&#13;an underwritten offering and concurrent private placement of 3,152,985 shares of common stock at $3.66 per share for net proceeds&#13;of $10,169,343. The underwritten offering shares were registered under the Company&amp;#8217;s Form S-3 shelf registration statement.&#13;There were 532,786 common stock that were sold in a private placement and subsequently registered under an effective Form S-1 on&#13;January 23, 2020. In addition, the Company&amp;#8217;s CEO invested $699,999 for 190,437 shares of common stock at $3.66 per share.&#13;In addition, certain employees participated in this offering by investing $475,000 and receiving 129,781 shares of common stock&#13;at $3.66 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock to be Issued to a Vendor&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, and March 31, 2019, the&#13;Company was obligated to issue 30,000 shares to a vendor for services related to investor relations. For the year ended March 31,&#13;2020 and March 31, 2019, the Company recorded the fair market value of the shares to be issued and recorded stock-based compensation&#13;of $96,000 and $144,000, respectively. The fair market value of the liability as of March 31, 2020 and March 31, 2019 was $240,000&#13;and $144,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Issuance of Restricted Shares&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 26, 2018, and December 31, 2019,&#13;the Board of directors approved the issuance of 340,000 and 390,000, shares of restricted stock, respectively, to officers, employees&#13;and consultants and the fair value for the restricted stock awards was valued at the closing price of the Company&amp;#8217;s stock&#13;on the date of grant. Restricted stock vests annually over five years. The fair market value of the restricted shares for stock-based&#13;expense is equal to the closing pricing of the Company&amp;#8217;s stock at the date of grant. Stock based compensation for the year&#13;ended March 31, 2020 and March 31, 2019 was $895,040 and $147,719, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Unvested as of April 1, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;390,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested (a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(67,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(16,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of March 31 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;646,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Option Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has an amended and restated Equity&#13;Incentive Option Plan (the &amp;#8220;2013 Plan&amp;#8221;), pursuant to which the Company may award officers, directors, employees, and&#13;non-employees with stock options, restricted stock units and restricted shares of the Company&amp;#8217;s common stock. The vesting&#13;terms of the options issued under the 2013 Plan are generally between two to four years and expire up to ten years after the grant&#13;date. On December 26, 2018 and February 13, 2019, the Board of Directors authorized the increase of an additional 600,000 and 1,000,000&#13;under the 2013 Plan, respectively. On March 4, 2020, the shareholders approved 1,000,000 shares of common stock authorized, resulting&#13;in a total of 4,100,000 shares eligible for issuance under the 2013 Plan. As of March 31, 2020, there are 191,067 shares available&#13;under the 2013 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#8217;s options for&#13;the year ended March 31, 2020 and March 31, 2019 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Of Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;        Average&lt;br /&gt;&#13;        Exercise&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Price - Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted &lt;br /&gt;&#13;Average &lt;br /&gt;&#13;Remaining &lt;br /&gt;&#13;Contractual &lt;br /&gt;&#13;Life- Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate Intrinsic&lt;br /&gt;&#13;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 10pt"&gt;Options outstanding as of April 1, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;510,904&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,919,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(20,759&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(33,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of March 31, 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,375,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,952,643&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;815,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,027,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(58,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(101,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(78,561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding as of March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,053,589&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,878,264&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exercisable as of March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,235,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,673,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, the Company has unrecognized&#13;stock-based compensation expense of approximately $4,899,000, related to unvested stock options and is expected to be expensed&#13;over the weighted average remaining service period of 2.7 years. The weighted average fair value of options granted during the&#13;year ended March 31, 2020 ad March 31, 2019 was approximately $4.03 and $3.11 per share, respectively, on the date of grant using&#13;the Black-Scholes option pricing model with the following assumption:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the Year Ended &lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the Year Ended &lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk -free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.5% - 3.2 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.5% - 3.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80.7% - 87.5 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;80.7% - 84.5 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5-10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes the components of&#13;stock-based compensation expense which includes common stock, stock options, warrants and restricted stock in the consolidated&#13;statements of operations for the year ended March 31, 2020 and March 31, 2019, respectively&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;687,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;572,918&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,889,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,977,403&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,577,649&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,550,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A modification of the exercise price to the&#13;January 2017 and March 2017 investor warrants from $4.25 per share to $3.66 per share was triggered by the December 2019 equity&#13;offering described above. As a result, the Company recognized the incremental value of $522,478, as a deemed dividend using the&#13;Black-Scholes pricing model with the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#8217;s outstanding&#13;warrants as of March 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Warrant Holders&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number Of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise &lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Date Of&lt;br /&gt;&#13;Expiration&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 49%"&gt;&lt;font style="font-size: 10pt"&gt;January 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,531,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 14%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%"&gt;&lt;font style="font-size: 10pt"&gt;January 2022 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;January 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,531,782&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;February 2022 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2017 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;76,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2017 offering - placement agent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,541&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2021 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2018 offering - investors&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,645,437&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;March 2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Third-party license agreement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;208,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;January 2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;March 2020 loan (see Note 10)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;172,187&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;March 2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,173,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;These warrants have down round protection.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the year ended March 31, 2020, there were&#13;985,694 warrants exercised for $3,968,944 and 985,694 common stock were issued at an average price per share of $4.03 per share.&#13;Warrant holders exercised 156,154 warrants on a cashless basis and the Company issued 73,461 common stock to the warrant holders.&#13;For the year ended March 31, 2019, no warrants were exercised.&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <XAIR:CurrentAssetsAndPrepaidExpensesTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 CURRENT ASSETS AND PREPAID EXPENSES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of current assets and prepaid expenses&#13;as of March 31,&amp;#160;2020&amp;#160;and March 31,&amp;#160;2019&amp;#160;is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;266,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;324,063&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,182&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;297,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Professional&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,259&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Value added tax receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;124,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;47,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;131,728&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;118,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,149,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;788,409&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</XAIR:CurrentAssetsAndPrepaidExpensesTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the accrued expenses as of March&#13;31, 2020 and March 31, 2019 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Vendors &amp;#8211; research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;484,756&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;103,320&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;476,638&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;780,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Income taxes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Employee salaries and benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;71,066&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;183,271&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;65,074&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,097,534&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,283,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 BASIC AND DILUTED NET INCOME (LOSS)&#13;PER COMMON SHARE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following potentially dilutive securities&#13;were not included in the calculation of diluted net income (loss) per share attributable to common stockholders because their effect&#13;would have been anti-dilutive for the periods presented:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 57%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,173,724&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,143,405&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Common stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,053,589&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,375,812&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;646,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;340,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,874,113&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,859,217&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <XAIR:LicenseAgreementTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 LICENSE AGREEMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 23, 2019, the Company entered into&#13;an agreement for commercial rights (the &amp;#8220;License Agreement&amp;#8221;) with Circassia Limited and its affiliates (collectively,&#13;&amp;#8220;Circassia&amp;#8221;) for persistent pulmonary hypertension of the newborn (&amp;#8220;PPHN&amp;#8221;) and future related indications&#13;at concentrations of&amp;#160;&lt;u&gt;&amp;#60;&lt;/u&gt;&amp;#160;80 ppm in the hospital setting in the United States and China. On December 18, 2019,&#13;the Company terminated the License Agreement, see Note 13. The Company would have received payments up to $32.55 million in up&#13;front and regulatory milestones, of which $31.5 million was associated with the U.S. market. All such payments were payable in&#13;cash or ordinary shares of Circassia, at the discretion of Circassia, with payments in cash discounted by approximately 5%. Royalties&#13;are payable only in cash.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;This contract was evaluated under ASC 606,&#13;which was adopted by the Company during fiscal 2019. Based upon the evaluation, it was determined that the contract consists of&#13;five performance obligations:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Performance Obligation 1: non-exclusive transfer of functional intellectual property rights to Circassia, which includes:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9675;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;the consummation of the License Agreement, which included significant pre-agreement negotiation, product specification, and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9675;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;the successful completion of the pre-submission meeting with the FDA. At this meeting the FDA reinforced their assessment of LungFit&amp;#8482; PH as a medical device and the requirements for approval.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Performance Obligation 2: ongoing support associated with the PMA submission and regulatory approval by the FDA. This also includes development activities including manufacturing readiness process ahead of the approval.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Performance Obligation 3: launch of the approved product in the field in the USA upon FDA regulatory approval&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Performance obligation 4: FDA approval of the product in the field for use in cardiac surgery&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Performance obligation 5: regulatory approval in China for marketing and sale of the product in China for any indication&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In consideration of the&#13;rights and licenses granted to Circassia by the Company, five milestones were included:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$7.35 million upon signing or 12,300,971 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31, 2019);&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3.15 million payable within five (5) business days following the successful completion of a Food and Drug Administration (the &amp;#8220;FDA&amp;#8221;) pre-submission meeting or 5,271,844 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31, 2019);&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$12.6 million payable on the sooner of ninety (90) days post FDA approval of the Product or the launch of the Product in the United States,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$8.4 million payable within five (5) business days following the approval by the FDA of the Product in certain hospital and clinic settings for use in cardiac surgery; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$1.05 million payable within five (5) business days following approval by the FDA equivalent in China for marketing and sale of the Product.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In addition, Circassia&#13;shall pay the Company the following royalty amounts until expiration of all of the applicable patents:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A one-time 5% royalty on the first cumulative $50 million in gross profit in the United States;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A one-time 5% royalty on the first cumulative $20 million in gross profit in China;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Thereafter, running royalty amounts of 15%&#13;of annual gross profit (United States &amp;#38; China combined) up to and including $100 million and 20% of annual gross profit (United&#13;States &amp;#38; China combined) exceeding $100 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following expiration of the patents, Circassia&#13;shall pay the Company a 14% royalty on annual gross profits up to and including $100 million and a 19% royalty on annual gross&#13;profits exceeding $100 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to the consideration constraints associated&#13;with milestones 3, 4, and 5, only the amounts associated with milestone 1 and 2 have been allocated. During the three months ended&#13;March 31, 2019, the Company met the first two milestones under the license agreement and received 17,572,815 ordinary shares valued&#13;at $9,987,295. This consideration was allocated to the first two performance obligations. one being the transfer of the intellectual&#13;property to Circassia, which was recognized at a point in time and was valued at $7,116,232 and the other being the ongoing support&#13;associated with the PMA submission and regulatory approval by the FDA, which was valued at $2,871,063 and recorded as deferred&#13;revenue to be recognized over a period of time from the commencement of the agreement to when management expects to submit the&#13;PMA. For the year ended March 31, 2020 and March 31, 2019, $1,390,104 and $607,769, respectively of such revenue associated with&#13;this second performance obligation has been recognized. As of March 31,&amp;#160;2020,&amp;#160;and March 31, 2019, deferred revenue was&amp;#160;$873,190&amp;#160;and&#13;$2,263,294, respectively.&lt;/p&gt;</XAIR:LicenseAgreementTextBlock>
    <XAIR:FacilityAgreementLoanTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 FACILITY AGREEMENT LOAN&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 17, 2020, the Company entered into&#13;a facility agreement with certain lenders pursuant to which the lenders shall loan to up to $25,000,000 in five tranches of $5,000,000&#13;per tranche at the option of the Company (&amp;#8220;Tranches&amp;#8221;), provided however that the Company may only utilize tranches&#13;three through five following FDA approval of our LungFit&amp;#8482; PH product. The loan(s) are unsecured with interest at 10% per&#13;year which is to be paid quarterly. The loans may be prepaid with certain prepayment penalties. The effective interest rate for&#13;this loan is 13.3% per year. Each tranche shall be repaid in installments commencing June 15, 2023 with all amounts outstanding&#13;under any tranche due on March 17, 2025. The first tranche was executed on March 17, 2020 and because the funds were held in escrow&#13;as of March 31, 2020 they are classified as restricted cash in the consolidated balance sheet. In connection with this utilization&#13;of the first tranche, the Company issued, in March 2020, warrants to the lender for the purchase of 172,826 shares of the Company&amp;#8217;s&#13;common stock at $7.26 per share. The warrants expire in five years. There are additional warrant issuances associated with each&#13;tranche.&amp;#160;If the second tranche of $ 5 million is utilized by the Company, the warrants that will be issued is up to twenty&#13;five percentage of its commitment value&amp;#160;&lt;font style="background-color: white"&gt;divided by the five day the volume weighed average&#13;price &amp;#8220;(VWAP&amp;#8221;) prior to utilization date. For tranches three to five, if any of these tranches are&amp;#160;&lt;/font&gt;utilized&#13;by the Company, the warrants that will be issued is up to ten percentage of its commitment value&amp;#160;&lt;font style="background-color: white"&gt;divided&#13;by the five day the VWAP.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result, the Company allocated the fair&#13;market value at the date of grant of the warrant to stockholders&amp;#8217; equity and debt discount valued at $594,979. The Black-Scholes&#13;pricing model was used with the following assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 80%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;87.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the facility agreement loan balance&#13;as of March 31, 2020 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 76%; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Face value of loan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Debt discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(594,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accretion of interest expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,562&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred offering costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(70,518&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Facility agreement loan balance&amp;#160;&amp;#8211; March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,339,065&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity of Facility Agreement Loan&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2025&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</XAIR:FacilityAgreementLoanTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 LOAN PAYABLE&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of&amp;#160;March 31,&amp;#160;2020,&amp;#160;and March&#13;31, 2019, in connection with the Company&amp;#8217;s insurance policy, a loan of $374,570 and $292,500, respectively was used to finance&#13;part of the premium. For the year ended March 31, 2020 and March 31, 2019,&amp;#160;the loan consists of&amp;#160;nine&amp;#160;payments&amp;#160;of&#13;$42,366 and ten payment of $29,687 bearing interest at 4.3% and 3.3% per annum, respectively. The outstanding balance as of March&#13;31, 2020 and March 31, 2019 was $335,358 and $263,604, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 INCOME TAXES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s foreign subsidiary is in&#13;Israel and subject to a corporate tax rate as follow: 2019 and 2018 &amp;#8211; 23%24%. December 2016, the Israeli Parliament approved&#13;the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), which&#13;reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January&#13;1, 2018. As of March 31, 2010, there is a net operating loss carry forward of&amp;#160;approximately&amp;#160;$15,726,000 which offset&#13;taxable income for an indefinite period of time.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under Section&amp;#160;382 of the Internal Revenue&#13;Code of 1986, as amended, changes in the Company&amp;#8217;s ownership may limit the amount of its net operating loss carryforwards&#13;that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of&#13;a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not performed a study&#13;to assess whether an ownership change for purposes of Section&amp;#160;382 has occurred, or whether there have been multiple ownership&#13;changes since the Company&amp;#8217;s inception, due to the significant costs and complexities associated with such study.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, the Company has approximately&#13;$19,400,000 of unused NOL carryforwards for federal tax purposes. Net operating loss carryforwards of approximately $1,375,000,&#13;which were generated prior to March 2018 expire through 2037. The net operating loss of approximately $18,025,000 can be carried&#13;forward indefinitely. The Company also has state net operating losses in the amount of approximately $20,187,000 expiring during&#13;the years 2035 to 2020. Under Section&amp;#160;382 of the Internal Revenue Code of 1986, as amended, changes in the Company&amp;#8217;s&#13;ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable&#13;income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than&#13;50% within a three-year period. The Company has not performed a study to assess whether an ownership change for purposes of Section&amp;#160;382&#13;has occurred, or whether there have been multiple ownership changes since the Company&amp;#8217;s inception, due to the significant&#13;costs and complexities associated with such study.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The components of net loss income before the&#13;provision for income taxes are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Year Ended&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the Year Ended&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 51%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Domestic&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 21%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(16,685,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,475,659&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3,411,236&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,082,791&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(20,096,804&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,558,450&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;There is no provision&#13;for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against&#13;its net deferred tax assets. The valuation allowance increased by approximately&amp;#160;$6,166,000&amp;#160;during the year ended March&#13;31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The tax effects of&#13;temporary differences that gave rise to significant portions of the deferred tax assets were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net operating loss carry forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,017,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,201,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;524,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;243,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;71,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Reserves and allowances - foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;880,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;608,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capital&amp;#160;loss&amp;#160;carry forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,571,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;966,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development - foreign&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;550,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred&amp;#160;revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;241,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(56,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Lease liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12,860,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,694,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(12,860,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,694,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal income tax at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(21,00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State income tax, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Permanent items&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36.10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(3.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4.77&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective income tax expense rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;For the year ended&#13;March 31, 2020 and 2019 the main reconciling item between the effective tax rate is the recognition of valuation allowances in&#13;respect to deferred taxes related to accumulated operating net operating losses carried forward due to the uncertainty of the realization&#13;of such deferred taxes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tax years 2016 through 2020 remain open to&#13;examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years 2014 through 2020&#13;remain open.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 27, 2020, the Coronavirus Aid, Relief&#13;and Economic Security Act (&amp;#8220;CARES Act&amp;#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act made various&#13;tax law changes including, among other things, (i) increasing the limitation under IRC Section 163(j) for 2019 and 2020 to permit&#13;additional expensing of interest, (ii) enacting a technical correction so that qualified improvement property can be immediately&#13;expenses under IRC Section 168(k) and (iii) making modification to the federal net operating loss rules including permitting federal&#13;net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to generate&#13;a refund of previously paid income taxes. The income tax provisions of the CARES Act had limited applicability to the Company as&#13;of March 31,2020, and therefore, the enactment of the CARES Act did not have any impact on the Company&amp;#8217;s consolidated financial&#13;statements as of March 31,2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;A reconciliation of&#13;the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2020 and&amp;#160;March 31,&amp;#160;2019&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31,2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year&amp;#160;Ended&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 22%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Decreases for the current year&amp;#8217;s tax position&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at the end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Company recorded&#13;a federal tax benefit in the amount of $154,300 related to the reversal of uncertain tax positions due to expiration of statute&#13;of limitations.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;13&amp;#160;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 22, 2013, the Company entered into&#13;a patent license agreement with CareFusion, pursuant to which it agreed to pay to the third party a non-refundable upfront fee&#13;of $150,000 and is obligated to pay 5% royalties of any licensed product net sales, but at least $50,000 per annum through the&#13;term of the agreement and the advance is credited against future royalties payments. As of December 31, 2019, the Company did not&#13;pay any royalties since the Company did not have any revenues from this license. The term of the agreement extends through the&#13;life of applicable patents and may be terminated by either party with 60 days&amp;#8217; prior written notice in the event of a breach&#13;of the agreement, and may be terminated unilaterally by CareFusion with 30 days&amp;#8217; prior written notice in the event that we&#13;do not meet certain milestones.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2015, BA Ltd. entered into an Option&#13;Agreement (the &amp;#8220;Option Agreement&amp;#8221;) with Pulmonox whereby BA Ltd. acquired the option to purchase certain intellectual&#13;property assets and rights (the &amp;#8220;Option&amp;#8221;) on September 7, 2016 for $25,000. On January 13, 2017, the Company exercised&#13;the Option and paid $500,000. The Company becomes obligated to make certain one-time development and sales milestone payments to&#13;Pulmonox, commencing with the date on which we receive regulatory approval for the commercial sale of the first product candidate&#13;qualifying under the agreement. These milestone payments are capped at a total of $87 million across three separate and distinct&#13;indications that fall under the agreement, with the majority of them, approximately $83 million, being sales related based on cumulative&#13;sales milestones for each of the three products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 31, 2018 the Company entered into&#13;an agreement (&amp;#8220;Agreement&amp;#8221;) with NitricGen, Inc. (&amp;#8220;NitricGen&amp;#8221;) acquire a global, exclusive, transferable&#13;license and associated assets including intellectual property, know-how, trade secrets and confidential information from NitricGen&#13;related to LungFit&amp;#8482;. The Company acquired the licensing right to use the technology and agreed to pay NitricGen a total of&#13;$2,000,000 in future payments based upon achieving certain milestones, as defined in the Agreement, and royalties on sales LungFit&amp;#8482;.&#13;The Company paid NitricGen $100,000 upon the execution agreement, $100,000 upon achieving the next milestone and issued 100,000&#13;options to purchase the Company&amp;#8217;s stock valued at $295,000 upon executing the agreement. The remaining future milestone payments&#13;are $1,800,000 of which $1,500,000 in&amp;#160;due after&amp;#160;six months after the first approval of LungFit&amp;#8482; by the Food and&#13;Drug Administration or the European Medicine Evaluation Agency.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2019, the Company entered&#13;into an agreement with a contract research organization to perform a pilot study for bronchiolitis. As of&amp;#160;March 31, 2020,&amp;#160;the&#13;remaining&amp;#160;cash&amp;#160;commitment under this agreement is approximately&amp;#160;$303,000.&amp;#160;The Company recorded $754,000&amp;#160;expense&amp;#160;for&#13;the year ended March 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain officer agreements contain a change&#13;of control provision for payment of severance arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2018, the Company entered into an&#13;operating lease for office space in Madison, Wisconsin. The lease commenced in March 2018. The lease agreement expires in April&#13;2021, at which point the Company has the option to renew the lease for one additional five-year term. The renewal period was not&#13;included the lease term for purposes of determining the lease liability or right-of-use asset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2018, the Company entered into an operating&#13;lease for office space in Garden City, New York. The lease commenced in July 2018. The lease agreement expires in June 2023, at&#13;which point the Company has the option to renew the lease for one additional three-year term. The renewal period was not included&#13;the lease term for purposes of determining the lease liability or right-of-use asset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has other operating lease agreements&#13;with commitments of less than one year or that are not significant. The Company elected the practical expedient option and as such&#13;these lease payments are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Other Information For The Year Ended March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 81%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash paid&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;81,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average remaining lease term &amp;#8212; operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.0. years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average discount rate &amp;#8212; operating leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Maturity of Lease Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;br /&gt;&#13;March 31, 2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 81%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;83,117&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,826&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,279&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;228,915&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(27,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;200,923&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;u&gt;Contingencies&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 16, 2018, Empery Asset Master, Ltd.,&#13;Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, &amp;#8220;Empery&amp;#8221;), filed a complaint in the Supreme&#13;Court of the State of New York, relating to the notice of adjustment of both the exercise price of and the number of warrant shares&#13;issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as a result of certain circumstances in&#13;connection with our February 2018 offering, the 166,672 warrants issued to Empery in January 2017 provide for adjustments to both&#13;the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery seeks monetary damages&#13;and declaratory relief under theories of breach of contract or contract reformation predicated on mutual mistake.&amp;#160;While the&amp;#160;Company&amp;#160;&#13;believes&amp;#160;that&amp;#160;it has&amp;#160;&amp;#160;complied with&amp;#160;the&amp;#160;applicable protective features&amp;#160;of the&amp;#160;2017 Warrants&amp;#160;and&#13;properly adjusted the&amp;#160;exercise price, if Empery were to prevail on all claims , the new adjusted total number of warrant shares&#13;could be as follows: 319,967 warrant shares for Empery Master, 159,869 warrant shares for Empery I and 252,672 warrant shares for&#13;Empery II and the exercise price could be reduced from&amp;#160;$3.66&amp;#160;to $1.57&amp;#160;per share.&amp;#160;While the Company has several&#13;meritorious defenses against the claims, the ultimate resolution of the matter, if unfavorable, could result in a material loss.&#13;On March 9, 2020, we filed a motion for summary judgment, which remains pending.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 18, 2019, the Company terminated&#13;the License Agreement with Circassia pursuant to which the Company had granted Circassia an exclusive royalty-bearing license&#13;to distribute, market and sell the Company&amp;#8217;s nitric oxide generator and delivery system in the United States and China.&#13;As previously described in Note 9, Circassia had agreed to pay the Company certain milestone and royalty payments, with the remaining&#13;milestone and royalty payments payable in cash or ordinary shares of Circassia at Circassia&amp;#8217;s option. The Company terminated&#13;the Agreement pursuant to section 13.3(b) of the Agreement, which provides for termination by either party upon the other party&amp;#8217;s&#13;material breach or default. The Company is evaluating other options for the commercialization of its generator and delivery system.&#13;In connection the termination of the license with Circassia, we may be subject to a variety of claims. Adverse outcomes in some&#13;or all of these claims, if filed,&amp;#160;may adversely affect our ability to conduct business and our financial condition and results&#13;of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&amp;#160;14&amp;#160;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 2, 2020, Beyond Air, Inc. entered&#13;into an At-The-Market Equity Offering for $50 million and utilized the Company&amp;#8217;s shelf registration statement. The Company&#13;may sell shares of our common stock having aggregate sales proceeds of up to $50,000,000 from time to time in this offering. If&#13;shares are sold, there is a three 3 percent fee paid to the sales agent.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 14, 2020, the Company entered into a&#13;$40 million New Purchase Agreement with LPC, that replaced the existing $20 million purchase agreement. The New Purchase Agreement&#13;provides for the issuance of up to $40 million of the Company&amp;#8217;s common stock which we may sell from time to time in our sole&#13;discretion to Lincoln Park over the next 36 months, subject to the conditions and limitations in the New Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the Initial Purchase from time&#13;to time on any trading day the Company selects that the closing sale price of our common stock is at least $0.25, we have the right,&#13;in our sole discretion, subject to the conditions and limitations in the Purchase Agreement, to direct LPC to purchase up to 80,000&#13;shares of our common stock (each such purchase, a &amp;#8220;Regular Purchase&amp;#8221;) over the 36-month term of the&amp;#160;New&amp;#160;Purchase&#13;Agreement; provided, however, that such limit may be increased to up to 100,000 shares if the last closing sale price of our common&#13;stock is at least $5.00 on the purchase date, may be increased to up to 120,000 shares if the last closing sale price of our common&#13;stock is at least $7.50 on the purchase date, and may be increased to up to 140,000 shares if the last closing sale price of our&#13;common stock is at least $10.00 on the purchase date (each subject to adjustment for any reorganization, recapitalization, non-cash&#13;dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement). The purchase price&#13;for shares of common stock to be purchased by Lincoln Park will be the equal to lesser of (i) the lowest sale price on the purchase&#13;date, as reported by Nasdaq, or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during&#13;the ten trading days prior to the purchase date. Lincoln Park&amp;#8217;s obligation under each Regular Purchase shall not exceed $2,000,000.&#13;The amount of the regular purchases can be modified upon the mutual agreement of the Company and LPC.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Beyond Air can also direct LPC to purchase&#13;additional amounts as accelerated purchases and additional accelerated purchases, under certain circumstances and provided the&#13;last closing sale price of our common stock is at least $1.00 per share, in an amount up to the lesser of (i) three times the number&#13;of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the trading volume on such accelerated purchase&#13;date. The purchase price for the additional shares is the lower of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;the closing sale price for the common stock on the date of sale; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;ninety-five percent (95%) of the volume weighted average price of the common stock on the Nasdaq Capital Market on the date of sale.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;There is no upper or lower&#13;limit on the price per share that Lincoln Park must pay for our common stock under the New Purchase Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than as described above, there are no&#13;trading volume requirements or restrictions under the New Purchase Agreement. We will control the timing and amount of any sales&#13;of our common stock to Lincoln Park. We may at any time, in our sole discretion terminate the New Purchase Agreement without fee,&#13;penalty or cost, upon one trading day written notice.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <XAIR:OtherRisksAndUncertaintiesPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Other Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks common to medical&#13;device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary&#13;technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the potential&#13;need to obtain additional financing. The Company is dependent on third party suppliers, in some cases single-source suppliers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There can be no assurance that the Company&amp;#8217;s&amp;#160;product&amp;#160;will&#13;be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an&#13;acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s products require approval&#13;or clearance from the U.S. Food and Drug Administration prior to commencing commercial sales in the United States. There can be&#13;no assurance that the Company&amp;#8217;s products will receive all of the required approvals or clearances. Approvals or clearances&#13;are also required in foreign jurisdictions in which the Company may license or sell its products. If the Company is denied such&#13;approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact on the Company&amp;#8217;s&#13;results of operations, financial position and liquidity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The development of our product candidates&#13;could be further disrupted and adversely affected by the recent outbreak of COVID-19. The spread of SARS CoV-2 from China to other&#13;countries has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020.&#13;We have addressed the impact COVID-19 may have on our business plans and our ability to conduct the preclinical studies and clinical&#13;trials as well as on our reliance on third-party manufacturing and our supply chain. However, there can be no assurance that this&#13;analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences. The extent to which&#13;the COVID-19 pandemic and global efforts to contain its spread will impact our operations will depend on future developments,&#13;which are still uncertain and cannot be predicted at this time.&lt;/p&gt;</XAIR:OtherRisksAndUncertaintiesPolicyTextBlock>
    <XAIR:RestrictedCashPolicyTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2020, restricted cash includes&#13;$5,000,000 of cash in an escrow account from the lenders of the facility agreement loan, See Note 10. Subsequent to March 31, 2020,&#13;the Company received the funds from the escrow account into a cash operating cash. In addition, as of March 31, 2020, restricted&#13;cash includes $619,000 of cash that is designated for a contract manufacturer. This cash is expected be used for material and parts&#13;that require a long lead time. Collateral for vehicle leases are invested in bank deposit accounts which is restricted and as of&#13;March 31, 2020 was $16,836 and as of March 31, 2019 was $16,934, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash equivalents are short-term highly liquid&#13;investments that are readily convertible to cash with original maturities of three months or less at acquisition. Restricted cash&#13;is collateral for vehicle leases and invested in bank deposit accounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table is the reconciliation of&#13;the presentation and disclosure of financial instruments as shown on the Company&amp;#8217;s consolidated statements of cash flows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended &lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;For The Year Ended&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;19,829,275&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,340,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,635,836&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;16,934&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents and restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25,465,111&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,357,137&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</XAIR:RestrictedCashPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2019-04-01to2020-03-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the accrued expenses as of March&#13;31, 2020 and March 31, 2019 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of&lt;br /&gt;&#13;March 31, 2019&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Vendors &amp;#8211; research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;484,756&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;103,320&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;476,638&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;780,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Income taxes payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;154,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Employee salaries and benefits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;71,066&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;183,271&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;65,074&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,084&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,097,534&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,283,102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <XAIR:PaymentOfOperatingLeaseLiabilityInOperatingActivities contextRef="From2019-04-01to2020-03-31" unitRef="USD" decimals="0">57679</XAIR:PaymentOfOperatingLeaseLiabilityInOperatingActivities>
    <XAIR:PaymentOfOperatingLeaseLiabilityInOperatingActivities contextRef="From2018-04-01to2019-03-31" unitRef="USD" xsi:nil="true" />
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-2" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-3" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-4" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-5" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-6" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-7" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-8" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-9" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-10" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-11" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-01" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-4" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-5" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-02" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">These warrants have down round protection.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">The Company elected to adopt Accounting Standards Update 2017-11 retrospective to outstanding financial instruments with down round feature by means of cumulative-effect adjustment to the beginning additional paid-in capital of $6,194,292 and accumulated deficit of $(516,358) as of April 1, 2018. This ASU affects all entities that issue financial instruments (for example, warrants or convertible instruments) that include down round features.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>xair-20200331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCAqbP9z5Z8yekhvWB9bWlKPyUuRwcXiiKP5IVG4VsN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:XAIR="http://beyondair.net/20200331" elementFormDefault="qualified" targetNamespace="http://beyondair.net/20200331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://beyondair.net/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" id="StatementsOfChangesInShareholdersEquityParenthetical">
	  <link:definition>00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
	  <link:definition>00000008 - Disclosure - Organization and Business</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FairValueMeasurement" id="FairValueMeasurement">
	  <link:definition>00000010 - Disclosure - Fair Value Measurement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000011 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity" id="ShareholdersEquity">
	  <link:definition>00000012 - Disclosure - Shareholder's Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" id="CurrentAssetsAndPrepaidExpenses">
	  <link:definition>00000013 - Disclosure - Current Assets and Prepaid Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000014 - Disclosure - Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" id="BasicAndDilutedNetIncomeLossPerCommonShare">
	  <link:definition>00000015 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/LicenseAgreement" id="LicenseAgreement">
	  <link:definition>00000016 - Disclosure - License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FacilityAgreementLoan" id="FacilityAgreementLoan">
	  <link:definition>00000017 - Disclosure - Facility Agreement Loan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/LoanPayable" id="LoanPayable">
	  <link:definition>00000018 - Disclosure - Loan Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000019 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000021 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000022 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
	  <link:definition>00000024 - Disclosure - Fair Value Measurement (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000025 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
	  <link:definition>00000026 - Disclosure - Shareholder's Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" id="CurrentAssetsAndPrepaidExpensesTables">
	  <link:definition>00000027 - Disclosure - Current Assets and Prepaid Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000028 - Disclosure - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" id="BasicAndDilutedNetIncomeLossPerCommonShareTables">
	  <link:definition>00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FacilityAgreementLoanTables" id="FacilityAgreementLoanTables">
	  <link:definition>00000030 - Disclosure - Facility Agreement Loan (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000031 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000032 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" id="OrganizationAndBusinessDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Organization and Business (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
	  <link:definition>00000035 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" id="SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails">
	  <link:definition>00000036 - Disclosure - Significant Accounting Policies - Schedule of Useful Life of Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" id="SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails">
	  <link:definition>00000037 - Disclosure - Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" id="SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails">
	  <link:definition>00000038 - Disclosure - Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" id="FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" id="PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Shareholder's Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" id="ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails">
	  <link:definition>00000043 - Disclosure - Shareholder's Equity - Schedule of Unvested Restricted Shares (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" id="ShareholdersEquity-ScheduleOfOptionActivityDetails">
	  <link:definition>00000044 - Disclosure - Shareholder's Equity - Schedule of Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" id="ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails">
	  <link:definition>00000045 - Disclosure - Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" id="ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails">
	  <link:definition>00000046 - Disclosure - Shareholder's Equity - Schedule of Stock-based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" id="ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails">
	  <link:definition>00000047 - Disclosure - Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" id="ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails">
	  <link:definition>00000048 - Disclosure - Shareholder's Equity - Summary of Company's Outstanding Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" id="CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails">
	  <link:definition>00000049 - Disclosure - Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" id="AccruedExpenses-SummaryOfAccruedExpensesDetails">
	  <link:definition>00000050 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" id="BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails">
	  <link:definition>00000051 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" id="LicenseAgreementsDetailsNarrative">
	  <link:definition>00000052 - Disclosure - License Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" id="FacilityAgreementLoanDetailsNarrative">
	  <link:definition>00000053 - Disclosure - Facility Agreement Loan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" id="FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails">
	  <link:definition>00000054 - Disclosure - Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" id="FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails">
	  <link:definition>00000055 - Disclosure - Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/LoanPayableDetailsNarrative" id="LoanPayableDetailsNarrative">
	  <link:definition>00000056 - Disclosure - Loan Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" id="IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails">
	  <link:definition>00000058 - Disclosure - Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" id="IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails">
	  <link:definition>00000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" id="IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails">
	  <link:definition>00000060 - Disclosure - Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" id="IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails">
	  <link:definition>00000061 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000062 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" id="CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails">
	  <link:definition>00000063 - Disclosure - Commitments and Contingencies - Schedule of Lease Other Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" id="CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails">
	  <link:definition>00000064 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://beyondair.net/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000065 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="xair-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="xair-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="xair-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="xair-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="XAIR_FirstTwoMilestoneOrdinaryShares" name="FirstTwoMilestoneOrdinaryShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FirstTwoMilestoneOrdinarySharesValue" name="FirstTwoMilestoneOrdinarySharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MilestonesPayment" name="MilestonesPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" name="RevenueRecognitionMilestoneMethodRevenueRecognized1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentsInCashDiscountedPercentage" name="PaymentsInCashDiscountedPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RevenueAllocatedToPerformanceObligations" name="RevenueAllocatedToPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OnetimeRoyaltyPercentage" name="OnetimeRoyaltyPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RoyaltyGrossProfitAmount" name="RoyaltyGrossProfitAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AnnualGrossProfitRoyaltyPercentage" name="AnnualGrossProfitRoyaltyPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AnnualGrossProfitRoyaltyAmount" name="AnnualGrossProfitRoyaltyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentOfMilestoneOrdinarySharesValue" name="PaymentOfMilestoneOrdinarySharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentOfMilestoneOrdinaryShares" name="PaymentOfMilestoneOrdinaryShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LicensedRightToUseTechnology" name="LicensedRightToUseTechnology" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IntangibleAssetsMilestonePayments" name="IntangibleAssetsMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NonrefundableUpfrontFee" name="NonrefundableUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentsForDevelopmentAndMilestonePayment" name="PaymentsForDevelopmentAndMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MilestonePayments" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SalesRelatedMilestonesPayments" name="SalesRelatedMilestonesPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" name="RevenueRecognitionMilestoneMethodRevenuesRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OptionsToPurchaseCommonStockValue" name="OptionsToPurchaseCommonStockValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuancePeriodTerm" name="StockIssuancePeriodTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockPurchaseCommitment" name="StockPurchaseCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NumberOfUnregisteredSharesOfCommonStock" name="NumberOfUnregisteredSharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLeaseAgreementExpireDateDescription" name="OperatingLeaseAgreementExpireDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RightOfUseLeaseAssetsCurrent" name="RightOfUseLeaseAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeemedDividendAsResultOfWarrantModification" name="DeemedDividendAsResultOfWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CumulativeAdjustment" name="CumulativeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncrementalValueOfWarrantsDueToModification" name="IncrementalValueOfWarrantsDueToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeemedDividendDueToWarrantModification" name="DeemedDividendDueToWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RemainingCommitmentUnderLicenseAgreement" name="RemainingCommitmentUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RightOfUseAssetCurrent" name="RightOfUseAssetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" name="IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" name="IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" name="FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CumulativeAdjustmentOne" name="CumulativeAdjustmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" name="StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" name="StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringExerciseOfWarrantsShares" name="StockIssuedDuringExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringExerciseOfWarrantsValue" name="StockIssuedDuringExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" name="StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" name="StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" name="StockIssuedDuringThePeriodSharesVestedRestrictedStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" name="StockIssuedDuringThePeriodValueVestedRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" name="UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" name="ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AdoptionOfAccountingStandardsUpdate" name="AdoptionOfAccountingStandardsUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" name="AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ProceedsfromIssuanceOfMarketOfferings" name="ProceedsfromIssuanceOfMarketOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RightofuseAssets" name="RightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLeaseLiabilities" name="OperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" name="AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_VendorsResearchAndDevelopment" name="VendorsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AccretionOfInterestExpense" name="AccretionOfInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_UnusedNetOperatingLossCarryforwards" name="UnusedNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLossCarryforwardsExpirationYears" name="OperatingLossCarryforwardsExpirationYears" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsResearchAndDevelopment" name="DeferredTaxAssetsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsRightofuseAsset" name="DeferredTaxAssetsRightofuseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FeePecentage" name="FeePecentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AgreementTermDescription" name="AgreementTermDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PurchaseAgreementDescription" name="PurchaseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TradingVolumePecentage" name="TradingVolumePecentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WeightedAveragePricePecentage" name="WeightedAveragePricePecentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" name="RealizedAndUnrealizedGainLossFromMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OperatingLeasesRightofuseAsset" name="OperatingLeasesRightofuseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NumberOfSharesIssuedForExerciseOfWarrants" name="NumberOfSharesIssuedForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" name="FederalTaxBenefitForReversalOfUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" name="AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncrementalValueOfWarrant" name="IncrementalValueOfWarrant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DeemedDividendFromWarrantModification" name="DeemedDividendFromWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WarrantsDescription" name="WarrantsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" name="ScheduleOfUsefulLifeOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LicensedRightToUseTechnologyPolicyTextBlock" name="LicensedRightToUseTechnologyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" name="ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" name="ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" name="ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" name="ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" name="ScheduleOfFacilityAgreementLoanTabletextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" name="ScheduleOfLeaseOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" name="CurrentAssetsAndPrepaidExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LicenseAgreementTextBlock" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FacilityAgreementLoanTextBlock" name="FacilityAgreementLoanTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RestrictedCashPolicyTextBlock" name="RestrictedCashPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" name="PaymentOfOperatingLeaseLiabilityInOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OptionAgreementMember" name="OptionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NitricGenIncMember" name="NitricGenIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandThirteenIncentiveOptionPlanMember" name="TwoThousandThirteenIncentiveOptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_JanuaryTwoThousandandSeventeenMember" name="JanuaryTwoThousandandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MarchTwoThousandSeventeenMember" name="MarchTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_InvestorOneMember" name="InvestorOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MutualFundsMember" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ExecutionAgreementMember" name="ExecutionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CircassiaPharmaceuticalsPLCMember" name="CircassiaPharmaceuticalsPLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ClinicalAndMedicalEquipmentMember" name="ClinicalAndMedicalEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MarchTwoThousandEighteenMember" name="MarchTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ThirdPartyLicenseAgreementMember" name="ThirdPartyLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ResearchAndDevelopmentExpensesMember" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_InsuranceMember" name="InsuranceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AfterSixMonthsMember" name="AfterSixMonthsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FirstObligationsMember" name="FirstObligationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SecondObligationsMember" name="SecondObligationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_HospitalAndClinicSettingsMember" name="HospitalAndClinicSettingsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_UnitedStatesAndChinaMember" name="UnitedStatesAndChinaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LPCMember" name="LPCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AdoptionTopicEightFourTwoMember" name="AdoptionTopicEightFourTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ComputersEquipmentMember" name="ComputersEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RestrictedCashMember" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_UnvestedStockOptionsMember" name="UnvestedStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FoodAndDrugAdministrationMember" name="FoodAndDrugAdministrationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_PatentLicenseAgreementMember" name="PatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CareFusionMember" name="CareFusionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CommonStockOptionsMember" name="CommonStockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_RestrictedSharesMember" name="RestrictedSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LincolnParkCorporationLLCMember" name="LincolnParkCorporationLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember" name="BoardOfDirectorsOfficersEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ConcurrentPrivatePlacementMember" name="ConcurrentPrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ProfessionalMember" name="ProfessionalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ContractResearchOrganizationMember" name="ContractResearchOrganizationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_OfficersEmployeesAndConsultantsMember" name="OfficersEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DirectorsAndEmployeesMember" name="DirectorsAndEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember" name="ChiefExecutiveOfficerDirectorsAndEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ValueAddedTaxReceivableMember" name="ValueAddedTaxReceivableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ValueAddedTaxesReceivableMember" name="ValueAddedTaxesReceivableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CommonStockOneMember" name="CommonStockOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CommonStockTwoMember" name="CommonStockTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FacilityAgreementMember" name="FacilityAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_NewPurchaseAgreementMember" name="NewPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_WarrantHoldersMember" name="WarrantHoldersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MarchTwoThousandTwentyMember" name="MarchTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LoanMember" name="LoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LendersMember" name="LendersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FiveTranchesMember" name="FiveTranchesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TranchesMember" name="TranchesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ILMember" name="ILMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" name="MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_AtTheMarketEquityOfferingMember" name="AtTheMarketEquityOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_BeyondAirIncMember" name="BeyondAirIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SalesAgentMember" name="SalesAgentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ContractManufacturerMember" name="ContractManufacturerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_ShareBasedCompensationAwardFiveTrancheMember" name="ShareBasedCompensationAwardFiveTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SecondTrancheMember" name="SecondTrancheMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_TwoThousandAndSeventeenWarrantsMember" name="TwoThousandAndSeventeenWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EmperyAssetMasterLtdMember" name="EmperyAssetMasterLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EmperyTaxEfficientLpMember" name="EmperyTaxEfficientLpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_EmperyTaxEfficientIILpMember" name="EmperyTaxEfficientIILpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" name="SupplementalDisclosureOfNoninvestingActivitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_CurrentAssetsAndPrepaidExpensesAbstract" name="CurrentAssetsAndPrepaidExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_LicenseAgreementAbstract" name="LicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_FacilityAgreementLoanAbstract" name="FacilityAgreementLoanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" name="IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" name="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>xair-20200331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://beyondair.net/role/DocumentAndEntityInformation" xlink:href="xair-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheets" xlink:href="xair-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:href="xair-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfOperations" xlink:href="xair-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfCashFlows" xlink:href="xair-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusiness" xlink:href="xair-20200331.xsd#OrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement" xlink:href="xair-20200331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment" xlink:href="xair-20200331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity" xlink:href="xair-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses" xlink:href="xair-20200331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreement" xlink:href="xair-20200331.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan" xlink:href="xair-20200331.xsd#FacilityAgreementLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayable" xlink:href="xair-20200331.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes" xlink:href="xair-20200331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEvents" xlink:href="xair-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurementTables" xlink:href="xair-20200331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:href="xair-20200331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityTables" xlink:href="xair-20200331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpensesTables" xlink:href="xair-20200331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:href="xair-20200331.xsd#FacilityAgreementLoanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesTables" xlink:href="xair-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:href="xair-20200331.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:href="xair-20200331.xsd#FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:href="xair-20200331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:href="xair-20200331.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:href="xair-20200331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:href="xair-20200331.xsd#AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:href="xair-20200331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:href="xair-20200331.xsd#FacilityAgreementLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:href="xair-20200331.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:href="xair-20200331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:href="xair-20200331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightOfUseLeaseAssetsCurrent" xlink:label="loc_XAIRRightOfUseLeaseAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_XAIRRightOfUseLeaseAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnology" xlink:label="loc_XAIRLicensedRightToUseTechnology" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_XAIRLicensedRightToUseTechnology" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeOperating" xlink:label="loc_us-gaapDividendIncomeOperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDividendIncomeOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:label="loc_XAIRRealizedAndUnrealizedGainLossFromMarketableSecurities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_XAIRRealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendFromWarrantModification" xlink:label="loc_XAIRDeemedDividendFromWarrantModification" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_XAIRDeemedDividendFromWarrantModification" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:label="loc_XAIRUnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRUnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:label="loc_XAIRChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdoptionOfAccountingStandardsUpdate" xlink:label="loc_XAIRAdoptionOfAccountingStandardsUpdate" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRAdoptionOfAccountingStandardsUpdate" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:label="loc_XAIRAmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRAmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:label="loc_XAIRPaymentOfOperatingLeaseLiabilityInOperatingActivities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_XAIRPaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsfromIssuanceOfMarketOfferings" xlink:label="loc_XAIRProceedsfromIssuanceOfMarketOfferings" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_XAIRProceedsfromIssuanceOfMarketOfferings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="loc_us-gaapProceedsFromBankDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromBankDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaapRepaymentsOfBankDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfBankDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="00000008 - Disclosure - Organization and Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement" xlink:title="00000010 - Disclosure - Fair Value Measurement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholder&apos;s Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:title="00000013 - Disclosure - Current Assets and Prepaid Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:title="00000015 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreement" xlink:title="00000016 - Disclosure - License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan" xlink:title="00000017 - Disclosure - Facility Agreement Loan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="00000018 - Disclosure - Loan Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurementTables" xlink:title="00000024 - Disclosure - Fair Value Measurement (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityTables" xlink:title="00000026 - Disclosure - Shareholder&apos;s Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:title="00000027 - Disclosure - Current Assets and Prepaid Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:title="00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:title="00000030 - Disclosure - Facility Agreement Loan (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="00000033 - Disclosure - Organization and Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Useful Life of Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="00000037 - Disclosure - Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:title="00000038 - Disclosure - Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:title="00000039 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000040 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - Shareholder&apos;s Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:title="00000043 - Disclosure - Shareholder&apos;s Equity - Schedule of Unvested Restricted Shares (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:title="00000044 - Disclosure - Shareholder&apos;s Equity - Schedule of Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:title="00000045 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000046 - Disclosure - Shareholder&apos;s Equity - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:title="00000047 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:title="00000048 - Disclosure - Shareholder&apos;s Equity - Summary of Company&apos;s Outstanding Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:title="00000049 - Disclosure - Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:title="00000050 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorsResearchAndDevelopment" xlink:label="loc_XAIRVendorsResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_XAIRVendorsResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="00000051 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - License Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:title="00000053 - Disclosure - Facility Agreement Loan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:title="00000054 - Disclosure - Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:title="00000055 - Disclosure - Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:title="00000056 - Disclosure - Loan Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000057 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="00000058 - Disclosure - Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="00000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsResearchAndDevelopment" xlink:label="loc_XAIRDeferredTaxAssetsResearchAndDevelopment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="loc_XAIRDeferredTaxAssetsRightofuseAsset" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsRightofuseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="loc_XAIRDeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:label="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:title="00000060 - Disclosure - Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:title="00000061 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:title="00000063 - Disclosure - Commitments and Contingencies - Schedule of Lease Other Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000065 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>xair-20200331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://beyondair.net/role/DocumentAndEntityInformation" xlink:href="xair-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheets" xlink:href="xair-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:href="xair-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfOperations" xlink:href="xair-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfCashFlows" xlink:href="xair-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusiness" xlink:href="xair-20200331.xsd#OrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement" xlink:href="xair-20200331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment" xlink:href="xair-20200331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity" xlink:href="xair-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses" xlink:href="xair-20200331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreement" xlink:href="xair-20200331.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan" xlink:href="xair-20200331.xsd#FacilityAgreementLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayable" xlink:href="xair-20200331.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes" xlink:href="xair-20200331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEvents" xlink:href="xair-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurementTables" xlink:href="xair-20200331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:href="xair-20200331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityTables" xlink:href="xair-20200331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpensesTables" xlink:href="xair-20200331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:href="xair-20200331.xsd#FacilityAgreementLoanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesTables" xlink:href="xair-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:href="xair-20200331.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:href="xair-20200331.xsd#FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:href="xair-20200331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:href="xair-20200331.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:href="xair-20200331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:href="xair-20200331.xsd#AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:href="xair-20200331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:href="xair-20200331.xsd#FacilityAgreementLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:href="xair-20200331.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:href="xair-20200331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:href="xair-20200331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustment" xlink:label="loc_XAIRCumulativeAdjustment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustment_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustmentOne" xlink:label="loc_XAIRCumulativeAdjustmentOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustmentOne_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:label="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:label="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrantsDueToModification" xlink:label="loc_XAIRIncrementalValueOfWarrantsDueToModification_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncrementalValueOfWarrantsDueToModification_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendDueToWarrantModification" xlink:label="loc_XAIRDeemedDividendDueToWarrantModification_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDeemedDividendDueToWarrantModification_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:label="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:label="loc_XAIRAdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsValue" xlink:label="loc_XAIRStockIssuedDuringExerciseOfWarrantsValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringExerciseOfWarrantsValue_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsShares" xlink:label="loc_XAIRStockIssuedDuringExerciseOfWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringExerciseOfWarrantsShares_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:label="loc_XAIRStockIssuedDuringThePeriodValueCashlessExciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodValueCashlessExciseOfWarrants_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:label="loc_XAIRStockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:label="loc_XAIRStockIssuedDuringThePeriodValueVestedRestrictedStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodValueVestedRestrictedStock_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:label="loc_XAIRStockIssuedDuringThePeriodSharesVestedRestrictedStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodSharesVestedRestrictedStock_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustment" xlink:label="loc_XAIRCumulativeAdjustment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustment_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="00000008 - Disclosure - Organization and Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement" xlink:title="00000010 - Disclosure - Fair Value Measurement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholder&apos;s Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:title="00000013 - Disclosure - Current Assets and Prepaid Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:title="00000015 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreement" xlink:title="00000016 - Disclosure - License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan" xlink:title="00000017 - Disclosure - Facility Agreement Loan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="00000018 - Disclosure - Loan Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurementTables" xlink:title="00000024 - Disclosure - Fair Value Measurement (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityTables" xlink:title="00000026 - Disclosure - Shareholder&apos;s Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:title="00000027 - Disclosure - Current Assets and Prepaid Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:title="00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:title="00000030 - Disclosure - Facility Agreement Loan (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="00000033 - Disclosure - Organization and Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NewPurchaseAgreementMember" xlink:label="loc_XAIRNewPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNewPurchaseAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ShareBasedCompensationAwardFiveTrancheMember" xlink:label="loc_XAIRShareBasedCompensationAwardFiveTrancheMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_XAIRShareBasedCompensationAwardFiveTrancheMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCapitalFundLLCMember" xlink:label="loc_XAIRLincolnParkCapitalFundLLCMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCapitalFundLLCMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnsecuredDebt_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PurchaseAgreementDescription" xlink:label="loc_XAIRPurchaseAgreementDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPurchaseAgreementDescription_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractManufacturerMember" xlink:label="loc_XAIRContractManufacturerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRContractManufacturerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCash_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IntangibleAssetsMilestonePayments" xlink:label="loc_XAIRIntangibleAssetsMilestonePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIntangibleAssetsMilestonePayments_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_80" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Useful Life of Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ComputersEquipmentMember" xlink:label="loc_XAIRComputersEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRComputersEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="00000037 - Disclosure - Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:title="00000038 - Disclosure - Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:title="00000039 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MutualFundsMember" xlink:label="loc_XAIRMutualFundsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_XAIRMutualFundsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CircassiaPharmaceuticalsPLCMember" xlink:label="loc_XAIRCircassiaPharmaceuticalsPLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRCircassiaPharmaceuticalsPLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000040 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - Shareholder&apos;s Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseAgreementMember" xlink:label="loc_XAIRStockPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRStockPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCapitalFundLLCMember" xlink:label="loc_XAIRLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DirectorsAndEmployeesMember" xlink:label="loc_XAIRDirectorsAndEmployeesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRDirectorsAndEmployeesMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmployeesMember" xlink:label="loc_XAIREmployeesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIREmployeesMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantHoldersMember" xlink:label="loc_XAIRWarrantHoldersMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRWarrantHoldersMember_430" xlink:type="arc" order="432" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ConcurrentPrivatePlacementMember" xlink:label="loc_XAIRConcurrentPrivatePlacementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_XAIRConcurrentPrivatePlacementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorMember" xlink:label="loc_XAIRVendorMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRVendorMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OfficersEmployeesAndConsultantsMember" xlink:label="loc_XAIROfficersEmployeesAndConsultantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIROfficersEmployeesAndConsultantsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnvestedStockOptionsMember" xlink:label="loc_XAIRUnvestedStockOptionsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRUnvestedStockOptionsMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandThirteenIncentiveOptionPlanMember" xlink:label="loc_XAIRTwoThousandThirteenIncentiveOptionPlanMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenIncentiveOptionPlanMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_470" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuancePeriodTerm" xlink:label="loc_XAIRStockIssuancePeriodTerm_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRStockIssuancePeriodTerm_470" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseCommitment" xlink:label="loc_XAIRStockPurchaseCommitment_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRStockPurchaseCommitment_470" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_470" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_470" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_XAIRProceedsFromIssuanceOfCommonStockGross_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRProceedsFromIssuanceOfCommonStockGross_470" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_470" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesEquitySecurities_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesEquitySecurities_470" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfUnregisteredSharesOfCommonStock" xlink:label="loc_XAIRNumberOfUnregisteredSharesOfCommonStock_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRNumberOfUnregisteredSharesOfCommonStock_470" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_470" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_470" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_470" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_470" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_470" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_470" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_470" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_470" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_470" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_470" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_470" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_470" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_470" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_470" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_470" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrant" xlink:label="loc_XAIRIncrementalValueOfWarrant_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRIncrementalValueOfWarrant_470" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_470" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_470" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfSharesIssuedForExerciseOfWarrants" xlink:label="loc_XAIRNumberOfSharesIssuedForExerciseOfWarrants_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRNumberOfSharesIssuedForExerciseOfWarrants_470" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:title="00000043 - Disclosure - Shareholder&apos;s Equity - Schedule of Unvested Restricted Shares (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:title="00000044 - Disclosure - Shareholder&apos;s Equity - Schedule of Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:title="00000045 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000046 - Disclosure - Shareholder&apos;s Equity - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ResearchAndDevelopmentExpensesMember" xlink:label="loc_XAIRResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_GeneralAndAdministrativeExpensesMember" xlink:label="loc_XAIRGeneralAndAdministrativeExpensesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRGeneralAndAdministrativeExpensesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:title="00000047 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:title="00000048 - Disclosure - Shareholder&apos;s Equity - Summary of Company&apos;s Outstanding Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_JanuaryTwoThousandandSeventeenMember" xlink:label="loc_XAIRJanuaryTwoThousandandSeventeenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRJanuaryTwoThousandandSeventeenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandSeventeenMember" xlink:label="loc_XAIRMarchTwoThousandSeventeenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandSeventeenMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenMember" xlink:label="loc_XAIRMarchTwoThousandEighteenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandEighteenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandTwentyMember" xlink:label="loc_XAIRMarchTwoThousandTwentyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandTwentyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InvestorOneMember" xlink:label="loc_XAIRInvestorOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRInvestorOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PlacementAgentMember" xlink:label="loc_XAIRPlacementAgentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRPlacementAgentMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ThirdPartyLicenseAgreementMember" xlink:label="loc_XAIRThirdPartyLicenseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRThirdPartyLicenseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LoanMember" xlink:label="loc_XAIRLoanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_XAIRLoanMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:title="00000049 - Disclosure - Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ResearchAndDevelopmentExpensesMember" xlink:label="loc_XAIRResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InsuranceMember" xlink:label="loc_XAIRInsuranceMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRInsuranceMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProfessionalMember" xlink:label="loc_XAIRProfessionalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRProfessionalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ValueAddedTaxReceivableMember" xlink:label="loc_XAIRValueAddedTaxReceivableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRValueAddedTaxReceivableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OtherMember" xlink:label="loc_XAIROtherMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIROtherMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:title="00000050 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="00000051 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockWarrantsMember" xlink:label="loc_XAIRCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockOptionsMember" xlink:label="loc_XAIRCommonStockOptionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRCommonStockOptionsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedSharesMember" xlink:label="loc_XAIRRestrictedSharesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRRestrictedSharesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - License Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementMember" xlink:label="loc_XAIRLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CircassiaPharmaceuticalsPLCMember" xlink:label="loc_XAIRCircassiaPharmaceuticalsPLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRCircassiaPharmaceuticalsPLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FoodAndDrugAdministrationMember" xlink:label="loc_XAIRFoodAndDrugAdministrationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_XAIRFoodAndDrugAdministrationMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_HospitalAndClinicSettingsMember" xlink:label="loc_XAIRHospitalAndClinicSettingsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_XAIRHospitalAndClinicSettingsMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="loc_countryCN_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnitedStatesAndChinaMember" xlink:label="loc_XAIRUnitedStatesAndChinaMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_XAIRUnitedStatesAndChinaMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaapIntellectualPropertyMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapIntellectualPropertyMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstObligationsMember" xlink:label="loc_XAIRFirstObligationsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_XAIRFirstObligationsMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondObligationsMember" xlink:label="loc_XAIRSecondObligationsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_XAIRSecondObligationsMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonesPayment" xlink:label="loc_XAIRMilestonesPayment_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonesPayment_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:label="loc_XAIRRevenueRecognitionMilestoneMethodRevenueRecognized1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueRecognitionMilestoneMethodRevenueRecognized1_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsInCashDiscountedPercentage" xlink:label="loc_XAIRPaymentsInCashDiscountedPercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsInCashDiscountedPercentage_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinarySharesValue" xlink:label="loc_XAIRPaymentOfMilestoneOrdinarySharesValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentOfMilestoneOrdinarySharesValue_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinaryShares" xlink:label="loc_XAIRPaymentOfMilestoneOrdinaryShares_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentOfMilestoneOrdinaryShares_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OnetimeRoyaltyPercentage" xlink:label="loc_XAIROnetimeRoyaltyPercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROnetimeRoyaltyPercentage_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyGrossProfitAmount" xlink:label="loc_XAIRRoyaltyGrossProfitAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyGrossProfitAmount_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyPercentage" xlink:label="loc_XAIRAnnualGrossProfitRoyaltyPercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAnnualGrossProfitRoyaltyPercentage_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyAmount" xlink:label="loc_XAIRAnnualGrossProfitRoyaltyAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAnnualGrossProfitRoyaltyAmount_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinaryShares" xlink:label="loc_XAIRFirstTwoMilestoneOrdinaryShares_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFirstTwoMilestoneOrdinaryShares_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinarySharesValue" xlink:label="loc_XAIRFirstTwoMilestoneOrdinarySharesValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFirstTwoMilestoneOrdinarySharesValue_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueAllocatedToPerformanceObligations" xlink:label="loc_XAIRRevenueAllocatedToPerformanceObligations_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueAllocatedToPerformanceObligations_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenueCurrent_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_240" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:title="00000053 - Disclosure - Facility Agreement Loan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LendersMember" xlink:label="loc_XAIRLendersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRLendersMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FiveTranchesMember" xlink:label="loc_XAIRFiveTranchesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRFiveTranchesMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TranchesMember" xlink:label="loc_XAIRTranchesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRTranchesMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondTrancheMember" xlink:label="loc_XAIRSecondTrancheMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRSecondTrancheMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansPayable_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantsDescription" xlink:label="loc_XAIRWarrantsDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRWarrantsDescription_80" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:title="00000054 - Disclosure - Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:title="00000055 - Disclosure - Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:title="00000056 - Disclosure - Loan Payable (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000057 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ILMember" xlink:label="loc_XAIRILMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_XAIRILMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:label="loc_XAIRMarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnusedNetOperatingLossCarryforwards" xlink:label="loc_XAIRUnusedNetOperatingLossCarryforwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRUnusedNetOperatingLossCarryforwards_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="loc_XAIROperatingLossCarryforwardsExpirationYears_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLossCarryforwardsExpirationYears_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:label="loc_XAIRFederalTaxBenefitForReversalOfUncertainTaxPositions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFederalTaxBenefitForReversalOfUncertainTaxPositions_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="00000058 - Disclosure - Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="00000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:title="00000060 - Disclosure - Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:title="00000061 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PatentLicenseAgreementMember" xlink:label="loc_XAIRPatentLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPatentLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionAgreementMember" xlink:label="loc_XAIROptionAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIROptionAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ExecutionAgreementMember" xlink:label="loc_XAIRExecutionAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRExecutionAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractResearchOrganizationMember" xlink:label="loc_XAIRContractResearchOrganizationMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRContractResearchOrganizationMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CareFusionMember" xlink:label="loc_XAIRCareFusionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRCareFusionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NitricGenIncMember" xlink:label="loc_XAIRNitricGenIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNitricGenIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyAssetMasterLtdMember" xlink:label="loc_XAIREmperyAssetMasterLtdMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyAssetMasterLtdMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientLpMember" xlink:label="loc_XAIREmperyTaxEfficientLpMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyTaxEfficientLpMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientIILpMember" xlink:label="loc_XAIREmperyTaxEfficientIILpMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyTaxEfficientIILpMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AfterSixMonthsMember" xlink:label="loc_XAIRAfterSixMonthsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRAfterSixMonthsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandAndSeventeenWarrantsMember" xlink:label="loc_XAIRTwoThousandAndSeventeenWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandAndSeventeenWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NonrefundableUpfrontFee" xlink:label="loc_XAIRNonrefundableUpfrontFee_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRNonrefundableUpfrontFee_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyPercentage" xlink:label="loc_XAIRRoyaltyPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyPercentage_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcquisitionCosts_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="loc_XAIRPaymentsForDevelopmentAndMilestonePayment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsForDevelopmentAndMilestonePayment_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonePayments" xlink:label="loc_XAIRMilestonePayments_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonePayments_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="loc_XAIRSalesRelatedMilestonesPayments_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSalesRelatedMilestonesPayments_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="loc_XAIRRevenueRecognitionMilestoneMethodRevenuesRecognized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueRecognitionMilestoneMethodRevenuesRecognized_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionsToPurchaseCommonStockValue" xlink:label="loc_XAIROptionsToPurchaseCommonStockValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROptionsToPurchaseCommonStockValue_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RemainingCommitmentUnderLicenseAgreement" xlink:label="loc_XAIRRemainingCommitmentUnderLicenseAgreement_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRemainingCommitmentUnderLicenseAgreement_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeaseAgreementExpireDateDescription" xlink:label="loc_XAIROperatingLeaseAgreementExpireDateDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLeaseAgreementExpireDateDescription_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_220" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:title="00000063 - Disclosure - Commitments and Contingencies - Schedule of Lease Other Information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000065 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AtTheMarketEquityOfferingMember" xlink:label="loc_XAIRAtTheMarketEquityOfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_XAIRAtTheMarketEquityOfferingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_BeyondAirIncMember" xlink:label="loc_XAIRBeyondAirIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirIncMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCorporationLLCMember" xlink:label="loc_XAIRLincolnParkCorporationLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCorporationLLCMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesAgentMember" xlink:label="loc_XAIRSalesAgentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRSalesAgentMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NewPurchaseAgreementMember" xlink:label="loc_XAIRNewPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNewPurchaseAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FeePecentage" xlink:label="loc_XAIRFeePecentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFeePecentage_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AgreementTermDescription" xlink:label="loc_XAIRAgreementTermDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAgreementTermDescription_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PurchaseAgreementDescription" xlink:label="loc_XAIRPurchaseAgreementDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPurchaseAgreementDescription_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TradingVolumePecentage" xlink:label="loc_XAIRTradingVolumePecentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRTradingVolumePecentage_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WeightedAveragePricePecentage" xlink:label="loc_XAIRWeightedAveragePricePecentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRWeightedAveragePricePecentage_70" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>xair-20200331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property Plant And Equipment By Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionAgreementMember" xlink:label="XAIR_OptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionAgreementMember" xlink:to="XAIR_OptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OptionAgreementMember_lbl" xml:lang="en-US">Option Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NitricGenIncMember" xlink:label="XAIR_NitricGenIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenIncMember" xlink:to="XAIR_NitricGenIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NitricGenIncMember_lbl" xml:lang="en-US">NitricGen, Inc [Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandThirteenIncentiveOptionPlanMember" xlink:label="XAIR_TwoThousandThirteenIncentiveOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenIncentiveOptionPlanMember" xlink:to="XAIR_TwoThousandThirteenIncentiveOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandThirteenIncentiveOptionPlanMember_lbl" xml:lang="en-US">2013 Incentive Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_JanuaryTwoThousandandSeventeenMember" xlink:label="XAIR_JanuaryTwoThousandandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_JanuaryTwoThousandandSeventeenMember" xlink:to="XAIR_JanuaryTwoThousandandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_JanuaryTwoThousandandSeventeenMember_lbl" xml:lang="en-US">January 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandSeventeenMember" xlink:label="XAIR_MarchTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandSeventeenMember" xlink:to="XAIR_MarchTwoThousandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MarchTwoThousandSeventeenMember_lbl" xml:lang="en-US">March 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PlacementAgentMember" xlink:label="XAIR_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PlacementAgentMember" xlink:to="XAIR_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InvestorOneMember" xlink:label="XAIR_InvestorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InvestorOneMember" xlink:to="XAIR_InvestorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_InvestorOneMember_lbl" xml:lang="en-US">Investors One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MutualFundsMember" xlink:label="XAIR_MutualFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MutualFundsMember" xlink:to="XAIR_MutualFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MutualFundsMember_lbl" xml:lang="en-US">Mutual Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ExecutionAgreementMember" xlink:label="XAIR_ExecutionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ExecutionAgreementMember" xlink:to="XAIR_ExecutionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ExecutionAgreementMember_lbl" xml:lang="en-US">Execution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CircassiaPharmaceuticalsPLCMember" xlink:label="XAIR_CircassiaPharmaceuticalsPLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CircassiaPharmaceuticalsPLCMember" xlink:to="XAIR_CircassiaPharmaceuticalsPLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CircassiaPharmaceuticalsPLCMember_lbl" xml:lang="en-US">Circassia Pharmaceuticals PLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseAgreementMember" xlink:label="XAIR_StockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockPurchaseAgreementMember" xlink:to="XAIR_StockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClinicalAndMedicalEquipmentMember" xlink:to="XAIR_ClinicalAndMedicalEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember_lbl" xml:lang="en-US">Clinical and Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorMember" xlink:label="XAIR_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VendorMember" xlink:to="XAIR_VendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenMember" xlink:label="XAIR_MarchTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandEighteenMember" xlink:to="XAIR_MarchTwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MarchTwoThousandEighteenMember_lbl" xml:lang="en-US">March 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ThirdPartyLicenseAgreementMember" xlink:label="XAIR_ThirdPartyLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ThirdPartyLicenseAgreementMember" xlink:to="XAIR_ThirdPartyLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ThirdPartyLicenseAgreementMember_lbl" xml:lang="en-US">Third Party License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ResearchAndDevelopmentExpensesMember" xlink:label="XAIR_ResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ResearchAndDevelopmentExpensesMember" xlink:to="XAIR_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InsuranceMember" xlink:label="XAIR_InsuranceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InsuranceMember" xlink:to="XAIR_InsuranceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_InsuranceMember_lbl" xml:lang="en-US">Insurance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OtherMember" xlink:label="XAIR_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherMember" xlink:to="XAIR_OtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OtherMember_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementMember" xlink:label="XAIR_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementMember" xlink:to="XAIR_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AfterSixMonthsMember" xlink:label="XAIR_AfterSixMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AfterSixMonthsMember" xlink:to="XAIR_AfterSixMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AfterSixMonthsMember_lbl" xml:lang="en-US">After Six Months [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstObligationsMember" xlink:label="XAIR_FirstObligationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstObligationsMember" xlink:to="XAIR_FirstObligationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FirstObligationsMember_lbl" xml:lang="en-US">First Obligation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondObligationsMember" xlink:label="XAIR_SecondObligationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondObligationsMember" xlink:to="XAIR_SecondObligationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SecondObligationsMember_lbl" xml:lang="en-US">Second Obligation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="country_CN" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US">China [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_HospitalAndClinicSettingsMember" xlink:label="XAIR_HospitalAndClinicSettingsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_HospitalAndClinicSettingsMember" xlink:to="XAIR_HospitalAndClinicSettingsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_HospitalAndClinicSettingsMember_lbl" xml:lang="en-US">Hospital and Clinic Settings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnitedStatesAndChinaMember" xlink:label="XAIR_UnitedStatesAndChinaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnitedStatesAndChinaMember" xlink:to="XAIR_UnitedStatesAndChinaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_UnitedStatesAndChinaMember_lbl" xml:lang="en-US">United States and China [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ComputersEquipmentMember" xlink:label="XAIR_ComputersEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ComputersEquipmentMember" xlink:to="XAIR_ComputersEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ComputersEquipmentMember_lbl" xml:lang="en-US">Computers Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCapitalFundLLCMember" xlink:label="XAIR_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LincolnParkCapitalFundLLCMember" xlink:to="XAIR_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_GeneralAndAdministrativeExpensesMember" xlink:label="XAIR_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GeneralAndAdministrativeExpensesMember" xlink:to="XAIR_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_GeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General and Administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnvestedStockOptionsMember" xlink:label="XAIR_UnvestedStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnvestedStockOptionsMember" xlink:to="XAIR_UnvestedStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_UnvestedStockOptionsMember_lbl" xml:lang="en-US">Unvested Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FoodAndDrugAdministrationMember" xlink:label="XAIR_FoodAndDrugAdministrationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FoodAndDrugAdministrationMember" xlink:to="XAIR_FoodAndDrugAdministrationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FoodAndDrugAdministrationMember_lbl" xml:lang="en-US">Food and Drug Administration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PatentLicenseAgreementMember" xlink:label="XAIR_PatentLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PatentLicenseAgreementMember" xlink:to="XAIR_PatentLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PatentLicenseAgreementMember_lbl" xml:lang="en-US">Patent License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CareFusionMember" xlink:label="XAIR_CareFusionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CareFusionMember" xlink:to="XAIR_CareFusionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CareFusionMember_lbl" xml:lang="en-US">CareFusion [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockWarrantsMember" xlink:label="XAIR_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockWarrantsMember" xlink:to="XAIR_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockOptionsMember" xlink:label="XAIR_CommonStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockOptionsMember" xlink:to="XAIR_CommonStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CommonStockOptionsMember_lbl" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedSharesMember" xlink:label="XAIR_RestrictedSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RestrictedSharesMember" xlink:to="XAIR_RestrictedSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RestrictedSharesMember_lbl" xml:lang="en-US">Restricted Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ConcurrentPrivatePlacementMember" xlink:label="XAIR_ConcurrentPrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ConcurrentPrivatePlacementMember" xlink:to="XAIR_ConcurrentPrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ConcurrentPrivatePlacementMember_lbl" xml:lang="en-US">Concurrent Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProfessionalMember" xlink:label="XAIR_ProfessionalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProfessionalMember" xlink:to="XAIR_ProfessionalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ProfessionalMember_lbl" xml:lang="en-US">Professional [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Dividend Yield [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Topic 842 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OfficersEmployeesAndConsultantsMember" xlink:label="XAIR_OfficersEmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OfficersEmployeesAndConsultantsMember" xlink:to="XAIR_OfficersEmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OfficersEmployeesAndConsultantsMember_lbl" xml:lang="en-US">Officers, Employees and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DirectorsAndEmployeesMember" xlink:label="XAIR_DirectorsAndEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DirectorsAndEmployeesMember" xlink:to="XAIR_DirectorsAndEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DirectorsAndEmployeesMember_lbl" xml:lang="en-US">Directors and Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmployeesMember" xlink:label="XAIR_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmployeesMember" xlink:to="XAIR_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ValueAddedTaxReceivableMember" xlink:label="XAIR_ValueAddedTaxReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ValueAddedTaxReceivableMember" xlink:to="XAIR_ValueAddedTaxReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ValueAddedTaxReceivableMember_lbl" xml:lang="en-US">Value added tax receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractResearchOrganizationMember" xlink:label="XAIR_ContractResearchOrganizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ContractResearchOrganizationMember" xlink:to="XAIR_ContractResearchOrganizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ContractResearchOrganizationMember_lbl" xml:lang="en-US">Contract Research Organization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income/Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="XAIR_FacilityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementMember" xlink:to="XAIR_FacilityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FacilityAgreementMember_lbl" xml:lang="en-US">Facility Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NewPurchaseAgreementMember" xlink:label="XAIR_NewPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NewPurchaseAgreementMember" xlink:to="XAIR_NewPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NewPurchaseAgreementMember_lbl" xml:lang="en-US">New Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantHoldersMember" xlink:label="XAIR_WarrantHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantHoldersMember" xlink:to="XAIR_WarrantHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WarrantHoldersMember_lbl" xml:lang="en-US">Warrant Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandTwentyMember" xlink:label="XAIR_MarchTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandTwentyMember" xlink:to="XAIR_MarchTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MarchTwoThousandTwentyMember_lbl" xml:lang="en-US">March 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LoanMember" xlink:label="XAIR_LoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanMember" xlink:to="XAIR_LoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LoanMember_lbl" xml:lang="en-US">Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LendersMember" xlink:label="XAIR_LendersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LendersMember" xlink:to="XAIR_LendersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LendersMember_lbl" xml:lang="en-US">Lenders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FiveTranchesMember" xlink:label="XAIR_FiveTranchesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FiveTranchesMember" xlink:to="XAIR_FiveTranchesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FiveTranchesMember_lbl" xml:lang="en-US">Five Tranches [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TranchesMember" xlink:label="XAIR_TranchesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TranchesMember" xlink:to="XAIR_TranchesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TranchesMember_lbl" xml:lang="en-US">Tranches [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ILMember" xlink:label="XAIR_ILMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ILMember" xlink:to="XAIR_ILMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ILMember_lbl" xml:lang="en-US">Israel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:label="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:to="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_lbl" xml:lang="en-US">March 2018 Expire Through 2037 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AtTheMarketEquityOfferingMember" xlink:label="XAIR_AtTheMarketEquityOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AtTheMarketEquityOfferingMember" xlink:to="XAIR_AtTheMarketEquityOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AtTheMarketEquityOfferingMember_lbl" xml:lang="en-US">At-The-Market Equity Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_BeyondAirIncMember" xlink:label="XAIR_BeyondAirIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirIncMember" xlink:to="XAIR_BeyondAirIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_BeyondAirIncMember_lbl" xml:lang="en-US">Beyond Air, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesAgentMember" xlink:label="XAIR_SalesAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesAgentMember" xlink:to="XAIR_SalesAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SalesAgentMember_lbl" xml:lang="en-US">Sales Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCorporationLLCMember" xlink:label="XAIR_LincolnParkCorporationLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LincolnParkCorporationLLCMember" xlink:to="XAIR_LincolnParkCorporationLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LincolnParkCorporationLLCMember_lbl" xml:lang="en-US">Lincoln Park Corporation LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractManufacturerMember" xlink:label="XAIR_ContractManufacturerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ContractManufacturerMember" xlink:to="XAIR_ContractManufacturerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ContractManufacturerMember_lbl" xml:lang="en-US">Contract Manufacturer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ShareBasedCompensationAwardFiveTrancheMember" xlink:label="XAIR_ShareBasedCompensationAwardFiveTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShareBasedCompensationAwardFiveTrancheMember" xlink:to="XAIR_ShareBasedCompensationAwardFiveTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ShareBasedCompensationAwardFiveTrancheMember_lbl" xml:lang="en-US">Five Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondTrancheMember" xlink:label="XAIR_SecondTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondTrancheMember" xlink:to="XAIR_SecondTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandAndSeventeenWarrantsMember" xlink:label="XAIR_TwoThousandAndSeventeenWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndSeventeenWarrantsMember" xlink:to="XAIR_TwoThousandAndSeventeenWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TwoThousandAndSeventeenWarrantsMember_lbl" xml:lang="en-US">2017 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyAssetMasterLtdMember" xlink:label="XAIR_EmperyAssetMasterLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyAssetMasterLtdMember" xlink:to="XAIR_EmperyAssetMasterLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EmperyAssetMasterLtdMember_lbl" xml:lang="en-US">Empery Asset Master, Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientLpMember" xlink:label="XAIR_EmperyTaxEfficientLpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyTaxEfficientLpMember" xlink:to="XAIR_EmperyTaxEfficientLpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EmperyTaxEfficientLpMember_lbl" xml:lang="en-US">Empery Tax Efficient, LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientIILpMember" xlink:label="XAIR_EmperyTaxEfficientIILpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyTaxEfficientIILpMember" xlink:to="XAIR_EmperyTaxEfficientIILpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EmperyTaxEfficientIILpMember_lbl" xml:lang="en-US">Empery Tax Efficient II, LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DocumentAndEntityInformationAbstract" xlink:label="XAIR_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DocumentAndEntityInformationAbstract" xlink:to="XAIR_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightOfUseLeaseAssetsCurrent" xlink:label="XAIR_RightOfUseLeaseAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightOfUseLeaseAssetsCurrent" xlink:to="XAIR_RightOfUseLeaseAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RightOfUseLeaseAssetsCurrent_lbl" xml:lang="en-US">Right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnology" xlink:label="XAIR_LicensedRightToUseTechnology" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicensedRightToUseTechnology" xlink:to="XAIR_LicensedRightToUseTechnology_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LicensedRightToUseTechnology_lbl" xml:lang="en-US">Licensing right to use technology</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Stock to be issued to a vendor</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Facility Agreement loan, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 16,056,360 and 8,714,815 shares issued and outstanding as of March 31, 2020 and March 31, 2019, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">License revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:label="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:to="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities_lbl" xml:lang="en-US">Realized and unrealized loss on available for sale marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeOperating" xlink:label="us-gaap_DividendIncomeOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendIncomeOperating" xlink:to="us-gaap_DividendIncomeOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendIncomeOperating_lbl" xml:lang="en-US">Dividend income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Benefit for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendFromWarrantModification" xlink:label="XAIR_DeemedDividendFromWarrantModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendFromWarrantModification" xlink:to="XAIR_DeemedDividendFromWarrantModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_DeemedDividendFromWarrantModification_lbl" xml:lang="en-US">Deemed dividend from warrant modification</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributed to common shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustment" xlink:label="XAIR_CumulativeAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CumulativeAdjustment" xlink:to="XAIR_CumulativeAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CumulativeAdjustment_lbl" xml:lang="en-US">Adjustment due to adoption of ASU-2017</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustmentOne" xlink:label="XAIR_CumulativeAdjustmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CumulativeAdjustmentOne" xlink:to="XAIR_CumulativeAdjustmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CumulativeAdjustmentOne_lbl" xml:lang="en-US">Adjustment due to adoption of ASU 2016-01</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">At the market stock issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">At the market stock issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to an underwritten offering and a private placement, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock pursuant to an underwritten offering and a private placement, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:to="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_lbl" xml:lang="en-US">Issuance of common stock pursuant to Purchase Agreement, net</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:to="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to Purchase Agreement, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrantsDueToModification" xlink:label="XAIR_IncrementalValueOfWarrantsDueToModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncrementalValueOfWarrantsDueToModification" xlink:to="XAIR_IncrementalValueOfWarrantsDueToModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncrementalValueOfWarrantsDueToModification_lbl" xml:lang="en-US">Incremental value of warrants due to a modification</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendDueToWarrantModification" xlink:label="XAIR_DeemedDividendDueToWarrantModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendDueToWarrantModification" xlink:to="XAIR_DeemedDividendDueToWarrantModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeemedDividendDueToWarrantModification_lbl" xml:lang="en-US">Deemed dividend due to a warrant modification</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:to="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of common stock pursuant to a private placement, net</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:to="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to a private placement, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:label="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:to="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_lbl" xml:lang="en-US">Warrant issued with debt issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsValue" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringExerciseOfWarrantsValue" xlink:to="XAIR_StockIssuedDuringExerciseOfWarrantsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsValue_lbl" xml:lang="en-US">Issuance of common stock upon the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsShares" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringExerciseOfWarrantsShares" xlink:to="XAIR_StockIssuedDuringExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsShares_lbl" xml:lang="en-US">Issuance of common stock upon the exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:label="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:to="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock upon cashless excise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:label="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:to="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_lbl" xml:lang="en-US">Issuance of common stock upon cashless excise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:label="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:to="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock_lbl" xml:lang="en-US">Vested restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:label="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:to="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock_lbl" xml:lang="en-US">Vested restricted stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CumulativeAdjustment" xlink:to="XAIR_CumulativeAdjustment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_CumulativeAdjustment_2_lbl" xml:lang="en-US">Cumulative-effect of adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:label="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:to="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_lbl" xml:lang="en-US">Payment of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:label="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:to="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities_lbl" xml:lang="en-US">Unrealized and realized loss on marketable securities to available for sale marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:label="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:to="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_lbl" xml:lang="en-US">Change of management's assessment of prior year research and development to licensing right to use technology</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdoptionOfAccountingStandardsUpdate" xlink:label="XAIR_AdoptionOfAccountingStandardsUpdate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdoptionOfAccountingStandardsUpdate" xlink:to="XAIR_AdoptionOfAccountingStandardsUpdate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_AdoptionOfAccountingStandardsUpdate_lbl" xml:lang="en-US">Adoption of ASU 2016-01</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:label="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:to="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance cost and deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Investment in available for sale marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from redemption of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows provided by from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Issuance of common stock in an underwritten offering and private placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Issuance of common stock in private placement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsfromIssuanceOfMarketOfferings" xlink:label="XAIR_ProceedsfromIssuanceOfMarketOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsfromIssuanceOfMarketOfferings" xlink:to="XAIR_ProceedsfromIssuanceOfMarketOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ProceedsfromIssuanceOfMarketOfferings_lbl" xml:lang="en-US">Issuance of common stock related to at the market offerings, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock, net of offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from credit facility loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="us-gaap_ProceedsFromBankDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Payment of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:label="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightofuseAssets" xlink:label="XAIR_RightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightofuseAssets" xlink:to="XAIR_RightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RightofuseAssets_lbl" xml:lang="en-US">Right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeaseLiabilities" xlink:label="XAIR_OperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseLiabilities" xlink:to="XAIR_OperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_OperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendAsResultOfWarrantModification" xlink:label="XAIR_DeemedDividendAsResultOfWarrantModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendAsResultOfWarrantModification" xlink:to="XAIR_DeemedDividendAsResultOfWarrantModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="XAIR_DeemedDividendAsResultOfWarrantModification_lbl" xml:lang="en-US">Deemed dividend as a result of a warrant modification</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" xlink:label="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" xlink:to="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity_lbl" xml:lang="en-US">Fair market value of warrants allocated to debt discount and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" xlink:label="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" xlink:to="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology_lbl" xml:lang="en-US">Fair market value of options issued to NitricGen for the licensing right to use technology</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow items:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholder's Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesAbstract" xlink:label="XAIR_CurrentAssetsAndPrepaidExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CurrentAssetsAndPrepaidExpensesAbstract" xlink:to="XAIR_CurrentAssetsAndPrepaidExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CurrentAssetsAndPrepaidExpensesAbstract_lbl" xml:lang="en-US">Current Assets And Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" xlink:label="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" xlink:to="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock_lbl" xml:lang="en-US">Current Assets and Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementAbstract" xlink:label="XAIR_LicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementAbstract" xlink:to="XAIR_LicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementTextBlock" xlink:label="XAIR_LicenseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementTextBlock" xlink:to="XAIR_LicenseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_LicenseAgreementTextBlock_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="XAIR_FacilityAgreementLoanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementLoanAbstract" xlink:to="XAIR_FacilityAgreementLoanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FacilityAgreementLoanAbstract_lbl" xml:lang="en-US">Facility Agreement Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanTextBlock" xlink:label="XAIR_FacilityAgreementLoanTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementLoanTextBlock" xlink:to="XAIR_FacilityAgreementLoanTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_FacilityAgreementLoanTextBlock_lbl" xml:lang="en-US">Facility Agreement Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Loan Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedCashPolicyTextBlock" xlink:label="XAIR_RestrictedCashPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RestrictedCashPolicyTextBlock" xlink:to="XAIR_RestrictedCashPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RestrictedCashPolicyTextBlock_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Exchange Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Investment in Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnologyPolicyTextBlock" xlink:label="XAIR_LicensedRightToUseTechnologyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicensedRightToUseTechnologyPolicyTextBlock" xlink:to="XAIR_LicensedRightToUseTechnologyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LicensedRightToUseTechnologyPolicyTextBlock_lbl" xml:lang="en-US">Licensed Right to Use Technology</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" xlink:label="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" xlink:to="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Life of Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Expected Amortization Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" xlink:label="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" xlink:to="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of Use Assets and Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested Restricted Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumption of Black-Scholes Option Pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" xlink:label="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" xlink:to="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Company's Outstanding Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" xlink:label="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" xlink:to="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Current Assets and Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potential Anti-Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" xlink:label="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" xlink:to="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock_lbl" xml:lang="en-US">Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" xlink:label="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" xlink:to="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock_lbl" xml:lang="en-US">Schedule of Facility Agreement Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Profit (Loss) Before Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Asset/Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Statutory US Federal Effective Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" xlink:label="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" xlink:to="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Other Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_2_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash equivalents and marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PurchaseAgreementDescription" xlink:label="XAIR_PurchaseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PurchaseAgreementDescription" xlink:to="XAIR_PurchaseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IntangibleAssetsMilestonePayments" xlink:label="XAIR_IntangibleAssetsMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IntangibleAssetsMilestonePayments" xlink:to="XAIR_IntangibleAssetsMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IntangibleAssetsMilestonePayments_lbl" xml:lang="en-US">Intangible assets milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Uncertain tax positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid-in-capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Estimated useful life of assets, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicensedRightToUseTechnology" xlink:to="XAIR_LicensedRightToUseTechnology_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_LicensedRightToUseTechnology_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightOfUseAssetCurrent" xlink:label="XAIR_RightOfUseAssetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightOfUseAssetCurrent" xlink:to="XAIR_RightOfUseAssetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RightOfUseAssetCurrent_lbl" xml:lang="en-US">Right of use asset short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Right of use asset long-term</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeasesRightofuseAsset" xlink:label="XAIR_OperatingLeasesRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeasesRightofuseAsset" xlink:to="XAIR_OperatingLeasesRightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLeasesRightofuseAsset_lbl" xml:lang="en-US">Total operating lease right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liability short-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability long-term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Total marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuancePeriodTerm" xlink:label="XAIR_StockIssuancePeriodTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuancePeriodTerm" xlink:to="XAIR_StockIssuancePeriodTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockIssuancePeriodTerm_lbl" xml:lang="en-US">Stock issuance period, term</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseCommitment" xlink:label="XAIR_StockPurchaseCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockPurchaseCommitment" xlink:to="XAIR_StockPurchaseCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_StockPurchaseCommitment_lbl" xml:lang="en-US">Stock purchase commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Average price per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsFromIssuanceOfCommonStockGross" xlink:label="XAIR_ProceedsFromIssuanceOfCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromIssuanceOfCommonStockGross" xlink:to="XAIR_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xml:lang="en-US">Sale of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfUnregisteredSharesOfCommonStock" xlink:label="XAIR_NumberOfUnregisteredSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfUnregisteredSharesOfCommonStock" xlink:to="XAIR_NumberOfUnregisteredSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NumberOfUnregisteredSharesOfCommonStock_lbl" xml:lang="en-US">Number of unregistered shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of common stock value issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock shares issued services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Number of restricted shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Options vesting terms</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Options vesting terms, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common stock, shares available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining service period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant excercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrant" xlink:label="XAIR_IncrementalValueOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncrementalValueOfWarrant" xlink:to="XAIR_IncrementalValueOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncrementalValueOfWarrant_lbl" xml:lang="en-US">Incremental value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfSharesIssuedForExerciseOfWarrants" xlink:label="XAIR_NumberOfSharesIssuedForExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfSharesIssuedForExerciseOfWarrants" xlink:to="XAIR_NumberOfSharesIssuedForExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NumberOfSharesIssuedForExerciseOfWarrants_lbl" xml:lang="en-US">Number of shares issued for exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of unvested options at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of unvested options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of unvested options, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of unvested options, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of unvested options, at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price - options outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price - options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price - options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price - options, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price - options, outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life - options outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining contractual life - options outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life - options exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value exercisable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Date of Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorsResearchAndDevelopment" xlink:label="XAIR_VendorsResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VendorsResearchAndDevelopment" xlink:to="XAIR_VendorsResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_VendorsResearchAndDevelopment_lbl" xml:lang="en-US">Vendors - research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income taxes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee salaries and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonesPayment" xlink:label="XAIR_MilestonesPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonesPayment" xlink:to="XAIR_MilestonesPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MilestonesPayment_lbl" xml:lang="en-US">Milestones payment</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:to="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1_lbl" xml:lang="en-US">Regulatory milestone amount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsInCashDiscountedPercentage" xlink:label="XAIR_PaymentsInCashDiscountedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsInCashDiscountedPercentage" xlink:to="XAIR_PaymentsInCashDiscountedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentsInCashDiscountedPercentage_lbl" xml:lang="en-US">Payments in cash discounted, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinarySharesValue" xlink:label="XAIR_PaymentOfMilestoneOrdinarySharesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfMilestoneOrdinarySharesValue" xlink:to="XAIR_PaymentOfMilestoneOrdinarySharesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentOfMilestoneOrdinarySharesValue_lbl" xml:lang="en-US">Payment of milestone ordinary shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinaryShares" xlink:label="XAIR_PaymentOfMilestoneOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfMilestoneOrdinaryShares" xlink:to="XAIR_PaymentOfMilestoneOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentOfMilestoneOrdinaryShares_lbl" xml:lang="en-US">Payment of milestone ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OnetimeRoyaltyPercentage" xlink:label="XAIR_OnetimeRoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OnetimeRoyaltyPercentage" xlink:to="XAIR_OnetimeRoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OnetimeRoyaltyPercentage_lbl" xml:lang="en-US">One-time royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyGrossProfitAmount" xlink:label="XAIR_RoyaltyGrossProfitAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyGrossProfitAmount" xlink:to="XAIR_RoyaltyGrossProfitAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RoyaltyGrossProfitAmount_lbl" xml:lang="en-US">Royalty gross profit amount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyPercentage" xlink:label="XAIR_AnnualGrossProfitRoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AnnualGrossProfitRoyaltyPercentage" xlink:to="XAIR_AnnualGrossProfitRoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AnnualGrossProfitRoyaltyPercentage_lbl" xml:lang="en-US">Annual Gross profit royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyAmount" xlink:label="XAIR_AnnualGrossProfitRoyaltyAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AnnualGrossProfitRoyaltyAmount" xlink:to="XAIR_AnnualGrossProfitRoyaltyAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AnnualGrossProfitRoyaltyAmount_lbl" xml:lang="en-US">Annual Gross profit royalty amount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinaryShares" xlink:label="XAIR_FirstTwoMilestoneOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstTwoMilestoneOrdinaryShares" xlink:to="XAIR_FirstTwoMilestoneOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FirstTwoMilestoneOrdinaryShares_lbl" xml:lang="en-US">First two milestone ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinarySharesValue" xlink:label="XAIR_FirstTwoMilestoneOrdinarySharesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstTwoMilestoneOrdinarySharesValue" xlink:to="XAIR_FirstTwoMilestoneOrdinarySharesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FirstTwoMilestoneOrdinarySharesValue_lbl" xml:lang="en-US">First two milestone ordinary shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueAllocatedToPerformanceObligations" xlink:label="XAIR_RevenueAllocatedToPerformanceObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueAllocatedToPerformanceObligations" xlink:to="XAIR_RevenueAllocatedToPerformanceObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RevenueAllocatedToPerformanceObligations_lbl" xml:lang="en-US">Revenue allocated to performance obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">License revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt instrument, maturity date, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants excersice price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants expire term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantsDescription" xlink:label="XAIR_WarrantsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantsDescription" xlink:to="XAIR_WarrantsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WarrantsDescription_lbl" xml:lang="en-US">Warrants description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt instrument measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementLoanAbstract" xlink:to="XAIR_FacilityAgreementLoanAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_FacilityAgreementLoanAbstract_2_lbl" xml:lang="en-US">Facility Agreement Loan - Schedule Of Facility Agreement Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face value of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AccretionOfInterestExpense" xlink:label="XAIR_AccretionOfInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AccretionOfInterestExpense" xlink:to="XAIR_AccretionOfInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AccretionOfInterestExpense_lbl" xml:lang="en-US">Accretion of interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermLoansPayable_2_lbl" xml:lang="en-US">Facility agreement loan balance - March 31, 2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayable_2_lbl" xml:lang="en-US">Loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Monthly payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayableCurrent_2_lbl" xml:lang="en-US">Outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Corporate tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnusedNetOperatingLossCarryforwards" xlink:label="XAIR_UnusedNetOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnusedNetOperatingLossCarryforwards" xlink:to="XAIR_UnusedNetOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_UnusedNetOperatingLossCarryforwards_lbl" xml:lang="en-US">Unused net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLossCarryforwardsExpirationYears" xlink:to="XAIR_OperatingLossCarryforwardsExpirationYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears_lbl" xml:lang="en-US">Operating loss carryforward expire description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowances increased</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:label="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:to="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions_lbl" xml:lang="en-US">Federal tax benefit for reversal of uncertain tax positions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Reserves and allowances - foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_lbl" xml:lang="en-US">Capital loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsResearchAndDevelopment" xlink:label="XAIR_DeferredTaxAssetsResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsResearchAndDevelopment" xlink:to="XAIR_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsResearchAndDevelopment_lbl" xml:lang="en-US">Research and development - foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsRightofuseAsset" xlink:to="XAIR_DeferredTaxAssetsRightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsLeaseLiability" xlink:to="XAIR_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Net deferred tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:label="XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract_lbl" xml:lang="en-US">Income Taxes - Schedule Of Statutory Us Federal Effective Tax Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal income tax at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xml:lang="en-US">Permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax expense rate</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:label="XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:to="XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract_lbl" xml:lang="en-US">Income Taxes - Schedule Of Unrecognized Tax Benefits Related To Uncertain Tax Positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Balance at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Decreases for the current year's tax position</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Balance at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NonrefundableUpfrontFee" xlink:label="XAIR_NonrefundableUpfrontFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NonrefundableUpfrontFee" xlink:to="XAIR_NonrefundableUpfrontFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_NonrefundableUpfrontFee_lbl" xml:lang="en-US">Non-refundable upfront fee</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyPercentage" xlink:label="XAIR_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyPercentage" xlink:to="XAIR_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRoyalties_2_lbl" xml:lang="en-US">Payment to royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCosts_lbl" xml:lang="en-US">Acquisition cost to purchase intellectual property assets and rights</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:to="XAIR_PaymentsForDevelopmentAndMilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment_lbl" xml:lang="en-US">Payments for development and milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonePayments" xlink:label="XAIR_MilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonePayments" xlink:to="XAIR_MilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_MilestonePayments_lbl" xml:lang="en-US">Milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="XAIR_SalesRelatedMilestonesPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesRelatedMilestonesPayments" xlink:to="XAIR_SalesRelatedMilestonesPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_SalesRelatedMilestonesPayments_lbl" xml:lang="en-US">Sales related milestones payments</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:to="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized_lbl" xml:lang="en-US">Future payments based on certain milestones</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Options to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionsToPurchaseCommonStockValue" xlink:label="XAIR_OptionsToPurchaseCommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionsToPurchaseCommonStockValue" xlink:to="XAIR_OptionsToPurchaseCommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OptionsToPurchaseCommonStockValue_lbl" xml:lang="en-US">Options to purchase common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RemainingCommitmentUnderLicenseAgreement" xlink:label="XAIR_RemainingCommitmentUnderLicenseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RemainingCommitmentUnderLicenseAgreement" xlink:to="XAIR_RemainingCommitmentUnderLicenseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_RemainingCommitmentUnderLicenseAgreement_lbl" xml:lang="en-US">Remaining commitment under license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeaseAgreementExpireDateDescription" xlink:label="XAIR_OperatingLeaseAgreementExpireDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseAgreementExpireDateDescription" xlink:to="XAIR_OperatingLeaseAgreementExpireDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLeaseAgreementExpireDateDescription_lbl" xml:lang="en-US">Operating lease agreement expire date description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants excersiced</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Proceeds from sales of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FeePecentage" xlink:label="XAIR_FeePecentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FeePecentage" xlink:to="XAIR_FeePecentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FeePecentage_lbl" xml:lang="en-US">Fee pecentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AgreementTermDescription" xlink:label="XAIR_AgreementTermDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AgreementTermDescription" xlink:to="XAIR_AgreementTermDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AgreementTermDescription_lbl" xml:lang="en-US">Agreement term description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Price per shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of common stok sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PurchaseAgreementDescription" xlink:to="XAIR_PurchaseAgreementDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="XAIR_PurchaseAgreementDescription_2_lbl" xml:lang="en-US">Purchase agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TradingVolumePecentage" xlink:label="XAIR_TradingVolumePecentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TradingVolumePecentage" xlink:to="XAIR_TradingVolumePecentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_TradingVolumePecentage_lbl" xml:lang="en-US">Trading volume pecentage</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WeightedAveragePricePecentage" xlink:label="XAIR_WeightedAveragePricePecentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WeightedAveragePricePecentage" xlink:to="XAIR_WeightedAveragePricePecentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_WeightedAveragePricePecentage_lbl" xml:lang="en-US">Weighted average price pecentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AccretionOfInterestExpense" xlink:to="XAIR_AccretionOfInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AccretionOfInterestExpense_doc" xml:lang="en-US">Accretion of interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:to="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance_doc" xml:lang="en-US">Warrant issued with debt issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdoptionOfAccountingStandardsUpdate" xlink:to="XAIR_AdoptionOfAccountingStandardsUpdate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AdoptionOfAccountingStandardsUpdate_doc" xml:lang="en-US">Adoption of ASU 2016-01.</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdoptionTopicEightFourTwoMember" xlink:label="XAIR_AdoptionTopicEightFourTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdoptionTopicEightFourTwoMember" xlink:to="XAIR_AdoptionTopicEightFourTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AdoptionTopicEightFourTwoMember_doc" xml:lang="en-US">ASU 842 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AfterSixMonthsMember" xlink:to="XAIR_AfterSixMonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AfterSixMonthsMember_doc" xml:lang="en-US">After Six Months [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AgreementTermDescription" xlink:to="XAIR_AgreementTermDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AgreementTermDescription_doc" xml:lang="en-US">Agreement term description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" xlink:to="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity_doc" xml:lang="en-US">air market value of warrants allocated to debt discount and stockholders' equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:to="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts_doc" xml:lang="en-US">Amortization of debt issuance cost and deferred financing fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AnnualGrossProfitRoyaltyAmount" xlink:to="XAIR_AnnualGrossProfitRoyaltyAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AnnualGrossProfitRoyaltyAmount_doc" xml:lang="en-US">Annual Gross profit royalty amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AnnualGrossProfitRoyaltyPercentage" xlink:to="XAIR_AnnualGrossProfitRoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AnnualGrossProfitRoyaltyPercentage_doc" xml:lang="en-US">Annual Gross profit royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AtTheMarketEquityOfferingMember" xlink:to="XAIR_AtTheMarketEquityOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_AtTheMarketEquityOfferingMember_doc" xml:lang="en-US">At-The-Market Equity Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BeyondAirIncMember" xlink:to="XAIR_BeyondAirIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BeyondAirIncMember_doc" xml:lang="en-US">Beyond Air, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember" xlink:label="XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember" xlink:to="XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_BoardOfDirectorsOfficersEmployeesAndConsultantsMember_doc" xml:lang="en-US">Board of Directors, Officers,Employees and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CareFusionMember" xlink:to="XAIR_CareFusionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CareFusionMember_doc" xml:lang="en-US">CareFusion [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:to="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_doc" xml:lang="en-US">Change of management&amp;amp;#8217;s assessment of prior year research and development to licensing right to use technology.</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember" xlink:label="XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember" xlink:to="XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ChiefExecutiveOfficerDirectorsAndEmployeesMember_doc" xml:lang="en-US">CEO, Directors and Employees [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CircassiaPharmaceuticalsPLCMember" xlink:to="XAIR_CircassiaPharmaceuticalsPLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CircassiaPharmaceuticalsPLCMember_doc" xml:lang="en-US">Circassia Pharmaceuticals PLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ClinicalAndMedicalEquipmentMember" xlink:to="XAIR_ClinicalAndMedicalEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ClinicalAndMedicalEquipmentMember_doc" xml:lang="en-US">Clinical and Medical Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockOneMember" xlink:label="XAIR_CommonStockOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockOneMember" xlink:to="XAIR_CommonStockOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CommonStockOneMember_doc" xml:lang="en-US">Common Stock One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockOptionsMember" xlink:to="XAIR_CommonStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CommonStockOptionsMember_doc" xml:lang="en-US">Common Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockTwoMember" xlink:label="XAIR_CommonStockTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockTwoMember" xlink:to="XAIR_CommonStockTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CommonStockTwoMember_doc" xml:lang="en-US">Common Stock Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CommonStockWarrantsMember" xlink:to="XAIR_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ComputersEquipmentMember" xlink:to="XAIR_ComputersEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ComputersEquipmentMember_doc" xml:lang="en-US">Computers Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ConcurrentPrivatePlacementMember" xlink:to="XAIR_ConcurrentPrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ConcurrentPrivatePlacementMember_doc" xml:lang="en-US">Concurrent Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ContractManufacturerMember" xlink:to="XAIR_ContractManufacturerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ContractManufacturerMember_doc" xml:lang="en-US">Contract Manufacturer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ContractResearchOrganizationMember" xlink:to="XAIR_ContractResearchOrganizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ContractResearchOrganizationMember_doc" xml:lang="en-US">Contract Research Organization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CumulativeAdjustment" xlink:to="XAIR_CumulativeAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CumulativeAdjustment_doc" xml:lang="en-US">Cumulative adjustment to the adoption.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CumulativeAdjustmentOne" xlink:to="XAIR_CumulativeAdjustmentOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CumulativeAdjustmentOne_doc" xml:lang="en-US">Cumulative adjustment to the adoption.(One)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" xlink:to="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_CurrentAssetsAndPrepaidExpensesTextBlock_doc" xml:lang="en-US">Current Assets and Prepaid Expenses [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendAsResultOfWarrantModification" xlink:to="XAIR_DeemedDividendAsResultOfWarrantModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeemedDividendAsResultOfWarrantModification_doc" xml:lang="en-US">Deemed dividend as a result of a warrant modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendDueToWarrantModification" xlink:to="XAIR_DeemedDividendDueToWarrantModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeemedDividendDueToWarrantModification_doc" xml:lang="en-US">Deemed dividend due to a warrant modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendFromWarrantModification" xlink:to="XAIR_DeemedDividendFromWarrantModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeemedDividendFromWarrantModification_doc" xml:lang="en-US">Deemed dividend from warrant modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsLeaseLiability" xlink:to="XAIR_DeferredTaxAssetsLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsLeaseLiability_doc" xml:lang="en-US">Deferred tax assets lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsResearchAndDevelopment" xlink:to="XAIR_DeferredTaxAssetsResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsResearchAndDevelopment_doc" xml:lang="en-US">Research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsRightofuseAsset" xlink:to="XAIR_DeferredTaxAssetsRightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsRightofuseAsset_doc" xml:lang="en-US">Deferred tax assets right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DirectorsAndEmployeesMember" xlink:to="XAIR_DirectorsAndEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DirectorsAndEmployeesMember_doc" xml:lang="en-US">Directors and Employees [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems_doc" xml:lang="en-US">Permanent items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmployeesMember" xlink:to="XAIR_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ExecutionAgreementMember" xlink:to="XAIR_ExecutionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ExecutionAgreementMember_doc" xml:lang="en-US">Execution Agreement [Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementLoanTextBlock" xlink:to="XAIR_FacilityAgreementLoanTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FacilityAgreementLoanTextBlock_doc" xml:lang="en-US">Facility Agreement Loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementMember" xlink:to="XAIR_FacilityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FacilityAgreementMember_doc" xml:lang="en-US">Facility Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" xlink:to="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology_doc" xml:lang="en-US">Fair market value of option to NitricGen for the licensed right to use technology.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:to="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions_doc" xml:lang="en-US">Federal tax benefit for reversal of uncertain tax positions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FeePecentage" xlink:to="XAIR_FeePecentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FeePecentage_doc" xml:lang="en-US">Fee pecentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstObligationsMember" xlink:to="XAIR_FirstObligationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FirstObligationsMember_doc" xml:lang="en-US">First Obligation Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstTwoMilestoneOrdinaryShares" xlink:to="XAIR_FirstTwoMilestoneOrdinaryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FirstTwoMilestoneOrdinaryShares_doc" xml:lang="en-US">First two milestone ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FirstTwoMilestoneOrdinarySharesValue" xlink:to="XAIR_FirstTwoMilestoneOrdinarySharesValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FirstTwoMilestoneOrdinarySharesValue_doc" xml:lang="en-US">First two milestone ordinary shares, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FiveTranchesMember" xlink:to="XAIR_FiveTranchesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FiveTranchesMember_doc" xml:lang="en-US">Five Tranches [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FoodAndDrugAdministrationMember" xlink:to="XAIR_FoodAndDrugAdministrationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_FoodAndDrugAdministrationMember_doc" xml:lang="en-US">Food and Drug Administration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_GeneralAndAdministrativeExpensesMember" xlink:to="XAIR_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_HospitalAndClinicSettingsMember" xlink:to="XAIR_HospitalAndClinicSettingsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_HospitalAndClinicSettingsMember_doc" xml:lang="en-US">Hospital and Clinic Settings [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ILMember" xlink:to="XAIR_ILMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ILMember_doc" xml:lang="en-US">Israel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncrementalValueOfWarrant" xlink:to="XAIR_IncrementalValueOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncrementalValueOfWarrant_doc" xml:lang="en-US">Incremental value of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IncrementalValueOfWarrantsDueToModification" xlink:to="XAIR_IncrementalValueOfWarrantsDueToModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IncrementalValueOfWarrantsDueToModification_doc" xml:lang="en-US">Incremental value of warrants due to a modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InsuranceMember" xlink:to="XAIR_InsuranceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_InsuranceMember_doc" xml:lang="en-US">Insurance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IntangibleAssetsMilestonePayments" xlink:to="XAIR_IntangibleAssetsMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IntangibleAssetsMilestonePayments_doc" xml:lang="en-US">Intangible assets milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_InvestorOneMember" xlink:to="XAIR_InvestorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_InvestorOneMember_doc" xml:lang="en-US">Investors One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:to="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts_doc" xml:lang="en-US">Issuance of common stock pursuant to a private placement, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:to="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares_doc" xml:lang="en-US">Issuance of common stock pursuant to a private placement, net of offering costs, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_JanuaryTwoThousandandSeventeenMember" xlink:to="XAIR_JanuaryTwoThousandandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_JanuaryTwoThousandandSeventeenMember_doc" xml:lang="en-US">January 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LPCMember" xlink:label="XAIR_LPCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LPCMember" xlink:to="XAIR_LPCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LPCMember_doc" xml:lang="en-US">LPC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LendersMember" xlink:to="XAIR_LendersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LendersMember_doc" xml:lang="en-US">Lenders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementMember" xlink:to="XAIR_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementTextBlock" xlink:to="XAIR_LicenseAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LicenseAgreementTextBlock_doc" xml:lang="en-US">License agreement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicensedRightToUseTechnology" xlink:to="XAIR_LicensedRightToUseTechnology_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LicensedRightToUseTechnology_doc" xml:lang="en-US">Licensed right to use technology.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicensedRightToUseTechnologyPolicyTextBlock" xlink:to="XAIR_LicensedRightToUseTechnologyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LicensedRightToUseTechnologyPolicyTextBlock_doc" xml:lang="en-US">Licensed Right to Use Technology [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LincolnParkCapitalFundLLCMember" xlink:to="XAIR_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LincolnParkCorporationLLCMember" xlink:to="XAIR_LincolnParkCorporationLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LincolnParkCorporationLLCMember_doc" xml:lang="en-US">Lincoln Park Corporation LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LoanMember" xlink:to="XAIR_LoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_LoanMember_doc" xml:lang="en-US">Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:to="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember_doc" xml:lang="en-US">March 2018 Expire Through 2037 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandEighteenMember" xlink:to="XAIR_MarchTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MarchTwoThousandEighteenMember_doc" xml:lang="en-US">March 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandSeventeenMember" xlink:to="XAIR_MarchTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MarchTwoThousandSeventeenMember_doc" xml:lang="en-US">March 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MarchTwoThousandTwentyMember" xlink:to="XAIR_MarchTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MarchTwoThousandTwentyMember_doc" xml:lang="en-US">March 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonePayments" xlink:to="XAIR_MilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MilestonePayments_doc" xml:lang="en-US">Milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MilestonesPayment" xlink:to="XAIR_MilestonesPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MilestonesPayment_doc" xml:lang="en-US">Milestones payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_MutualFundsMember" xlink:to="XAIR_MutualFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_MutualFundsMember_doc" xml:lang="en-US">Mutual Funds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NewPurchaseAgreementMember" xlink:to="XAIR_NewPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NewPurchaseAgreementMember_doc" xml:lang="en-US">New Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NitricGenIncMember" xlink:to="XAIR_NitricGenIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NitricGenIncMember_doc" xml:lang="en-US">NitricGen, Inc [Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NonrefundableUpfrontFee" xlink:to="XAIR_NonrefundableUpfrontFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NonrefundableUpfrontFee_doc" xml:lang="en-US">Non-refundable upfront fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfSharesIssuedForExerciseOfWarrants" xlink:to="XAIR_NumberOfSharesIssuedForExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NumberOfSharesIssuedForExerciseOfWarrants_doc" xml:lang="en-US">Number of shares issued for exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_NumberOfUnregisteredSharesOfCommonStock" xlink:to="XAIR_NumberOfUnregisteredSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_NumberOfUnregisteredSharesOfCommonStock_doc" xml:lang="en-US">Number of unregistered shares of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OfficersEmployeesAndConsultantsMember" xlink:to="XAIR_OfficersEmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OfficersEmployeesAndConsultantsMember_doc" xml:lang="en-US">Officers, Employees and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OnetimeRoyaltyPercentage" xlink:to="XAIR_OnetimeRoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OnetimeRoyaltyPercentage_doc" xml:lang="en-US">One-time royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseAgreementExpireDateDescription" xlink:to="XAIR_OperatingLeaseAgreementExpireDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLeaseAgreementExpireDateDescription_doc" xml:lang="en-US">Operating lease agreement expire date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseLiabilities" xlink:to="XAIR_OperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLeaseLiabilities_doc" xml:lang="en-US">Operating lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeasesRightofuseAsset" xlink:to="XAIR_OperatingLeasesRightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLeasesRightofuseAsset_doc" xml:lang="en-US">Operating lease right-of-use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLossCarryforwardsExpirationYears" xlink:to="XAIR_OperatingLossCarryforwardsExpirationYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OperatingLossCarryforwardsExpirationYears_doc" xml:lang="en-US">Operating loss carryforward expire term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionAgreementMember" xlink:to="XAIR_OptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OptionAgreementMember_doc" xml:lang="en-US">Option Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OptionsToPurchaseCommonStockValue" xlink:to="XAIR_OptionsToPurchaseCommonStockValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OptionsToPurchaseCommonStockValue_doc" xml:lang="en-US">Options to purchase common stock, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherMember" xlink:to="XAIR_OtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OtherMember_doc" xml:lang="en-US">Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_OtherRisksAndUncertaintiesPolicyTextBlock_doc" xml:lang="en-US">Other Risks and Uncertainties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PatentLicenseAgreementMember" xlink:to="XAIR_PatentLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PatentLicenseAgreementMember_doc" xml:lang="en-US">Patent License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfMilestoneOrdinaryShares" xlink:to="XAIR_PaymentOfMilestoneOrdinaryShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentOfMilestoneOrdinaryShares_doc" xml:lang="en-US">Payment of milestone ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfMilestoneOrdinarySharesValue" xlink:to="XAIR_PaymentOfMilestoneOrdinarySharesValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentOfMilestoneOrdinarySharesValue_doc" xml:lang="en-US">Payment of milestone ordinary shares, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:to="XAIR_PaymentsForDevelopmentAndMilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentsForDevelopmentAndMilestonePayment_doc" xml:lang="en-US">Payments for development and milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentsInCashDiscountedPercentage" xlink:to="XAIR_PaymentsInCashDiscountedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentsInCashDiscountedPercentage_doc" xml:lang="en-US">Payments in cash discounted, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PlacementAgentMember" xlink:to="XAIR_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsFromIssuanceOfCommonStockGross" xlink:to="XAIR_ProceedsFromIssuanceOfCommonStockGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ProceedsFromIssuanceOfCommonStockGross_doc" xml:lang="en-US">Proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProceedsfromIssuanceOfMarketOfferings" xlink:to="XAIR_ProceedsfromIssuanceOfMarketOfferings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ProceedsfromIssuanceOfMarketOfferings_doc" xml:lang="en-US">Issuance of common stock related to at the market offerings, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ProfessionalMember" xlink:to="XAIR_ProfessionalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ProfessionalMember_doc" xml:lang="en-US">Professional [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PurchaseAgreementDescription" xlink:to="XAIR_PurchaseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PurchaseAgreementDescription_doc" xml:lang="en-US">Purchase agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:to="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities_doc" xml:lang="en-US">Realized and unrealized gain (loss) from marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RemainingCommitmentUnderLicenseAgreement" xlink:to="XAIR_RemainingCommitmentUnderLicenseAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RemainingCommitmentUnderLicenseAgreement_doc" xml:lang="en-US">Remaining commitment under license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ResearchAndDevelopmentExpensesMember" xlink:to="XAIR_ResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">Research and Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedCashMember" xlink:label="XAIR_RestrictedCashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RestrictedCashMember" xlink:to="XAIR_RestrictedCashMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RestrictedCashMember_doc" xml:lang="en-US">Restricted Cash [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RestrictedCashPolicyTextBlock" xlink:to="XAIR_RestrictedCashPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RestrictedCashPolicyTextBlock_doc" xml:lang="en-US">Restricted Cash [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RestrictedSharesMember" xlink:to="XAIR_RestrictedSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RestrictedSharesMember_doc" xml:lang="en-US">Restricted Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueAllocatedToPerformanceObligations" xlink:to="XAIR_RevenueAllocatedToPerformanceObligations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RevenueAllocatedToPerformanceObligations_doc" xml:lang="en-US">Revenue allocated to performance obligations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:to="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1_doc" xml:lang="en-US">The amount of consideration recognized during the period for the milestone or milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:to="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized_doc" xml:lang="en-US">The amount of consideration recognized during the period for the milestone or milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightOfUseAssetCurrent" xlink:to="XAIR_RightOfUseAssetCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RightOfUseAssetCurrent_doc" xml:lang="en-US">Right of use asset short-term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightOfUseLeaseAssetsCurrent" xlink:to="XAIR_RightOfUseLeaseAssetsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RightOfUseLeaseAssetsCurrent_doc" xml:lang="en-US">Right-of-use lease assets, current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RightofuseAssets" xlink:to="XAIR_RightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RightofuseAssets_doc" xml:lang="en-US">Right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyGrossProfitAmount" xlink:to="XAIR_RoyaltyGrossProfitAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RoyaltyGrossProfitAmount_doc" xml:lang="en-US">Royalty gross profit amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_RoyaltyPercentage" xlink:to="XAIR_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesAgentMember" xlink:to="XAIR_SalesAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SalesAgentMember_doc" xml:lang="en-US">Sales Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SalesRelatedMilestonesPayments" xlink:to="XAIR_SalesRelatedMilestonesPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SalesRelatedMilestonesPayments_doc" xml:lang="en-US">Sales related milestones payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_doc" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" xlink:to="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" xlink:to="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of Current Assets and Prepaid Expenses [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" xlink:to="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock_doc" xml:lang="en-US">Schedule of Facility Agreement Loan [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" xlink:to="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfLeaseOtherInformationTableTextBlock_doc" xml:lang="en-US">Schedule of Lease Other Information [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" xlink:to="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock_doc" xml:lang="en-US">Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" xlink:to="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule of right-of use assets and operating lease liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" xlink:to="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of useful life of assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondObligationsMember" xlink:to="XAIR_SecondObligationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SecondObligationsMember_doc" xml:lang="en-US">Second Obligation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_doc" xml:lang="en-US">The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuancePeriodTerm" xlink:to="XAIR_StockIssuancePeriodTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuancePeriodTerm_doc" xml:lang="en-US">Stock issuance period, term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringExerciseOfWarrantsShares" xlink:to="XAIR_StockIssuedDuringExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsShares_doc" xml:lang="en-US">Issuance of common stock upon the exercise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringExerciseOfWarrantsValue" xlink:to="XAIR_StockIssuedDuringExerciseOfWarrantsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringExerciseOfWarrantsValue_doc" xml:lang="en-US">Issuance of common stock upon the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:to="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares_doc" xml:lang="en-US">Issuance of common stock pursuant to Purchase Agreement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:to="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue_doc" xml:lang="en-US">Issuance of common stock pursuant to Purchase Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:to="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants_doc" xml:lang="en-US">Issuance of common stock upon cashless excise of warrants, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:to="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock_doc" xml:lang="en-US">Vested restricted stock, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:to="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants_doc" xml:lang="en-US">Issuance of common stock upon cashless excise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:to="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock_doc" xml:lang="en-US">Vested restricted stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockOptionPlanMember" xlink:label="XAIR_StockOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockOptionPlanMember" xlink:to="XAIR_StockOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockOptionPlanMember_doc" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockPurchaseAgreementMember" xlink:to="XAIR_StockPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockPurchaseAgreementMember_doc" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_StockPurchaseCommitment" xlink:to="XAIR_StockPurchaseCommitment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_StockPurchaseCommitment_doc" xml:lang="en-US">Stock purchase commitment amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract_doc" xml:lang="en-US">Supplemental disclosure of non-investing activities [Abstrtact]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ThirdPartyLicenseAgreementMember" xlink:to="XAIR_ThirdPartyLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ThirdPartyLicenseAgreementMember_doc" xml:lang="en-US">Third Party License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TradingVolumePecentage" xlink:to="XAIR_TradingVolumePecentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TradingVolumePecentage_doc" xml:lang="en-US">Trading volume pecentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TranchesMember" xlink:to="XAIR_TranchesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TranchesMember_doc" xml:lang="en-US">Tranches [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandThirteenIncentiveOptionPlanMember" xlink:to="XAIR_TwoThousandThirteenIncentiveOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandThirteenIncentiveOptionPlanMember_doc" xml:lang="en-US">2013 Incentive Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnitedStatesAndChinaMember" xlink:to="XAIR_UnitedStatesAndChinaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_UnitedStatesAndChinaMember_doc" xml:lang="en-US">United States and China [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:to="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities_doc" xml:lang="en-US">Unrealized and realized loss on marketable securities to available for sale marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnusedNetOperatingLossCarryforwards" xlink:to="XAIR_UnusedNetOperatingLossCarryforwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_UnusedNetOperatingLossCarryforwards_doc" xml:lang="en-US">Unused net operating loss carry forward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_UnvestedStockOptionsMember" xlink:to="XAIR_UnvestedStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_UnvestedStockOptionsMember_doc" xml:lang="en-US">Unvested Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ValueAddedTaxReceivableMember" xlink:to="XAIR_ValueAddedTaxReceivableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ValueAddedTaxReceivableMember_doc" xml:lang="en-US">Value added tax receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ValueAddedTaxesReceivableMember" xlink:label="XAIR_ValueAddedTaxesReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ValueAddedTaxesReceivableMember" xlink:to="XAIR_ValueAddedTaxesReceivableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ValueAddedTaxesReceivableMember_doc" xml:lang="en-US">Value Added Taxes Receivable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VendorMember" xlink:to="XAIR_VendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_VendorMember_doc" xml:lang="en-US">Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_VendorsResearchAndDevelopment" xlink:to="XAIR_VendorsResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_VendorsResearchAndDevelopment_doc" xml:lang="en-US">Vendors - research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantHoldersMember" xlink:to="XAIR_WarrantHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WarrantHoldersMember_doc" xml:lang="en-US">Warrant Holders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WeightedAveragePricePecentage" xlink:to="XAIR_WeightedAveragePricePecentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WeightedAveragePricePecentage_doc" xml:lang="en-US">Weighted average price pecentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:to="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Capital loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ShareBasedCompensationAwardFiveTrancheMember" xlink:to="XAIR_ShareBasedCompensationAwardFiveTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_ShareBasedCompensationAwardFiveTrancheMember_doc" xml:lang="en-US">Five Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_SecondTrancheMember" xlink:to="XAIR_SecondTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_SecondTrancheMember_doc" xml:lang="en-US">Second Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_WarrantsDescription" xlink:to="XAIR_WarrantsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_WarrantsDescription_doc" xml:lang="en-US">Warrants description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_TwoThousandAndSeventeenWarrantsMember" xlink:to="XAIR_TwoThousandAndSeventeenWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_TwoThousandAndSeventeenWarrantsMember_doc" xml:lang="en-US">2017 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyAssetMasterLtdMember" xlink:to="XAIR_EmperyAssetMasterLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EmperyAssetMasterLtdMember_doc" xml:lang="en-US">Empery Asset Master, Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyTaxEfficientLpMember" xlink:to="XAIR_EmperyTaxEfficientLpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EmperyTaxEfficientLpMember_doc" xml:lang="en-US">Empery Tax Efficient, LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_EmperyTaxEfficientIILpMember" xlink:to="XAIR_EmperyTaxEfficientIILpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_EmperyTaxEfficientIILpMember_doc" xml:lang="en-US">Empery Tax Efficient II, LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:to="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_doc" xml:lang="en-US">Payment of operating lease liability in operating activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_2_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendFromWarrantModification" xlink:to="XAIR_DeemedDividendFromWarrantModification_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeemedDividendFromWarrantModification_3_lbl" xml:lang="en-US">DeemedDividendFromWarrantModification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:to="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities_3_lbl" xml:lang="en-US">PaymentOfOperatingLeaseLiabilityInOperatingActivities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:to="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology_3_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_AdoptionOfAccountingStandardsUpdate" xlink:to="XAIR_AdoptionOfAccountingStandardsUpdate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_AdoptionOfAccountingStandardsUpdate_3_lbl" xml:lang="en-US">AdoptionOfAccountingStandardsUpdate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_2_lbl" xml:lang="en-US">Repayments of Bank Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_OperatingLeaseLiabilities" xlink:to="XAIR_OperatingLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_OperatingLeaseLiabilities_3_lbl" xml:lang="en-US">OperatingLeaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_DeemedDividendAsResultOfWarrantModification" xlink:to="XAIR_DeemedDividendAsResultOfWarrantModification_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_DeemedDividendAsResultOfWarrantModification_3_lbl" xml:lang="en-US">DeemedDividendAsResultOfWarrantModification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_LicenseAgreementTextBlock" xlink:to="XAIR_LicenseAgreementTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_LicenseAgreementTextBlock_3_lbl" xml:lang="en-US">LicenseAgreementTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="XAIR_FacilityAgreementLoanTextBlock" xlink:to="XAIR_FacilityAgreementLoanTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="XAIR_FacilityAgreementLoanTextBlock_3_lbl" xml:lang="en-US">FacilityAgreementLoanTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>xair-20200331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: XAIR 20200331 10K FY DFN.xfr; Date: 2020%2D06%2D23T20:23:43Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://beyondair.net/role/DocumentAndEntityInformation" xlink:href="xair-20200331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheets" xlink:href="xair-20200331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:href="xair-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfOperations" xlink:href="xair-20200331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:href="xair-20200331.xsd#StatementsOfChangesInShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/StatementsOfCashFlows" xlink:href="xair-20200331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusiness" xlink:href="xair-20200331.xsd#OrganizationAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement" xlink:href="xair-20200331.xsd#FairValueMeasurement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment" xlink:href="xair-20200331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity" xlink:href="xair-20200331.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses" xlink:href="xair-20200331.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreement" xlink:href="xair-20200331.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan" xlink:href="xair-20200331.xsd#FacilityAgreementLoan" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayable" xlink:href="xair-20200331.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes" xlink:href="xair-20200331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEvents" xlink:href="xair-20200331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurementTables" xlink:href="xair-20200331.xsd#FairValueMeasurementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:href="xair-20200331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityTables" xlink:href="xair-20200331.xsd#ShareholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpensesTables" xlink:href="xair-20200331.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:href="xair-20200331.xsd#FacilityAgreementLoanTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesTables" xlink:href="xair-20200331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:href="xair-20200331.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="xair-20200331.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:href="xair-20200331.xsd#SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:href="xair-20200331.xsd#FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:href="xair-20200331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:href="xair-20200331.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:href="xair-20200331.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:href="xair-20200331.xsd#ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:href="xair-20200331.xsd#CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:href="xair-20200331.xsd#AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:href="xair-20200331.xsd#BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:href="xair-20200331.xsd#LicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:href="xair-20200331.xsd#FacilityAgreementLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:href="xair-20200331.xsd#FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:href="xair-20200331.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:href="xair-20200331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:href="xair-20200331.xsd#IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="xair-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="xair-20200331.xsd#CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:href="xair-20200331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DocumentAndEntityInformationAbstract" xlink:label="loc_XAIRDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightOfUseLeaseAssetsCurrent" xlink:label="loc_XAIRRightOfUseLeaseAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_XAIRRightOfUseLeaseAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnology" xlink:label="loc_XAIRLicensedRightToUseTechnology" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_XAIRLicensedRightToUseTechnology" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:label="loc_XAIRRealizedAndUnrealizedGainLossFromMarketableSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_XAIRRealizedAndUnrealizedGainLossFromMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendIncomeOperating" xlink:label="loc_us-gaapDividendIncomeOperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDividendIncomeOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendFromWarrantModification" xlink:label="loc_XAIRDeemedDividendFromWarrantModification" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_XAIRDeemedDividendFromWarrantModification" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustment" xlink:label="loc_XAIRCumulativeAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustmentOne" xlink:label="loc_XAIRCumulativeAdjustmentOne" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:label="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:label="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodPursuantToPurchaseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrantsDueToModification" xlink:label="loc_XAIRIncrementalValueOfWarrantsDueToModification" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIncrementalValueOfWarrantsDueToModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendDueToWarrantModification" xlink:label="loc_XAIRDeemedDividendDueToWarrantModification" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRDeemedDividendDueToWarrantModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:label="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:label="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:label="loc_XAIRAdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsValue" xlink:label="loc_XAIRStockIssuedDuringExerciseOfWarrantsValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringExerciseOfWarrantsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringExerciseOfWarrantsShares" xlink:label="loc_XAIRStockIssuedDuringExerciseOfWarrantsShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:label="loc_XAIRStockIssuedDuringThePeriodValueCashlessExciseOfWarrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodValueCashlessExciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:label="loc_XAIRStockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodSharesCashlessExciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:label="loc_XAIRStockIssuedDuringThePeriodValueVestedRestrictedStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodValueVestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:label="loc_XAIRStockIssuedDuringThePeriodSharesVestedRestrictedStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRStockIssuedDuringThePeriodSharesVestedRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CumulativeAdjustment" xlink:label="loc_XAIRCumulativeAdjustment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRCumulativeAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:label="loc_XAIRPaymentOfOperatingLeaseLiabilityInOperatingActivities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRPaymentOfOperatingLeaseLiabilityInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:label="loc_XAIRUnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRUnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:label="loc_XAIRChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AdoptionOfAccountingStandardsUpdate" xlink:label="loc_XAIRAdoptionOfAccountingStandardsUpdate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRAdoptionOfAccountingStandardsUpdate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:label="loc_XAIRAmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_XAIRAmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsfromIssuanceOfMarketOfferings" xlink:label="loc_XAIRProceedsfromIssuanceOfMarketOfferings" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_XAIRProceedsfromIssuanceOfMarketOfferings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromBankDebt" xlink:label="loc_us-gaapProceedsFromBankDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromBankDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaapRepaymentsOfBankDebt" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfBankDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:label="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightofuseAssets" xlink:label="loc_XAIRRightofuseAssets" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="loc_XAIRRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeaseLiabilities" xlink:label="loc_XAIROperatingLeaseLiabilities" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="loc_XAIROperatingLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeemedDividendAsResultOfWarrantModification" xlink:label="loc_XAIRDeemedDividendAsResultOfWarrantModification" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="loc_XAIRDeemedDividendAsResultOfWarrantModification" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" xlink:label="loc_XAIRAirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="loc_XAIRAirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" xlink:label="loc_XAIRFairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRSupplementalDisclosureOfNoninvestingActivitiesAbstract" xlink:to="loc_XAIRFairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusiness" xlink:title="00000008 - Disclosure - Organization and Business">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement" xlink:title="00000010 - Disclosure - Fair Value Measurement">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment" xlink:title="00000011 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholder&apos;s Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses" xlink:title="00000013 - Disclosure - Current Assets and Prepaid Expenses">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesAbstract" xlink:label="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesTextBlock" xlink:label="loc_XAIRCurrentAssetsAndPrepaidExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" xlink:to="loc_XAIRCurrentAssetsAndPrepaidExpensesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses" xlink:title="00000014 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare" xlink:title="00000015 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreement" xlink:title="00000016 - Disclosure - License Agreement">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementAbstract" xlink:label="loc_XAIRLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementTextBlock" xlink:label="loc_XAIRLicenseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRLicenseAgreementAbstract" xlink:to="loc_XAIRLicenseAgreementTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan" xlink:title="00000017 - Disclosure - Facility Agreement Loan">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="loc_XAIRFacilityAgreementLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanTextBlock" xlink:label="loc_XAIRFacilityAgreementLoanTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_XAIRFacilityAgreementLoanTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayable" xlink:title="00000018 - Disclosure - Loan Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_XAIROtherRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIROtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedCashPolicyTextBlock" xlink:label="loc_XAIRRestrictedCashPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRRestrictedCashPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnologyPolicyTextBlock" xlink:label="loc_XAIRLicensedRightToUseTechnologyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRLicensedRightToUseTechnologyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="loc_XAIRRecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRRecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="loc_XAIRScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock" xlink:label="loc_XAIRScheduleOfUsefulLifeOfAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRScheduleOfUsefulLifeOfAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" xlink:label="loc_XAIRScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurementTables" xlink:title="00000024 - Disclosure - Fair Value Measurement (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityTables" xlink:title="00000026 - Disclosure - Shareholder&apos;s Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" xlink:label="loc_XAIRScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_XAIRScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables" xlink:title="00000027 - Disclosure - Current Assets and Prepaid Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesAbstract" xlink:label="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" xlink:label="loc_XAIRScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" xlink:to="loc_XAIRScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables" xlink:title="00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanTables" xlink:title="00000030 - Disclosure - Facility Agreement Loan (Tables)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="loc_XAIRFacilityAgreementLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" xlink:label="loc_XAIRScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_XAIRScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock" xlink:label="loc_XAIRScheduleOfFacilityAgreementLoanTabletextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_XAIRScheduleOfFacilityAgreementLoanTabletextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ScheduleOfLeaseOtherInformationTableTextBlock" xlink:label="loc_XAIRScheduleOfLeaseOtherInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_XAIRScheduleOfLeaseOtherInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative" xlink:title="00000033 - Disclosure - Organization and Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NewPurchaseAgreementMember" xlink:label="loc_XAIRNewPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNewPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ShareBasedCompensationAwardFiveTrancheMember" xlink:label="loc_XAIRShareBasedCompensationAwardFiveTrancheMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_XAIRShareBasedCompensationAwardFiveTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCapitalFundLLCMember" xlink:label="loc_XAIRLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PurchaseAgreementDescription" xlink:label="loc_XAIRPurchaseAgreementDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPurchaseAgreementDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractManufacturerMember" xlink:label="loc_XAIRContractManufacturerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRContractManufacturerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IntangibleAssetsMilestonePayments" xlink:label="loc_XAIRIntangibleAssetsMilestonePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRIntangibleAssetsMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Useful Life of Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ComputersEquipmentMember" xlink:label="loc_XAIRComputersEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRComputersEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails" xlink:title="00000037 - Disclosure - Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicensedRightToUseTechnology" xlink:label="loc_XAIRLicensedRightToUseTechnology" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRLicensedRightToUseTechnology" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails" xlink:title="00000038 - Disclosure - Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RightOfUseAssetCurrent" xlink:label="loc_XAIRRightOfUseAssetCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIRRightOfUseAssetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeasesRightofuseAsset" xlink:label="loc_XAIROperatingLeasesRightofuseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_XAIROperatingLeasesRightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails" xlink:title="00000039 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MutualFundsMember" xlink:label="loc_XAIRMutualFundsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_XAIRMutualFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CircassiaPharmaceuticalsPLCMember" xlink:label="loc_XAIRCircassiaPharmaceuticalsPLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRCircassiaPharmaceuticalsPLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000040 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ClinicalAndMedicalEquipmentMember" xlink:label="loc_XAIRClinicalAndMedicalEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_XAIRClinicalAndMedicalEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquityDetailsNarrative" xlink:title="00000042 - Disclosure - Shareholder&apos;s Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseAgreementMember" xlink:label="loc_XAIRStockPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCapitalFundLLCMember" xlink:label="loc_XAIRLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DirectorsAndEmployeesMember" xlink:label="loc_XAIRDirectorsAndEmployeesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRDirectorsAndEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmployeesMember" xlink:label="loc_XAIREmployeesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIREmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantHoldersMember" xlink:label="loc_XAIRWarrantHoldersMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRWarrantHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ConcurrentPrivatePlacementMember" xlink:label="loc_XAIRConcurrentPrivatePlacementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_XAIRConcurrentPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorMember" xlink:label="loc_XAIRVendorMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OfficersEmployeesAndConsultantsMember" xlink:label="loc_XAIROfficersEmployeesAndConsultantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIROfficersEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnvestedStockOptionsMember" xlink:label="loc_XAIRUnvestedStockOptionsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRUnvestedStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandThirteenIncentiveOptionPlanMember" xlink:label="loc_XAIRTwoThousandThirteenIncentiveOptionPlanMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_XAIRTwoThousandThirteenIncentiveOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockIssuancePeriodTerm" xlink:label="loc_XAIRStockIssuancePeriodTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRStockIssuancePeriodTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_StockPurchaseCommitment" xlink:label="loc_XAIRStockPurchaseCommitment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRStockPurchaseCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_XAIRProceedsFromIssuanceOfCommonStockGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesEquitySecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesEquitySecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfUnregisteredSharesOfCommonStock" xlink:label="loc_XAIRNumberOfUnregisteredSharesOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRNumberOfUnregisteredSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncrementalValueOfWarrant" xlink:label="loc_XAIRIncrementalValueOfWarrant" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRIncrementalValueOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NumberOfSharesIssuedForExerciseOfWarrants" xlink:label="loc_XAIRNumberOfSharesIssuedForExerciseOfWarrants" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_XAIRNumberOfSharesIssuedForExerciseOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails" xlink:title="00000043 - Disclosure - Shareholder&apos;s Equity - Schedule of Unvested Restricted Shares (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails" xlink:title="00000044 - Disclosure - Shareholder&apos;s Equity - Schedule of Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_XAIRSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_XAIRSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_XAIRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_XAIRShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails" xlink:title="00000045 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000046 - Disclosure - Shareholder&apos;s Equity - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ResearchAndDevelopmentExpensesMember" xlink:label="loc_XAIRResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_GeneralAndAdministrativeExpensesMember" xlink:label="loc_XAIRGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails" xlink:title="00000047 - Disclosure - Shareholder&apos;s Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails" xlink:title="00000048 - Disclosure - Shareholder&apos;s Equity - Summary of Company&apos;s Outstanding Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_JanuaryTwoThousandandSeventeenMember" xlink:label="loc_XAIRJanuaryTwoThousandandSeventeenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRJanuaryTwoThousandandSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandSeventeenMember" xlink:label="loc_XAIRMarchTwoThousandSeventeenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenMember" xlink:label="loc_XAIRMarchTwoThousandEighteenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandTwentyMember" xlink:label="loc_XAIRMarchTwoThousandTwentyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InvestorOneMember" xlink:label="loc_XAIRInvestorOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRInvestorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PlacementAgentMember" xlink:label="loc_XAIRPlacementAgentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ThirdPartyLicenseAgreementMember" xlink:label="loc_XAIRThirdPartyLicenseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRThirdPartyLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LoanMember" xlink:label="loc_XAIRLoanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_XAIRLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails" xlink:title="00000049 - Disclosure - Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CurrentAssetsAndPrepaidExpensesAbstract" xlink:label="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRCurrentAssetsAndPrepaidExpensesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ResearchAndDevelopmentExpensesMember" xlink:label="loc_XAIRResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_InsuranceMember" xlink:label="loc_XAIRInsuranceMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRInsuranceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ProfessionalMember" xlink:label="loc_XAIRProfessionalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRProfessionalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ValueAddedTaxReceivableMember" xlink:label="loc_XAIRValueAddedTaxReceivableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIRValueAddedTaxReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OtherMember" xlink:label="loc_XAIROtherMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_XAIROtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails" xlink:title="00000050 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_VendorsResearchAndDevelopment" xlink:label="loc_XAIRVendorsResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_XAIRVendorsResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails" xlink:title="00000051 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockWarrantsMember" xlink:label="loc_XAIRCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CommonStockOptionsMember" xlink:label="loc_XAIRCommonStockOptionsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRCommonStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RestrictedSharesMember" xlink:label="loc_XAIRRestrictedSharesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_XAIRRestrictedSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LicenseAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - License Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LicenseAgreementMember" xlink:label="loc_XAIRLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CircassiaPharmaceuticalsPLCMember" xlink:label="loc_XAIRCircassiaPharmaceuticalsPLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRCircassiaPharmaceuticalsPLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FoodAndDrugAdministrationMember" xlink:label="loc_XAIRFoodAndDrugAdministrationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_XAIRFoodAndDrugAdministrationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_HospitalAndClinicSettingsMember" xlink:label="loc_XAIRHospitalAndClinicSettingsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_XAIRHospitalAndClinicSettingsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="loc_countryCN" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCN" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnitedStatesAndChinaMember" xlink:label="loc_XAIRUnitedStatesAndChinaMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_XAIRUnitedStatesAndChinaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaapIntellectualPropertyMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapIntellectualPropertyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstObligationsMember" xlink:label="loc_XAIRFirstObligationsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_XAIRFirstObligationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondObligationsMember" xlink:label="loc_XAIRSecondObligationsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_XAIRSecondObligationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonesPayment" xlink:label="loc_XAIRMilestonesPayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonesPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:label="loc_XAIRRevenueRecognitionMilestoneMethodRevenueRecognized1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueRecognitionMilestoneMethodRevenueRecognized1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsInCashDiscountedPercentage" xlink:label="loc_XAIRPaymentsInCashDiscountedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsInCashDiscountedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinarySharesValue" xlink:label="loc_XAIRPaymentOfMilestoneOrdinarySharesValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentOfMilestoneOrdinarySharesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentOfMilestoneOrdinaryShares" xlink:label="loc_XAIRPaymentOfMilestoneOrdinaryShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentOfMilestoneOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OnetimeRoyaltyPercentage" xlink:label="loc_XAIROnetimeRoyaltyPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROnetimeRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyGrossProfitAmount" xlink:label="loc_XAIRRoyaltyGrossProfitAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyGrossProfitAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyPercentage" xlink:label="loc_XAIRAnnualGrossProfitRoyaltyPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAnnualGrossProfitRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AnnualGrossProfitRoyaltyAmount" xlink:label="loc_XAIRAnnualGrossProfitRoyaltyAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAnnualGrossProfitRoyaltyAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinaryShares" xlink:label="loc_XAIRFirstTwoMilestoneOrdinaryShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFirstTwoMilestoneOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FirstTwoMilestoneOrdinarySharesValue" xlink:label="loc_XAIRFirstTwoMilestoneOrdinarySharesValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFirstTwoMilestoneOrdinarySharesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueAllocatedToPerformanceObligations" xlink:label="loc_XAIRRevenueAllocatedToPerformanceObligations" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueAllocatedToPerformanceObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative" xlink:title="00000053 - Disclosure - Facility Agreement Loan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="loc_XAIRFacilityAgreementLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementMember" xlink:label="loc_XAIRFacilityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRFacilityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LendersMember" xlink:label="loc_XAIRLendersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRLendersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FiveTranchesMember" xlink:label="loc_XAIRFiveTranchesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRFiveTranchesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TranchesMember" xlink:label="loc_XAIRTranchesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRTranchesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SecondTrancheMember" xlink:label="loc_XAIRSecondTrancheMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_XAIRSecondTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WarrantsDescription" xlink:label="loc_XAIRWarrantsDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRWarrantsDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails" xlink:title="00000054 - Disclosure - Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="loc_XAIRFacilityAgreementLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails" xlink:title="00000055 - Disclosure - Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FacilityAgreementLoanAbstract" xlink:label="loc_XAIRFacilityAgreementLoanAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AccretionOfInterestExpense" xlink:label="loc_XAIRAccretionOfInterestExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_XAIRAccretionOfInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRFacilityAgreementLoanAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/LoanPayableDetailsNarrative" xlink:title="00000056 - Disclosure - Loan Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxesDetailsNarrative" xlink:title="00000057 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ILMember" xlink:label="loc_XAIRILMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_XAIRILMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:label="loc_XAIRMarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRMarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_UnusedNetOperatingLossCarryforwards" xlink:label="loc_XAIRUnusedNetOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRUnusedNetOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLossCarryforwardsExpirationYears" xlink:label="loc_XAIROperatingLossCarryforwardsExpirationYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLossCarryforwardsExpirationYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:label="loc_XAIRFederalTaxBenefitForReversalOfUncertainTaxPositions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFederalTaxBenefitForReversalOfUncertainTaxPositions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails" xlink:title="00000058 - Disclosure - Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails" xlink:title="00000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:label="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsResearchAndDevelopment" xlink:label="loc_XAIRDeferredTaxAssetsResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsRightofuseAsset" xlink:label="loc_XAIRDeferredTaxAssetsRightofuseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsRightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_DeferredTaxAssetsLeaseLiability" xlink:label="loc_XAIRDeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_XAIRDeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails" xlink:title="00000060 - Disclosure - Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:label="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="loc_XAIREffectiveIncomeTaxRateReconciliationPermanentItems" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_XAIREffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails" xlink:title="00000061 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)">
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:label="loc_XAIRIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_XAIRIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000062 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PatentLicenseAgreementMember" xlink:label="loc_XAIRPatentLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRPatentLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionAgreementMember" xlink:label="loc_XAIROptionAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIROptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ExecutionAgreementMember" xlink:label="loc_XAIRExecutionAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRExecutionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_ContractResearchOrganizationMember" xlink:label="loc_XAIRContractResearchOrganizationMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRContractResearchOrganizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_CareFusionMember" xlink:label="loc_XAIRCareFusionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_XAIRCareFusionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NitricGenIncMember" xlink:label="loc_XAIRNitricGenIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRNitricGenIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyAssetMasterLtdMember" xlink:label="loc_XAIREmperyAssetMasterLtdMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyAssetMasterLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientLpMember" xlink:label="loc_XAIREmperyTaxEfficientLpMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyTaxEfficientLpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_EmperyTaxEfficientIILpMember" xlink:label="loc_XAIREmperyTaxEfficientIILpMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIREmperyTaxEfficientIILpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AfterSixMonthsMember" xlink:label="loc_XAIRAfterSixMonthsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_XAIRAfterSixMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TwoThousandAndSeventeenWarrantsMember" xlink:label="loc_XAIRTwoThousandAndSeventeenWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_XAIRTwoThousandAndSeventeenWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NonrefundableUpfrontFee" xlink:label="loc_XAIRNonrefundableUpfrontFee" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRNonrefundableUpfrontFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RoyaltyPercentage" xlink:label="loc_XAIRRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquisitionCosts" xlink:label="loc_us-gaapAcquisitionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcquisitionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PaymentsForDevelopmentAndMilestonePayment" xlink:label="loc_XAIRPaymentsForDevelopmentAndMilestonePayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPaymentsForDevelopmentAndMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_MilestonePayments" xlink:label="loc_XAIRMilestonePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesRelatedMilestonesPayments" xlink:label="loc_XAIRSalesRelatedMilestonesPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRSalesRelatedMilestonesPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:label="loc_XAIRRevenueRecognitionMilestoneMethodRevenuesRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRevenueRecognitionMilestoneMethodRevenuesRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OptionsToPurchaseCommonStockValue" xlink:label="loc_XAIROptionsToPurchaseCommonStockValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROptionsToPurchaseCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_RemainingCommitmentUnderLicenseAgreement" xlink:label="loc_XAIRRemainingCommitmentUnderLicenseAgreement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRRemainingCommitmentUnderLicenseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_OperatingLeaseAgreementExpireDateDescription" xlink:label="loc_XAIROperatingLeaseAgreementExpireDateDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIROperatingLeaseAgreementExpireDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails" xlink:title="00000063 - Disclosure - Commitments and Contingencies - Schedule of Lease Other Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000064 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://beyondair.net/role/SubsequentEventsDetailsNarrative" xlink:title="00000065 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AtTheMarketEquityOfferingMember" xlink:label="loc_XAIRAtTheMarketEquityOfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_XAIRAtTheMarketEquityOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_BeyondAirIncMember" xlink:label="loc_XAIRBeyondAirIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRBeyondAirIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_LincolnParkCorporationLLCMember" xlink:label="loc_XAIRLincolnParkCorporationLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_XAIRLincolnParkCorporationLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_SalesAgentMember" xlink:label="loc_XAIRSalesAgentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_XAIRSalesAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_NewPurchaseAgreementMember" xlink:label="loc_XAIRNewPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_XAIRNewPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_FeePecentage" xlink:label="loc_XAIRFeePecentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRFeePecentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_AgreementTermDescription" xlink:label="loc_XAIRAgreementTermDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRAgreementTermDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_PurchaseAgreementDescription" xlink:label="loc_XAIRPurchaseAgreementDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRPurchaseAgreementDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_TradingVolumePecentage" xlink:label="loc_XAIRTradingVolumePecentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRTradingVolumePecentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="xair-20200331.xsd#XAIR_WeightedAveragePricePecentage" xlink:label="loc_XAIRWeightedAveragePricePecentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_XAIRWeightedAveragePricePecentage" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796716464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Useful Life of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ComputersEquipmentMember', window );">Computers Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember', window );">Clinical and Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of assets</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life of assets, description</a></td>
<td class="text">Shorter of term of lease or estimated useful life of the asset<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ComputersEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ComputersEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804644448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 ORGANIZATION AND BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beyond Air, Inc. (&#8220;Beyond Air&#8221;
or the &#8220;Company&#8221;) was incorporated on April 24, 2015. On June 25, 2019, the Company&#8217;s name was changed to Beyond
Air, Inc. from AIT Therapeutics, Inc. The Company has the following wholly-owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beyond Air, Ltd was incorporated in Israel
on May 1, 2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advanced Inhalation Therapies (AIT), a wholly
owned subsidiary of Beyond Air, Ltd which was incorporated on August 29, 2014, in Delaware.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beyond Air Australia Pty Ltd was incorporated
on December 17, 2019 in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beyond Air Ireland Limited was incorporated
on March 5, 2020 in Ireland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is an a clinical-stage medical
device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory
conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors. S<font style="background-color: white">ince
its inception, the Company has devoted substantially all of its efforts to research and development.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is developing a nitric oxide (&#8220;NO&#8221;)
generator and delivery system (the &#8220;LungFit&#8482; system&#8221;) that is capable of generating NO from ambient air. LungFit&#8482;
can generate NO up to 400 parts per million (&#8220;ppm&#8221;) for delivery to a patient&#8217;s lungs. LungFit&#8482; can deliver
NO either continuously or for a fixed amount of time at various flow rates and has the ability to either titrate dose on demand
or maintain a constant dose. Our current areas of focus with the LungFit&#8482; are persistent pulmonary hypertension of the newborn
(&#8220;PPHN&#8221;), severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), bronchiolitis (&#8220;BRO&#8221;) and nontuberculous
mycobacteria (&#8220;NTM&#8221;). The Company&#8217;s current product candidates will be subject to premarket reviews and approvals
by the U.S. Food and Drug Administration, or the FDA, as well as similar regulatory agencies in other countries or regions. If
approved, our system will be marketed as a medical device in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity Risks and Uncertainty</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The&#160;Company has incurred cash used in
operating activities of&#160;$15.2&#160;million for the year ended March 31, 2020, and has accumulated losses of&#160;$57.6&#160;million.
The Company has&#160;cash,&#160;cash equivalents&#160;and restricted cash&#160;of&#160;$25.5&#160;million as of March 31, 2020.
Based on management&#8217;s current business plan, the Company estimates it will have enough cash for at least one year from the
date of filing these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s future capital needs and
the adequacy of its available funds beyond one year will depend on many factors, including, but not necessarily limited to, the
actual cost and time necessary for clinical studies and other actions needed to obtain regulatory approval of our medical devices
in development as well as the cost to launch our first product for PPHN, assuming approval of our Premarketing Application (&#8220;PMA&#8221;)
which is expected to be filed in the third quarter of calendar 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will be required to raise additional
funds through sale of equity or debt securities or through strategic collaboration and/or licensing agreements, to fund operations
and continue our clinical trials until we are able to generate enough product or royalty revenues, if any. Financing may not be
available on acceptable terms, or at all, and our failure to raise capital when needed could have a material adverse effect on
our growth plans, our results of operations and our financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 2, 2020, Beyond Air, Inc. entered
into an At-The-Market Equity Offering for $50 million and utilized the Company&#8217;s shelf registration statement, see Note&#160;14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2020, the Company entered into
a $25 million&#160;unsecured&#160;loan facility agreement (the &#8220;Facility Agreement&#8221;) with certain lenders that is unsecured.&#160;As
of March 31, 2020, the Company has drawn down of the first of five tranches of $5 million which is include in restricted cash.&#160;The
Company has the ability to drawn down on&#160;an additional&#160;$5 million tranche&#160;prior to&#160;the&#160;PMA filing,&#160;see
Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 14, 2020, the Company entered into
a $40 million purchase agreement (&#8220;New Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;),
that replaces the existing $20 million purchase agreement. The New Purchase Agreement provides for the issuance of up to $40 million
of the Company&#8217;s common stock through May 2023 at the Company&#8217;s discretion., The Company utilized the shelf registration
statement, see Note&#160;14.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796698208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfLeaseOtherInformationTableTextBlock', window );">Schedule of Lease Other Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company elected the practical expedient
option and as such these lease payments are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Other Information For The Year Ended March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 81%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">81,001</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for new operating lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average remaining lease term &#8212; operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.0. years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average discount rate &#8212; operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.3</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity of Lease Liabilities</b></font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br />
March 31, 2020</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating Leases</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 81%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83,117</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,826</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,693</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,279</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">228,915</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Less: interest</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(27,992</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Present value of lease liabilities</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,923</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfLeaseOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Lease Other Information [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfLeaseOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6815554400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="nump">$ 1,390,104<span></span>
</td>
<td class="nump">$ 7,724,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(10,648,920)<span></span>
</td>
<td class="num">(3,929,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(883,119)<span></span>
</td>
<td class="num">(6,852,988)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(18,141,935)<span></span>
</td>
<td class="num">(3,058,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities', window );">Realized and unrealized loss on available for sale marketable securities</a></td>
<td class="num">(2,075,602)<span></span>
</td>
<td class="num">(3,581,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendIncomeOperating', window );">Dividend income</a></td>
<td class="nump">115,716<span></span>
</td>
<td class="nump">86,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(30,543)<span></span>
</td>
<td class="num">(1,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">35,560<span></span>
</td>
<td class="num">(920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,034)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other loss</a></td>
<td class="num">(1,954,869)<span></span>
</td>
<td class="num">(3,499,905)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(20,096,804)<span></span>
</td>
<td class="num">(6,588,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">154,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,942,504)<span></span>
</td>
<td class="num">(6,558,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeemedDividendFromWarrantModification', window );">Deemed dividend from warrant modification</a></td>
<td class="num">(522,478)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributed to common shareholder</a></td>
<td class="nump">$ 20,464,982<span></span>
</td>
<td class="num">$ (6,558,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="nump">11,506,212<span></span>
</td>
<td class="nump">8,498,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeemedDividendFromWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend from warrant modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeemedDividendFromWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Realized and unrealized gain (loss) from marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RealizedAndUnrealizedGainLossFromMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating dividend income on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795122160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 PROPERTY AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following
as of March 31, 2020 and March 31, 2019, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical and medical equipment</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">357,795</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">357,795</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">73,982</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">42,782</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,895</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">41,464</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,336</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,336</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">491,008</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">447,377</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation and amortization</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(279,671</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(202,505</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">211,337</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">244,872</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization expense for
the year ended March 31, 2020 and March 31, 2019 was $77,166 and $64,787 respectively</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793393040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Income (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Income (Loss) Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 BASIC AND DILUTED NET INCOME (LOSS)
PER COMMON SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following potentially dilutive securities
were not included in the calculation of diluted net income (loss) per share attributable to common stockholders because their effect
would have been anti-dilutive for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2019</b></p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,173,724</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,143,405</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Common stock options</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,053,589</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,375,812</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted shares</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">646,800</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">340,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,874,113</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,859,217</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804574192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s foreign subsidiary is in
Israel and subject to a corporate tax rate as follow: 2019 and 2018 &#8211; 23%24%. December 2016, the Israeli Parliament approved
the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), which
reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January
1, 2018. As of March 31, 2010, there is a net operating loss carry forward of&#160;approximately&#160;$15,726,000 which offset
taxable income for an indefinite period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Section&#160;382 of the Internal Revenue
Code of 1986, as amended, changes in the Company&#8217;s ownership may limit the amount of its net operating loss carryforwards
that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of
a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not performed a study
to assess whether an ownership change for purposes of Section&#160;382 has occurred, or whether there have been multiple ownership
changes since the Company&#8217;s inception, due to the significant costs and complexities associated with such study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the Company has approximately
$19,400,000 of unused NOL carryforwards for federal tax purposes. Net operating loss carryforwards of approximately $1,375,000,
which were generated prior to March 2018 expire through 2037. The net operating loss of approximately $18,025,000 can be carried
forward indefinitely. The Company also has state net operating losses in the amount of approximately $20,187,000 expiring during
the years 2035 to 2020. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, changes in the Company&#8217;s
ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable
income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than
50% within a three-year period. The Company has not performed a study to assess whether an ownership change for purposes of Section&#160;382
has occurred, or whether there have been multiple ownership changes since the Company&#8217;s inception, due to the significant
costs and complexities associated with such study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The components of net loss income before the
provision for income taxes are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Year Ended<br />
March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Year Ended<br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Domestic</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 21%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(16,685,568</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,475,659</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Foreign</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,411,236</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,082,791</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(20,096,804</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,558,450</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There is no provision
for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against
its net deferred tax assets. The valuation allowance increased by approximately&#160;$6,166,000&#160;during the year ended March
31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The tax effects of
temporary differences that gave rise to significant portions of the deferred tax assets were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forward</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,017,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,201,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">524,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">243,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">120,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Reserves and allowances - foreign</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">880,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">608,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Capital&#160;loss&#160;carry forward</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,571,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">966,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development - foreign</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred&#160;revenue</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">241,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use asset</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(56,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Lease liability</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">56,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,860,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,694,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(12,860,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,694,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax asset</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%"><font style="font: 10pt Times New Roman, Times, Serif">Federal income tax at statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.00</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21,00</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">State income tax, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7.08</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6.62</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Permanent items</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.48</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30.67</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36.10</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Research and development tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1.39</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3.71</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3.69</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4.77</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Effective income tax expense rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the year ended
March 31, 2020 and 2019 the main reconciling item between the effective tax rate is the recognition of valuation allowances in
respect to deferred taxes related to accumulated operating net operating losses carried forward due to the uncertainty of the realization
of such deferred taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax years 2016 through 2020 remain open to
examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years 2014 through 2020
remain open.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 27, 2020, the Coronavirus Aid, Relief
and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act made various
tax law changes including, among other things, (i) increasing the limitation under IRC Section 163(j) for 2019 and 2020 to permit
additional expensing of interest, (ii) enacting a technical correction so that qualified improvement property can be immediately
expenses under IRC Section 168(k) and (iii) making modification to the federal net operating loss rules including permitting federal
net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to generate
a refund of previously paid income taxes. The income tax provisions of the CARES Act had limited applicability to the Company as
of March 31,2020, and therefore, the enactment of the CARES Act did not have any impact on the Company&#8217;s consolidated financial
statements as of March 31,2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A reconciliation of
the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2020 and&#160;March 31,&#160;2019
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,2020</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year&#160;Ended<br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 53%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at beginning of period</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 22%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Decreases for the current year&#8217;s tax position</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(154,300</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance at the end of period</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company recorded
a federal tax benefit in the amount of $154,300 related to the reversal of uncertain tax positions due to expiration of statute
of limitations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " "JBM=0Z<9H"NX    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/2L0P$(=?17)O)TUAA=#M1?&D(+B@> O)[&ZP^4,RTN[;V\;=
M+J(/X#$SOWSS#4RGH]0AX7,*$1-9S#>3&WR6.F[9D2A*@*R/Z%2NYX2?F_N0
MG*+YF0X0E?Y0!P3!^08<DC**%"S *JY$UG=&2YU044AGO-$K/GZFH<",!AS0
MH:<,3=T ZY>)\30-'5P!"XPPN?Q=0+,22_5/;.D .R>G;-?4.([UV);<O$,#
M;T^/+V7=ROI,RFN<?V4KZ11QRRZ37]N[^]T#ZP47O.*;2K2[YE8*+D7SOKC^
M\+L*NV#LWOYCXXM@W\&ON^B_ %!+ P04    " "JBM=0F5R<(Q &  "<)P
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M\FB5%(D&HUY2N((6MVR8+%&=U#K/$)ZQDD+6$(90> Y/6]+P,+S.(83GJZ2
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M'0<$GX7J)K+/^DK2#P1MARH)QE)=_ -02P,$%     @ JHK74,UIYE>& P
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MI,3J+H&Z2W:^-^(09 1F*8'\!W8<U=(1N;+A7''WL9>0P$M0S9I++LETB[P
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M;KZZ\+TZO5D_7=3EH?NO@=GY7Q?N_P=02P,$%     @ JHK74*9]F:R[ 0
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MYU\V]K]!=."E)#=^A#K_P19#0N/"\8,_FVG,)L-A/_\@MGSC\@]02P,$%
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M4]MNW" 0_17$!X0UZURZLBUE4U6ME$BK5&V?67MLHX!Q :^3O^^ '==MK;X
M,\PY<V88LM'8%]<">/*J5>=RVGK?'QAS90M:N"O30X<WM;%:>#1MPUQO0501
MI!7CN]T-TT)VM,BB[V2+S Q>R0Y.EKA!:V'?CJ#,F-.$OCN>9=/ZX&!%UHL&
MOH+_UI\L6FQAJ:2&SDG3$0MU3N^3PS$-\3'@NX31K<XD5'(VYB487ZJ<[H(@
M4%#ZP"!PN\ #*!6(4,;/F9,N*0-P?7YG_Q1KQUK.PL&#43]DY=N<WE%202T&
MY9_-^!GF>JXIF8M_A LH# ]*,$=IE(LK*0?GC9Y94(H6K],NN[B/TPU/9M@V
M@,\ O@#N8AXV)8K*/PHOBLR:D=BI][T(3YP<./:F#,[8BGB'XAUZ+T7R(<W8
M)1#-,<<IAJ]CE@B&[$L*OI7BR/^!\VWX?E/A/L+W?RB\WB9(-PG22)#^M\2M
MF)N_DK!53S78)DZ3(Z49NCC)*^\RL/<\OLGO\&G:GX1M9.?(V7A\V=C_VA@/
M*&5WA2/4X@=;# 6U#\=;/-MIS";#FW[^06SYQL4O4$L#!!0    ( *N*UU!"
MJI=\M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;'U386_;
M(!#]*X@?4!*2M6ED6VHZ39NT25&G=9^)?;91@?, Q]V_'V#7\S9K7X [[KU[
M=QS9@/;%M0">O&IE7$Y;[[LC8ZYL00MW@QV8<%.CU<('TS;,=19$E4!:,;[9
MW#(MI*%%EGQG6V38>R4-G"UQO=;"_CR!PB&G6_KF>))-ZZ.#%5DG&O@*_EMW
MML%B,TLE-1@GT1 +=4X?ML?3/L:G@&<)@UN<2:SD@O@2C4]53C=1$"@H?600
M8;O"(R@5B8*,'Q,GG5-&X/+\QOXAU1YJN0@'CZB^R\JW.3U04D$M>N6?</@(
M4SWO*)F*_PQ74"$\*@DY2E0NK:3LG4<]L00I6KR.NS1I'\:;W>T$6P?P"<!G
MP"'E86.BI/R]\*+(+ [$CKWO1'SB[9&'WI31F5J1[H)X%[S78GM_E[%K))IB
M3F,,7\;,$2RPSRGX6HH3_P?.U^&[586[!-_]H?"P3K!?)=@G@OU_2UR+N?\K
M"5OT5(-MTC0Y4F)OTB0OO// /O#T)K_#QVG_(FPCC2,7].%E4_]K1 ]!RN8F
MC% ;/MAL**A]/-Z%LQW';#0\=M,/8O,W+GX!4$L#!!0    ( *N*UU!?3=3P
MLP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U3VV[4,!#]
M%<L?4.\Z"U2K)%*W"($$TJH(>/8FD\2J+\%V-N7O&3MI")#VQ?:,YYPY,Q[G
MHW6/O@,(Y$DKXPO:A= ?&?-5!UKX&]N#P9O&.BT"FJYEOG<@Z@32BO'=[BW3
M0AI:YLEW=F5NAZ"D@;,C?M!:N%\G4'8LZ)X^.QYDVX7H8&7>BQ:^0OC6GQU:
M;&&II0;CI37$05/0N_WQ=(CQ*>"[A-&OSB16<K'V,1J?ZH+NHB!04(7(('"[
MPCTH%8E0QL^9DRXI(W!]?F;_D&K'6B["P[U5/V0=NH+>4E)#(P85'NSX$>9Z
MWE R%_\9KJ P/"K!')55/JVD&GRP>F9!*5H\3;LT:1^GFRR;8=L /@/X KA-
M>=B4*"E_+X(H<V='XJ;>]R(^\?[(L3=5=*96I#L4[]%[+?%!<W:-1'/,:8KA
MJYC]$L&0?4G!MU*<^']PO@W/-A5F"9[]I?"%_(=-@D,B.+Q:XE;,ORK9JJ<:
M7)NFR9/*#B9-\LJ[#.P=3V_R)WR:]B_"M=)X<K$!7S;UO[$V $K9W> (=?C!
M%D-!$^+Q'9[=-&:3$6P__R"V?./R-U!+ P04    " "KBM=0I[7'0;0!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q]4V&/G" 0_2N$'W"X
MZ+:7C9K<7M.T29MLKFG[F=51R8%C =?KOR^@9VUK^@688=Z;-\.03VB>;0?@
MR(M6O2UHY]QP8LQ6'6AA[W" WM\T:+1PWC0MLX,!44>05HPGR1NFA>QIF4??
MQ90YCD[)'BZ&V%%K87Z>0>%4T -]=3S)MG/!P<I\$"U\ ?=UN!AOL96EEAIZ
M*[$G!IJ"/AQ.YRS$QX!O$B:[.9-0R17Q.1@?ZX(F01 HJ%Q@$'Z[P2,H%8B\
MC!\+)UU3!N#V_,K^/M;N:[D*"X^HOLO:=06]IZ2&1HS*/>'T 99ZCI0LQ7^"
M&R@?'I3X'!4J&U=2C=:A7EB\%"U>YEWV<9_FFV.ZP/8!? 'P%7 ?\[ Y453^
M3CA1Y@8G8N;>#R(\\>'$?6^JX(RMB'=>O/7>6\F3-&>W0+3$G.<8OHDYK!',
MLZ\I^%Z*,_\'SO?AZ:["-,+3/Q1F^P39+D$6";+_EK@7<_PK"=OT5(-IXS19
M4N'8QTG>>->!?>#Q37Z'S]/^69A6]I9<T?F7C?UO$!UX*<F='Z'.?[#54-"X
M<'SKSV8>L]EP."P_B*W?N/P%4$L#!!0    ( *N*UU 7V:<ZM $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;'U3VV[<(!#]%<0'!"^[358K
MVU(V4=5*C;1*U/:9M<<V"A<7\#KY^P FKMNZ>0%FF'/FS##DHS;/M@-PZ$4*
M90O<.=<?"+%5!Y+9*]V#\C>--I(Y;YJ6V-X JR-("D*S[)I(QA4N\^@[F3+7
M@Q-<P<D@.TC)S.L1A!X+O,'OCD?>=BXX2)GWK(4G<-_[D_$6F5EJ+D%9KA4R
MT!3X=G,X[D)\#/C!8;2+,PJ5G+5^#L;7NL!9$ 0"*A<8F-\N< ="!"(OXU?B
MQ'/* %R>W]D_Q]I]+6=FX4Z+G[QV78'W&-70L$&X1SU^@53/)XQ2\=_@ L*'
M!R4^1Z6%C2NJ!NNT3"Q>BF0OT\Y5W,=TLT^P=0!- #H#]C$/F1)%Y??,L3(W
M>D1FZGW/PA-O#M3WI@K.V(IXY\5;[[V4-+O.R240I9CC%$,7,9LY@GCV.05=
M2W&D_\#I.GR[JG ;X=O_*/R#8+=*L(L$NP]+7(NY^2L)6?14@FGC-%E4Z4'%
M25YXYX&]I?%-?H=/T_[ 3,N516?M_,O&_C=:._!2LBL_0IW_8+,AH''A>.//
M9AJSR7"Z3S^(S-^X? -02P,$%     @ JXK74+>;Q1FT 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL?5/;;M0P$/T5RQ]09[T!EE42J5N$
M0 )I541Y]B:3B^I+L)U-^7O&3AH"37FQ/>,Y9\Z,Q]EH[*-K 3QY4E*[G+;>
M]T?&7-F"$N[&]*#QIC96"8^F;9CK+8@J@I1D/$G>,B4Z38LL^LZVR,S@9:?A
M;(D;E!+VUPFD&7.ZH\^.^ZYI?7"P(NM% ]_ ?^_/%BVVL%2= NTZHXF%.J>W
MN^,I#?$QX*&#T:W.)%1R,>8Q&)^KG"9!$$@H?6 0N%WA#J0,1"CCY\Q)EY0!
MN#X_LW^,M6,M%^'@SL@?7>7;G!XHJ: 6@_3W9OP$<SUO*)F+_P)7D!@>E&".
MTD@75U(.SALULZ 4)9ZFO=-Q'Z<;GLZP;0"? 7P!'&(>-B6*RC\(+XK,FI'8
MJ?>]"$^\.W+L31F<L17Q#L4[]%X+GAPR=@U$<\QIBN&KF-T2P9!]2<&W4ISX
M"SC?AN\W%>XC?/^*PK\(TDV"-!*D_RUQ*^;]/TG8JJ<*;!.GR9'2##I.\LJ[
M#.PMCV_R)WR:]J_"-IUVY&(\OFSL?VV,!Y22W. (M?C!%D-"[</Q'9[M-&:3
MX4T__R"V?./B-U!+ P04    " "KBM=0B9Q );,!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6Q]4V%OW" ,_2N('U 2[M96IR12K].T29MT
MZK3U,Y<X"2K$*9!+]^\'),W2+ML7P,;O^=F8;$3S9%L 1UZTZFQ.6^?Z V.V
M;$$+>X4]=/ZF1J.%\Z9IF.T-B"J"M&(\2:Z9%K*C119])U-D.#@E.S@98@>M
MA?EU!(5C3E/ZZGB03>N"@Q59+QKX#NY'?S+>8@M+)35T5F)'#-0YO4L/QWV(
MCP$_)8QV=2:ADC/B4S"^5#E-@B!04+K (/QV@7M0*A!Y&<\S)UU2!N#Z_,K^
M*=;N:SD+"_>H'F7EVIS>4E)!+0;E'G#\#',]'RB9B_\*%U ^/"CQ.4I4-JZD
M'*Q#/;-X*5J\3+OLXCY.-_QFAFT#^ S@"^ VYF%3HJC\HW"BR R.Q$R][T5X
MXO3 ?6_*X(RMB'=>O/7>2\'3)&.70#3''*<8OHI)EPCFV9<4?"O%D?\%Y]OP
MW:;"783OWBC\1_[])L$^$NS_6^)6S'N5;-53#::)TV1)B4,7)WGE70;VCL<W
M^1,^3?LW81K967)&YU\V]K]&=."E)%=^A%K_P19#0>W"\<:?S31FD^&PGW\0
M6[YQ\1M02P,$%     @ JXK74#?C*@.T 0  T@,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL?5/;;M0P$/T5RQ]0;YP4JE42J=L*@032J@AX]B:3
MB^I+L)U-^7O&3AH"1'VQ/>,Y9\Z,Q_ED[+/K #QY45*[@G;>#T?&7-6!$N[&
M#*#QIC%6"8^F;9D;+(@Z@I1D_'!XQY3H-2WSZ#O;,C>CE[V&LR5N5$K87R>0
M9BIH0E\=3WW;^>!@93Z(%KZ"_S:<+5IL9:E[!=KU1A,+34'OD^,I"_$QX'L/
MD]N<2:CD8LQS,#[5!3T$02"A\H%!X':%!Y R$*&,GPLG75,&X/;\ROXAUHZU
M7(2#!R-_]+7O"GI'20V-&*5_,M-'6.JYI60I_C-<06)X4((Y*B-=7$DU.F_4
MPH)2E'B9]U['?9IOTG2![0/X N KX"[F87.BJ/Q1>%'FUDS$SKT?1'CBY,BQ
M-U5PQE;$.Q3OT'LM>9+F[!J(EIC3',,W,<D:P9!]3<'W4ISX?W"^#T]W%:81
MGOZE,-LGR'8)LDB0O5GB7LSM/TG8IJ<*;!NGR9'*C#I.\L:[#NP]CV_R)WR>
M]B_"MKUVY&(\OFSL?V.,!Y1RN,$1ZO"#K8:$QH?C>SS;><QFPYMA^4%L_<;E
M;U!+ P04    " "KBM=0-"G'J;4!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q]4V%OVR 0_2N('U!BDK919%MJ6E6=M$E1JVV?B7VV4<&X
M@./NW_? KN=MUKX =]Q[]^XXTL'85]< >/*N5>LRVGC?'1AS10-:N"O308LW
ME;%:>#1MS5QG0901I!7CF\T-TT*V-$^C[V3SU/1>R19.EKA>:V%_'4&9(:,)
M_70\R[KQP<'RM!,UO(#_WITL6FQF*:6&UDG3$@M51N^2PW$7XF/ #PF#6YQ)
MJ.1LS&LPOI09W01!H*#P@4'@=H%[4"H0H8RWB9/.*0-P>?YD?XRU8RUGX>#>
MJ)^R]$U&]Y244(E>^6<S/,%4SS4E4_%?X0(*PX,2S%$8Y>)*BMYYHR<6E*+%
M^[C+-N[#>'/-)]@Z@$\ /@/V,0\;$T7E#\*+/+5F(';L?2?"$R<'CKTI@C.V
M(MZA>(?>2\Z3FY1= M$4<QQC^"(FF2,8LL\I^%J*(_\'SM?AVU6%VPC?_J'P
M=IU@MTJPBP2[_Y:X%K/_*PE;]%2#K>,T.5*8OHV3O/#. WL7'Y']#A^G_9NP
MM6P=.1N/+QO[7QGC :5LKG"$&OQ@LZ&@\N%XBV<[CMEH>---/XC-WSC_ %!+
M P04    " "KBM=0G'L)RK0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q]4]MNW" 0_17$!P2;W;3)RK:4352U4BNM4K5Y9NVQC0+&!;Q.
M_[X#=EPKL?("S'#.F0M#-AK[[%H 3UZTZEQ.6^_[ V.N;$$+=V5ZZ/"F-E8+
MCZ9MF.LMB"J2M&(\23XQ+61'BRSZ3K;(S."5[.!DB1NT%O;O$909<YK25\>C
M;%H?'*S(>M' 3_"_^I-%BRTJE=30.6DZ8J'.Z5UZ..X#/@)^2QC=ZDQ")6=C
MGH/QK<II$A("!:4/"@*W"]R#4D$(T_@S:](E9""NSZ_J7V+M6,M9.+@WZDE6
MOLWI#245U&)0_M&,7V&NYYJ2N?CO< &%\) )QBB-<G$EY>"\T;,*IJ+%R[3+
M+N[C=,-O9]HV@<\$OA!N8APV!8J9/P@OBLR:D=BI][T(3YP>./:F#,[8BGB'
MR3OT7@J>WF;L$H1FS''"\!4F71 ,U9<0?"O$D;^C\VWZ;C/#7:3OUG2>; OL
M-P7V46#_88D;&/ZV2+;JJ0;;Q&ERI#1#%R=YY5T&]H['-_D/GZ;]A["-[!PY
M&X\O&_M?&^,!4TFN<(1:_&"+H:#VX?@9SW8:L\GPII]_$%N^<?$/4$L#!!0
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M0 1A*BPRAR)S0+ (1  FS[!(!44J0$ #$82)9,X"BBP 07CQ"!.Y>)KA"LH
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ML-50T/AP?(=G.X_9;'@S+#^(K=^X_ U02P,$%     @ JXK74'KC,ERW 0
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M)UYRI;4#GTIRYW-I?!=/"P&5"].=GYOA+0\+I]NQ3<GTK\C_ E!+ P04
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M! ]F5UOS'JT!@UK;:6KF<KZ5<Z#%L#PX9'WUBK]02P,$%     @ JXK74)6
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MOBYW4BJA]<0W6LE![X'&BU+L5'?*]7G3;P3Z"R6/PR8G&G=:B_]02P,$%
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M? P8G)29)GHN^ENM#Q1OAPL;CU^-X@]02P,$%     @ JXK74+*,*0<4 @
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MP00X@ T5+- Z@1:_?^PP+P9RQ0X*V'EX@?7*";3T$F#86!AREJM@V%IXB;<
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MK#A-E-H9? "*3D"91)E&,CT#%3(X#XH_ UAI.%8FZ[)#(@DX:3A.HC$ )\T
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M8OM<7CA75 ?C;W1!5[HAC@M&+\I,$ST7?5?H%XIW0\?SQK9;_ 502P,$%
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MS7UR__I:" V&,%R9HVG,LS8'#&IMMZG9R_%RCX$6_?1NX?GQ+/X!4$L#!!0
M   ( *N*UU!J2CM1;P,  &(0   9    >&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;)58[6Z;,!1]%<0#!&SSU2J)U&::-FF3JD[;?M/$25 !9^ DW=O/-C0E
M^+AE?THPU^><ZQM.[NW\+)KG=L^Y]%ZJLFX7_E[*PVT0M.L]K_)V)@Z\5D^V
MHJERJ6Z;7= >&IYOS*:J#&@8)D&5%[6_G)NUAV8Y%T=9%C5_:+SV6%5Y\_>>
ME^*\\(G_NO!8[/92+P3+^2'?\1]<_CP\-.HNN*!LBHK7;2%JK^';A7]';E>,
MZ@TFXE?!S^W@LZ=3>1+B6=]\W2S\4"OB)5]+#9&KRXFO>%EJ)*7C3P_J7SCU
MQN'G5_3/)GF5S%/>\I4H?Q<;N5_XF>]M^#8_EO)1G+_P/J'8]_KLO_$3+U6X
M5J(XUJ)LS5]O?6REJ'H4):7*7[IK49OKN7N2QOTVO('V&^AE0\3>W<#Z#>QM
M@\F]$V8R_93+?#EOQ-EKNF(=<OV=(+=,G>5:+YJC,\]4LJU:/2UC&LV#DP;J
M8^Z[&#J(B1)VB0D4_H6$0A)J *(KDGA$TL4D)J;N8DC*TH&8*R(&B1@@2C!
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M),>/U3.[)Y(-,HMYLH-N[=P[DU:9T7N)L[P =VLT:7:C)EUHTK>*_5J!_ID
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M(]%!2B6T0S33M$]Z<!\6N3@H\QKK][J;7KN%DE4_F0?#SX/E/U!+ P04
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MRDQ7>BY<IW +Q?NQ":*I$Y=_ 5!+ P04    " "KBM=0M>Q_>;0"  "4"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R%EE%OFS 0Q[\*XKW%QMA
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M>SX,C.$@63<.0V^:R,4_4$L#!!0    ( *N*UU"364R4!@(  'X%   9
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M FK-?*,.E/:,\O'GAN!=  TCGI'<=X) TQ$?..((R#CU\^- _8[06#OP1H"
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M.+)_E,/ "1;]["MD=R]\]^"'QXMX-%_$T\6(OKF*E^-9O!K/#\\'+E14W$;
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M>$M$\\;SS?  X*_,/J)/WX 51L<?/YU8-E*#Q*FM+@]GY9P+&,S/8"E%^6S
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M:1/LY/QYJ)86S.D!%'TDT1N@1$OU./D-:F;\D;1\J(B)P_4$!2P6/"D0 KR
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M1M9U1W4/U##BI3J&S3M :@0<'1J@"?V :#3T6S\W/T+V+QO8=J-D1F)9HN\
M'7CY'NUDU"<-O>?;&=8$I@,D&Q*.FF+L:4FY^Q3=O4]*=GQ5'!8A+@>#5?O-
MO?N\\V=MT)2^W:.04Z\0&D*&C9EN;X$=1D2(M6@-F>-IPHNWL>07?6!.V<3+
ME++M1?]9,J-/=NSTZG!,^2=L7G7"C6T !I.BZBW.<Y8)8@M;=U[DKPR%?_</
MAFS/756X(3+R9U'>S>]@'E? (B3<J6J]KX>@P;F3C"C$O*"K 46%3AE]>\$+
M=%V R6SIA$W/A&DLI("^WW'>VW27/-/QUS2//J,T@R]OY&ZVKT^G21I[4OM1
M<_U8UHM;D2G-][2(=Z3#&TL2V:#38U\2ZP8Q5.[ICG)R%\T3XR&DIS D@<]U
M0R/OZYLR3?X@E?+3KQ?O!N,U?Y\+?>#?G1.:Z?@,9%E"C"STNQJTM'C-CD6\
M@Y-'?U>D.6="5[\5):@2/Z?)#JYP$"C>IB ]R9S6"5$8 KC@ P9AK!FL'L?H
MMY2U2F"H\/5*E'TY&CN&/484#["9@0_2.0H\*Q$]!7O1[1 (V.5<:V@5QO.)
MR7?*5*2-,O !,W#'XA1\1-YIY-?/R+LRD,8_%T\8,8B%IQ[@W11)3';/H&X9
MNLII3JQR+SC (F/!0<X9OMUT97B3+'MRAV[W#5/12/6#>_B?^Y3O_#69C+7H
MR=[=E;>,/2^*^NT*, C\.!QJNR@#2?7C;]*L]3[!3GA.G(87502(=T'@4O$<
M\.X"M]_MC)754A(A9]\5'N26/06Z;^A'':(]M:%Z+/S)+EZ_"],S*>Z+.V?J
MIP*M6M!;T?'[R' C 1 ED:IGZ'^1$13#QS3D/)X$Z*B<ZNH9I>N6:@ __1&B
MMPV><*["WCZ+%)@2/>)$.?6_8OO&2ED*LC8BEZTO,BE;=J<CD>?92:B0L(5U
M-6)JW1%3P]_E7<&@:P'/ 4?CP.MM!GQ%/G=3H">J\T)ZHI+N$ODRNYS<M""2
M=]NAARBY\%#G[SNQZ'3EK%JW>U8]V/C"B(G<)RDT\A@DA\HR7:B,O.-DUM-
MBLCIJN+AD4H#LAF<D]'8)]M5_</!S;A)\C_P7J$4\D(%F8!^!C<I\V'K"<@P
MA/$[[C^\63D@B%5V4;V):1^L!P!A4W@W8[IP<-?@LB(O3K\AS"ZZ3;<H%F#Q
M,&5V4J(Y4+4!+,#VBMO;@0P\H!)4X1Z;QA:SF*^LTF&3?9']H&Z(2B'#8>U?
MD-_Q-NA;]^F62N*047BGC@BOB JA54\[@F%Q*X8F_I?*',UMM08]=,:FIM6F
M+)YTRQUG5G>K6OYM)RX7S[BR7BR0C%?[&V;:Q*8;DPO(56\"#TXA#H=_#*?$
MKG")"=H@)OM=+YQ9$W?&!_TM,<&61$>+\3K8$/4LPX]P#NS4(@2!'I;/P$I)
M,>$QO9C03<HAUULR*U1_RUD<5NH*%>6=2HQ@9'%KQ<(.(ZJHN.  7U,@Y9V4
MI&%5D5&+K/"$%TIOC?58>]3 '@18JFD4UT"A<C1>Q*OIPCW4*+=A'UI/9V'I
MC2$38\ V4"3>@^#ERBGW(&(HN(C*ILDLR%S=627*MV2+ 4@_LP;9&8Y,%E<!
M<BK+B=77-LR%= FD&#UP$3>,9Z644 X; =^J).;2*#YD\,@.[S'E^+^PQ\PM
M'+R-6616J:I+^2&9NDB,:'0.4]CVQW6G(2$6X5["!MW.:\\#6P7),!9J6;TQ
M[V&9.&$MAM:*ZK_T!&A8O>6>HB,LA;>:K./)<H[_B*>S43P934UC[Z-YO)C.
MB=*8E@Z,V04(.$((XVPQC\?C,7]GOHS'TR6<,2M(H1)"OJO_2BNG/V'L[XD#
M/=5M6J*[X2'#NWH'!C(;:FE)H6>BOSWH5P_( YE3"H)(+O#MCK+*.! -DG4K
MVJ/33Y]280H2)J;D,XD4JV0P[ I%GV9K#D!CA?6VI5U..=&$5))PN,S.^LFZ
M)QI83(IV 7D_ F4<9R<1HI;K[/99%T/#'5<2[TGLD#]&QUGS<=\!4MSLLCO:
M!'Q9[#$=CUZ&M]V"$&/@N>I1,=FD^-C7$XMW%L1>XR$-C7W'QY&>CF%@2Q:Z
MGX:HXACY/*X8-@8&J5Y:W3 ZK9U8\,""3ZED+='[;;JR)"<NVC39W!L=*-9W
M84ZD$N"O44"EWF DJBB*MF%MRCL8)"C+7[M7T=!X'A#<BKCNW_?;.PU(V,-Z
M8Y(3QIO9PAD]HT8WBL=I.XO9?8Z4QY24W!1?&6ZJ"^:9]PQ-'AZ[8L[>H[?Z
MIM*B@IN3'H(*9Z938[+9\$N4)3M(0&"G!GU#%+:@ERE$0"?5.0\]E\PY*2SE
M:"1$Z%V!?:WYD3.?)O=5YA9"J_8HN3I/SFZM-1@]E1,AD.+A]%A83+KR(\^.
MH1I92@G4%(ZY256'0GG>O:%,6QWK:*0R'-JV0O13#LYL_0.(Y  ,CRI1'YQN
MVZW7(0@2V@*Z^/VW7*,]P7F1<D,, DXS!CI(8VLN_T8^DR2BF!8?)*::@*B
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MWGOWV2_6ZD<DHWZ(MU>NBQILWOAZ_YPBQ$FROHY%>6T$=J'J<A2JDR6RL$(
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ML)MQ^DAB5\4.@>P@)235T4Z,6R*YY[L>BF5ONAU<W%I""!EC?Z_B)9UW>"A
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M^T=MG-4,!;FBI'C4./*^QGC:'Z2]2C(S?[]Z+*42VM7IYRM8VZ^#"=,Q=P!
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M+.58" #3NP(=6_-#]S%/[JO,+4S@WZ. ZSPYN[5>60FKW"*N6;RU'@NC$@Y
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M1CC?A1-OJ!K7%43]:IR'YZ<E*+X)2N-9FD=QF06G:U'](Z\24MS2.<AX>1&
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ME\U7-+ARP&%ZW.T*^%!X!R?I]V5KOR4G)\T]B;7)K]AC;D&T"Z]N-U1OM$&
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MG!B&W-#3_:E!)TN?0*'+$]\WS?:G_P)02P,$%     @ JXK74/#G*)]0 @
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M50ZCT2@;5ERJX.QT>Z^I&<(#78N\EEJYD_[$@Q1/=G?='S+N"CR*>SX?!Z.
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M)8?KZ\TO\>O4/Q%A6E&>?P-02P,$%     @ JXK74#!OJ4SU 0  CR8  !,
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "JBM=0Z<9H"NX    K @  $0
M        @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "JBM=0
MF5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( *J*UU#Y3W*SS0(  )@+   8              "
M ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "JBM=0
MW&#/34,$  "<$P  &               @ 'Z"P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ JHK74&!S-H(] @  M@<  !@
M     ( !<Q   'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M *J*UU#-:>97A@,   \.   8              "  >82  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " "JBM=0SV0;BQ,&  #&(   &
M            @ &B%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ JHK74*9]F:R[ 0  " 0  !@              ( !ZQP  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *J*UU")S\@ AP4  (X;
M   8              "  =P>  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " "KBM=01C:,%K !  #2 P  &               @ &9)
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ JXK74*Z58BFU
M 0  T@,  !@              ( !?R8  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( *N*UU!J!O<0M0$  -(#   9              "
M 6HH  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ JXK7
M4&=)"*:T 0  T@,  !D              ( !5BH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " "KBM=0MLNMF+0!  #2 P  &0
M        @ %!+   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( *N*UU!"JI=\M0$  -(#   9              "  2PN  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ JXK74%]-U/"S 0  T@,
M !D              ( !&#   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " "KBM=0I[7'0;0!  #2 P  &0              @ $",@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *N*UU 7V:<Z
MM $  -(#   9              "  >TS  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ JXK74+>;Q1FT 0  T@,  !D
M ( !V#4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "K
MBM=0B9Q );,!  #2 P  &0              @ '#-P  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *N*UU WXRH#M $  -(#   9
M          "  :TY  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ JXK74#0IQZFU 0  T@,  !D              ( !F#L  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "KBM=0G'L)RK0!  #2
M P  &0              @ &$/0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( *N*UU <JSO]J@(  !0+   9              "  6\_
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ JXK74# _
M(P?@ 0   04  !D              ( !4$(  'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " "KBM=0%>]5B[D!  #2 P  &0
M    @ %G1   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M *N*UU#:BP7'M@$  -(#   9              "  5=&  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ JXK74/,VKO'Z 0  RP4  !D
M             ( !1$@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " "KBM=0PJ ;/[<!  #2 P  &0              @ %U2@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *N*UU!(Z$G1M@$
M -(#   9              "  6-,  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ JXK74'KC,ERW 0  T@,  !D              ( !
M4$X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "KBM=0
MA**-],<!   W!   &0              @ $^4   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( *N*UU"*]D &W0$   $%   9
M      "  3Q2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ JXK74)6 @[O% 0  -P0  !D              ( !4%0  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "KBM=0'B@>[<4"  #J"@
M&0              @ %,5@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( *N*UU :Y&>82@,  '4-   9              "  4A9  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ JXK74*P;JX#R
M 0  ^ 0  !D              ( !R5P  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " "KBM=0I\G$!?D!  #(!0  &0
M@ 'R7@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *N*
MUU#:L<8S#P(  $$&   9              "  2)A  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ JXK74+*,*0<4 @  '@8  !D
M         ( !:&,  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " "KBM=039ZWZ8H"  #G"@  &0              @ &S90  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *N*UU#O^B7MX0$  &8$
M   9              "  71H  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ JXK74.>,MK!; @  ]P<  !D              ( !C&H
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "KBM=04;/)
MJ$@'  !J+   &0              @ $>;0  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( *N*UU!J<[E14P(  (('   9
M  "  9UT  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MJXK74/U-1'-S P  #0X  !D              ( !)W<  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " "KBM=0+\:X.40"  #B!P  &0
M            @ '1>@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( *N*UU#/0<\<&P(  ,L%   9              "  4Q]  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ JXK74%>FL[S? 0
M2 4  !D              ( !GG\  'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " "KBM=0:DH[46\#  !B$   &0              @ &T
M@0  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( *N*UU A
M'AI]3@(  *P'   9              "  5J%  !X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ JXK74!H@'4,U @  G 8  !D
M     ( !WX<  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *N*UU!S)X/$_0$  ',%   9              "
M 6B6  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ JXK7
M4*;(F2 K @  #08  !D              ( !G)@  'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " "KBM=057WWD],"  #<"@  &0
M        @ '^F@  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( *N*UU!>8)!J) (  )4%   9              "  0B>  !X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ JXK74+7L?WFT @  E H
M !D              ( !8Z   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " "KBM=0K.?__DT"  "=!P  &0              @ %.HP
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( *N*UU"364R4
M!@(  'X%   9              "  =*E  !X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ JXK74'MA.(ME!   (18  !D
M ( !#Z@  'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " "K
MBM=0EU1;I^$!  "@!   &0              @ &KK   >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( *N*UU"S20@P!P(  ,D%   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *N*UU!?ER#R\ 0  %@K   /
M      "  >9# 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "KBM=0VKGW
M5R\"   X)P  &@              @ $#20$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "KBM=0,&^I3/4!  "/)@  $P
M    @ %J2P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #@4  "0
%30$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6825027280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Agreement Loan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,570<span></span>
</td>
<td class="nump">$ 292,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants excersice price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Lenders [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants excersice price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 594,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Lenders [Member] | Five Tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">Each tranche shall be repaid in installments commencing June 15, 2023 with all amounts outstanding under any tranche due on March 17, 2025. The first tranche was executed on March 17, 2020 and because the funds were held in escrow as of March 31, 2020 they are classified as restricted cash in the consolidated balance sheet.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Lenders [Member] | Tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Lenders [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_WarrantsDescription', window );">Warrants description</a></td>
<td class="text">The warrants that will be issued is up to twenty five percentage of its commitment value divided by the five day the volume weighed average price "(VWAP") prior to utilization date. For the tranches three to five, if any of these tranches are utilized by the Company, the warrants that will be issued is up to ten percentage of its commitment value divided by the five day the VWAP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_LendersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_LendersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_FiveTranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_FiveTranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_TranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_TranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6818557136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax, description</a></td>
<td class="text">The Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,726,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_UnusedNetOperatingLossCarryforwards', window );">Unused net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OperatingLossCarryforwardsExpirationYears', window );">Operating loss carryforward expire description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 2018 expire through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowances increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions', window );">Federal tax benefit for reversal of uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OperatingLossCarryforwardsExpirationYears', window );">Operating loss carryforward expire description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Expiring during the years 2035 to 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember', window );">March 2018 Expire Through 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=XAIR_ILMember', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal tax benefit for reversal of uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FederalTaxBenefitForReversalOfUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLossCarryforwardsExpirationYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforward expire term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLossCarryforwardsExpirationYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_UnusedNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unused net operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_UnusedNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenExpireThroughTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=XAIR_ILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=XAIR_ILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804561984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract', window );"><strong>Income Taxes - Schedule Of Unrecognized Tax Benefits Related To Uncertain Tax Positions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 154,300<span></span>
</td>
<td class="nump">$ 154,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decreases for the current year's tax position</a></td>
<td class="num">(154,300)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 154,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803660848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 14, 2020 </div>
<div>USD ($) </div>
<div>Number </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 799,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Corporation LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per shares | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_TradingVolumePecentage', window );">Trading volume pecentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_WeightedAveragePricePecentage', window );">Weighted average price pecentage</a></td>
<td class="num">(95.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lincoln Park Corporation LLC [Member] | New Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AgreementTermDescription', window );">Agreement term description</a></td>
<td class="text">Over the next 36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per shares | $ / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stok sold | shares</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">The Purchase Agreement, to direct LPC to purchase up to 80,000 shares of our common stock (each such purchase, a "Regular Purchase") over the 36-month term of the Purchase Agreement; provided, however, that such limit may be increased to up to 100,000 shares if the last closing sale price of our common stock is at least $5.00 on the purchase date, may be increased to up to 120,000 shares if the last closing sale price of our common stock is at least $7.50 on the purchase date, and may be increased to up to 140,000 shares if the last closing sale price of our common stock is at least $10.00 on the purchase date (each subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement). The purchase price for shares of common stock to be purchased by Lincoln Park will be the equal to lesser of (i) the lowest sale price on the purchase date, as reported by Nasdaq, or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during the ten trading days prior to the purchase date. Lincoln Park's obligation under each Regular Purchase shall not exceed $2,000,000. The amount of the regular purchases can be modified upon the mutual agreement of the Company and LPC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days | Number</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At-The-Market Equity Offering [Member] | Beyond Air, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sales of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At-The-Market Equity Offering [Member] | Beyond Air, Inc [Member] | Sales Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FeePecentage', window );">Fee pecentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AgreementTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AgreementTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FeePecentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee pecentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FeePecentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_TradingVolumePecentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading volume pecentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_TradingVolumePecentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_WeightedAveragePricePecentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price pecentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_WeightedAveragePricePecentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LincolnParkCorporationLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LincolnParkCorporationLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_NewPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_NewPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=XAIR_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=XAIR_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_BeyondAirIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_BeyondAirIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_SalesAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_SalesAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811912240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,577,649<span></span>
</td>
<td class="nump">$ 2,550,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">687,674<span></span>
</td>
<td class="nump">572,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_GeneralAndAdministrativeExpensesMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,889,975<span></span>
</td>
<td class="nump">$ 1,977,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6824935392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 12, 2019</div></th>
<th class="th"><div>Jun. 03, 2019</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
<th class="th"><div>Dec. 26, 2018</div></th>
<th class="th"><div>Aug. 10, 2018</div></th>
<th class="th"><div>Aug. 10, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jul. 02, 2019</div></th>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 799,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Sale of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of common stock value issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">799,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,649<span></span>
</td>
<td class="nump">2,550,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Stock to be issued to a vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,968,944<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_NumberOfSharesIssuedForExerciseOfWarrants', window );">Number of shares issued for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant excercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IncrementalValueOfWarrant', window );">Incremental value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">985,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenIncentiveOptionPlanMember', window );">2013 Incentive Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Options vesting terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Expire up to ten years after the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for future issuance</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,040<span></span>
</td>
<td class="nump">$ 147,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=XAIR_UnvestedStockOptionsMember', window );">Unvested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_VendorMember', window );">Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares issued services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Stock to be issued to a vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_OfficersEmployeesAndConsultantsMember', window );">Officers, Employees and Consultants [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=XAIR_ConcurrentPrivatePlacementMember', window );">Concurrent Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,169,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 699,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=XAIR_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=XAIR_WarrantHoldersMember', window );">Warrant Holders [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_NumberOfSharesIssuedForExerciseOfWarrants', window );">Number of shares issued for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2013 Incentive Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2013 Incentive Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_LincolnParkCapitalFundLLCMember', window );">Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,839,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_NumberOfUnregisteredSharesOfCommonStock', window );">Number of unregistered shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember', window );">Purchase Agreement [Member] | CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember', window );">Purchase Agreement [Member] | Directors and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,910,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuancePeriodTerm', window );">Stock issuance period, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,000<span></span>
</td>
<td class="nump">1,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,344,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,185<span></span>
</td>
<td class="nump">$ 7,745,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember', window );">Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockPurchaseCommitment', window );">Stock purchase commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncrementalValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncrementalValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NumberOfSharesIssuedForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NumberOfSharesIssuedForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NumberOfUnregisteredSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of unregistered shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NumberOfUnregisteredSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuancePeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance period, term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuancePeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenIncentiveOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=XAIR_TwoThousandThirteenIncentiveOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=XAIR_UnvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=XAIR_UnvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_OfficersEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_OfficersEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=XAIR_ConcurrentPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=XAIR_ConcurrentPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_WarrantHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_WarrantHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_DirectorsAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_DirectorsAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795139088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table is the reconciliation of
the presentation and disclosure of financial instruments as shown on the Company&#8217;s consolidated statements of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended </b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">19,829,275</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">1,340,203</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,635,836</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,934</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Cash and cash equivalents and restricted cash</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">25,465,111</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,357,137</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock', window );">Schedule of Useful Life of Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Computers equipment</font></td>
    <td style="width: 65%"><font style="font: 10pt Times New Roman, Times, Serif">Three years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Seven years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Clinical and medical equipment</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fifteen years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Shorter of term of lease or estimated useful life of the asset</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Expected Amortization Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected amortization expense for the next
five year and thereafter is as follows for the year ended March 31,:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">222,378</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">412,763</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock', window );">Schedule of Right-of Use Assets and Operating Lease Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The right-of use assets and operating lease
liability is as follows as of March 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">Right of use asset short-term</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,970</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right of use asset long-term</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">128,757</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">195,727</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability short-term</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">69,342</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability long-term</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">131,581</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,923</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash and Cash Equivalents and Restricted Cash [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of right-of use assets and operating lease liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfRightofUseAssetsAndOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of useful life of assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfUsefulLifeOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645347824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Assets and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CurrentAssetsAndPrepaidExpensesAbstract', window );"><strong>Current Assets And Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock', window );">Schedule of Current Assets and Prepaid Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of current assets and prepaid expenses
as of March 31,&#160;2020&#160;and March 31,&#160;2019&#160;is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">266,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">324,063</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Insurance</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">471,982</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">297,945</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Professional</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">156,259</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value added tax receivable</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">124,517</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47,889</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">131,728</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">118,512</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CurrentAssetsAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CurrentAssetsAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Assets and Prepaid Expenses [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfCurrentAssetsAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6652030096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract', window );"><strong>Income Taxes - Schedule Of Statutory Us Federal Effective Tax Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(7.08%)<span></span>
</td>
<td class="num">(6.62%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">2.48%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">30.67%<span></span>
</td>
<td class="nump">36.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="num">(1.39%)<span></span>
</td>
<td class="num">(3.71%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(3.69%)<span></span>
</td>
<td class="num">(4.77%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax expense rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncomeTaxesScheduleOfStatutoryUsFederalEffectiveTaxRateDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6906228064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 83,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">64,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">64,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">16,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">228,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(27,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 200,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6652030096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799867600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity - Schedule of Unvested Restricted Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options at beginning of period | shares</a></td>
<td class="nump">340,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of unvested options, granted | shares</a></td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of unvested options, vested | shares</a></td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of unvested options, forfeited | shares</a></td>
<td class="num">(16,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options, at end of period | shares</a></td>
<td class="nump">646,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning of period | $ / shares</a></td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested | $ / shares</a></td>
<td class="nump">4.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited | $ / shares</a></td>
<td class="nump">4.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending of period | $ / shares</a></td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6815558160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include
the accounts of the Company and the accounts of its wholly owned subsidiaries. All intercompany balances and transactions have
been eliminated in the accompanying financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the
Company&#8217;s evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and
clinical trials, stock-based compensation, warrant fair value determination and associated debt discount and classification within
stockholders&#8217; equity, assumptions associated with revenue recognition, and the determination of deferred tax attributes
and the valuation allowance thereon.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Other Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks common to medical
device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the potential
need to obtain additional financing. The Company is dependent on third party suppliers, in some cases single-source suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There can be no assurance that the Company&#8217;s&#160;product&#160;will
be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an
acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s products require approval
or clearance from the U.S. Food and Drug Administration prior to commencing commercial sales in the United States. There can be
no assurance that the Company&#8217;s products will receive all of the required approvals or clearances. Approvals or clearances
are also required in foreign jurisdictions in which the Company may license or sell its products. If the Company is denied such
approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact on the Company&#8217;s
results of operations, financial position and liquidity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The development of our product candidates
could be further disrupted and adversely affected by the recent outbreak of COVID-19. The spread of SARS CoV-2 from China to other
countries has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020.
We have addressed the impact COVID-19 may have on our business plans and our ability to conduct the preclinical studies and clinical
trials as well as on our reliance on third-party manufacturing and our supply chain. However, there can be no assurance that this
analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences. The extent to which
the COVID-19 pandemic and global efforts to contain its spread will impact our operations will depend on future developments,
which are still uncertain and cannot be predicted at this time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s license revenue was from
two milestone payments from a terminated license for sales and marketing rights agreement, see Note 11. The Company is seeking
additional partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company relies on two vendors to manufacture
its delivery system. The Company is reliant on the vendors for commercial manufacturing of our LungFit&#8482; generator and delivery
systems and nitrogen dioxide filters for both clinical studies and commercial supply, if regulatory approval is received.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash and cash equivalents and marketable securities. The Company
maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts in major banks in Israel and the U.S.,
the balances of which, at times, may exceed federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no off-balance-sheet concentration
of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RestrictedCashPolicyTextBlock', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, restricted cash includes
$5,000,000 of cash in an escrow account from the lenders of the facility agreement loan, See Note 10. Subsequent to March 31, 2020,
the Company received the funds from the escrow account into a cash operating cash. In addition, as of March 31, 2020, restricted
cash includes $619,000 of cash that is designated for a contract manufacturer. This cash is expected be used for material and parts
that require a long lead time. Collateral for vehicle leases are invested in bank deposit accounts which is restricted and as of
March 31, 2020 was $16,836 and as of March 31, 2019 was $16,934, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents are short-term highly liquid
investments that are readily convertible to cash with original maturities of three months or less at acquisition. Restricted cash
is collateral for vehicle leases and invested in bank deposit accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table is the reconciliation of
the presentation and disclosure of financial instruments as shown on the Company&#8217;s consolidated statements of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended </b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">19,829,275</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">1,340,203</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,635,836</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,934</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Cash and cash equivalents and restricted cash</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">25,465,111</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,357,137</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue when we transfer
promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange
for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the
transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue
when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each
contract, assess whether each promised good or service is distinct and identify those that are performance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company must use judgment to determine:
a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations
are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included
in the transaction price. The transaction price is allocated to each performance obligation on an estimated stand-alone selling
price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied,
see, Note 9.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Where a portion of non-refundable up-front
fees or other payments received are allocated to continuing performance obligations under the terms of a license arrangement,
they are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Segment reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are identified as components
of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed
our business as one segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are charged
to the statement of operations as incurred. Research and development expenses include salaries, costs incurred by outside laboratories,
manufacturer&#8217;s, consultants, accredited facilities in connection with clinical trials and preclinical studies and stock
based-compensation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Exchange Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Foreign Exchange Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BA Ltd.&#8217;s operations are in Israel and
Beyond Air&#8217;s operations are in the United States. The Company&#8217;s management believes that the U.S. dollar is the currency
of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.
Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company&#8217;s transactions and balances denominated
in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to U.S. dollars
in accordance with the Accounting Standards Board Codification Topic 830, &#8220;Foreign Currency Matters&#8221;.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures the cost of employee and
non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.
Fair value for restricted stock awards is valued using the closing price of the Company&#8217;s stock on the date of grant. That
cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite
service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model.
The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity
instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and
does not anticipate paying dividends in the foreseeable future. Due to the Company&#8217;s limited trading history, the Company
utilizes an implied volatility based on an aggregate of guideline companies. In 2020, the Company began to blend its historical
volatility with the peer group in order to obtain expected volatility. The peer companies were based similar publicly traded peer
companies. The Company routinely reviews its calculation of volatility based on, the Company&#8217;s life cycle, its peer group,
and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation expense for options and warrants
granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to
fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted, was
expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense, depending
upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued ASU No.
2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing accounting
standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee
awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant
date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all non-employee awards became
fixed at the start of the fourth quarter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investment in Marketable Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Marketable Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in equity marketable securities
classified available-for-sale are carried at fair value with the changes in unrealized gains and losses recognized in the Company&#8217;s
results in operations. Realized gains and (losses) from the sale of marketable securities are recognized in the statement of operations
using the specific identification method on a trade date basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and accumulated amortization. Depreciation and amortization is calculated using the straight-line method
over the estimated useful life of the assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Computers equipment</font></td>
    <td style="width: 65%"><font style="font: 10pt Times New Roman, Times, Serif">Three years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Seven years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Clinical and medical equipment</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Fifteen years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Shorter of term of lease or estimated useful life of the asset</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_LicensedRightToUseTechnologyPolicyTextBlock', window );">Licensed Right to Use Technology</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Licensed Right
to Use Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Licensed right to use technology&#160;that
is considered platform technology is recorded as&#160;an intangible asset&#160;which resulted&#160;from the NitricGen transaction,
see Note 11. The intangible asset was valued based upon the fair value of the options issued to NitricGen and the cash paid for
this transaction. The license&#160;also&#160;contains two future milestone additional payments aggregating $1,800,000. The intangible
asset is being amortized on a straight-line method over its estimated useful life of thirteen years.&#160;The expected amortization
expense for the next five year and thereafter is as follows for the year ended March 31,:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">222,378</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">412,763</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Impairment of Long-Lived
Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assess the impairment of long-lived
assets on an ongoing basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Factors we consider that could trigger an impairment review include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">significant underperformance relative to expected historical or projected future operating results,</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">significant changes in the manner of our use of the acquired assets or the strategy for our overall business,</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">significant negative regulatory or economic trends, and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">significant technological changes, which would render equipment and manufacturing processes obsolete.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">Recoverability of assets that will continue to be used in our
operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the
asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated
future costs. There were no events during the reporting periods that were deemed to be a triggering event that would require an
impairment assessment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using
the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized
when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not
that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded a valuation allowance to the full extent
of our net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files a U.S. Federal, various state,
and International income tax returns. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing
facts and circumstances. Such adjustment is reflected in the tax provision when appropriate<b>. </b>The Company will recognize
interest and penalties, if any, related to unrecognized tax benefits in income taxes in the statements of operations. The Company
has recorded a liability in accrued expenses of $0 and $154,300 for uncertain tax positions as of March 31, 2020 and March 31,
2019 and reversed this accrual for the year ended March 31, 2020 which resulted in income, respectively. Tax years 2016 through
2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years
2014 through 2020 remain open.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) Per Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share attributable
to common stockholders is computed by dividing the net loss and a deemed dividend from a warrant modification attributable to
common stockholders by the weighted average number of common shares outstanding for the period. The dilutive effect of outstanding
options, warrants, restricted stock and other stock-based compensation awards is reflected in diluted net income (loss) per share
by application of the treasury stock method. The calculation of diluted net income (loss) attributed to common shareholders per
share excludes all anti-dilutive common shares. For periods in which the Company has reported net losses, diluted net loss per
share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because
such common shares are not assumed to have been issued if their effect is anti-dilutive, see Note 8.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Adopted Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In July
2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives
and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all entities that
issue financial instruments (for example, warrants or convertible instruments) that include down round features. This ASU relates
to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include
down round features affect entities that present earnings per share in accordance with the guidance in Topic 260. The Company elected
to adopt Update ASU&#160;2017-11 during&#160;the third quarter of 2018, retrospective to outstanding financial instruments with
down round feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital by $6,194,292 and
decreasing accumulated deficit by $516,358 as of April 1, 2018.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2019, the Company adopted Accounting
Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which generally requires lessees to recognize operating
and financing lease liabilities and corresponding right-of-use assets on the balance sheet and to provide enhanced disclosures
surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The Company early adopted the new
guidance using the modified retrospective transition approach and practical expedients to all leases existing at the date of initial
application and not restating comparative periods. See Note 11. As of April 1, 2019, the adoption date, the Company has identified
three operating lease arrangements. The adoption of ASC 842 resulted in the recognition of operating lease liabilities and right-of-use
assets of approximately of&#160;$264,570&#160;and&#160;$258,605,&#160;respectively. The right-of use assets and operating lease
liability is as follows as of March 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">Right of use asset short-term</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,970</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right of use asset long-term</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">128,757</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">195,727</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability short-term</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">69,342</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Operating lease liability long-term</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">131,581</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,923</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating lease liabilities and their corresponding
right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments
to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in our leases is
typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed
rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar
term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases
in determining the appropriate incremental borrowing rates. The weighted average discount rate and remaining term on lease obligation
is approximately 8.3% and 3.0 years. Operating lease expense is recognized on a straight-line basis over the lease term and is
included in general and administrative expenses. Amortization expense for finance (capital) leases is recognized on a straight-line
basis over the lease term and is included in general and administrative expenses and research and development expenses, while interest
expense for finance leases is recognized using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">In August 2018, the FASB&#160;<font style="background-color: white">issued
ASU 2018-13, &#8220;</font>Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for
Fair Value Measurement&#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average of significant
unobservable inputs used to develop Level 3 fair value measurements. The guidance is effective for the Company&#8217;s interim
and annual reporting periods beginning with the Company&#8217;s fiscal year ended March 31, 2021, and early adoption is permitted.
The Company is evaluating the impact of this accounting standard update on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Standards&#160;Not
Yet Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">In December 2019, the Financial Accounting Standards Board
(&#8220;FASB&#8221;) issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#8221;
as part of its initiative to reduce complexity in the accounting standards. The standard eliminates certain exceptions related
to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition
of deferred tax liabilities for outside basis differences. The standard also clarifies and simplifies other aspects of the accounting
for income taxes. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December
15, 2020. Early adoption is permitted. The Company does not anticipate the adoption of this guidance to have a material impact
on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LicensedRightToUseTechnologyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensed Right to Use Technology [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LicensedRightToUseTechnologyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804654368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Unvested Restricted Shares</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Of Shares</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%"><font style="font: 10pt Times New Roman, Times, Serif">Unvested as of April 1, 2019</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">340,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.62</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">390,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.23</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Vested (a)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(67,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.62</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(16,200</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.65</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of March 31 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">646,800</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.99</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#8217;s options for
the year ended March 31, 2020 and March 31, 2019 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Of Options</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br />
        Average<br />
        Exercise</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price - Options</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Life- Options</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate Intrinsic<br />
Value</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 47%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding as of April 1, 2018</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">510,904</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.32</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,919,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.54</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(20,759</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.42</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(33,333</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,375,812</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.48</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,952,643</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">815,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.51</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,027,240</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(58,662</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.59</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(101,619</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(78,561</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.03</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of March 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,053,589</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.77</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.4</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,878,264</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Exercisable as of March 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,235,674</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.39</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.8</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,673,690</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumption of Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value of options
granted during the year ended March 31, 2020 ad March 31, 2019 was approximately $4.03 and $3.11 per share, respectively, on the
date of grant using the Black-Scholes option pricing model with the following assumption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Year Ended <br />
March 31, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Year Ended <br />
March 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Risk -free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.5% - 3.2 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.5% - 3.2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80.7% - 87.5 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80.7% - 84.5 </font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected terms (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-10</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-10</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year Ended<br />
March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year Ended March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">687,674</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">572,918</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,889,975</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,977,403</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total stock-based compensation expense</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,577,649</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,550,321</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock', window );">Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Company recognized the incremental
value of $522,478, as a deemed dividend using the Black-Scholes pricing model with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 80%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term in years</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.2</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">87</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Company's Outstanding Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#8217;s outstanding
warrants as of March 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrant Holders</b></font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number Of Warrants</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br />
Price</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date Of<br />
Expiration</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">January 2017 offering - investors</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,531,782</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 13%"><font style="font: 10pt Times New Roman, Times, Serif">January 2022</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">January 2017 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,531,782</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">February 2022</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2017 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">76,662</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2021</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2017 offering - placement agent</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7,541</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2021</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2018 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,645,437</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2022</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Third-party license agreement</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">208,333</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">January 2024</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2020 loan&#160;(see Note 10)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">172,187</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.26</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">March 2025</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,173,724</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">These warrants have down round protection.</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfClassOfWarrantsOrRightsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>433</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfChangesInShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Shareholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity</Role>
      <ShortName>Shareholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Current Assets and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses</Role>
      <ShortName>Current Assets and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare</Role>
      <ShortName>Basic and Diluted Net Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Facility Agreement Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FacilityAgreementLoan</Role>
      <ShortName>Facility Agreement Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoanPayable</Role>
      <ShortName>Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://beyondair.net/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/FairValueMeasurement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Shareholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/ShareholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Current Assets and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CurrentAssetsAndPrepaidExpensesTables</Role>
      <ShortName>Current Assets and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Income (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Facility Agreement Loan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FacilityAgreementLoanTables</Role>
      <ShortName>Facility Agreement Loan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/FacilityAgreementLoan</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://beyondair.net/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Organization and Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/OrganizationAndBusinessDetailsNarrative</Role>
      <ShortName>Organization and Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/OrganizationAndBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Significant Accounting Policies - Schedule of Useful Life of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfUsefulLifeOfAssetsDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Useful Life of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfFutureExpectedAmortizationExpenseDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SignificantAccountingPolicies-ScheduleOfRight-ofUseAssetsAndOperatingLeaseLiabilityDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FairValueMeasurement-ScheduleOfFairValueOfAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/PropertyAndEquipmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Shareholder's Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholder's Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/ShareholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Shareholder's Equity - Schedule of Unvested Restricted Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-ScheduleOfUnvestedRestrictedSharesDetails</Role>
      <ShortName>Shareholder's Equity - Schedule of Unvested Restricted Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Shareholder's Equity - Schedule of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-ScheduleOfOptionActivityDetails</Role>
      <ShortName>Shareholder's Equity - Schedule of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelDetails</Role>
      <ShortName>Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Shareholder's Equity - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Shareholder's Equity - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-ScheduleOfAssumptionOfBlack-scholesOptionPricingModelOfWarrantsDetails</Role>
      <ShortName>Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Shareholder's Equity - Summary of Company's Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/ShareholdersEquity-SummaryOfCompanysOutstandingWarrantsDetails</Role>
      <ShortName>Shareholder's Equity - Summary of Company's Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CurrentAssetsAndPrepaidExpenses-ScheduleOfCurrentAssetsAndPrepaidExpensesDetails</Role>
      <ShortName>Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/AccruedExpenses-SummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfPotentialAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/BasicAndDilutedNetIncomeLossPerCommonShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - License Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LicenseAgreementsDetailsNarrative</Role>
      <ShortName>License Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/LicenseAgreement</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Facility Agreement Loan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FacilityAgreementLoanDetailsNarrative</Role>
      <ShortName>Facility Agreement Loan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/FacilityAgreementLoanTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantDetails</Role>
      <ShortName>Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/FacilityAgreementLoan-ScheduleOfFacilityAgreementLoanDetails</Role>
      <ShortName>Facility Agreement Loan - Schedule of Facility Agreement Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Loan Payable (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/LoanPayableDetailsNarrative</Role>
      <ShortName>Loan Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/LoanPayable</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes-ScheduleOfProfitLossBeforeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Profit (Loss) Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes-ScheduleOfDeferredTaxAssetliabilityDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Asset/Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes-ScheduleOfStatutoryUsFederalEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Statutory US Federal Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/IncomeTaxes-ScheduleOfUnrecognizedTaxBenefitsRelatedToUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Commitments and Contingencies - Schedule of Lease Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfLeaseOtherInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/CommitmentsAndContingencies-ScheduleOfMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xair-20200331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://beyondair.net/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://beyondair.net/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>xair-20200331.xml</File>
    <File>xair-20200331.xsd</File>
    <File>xair-20200331_cal.xml</File>
    <File>xair-20200331_def.xml</File>
    <File>xair-20200331_lab.xml</File>
    <File>xair-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811690768">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/Loss [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 840<span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
<td class="nump">$ 32,141,110<span></span>
</td>
<td class="num">$ (30,569,764)<span></span>
</td>
<td class="num">$ (2,986)<span></span>
</td>
<td class="nump">$ 1,544,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,397,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CumulativeAdjustment', window );">Adjustment due to adoption of ASU-2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,194,292<span></span>
</td>
<td class="num">(516,358)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,677,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CumulativeAdjustmentOne', window );">Adjustment due to adoption of ASU 2016-01</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,986<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">At the market stock issuance of common stock, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">799,156<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">799,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At the market stock issuance of common stock, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,699<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,550,321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,550,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,558,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,558,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 871<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">41,693,578<span></span>
</td>
<td class="num">(37,644,572)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,024,877<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,714,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,644<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,841,649<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,478,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock pursuant to an underwritten offering and a private placement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 315<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,169,028<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,169,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock pursuant to an underwritten offering and a private placement, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,152,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue', window );">Issuance of common stock pursuant to Purchase Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,744,870<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,745,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares', window );">Issuance of common stock pursuant to Purchase Agreement, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IncrementalValueOfWarrantsDueToModification', window );">Incremental value of warrants due to a modification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">522,478<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeemedDividendDueToWarrantModification', window );">Deemed dividend due to a warrant modification</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(522,478)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(522,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts', window );">Issuance of common stock pursuant to a private placement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,839,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,839,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares', window );">Issuance of common stock pursuant to a private placement, net, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,583,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance', window );">Warrant issued with debt issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">594,979<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringExerciseOfWarrantsValue', window );">Issuance of common stock upon the exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 99<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,968,845<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,968,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringExerciseOfWarrantsShares', window );">Issuance of common stock upon the exercise of warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">985,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants', window );">Issuance of common stock upon cashless excise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants', window );">Issuance of common stock upon cashless excise of warrants, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock', window );">Vested restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock', window );">Vested restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,942,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,942,504)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,606<span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
<td class="nump">$ 75,702,915<span></span>
</td>
<td class="num">$ (57,587,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,092,445<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,056,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company elected to adopt Accounting Standards Update 2017-11 retrospective to outstanding financial instruments with down round feature by means of cumulative-effect adjustment to the beginning additional paid-in capital of $6,194,292 and accumulated deficit of $(516,358) as of April 1, 2018. This ASU affects all entities that issue financial instruments (for example, warrants or convertible instruments) that include down round features.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issued with debt issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AdjustmentToAdditionalPaidInCapitalToWarrantIssuedWithDebtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CumulativeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative adjustment to the adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CumulativeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CumulativeAdjustmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative adjustment to the adoption.(One)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CumulativeAdjustmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeemedDividendDueToWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend due to a warrant modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeemedDividendDueToWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IncrementalValueOfWarrantsDueToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental value of warrants due to a modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IncrementalValueOfWarrantsDueToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to a private placement, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to a private placement, net of offering costs, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IssuanceOfCommonStockPursuantToPrivatePlacementNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon the exercise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to Purchase Agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodPursuantToPurchaseAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon cashless excise of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodSharesCashlessExciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested restricted stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodSharesVestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon cashless excise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodValueCashlessExciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vested restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_StockIssuedDuringThePeriodValueVestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812094320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 19, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Beyond Air, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001641631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,811,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,841,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6610319056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Future Expected Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 38,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">38,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">38,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">38,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">38,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">222,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_LicensedRightToUseTechnology', window );">Total</a></td>
<td class="nump">$ 412,763<span></span>
</td>
<td class="nump">$ 495,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LicensedRightToUseTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensed right to use technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LicensedRightToUseTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795287296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principles of Consolidation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include
the accounts of the Company and the accounts of its wholly owned subsidiaries. All intercompany balances and transactions have
been eliminated in the accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses for the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company&#8217;s
evaluates its significant estimates including accruals for expenses under consulting, licensing agreements, and clinical trials,
stock-based compensation, warrant fair value determination and associated debt discount and classification within stockholders&#8217;
equity, assumptions associated with revenue recognition, and the determination of deferred tax attributes and the valuation allowance
thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Other Risks and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks common to medical
device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the potential
need to obtain additional financing. The Company is dependent on third party suppliers, in some cases single-source suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There can be no assurance that the Company&#8217;s
product will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured
at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if
at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s products require approval
or clearance from the U.S. Food and Drug Administration prior to commencing commercial sales in the United States. There can be
no assurance that the Company&#8217;s products will receive all of the required approvals or clearances. Approvals or clearances
are also required in foreign jurisdictions in which the Company may license or sell its products. If the Company is denied such
approvals or clearances or such approvals or clearances are delayed, it may have a material adverse impact on the Company&#8217;s
results of operations, financial position and liquidity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The development of our product candidates could
be further disrupted and adversely affected by the recent outbreak of COVID-19. The spread of SARS CoV-2 from China to other countries
has resulted in the Director General of the World Health Organization declaring COVID-19 a pandemic on March 11, 2020. We have
addressed the impact COVID-19 may have on our business plans and our ability to conduct the preclinical studies and clinical trials
as well as on our reliance on third-party manufacturing and our supply chain. However, there can be no assurance that this analysis
will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences. The extent to which the COVID-19
pandemic and global efforts to contain its spread will impact our operations will depend on future developments, which are still
uncertain and cannot be predicted at this time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s license revenue was from
two milestone payments from a terminated license for sales and marketing rights agreement, see Note 9. The Company is seeking additional
partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company relies on two vendors to manufacture
its delivery system. The Company is reliant on the vendors for commercial manufacturing of our LungFit&#8482; generator and delivery
systems and nitrogen dioxide filters for both clinical studies and commercial supply, if regulatory approval is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Financial Instruments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist principally of cash and cash equivalents and marketable securities. The Company
maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts in major banks in Israel and the U.S.,
the balances of which, at times, may exceed federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no off-balance-sheet concentration
of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, restricted cash includes
$5,000,000 of cash in an escrow account from the lenders of the facility agreement loan, See Note 10. Subsequent to March 31, 2020,
the Company received the funds from the escrow account into a cash operating cash. In addition, as of March 31, 2020, restricted
cash includes $619,000 of cash that is designated for a contract manufacturer. This cash is expected be used for material and parts
that require a long lead time. Collateral for vehicle leases are invested in bank deposit accounts which is restricted and as of
March 31, 2020 was $16,836 and as of March 31, 2019 was $16,934, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents are short-term highly liquid
investments that are readily convertible to cash with original maturities of three months or less at acquisition. Restricted cash
is collateral for vehicle leases and invested in bank deposit accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table is the reconciliation of
the presentation and disclosure of financial instruments as shown on the Company&#8217;s consolidated statements of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended </b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For The Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2019</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">19,829,275</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">1,340,203</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,635,836</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16,934</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Cash and cash equivalents and restricted cash</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">25,465,111</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,357,137</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue when we transfer
promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange
for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the
transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue
when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each
contract, assess whether each promised good or service is distinct and identify those that are performance obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company must use judgment to determine:
a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations
are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.
The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included
in the transaction price. The transaction price is allocated to each performance obligation on an estimated stand-alone selling
price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied,
see, Note 9.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Where a portion of non-refundable up-front
fees or other payments received are allocated to continuing performance obligations under the terms of a license arrangement, they
are recorded as contract liabilities and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Segment reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are identified as components
of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed
our business as one segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are charged
to the statement of operations as incurred. Research and development expenses include salaries, costs incurred by outside laboratories,
manufacturer&#8217;s, consultants, accredited facilities in connection with clinical trials and preclinical studies and stock based-compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Foreign Exchange Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BA Ltd.&#8217;s operations are in Israel and
Beyond Air&#8217;s operations are in the United States. The Company&#8217;s management believes that the U.S. dollar is the currency
of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.
Thus, the functional and reporting currency of the Company is the U.S. dollar. The Company&#8217;s transactions and balances denominated
in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to U.S. dollars
in accordance with the Accounting Standards Board Codification Topic 830, &#8220;Foreign Currency Matters&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures the cost of employee and
non-employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.
Fair value for restricted stock awards is valued using the closing price of the Company&#8217;s stock on the date of grant. That
cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite
service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model.
The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity
instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and
does not anticipate paying dividends in the foreseeable future. Due to the Company&#8217;s limited trading history, the Company
utilizes an implied volatility based on an aggregate of guideline companies. In 2020, the Company began to blend its historical
volatility with the peer group in order to obtain expected volatility. The peer companies were based similar publicly traded peer
companies. The Company routinely reviews its calculation of volatility based on, the Company&#8217;s life cycle, its peer group,
and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compensation expense for options and warrants
granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measured, and is recognized over the service period. The expense was previously adjusted to
fair value at the end of each reporting period until such awards vested, and the fair value of such instruments, as adjusted, was
expensed over the related vesting period. Adjustments to fair value at each reporting date resulted in income or expense, depending
upon the estimate of fair value and the amount of expense recorded prior to the adjustment. In June 2018, the FASB issued ASU No.
2018-07, Stock-based Compensation: Improvements to Nonemployee Share-based Payment Accounting, which amends the existing accounting
standards for share-based payments to nonemployees. This ASU aligns much of the guidance on measuring and classifying nonemployee
awards with that of awards to employees. Under the new guidance, the measurement of nonemployee equity awards is fixed on the grant
date. We adopted this ASU the fourth quarter of fiscal 2019, and as a result, the fair value of all non-employee awards became
fixed at the start of the fourth quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investment in Marketable Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in equity marketable securities
classified available-for-sale are carried at fair value with the changes in unrealized gains and losses recognized in the Company&#8217;s
results in operations. Realized gains and (losses) from the sale of marketable securities are recognized in the statement of operations
using the specific identification method on a trade date basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less
accumulated depreciation and accumulated amortization. Depreciation and amortization is calculated using the straight-line method
over the estimated useful life of the assets as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%"><font style="font-size: 10pt">Computers equipment </font></td>
    <td style="width: 65%"><font style="font-size: 10pt">Three years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Furniture and fixtures </font></td>
    <td><font style="font-size: 10pt">Seven years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Clinical and medical equipment </font></td>
    <td><font style="font-size: 10pt">Fifteen years</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Leasehold improvements </font></td>
    <td><font style="font-size: 10pt">Shorter of term of lease or estimated useful life of the asset</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Licensed Right
to Use Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Licensed right to use technology that is considered
platform technology is recorded as an intangible asset which resulted from the NitricGen transaction, see Note 11. The intangible
asset was valued based upon the fair value of the options issued to NitricGen and the cash paid for this transaction. The license
also contains two future milestone additional payments aggregating $1,800,000. The intangible asset is being amortized on a straight-line
method over its estimated useful life of thirteen years. The expected amortization expense for the next five year and thereafter
is as follows for the year ended March 31,:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font-size: 10pt">2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">38,077</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2025</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">38,077</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">222,378</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">412,763</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Impairment of Long-Lived
Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assess the impairment of long-lived
assets on an ongoing basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable.
Factors we consider that could trigger an impairment review include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font-size: 10pt">&#9679;</font></td>
    <td><font style="font-size: 10pt">significant underperformance relative to expected historical or projected future operating results,</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#9679;</font></td>
    <td><font style="font-size: 10pt">significant changes in the manner of our use of the acquired assets or the strategy for our overall business,</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#9679;</font></td>
    <td><font style="font-size: 10pt">significant negative regulatory or economic trends, and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&#9679;</font></td>
    <td><font style="font-size: 10pt">significant technological changes, which would render equipment and manufacturing processes obsolete.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recoverability of assets that will continue
to be used in our operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to
be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market
growth rates, and estimated future costs. There were no events during the reporting periods that were deemed to be a triggering
event that would require an impairment assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using
the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities
of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized
when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not
that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of March 31, 2020, and March 31, 2019, the Company recorded a valuation allowance to the full extent
of our net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files a U.S. Federal, various state,
and International income tax returns. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing
facts and circumstances. Such adjustment is reflected in the tax provision when appropriate<b>. </b>The Company will recognize
interest and penalties, if any, related to unrecognized tax benefits in income taxes in the statements of operations. The Company
has recorded a liability in accrued expenses of $0 and $154,300 for uncertain tax positions as of March 31, 2020 and March 31,
2019 and reversed this accrual for the year ended March 31, 2020 which resulted in income, respectively. Tax years 2016 through
2020 remain open to examination by federal and state tax jurisdictions. The Company files tax returns in Israel for which tax years
2014 through 2020 remain open.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) Per Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share attributable
to common stockholders is computed by dividing the net loss and a deemed dividend from a warrant modification attributable to common
stockholders by the weighted average number of common shares outstanding for the period. The dilutive effect of outstanding options,
warrants, restricted stock and other stock-based compensation awards is reflected in diluted net income (loss) per share by application
of the treasury stock method. The calculation of diluted net income (loss) attributed to common shareholders per share excludes
all anti-dilutive common shares. For periods in which the Company has reported net losses, diluted net loss per share attributable
to common stockholders is the same as basic net loss per share attributable to common stockholders, because such common shares
are not assumed to have been issued if their effect is anti-dilutive, see Note 8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Adopted Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In July
2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives
and Hedging (Topic 815) Accounting for Certain Financial Instruments with Down Round Features. This ASU affects all entities that
issue financial instruments (for example, warrants or convertible instruments) that include down round features. This ASU relates
to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include
down round features affect entities that present earnings per share in accordance with the guidance in Topic 260. The Company elected
to adopt Update ASU 2017-11 during the third quarter of 2018, retrospective to outstanding financial instruments with down round
feature by means of cumulative-effect adjustment by increasing beginning additional paid-in capital by $6,194,292 and decreasing
accumulated deficit by $516,358 as of April 1, 2018.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2019, the Company adopted Accounting
Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which generally requires lessees to recognize operating
and financing lease liabilities and corresponding right-of-use assets on the balance sheet and to provide enhanced disclosures
surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The Company early adopted the new
guidance using the modified retrospective transition approach and practical expedients to all leases existing at the date of initial
application and not restating comparative periods. See Note 11. As of April 1, 2019, the adoption date, the Company has identified
three operating lease arrangements. The adoption of ASC 842 resulted in the recognition of operating lease liabilities and right-of-use
assets of approximately of $264,570 and $258,605, respectively. The right-of use assets and operating lease liability is as follows
as of March 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font-size: 10pt">Right of use asset short-term</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">66,970</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Right of use asset long-term</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">128,757</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">195,727</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Operating lease liability short-term</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">69,342</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Operating lease liability long-term</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">131,581</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">200,923</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating lease liabilities and their corresponding
right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments
to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in our leases is
typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed
rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar
term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases
in determining the appropriate incremental borrowing rates. The weighted average discount rate and remaining term on lease obligation
is approximately 8.3% and 3.0 years. Operating lease expense is recognized on a straight-line basis over the lease term and is
included in general and administrative expenses. Amortization expense for finance (capital) leases is recognized on a straight-line
basis over the lease term and is included in general and administrative expenses and research and development expenses, while interest
expense for finance leases is recognized using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB <font style="background-color: white">issued
ASU 2018-13, &#8220;</font>Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for
Fair Value Measurement&#8221;, which adds disclosure requirements to Topic 820 for the range and weighted average of significant
unobservable inputs used to develop Level 3 fair value measurements. The guidance is effective for the Company&#8217;s interim
and annual reporting periods beginning with the Company&#8217;s fiscal year ended March 31, 2021, and early adoption is permitted.
The Company is evaluating the impact of this accounting standard update on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Standards Not
Yet Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, &#8220;Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes.&#8221; as part of its initiative to reduce complexity in the accounting standards. The standard eliminates certain exceptions
related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the
recognition of deferred tax liabilities for outside basis differences. The standard also clarifies and simplifies other aspects
of the accounting for income taxes. The standard is effective for fiscal years, and interim periods within those fiscal years,
beginning after December 15, 2020. Early adoption is permitted. The Company does not anticipate the adoption of this guidance to
have a material impact on its consolidated financial statements and related disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812240336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 13, 2020</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 17, 2020</div></th>
<th class="th"><div>Apr. 02, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,250,049)<span></span>
</td>
<td class="nump">$ 1,341,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,587,076)<span></span>
</td>
<td class="num">(37,644,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 799,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Five Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member] | Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | New Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">The Company entered into a $40 million purchase agreement ("New Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), that replaces the existing $20 million purchase agreement. The New Purchase Agreement provides for the issuance of up to $40 million of the Company's common stock through May 2023 at the Company's discretion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=XAIR_ShareBasedCompensationAwardFiveTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=XAIR_ShareBasedCompensationAwardFiveTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_NewPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_NewPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001493152-20-011662-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-20-011662-xbrl.zip
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M#G*($(D/UN3=\(F)&P7(RP(X:,0J$!66^L8Y$@'2"*^4 > WXF/*7U)>E5B
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MF/*MR?7D>P_U<>+&N';*K>$K>YOM3[3)8#"N"-Z&WFIU$' \[JMRPOR&*6N
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M;MN%=_<05^_)>UR<MEW/WFS?W5<C0)OOZV>0-)O#\K#2? Q:[45)/W[!8)>
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MD<;$WU$+0=RFC0H4&I ?JT 4*K1_^W1SXR:5++_127^FQ.>[3"VZ!R-!PHW
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M;;EQ)$D3OE^S?0?86-::T@SBD"#!0]7LF*F4RBZ-9:7TIU35TWL'D4$)72#
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M\7[+/>Z0N-MP=S5*KPZ&S=[NFV,WG9[M=-87W=K;=H<<67?[=G>U9L5U7G>
MD?5V8[7$1/VTP''JK[-6LV5W5W/,JA']/3"_=A+DW\M>LK->WW:[APE%NI<;
MTFDTU_>0#HF9=0OX[Z54K3^>LO96[]L1S5-;\8\M0[OIMFVWO^O8[ZFQV+@,
M-H J?Y)O&;IJ[*J6\239\[%TNP^6IU.?L3A;*'6D'NW3U?2N4FRG[=K=WND
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M'5>&-CTRH]X(9@L(VO>$[L85TSMRDD6ZU+,VM]4S64[*/_Y#BR.M)<])3G=
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M-5F[LIGJI>$+:,ZY#?1#ZSJ)/1&P%(36[]ZKQ<U6K2/AT<7H&0M$1R!/3U[
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M-:S/432BCWR*LT?K8C2!:PCM%]:84C%__G1A8X7_BX#W84\ W.^!%\,K'K.
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MC&S%ECG>G8ERS]'XY^"S +] 8!P@5.4>ZJWT##) CS>*HR7]CX24_Y6*E>U
MO.4O?; (\8'-ANN'NQ9Y3'!,/>E@D!E9*O(J88W=N&@#TMU/"8^_75S<JIA
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MQ0E'++4'P04>:3+;2#''7E;4VI)13Z,ZN]P8+:IM>5&7E.V7-W%P<(W>SZ*
M?2$1?!;N<.X-&?MPB\K7/D18@5!Z]1C6,=T85,145MI'"R/3]K#:R(HZ3*=!
MK>L0W(HL!V4Y(E66,\'/F< &@HZ[!*\J8*437^H(\'5L7 44BL<K,J7(%EW_
M/M5V4K*1'D8%E<F3O%B+9=>&KB,[)*\5+'9U("&J;8:CWHL?"7?X@Q?^A58
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M?(O5G.J2+>P=Y2Q)0\+.RE98(6Q5D;DC&VCW"#5_I_ISSZ)^:!;H, K/P6X
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M<P[UT C%S&,[3M_,R0J?\AZ78SM5WQ9,F,C1+O"08:NO$B+I0NF"D%ETS!P
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MYEF8,;DD8Y6+^51 $*/Y1ZIE 4R-2/:>J3O=>"+OB2S'4UV/PH_SFDH)C]0
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M29\I;, QWJ' CO681,5F'4?78%WT.4TMJ5$>)]YL]5F-?+ZX^]5B&; N[OX
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MFUP:8[DD%?*=]F;+>U.<\RW/GJIC?:&;-Z;1(V:9#7?.&[/(0(_B^&+L9GD
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MR-A+0;PO?PSOH;_#R4A?, &>@\#D);U:Y<@.;F[=4&T/"\CC1+@?&^.*F!%
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M54^<?2;.,@JZB)_)535\7V5>\._0Z]!^1FDXFJA8V&R4%FY).7180R-+?[F
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M57R:*33=_5&$(J8L]8-(7X0(K?0E0L:,HRSF?#7C '^? @]D4366#<H_4?L
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M\6S0[0U^63&NN0+%;UD@[Z;\UI"Y&RUS5NMG*XS"<_%]&&0)RB:(;9B,X>B
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MRSY3,^D\\5J-R<6]%?R2,P1KZBJ:S/#++V]09**W^%_X\S]02P,$%     @
MJXK74-&>=$E)&    A ! !$   !X86ER+3(P,C P,S,Q+GAS9.T]:W/;.)*?
M[ZKN/_!<=;6S'QS']B0SR2:[)3^4]8T?*EO.S.Z7+9B$)%PH0 .0MC6__M
MGP )4K)\9$[:VLK(1*/1+SRZT0 ^_>UY'GJ/F O"Z.>]PS=O]SQ,?180.OV\
M=W^W/[@[O;C8\_[VU__X=T_^[]-_[N][0X+#X*-WQOS]"SIA?_&NT1Q_]+Y@
MBCF*&/^+]Q6%,7QA0Q)B[IVR^2+$$98%NJ6/WKLWQ[ZWO]\"[5=, \;O;R\R
MM+,H6GP\.'AZ>GI#V2-Z8OR;>..S=NCN6,Q]G.'Z;7!QZQV]/7K[]OCXT#M\
M^XLW_(=W-KQ^\SR1?)RA2,) \7\=G;U]+_\Y.AX?O?UX=/SQQ^-_MFPP0E$L
ML@;?/K]-_M>N^A41?E;YP_NKA?CI^9;\-L7TY_@,T2?Q*SH=_/XP^O#'NW_^
MO,3?9H^_GGQX^#7\9;2\CV^?_-\(^67T[N+KEQ^_BFO=Y"?AS_ <>5+U5'S>
M*XCSZ?@-X],#*8W#@]^N+N\4W)X&_/@<$OJM"OSPPX</!ZHT!;4@GQ]XF*(^
M/H#B!R1PAEF6$@<\H2)"U"_!!U%6H0C\[D 7ED!))>A[#4I2T  ;< +[;Z;L
M\4 62/C##_MO#_>/#U/P6.Q/$5ID529(/"C42<$!F(U5A;,0B\HZJJ2BDN"1
M#2\_5H/N1\M%50-9444URBB-Y]7R#R)^ /4.)-"^A,*<^%F]YDKE"I++&O+2
MD@KJH(=F%1[PDM$ $?Z&8BT!Z+=RS KQ'--HR/C\#$]0'$J9_1ZCD$P(#O:\
M"/$ICJ!#B07R<1.ZM%LB2IGLO7+ 2K[ M\6"R.XI/_S;)[#CCZ"WL:3=@Q]R
MF*I!#J4'LG/'0.> !N<T(M$2>CJ?JR;V/!)\WG-"0*.2!-5L@">$$D5;,IX<
M>OM>6KWX$]' T[B\ K)/!R:: O)8X."&_E7]7G L)!I5Z5)^2"HF(#65?!3Z
M<;A:G9R4RBK)AU3<ZRG@!(4PD-S-,(Z$EGCYDUO$1U*N,)[C1,:GC H6DD!^
M";P$D:<Q[>0K1HA+QF8X(I+<"F&7R]V2/VXO>>^'$N(_;Z<F,F&)F\G- A9F
MLKG$Y&O*W!KXT:6!'*/')EZ.<R?[TQFB4RPNZ-U,6N6,A8%< I__'LOAV%:&
M"]BMG7?MM9,TXA'J%9OYDZ<;VJG,H86*(6VMFFYEOM^8,G=CH:5<)&;#D#U5
M#(5YD5L]/ZV@'HG24SBW4_(W?(HH^4,1)I>T)[$@%(M$]G6%;NG_#&M;Z12'
M3,0<RS^*:-1B-T6TG2*_(U,JW1X?22?"]UDL5_YT.I+VZ1.<&KT3Q"W^#Z;X
M"\B\')N7HMM.)0SE7RIF<X41R D&!"W[RA*GR _?FB(''#HDY!6P;*>D1YS)
MU6:T!(=93GF+7-*5)6Y)'YJ23G%H)SK%LIV2KEW KKA6/3RRAI <PY_$5B]#
M3V,.R[6!$-*1E88[XGB!2'#^O,!4I,-W$Y!;^L>F]!-TGL:G+#W!Z*4HMU,9
M<C;C,3:$;WYT"_M'4]A)]2V7[ D2Q)>6>T;"6"Z:KW%T07TVQY=,B!'FIVP^
M9]J'2L-&K>'=^GAGZD-A5C:?X/8D<D]C]WX _'_V1GH+2S:A1ZKMU-DE\<%B
M!U.."\L9ZZM;_N]-^2?UO0S!=@IWB'P2REDO$\,E0S1=,%85N<7\D[UBU$AR
M.7N 9CN%#9R/T!(]A,GP4OS@%JSE?$)5+ZF[G=+48^48/:<S9/&#6YJ6+YF,
MNZKN=DH3YAD2J?B1G.].F7*F,<U]=Q> 4]I'EAM90*5FP!*R[13_7?P@\.^Q
MY.?\$>22>#CF5[>@+2\RK^]I!%LJ7%?8:84(5;M(U9'M9KHC5=X/Z:]M#9.[
MA#Z&&:Z-=A) MVXL)[11-QKMEFJF*FA85(BCW*T'RS^M#BUNN?BK(HE%\3O*
MW>*WW-'J>..6B]\.,)8&H[I2M^@M3[0J"+GE@F\(-!:UT [4K1++:VT1F=QR
M#1G1R*)&JHO<&K#<6S-<N>7B;A^'+&IBY5IN)5E>\SHQS"U79&50K;RBJ@=P
MJN>X8K>V,O:VY1HH1(F*<K<_NZ5M^=K%$-*6B]@1*BI-W8U@;A58?K8SKK3E
M.JG)>3K#$2*AN$8<$F<?L3-!R@)VZ\?RM6L3IKP?$M1>AGM+U>2,<%0K:[4J
M;I59;GEC>&2GN!:*VX<#;4$<8IWK":.=_ ^X>H\H3,:_6RPB3GRYBH*R1*PM
M-+P^;K<I6"&")E.0$ DE60*J&H3A1X$<]3$G2)>G9K0S'J>"[P6>Q.$EF<C?
MVC==RT[JT;A-P@Y=K&02NED/VH4_$^=ZI_I6.AO&D90YN,/0:P9SQJ-D)DU<
MY+4LH356MV%8 935#$-3X:5D>$4ZT@C SD[::?263&?1/H,^GL7$DF-1='J)
MD<"7!#THOW MBUD#O]MVK-#/:K:3T@.C2S%>E]'D*:*\C*IM-Z2J+9OBB) 6
MIU.#U&\JNWP]6;_[LSHJMWE80:>:C2)C1,F!\ID&S*+0_K8;0M7F4;6'T0K2
MJ<8?K>!4W8;3SI^HUTZA;SE44J^SEO7=FFQY5,'HD WJWE(EVUN(-2Y^,YQ;
M::U./NPZ7[U>BMX3?93>*RXXU0K<<,5>@L&M2SN%I4J7ANN5M%ATO'6;NR[H
M4-3-0D5 ?=D5K/7RZO7<:K5#;\UJU>UX:4,[73IT(A>!\5S)ZV9R$B+_V[[P
M)2P66H@CV2NDMW#% ARV5_0:2-U68$?=FJT@)P+^TF3<:3)2"TD(\10E.S-Q
M:/0N8E)\<$E8 +?'82KJ@RPOQ^,VAG:I0F5C*+3K%1O>Q5$V.T;<3'Z%11(U
M0["OAMYM*G8$[A7&#0F54K4S(UO/\7R.^/)F MT.T:6XB2.X/A"NM&QM*RO@
M<!N$'5:K,0C=HMJRT6W*TD*K.XVWRTDL;L.Y(4LVL'&L;JNPHFEM,AV-C;TV
MN9';;2I&!F3>JXV"DB6L6LFIZ'=6O,U*J"QU?3O=<KLUV#YSLAA38Y$4 $'A
M0/Z['T!5\HCOL!]S.W;^JBVX;<.*X*V5QVG$]U+*/$7:64*:E].V[29E'EBO
MR>9I!G,KUXKT60?==TD[[FS<:KVT W7KQHK<U6;H[A3D4%!I&R-WF7)W1NB]
MQRO$O^%([0(.HB^PB,V\*F,;\W4;<1M%Q4FX:J,P-U2*GEF!K&S[4U.6[(*B
MR%/$%7RX;1^0F]3NZO'M#,>)P6T55ARPG54T#2A;JNK"/1LULZX#P*TH^V*9
MPL4<NX&\XM1%M09< &X-6*&O\DF,G08L#93S "8D@B7^"9XP7E* I9BV]=SZ
MLB)3)7U9:0.RF=0'T4T9BMVILZ"6,SS!G.- ?E?QF; RUV_-NFZU.N_4,=2:
M-@6%.I!TL,O/<RI6/>83,;Z\%T,<8(["\\D$P[XO@-ZB"+?0<'LD3E6_MX)+
M#E5G;7KW=U[2JI<UJPP &MYIO4IA]Y1CGTTI^4-URQ-,)2F1N,4A7/D]9O?4
MQUR*C<K"$1.*QC:C]XOPNFW#?2[2S$K)R5"6D!+B)91X8^9EM"B(C)IM-QC'
MX<GJ!=8J%=PJ7O7<Y6X%UJBR0M]4Z>HWT0SSPJ-)Y3VCE^-Q*]B^J=>IX'*G
MUNGVJN'BLT^[_MI&:5=RLN1R$92HKR[Q?E/(W&9@1:96,8.T\=PD=JGWM;?]
MU63]-D&YU6>GDIFW ?[_'IKA'\B#NL433ST2^3&2Y9_W!(%'0?>2;S..)Y_W
MGJ5Z]M-G^/XE67OS/ ]3$$#M>"12:=241M)PB@)QW\)B/6(ID:@D>=E!#E+B
M4P01B:#ZJ-",!^W( >%@$RR'Z&%5EF45'+XBKY> ?Z-,2NM;E4G#8%^)U=.\
ME8TR++O.J@R7>]LK\7N6-5)D-WGH\B!_Z3+YVWP-\Y-DG/'(H]:[FJXG7/7C
MLY?,5Z@<5>"O_;3>/GS:/SS:/SY\\RR"G-)5B,C%L!H1:;TUB' ^)%M%A:BK
M!#_V\]IM"7 ^2ULC!M5^9<4#'$8B_;*?HUJ'&N@]8D/D*%QKT-/BK=LVIE*L
M>:TK@JU\ %LY?/]"8M8C9&TJ2L:GCOWR9:.6+*LM5DS_>(F]F \>MS*5M)(V
M$W@"^644K&NR-AT-]IH\9ZR6G_#^\;^&A(MH_,2N2(A%Q"B^X0&AB"_UZ:$]
M1?CGO68P$H:P(_9Y+^(Q3 ?P\O9'.4T0%HS5;!;$^NG./4_/;AI"J/H7$9X#
ME&1;KF'E)!(#Y!?.XD4*2"3("QA1N^0MN4EA5V!)ESWHYV(_[_D<!R0J<SJ7
M[42RC0WPFM$M1FBIG\S0C%45]):+6RR=E%@N/U2($*IGY%_A:,:",L ?.#A,
M^5RO:F\ED2A+7%!U?8_TZ6!<P\$(<Q^\@6EFN:T@5^Z*<DR'<L"P.;T.PA &
M+P@W2^I4G$C*\N8A)%/5N#"4V0:^MQJ\D9C('-^R)0JCI:TW1WDC3WJE&KV2
MLC1%LHX0>C-V, >3RI137]Y;90PHC5%8(+E6+:T@NU50'8EE-35"K:^L #^\
M_M!W,VDS;[<%[JUE-C'0EM$>K+>2M.- W<\S9O<"C[$_HRQDTV7*1@-,^X[U
M?VJ2%[+CTRF1E.DC,)D.TLDW9:\-8&]-\9I1CB<Q#8"\^\6$,QH-<=;5ZHO[
M.I+4#O)KC>G5O6<1<[S!]=Z0\3.Y^ F9NBQE0 /3@LQE7YL*O;6XVG[T7?6;
M.R2)3=(7+'<K8ZD1JK?\M76M1.Y;K>J5E:OV5A+ZB+20[DC,_1D2.#FS!0?P
M2\N2-H!KSW6O;<Y Y(40,;0VTO1@/L_LN+9XS1$T_;HITHLBUUO7)=(KB_NJ
MB^MX_H"YSMZ:$A%AGEX<I,Z+IR:53=&MP;M>*Y;OC\R.+IP_+PC'9RHM4?B<
M+#0)::=:J<ZZ+$9<-K&)81.6N.KF74VO6A F1ZFS\=$-T]/E\!D(/C@CCR3
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M-8KT0E> YRV$3FJ0OA3C_\"(2TN0__KPIEUA6W/,M$\AS<?EG;QV([TURD'
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M<&=2'(Y,=.7BX"(.V9._-]E#%/K7,U@A*(_9&:!PU*TI%*N8V+3$Y=Z$)N&
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MSM8QG#9'AO92K<!0 (?TU6I2KD#J"V1V=US47.-7[C(?D6*[X5=;[W)@<B$
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ML;S2,A\J&U_-8<S8;FLB!<!<1U#6&7)-P&VS<;>_*6%SE-&<YLOH.8FIX/M
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M\$H[4[>Q:I'"Y(*'CI:%>ANZGGA[C\?L7U*Y5C4U=6>F)UJ08G#!:%FZ#Y.
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M  "$0P< %0   'AA:7(M,C R,# S,S%?;&%B+GAM;.R]>7/E.)(G^/^:[7?
M9N]L59N%*C,BJNO([IZQ%SJRU*T(:25%YN26C951))[$3C[R%0^%5)]^<?#&
M23X2\!<Y8SV5"LD=_ 'XP7$YW/_M?[SL$O2,\R+.TG__YNWOOOL&X33,HCA]
M_/=O/M^=;.Y.+R^_0449I%&09"G^]V_2[)O_\=__S_\#D?_W;__7R0FZB'$2
M?8_.LO#D,MUF_XH^!3O\/?H!IS@/RBS_5_1CD%3T-]E%G. <G6:[?8)+3/[
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M?/AW9WTN@]7V>?^/,/I<@DCH<RX#[*AJ\R7((WKUK5E2CF1<KBFE\/J+RH&
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M'VZ>5=)@6&B$*"YY.P741OP%9B@[+^FK.'B(D[A\-9I&O8XG;W8U?(43NZ@
MAFHV*,4U62VXJ!%3K,<NXKPHKQ^2^)&=!6E69"I)9VLR/=1V5287\\X(,S9Q
MJB/"J)->W:$!DQZ(K+B@%'7GQJ 'VWDPR.5@T$$/;LP'+KT&(>9'U6I/DW_
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MZ^UYD*?T<N(&YW=/I$X?7N4%Z-:W:W[1Z6IY_:8;K+W7^YSWH>2NCL*^H*>
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MT5,*P: -CX-&,QO?X;#*R6H-%WKR:#5<4L@">I](&G$P=#)CE 1QK350T:K
MH-9-CO=!')V_T. F-*HCRR([F/@5S6"EZ9)J$ZK2IYR%&ACJV6,=4Y G!PX'
MBS0V4>YYD0CS,@^FI>(I[RV-AWR]_5S@*TP3:VD(9B'O[.FN#>SVR:Y.V#N%
M;!$*$R)5.<FV)U6!44*U0"WQ;2R51YMDM#[^2%)F99!<V>[^5#D3:"$CL[):
MX,:0&JB($?(^(QR^Q^%3FB79X_BBWD+>8<A&,^Q>O$:U, P+8H%0C-1(5:A7
M4$Z54)DA:DO*5@^&);G>8QI!,GUDIK&SE&P8*(:(0<>EI;&"W[<\6@6G9'O&
M^4-&IB2-+;(!>V0SUTV>D4J5KS<$-(N=\?<JWM/3^4]*NNE5W*ZUS>"'BVRU
MO'?#-@'DF&.-"EM*XT;^#4KQ(AXK2ZV/M#.\CQ61>BD$<0VD6OQ<WV^N$*1K
MDJLX>(@3=KQ 8PM2[Y8GGHV6Q] WW)S8J[MDS-1*]3EEJPO&!DT$+*RU+C<?
M+J\N[R_/[]#FTQFZ^\OF]OPOUU=GY[=WOT'G_^_GR_N?P5'5[EI/I^")CA87
M?&IIB)2;=M67=(HP.+4)PZQ*R^(F>*6'K893 86PT\E0"W@P.4HEP7!("T]P
M+*B%T9Y+@R%/7N%(' WJ*JOD'5-(#WO$(KDP)")I$4JX1.47.[Y>ADMG>(L)
MZNB61G>N#(9()>PVH[H.\#"KNDP2#'^T\,3LZEP8Y5P:"'DJ?)_=XB0H<703
MY&9+I%-P2B(C\ &1E-)PR&2"*'I8DO4Z/>!\P"BF86$B^H\ $79%V2(A8I8^
MYVP,[:N>8B8E?R>=J@JHCSK'&F#H9@53N-AME.HCSF91#N14_2H+4KOUN%32
MZ<9.#76PHQ/%P#!(C4TX*""2L-;?U@MOWRMNNZ6VYS6V\633>H4]O.(%M^=7
M&,U/I!_GS&A]/0"3FE@-BWFM4X)]C:<&?'237/IXC_-=W_PJ+;1,U.TTIP8[
MG.=$.4 3G1*<D'\M"!E5T.8QQ_SY4T*T -W1]4RQV5A[F^L,DQS8V4T[K26$
M1R<E(1*\B8T^48_+'7O[D$8TAR6Q?S@-U2S1:CA]J&*&/GB>HA8'8W#,&,6L
MHZT&?Y'2UX%!L<D7Q%"NA*== A_!M>_DBUX6LJ)6^ WS/(&R&+K)ZU-55B?=
M$SNII.,7 RJHHQ<"8S$PQ%%C$UV5FM/N.NK)__W=[[[[[KNW:!_DZ)DJ(K+*
M1@4EUO?H[7=OR!_I_^>_(3:L*I^R//X'CMZ@]I?U(2>U;]FRT5.6F4#KZ##:
MAYZ"F.NI4@9R/#_V9<"03P%,-A-VP78,M-/R[NT?WGSW+W]X\_X/WS'*_>G-
M']_^_LV?WOZ+GHXH*&C$@X^DE9[0^[=O$"4,$^K_ZNV?WR!2QAZS6+D)$&MZ
MGY,-;Y6_&FDL$W1)9#70/I5%*3=D_C,G<XH?Z5V.;N>@1"AL(&I!5%!)&&S9
M1!$+Y1$D-T$<7::GP3XFVQS57;M*VJG_@A[RP'M!+@K&'.KQ"9X+K32B#_!.
MXA2%7 $&EVYQ&<0ICLZ#/"5&M-B$8;6KV%WH&:9Y0-4/U\V*;E^QVU9D^*3=
MI 6&=]90)<XSC2"*N"0,[HG;(>M]D^^-J-T&%-9IF1*?_-"L +OW-'E/FT\+
M%6J0_-T-![%2'5A\LT0K?V]Q/"[NP[WY39!?YRP$6\26E3<X9X<X5AM[M;*_
M\Q)3A=1'*"I-,#/J)+CJ@Y:"[WC;G2Y$6O+8MYMVDVW5(J*2/QJJ*J"FWU@#
M*.T4,(UT$\Y-X-*.I<Z;0KE&P3?=AL!-5./2H&DV@&A+,7[<!I=>ZD#MUEJ^
MB:8(U6ZI IIRYF#M*MY!OFJ8N,RSTO1T(3%E@6>A!H:,]E@5-QDPUW5"-@3C
MHDZKX8ET-LLYC3A$DEDNY(;D KJ*$ZJE7<(II;V22[UX4XC")95VV28E%*0U
MVX3,.G8J7FEE6*J!SJDS :05R\"MT"[3,-OA-@."P<]-*>V28 ;(?6XI1,'0
M2H]OS"@NC;IT%= 24]2/BR](=U%/4(KLI[A\.JW((-CA_/PE3"I*?1H]B/Q?
M=!^\**_N9I3D]O)T=E6'MZF3BP%#WOG8Y9$0,:SGYNW;FCJJL"GABD;>RX,I
M%6SI0ZFQ,!B2F1"J7T3!BGQQBPM,G>HV:71&6)YD+"!>72GE -/J.,YX8(8_
MRGR@5H#FVV8#5I(0@>DP?\FHTX)!MQ]P2L9!0BJTB79Q&M,Q0]TW]80S:KFD
MG&45^J0SJ$"CG1W<,?%J+<:[8* '@WJM!>;+U:NL4+W+DDIZF2M%J-)9LA.#
MY3>B!JAY,$R$8!#F4Y9FPPHT>1ST"RX+/9=DLJY&GUI&)3 +,5ND\@0;,=^Z
M_I:R[I_72J6!@X0>"!-[^CG-ZW_\$,0I'0]TER)+4#.J[2$%N4N^<4A%NZP<
M<TKQ3L>#H8OK.*[.YM.J+8W91Y2E*'@.XH2E*-IF.2H"\L,.;MJBL_@YCG :
M\1':6GO%F%9*.XV.IH<\"(TF%_5.2CM\0I2]6KHVCC (=)F6F#2+86<J2+D]
M_Y5"')[[#D2@+?SE\,3C7B[5G&3 (,A%EN/X,>6QD<+7^SQ("S+[QUG:&. /
MF%A*K#[;G52"2V+-J%J?=!/4P5BLZ9B%,#*\!$+2\(G\'J-'HKC00F^A#2E=
M@2J7KZHME4')Z3;5J@*#':M6 PS[K&#*-Q2P3G>GL@L(L29Q"@:=C&<A4^G$
MGVYEC%1PSD2Z@YSF>BU.*U*C>DV9I;5=YG+$.N/B_(5LP[,\BM,@?[TL\:Z@
MX>/HQ5R6)*PQ^')">Q6]TA?=NP>LVG2BB\$JGX,UL-:OZ'AH?L(EWX8_L(*;
M0Z22%@UIF)*ZUC;F T[Q5OD 7"GM?G@H(8O4%D3!+!_T^,9LJO_*CG'@,8EP
MW7A?,I)QNE*0P1NL#OH"L R7#)K*U*QT-'U& VQ&S8$/M9\_!3G9:Y4?LRC>
MQB&SG[*33DM%9T?/DRK2'C5;:4$YI)F,6,R>0751U!SOT>9#7[@ZVO7T 5J>
M37/:?9_U7%[K1^@?@B(.;0:932G>K)=]%97VS5P$8 MH#5ZY' O*,H\?JI)G
M\0AK/^<N^ 4,7C=17YJG2ZQJU,,G3BAT15,9M5SRUK(*?9X:5,"LW>QP*BG8
MAL9#)^B!JG(W+*X,@W\_89IG&4>;9[(_>L2?JMT#SJ^WK+:]UP-VM)Q;F$NV
M'E;A/HGGE02&VP?!'U.^*0P%O#24LN)HX,:^Y1T\+8$[*-JW"_>:7 !C(;>!
MJV0 AT&K^A)@2">%)>;A:I^.,#$@[T9:6%=QBMDYD:F2/4$O[!" 2AG22L%C
MR1B:ABE4%#%9+5U6;?:9T>3>.6UXLBB)LXBT7%[J5N,:G,*954#^&0*Y^;=]
MBNKY_:G5HU._+TUMB6+YTK1F2?/(=*4SK%,>$C-^QIOHOZJ"97"0'9W(Y9R=
M4.E@M@=2,B'O-MJ$3 R4VPB@J,(LH6:4[>G!$ET<;NX^DTY\^T>';+A.QRLZ
MO:A73O3 :FE!Y. RHP,WF1PTLOL?B)4',K?0.9$';3BK<F+J;IB)9+%G/N$O
M["_J1:&5KO/PM[;5$=8P)D7O?)R#5B!HB<JGQI>:1TE@,3CH3-;?W/+P"6!R
MDBFJS*?JF4P5E %055$A"ZZ.-*&350[W8+8NM1A;W[RROUVSJ:$X?\%Y&!?*
M8\@9Y0#@LKF:MB986@ATAAN1"X[G"F*C:I]11U^N3?_*5Q2P2<X'^ (LUQ8$
M@.86%;4VWT=)=#/T@YD.RZQWB_SB/E-D66&-\A"0-CC-=M1-BKD>W-+L!$5<
MXCN</\<AY@UXB\/L,66EZ%(JK?]9MXEVW#3B,&//NM\$,U(=550\O2:#^(25
M2<=U6RB,8:N;I]GKAAGS>ZT'8!H2JV&[NF)*8*AKB]1Z3ME7.?U+R0YC4E2E
M$<Z_Y'%98GHFL\4Y2\E'HWJ@?1X_!R5&^R0(V2W,L>R 9]!WH B OY**6"^;
MCH+!(E1W%%[YCD*H\?U3/7'<U,CO,_)3^$1FAC;MO6RI<W!ISLZV#Z]R>_P]
MORCOE%\&_ZQQT)2(VB(7,=9+,IR/^,6:K"D.-L>'E3Z,Y+RL(V;YH )+TGQE
M@WZ9ACG[6)#PA=>V]L,OSBI\GYF>3TQ2=T;G&95JZ3M!%P9=IP.6A#UN2J@3
M8Q.>UN\IBO9V<]&7%5;/>!C^6>]XU)J>'O*8JJ)XR:-2@\&\25A-CWA:FJWQ
MD$=E_&J[?+WM9V;IC#Q?8=\T"^Q/N+S>7M>K\-.L**4S_@*%NC.42S5 9SX/
M+1$&M9>JQKR-WTK'$VN- O7J=[&BCV=$*%;%"Y7[E8R.PU?+GLX_NN-VY6E[
M.PGR+02-V'^&'\JF5K+V7*)49R-DN29H!\?A1<(8%XO50WBC5*^)> XE](5H
MH8BHM2XRK@Y#FOO>;I-A?[BGU/5WS&&HCOI,0Z$(@X83T4Z[LZ=>6OU[^V:?
MZ(^!$P[?U,J0.&A[L*;2/!H6SEL&:&GH[?Z#C:C3H'A*<%&<OPPK.NV8T5 4
M@%-AJ\I:G AKRP%*XTG@IY$ZK NCL3X]F=>V=GQL+D-H4UD &&U770M*ZPN"
MSFDK](N1VJ^Q_A$7)8YNR?_F<5C6&<)GF !%.0!(;:ZFK8V6%@*=S$;D8R)S
M692WPIS'GFSO OS4%@2 H!85M3:Y1TE1,W1+CMJ8TA5=O2:&+W0;-D#GPB7'
M-2=ZX=J.='/",[SW\.K^/-6F9M"@G!&<8<U&GQ?FP$=$#%.3*T$>$.A@Q9;O
M^;1?9/DG_&43AEE%PR$_WN192G[D!_[%YB66&IM)!3CNL6></V0%UO77//C"
MB\I6B2:T3J,@CPKT>1_1.Y._4DW7P68.C!X!IIO,$(5,]:WP"=YN<5C235#0
MZD%Q.Z\#$EUOZ?[O(LF^F#(RZU6\Q(W2@)=&D)+(@UF;6(!41Y4B#*-*B&F!
M2V1/%E04'3%GU/TG^O#ZN<#19=IF]-J$9+2PM&^F')4S"G(<&7=F14>KYXFE
M@"'Q;.B"$:5LWC(VLX#/;1(2%+1%P"#WX$T>?5"7AG&"!SN-^VP9^J_S*6^O
M0Q=N+.6+T(6^ V:0K5@Y==RC@OKAY,W'J/,-#QU,?DM_IN>^Z+<5?2$:I_^,
M]O67T<,KX*%[AO>D1C%S.B4_)YC^0/.'[[*\C/\A<S^>INHT\>>$R@RR@%KH
M@:'^!+"B"W*GRA_5]71@\+$)W3U\NJW;YTN$G0>'5 (6CDX$22B;/"N4Q_4J
MOK7U5Y@@-&1GE,LZ3<JH@SO(Q2@3!&.?=.B$S(OMO)A0X:7RTBKNGVZ"5[ZY
M'$*\BH.'.(G+5^GJ0'86,K,@9_=/!U6T/92:50JHG#N'U&!,U;HL'KEGR-JD
M*6\EWG89Z>FZ]CJ5Y:*_S]HL+!=9?A<D6"8E:Z0E2W?&\.6;I*7]<D5[-\GK
MU&<\,KH/L#5E^P^V-R(+S5U;%"K:LMB3AN:;+(->0;XJEUTKX##++GV]_1BD
MP6-]OU 4N"BXS;C)XRS_&0?Y+2[(_X9/-+$&?L9)MN<.[U=Q2"8K8@9N:3Z-
M^XQL,.]Q^)1F2?;X*NN)E3_H+OBQBX;K[D;6_!JHZ<I%385#1IYBG<QJN_:K
MORE0T'Z7_FE/OXQ>R4>I&P;[-D\$TWV=CN>D^3[**0#ZJXI,CV6+8;4W2CR6
MWO6VNP)L;P#Y!:"LN:W4'+XRLJY$[QF140<4P>WQBH=PJX0:5Q&J=RQRO>T_
M5V*/^=BXV^(\Q]%%G))?ZUY'SR_+'?4.K&['QYD%P5@H'8A>H&RO.$K;P?,U
M%!+-VH;R,M&V*11M,933818H@VQQSC#_;V_#5#_O,US73"G <<[JB14;I;&V
MU/;.[-F0Y0N% L7I]U"Y>9/C?1"WH[0^>B+CED6FHTLIP40?6IA?SDZIL)Z_
M-B5!64HL4@OA)))*(++CS.EB-F"BS#[O>9G-T218PUROJ(J;X)6EXLV#2'76
M;:OLE]RZ"NG)+-.$=LTR";7"T[% >RX+F)-Y109Q?3XJ'D!.4_7.1T5EC&P<
MZ1T%%^68)4RD@N"M8S,EW.)GG"K#T%OH^>6@HAIZ HZ4X+-/#EAT9J@W3CD7
M@T$]>^^_@]T'H?IU'N;/Z92>948V/CIR3L8M>TAUE(YABII?IL^X6,)A65L0
M &);5-2"X)I2P!P-S(9N<EB.FQ+ D;N^S*?WGN'?JSBWN2R?J.N2PI.JTV>M
ME2*T??\4T&+D7TI)=F$5I\XNH!<B;9Z%&$?%!>E[>D6_2:./04DAOM([0WL"
M3R_'*9GG5G- [*F%@+'&<Y$+_DIU.=P4DW4RWK4W:)!)/A[<I!YDC52^WI#:
ME:0QZ!/JO213^)P"O-IH8\6TAEJI#=Y:FY +1&[2!#!'!*[+3F9QHPB#N?;+
MJ(/785 7R(<MC(]BYZ?&K=SY]?=[W2X0[N)84?/VTOO0G9^V( #$MJBH!<$U
MI8!9:\R&KMGY]=G.EAZ=7P,THO>76HVKQR5-!1DD-]5#$H=-"&^+I9I!W]<"
MVJI:JH6S5AD,B:<BM@[F1S>(NHQT\GCL[(% (T:]? "3G?F4#B+73VACF;)O
MFJLK9.*XJ F:X$JX4]CMBL"JYUAUO;:#>O$M;C-FY<^O[!3=/;>:4I'N>96-
MEG<23H9J3< <)W3OR!Z"E"R\-3^6:,E7'*$][:4'F32:!WK^K:BD&F8#VE/R
M3MNI2&U9*Z<D/$9>Q2DN2$5S',4VD_I(WA<#I;!5S!L(@V2<#*'^G#9DHF@;
MA.Q!*4JR ,AC^GZ]/@3I+]0_WJ().E%?G!J#5=&ID0/)I!$X/8G@D.86[^OC
MW^NM@31R49>DT8'MDT8F!^W478-1\[ =#G'ZW*^#\3?95&RN-4457]9'!5YE
MA<;R(*V1 J3>*JV51VG9>T?)PR_#Q994P\?-H@:Z["I1(@[-BIFA:HR9^-X.
M"M7Z-_QT4W'-+N:+9CA%-IX!<CUO?AJZ:BC],F1*(.V=#NDTH\>//OA;9B!T
MM+\$.O@6">KUWF'7>D=Q;ZW&;75O#?<2CU:6_G_J1O(<)'2ZZ/**T#]LTFCX
MBYXDSTDBOD (DRIB"?Q"]NKUEDQ4YRR.N:+178-P.8S\-'!_*+I% &LX>ZF[
MZ#7+->FE$34-;[B!P-V7ZLA/;8H>^O>OP#ZT3746%_NL")(?\JS:TT@0<4&&
M3AFG%8[JQR!D0E^C#R=#.!K;,+-Q%[,,$[_O(<W-71GDY6K685[]9:X_=O:
M7O,]X,<X3>DZ@GISLDIZRKGSJZ(NP!Q-7NI_&'DQ^;45;0_)D5CM]PESQ@@2
M6IDD*ZH<7V\_96EL_?3NH)+<94D\J*I=FL19Q7@_9S@<NQ",NU<8BMK2*&73
M+#UA+)9Y'1\<ST=!91:%,-M6!9:&WE'(.*.?"EY+K+$ #,HH4(W)P,1HU],(
MC#R<S4K=+(^MK @VK!%VUO%&P"T#E))08BA8H30%75\[?/49)D:)S,ST,"F-
M-G2:KY*R3;+],8OB;1S*\CQ,5W=&HAF5:FDU01?*C<Q,W&+,#EH"F9QX$<0P
MH8"NM$@Q+$-@<RF(=KVRU@KR&>?<@Y%ES>YROF\25@J.[C-ZZ\16E!5[J:;.
M2MMOI67*=1?\<\%FZ *!+E HC.EVP9J,!\,%X67C\_I,2^_?BJ.@^0!UD&5W
MF5']#;8]*7I?^0W;O*QFORG.01OPF[#[[%-,=TB/.+W(<AY[&D>VL= 7*-39
M$%FL =KQ<7"), ;'4M6P&AGUI2F[TN>C@G_E!YRR\ WTJG7U".0+7;D2PI'=
M6/>6-.U""E^6>&=\6&FO[_3"=6JU!O>MMLK>J3\7\83]>MB\IT0Q+0A,Q-T2
MTV.QFR"./F%UR.>1E-N0>5*(PP!Y Q$P=)+C$J_BN!2B06FAT(*FW+P/7G!A
M8H8HZ#B>H@+H*(#B2 H01130)!>V1!"55!(04Z[SQR"M0^*?DKD\2^(HJ--7
MWM#,(L04\NC[M2$-DC:_MVE.7*ALIPG_EFR.08+ )0H&P_HE:R.<A?7*?H,&
MI;-M5K]\.C&W7T#=)\#EFC^HP;IKB'O\4GY(U"\9E__,T0P^32,M-@XEW_@Z
MAJ2Z8KK1R8;CAZJ@3^J N!YV28QN2 .$%LGK-0I.4] ;@0\2R2NEP?#1"%$1
M09^>%#0:X,SX7?R8LD/PM!3K9S+.MLI.4V5/JM @=;:5)A@Z3H(K' MTRDA"
M4QC<I"=T[,RO,^8FXZ=7<<E#&_!]]NGDP7#. J3TF)7IH)X2.#LHJYG)_!ET
M?+--:^RT"J#Y9C)M/<)]Q %5@1.^4QF6U&#6+/0<O\JSJ\;H59Y>"0SK;)%*
M7N4QO3>(:;+-1*L+SN(I:VF_.9]6! B&6FZJI^C#YZW]9K@I8LA=&(3E?@X&
M2SD6<DDZ.< ^K8828(@CA36F!A<"9\9$3YA/68GM;=@$?:?;V*G5&NQD;97!
M,' J8F$_^Q3DF.O_ID#G:WHJG?+TG=PQFA]%TLNO.@^H]K6$M:HSKZ.)E6E]
MBRSUO/-K!ECA^4Z=KI6KHPV_L&'I6L\72D@XCVDJRS91%PK7I!9MDN)1L,UD
MR49T"U:@VV+!C&AR%UI%EJ S2$R'<UH-Q\&,3-!'P8Q4XMXI9X]1$L6(:3"*
M-3K@EG>CA,5-]09I8^T7>[-+\W!Q-K?*DENUJ46!8?5A^%5YA&'9T?,@IV_5
M:1P-MHHU;7"5XDZWN@;0@TVO0A8,RPP A8UP+8Z(/&(*X*SFN$8FNZB1]\DJ
MK6U3"H/EE<D^?0B*.&33\5F<5/15#@V35;M9_O8J*XI_9ISCD<4Y]5;:>M3O
M*3:/.<::^PF#K+.MA0ENNY50"7KGC VZ,5]J<=3*.R*#=N.I$?9&!_764BD)
MZO&U":4O8ES4$>3;[UQE0:HS%08%AX_M+(#W'M)II&%8#AN(XD5Y'?^_54)7
M"\3FGL(5K24Q:?AEB]JFZ,5!&18KJ(YXL\S*MWDGS7>$AKV42MCEFE</N+_@
ME4MZMS]6\,08#0]ESQ\,W 9J6!G3]DDI[8](VJV30A0HE8RK'6)\4'U"!(,]
M[1,Z:TNDU?#R?-'.)FG$P;#)C%'QLI&H0+91DGJ9#)5>Q3//M"9+)P^9:2;C
MU5$-RGDT/5V*2_ZN,8U.6:#+1YR&@Z-V@SF;6(;3:,)SJC>(J3JE ##4G(-:
MN)KNRF"GE(-2(%M*J\J;;.?40L"16FM?IY5P7+0VNESH> V#P7?50X'_7A&(
MY\\6<0K4XDY]& V@!RZ+"EDP3#, %./N-.*(RX,SBN,*&1UEU?(^2:5WA%4)
M@Z65T=%US"L89!J\SV>O2%_-\ZE.Q>WL:08_G"O5\F"(90%2?/P1DREO3WW"
MLNTP3@D,EGTN\/7VO"CC75 J,X6-A5PR20ZPSYVA!!BV2&&-^?&9IY=KQ=:*
M]5T^X?PV+GZA2[K/I,WS,HA3ZNJE-RQ3E=W% I]:H2XVN*VF=R+-@BN$8J'Z
MB!7 %N*#(F"8H%/:UVG)<WY0I#SO.OU);8C5&HZG.1/TT2RG$O?.-GN,XEZO
MIP&$4^TK]UXDH\N4;!8JMB?E8T?1 I:Z7F(1V%1'&I- IPB&>U/0"E?H;82W
MGL9:&5(&^8TLIE"#@KO<*3; NT0J.FGOI+&&**18Z3)$G8))=WB+R=:SPC1K
M,3TKHX<:/\7ETVE5E-D.YW;[OZF%N#1A\RK8MV732O#.SX-@BYQEA<#@ZAU^
MI-;U%N^SO(V0]6I'44M=I\=?4ZHS. JS403#PREHA2,RKHM:91A$))8<D]:D
M*0?/R !),A9:HWZ+I%WC66FZ-8_651G:1*,:& +:8Y7,V$R3/^3H=&&P\"++
M<?R8\E?&9"SE05K0+'UD,T2JROZ9\+V1G8D\H#RG>Y)#JSW8I\PM# R[#ZV!
ML)_AY:$FV3?JEPB#^*?9CHY=?E* $YKTZ#0K2DN:6VL[OO6?4J71=;^-*AC"
M3L,KK AH=)F3#T%!=U&]DF PDT>K^8C+IRSB>5[,QSX&'?=1KPSPQ2!8"@4P
MC+-!*3KS-7(H3A%/6D6]DM$=#JL\AG.*K8P49V<-[=5!Q/RSL(>VNE!>[\S$
M[2;<G_X9J31'F\6QY"1UUT]-IU1J_/C41M>[69P)6/$R-4*W3>H\>JE\#RQU
MWN5N3RA,A\)U?A87^ZP(DNOM598^7L7/..*AF>Q,Y;RBG'KB'U#9@8?^C'*\
MTWH!\,(BH"V*.DO0(DY8&75$+R ,;UXJ6+)8*>[ES8@-&Q6RT"9P T[XST7&
M04[L"&74\AEVQH)>!A4P=LT.YYAE\K SB\2;689TG_"77LZ3/$O)CR'N;=#L
M6#B]&*>9;F=6<I#P=F(98(@[$[AX&$^]?9)7M(FR/;U$[R6[N2O)KB?(H_4<
M+_BW+UDNZ>[#[7<_9>7/N*R163EF'%2@0\>-!2K><^PXH#3O?%ZL"DIF\T*E
MQ$:D7$0*;MB_$M'OPB<<50F^WE(7%?H.B_R'GB8\!TG],FOH^G)/#\6T5#^X
M2&=D7ZCR+=T/+ \&X9>IA'",7Y?*7B?0Y.7LL1[]H5<T^^7"7E-&WG\N\+9*
MKN(M^9EO\Z90W*SM@<VV59(0UZ0*C:.6>'5TY$4@6@;])Z2M?@,SHVZJ<8G9
M8<1E2N:(QYC&U&50+ZJ2OO_>48<9G@JU=G70\GB=3SAUIUJA<09>5PN6[WW8
MK%@IW=CB);&HS<RB]\ML8CFO;N'9>75&344;V/]ZC^DS@O3Q"@<%;B)2OTZQ
M_/-+]3 C'-H$DIEB;I'>A\*R]="QGQ5]PJ>8?E*(MGS$/H#:+\":=:ZW[3N)
MMFEZP=OK#(W1=7I+K\AS4A\:!5F_?%KI&S[FG46;1S;Q+/(![\-MS5IIIYXN
MEVB[JF.CK_<Q&.--Z0@PVY<#FA?'//\->!RVAJHC)N0\C=T@_90QARC<V^PS
M5[S/9-58;,(R?C:MEQ8JTX]I/Z#Z<E,^HT PM%^B%MH=>%UH_^R'W5@!,=!=
M_1DJYHS:]T5E37"]YS[8\X;&_(+]C(]#&T(^2.:6"G"D'%@5W7#A^JC1ASM&
M;H)7E@KC2Y!'_9K351EK#K(JJW;\=[/'RR$?\3UV#F\@TSB:_P708^K@:NG&
M5Z=+__4A"<)?3LC?,QI<J1Y[-V26HOOWCUF$$[@#L&]Z%IV8CF$R6FX".O))
M9_9$P]_>/ AO;YR=W)XF05%<;W\*\IQLN(KKG)VH39\_EBO6Q]WTH8T@NY^>
M6Z9WTB]<D27G 2K5  $W)TB3M(^;;<*T,+4\3S/#O&HK)H=IA7D?*DO50(QC
MNML%^2L/-+G;!^GK;\B J,J"^B[1T;#4(##/#X9\W5/FA&E%^9@'YE169ONG
ME..=Q N U_HB'4O*]JX)Q#3*$Y?TY@+\&&O;BLFMLTG;.Y-G0];87YAIL7LU
M3,LXH@EQXV?</:0^?PF3*L(1#U6UVU<E6ZM=;Z?F/E[C0YZXOW!#*<;(0E^!
M.):6K9KV H^LF<C7@@31CYZ<U5]=,%* <>%3[SO8MJ.WQ>%WZSQX ;]A+W^@
M*[%V@S1E1;34-SPLE99M'LD::ID/>!]&:]9*?P7>WS;W/M4Z;O"OU?X;08G8
M!WL;[-5'F#R]*JUH:3=\K KP,#8F5$Q"? MM:*RVAZQW)P*<.;>K+'_Z^0%O
MLQQW*>W(?XHR#LE^J8[V-7'',+-4/TNI@YI OFZ:5:3W<;!L/0PN3=NX;!X<
M\_(A/73O6N ,;S'9\4<$G,S[<.*XF%B:G_$PJ\KR<3"I*(#\GX-?Q_NF/)9N
MEI7X+5A?[O/M%M.+P&[@WP8EOL642P0PVQ=-I/^<(OV,@?F5EP^$Z>4!' VS
M*Z&_,P[*BI#Y%7V^0Q<XPCG9)[=?8@.%?@7:Z/B<YJ3>CVG\#V8=/N 4DQFM
MN,V2A$R*U,UDXMB87J"?D3&WXO)Q,;4T@*-B9A7T_JU=D6P$-(6B.AXJNL^Z
MA$E,XB8KXD4B\!HWNNP)$LO>=)F2==O./!',*<##1G="Q20;70MM[^2=#5E'
M5OXDC:?SZI4#PV!?8;+(PHKW>1_)S)/;>KC-*LFEB3Z@JGW;/*,8[[P^'+N.
MX(UB1W;+%V$K=O8]:;_K[88>;3ZRPZ7-2RS-02D5_-L[:*'Q]##%Q&X)T<]H
M+Y,E8D^+W<?W_\W-4OD4I&BH]%?Z 6UVYA5[[Q,N65:H/'N.(QQ]>/U<T$?U
M+7%K!\Q8GE;47MMQ/^N&Y@S00J_3Z"\5]2TE:YZL?1(=M)J>>O,6TU48CIHK
MPDT85KN*K=/(?C\.8VD2=+,6O%$Z ?.X\WJB*,D*,*X'E%1BP**[IRPO[W&^
MZT6#5[3)E *<)HR87+%!S@AK;3 69C)DJ7W!H^A2NRZP?P$OL'^(<5107P4:
M&"X@G+C.[P)V5,.<-14M9:/H^!FX945&S\ -6F"H:0U5$K.?*2+:8"BN5>E"
M%#,U&$3\G+*A02>!AU+1!",9IXG:9? &>=K[ F!((T,E9&EO9,B<JK];=CU\
MMZ?9;E>_7[4>O7TE>*L?>\CVPSADVJB@ZBN=W-V0IG@BN];6#^$,%V$>,_\9
MV?F07M[9N9P-[/883B?L?4#;(A184ZN@H-%Y@Z)."X;M'X;V5.X;AD*.\U=*
M (Y25?8DH%D=*3I-YN@03.;H3]7N >?7VW:/7R=K5>VD-/).0[&;8 _.8E3"
MWJV.+4(A'P"3IW-3=\12<)65)JAQ-,F/<4+HG*6X?K0_YHNMDK.IRKH"[7QE
MU/!.GTDPQ<PEC1X*^#NI7:.)]K4J#!NE#FK:!0I6#"P[5:>);R=49I#CUD+/
M.R%G@#71DAXFTTC."5&!04>%+X%RAZB0=KN[UD(>[K.EHF"HI<<G[KT;_XLR
M>$%[&_^+%;MA$T7L^T%R$\1D9)P&^[@,$EDW*$3A;;A-0(4[AE8>T0>Y)W%Z
M$G(5&*-;<3&MJ+U2VN7H-D#NTTHA"F9TZ_&-N=2%7$[8E7_B_<I_B)]%7KAN
MHU";.V2D .AJV ZGJ8/R.G;V254TJTZ(H_XG3''B:$/L7_"(S^*"I?*A+JXW
M.*=I?JQ:R:88?W;"OI)JOIK+ $I@:^!C1C>**.":**I540[& 5I;U5N\(\NA
MYH_TTO7MG!:3%@.&S)I*6I-94L9QD%D-W$CFO%%%)5&#P6:)R\#PN%7(7=63
MM'=#F%*F9Q>1Z=4W>(W8%^AT!)09V17H]AY+5$7J8$*=2D*9ITEN?X:_[F6N
M/&+]AU?JHZER,[50@[>_G ):2&[?Y?J^;PZ5V(+5PK,40*8(X^FFE2:(7!'Z
MLTT+-3!3KSW6,1O/BS+>,=_*WI$FO<.!M!%25J]%W]3S&:MFUXEE@""HKGI6
M5)45 )^T&M03Z0O0[4&3#$^2!N\3?BGOO^#D&7_,TO))1>Y#"X5QUS2E >QN
MH6Q*!#,>%JG&>( 0%KX]1N+_C(/\_DNV2%.U9<&E^:BZ\]E=%W2DI!ZBEW#Y
MW=%RF7Q^NC^ H33@?.Y7^4!&TZ*.F=,]_!)6OS]65E^0=EVLD7AAL#G=K_!A
ME*8E'3&C>_ EA/[]T1*:R"[71JPPX(3N5?A 0A/98R9T!U]"Z'\Y1D)OMB7.
M%V7UJ$2XU)96?3Z_!\4=*<EE=1@S_?X)YSB@@HXO$9C3\%4<4J 1<^2XSS[3
M>\+P*<V2[''@-V04AG-A8 ]5Z(IL >\SA=_\R%.FSDPA@ZZ2=.8AKX?:LD$N
MYGVDFK$)[W&H,#W ;)V14$$?HI^8[KZ/QW_LO=O[6ISK[_+LP%KT4T(O]I9P
M45",VB'0@B'(MM6H'_K,,VDX&\5VT-O1K!>',:JM,$J->N]YE,H!$<1 ;QU=
M)4;73@/./#P1KZU/[RLTX]S6Z!/1G-QMG1)8)U\=5OM>LS+5[CMM0E<=S=#2
M+W %6YC8!+5>L6<^ME%[NAP[&ONG$8?70S9@Y;W4BV7$P\> "VETAO<Y#GDD
MZ4T:]?>_BM;0:K@\V;" WJ><1AR,S39C'/.LK\&<&H.>#L++9(%>V1OIASPK
M)KL?U4H@_(T&%;!R,&(:8&AG!5,28H<I,=;A1N,->J0Z,!@WB);8C1/R<X(E
M0TS9#(IF6ZYXERQ>NE$&#UT7*MO-R/@S'QDI?J2 =2N A>NE"]49Z0PZ-!?U
M3_)S+)V\X^6=\=F!%59;VY?JCR"\I)6GN3,_D"U"1+-KDM4 7UQT$9N+#Z^=
M3!UF9-,F45"TVH+E>TH[OTRS*-+0'U8XF'7!TC729J6AVB</5!WUO]$/+EZ@
MA]>!8/TAQ+Z$_LJ^!>0AB+'%5 UV%:?XLL0[U8IXB8*=CKG%&F(PV XN%<XH
M6ZHJPO"R&%*&$44_@=@W7$?N+_+R;[<4Y?@!W. /< Z+Y+"$+J'9K6DJQR!!
M'W%05#GO!4A/V'B49!9?]31+BSAB)XU9>HM#3'TFKM-[0I^"9@%0'A)-+,.I
M/9I3O8'IF5( '"LS [4R/FI!+4;A*)PNP]R$_[W!>9Q%]!V\[')1*>HNN94>
M;)?&2B[GG2X6X$2;1J2[&,M[)O]FD: #.D8T9*3AH.-2<DRC%W7+"#78(2-$
M.4",4(*3,V+?6(NPE:>'&=7A84T7G^>:D*UL)510YE/7P$G3G$41GF8YZ\HI
M)CFCOG>*'@!:H&[ MZ.+3&B+\_0FCYE!9K4R-\)(W!/_I* 57!O(0N25#*!P
MG%L'X-E363H?UNNEM=(-F+(DR.[7)FFZ2T$PJ2I=,@(K->]TFHYU^;06Z]X2
MK)&5!)C;JSU@(<X[+HE)4'4@H EG\QS$"3U*O<A8RJ3.ZX6G3NK^K;HNFU"
MTZO/R14;7&Y::WNW-+,AJY9#BWLO*>:R9ME& T,_Q@49C3CB2SBI)>D;5FM5
M9[/9Q,JTTYFEGG>6S0"KSGU1]?1GG"^MN91M3D-P=$;8GS[R$Q%>R4_X"_N3
M_)+"2A/.&?9,W.I.[?<>F^UP!&.*ZV\+K395:GGG=VDZV,(5F4S8N^&P12B]
MT"IJ(HVW5["LPX]!4N$YQF&H>#2V00';TC0\4VU8!D)G OGOZ9H*Y\^$A,JK
M^HF%.#4ELRIH/;L))< Q.G-@"X%E^^PM!F:IJ#5A\'B3L,+K-9G@95"_<5=M
M'RR5G>[A)E5HL'^STH1F;R>AEE[$U)X=84\+!C>U([$+]<S$F#^*[J' W,+
MV%QCA:UMK[*DX[#!)OCJ-44OH/? )@.A^UP_+_8_/Y*ZM0VERO*P[">.PDM0
MTSB+^ M*RH<SC):OE/@6F.580\]<F'EU %G:+%)[%G]@<5=;V1>.;C0-FV;Q
MP<2+_[K&TJ!.5D,)8*3MV2W1' 5W60'YA+ZIRJ<LISD>EVY[FR\>Q;BS;[I%
MQJ'Y<\<_+JWKJ$EJ6:\B@U;E*QFA=4OT;@=_(+JJ=Z[K?>ZHQJ:AT18=F(IO
M?3VC4E]!W7';FW94-LIHF^5H6Y55CEN7"A@#]7RW3[)7C.O31'FK?<I2NB3
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M1S85/=D263JRF3#*B?17.'3/7_8X)"OQ'[.$%)/$Y:NKP:OZ\M$.7WU3KC:
MY9_].H>PMJ[C0=P(H^=6^BL>P&?Q<QR1A8;KX3O\[M$/7EDSKCYT^Q_]N@>N
MI*;C8=N(H-<8)Y!6RW.V%KJV6,5AP>*#1[';M6ZX17:[QJ_!&I5K5E$YBY)U
M\ []-D[1*P[RXI\]G7]N$C;,<20W3Q1M6D@MMYVFXY-)75=/!#SN.*9UPGB
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MN^2C+T2+K$<?^"^HGB=&9'O.:<)6>BA/9IT[^L0@R*/B\SX:Y;:SU8'6I[:
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M1[,YI0!CX@%5$,A*RZ+KJ;:T-Z@I[TU;(%M:]8KT:DM.@QQ?5 6-B2KOXK$
MK-Y3H!.#+31B?AN;)9J^WGX,TH#'IREHJNJBH#]>;V_R.,OI8QEY4MW[C ?@
M(],/BTURGWVF40G"IS1+LD=QT[SJUX#1P$%5%5G#R6C?M5_]?X+=_E_I__^G
M/[U[^\=_+5BF!8Z"95"B.%BV*Y0K4R%G=91$NLI@V1GHKRH60:)!M-;9^.E3
MC+?G+SBL:(+0VG*UMHPT6FO#U!/?]#*<S7ESJ]<;4=,*@#9(9J$7>']^_::;
MX!A_NZFML:Y>-C&G<1Z2 1<'-T]!O@M"3"H:!DEQ<W6JZE"3!K >M(0K=%FC
MAT:*B&CZG1')+R@2FED$1_0GNM%BEE#5928-8%UF"5?HLEJ/C:]:$[6J:V^#
M>L&EKVF0?*6QE\JY,^@:F!UA)$+ .*)&*-"">T S642$_0[>'FX>9MRB"_J"
M<+M!@E+?%768=7?C4NNQ()?S,2[5O@DR(;"$,'DA#,A A*&,R^9:T=P'0TFP
M'2&%J>V--E"GYR[95V5]<ZM=WB@$P76(#J6D/[CXQ!7,>KV1UJFG;_+XF<;W
M2\B:6-LK>@5HO6.%5NRE1@W5>JA5]-U=91Z$Y<<@K;;DOU6.<W5'*43!=9$>
MIZ1SF +J:X#HE>9,[3I_#-+:I\#0.VH5F+UDQ*OLK483]57]=ENUJY* G@!U
M;MAB1TF$@'6-&J'0&:TH"EI9>JA*<]L'M=.IGP,K227(ILZJ.X@<_![I0,[K
ME-^2 O[93\^PB7##$B5OTN@FQS16=_T8I;C'+^4'LG'[1=)5=HK0^FX2:K$S
M^;)AT^65KDM 31'HK[00Q$KQ8O?.J)-L=!8_QQ%.HTU!+'.5E*WCY<<LBK=Q
M.&BAME,GZ,+JU^G QUW+2T!1700*2/?2RRM2#+W1"AK/4K3KE>7%F [K>E;A
M]@W1A+Y5J4'N5@-F4X]&%:9V%VQ/7I _3.](A1;D?M1#-G4CBS$%J NYY_!]
M\,(G!76,-QMY:-UF U;LL-J9N@Q>F%\ F2F'\=[\>-H+M9$[29B[3*X'O.NT
MH,7,EG*G#2#]1IU%LFU58/9OBPX;*D#O*2E:FU'&O6C(:H5ZT;#?^>FP"9XF
M1^-4,MU_!*3KR/EV2T"1W>AE&F8[3$A'T[[0?/!I2$PSJ_X-SG=!2AKCLL0[
M\:'1]")@]>1L_$)0J$8(Q53*3W\:QA?H,64WCL21XZ6AN3]9EK;/4%4MKA $
MUO1ZE$(?-.*H>X5;]X:/SK@(0K:.;,%<94&J/JO2B\/J&"NL0I#66JG7.U3-
MBT42*J 8)PHYX+VA'262;O!ILBZ"T=OKZSKLQ*>XS./P$:<769/K/K+RM#^X
M1&B]NTQU1!Y(7J;7P5_*#/'2?\ IVF8YNP=(ZF_,\H-?C3Z81@-/R/KH T[Q
M-BY)8]R2O6!>!,GU]C-1SLL@3LG?;[*"Q382UXHSR@!&D=D5$ -ILY+8?NV!
ME\7Z/Z]+8_NVICPFM6]*]-3]MJ',@768@$P;TMQ/V\9Y45X_)/%CH',GE8L!
M:V\=1J'EJ3#JI!&7]CM+4DS4[3%.<%%F*;[.HS@-<IY076+2]/( >\<(5MY-
MY9<,[1H]E-6*=91Q?\-&71LVB4_M+Z9T5)W61SRCY][P)8FG#GS&-!)Z^*0\
ML!!%H'6. I_8%<\8-9)^+5R61?38/Z\>-]$N3N.BS'7>:P9Y8/UA!5;H'*+%
MCF6I'AHJ>NTKLBN@JT12HSZH9]RXERBZS$X-5L]-PCSNP%J9]>%0O>>)X[$?
M_Y(5++XK#:J0T!=N=[BDH4)5'6B0A]5S=F#'7=9H\; 03 \UBE[[ZO)*T2G-
M'V"U_@C5N)DOBSP@,+PV:!KF[/@K2(91_\065DD":W(#3*$/.GDA-*&7A9>R
M @5SJM+Z&TW0/9)>4P*?TH]%YU#FW0OI,BTJNM)4/0T>_1U:-\G B5U12WFV
M;"4!1=.O<%^-=HO69-N5-+U! UIGV,$5NZ?1:YQ1N@UHDUO8T]!XIC!R];MY
M00):C\CAB3W Y0KOS^6;B*W7V]Y[UILJI[\M[[/Q6[U/N+S>-O$&Y;%M#RX1
M6)<N5!UQZ5<'MAVDD M_0?NZ;#Y=[>M'C_OF V]0BIG?6-9$?:21<3V-UT/;
M1G%LNU"Y7QF1M,? "]/IC<^CX_\(TBK(7^^_9/=/6570?!UI=(>?"5R,50=A
M-DJP"#$!\;BW:U6:EN2/:X?WN+H9!:KJUZ'W1V>!/ 1 +0?:O\#JZ#$L(?']
MC=]X5U<XI:'U58W:_RNPAI5 $QJ7R_AM8.XR8O*RDHL!:W(=1J'MN3 0%ZLQ
M=+4/HE(2=E^8/ ^;[NCRXOI^_SK)H>UX?-5FN*%=0?0JT]7C)DOB\-4XAFQT
MCZ?SY,"5?7G;]"4I!'6EH+_R<I#WT9>&69+>!/DO=8;#BRJ-KI2!20WRT+K1
M!JS8=4P+4354ZR&J^ 9=>8Y*VJ]0EN\S?@%NUUL2>;B]I0:K[ZU.SW]?98%J
MG]K]"5@/C'$)C4T$O#;J1R+XU-LMLVR,9*=\_K*/<YIB/:L>^W^_?XKS\I5M
MJ!5]<7")L+IPJ>J,>YZ52\\:_H1X4:@NB_SNO=WY@VM.3.SP8^I-VZZ"U"VF
MPSN#/.R.L3NR:WL&UH"Y_T*POUIV2U\8=I](D*HZY-UW?CO$>"L-_!;:]M;Y
M(XP[YA9&4>-5MW<C ;2]1_"4[5TT#>ZGO:NRXGLOU0&S( &LO17PA/9F<FRS
MZ/>T^1/^<D-:X2DPGSBK16'U@1'GN#.( FHT@!P_MR])U0D211%@W:#")S1_
M(SC(C^BEU;,TQULR)H.'!'_>D[^DY0467QXIY("UOQ:DT E9>M*)HXK+TV3)
M7B:"3Q7EP/66NS%0?P4<763Y^0O.P[CH.7R*?6.K":RW)L(6^H_I4]\,[HO!
M<F'3O-=9CG!=2-_'U6NO?B;,?(R+$N<XXA4>^+DH^]2@![-'[4"K^[/JZ3>=
M._+;\=*9\_*M'F%^U4/RJ;:Y4Q',Y*G7*2[C'3:G.%<) NLJ/4JA=U)\0N6A
MY#"_)M\/Z+,I%HZS78GR<]2SH,1GN CS>"]]S3%%&5BO34<N]&131!V0M/-:
MP/P0.J*.C%%7#H#^;<*MQA*G5J4DY)X389JZR6_<V"%Z8_11O3CDCK&,/#KN
M'>9=<I)M3_Q&'>WJDA7%*5F_OI)%+5G'1@6S$*P-:&IDW2@R:$+M/#O8FGXD
M!:"P5T)C#LEJ<N>I,VU"+4JEH'62?9!%+@OD:*E.]'B?-4=>O<V(/-"*40-B
MSYCARGNIH"Y8^^8TL+_+\AE?Y;I\4F8,Z_T-6$<(P(0FIQ)^1P-%<!L7O]!=
M71OUC2YA3#Z+UIH .V4";'F7L0+83G90!!1GQ1NRVD]+2T]ZG3"LOK- *H2R
M9BH(EG-]?1=YO;4-S692@-9-5FC%KF)J]' /5G0V4WWDJP8KK>/J.-WJP:;W
M?*X@&H>+BRSOI0DA<\#8)4/5D69-D)UI#5O1H06[0NFE2F&SGA #P6N?7J:G
M0?%T%A=A5J4ECC3GN&85F+UHQ*OLOC@E.^#B"46M[AO?Y[SMN^W-HV99(A$"
MUC=JA$)OM&F8F:S?U4>>A1A'!<U6)GUG_T.>%9(UB)4:L!Z:@EGHLUJ9)V:+
M%3$#_ R@&MIV4"\>\;T)@Z#N0:T6S ZT@6P=Y2''"=D51"S(0\G"U-<A[9NP
M#@6DN"&D";:X*$@#!8G*5 HBX'I1CD\RY%I!OS9R[$"GNWG4"0/K"#-2H4N:
MH\#N2M'W->(M#I+X'SAB!SAY_8\?@CBE]P74U'/[0!VY[G!8Y?(KQEFEP.K.
M0ZH@9D;DZFQY7[6EH4>:M.&W]"+EG_E$N&O+1$5;J"<>T$5L\LJ]Q38A6]X2
M8WU7TO P>51\RLJ?<;FAN<C)BMEPGGE0:=!X<7A51'[P,A$O%'6EHK981,I%
MI&!4EPSE./06[PB+66BHW2YFB>H_TT GXY-$"2?L%*%U_R348D_7ZFS5Q/6)
M12 %-.E\NKG T[B797PU!!*W48+6C=:(M6EN>\K30H@?$ >+ *!.[<0&T&,+
M=4@LN9RSZ%@ZF'WF"$+@F*)"*&%&+8JHK-=%]A"V>7[62$/N#]OY==0Q4*;.
M!A:_ C".D;X8U%Z18-1T!Y?V/%*><5KA3<)L,([NLQN<;S.:I3?$O1Q5DGZQ
M4X364Y-0BWW'U%'0Z#.7EJX$E'5%>%K ,( T,_-CRC+AM7<R'W'YE$5# ;(-
M>ZOJV2EE@.SD&148]_?]$^GK'=V-\*.^M(@C7 >WR5MM%%7L)(^>]Q$RQ%G4
M9JGL7UAV_X#-C:)KE]G<Z)5QG-P0*_!U<X,Z)%]O/]=NS*=5GDMWK5(Q8#VL
MPR@8=!8:CKX%:QRQ4?&4Y>6)-S?>#CY_L\$R YC[0Q2&VBM*I-*^:9SDZ\<G
M3.T-"KFBOP[J//XE*Z.1 ,".$-%I&Y\WNY_6YN_'V&TJO<.)RPVSN6*K*P2!
MM;X>I= +]>NY1RJ/]DRAGG1\]H;&"P;X,T;;]XNW,)XMW@5D5:!S91D+P&IM
M!;IQ8S,Q .XK#,<MO\(7PON(=EXO#K G3%CE_=+X-.R$0$9^9H2[\ E'54*]
M;8*"'F'3_YS_O8J?"5P"BOQF>$IV3V\4U:=_!Y8'K)\7J8Q A+I4NE!F1XCL
MH3W]H5<T^Z5PULC*]WW4V&N5A*QENI ?USE;YS#W8]:F9$U4[>I73M:TF5LF
M6.H<6"$=?3I=^J\/21#^<D+^GE%+4S_FNR$$HEOFCUE$ZDVD&B#PV,2W(7PA
M38;638[W01PU5V'V#)I2#EC6S*B$UM#P\A OD%F7NLC>72,P0EP$(7MTWUZ$
MTVC-#&-I00,+;:B=;P]=U^5-*;W'5#S<-;!N9D<8[+G>9<J._FD#68]V"VVH
MW6P/7=?-K!3$GSOVR@'7S?5$Q.:AWIQ'V1[GW &.O5O:E#_0^:F=,:V9L,P'
MH))ET=KI^#1<,/0^Q6U*G"/^-<0^1SVSV0=[2PMPU*M/Z9I#;#J?RB/"O%J3
M;6Z14.EU8'UTA&K"LW2W GS]D:F"[(#C#VF5;95<Q5OR,V\>:YZ85*'RP1*W
MKM\K5@3IUBW[9]WS0/H6$XFHYZ*@.A&4RP'K-2U(H8N8-.K$_9X24J>=#V3X
M1Z?9CNY#^)Z8SB./;,WZX;43J4_8-C1"4!T%A<T]Q65ZPVZ#+],RC],B#N5/
MO=?\&#!*K%]3V0W^(U4[83'LXD:'OR5GC[3J=023&E[FDZUHEK.YH+[6#V@\
MJ"2L^&GIPRL*]OODM1&G;V23C&8CXV72%,!LT;)C7@?^DLNQ1GTPM_N#HMVO
MJ[*@7OJD+C]AEALEVCR3:?(1]YS%2<L&(8W+?H_SG>AQY $#0/)[:8#QF&C4
M4<#U"<\[G_VV!!;EC#FRU&P.6! UE'4XWM#GX;^Y27]./Z9G]^E?R'_N?H/X
M9N]-'3PYV.T3_(9(O?WY7SZ^?7_V&SJJ2 .SX^1ND-%@R^2[;$"F&+WB("<E
MQ,\8[0BDI^(-6YR5-(T2QBF*@E=/-Q/T#6CS-I3;(=K4(MWE<L HJ04I3-'L
M^6O[DIF;Q#?^@N&UZ'%TQFRV&.Y;$1#'6A-H=UG"MG[27.W)CW0LRF*=>\U/
M;U%EQ:+*4O'H>EBWV)G7P3 ZEBS4N 6ZJ7):B[*+0-B>%-L.9_NR@'?_Y(I8
M,V)?%TB=V\7L+;#&O$TK6%H!ZZ*^ F+,LA1Z7@#C Z<^=4)(<%&<OQB2F\PM
MZ%BX8%6+:7-&6!=&)@[8ZX)1(_R("[*EZ+W9DF9&F57*<;%!5X4Q%;@LV9"U
M_CUUY%Z0'<W,VP)C7UO.L72V3246&_D0B7#H@/__R[O:WK9Q)/Q7^.U:P 5N
M=P^XSTF3] RT2= Z!QSZH5 D>L-=A?+IQ4WNUQ^'I%Y)2I1CFV/OA]W-RC/#
MAWQ&%%]GW$9.R@7V\+J/LON&2_T2BEK+ND^'.=N-*IJ"1[O6/PJT[TI#*82^
MXH!H7]RI3^>E@?//2S2^F37'A!$2,B^[IN(%67[-7CW:,#'CS+1RB$DQ0-KY
MZ&4XT#%N E[9^59M-JETBRB]4IM052X& +<99WPK^G?QG;B(2[:5T;8N'@NY
MQF_2M9,99&R^I0X&V1UC]>Z>L 9C(9[Q#XU!$C46R7=ILQ1/@KR:JR>6)_=1
M7KYZQN^?4L!%KR=:<Q=8J!&IARR8_RJ/8"?MWUDJ*GY/75?N[&+(N!G#:#"B
MA,E62I,-#7D%3X#A\9,S/$W_9W2-;F*S-+84"NOI/[/54U85$4]6>AMWR8%U
MMJ63H^TYRL@(FH]\2-^O?__E-](HH1FD/W F9YA1J9*Z/C$>.>ASB^(B:Q+G
MD!JE0)2&NC('.H%YJ<.O0B#7.VX+X[K*+K812^'A39;#)5"OJ+?[,XV-]SW7
MR_23O!LAM_D?F6)0O,S6L+@RQ'A=ICQ.4XA2$870?>!509-;6KIS+EI<:%('
MFV_X C9)!TT5#-Z25))H]4#4;>7R7V>-R#7\<8MB(VH"I\F/4B#=Q:^P@R1U
M629):+**7B!H,MO"B^Y@9E0:%SD^4(T%:G65!Y1(&;U Q"VM=N@ M#VT,DZ8
ME0AG!6TJ1UN_]@1O]R)3'K$?.<':/4FJ$:E'OL[SI8-Q17F2N5*3=G]$QH*)
MS-Q= A$$C5O8(V$[6MLAC;'YQZ':^2C(!]CP:\-[=U*S!1F'Z#WJ?V5I0G/7
M",0FA(N1$83&Z7M]'57+!GU#!A<)X)+MR"+DJ#0R/CR@3EZ+@.L[H9<FK^B:
MYKG\VM47'E_J9SI$1N\Z"4\N*:=K5HH9RH:543J<K!BL[KT$7)YPJ.H-O4?%
M^"./5(@UP:-U")QM'55'/O\)AV[DO?5$XY"C6Q69-"K+G#U6:GHOYO]BQ%+%
M)9/_1Y\W60[Y4!,&B<6H-".SZFBHG<EER+FEXYH?X+EA6ZI7HUV[^3.4<7G:
M#LB'3@1R1 N&W>&7UW$GF#)ED!'B!.BX?8RAY>M#>V,IXRPRN%K>#= Q&BJ"
MIX7K[-.(;\ WB! .>S4UONE]*;<6+F[F0+;L1/VS$ZHMX&MR+7K8_%5^T;]$
M14GSSV7BX,@MBHN829Q#-I2""IY&E,J"""4$Q(A!UO5ZS6(&8<(VH\381#$2
M,X+308S0((V*8.8>&3'+Y0QJ6F'LY!A(?>@ARV5PAO2E_[NU(\;1DC<_M$?8
M#.IVLH*+T[=4P9')7D7Z<(5V8KSS8WN8[]@#D:KX\'L4;;JYIF!G"@X9%%^_
M/9COJI?"CU]_I(_IT=CMU4NS.@_G6#8MN5,G]<@[H5F\#_7&UE5R)N^P"B#B
MPH[+6-;0V3BT7-!&=K<NNF:=:,] S5AWH*)K&W%84PI1\XZ &S9U1S2T_W:@
M3+0XSJ;V:>- 3;O*Q;>\RE_EE\&( N"60M30(^#,D[Q*5'T(%RK:::"6EQ">
MU"X6Y @H7VTM;TK]^ >:EA\!9[WXHT7_1I0PN1BLUM]'.#H96-CQ8F=*!]%;
MX@UUI(^26]Y*/-S0WIV6VS&T=RL@HL</Y]Q4XX%8^D2YF VFHBX7R3/C#&Z)
MP=G[$9XF5! QY8MTR)76DU3U-0.SU2P&+'F</5/8L+4Q9!%#Q,H8NB$3C2Q1
MPN0=B+\/U/Q+7E(((C#R<@Q$$#6["YD1+$/+!7;UVXQG?4<9:76G,*+VG\8X
M9**KT?B_5@KW"M3O[(UX#F%8&:\$/OVB9KRXE.="E)P\@7K](CK/+$\8C_+7
M94F?"U$Q&7XU2U/9&,KA[*_3P8K[\1L:USA&+<W7O-.?ZK,U3<&D+;D^YZ/E
M9>$+TB^,U*6%.3=&GVERQ;8LH3R!!M3;ME^RA*U9'%D/%GAI(7"1'< .F?;2
M#M7+T[)U_N;6V2K[**,T=:<^EU'!8FO?/\\$IB_"CLB-[P0M^\,CTAB#J;HR
M1[KV%D1:#+6<(H.L=:)\6U=3AD((7L9I;,9:BI1<D(YLR$8WSNPY6]Z01/3>
M3 "T<O!!!ILG]1YI)QB]^IC)])]!!KS!-\3#OU=[ ._8#)]G+03S'Y_ $>_6
M7R(>*8<L8.>L*!3\^YQE^7]HE-M7G5:9"O(BJB$S2*VRAX*N:/S$90X.PT,.
M6AH63SI.)8W]SB1AT ]%*9%I/1E$EI2'U4.XU46B<EG<K2_B&,[KB^I\@R\0
MW.)^V$"*&,,Y/'2P4#P'JDG4I&ZXR37L>M$KJOZ[Y#I'[. :!R2'@WR3[L,"
MNUE"](U_8P4LLUUIAKRK#;Z'%W20@E<N^*I,GD%/+YB5UYX*.>[E'"&/$L?R
MHX\F:IY' 7OR6ML@VLB"2#.8Z,PKFDP<EO#1PTZE"ZX_D6"!A#]]8=:N[HF^
MPL4"^V&,2274]+FP>G)7JQ.M'X@X/1. J$;Q?RN63\9_FJ6(B,!Y>!T3)AF*
M2>N3U@!I+6"A\3Z'S9'R%:+#E6(8 (<=C'@'\[4Q$SH-VH?5VLI"!M8K%\U1
M$6DJW$(P!/47V&"9.KE\%9.N9,F79B1;QQJPIS8B>G< ;5OY!1ND-@*9.M^!
M'=$!OR>-*1)LC:,]-+/1KGBWOHSXGU?TT?JBVN00<38*SSSR4PO#G0P0)R ?
MN .]6P.(.B7&QZRPSR!'Q!'QX8/2V2<*4D"+-.E!I!ZN#O"&<0%MUP[0HHV(
MO!U S^P &U/A.T! "?_ AW8;I>" [6T?^$%\S_L/.I)U&NCA"#U.JT3F3HSE
MDN?7J*37ZS6-K5WK<1$@\K- %1_Z*AA>*&_MV%^0SJ4O^2,,QX;/>@H*$K%,
MNQ:D 49J9 2@$87M%'V_J=$5*S99$:6?\JS:P)H]*V)U8H4F[7F5O7O^S/(1
MK) 'K?;!O+[U[!H1D9#4@>H.J,[AI1 [+_8-1]MVK5,2@0]Y G2>UQUJA#\9
M=@'.7Z5EDRUNQOFP45TL;.T">?RLV*B-$(P.4Z&LZ$MYF=KRWSDEL; U#="\
MW>/0",'$313+<Q0-FL]9Q-UTC(MCX<03I1'+;%0MU'3?M59XGZ4L?K52-5<7
MT1A_-F1C5:"_*MI?%!4/I1GR7?\7[!%I,%0TAN8LN >?+EE$_$U"=)Q?%QH(
MR>F/JNWKG%T)1$0X@(U$*I%#]>]7=!V)H0+Y#.9"M?N;9CQ[GSDB8G4_]3C0
MW"Y4J)4XKIZK-!*0KN@FIS&3XUKQ=TIU@-R+YRPOV?_D\UG[C?NRC<B%]EXE
MXUQ>6P#IEK @31GJ1FZGE 7.W4Q'@-SVT/GE:RNB]R-D^%QU8W_)Q;M2J8T-
M.(VV>HJXSMERF^E4+K>5*T36T0I',&P/5^>Q6P9=#-VK!K Y8;V- $@6=:B-
M#AA]&+$4<.JD/?*Z@D(D_I28SL[)5;[V)5<+W<?U\7[9B/K?HU<YG(<K0/*
MKH1T=@Y^D^5KRH+YN%'\7\+-W;4.Y^D-IC-V]N9[-4A5\@E6E*_$<.\F8KDS
MGAD&7'^M@8Y_<Z 8 S7);#1>(@$30$P <MC(<;O2I6O:N3=\@ &_JY!S\/?)
MNAW >1OW[)1ZJH/T_D>S$KP>9*SB+N8<QB0>M3ND&W;*/=WQA:[-]0O-8U;
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M188F<8>-V+?80\3X7JIAI#"OC78RD*B0%GW#HM,%T[(CEL8'&4ONQ30VW(4
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M\87NH\_B+_&X?B3^!=L.XLG_ 5!+ P04    " "KBM=0S.L^(-)6  "QH 4
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M_9%NUD=Y%Z-J'\70R\$'D5L;;\ NTD2Q2F[L)M-OLK&.GY,T=MQM?F3@/).
M=_\;HX61ONLR6";;A J7W^U)B/O](GIYYQ'_W<?W'SZS'\[8#V?O/Q0W>_Z-
M_NJW?! /9.&S;X<INTW5,G3:M+UE<Z15G1C'[BB*Z>)&(2O[=&*WI@G[EY&*
M%N_6_&;"F;OT@ZT2S>-HI2O+0FZ1@I&J>.D0CH_!!>6$N@$W=-*\_A?9R$#8
M:PI$X0,^& 1<6\&A9&1&^VT7?[T%4.H?,4F]C4>KPIZ2V(\H"QZ[!2J7>J,I
M4/R?,(J_E6LK.(SI<#PVI.O 6;3+O]$$*/<?,,F]E4LK\BZ"Z==^XCK!WXD3
M2U5?W!J(PI\PH:#BW>+J^RL)@O\*HV_A(W7?HY!X-TF2D5BV"@M)@-#\B D:
MD!0LXO-+%&14A/&&USI(9+CL-07B\6=\> BXMNFEYE/X@:Q9%EVXR.LN2)U5
M 040E9_PH2*7@45P;L*4L)'3_3LUJTXQ3ADX(@H@.)_Q@2.7@45P^!2^H*O=
M(HJEN[M&0_#>#A\6K2Q;A.!QY01!\]I^&P2-AE ($.ZO6UFV",'5BL0+:C._
MQ-&W=%DDV<B@$!! (4&U^0:(P"8TK[/8"?.CEGQ_*L6EI344%%1;<A7S-NW5
MDOKC@#E2;P=% =4&7<RP1?E/L^? =Z^#R)$Z4;5F4.FCVI@+V;6YT\@3TUA6
M;IY57LG$E.XWI'10>!!NSB$"L1K*S>,ZN?6\IK\3N%B2YE!T4&W5E>PC (4%
MV\"05!I# 4&U2U>PW@+'7]_M<7=+?V'NM+N]D&#M>/OCZ&RT+89&?[Z(PB0*
M?(_EQXP*^E'105>M*I5J[B3/'* L.5LXSOH=._-^1X(T*7_#3\$K*E;\^K?M
M""?S:S^D8_+I%"CR=21'X04YC+KSI#F<O2+G7<E(LYVM8W$MN=8GCH"3_DQ8
M7VB4UQ& H.PUMW98+I=P&PP"5G&@(;A<GUXX<;RA/@G/T!:C R2W=L@. B+J
MPA(F$.N%$,01XZ*]H+FUH_@.($DYQ@%*?L.!9=/O;MPHH9$263NS[P 0@'L<
M,-7OP;':"2SOM<:J&"X0L;5#_@ZP:4CC4/@$:9F\G 4O=\)S<%5 ,!HYB;6#
M?!WQJ]G -&> LZ,;$/V'!3K, Y7PZ=CSZRVW.=?"$?+AI5'J!+QEOW.EN"GI
M<<V9151S9L1=AE$0+=I"S8Q&3F+M.!_D5:O'CVF2U&OP["8WYU$\:11DUL[T
M=?8](-8[SZ87$C]'U$@>,)_Z<AWR>C;3P,G#6V51FWL9P'(J>XD".@!#.,<Q
M"W-V5&N4S>P _8""_?6H'VPJ]ZNH#O$SD5H=#W5P"-Z#O52#PZ-YNG+",?,J
MHP8'^V0T]O(2NL(@1!%U1+ H-I@4I0#47KZ@O;T,!KC (Q GR-!AE6[V>9,"
M)"*QE^=P $9R_G' 5%8_>" O),S4DTC4WEZF0U> Y)PC02<CLZBH4C!U8M L
MDM'8RWCHC))2 CB0$A2R5:*EHK.7$M$5,9@D<*#&*@F!_8?6QE!\C,4YM/&1
M\(P$% V7X0!?X:.QR(0^)! G89 [9X$QN(]"MZ-EK))"D386"SEPIP66SO!#
MD+=1N)B1>%6U/C)3V]8:"K>QT,BA&VN)#-"97I#-A6,R@&#'6[&Y@.?O6O*C
M9$10D(\1(>D",OA!0-OSKTMHN8=@\L=CA$VZ #>4$/*TM!-\P(I4Q-;&4*2,
MQ4^TL9'PC .4R@T657+H7DLH',8")9UL7!NW.+"8Q?PUG T$C;:V4#R,A4&T
M\1!SK.]??,[]BY L6!C,OH<Q]CQ^'.@$4\?W;L(+9^U3UT<2V1<10'$U%C[1
MQE7!.X[I]L#J:X;$NW+BD+HZR=AULU7&@ZB79.Z[OC3I6DT+SL!& QM<(C@0
MW&=0QP.$(V0L--*#K_=6-F0J)[A[V@@<9[0Q$:!L>M4!NQ<PIURL2Y+Z;F7=
MJ-W&_ 2_C3GZ0ZV_/YYN9QYGDT>E/HGYF#WNW4U)S._)0_=]8OKAWN;4DQ".
MA;8^YKS4P3A+EU','@N HKE/9_O>9V\PBD2"%SY>1E(3NI+&]@70GF&KBP(O
M9/)J*Q(&NY1;,786T3-XABJN]!I9TU\&0<2V;Y >@*2&<-"A"5_^I$2V+Y+V
M@Q[NA6]OH*I53TA@^]YIGVAA7.\T2XN)6.NRTAD\GN@/,]@R=_0]^Y;%A+W.
MS1-UZ"Z\?;_^@VR_ONMH%,U'E:[LJ63^2MIV8.K-N9# :I";)VY?4]UD1_IL
M/+_ZZ?(B2U(ZUOCJU0TRIE3L+AK]/_;PFRSJW:$SRSMU!8I[$?#.XL)A1[?9
M<N7KR6JUE9#8WI_K@:?D'0=$#U2&= RL+-$E5;<@XG=MBS'+)I^4S/:>7"W\
MO9H_:BD,_Q3X"PG92Z*4R[&W\D/^OADKA*^$6TEH>Q^O"SA0$L.'?"N8W:/N
M .-;;6Q[8]_1[.[S._1#R?LHC.K<E;64E*LJ@-1V!$ /9K L3)62(D[ (@S4
M@+"7BO-_?''\D"D<<]C:BI2UX,.+,W7KRW80  Y!=#"OF#RF2__%]^B^-.=Y
M:V_$DT](8#LDH(V@BB%,,/%W?DBB=F7W&MJN5-45%@''P_=AKJ.8^(LPOVCG
M;OA#'.P%IR@L+<<YF=,VTG"!5B>V2V%U58$.DL(Q6WDM2"'7$H]506>]YE57
M)&$"P0%>!]QZ@ Q)G$<'HT%N.W8;J3(0Z8<99787%L]M2MZ.6A:27+U2B5&<
M_-")-S=4C F[(,M"F%$0<#GE*Y4J>FWHH]8+=NEIV!$ >!LZ2EDOYMXY"<E<
MEC(O)+!>"JR+;@@91[(^D!02?6HTLU[D2W,=:&,275G?2T)Y\<H-'+,GOSHQ
M]1+3N\CSY[[+I2N(4P!IK1?^ N*FP=);V4C5='3\XO@!"[3,HLH!?Y'*?^XD
MO@N<JI".K!<;.V RPP4U]&6TO&I59KUQYMB9F!]DJ2Q324EHO8R9'OY 0>!8
M7G\EK HV\<8OU!]<D/ML]4SBR9P/O)*I P:S:W_6"Y_I87R8V+#E.UTLG7!!
MDIN0C[_]0E8M >I/\ 2HHN^1'XZJO?^[LXZ2OXR*CZ"XQ-2M&@>(W.K-TF*$
M,WD-IF8[U83<TV0CLU(+GKT;IG6.JN$Z#(#0*4SX]AH 2J4M,F!J:B5"H#+\
M:CD^#"CDJL2>A8Y"7C'HU8< TDXV1&S:.:GDP]GT*>MCNXQ6CM^VPRP]K_;F
MR%"1:5S3E6QGJ'(ZCR/1_8XP_T<,3$M3VPF97> 0<HS#EZ_5H%%!TMK8=NIE
M%U D7.. 15!"1@60@LQVTF07J$"2P %:LX","BU1>]L)D%U@DO.. Y]*01]^
MVLT8HYM+$B;^2W&8I9Q@\"YLYS=VFFRZ$L(![)$J(9GW*_:V=^8+(*U)[$<>
M'4&<VH\':UQ^['[CT;PGHH01<*G1"HJ"0[R+W"A0&S#V_I$EO$RNX,RNO2D:
MQT.(C'CL_1@Z#<E.PK:0FVB O#4:CT%;OA5F$:TE^1WQRRRF<W/*IQ8OSG!/
MOO&_2(,]('(TS@%HQ8&* S6"N='M#N$>O>W[$(=B*! (:A"YWO&_3=8\$^WJ
ME<2NG\B.%SMT9?NB1"_34RHFU"CGFMD/S-*^;-^\Z&<*#P#HW8*?S")!2(<S
M\^S0L;-M)]US<A@>"-WG)'Y*'DG\XKLD9_R!N-$BY+TH2H6;_[+MNQM@)3H6
M"#A43F8:>7"CVXI1D%J_Y]'+$E&3 VK8BBUS)]QJM-9O>_1C\WM%3K YW1O
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M#,%*H"\8'+.8FAV7$"]A-\!877[J:Y))_.CP+$E>'$$,)(36^LD!%$"X('
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M8G\5D"JK## 5:]96C8NE3^97K\3-V"'#9#[W71++#)V4 .RCFC!['96R AM
M&(8*65_Z,7%I8[;%OUJM@VA#),DZC$1* <6A_]/"PW%0,F<4")CP.PO<R'K?
M@\"/*^1?>0@K_8_\"%4JZ?:FT+2F_O.:^A&W3  X,F4>L^?$]WPGWCPZW*EA
M,43Y.8:$Y(V[:&H!5(H'V 1U-ZQ[9T5_K,2/57GQ$%HD,*M4MPD;@#-3SUV7
M%6RGL?_BI&0:.*[ZP$)-!EV.C.5]PC6M_OPU3!XX3"08LVUBU&%@&2OSJP^6
M@B-,*/&%F=GP.-U4C\O.-]6_R%<VG3Z0V$##2YV.1"I5JI'H@6JM:VN+ U=]
M;98 9W9Q^X6$7B0.); V]2;0F*FQHW:QBE07J3:^#.V3B@A$LMV=T>TP72.3
M+$@=V<T0_L %C!8J=&-EKV!"UY($CH4GMZ'*>\*-9CC,C.GEH\%TH61_1IX'
M*F1UQT[HL;1WYD4I]U-&OH9#?5I57S??LQ/_*"HL/Y DC7WVTCOWJ9]"/TT>
M'I]4^P,%F75+;7)^['DI  GV7.2JCP7[*7RA(R]&/5G+<T,9A8P >CS_YR$#
MKA("IA6]B-JJYG&CF;U8]?'G;:N$<(!7CE]1M:76"L=J:MH9J_-<J.-/EDNX
M +THG/Y/FZX)A&YV#S[[%LV6498XH3=;^G%*2'@3NI0!=KS-#2T;AW2%TNO"
M7MZ30*[[JTT7F> P8=LKN/E%/68#HI#?"Y"?R\G)<$P9XV=S<B$4>OG9KM5K
MC$UE_ 3-D0 *4=8&2 *&4&SJNCA_OWW4J,!BRB)*E4KFO['1HS)_NV,J%OKS
M/?[69!0^$)=0V^U-PDI$''20#>G&=AF6WBXGBT^]X=(T%.?FH[A)DLRA"_&4
MQ'[DS4B\$G@DPM:VK^KUCY647?.0E'<&*3LK/Q44OMF[85AM;;UJB3E(Q,)!
M9R[O,V;/"]<J8;I$O!MM:PGHQ7:)N&-82[ PT:G!-/:Y!>$C!T'>H+!=3>X8
M\+8*R9"1G<:12XB77%-&2PL_F3.#$H5\,*(2<HP:2FS[72,S)EA/=#BFHG+,
MLMPQ)2D09W-99*8F)UALW:N*D?BPXZ">,@9>'#]@,8SK*&86:?>\2[Z'V_U;
MDDZ@T0=08^R=+W75&'U!&C+PI:_P%,9DX2=4SXB7^PVJ><_(P=1 ('\:#I!:
M[&.R\=O=&O$NJ8Z%BWS'EH_[GGSC?Y(&:V'T0,B-Q=G-N6): K29 ]!CUE&Q
MC8 ZZ&(2>Q<PC>N%2DZHYS]_W+C[]&^20V$>4*A+3P!O9O;+K%W^>^;#\.=@
M.R\;+?W8NR!L=?T02A2'\1@'O//"S=F3SM4K^U&R,$#IH>@/+TZG)\'AVX_+
MC,RB2@H]Y!%4&8W]BX.F-$,M*1PV0&J_&GFQG''%,Q-=^X-JPH#BA@=*!)66
M=!4._\\OE,DMWQ\4&XW>OF+_GJO1O4G/:+PA/7OP%\O41)'TMH] M6QX44T#
M6 Q<R<H(X=CS?$;B!+D1'V?I,HK]?^V>].A1Z2 ?A2KA@"*RQQ#;FU+*@KW*
M4<07EEMG4".%7[17G0J].BI0PJ&+Y:WG(FK1SO1]5%RCXOPE,_924O7O%U&2
MWD?IWTGZ0-QH$<K-H\%/@G/"!J>-QG'"H8Z<KV>U_)Z;\BON]DVR-$F=T*/N
MR*^$^2-4%B\D=A;D@;#D9/K[BRCDCQ!E3L"2'3\JK.:Q!V.]5(59@VH'6T3*
MW>GZ22$!OGXD-V&^GVL(X>J5Q*Z?$'Z"=8 KT.<@H,H\P+. XV.)0XDO B=)
M)O/B.L<DYKN^VGBW?TR*OR:2.%#'[J"*-;QCAH/D:RC7Z"9T8\Z4$_#3TNT(
M!-E%DO90X 9T"J#@&/WDW>Y7MJEK%TX0$.]\T]0SS6FLTS'^$B2]3FA]F>-0
MH&K";#'2TC;)WR.74$&A'U[P'B(MA*5FVJZA7$=Q.?3=^J-(+@700[$?4$A=
M4P+"V8W@[>FSW=7YLI!.Y1"3\U8\)KWEH_8J]2?XJ]3T;\6W1M%\5'YMM/M<
M3IMLGZ\^/5I]G)ASSL--2'G(^+YFDBY)/%LZ8;&1V0:=<J4W$(36'X+EF]6P
MUZZ/C4CGE6:=)S&D3IS:3TLR)[;ZCMR&'C='8/O6N64];@<$AR-LCNM?^-2U
MJ8;-$=B^:6]9#=L!T;>FGW-K&I(%2Q1\RY:4NKISXEO6XI9!V*XA8%F1A;"<
M='E([JU6Z:>WJ<DM$NG%Q[T*?Q^ZW#ANXH[6)9W)UXX?\_BU534'C,YV10(L
M^@\&\K3YT]EKH)P?VD.T780!U?:QRTQYDYI>W\Z@U'3M(=JN4H%JAWK2]/I^
M)Z/*@%+-]<9GNRP'CLVK%IAO7<'?BC^OL:,U5UYD,"Z]P=TNKC/G7#)C-_5?
MV)/7LI/F'[J>-.??&)4?.1TO']G&[>=V&XNSB3_UIH^+51+^G4<&6C>+JL('
M)C[VM@][U6)&XJS)*CA47Q$K<[ED9UL=^AK&66MG(?V.3YKV]S$&3T=E'WO;
MIZ!J,9]TT*:W]?9/+V6<GTXIO?K2P&[&F];!ED_9KEQ_% T4BOBD?[+;Q'U=
MI.UK &_[&*\;'+^33>OO]4(X\H,ZHW>[!UHN]&"A;6_&659GS7&\C6,Y(^ @
MB>@<RGO+5M*2:FJ/Y(T<JAE":"#Z^48<69U#WF$'N34$<MJ/M6Q6[:@Q> #6
M'S@X=O#@"!NR U58]-(L8_!9+8-G[8DLJCC65NF(/^MJ8R36*^[+%=6:7-"M
M_D<5P$ +'II[#0!N3NW@]$9B P<(3[P6Z=CAGI#L-!CK#Q0<1<D/P F1->['
M\[^A?/IAXKNF\F_5G[1>*O[8NZUVF=L^*Y YI[VE4BG5;>MM&?ND]5+P0'?3
ML,S?AB7;"_CR8N+',FJPKUNO]G[,C3@(B5-J$Z856"/B::Z<N]TU^ W&./OQ
MC^MB.LYV9>^;ULNS'WM7(I#Z&[]'-4Z2;,5E,9F?!X[[]2QQ:5N2Y )B<5PZ
M<>\BCP322U9_ZGK):C< ]J]\"(_Y$,H+6,4@1GP4IUM872\OT$6<J?^,*;OL
M8D*]G<H.[,T2B\:@,?3J"38&R=\VRP)+I%]IBP.!=OT1(5 9?M73[@^%)$XK
M"-!_-:5/?_7; UL%QJ]^F\#IWRM_'H*,ZR.N7/FR(=4[(LC++D=9-K LV;K0
MV@5:#G5WE?/($KWS0W^5K60R;32Q=B&P*;,]B;;R8B3N 1.M\ZH4;;V)M5MV
M:M&V\8(CI'1''.;W,=MU$ZZS=$8_*#"\!8F88@BV6,E$14N0P7(9L>,6/6!*
M&AS0J)0- %+)D F3?[RXUK;LQVX3E3SXR=?KF+#M+*'H4).2FHAOP3]M^^ZZ
MV/WN*]"E"P,.D]TKNU>O:\)>XO@E"F@W =VK'5'O1!^W?5_>CN;)H7C#NG?I
MO_@>"3T+FE?_M.U+]';UK@T&1%K7)5@L8]=41A'@F[:ORNOIF5'!HW\CBU<^
M.=N3 6,F3(@TM/YCU]!ZY9NCZD='Q5=/H?13*/T42D<:6CA>*%T;A9O0C59D
M-T#V)29 :;Q'2C0@7*1\& G*]X6/*O"C(,.!$4#W8(#U% $2)' ^4-E0OI;C
MT+LD+R2(UNS;Q;J;"*/1C!9&:CNJ M*Q:GJECD0,/57^A80D=@(Z@K&W\D.?
MK8"I_T) L$");0<=M('1DPJ.G=PXX)T7#\WN[6"+H8M-'93>]BP#[[#T!()^
MMZ21E;1[+UFZB?KST?*3:*MR1*<-UFF#==I@(77D$6^P3J?I[:?IEO=5I]/T
M(9RF-P=8C1<+/7P!<VVTMGU"M18J$!,+!(=SWQPOKR6R.\W4Q5! ;GN?=C",
M4K'@1++MB+#KE&SKP_;!:V]34RP@G,"V9;OH BOKP_9)Y\' J@6$ ]ARYSJF
MNL>*-%1O[['U0@RGFM+R2SK@6 I4!O@1:VIA-_3V>['M O4"I4@X6(-CV6KE
MQ)O)G,7UG'!3JQH$B8#]I!4!R[_&@EG%]\HFE<^>XERG.-<ISH4]JH(XSL5S
MO-C[E?+@5J/9@&3?&#F.,-9V4*K8U5Y#'))OU1J1X,T>\_^G$V9TF9Q]BV;+
M*$OHLDC_[Y&\4"8(":7GR3!2VYZ60%>JY\<Z,C!TL'_'$@LJ X AH*2R'4X
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M#'D!+TD5P)9VZ*_<"<9M='?RP%ZMS@CSSQ>AS_,CRA'<D709>?4&_R)>VV-
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MC#@MT0.YMR-[F7,/(X6B8'GOJR,'LS&*<<")B#>+J.6;1_&*Q9XJ9X/RP 2
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MX3R*5_S;TM*3G_0J*]5K4?+/C?CW1I4/'EAF\E1UJ1/#=?=-$@\O"$3M+><
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M%6-!G+=(77SQH/@+^\\S743I;_X_4$L! A0#%     @ JXK74)_UCE [ P$
M5 <+ !$              ( !     'AA:7(M,C R,# S,S$N>&UL4$L! A0#
M%     @ JXK74-&>=$E)&    A ! !$              ( !:@,! 'AA:7(M
M,C R,# S,S$N>'-D4$L! A0#%     @ JXK74(0*6@T,%P  R!X! !4
M         ( !XAL! 'AA:7(M,C R,# S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M *N*UU#TLS!S*CD  +VG P 5              "  2$S 0!X86ER+3(P,C P
M,S,Q7V1E9BYX;6Q02P$"% ,4    " "KBM=0(RBY*]N!  "$0P< %0
M        @ %^; $ >&%I<BTR,#(P,#,S,5]L86(N>&UL4$L! A0#%     @
MJXK74,SK/B#25@  L: % !4              ( !C.X! 'AA:7(M,C R,# S
@,S%?<')E+GAM;%!+!08     !@ & (H!  "110(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804606496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 LOAN PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of&#160;March 31,&#160;2020,&#160;and March
31, 2019, in connection with the Company&#8217;s insurance policy, a loan of $374,570 and $292,500, respectively was used to finance
part of the premium. For the year ended March 31, 2020 and March 31, 2019,&#160;the loan consists of&#160;nine&#160;payments&#160;of
$42,366 and ten payment of $29,687 bearing interest at 4.3% and 3.3% per annum, respectively. The outstanding balance as of March
31, 2020 and March 31, 2019 was $335,358 and $263,604, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804579376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 FAIR VALUE MEASUREMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments primarily
include cash, cash equivalents, restricted cash, marketable&#160;securities,&#160;accounts&#160;payable, loan payable and credit
facility loan.&#160;Due to the short-term nature of cash and accounts payable, the carrying amounts of these assets and liabilities
approximate their fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a
liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance
establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value.
A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets
for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 58px"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 -</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">quoted prices in active markets for identical assets or liabilities;</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Level 2 -</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Level 3 -</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any marketable securities
as of March 31, 2020.&#160;As of March 31, 2019, the fair value of the Company&#8217;s marketable securities was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets</b></font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Marketable securities -</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 42%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Circassia Pharmaceuticals plc (Note 9)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,649,486</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,649,486</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Mutual funds</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">893,181</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">893,181</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,542,667</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,542,667</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636249920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the accrued expenses as of March
31, 2020 and March 31, 2019 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of<br />
March 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Vendors &#8211; research and development</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">484,756</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">103,320</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Professional fees</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">476,638</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">780,127</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Income taxes payable</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">154,300</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Employee salaries and benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">71,066</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">183,271</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">65,074</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,084</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,097,534</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,283,102</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6824821696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,263,294<span></span>
</td>
<td class="nump">$ 873,190<span></span>
</td>
<td class="nump">$ 2,263,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390,104<span></span>
</td>
<td class="nump">7,724,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1', window );">Regulatory milestone amount</a></td>
<td class="nump">$ 31,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentsInCashDiscountedPercentage', window );">Payments in cash discounted, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FirstTwoMilestoneOrdinaryShares', window );">First two milestone ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,572,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FirstTwoMilestoneOrdinarySharesValue', window );">First two milestone ordinary shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,987,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,263,294<span></span>
</td>
<td class="nump">873,190<span></span>
</td>
<td class="nump">2,263,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,901,049<span></span>
</td>
<td class="nump">607,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Second Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,871,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Intellectual Property [Member] | First Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueAllocatedToPerformanceObligations', window );">Revenue allocated to performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,116,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentOfMilestoneOrdinarySharesValue', window );">Payment of milestone ordinary shares, value</a></td>
<td class="nump">$ 3,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentOfMilestoneOrdinaryShares', window );">Payment of milestone ordinary shares</a></td>
<td class="nump">5,271,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyPercentage', window );">Annual Gross profit royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyAmount', window );">Annual Gross profit royalty amount</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OnetimeRoyaltyPercentage', window );">One-time royalty percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RoyaltyGrossProfitAmount', window );">Royalty gross profit amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member] | China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OnetimeRoyaltyPercentage', window );">One-time royalty percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RoyaltyGrossProfitAmount', window );">Royalty gross profit amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member] | United States and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyPercentage', window );">Annual Gross profit royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyAmount', window );">Annual Gross profit royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member] | Food and Drug Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentOfMilestoneOrdinarySharesValue', window );">Payment of milestone ordinary shares, value</a></td>
<td class="nump">$ 7,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentOfMilestoneOrdinaryShares', window );">Payment of milestone ordinary shares</a></td>
<td class="nump">12,300,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Circassia Pharmaceuticals PLC [Member] | Hospital and Clinic Settings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_MilestonesPayment', window );">Milestones payment</a></td>
<td class="nump">$ 32,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member] | Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyPercentage', window );">Annual Gross profit royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyAmount', window );">Annual Gross profit royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember', window );">License Agreement [Member] | Maximum [Member] | Circassia Pharmaceuticals PLC [Member] | United States and China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyPercentage', window );">Annual Gross profit royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AnnualGrossProfitRoyaltyAmount', window );">Annual Gross profit royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AnnualGrossProfitRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Gross profit royalty amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AnnualGrossProfitRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AnnualGrossProfitRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Gross profit royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AnnualGrossProfitRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FirstTwoMilestoneOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First two milestone ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FirstTwoMilestoneOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FirstTwoMilestoneOrdinarySharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First two milestone ordinary shares, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FirstTwoMilestoneOrdinarySharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_MilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_MilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OnetimeRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One-time royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OnetimeRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentOfMilestoneOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentOfMilestoneOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentOfMilestoneOrdinarySharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone ordinary shares, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentOfMilestoneOrdinarySharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentsInCashDiscountedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments in cash discounted, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentsInCashDiscountedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RevenueAllocatedToPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue allocated to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RevenueAllocatedToPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RevenueRecognitionMilestoneMethodRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RoyaltyGrossProfitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty gross profit amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RoyaltyGrossProfitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=XAIR_SecondObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=XAIR_SecondObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=XAIR_FirstObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=XAIR_FirstObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_CircassiaPharmaceuticalsPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_CircassiaPharmaceuticalsPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=XAIR_UnitedStatesAndChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=XAIR_UnitedStatesAndChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=XAIR_FoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=XAIR_FoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=XAIR_HospitalAndClinicSettingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=XAIR_HospitalAndClinicSettingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6654418752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="nump">$ 374,570<span></span>
</td>
<td class="nump">$ 292,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly payments</a></td>
<td class="nump">$ 42,366<span></span>
</td>
<td class="nump">$ 29,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Outstanding balance</a></td>
<td class="nump">$ 335,358<span></span>
</td>
<td class="nump">$ 263,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796753392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current Assets and Prepaid Expenses - Schedule of Current Assets and Prepaid Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,110,534<span></span>
</td>
<td class="nump">$ 788,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">266,510<span></span>
</td>
<td class="nump">324,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_InsuranceMember', window );">Insurance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">471,982<span></span>
</td>
<td class="nump">297,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_ProfessionalMember', window );">Professional [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">156,259<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_ValueAddedTaxReceivableMember', window );">Value added tax receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">124,517<span></span>
</td>
<td class="nump">47,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=XAIR_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 131,728<span></span>
</td>
<td class="nump">$ 118,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_InsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_InsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_ProfessionalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_ProfessionalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_ValueAddedTaxReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_ValueAddedTaxReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=XAIR_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=XAIR_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796846144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity - Schedule of Assumption of Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.70%<span></span>
</td>
<td class="nump">80.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.50%<span></span>
</td>
<td class="nump">84.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802292736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 491,008<span></span>
</td>
<td class="nump">$ 447,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(279,671)<span></span>
</td>
<td class="num">(202,505)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">211,337<span></span>
</td>
<td class="nump">244,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember', window );">Clinical and Medical Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">357,795<span></span>
</td>
<td class="nump">357,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">73,982<span></span>
</td>
<td class="nump">42,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">53,895<span></span>
</td>
<td class="nump">41,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,336<span></span>
</td>
<td class="nump">$ 5,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=XAIR_ClinicalAndMedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6823288768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RemainingCommitmentUnderLicenseAgreement', window );">Remaining commitment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,000<span></span>
</td>
<td class="nump">$ 754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,097,534<span></span>
</td>
<td class="nump">$ 1,567,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OperatingLeaseAgreementExpireDateDescription', window );">Operating lease agreement expire date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease agreement expires in June 2023<span></span>
</td>
<td class="text">The lease agreement expires in April 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants excersiced | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants excersice price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandAndSeventeenWarrantsMember', window );">2017 Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants excersice price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandAndSeventeenWarrantsMember', window );">2017 Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants excersice price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_NitricGenIncMember', window );">NitricGen, Inc [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_EmperyAssetMasterLtdMember', window );">Empery Asset Master, Ltd [Member] | 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants excersiced | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_EmperyTaxEfficientLpMember', window );">Empery Tax Efficient, LP [Member] | 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants excersiced | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_EmperyTaxEfficientIILpMember', window );">Empery Tax Efficient II, LP [Member] | 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants excersiced | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_PatentLicenseAgreementMember', window );">Patent License Agreement [Member] | CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_NonrefundableUpfrontFee', window );">Non-refundable upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment to royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember', window );">Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition cost to purchase intellectual property assets and rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentsForDevelopmentAndMilestonePayment', window );">Payments for development and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_SalesRelatedMilestonesPayments', window );">Sales related milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_ExecutionAgreementMember', window );">Execution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_ExecutionAgreementMember', window );">Execution Agreement [Member] | After Six Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_ExecutionAgreementMember', window );">Execution Agreement [Member] | NitricGen, Inc [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payment to royalties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized', window );">Future payments based on certain milestones</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options to purchase common stock | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OptionsToPurchaseCommonStockValue', window );">Options to purchase common stock, value</a></td>
<td class="nump">$ 295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_ContractResearchOrganizationMember', window );">Contract Research Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_NonrefundableUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_NonrefundableUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLeaseAgreementExpireDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease agreement expire date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLeaseAgreementExpireDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OptionsToPurchaseCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase common stock, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OptionsToPurchaseCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentsForDevelopmentAndMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for development and milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentsForDevelopmentAndMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RemainingCommitmentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RemainingCommitmentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RevenueRecognitionMilestoneMethodRevenuesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SalesRelatedMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales related milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SalesRelatedMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398226&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398226&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandAndSeventeenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=XAIR_TwoThousandAndSeventeenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_NitricGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_NitricGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_EmperyAssetMasterLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_EmperyAssetMasterLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_EmperyTaxEfficientLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_EmperyTaxEfficientLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_EmperyTaxEfficientIILpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_EmperyTaxEfficientIILpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_ExecutionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_ExecutionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_AfterSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_AfterSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_ContractResearchOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_ContractResearchOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607634928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;13&#160;COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>License Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 22, 2013, the Company entered into
a patent license agreement with CareFusion, pursuant to which it agreed to pay to the third party a non-refundable upfront fee
of $150,000 and is obligated to pay 5% royalties of any licensed product net sales, but at least $50,000 per annum through the
term of the agreement and the advance is credited against future royalties payments. As of December 31, 2019, the Company did not
pay any royalties since the Company did not have any revenues from this license. The term of the agreement extends through the
life of applicable patents and may be terminated by either party with 60 days&#8217; prior written notice in the event of a breach
of the agreement, and may be terminated unilaterally by CareFusion with 30 days&#8217; prior written notice in the event that we
do not meet certain milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2015, BA Ltd. entered into an Option
Agreement (the &#8220;Option Agreement&#8221;) with Pulmonox whereby BA Ltd. acquired the option to purchase certain intellectual
property assets and rights (the &#8220;Option&#8221;) on September 7, 2016 for $25,000. On January 13, 2017, the Company exercised
the Option and paid $500,000. The Company becomes obligated to make certain one-time development and sales milestone payments to
Pulmonox, commencing with the date on which we receive regulatory approval for the commercial sale of the first product candidate
qualifying under the agreement. These milestone payments are capped at a total of $87 million across three separate and distinct
indications that fall under the agreement, with the majority of them, approximately $83 million, being sales related based on cumulative
sales milestones for each of the three products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2018 the Company entered into
an agreement (&#8220;Agreement&#8221;) with NitricGen, Inc. (&#8220;NitricGen&#8221;) acquire a global, exclusive, transferable
license and associated assets including intellectual property, know-how, trade secrets and confidential information from NitricGen
related to LungFit&#8482;. The Company acquired the licensing right to use the technology and agreed to pay NitricGen a total of
$2,000,000 in future payments based upon achieving certain milestones, as defined in the Agreement, and royalties on sales LungFit&#8482;.
The Company paid NitricGen $100,000 upon the execution agreement, $100,000 upon achieving the next milestone and issued 100,000
options to purchase the Company&#8217;s stock valued at $295,000 upon executing the agreement. The remaining future milestone payments
are $1,800,000 of which $1,500,000 in&#160;due after&#160;six months after the first approval of LungFit&#8482; by the Food and
Drug Administration or the European Medicine Evaluation Agency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2019, the Company entered
into an agreement with a contract research organization to perform a pilot study for bronchiolitis. As of&#160;March 31, 2020,&#160;the
remaining&#160;cash&#160;commitment under this agreement is approximately&#160;$303,000.&#160;The Company recorded $754,000&#160;expense&#160;for
the year ended March 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain officer agreements contain a change
of control provision for payment of severance arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, the Company entered into an
operating lease for office space in Madison, Wisconsin. The lease commenced in March 2018. The lease agreement expires in April
2021, at which point the Company has the option to renew the lease for one additional five-year term. The renewal period was not
included the lease term for purposes of determining the lease liability or right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2018, the Company entered into an operating
lease for office space in Garden City, New York. The lease commenced in July 2018. The lease agreement expires in June 2023, at
which point the Company has the option to renew the lease for one additional three-year term. The renewal period was not included
the lease term for purposes of determining the lease liability or right-of-use asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has other operating lease agreements
with commitments of less than one year or that are not significant. The Company elected the practical expedient option and as such
these lease payments are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Other Information For The Year Ended March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 81%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">81,001</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for new operating lease liabilities:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average remaining lease term &#8212; operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3.0. years</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average discount rate &#8212; operating leases</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.3</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity of Lease Liabilities</b></font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br />
March 31, 2020</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Operating Leases</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 81%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">83,117</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,826</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,693</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16,279</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total lease payments</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">228,915</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Less: interest</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(27,992</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Present value of lease liabilities</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,923</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><u>Contingencies</u></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 16, 2018, Empery Asset Master, Ltd.,
Empery Tax Efficient, LP and Empery Tax Efficient II, LP, (collectively, &#8220;Empery&#8221;), filed a complaint in the Supreme
Court of the State of New York, relating to the notice of adjustment of both the exercise price of and the number of warrant shares
issuable under warrants issued to Empery in January 2017. The Empery Suit alleges that, as a result of certain circumstances in
connection with our February 2018 offering, the 166,672 warrants issued to Empery in January 2017 provide for adjustments to both
the exercise price of the warrants and the number of warrant shares issuable upon such exercise. Empery seeks monetary damages
and declaratory relief under theories of breach of contract or contract reformation predicated on mutual mistake.&#160;While the&#160;Company&#160;
believes&#160;that&#160;it has&#160;&#160;complied with&#160;the&#160;applicable protective features&#160;of the&#160;2017 Warrants&#160;and
properly adjusted the&#160;exercise price, if Empery were to prevail on all claims , the new adjusted total number of warrant shares
could be as follows: 319,967 warrant shares for Empery Master, 159,869 warrant shares for Empery I and 252,672 warrant shares for
Empery II and the exercise price could be reduced from&#160;$3.66&#160;to $1.57&#160;per share.&#160;While the Company has several
meritorious defenses against the claims, the ultimate resolution of the matter, if unfavorable, could result in a material loss.
On March 9, 2020, we filed a motion for summary judgment, which remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 18, 2019, the Company terminated
the License Agreement with Circassia pursuant to which the Company had granted Circassia an exclusive royalty-bearing license
to distribute, market and sell the Company&#8217;s nitric oxide generator and delivery system in the United States and China.
As previously described in Note 9, Circassia had agreed to pay the Company certain milestone and royalty payments, with the remaining
milestone and royalty payments payable in cash or ordinary shares of Circassia at Circassia&#8217;s option. The Company terminated
the Agreement pursuant to section 13.3(b) of the Agreement, which provides for termination by either party upon the other party&#8217;s
material breach or default. The Company is evaluating other options for the commercialization of its generator and delivery system.
In connection the termination of the license with Circassia, we may be subject to a variety of claims. Adverse outcomes in some
or all of these claims, if filed,&#160;may adversely affect our ability to conduct business and our financial condition and results
of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804602608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any marketable securities
as of March 31, 2020.&#160;As of March 31, 2019, the fair value of the Company&#8217;s marketable securities was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets</b></font></td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Marketable securities -</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 42%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Circassia Pharmaceuticals plc (Note 9)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,649,486</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,649,486</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Mutual funds</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">893,181</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">893,181</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,542,667</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,542,667</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804732160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the accrued expenses as of March
31, 2020 and March 31, 2019 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of<br />
March 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Vendors &#8211; research and development</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">484,756</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">103,320</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Professional fees</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">476,638</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">780,127</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Income taxes payable</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">154,300</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Employee salaries and benefits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">71,066</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">183,271</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">65,074</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,084</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,097,534</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,283,102</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804579376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholder's Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 SHAREHOLDER&#8217;S EQUITY </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 10, 2018 the Company entered into
a Purchase Agreement with Lincoln Park Financial Corporation (&#8220;LPC&#8221;). The Company may sell and issue LPC and LPC is
obligated to purchase up to $20 million in value of shares of common stock from time to time over three years. The Company also
entered into a registration rights agreement with LPC whereby the Company filed a registration statement with the SEC and the shares
of the Company&#8217;s common stock that may be issued to LPC under the terms of the Purchase Agreement. The Company may direct
LPC, at its sole discretion, and subject to certain conditions, to purchase up to 10,000 shares of common stock on any business
day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased
under certain circumstances provided, however that LPC cannot make any single purchase that exceeds $750,000. The purchase price
of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the
time of sales as described in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From the execution of the Purchase Agreement
on August 10, 2018 to March 31, 2019, the Company issued and sold to LPC 297,000 shares of common stock at an average price of
$4.53 per shares for net proceeds of $1,344,185. Net proceeds after offering costs for these transactions were $799,185. For the
year ended March 31, 2020 the Company issued and sold to LPC 1,420,000 shares of common stock at an average price of $5.45 per
shares for net proceeds of $7,745,012. There is $10,910,804 remaining on the Purchase Agreement. This agreement was replaced in
May 2020, see Note 14.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 2, 2019, the SEC declared effective,
the Company&#8217;s Form S-3 shelf registration statement which allows the Company to sell up to $100 million of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 3, 2019, the Company entered into a
purchase agreement with investors for the issuance of 1,583,743 shares of common stock, resulting in net proceeds of $7,839,495.
The Company&#8217;s CEO invested $300,000 and received 58,253 shares of common stock at $5.15 per share. In addition, certain directors
and employees invested $610,000 for an aggregate of 118,254 shares of common stock, representing a purchase price of $5.15 per
share. The Company registered the shares sold in June 2019 in a registration statement on Form S-3 that was declared effective
in September 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 12, 2019, the Company closed on
an underwritten offering and concurrent private placement of 3,152,985 shares of common stock at $3.66 per share for net proceeds
of $10,169,343. The underwritten offering shares were registered under the Company&#8217;s Form S-3 shelf registration statement.
There were 532,786 common stock that were sold in a private placement and subsequently registered under an effective Form S-1 on
January 23, 2020. In addition, the Company&#8217;s CEO invested $699,999 for 190,437 shares of common stock at $3.66 per share.
In addition, certain employees participated in this offering by investing $475,000 and receiving 129,781 shares of common stock
at $3.66 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock to be Issued to a Vendor</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, and March 31, 2019, the
Company was obligated to issue 30,000 shares to a vendor for services related to investor relations. For the year ended March 31,
2020 and March 31, 2019, the Company recorded the fair market value of the shares to be issued and recorded stock-based compensation
of $96,000 and $144,000, respectively. The fair market value of the liability as of March 31, 2020 and March 31, 2019 was $240,000
and $144,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Issuance of Restricted Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 26, 2018, and December 31, 2019,
the Board of directors approved the issuance of 340,000 and 390,000, shares of restricted stock, respectively, to officers, employees
and consultants and the fair value for the restricted stock awards was valued at the closing price of the Company&#8217;s stock
on the date of grant. Restricted stock vests annually over five years. The fair market value of the restricted shares for stock-based
expense is equal to the closing pricing of the Company&#8217;s stock at the date of grant. Stock based compensation for the year
ended March 31, 2020 and March 31, 2019 was $895,040 and $147,719, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Of Shares</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Grant Date</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Fair Value</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Unvested as of April 1, 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">340,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">4.62</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">390,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.23</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested (a)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(67,000</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.62</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(16,200</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4.65</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding as of March 31 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">646,800</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.99</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Option Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an amended and restated Equity
Incentive Option Plan (the &#8220;2013 Plan&#8221;), pursuant to which the Company may award officers, directors, employees, and
non-employees with stock options, restricted stock units and restricted shares of the Company&#8217;s common stock. The vesting
terms of the options issued under the 2013 Plan are generally between two to four years and expire up to ten years after the grant
date. On December 26, 2018 and February 13, 2019, the Board of Directors authorized the increase of an additional 600,000 and 1,000,000
under the 2013 Plan, respectively. On March 4, 2020, the shareholders approved 1,000,000 shares of common stock authorized, resulting
in a total of 4,100,000 shares eligible for issuance under the 2013 Plan. As of March 31, 2020, there are 191,067 shares available
under the 2013 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#8217;s options for
the year ended March 31, 2020 and March 31, 2019 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Of Options</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted<br />
        Average<br />
        Exercise</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Price - Options</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted <br />
Average <br />
Remaining <br />
Contractual <br />
Life- Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Aggregate Intrinsic<br />
Value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%"><font style="font-size: 10pt">Options outstanding as of April 1, 2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">510,904</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">4.32</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,919,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.54</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(20,759</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.42</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(33,333</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4.25</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Outstanding as of March 31, 2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,375,812</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.48</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.2</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7,952,643</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">815,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.51</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,027,240</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(58,662</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3.59</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(101,619</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(78,561</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.03</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding as of March 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,053,589</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.77</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8.4</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,878,264</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable as of March 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,235,674</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.39</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.8</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6,673,690</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, the Company has unrecognized
stock-based compensation expense of approximately $4,899,000, related to unvested stock options and is expected to be expensed
over the weighted average remaining service period of 2.7 years. The weighted average fair value of options granted during the
year ended March 31, 2020 ad March 31, 2019 was approximately $4.03 and $3.11 per share, respectively, on the date of grant using
the Black-Scholes option pricing model with the following assumption:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Year Ended <br />
March 31, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Year Ended <br />
March 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Risk -free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.5% - 3.2 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2.5% - 3.2</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80.7% - 87.5 </font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">80.7% - 84.5 </font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%"><font style="font-size: 10pt">Dividend yield</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected terms (in years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-10</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5-10</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the components of
stock-based compensation expense which includes common stock, stock options, warrants and restricted stock in the consolidated
statements of operations for the year ended March 31, 2020 and March 31, 2019, respectively</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended<br />
March 31, 2020</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended March 31, 2019</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Research and development</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">687,674</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">572,918</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">General and administrative</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2,889,975</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,977,403</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total stock-based compensation expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,577,649</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,550,321</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A modification of the exercise price to the
January 2017 and March 2017 investor warrants from $4.25 per share to $3.66 per share was triggered by the December 2019 equity
offering described above. As a result, the Company recognized the incremental value of $522,478, as a deemed dividend using the
Black-Scholes pricing model with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font-size: 10pt">Expected term in years</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">2.2</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">87</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Risk-free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.7</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#8217;s outstanding
warrants as of March 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Warrant Holders</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Of Warrants</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercise <br />
Price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Date Of<br />
Expiration</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 49%"><font style="font-size: 10pt">January 2017 offering - investors</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">1,531,782</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 14%; text-align: right"><font style="font-size: 10pt">3.66</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%"><font style="font-size: 10pt">January 2022 </font></td>
    <td style="width: 1%"><font style="font-size: 10pt">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">January 2017 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,531,782</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">February 2022 </font></td>
    <td><font style="font-size: 10pt">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">March 2017 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">76,662</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">March 2021</font></td>
    <td><font style="font-size: 10pt">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">March 2017 offering - placement agent</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,541</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.66</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">March 2021 </font></td>
    <td><font style="font-size: 10pt">(a)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">March 2018 offering - investors</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,645,437</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">March 2022</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Third-party license agreement</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">208,333</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.80</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">January 2024</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">March 2020 loan (see Note 10)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">172,187</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">7.26</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">March 2025</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,173,724</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font-size: 10pt">(a)</font></td>
    <td><font style="font-size: 10pt">These warrants have down round protection.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended March 31, 2020, there were
985,694 warrants exercised for $3,968,944 and 985,694 common stock were issued at an average price per share of $4.03 per share.
Warrant holders exercised 156,154 warrants on a cashless basis and the Company issued 73,461 common stock to the warrant holders.
For the year ended March 31, 2019, no warrants were exercised.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6653300736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_LicenseAgreementAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_LicenseAgreementTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 LICENSE AGREEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 23, 2019, the Company entered into
an agreement for commercial rights (the &#8220;License Agreement&#8221;) with Circassia Limited and its affiliates (collectively,
&#8220;Circassia&#8221;) for persistent pulmonary hypertension of the newborn (&#8220;PPHN&#8221;) and future related indications
at concentrations of&#160;<u>&#60;</u>&#160;80 ppm in the hospital setting in the United States and China. On December 18, 2019,
the Company terminated the License Agreement, see Note 13. The Company would have received payments up to $32.55 million in up
front and regulatory milestones, of which $31.5 million was associated with the U.S. market. All such payments were payable in
cash or ordinary shares of Circassia, at the discretion of Circassia, with payments in cash discounted by approximately 5%. Royalties
are payable only in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This contract was evaluated under ASC 606,
which was adopted by the Company during fiscal 2019. Based upon the evaluation, it was determined that the contract consists of
five performance obligations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Performance Obligation 1: non-exclusive transfer of functional intellectual property rights to Circassia, which includes:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9675;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the consummation of the License Agreement, which included significant pre-agreement negotiation, product specification, and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9675;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the successful completion of the pre-submission meeting with the FDA. At this meeting the FDA reinforced their assessment of LungFit&#8482; PH as a medical device and the requirements for approval.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Performance Obligation 2: ongoing support associated with the PMA submission and regulatory approval by the FDA. This also includes development activities including manufacturing readiness process ahead of the approval.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Performance Obligation 3: launch of the approved product in the field in the USA upon FDA regulatory approval</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Performance obligation 4: FDA approval of the product in the field for use in cardiac surgery</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Performance obligation 5: regulatory approval in China for marketing and sale of the product in China for any indication</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration of the
rights and licenses granted to Circassia by the Company, five milestones were included:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$7.35 million upon signing or 12,300,971 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31, 2019);</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$3.15 million payable within five (5) business days following the successful completion of a Food and Drug Administration (the &#8220;FDA&#8221;) pre-submission meeting or 5,271,844 ordinary shares of Circassia (received in quarter four of fiscal year ended March 31, 2019);</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$12.6 million payable on the sooner of ninety (90) days post FDA approval of the Product or the launch of the Product in the United States,</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$8.4 million payable within five (5) business days following the approval by the FDA of the Product in certain hospital and clinic settings for use in cardiac surgery; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">$1.05 million payable within five (5) business days following approval by the FDA equivalent in China for marketing and sale of the Product.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, Circassia
shall pay the Company the following royalty amounts until expiration of all of the applicable patents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">A one-time 5% royalty on the first cumulative $50 million in gross profit in the United States;</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">A one-time 5% royalty on the first cumulative $20 million in gross profit in China;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thereafter, running royalty amounts of 15%
of annual gross profit (United States &#38; China combined) up to and including $100 million and 20% of annual gross profit (United
States &#38; China combined) exceeding $100 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following expiration of the patents, Circassia
shall pay the Company a 14% royalty on annual gross profits up to and including $100 million and a 19% royalty on annual gross
profits exceeding $100 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the consideration constraints associated
with milestones 3, 4, and 5, only the amounts associated with milestone 1 and 2 have been allocated. During the three months ended
March 31, 2019, the Company met the first two milestones under the license agreement and received 17,572,815 ordinary shares valued
at $9,987,295. This consideration was allocated to the first two performance obligations. one being the transfer of the intellectual
property to Circassia, which was recognized at a point in time and was valued at $7,116,232 and the other being the ongoing support
associated with the PMA submission and regulatory approval by the FDA, which was valued at $2,871,063 and recorded as deferred
revenue to be recognized over a period of time from the commencement of the agreement to when management expects to submit the
PMA. For the year ended March 31, 2020 and March 31, 2019, $1,390,104 and $607,769, respectively of such revenue associated with
this second performance obligation has been recognized. As of March 31,&#160;2020,&#160;and March 31, 2019, deferred revenue was&#160;$873,190&#160;and
$2,263,294, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812076720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,942,504)<span></span>
</td>
<td class="num">$ (6,558,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">159,403<span></span>
</td>
<td class="nump">64,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,577,649<span></span>
</td>
<td class="nump">2,399,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">62,875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities', window );">Payment of operating lease liability</a></td>
<td class="num">(57,679)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities', window );">Unrealized and realized loss on marketable securities to available for sale marketable securities</a></td>
<td class="nump">2,075,602<span></span>
</td>
<td class="nump">3,498,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology', window );">Change of management's assessment of prior year research and development to licensing right to use technology</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AdoptionOfAccountingStandardsUpdate', window );">Adoption of ASU 2016-01</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts', window );">Amortization of debt issuance cost and deferred financing fees</a></td>
<td class="nump">4,652<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="num">(361,395)<span></span>
</td>
<td class="num">(729,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,091,557<span></span>
</td>
<td class="nump">322,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(470,105)<span></span>
</td>
<td class="nump">276,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,390,104)<span></span>
</td>
<td class="nump">2,263,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(15,250,049)<span></span>
</td>
<td class="nump">1,341,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in available for sale marketable securities</a></td>
<td class="num">(37,320,235)<span></span>
</td>
<td class="num">(12,222,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from redemption of marketable securities</a></td>
<td class="nump">41,787,299<span></span>
</td>
<td class="nump">10,485,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(43,631)<span></span>
</td>
<td class="num">(56,475)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,423,433<span></span>
</td>
<td class="num">(1,793,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of common stock in an underwritten offering and private placement, net of offering costs</a></td>
<td class="nump">10,169,343<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of common stock in private placement, net of offering costs</a></td>
<td class="nump">7,839,495<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ProceedsfromIssuanceOfMarketOfferings', window );">Issuance of common stock related to at the market offerings, net of offering costs</a></td>
<td class="nump">7,745,012<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of offering cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">799,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from credit facility loan</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from loan</a></td>
<td class="nump">375,570<span></span>
</td>
<td class="nump">292,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Payment of loan</a></td>
<td class="num">(303,806)<span></span>
</td>
<td class="num">(28,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">3,968,944<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(70,618)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">210,650<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">34,934,590<span></span>
</td>
<td class="nump">1,071,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">24,107,974<span></span>
</td>
<td class="nump">618,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">1,357,137<span></span>
</td>
<td class="nump">738,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">25,465,111<span></span>
</td>
<td class="nump">1,357,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RightofuseAssets', window );">Right of use assets</a></td>
<td class="nump">258,605<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">264,570<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeemedDividendAsResultOfWarrantModification', window );">Deemed dividend as a result of a warrant modification</a></td>
<td class="nump">522,478<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity', window );">Fair market value of warrants allocated to debt discount and stockholders' equity</a></td>
<td class="nump">594,979<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology', window );">Fair market value of options issued to NitricGen for the licensing right to use technology</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of cash flow items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">23,112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AdoptionOfAccountingStandardsUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adoption of ASU 2016-01.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AdoptionOfAccountingStandardsUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>air market value of warrants allocated to debt discount and stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AirMarketValueOfWarrantsAllocatedToDebtDiscountAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of debt issuance cost and deferred financing fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AmortizationOfDebtIssuanceCostsAndDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change of management&amp;amp;#8217;s assessment of prior year research and development to licensing right to use technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ChangeOfManagementsAssessmentOfPriorYearResearchAndDevelopmentToLicensingRightToUseTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeemedDividendAsResultOfWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend as a result of a warrant modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeemedDividendAsResultOfWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair market value of option to NitricGen for the licensed right to use technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FairMarketValueOfOptionToNitricgenForLicensedRightToUseTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of operating lease liability in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_PaymentOfOperatingLeaseLiabilityInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ProceedsfromIssuanceOfMarketOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock related to at the market offerings, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ProceedsfromIssuanceOfMarketOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental disclosure of non-investing activities [Abstrtact]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SupplementalDisclosureOfNoninvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized and realized loss on marketable securities to available for sale marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_UnrealizedLossOnMarketableSecuritiesToAvailableForSaleMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799607040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Fair Value of Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,542,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=XAIR_CircassiaPharmaceuticalsPLCMember', window );">Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember', window );">Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,542,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,649,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Circassia Pharmaceuticals PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Mutual Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=XAIR_CircassiaPharmaceuticalsPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=XAIR_CircassiaPharmaceuticalsPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=XAIR_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799625184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,056,360<span></span>
</td>
<td class="nump">8,714,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,056,360<span></span>
</td>
<td class="nump">8,714,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804734912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,829,275<span></span>
</td>
<td class="nump">$ 1,340,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5,635,836<span></span>
</td>
<td class="nump">16,934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 25,465,111<span></span>
</td>
<td class="nump">$ 1,357,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6642307200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Profit (Loss) Before Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The components of net loss income before the
provision for income taxes are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Year Ended<br />
March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Year Ended<br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Domestic</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 21%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(16,685,568</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,475,659</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Foreign</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,411,236</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(2,082,791</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(20,096,804</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,558,450</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Asset/Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The tax effects of
temporary differences that gave rise to significant portions of the deferred tax assets were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forward</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,017,000</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,201,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">524,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">243,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">71,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">120,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Reserves and allowances - foreign</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">880,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">608,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Capital&#160;loss&#160;carry forward</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,571,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">966,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development - foreign</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">550,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred Revenue</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">241,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Right-of-use asset</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(56,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Lease liability</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">56,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12,860,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,694,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(12,860,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,694,000</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax asset</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory US Federal Effective Tax Rate</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%"><font style="font: 10pt Times New Roman, Times, Serif">Federal income tax at statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.00</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21,00</font></td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">State income tax, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7.08</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6.62</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Permanent items</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.48</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">30.67</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">36.10</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Research and development tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(1.39</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3.71</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3.69</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4.77</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Effective income tax expense rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Related To Uncertain Tax Positions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">A reconciliation of
the of unrecognized tax benefits related to uncertain tax positions for the year ended March 31, 2020 and 2019 as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,2020</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year&#160;Ended<br />
March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 53%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at beginning of period</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 22%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Decreases for the current year&#8217;s tax position</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(154,300</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balance at the end of period</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">154,300</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795264112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_VendorsResearchAndDevelopment', window );">Vendors - research and development</a></td>
<td class="nump">$ 484,756<span></span>
</td>
<td class="nump">$ 103,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">476,638<span></span>
</td>
<td class="nump">780,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">154,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee salaries and benefits</a></td>
<td class="nump">71,066<span></span>
</td>
<td class="nump">183,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">65,074<span></span>
</td>
<td class="nump">62,084<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,097,534<span></span>
</td>
<td class="nump">$ 1,567,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_VendorsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vendors - research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_VendorsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801631984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Agreement Loan - Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument measurement input</a></td>
<td class="nump">87.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument measurement input</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument measurement input</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802890832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Profit (Loss) Before Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="num">$ (16,685,568)<span></span>
</td>
<td class="num">$ (4,475,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(34,112,236)<span></span>
</td>
<td class="num">(2,082,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (20,096,804)<span></span>
</td>
<td class="num">$ (6,588,450)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6655060800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Assets and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CurrentAssetsAndPrepaidExpensesAbstract', window );"><strong>Current Assets And Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CurrentAssetsAndPrepaidExpensesTextBlock', window );">Current Assets and Prepaid Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 CURRENT ASSETS AND PREPAID EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of current assets and prepaid expenses
as of March 31,&#160;2020&#160;and March 31,&#160;2019&#160;is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">266,510</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">324,063</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Insurance</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">471,182</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">297,945</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Professional</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">156,259</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Value added tax receivable</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">124,127</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47,889</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">131,728</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">118,512</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,149,806</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">788,409</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CurrentAssetsAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CurrentAssetsAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CurrentAssetsAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Assets and Prepaid Expenses [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CurrentAssetsAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804574192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Agreement Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FacilityAgreementLoanAbstract', window );"><strong>Facility Agreement Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FacilityAgreementLoanTextBlock', window );">Facility Agreement Loan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 FACILITY AGREEMENT LOAN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2020, the Company entered into
a facility agreement with certain lenders pursuant to which the lenders shall loan to up to $25,000,000 in five tranches of $5,000,000
per tranche at the option of the Company (&#8220;Tranches&#8221;), provided however that the Company may only utilize tranches
three through five following FDA approval of our LungFit&#8482; PH product. The loan(s) are unsecured with interest at 10% per
year which is to be paid quarterly. The loans may be prepaid with certain prepayment penalties. The effective interest rate for
this loan is 13.3% per year. Each tranche shall be repaid in installments commencing June 15, 2023 with all amounts outstanding
under any tranche due on March 17, 2025. The first tranche was executed on March 17, 2020 and because the funds were held in escrow
as of March 31, 2020 they are classified as restricted cash in the consolidated balance sheet. In connection with this utilization
of the first tranche, the Company issued, in March 2020, warrants to the lender for the purchase of 172,826 shares of the Company&#8217;s
common stock at $7.26 per share. The warrants expire in five years. There are additional warrant issuances associated with each
tranche.&#160;If the second tranche of $ 5 million is utilized by the Company, the warrants that will be issued is up to twenty
five percentage of its commitment value&#160;<font style="background-color: white">divided by the five day the volume weighed average
price &#8220;(VWAP&#8221;) prior to utilization date. For tranches three to five, if any of these tranches are&#160;</font>utilized
by the Company, the warrants that will be issued is up to ten percentage of its commitment value&#160;<font style="background-color: white">divided
by the five day the VWAP.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Company allocated the fair
market value at the date of grant of the warrant to stockholders&#8217; equity and debt discount valued at $594,979. The Black-Scholes
pricing model was used with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 80%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term in years</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">87.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the facility agreement loan balance
as of March 31, 2020 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Face value of loan</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Debt discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(594,979</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accretion of interest expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,562</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Deferred offering costs</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(70,518</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Facility agreement loan balance&#160;&#8211; March 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,339,065</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Maturity of Facility Agreement Loan</b></font></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td>
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,750,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">750,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000,000</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FacilityAgreementLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FacilityAgreementLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FacilityAgreementLoanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility Agreement Loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FacilityAgreementLoanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6815972336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>Number</div>
</th>
<th class="th">
<div>Apr. 02, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 16,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_IntangibleAssetsMilestonePayments', window );">Intangible assets milestone payments</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">75,702,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,693,578<span></span>
</td>
<td class="nump">$ 6,194,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(57,587,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,644,572)<span></span>
</td>
<td class="nump">$ 516,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">200,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 128,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=XAIR_ContractManufacturerMember', window );">Contract Manufacturer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember', window );">Facility Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_IntangibleAssetsMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_IntangibleAssetsMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=XAIR_ContractManufacturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=XAIR_ContractManufacturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=XAIR_FacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804580176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Agreement Loan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FacilityAgreementLoanAbstract', window );"><strong>Facility Agreement Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock', window );">Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the Company allocated the fair
market value at the date of grant of the warrant to stockholders&#8217; equity and debt discount valued at $594,979. The Black-Scholes
pricing model was used with the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 80%"><font style="font: 10pt Times New Roman, Times, Serif">Expected term in years</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">87.5</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.7</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock', window );">Schedule of Facility Agreement Loan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the facility agreemetn loan balance
as of March 31, 2020 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Face value of loan</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,000,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Debt discount</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(594,979</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accretion of interest expense</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,562</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Deferred offering costs</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(70,518</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Facility agreement loan balance&#160;&#8211; March 31, 2020</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,339,065</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FacilityAgreementLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FacilityAgreementLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Facility Agreement Loan [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfFacilityAgreementLoanTabletextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Pricing Model Assumptions of Fair Market Value at Grant of Warrant [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ScheduleOfPricingModelAssumptionsOfFairMarketValueAtGrantOfWarrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797003664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Apr. 02, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CumulativeAdjustment', window );">Cumulative-effect of adjustment</a></td>
<td class="nump">$ 6,194,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 [Member] | Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_CumulativeAdjustment', window );">Cumulative-effect of adjustment</a></td>
<td class="num">$ (516,358)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_CumulativeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative adjustment to the adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_CumulativeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811865584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Right-of Use Assets and Operating Lease Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RightOfUseAssetCurrent', window );">Right of use asset short-term</a></td>
<td class="nump">$ 66,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset long-term</a></td>
<td class="nump">128,757<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_OperatingLeasesRightofuseAsset', window );">Total operating lease right-of-use asset</a></td>
<td class="nump">195,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability short-term</a></td>
<td class="nump">69,342<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability long-term</a></td>
<td class="nump">131,581<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 200,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_OperatingLeasesRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_OperatingLeasesRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RightOfUseAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RightOfUseAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6815462928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,829,275<span></span>
</td>
<td class="nump">$ 1,340,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5,635,836<span></span>
</td>
<td class="nump">16,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,542,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">1,149,806<span></span>
</td>
<td class="nump">788,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_RightOfUseLeaseAssetsCurrent', window );">Right-of-use lease assets</a></td>
<td class="nump">66,970<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">26,681,887<span></span>
</td>
<td class="nump">8,688,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_LicensedRightToUseTechnology', window );">Licensing right to use technology</a></td>
<td class="nump">412,763<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">128,757<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">211,337<span></span>
</td>
<td class="nump">244,872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">27,434,744<span></span>
</td>
<td class="nump">9,428,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,256,229<span></span>
</td>
<td class="nump">1,164,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,097,534<span></span>
</td>
<td class="nump">1,567,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">873,190<span></span>
</td>
<td class="nump">2,263,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Stock to be issued to a vendor</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">69,342<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable</a></td>
<td class="nump">335,358<span></span>
</td>
<td class="nump">263,604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,871,653<span></span>
</td>
<td class="nump">5,403,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">131,581<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Facility Agreement loan, net</a></td>
<td class="nump">4,339,065<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total long-term liabilities</a></td>
<td class="nump">9,342,299<span></span>
</td>
<td class="nump">5,403,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 16,056,360 and 8,714,815 shares issued and outstanding as of March 31, 2020 and March 31, 2019, respectively</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">75,702,915<span></span>
</td>
<td class="nump">41,693,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(57,587,076)<span></span>
</td>
<td class="num">(37,644,572)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">18,092,445<span></span>
</td>
<td class="nump">4,024,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 27,434,744<span></span>
</td>
<td class="nump">$ 9,428,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_LicensedRightToUseTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensed right to use technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_LicensedRightToUseTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_RightOfUseLeaseAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use lease assets, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_RightOfUseLeaseAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803247072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Asset/Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 9,017,000<span></span>
</td>
<td class="nump">$ 4,201,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">524,000<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and allowances - foreign</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">608,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward', window );">Capital loss carryforward</a></td>
<td class="nump">1,571,000<span></span>
</td>
<td class="nump">966,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsResearchAndDevelopment', window );">Research and development - foreign</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">241,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsRightofuseAsset', window );">Right-of-use asset</a></td>
<td class="num">(56,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax</a></td>
<td class="nump">12,860,000<span></span>
</td>
<td class="nump">6,694,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,860,000)<span></span>
</td>
<td class="num">(6,694,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Capital loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6804592928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Potential Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">8,874,113<span></span>
</td>
<td class="nump">8,859,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockWarrantsMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,173,724<span></span>
</td>
<td class="nump">6,143,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,053,589<span></span>
</td>
<td class="nump">2,375,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_RestrictedSharesMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">646,800<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_CommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_RestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=XAIR_RestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634011456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Facility Agreement Loan - Schedule of Facility Agreement Loan (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_FacilityAgreementLoanAbstract', window );"><strong>Facility Agreement Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(594,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_AccretionOfInterestExpense', window );">Accretion of interest expense</a></td>
<td class="nump">4,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(70,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Facility agreement loan balance - March 31, 2020</a></td>
<td class="nump">$ 4,339,065<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_AccretionOfInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_AccretionOfInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_FacilityAgreementLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_FacilityAgreementLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802361248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's Equity - Schedule of Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at beginning of period</a></td>
<td class="nump">2,375,812<span></span>
</td>
<td class="nump">510,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">815,000<span></span>
</td>
<td class="nump">1,919,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="num">(58,662)<span></span>
</td>
<td class="num">(20,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(78,561)<span></span>
</td>
<td class="num">(33,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding at end of period</a></td>
<td class="nump">3,053,589<span></span>
</td>
<td class="nump">2,375,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable at end of period</a></td>
<td class="nump">1,235,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price - options outstanding at beginning of period</a></td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options, granted</a></td>
<td class="nump">5.51<span></span>
</td>
<td class="nump">4.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options, exercised</a></td>
<td class="nump">3.59<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options, forfeited</a></td>
<td class="nump">4.03<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price - options, outstanding at end of period</a></td>
<td class="nump">4.77<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable at end of period</a></td>
<td class="nump">$ 4.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life - options outstanding at beginning of period</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life - options outstanding at end of period</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life - options exercisable at end of period</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding at beginning of period</a></td>
<td class="nump">$ 7,952,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate intrinsic value, granted</a></td>
<td class="nump">2,027,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="num">(101,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value outstanding at end of period</a></td>
<td class="nump">9,878,264<span></span>
</td>
<td class="nump">$ 7,952,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value exercisable at end of period</a></td>
<td class="nump">$ 6,673,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">XAIR_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>XAIR_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795177360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 77,166<span></span>
</td>
<td class="nump">$ 64,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6802304752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholder's Equity - Summary of Company's Outstanding Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">5,173,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_ThirdPartyLicenseAgreementMember', window );">Third Party License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">208,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Jan. 31,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_JanuaryTwoThousandandSeventeenMember', window );">January 2017 [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,531,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Jan. 31,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_JanuaryTwoThousandandSeventeenMember', window );">January 2017 [Member] | Investors One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,531,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Feb. 28,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandSeventeenMember', window );">March 2017 [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">76,662<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandSeventeenMember', window );">March 2017 [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">7,541<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenMember', window );">March 2018 [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,645,437<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Mar. 21,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandTwentyMember', window );">March 2020 [Member] | Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">172,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">Mar. 21,  2025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These warrants have down round protection.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_ThirdPartyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_ThirdPartyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_JanuaryTwoThousandandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_JanuaryTwoThousandandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_InvestorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_InvestorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_MarchTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=XAIR_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_MarchTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=XAIR_MarchTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=XAIR_MarchTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=XAIR_LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=XAIR_LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6645390992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Other Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid</a></td>
<td class="nump">$ 81,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795294896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Income (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Anti-Dilutive Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following potentially dilutive securities
were not included in the calculation of diluted net income (loss) per share attributable to common stockholders because their effect
would have been anti-dilutive for the periods presented:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2019</b></p></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,173,724</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,143,405</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Common stock options</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,053,589</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,375,812</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted shares</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">646,800</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">340,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,874,113</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,859,217</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812023568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;14&#160;SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 2, 2020, Beyond Air, Inc. entered
into an At-The-Market Equity Offering for $50 million and utilized the Company&#8217;s shelf registration statement. The Company
may sell shares of our common stock having aggregate sales proceeds of up to $50,000,000 from time to time in this offering. If
shares are sold, there is a three 3 percent fee paid to the sales agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 14, 2020, the Company entered into a
$40 million New Purchase Agreement with LPC, that replaced the existing $20 million purchase agreement. The New Purchase Agreement
provides for the issuance of up to $40 million of the Company&#8217;s common stock which we may sell from time to time in our sole
discretion to Lincoln Park over the next 36 months, subject to the conditions and limitations in the New Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the Initial Purchase from time
to time on any trading day the Company selects that the closing sale price of our common stock is at least $0.25, we have the right,
in our sole discretion, subject to the conditions and limitations in the Purchase Agreement, to direct LPC to purchase up to 80,000
shares of our common stock (each such purchase, a &#8220;Regular Purchase&#8221;) over the 36-month term of the&#160;New&#160;Purchase
Agreement; provided, however, that such limit may be increased to up to 100,000 shares if the last closing sale price of our common
stock is at least $5.00 on the purchase date, may be increased to up to 120,000 shares if the last closing sale price of our common
stock is at least $7.50 on the purchase date, and may be increased to up to 140,000 shares if the last closing sale price of our
common stock is at least $10.00 on the purchase date (each subject to adjustment for any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement). The purchase price
for shares of common stock to be purchased by Lincoln Park will be the equal to lesser of (i) the lowest sale price on the purchase
date, as reported by Nasdaq, or (ii) the arithmetic average of the three lowest closing sale prices for our common stock during
the ten trading days prior to the purchase date. Lincoln Park&#8217;s obligation under each Regular Purchase shall not exceed $2,000,000.
The amount of the regular purchases can be modified upon the mutual agreement of the Company and LPC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beyond Air can also direct LPC to purchase
additional amounts as accelerated purchases and additional accelerated purchases, under certain circumstances and provided the
last closing sale price of our common stock is at least $1.00 per share, in an amount up to the lesser of (i) three times the number
of shares purchased pursuant to the corresponding Regular Purchase or (ii) 30% of the trading volume on such accelerated purchase
date. The purchase price for the additional shares is the lower of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the closing sale price for the common stock on the date of sale; and</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">ninety-five percent (95%) of the volume weighted average price of the common stock on the Nasdaq Capital Market on the date of sale.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no upper or lower
limit on the price per share that Lincoln Park must pay for our common stock under the New Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than as described above, there are no
trading volume requirements or restrictions under the New Purchase Agreement. We will control the timing and amount of any sales
of our common stock to Lincoln Park. We may at any time, in our sole discretion terminate the New Purchase Agreement without fee,
penalty or cost, upon one trading day written notice.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796692208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following
as of March 31, 2020 and March 31, 2019, respectively:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 57%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical and medical equipment</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">357,795</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">357,795</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">73,982</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">42,782</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">53,895</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">41,464</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,336</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,336</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">491,008</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">447,377</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation and amortization</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(279,671</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(202,505</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">211,337</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">244,872</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
